(lp0
(dp1
S'line'
p2
S'Cox proportional hazards model showed that TIMP1 was an independent prognostic indicator of disease-free survival (HR = 2.603, 95 % CI: 1.115-6.077, p = 0.027) and overall survival (HR = 2.907, 95 % CI: 1.254-6.737, p = 0.013) for patients with colon cancer.\n'
p3
sS'genes'
p4
(lp5
(dp6
S'index'
p7
I43
sS'uniprot'
p8
VP01033
p9
sS'lengthInChars'
p10
I5
sS'name'
p11
VTIMP1
p12
sS'lengthInWords'
p13
I1
sasS'diseases'
p14
(lp15
(dp16
g7
I245
sS'cui'
p17
VC0699790
p18
sg10
I12
sg11
Vcolon cancer
p19
sg13
I2
sasa(dp20
g2
S'TIMP1 might play an important role in promoting tumorigenesis and metastasis of human colon cancer and function as a potential prognostic indicator for colon cancer.\n'
p21
sg4
(lp22
(dp23
g7
I0
sg8
VP01033
p24
sg10
I5
sg11
VTIMP1
p25
sg13
I1
sasg14
(lp26
(dp27
g7
I86
sg17
VC0699790
p28
sg10
I12
sg11
Vcolon cancer
p29
sg13
I2
sa(dp30
g7
I86
sg17
VC0699790
p31
sg10
I12
sg11
Vcolon cancer
p32
sg13
I2
sa(dp33
g7
I48
sg17
VC0007621
p34
sg10
I13
sg11
Vtumorigenesis
p35
sg13
I1
sa(dp36
g7
I66
sg17
VC0027627
p37
sg10
I10
sg11
Vmetastasis
p38
sg13
I1
sasa(dp39
g2
S'According to the WHO diagnosis criteria 2016 standard diagnostic procedure in myeloproliferative neoplasms includes bone marrow biopsy and the detection of one of the acquired and typical MPN mutations in the JAK2, MPL or CALR gene.In contrast, patients with thrombocytopenia more often suffer from bleeding complications, however, in antiphospholipid syndrome or thrombotic microangiopathy (TMA) thrombotic events occur in spite of a low platelet count.\n'
p40
sg4
(lp41
(dp42
g7
I222
sg8
VP27797
p43
sg10
I9
sg11
VCALR gene
p44
sg13
I2
sa(dp45
g7
I215
sg8
VP40238
p46
sg10
I3
sg11
VMPL
p47
sg13
I1
sa(dp48
g7
I209
sg8
S''
p49
sg10
I4
sg11
VJAK2
p50
sg13
I1
sasg14
(lp51
(dp52
g7
I335
sg17
VC0085278
p53
sg10
I25
sg11
Vantiphospholipid syndrome
p54
sg13
I2
sa(dp55
g7
I364
sg17
VC2717961
p56
sg10
I26
sg11
Vthrombotic microangiopathy
p57
sg13
I2
sa(dp58
g7
I392
sg17
VC2717961
p59
sg10
I3
sg11
VTMA
p60
sg13
I1
sa(dp61
g7
I299
sg17
VC0019080
p62
sg10
I8
sg11
Vbleeding
p63
sg13
I1
sa(dp64
g7
I97
sg17
VC0027651
p65
sg10
I9
sg11
Vneoplasms
p66
sg13
I1
sa(dp67
g7
I287
sg17
VC0683278
p68
sg10
I6
sg11
Vsuffer
p69
sg13
I1
sasa(dp70
g2
S'Myeloproliferative disease burden in each of the JAK2, CALR and MPL MPNs is best reflected by the degree of anemia, splenomegaly, mutation allele burden, bone marrow cellularity and myelofibrosis.\n'
p71
sg4
(lp72
(dp73
g7
I64
sg8
VP40238
p74
sg10
I8
sg11
VMPL MPNs
p75
sg13
I2
sa(dp76
g7
I49
sg8
g49
sg10
I4
sg11
VJAK2
p77
sg13
I1
sa(dp78
g7
I55
sg8
VP27797
p79
sg10
I4
sg11
VCALR
p80
sg13
I1
sasg14
(lp81
(dp82
g7
I0
sg17
VC0027022
p83
sg10
I26
sg11
VMyeloproliferative disease
p84
sg13
I2
sa(dp85
g7
I108
sg17
VC0002871
p86
sg10
I6
sg11
Vanemia
p87
sg13
I1
sa(dp88
g7
I182
sg17
VC0001815
p89
sg10
I13
sg11
Vmyelofibrosis
p90
sg13
I1
sasa(dp91
g2
S'The key component of the Beta-catenin destruction complex glycogen synthase kinase 3Beta (GSK-3Beta), one of the major target for BIO, polyubiquitination and degradation of the main oncoprotein Beta-catenin in colorectal cancer (CRC).\n'
p92
sg4
(lp93
(dp94
g7
I58
sg8
VP13807
p95
sg10
I30
sg11
Vglycogen synthase kinase 3Beta
p96
sg13
I4
sa(dp97
g7
I25
sg8
VP35222
p98
sg10
I12
sg11
VBeta-catenin
p99
sg13
I1
sa(dp100
g7
I90
sg8
VP49841
p101
sg10
I9
sg11
VGSK-3Beta
p102
sg13
I1
sa(dp103
g7
I25
sg8
VP35222
p104
sg10
I12
sg11
VBeta-catenin
p105
sg13
I1
sasg14
(lp106
(dp107
g7
I210
sg17
VC1527249
p108
sg10
I17
sg11
Vcolorectal cancer
p109
sg13
I2
sa(dp110
g7
I229
sg17
VC1527249
p111
sg10
I3
sg11
VCRC
p112
sg13
I1
sasa(dp113
g2
S'STAG1 inactivation inhibits the proliferation of STAG2 mutated but not wild-type bladder cancer and Ewing sarcoma cell lines.\n'
p114
sg4
(lp115
(dp116
g7
I0
sg8
g49
sg10
I5
sg11
VSTAG1
p117
sg13
I1
sa(dp118
g7
I49
sg8
g49
sg10
I5
sg11
VSTAG2
p119
sg13
I1
sasg14
(lp120
(dp121
g7
I6
sg17
VC0544461
p122
sg10
I12
sg11
Vinactivation
p123
sg13
I1
sa(dp124
g7
I100
sg17
VC0553580
p125
sg10
I13
sg11
VEwing sarcoma
p126
sg13
I2
sa(dp127
g7
I81
sg17
VC0699885
p128
sg10
I14
sg11
Vbladder cancer
p129
sg13
I2
sa(dp130
g7
I32
sg17
VC0334094
p131
sg10
I13
sg11
Vproliferation
p132
sg13
I1
sasa(dp133
g2
S'Restoration of STAG2 expression in a mutated bladder cancer model alleviates the dependency on STAG1.\n'
p134
sg4
(lp135
(dp136
g7
I95
sg8
g49
sg10
I5
sg11
VSTAG1
p137
sg13
I1
sa(dp138
g7
I15
sg8
g49
sg10
I5
sg11
VSTAG2
p139
sg13
I1
sasg14
(lp140
(dp141
g7
I45
sg17
VC0699885
p142
sg10
I14
sg11
Vbladder cancer
p143
sg13
I2
sasa(dp144
g2
S'However, the effect of STAG2 on the bladder cancer cell proliferation, migration, and invasion has not yet been fully clarified.\n'
p145
sg4
(lp146
(dp147
g7
I23
sg8
g49
sg10
I5
sg11
VSTAG2
p148
sg13
I1
sasg14
(lp149
(dp150
g7
I86
sg17
VC2699153
p151
sg10
I8
sg11
Vinvasion
p152
sg13
I1
sa(dp153
g7
I56
sg17
VC0334094
p154
sg10
I13
sg11
Vproliferation
p155
sg13
I1
sa(dp156
g7
I36
sg17
VC0699885
p157
sg10
I14
sg11
Vbladder cancer
p158
sg13
I2
sasa(dp159
g2
S'Collectively, these data suggest that STAG2 acts as a tumor suppressor gene in bladder cancer and may be a potential therapeutic target in BC.\n'
p160
sg4
(lp161
(dp162
g7
I38
sg8
g49
sg10
I5
sg11
VSTAG2
p163
sg13
I1
sasg14
(lp164
(dp165
g7
I54
sg17
VC0027651
p166
sg10
I5
sg11
Vtumor
p167
sg13
I1
sa(dp168
g7
I79
sg17
VC0699885
p169
sg10
I14
sg11
Vbladder cancer
p170
sg13
I2
sasa(dp171
g2
S'Recent whole-genome sequencing studies have identified that genetic alterations of stag2 are common in bladder cancer (BC).\n'
p172
sg4
(lp173
(dp174
g7
I83
sg8
g49
sg10
I5
sg11
Vstag2
p175
sg13
I1
sasg14
(lp176
(dp177
g7
I103
sg17
VC0699885
p178
sg10
I14
sg11
Vbladder cancer
p179
sg13
I2
sa(dp180
g7
I119
sg17
VC0699885
p181
sg10
I2
sg11
VBC
p182
sg13
I1
sasa(dp183
g2
S'Our findings indicate that loss of STAG2 function plays a more important role in non-invasive than that in muscle-invasive bladder cancer and suggest that cohesin complex-independent functions are likely to be important in these cases.\n'
p184
sg4
(lp185
(dp186
g7
I35
sg8
g49
sg10
I5
sg11
VSTAG2
p187
sg13
I1
sasg14
(lp188
(dp189
g7
I114
sg17
VC0859917
p190
sg10
I23
sg11
Vinvasive bladder cancer
p191
sg13
I3
sasa(dp192
g2
S'Loss of expression was often observed in chromosomally stable tumors, and STAG2 knockdown in bladder cancer cells did not increase aneuploidy.\n'
p193
sg4
(lp194
(dp195
g7
I74
sg8
g49
sg10
I5
sg11
VSTAG2
p196
sg13
I1
sasg14
(lp197
(dp198
g7
I62
sg17
VC0027651
p199
sg10
I6
sg11
Vtumors
p200
sg13
I1
sa(dp201
g7
I93
sg17
VC0699885
p202
sg10
I14
sg11
Vbladder cancer
p203
sg13
I2
sa(dp204
g7
I131
sg17
VC0002938
p205
sg10
I10
sg11
Vaneuploidy
p206
sg13
I1
sasa(dp207
g2
S'Our studies suggest that STAG2 has a role in controlling chromosome number but not the proliferation of bladder cancer cells.\n'
p208
sg4
(lp209
(dp210
g7
I25
sg8
g49
sg10
I5
sg11
VSTAG2
p211
sg13
I1
sasg14
(lp212
(dp213
g7
I87
sg17
VC0334094
p214
sg10
I13
sg11
Vproliferation
p215
sg13
I1
sa(dp216
g7
I104
sg17
VC0699885
p217
sg10
I14
sg11
Vbladder cancer
p218
sg13
I2
sasa(dp219
g2
S'These findings identify STAG2 as one of the most commonly mutated genes in bladder cancer.\n'
p220
sg4
(lp221
(dp222
g7
I24
sg8
g49
sg10
I5
sg11
VSTAG2
p223
sg13
I1
sasg14
(lp224
(dp225
g7
I75
sg17
VC0699885
p226
sg10
I14
sg11
Vbladder cancer
p227
sg13
I2
sasa(dp228
g2
S'To analyze the cellular antigens of human B-cell lineage, a monoclonal antibody, NU-B1, was raised using the acute lymphoblastic leukemia (ALL) cell line NALM-16 as the immunogen.\n'
p229
sg4
(lp230
sg14
(lp231
(dp232
g7
I109
sg17
VC1961102
p233
sg10
I28
sg11
Vacute lymphoblastic leukemia
p234
sg13
I3
sa(dp235
g7
I139
sg17
VC1961102
p236
sg10
I3
sg11
VALL
p237
sg13
I1
sasa(dp238
g2
S'In a clinical study, NU-B1 reacted specifically with leukemias/lymphomas of B-cell lineage: all 43 cases of ALL including common ALL and biphenotypic leukemia, all 4 cases of B-cell ALL, 6/7 B-cell type malignant lymphomas and 2/4 B-cell chronic lymphocytic leukemias.\n'
p239
sg4
(lp240
sg14
(lp241
(dp242
g7
I238
sg17
VC0023434
p243
sg10
I29
sg11
Vchronic lymphocytic leukemias
p244
sg13
I3
sa(dp245
g7
I122
sg17
VC1292769
p246
sg10
I10
sg11
Vcommon ALL
p247
sg13
I2
sa(dp248
g7
I63
sg17
VC0024299
p249
sg10
I9
sg11
Vlymphomas
p250
sg13
I1
sa(dp251
g7
I203
sg17
VC0024299
p252
sg10
I19
sg11
Vmalignant lymphomas
p253
sg13
I2
sa(dp254
g7
I53
sg17
VC0023418
p255
sg10
I9
sg11
Vleukemias
p256
sg13
I1
sa(dp257
g7
I53
sg17
VC0023418
p258
sg10
I8
sg11
Vleukemia
p259
sg13
I1
sasa(dp260
g2
S'As Imeglimin did show a full prevention of Beta-cell apoptosis, and since angiopathy represents a major complication of diabetes, we studied Imeglimin protective effects on hyperglycemia-induced death of human endothelial cells (HMEC-1).\n'
p261
sg4
(lp262
sg14
(lp263
(dp264
g7
I120
sg17
VC0011849
p265
sg10
I8
sg11
Vdiabetes
p266
sg13
I1
sa(dp267
g7
I173
sg17
VC0020456
p268
sg10
I13
sg11
Vhyperglycemia
p269
sg13
I1
sa(dp270
g7
I74
sg17
VC0042373
p271
sg10
I10
sg11
Vangiopathy
p272
sg13
I1
sa(dp273
g7
I104
sg17
VC0009566
p274
sg10
I12
sg11
Vcomplication
p275
sg13
I1
sasa(dp276
g2
S'We conclude that Imeglimin prevents hyperglycemia-induced cell death in HMEC-1 through inhibition of PTP opening without inhibiting mitochondrial respiration nor affecting cellular energy status.\n'
p277
sg4
(lp278
(dp279
g7
I101
sg8
g49
sg10
I3
sg11
VPTP
p280
sg13
I1
sasg14
(lp281
(dp282
g7
I36
sg17
VC0020456
p283
sg10
I13
sg11
Vhyperglycemia
p284
sg13
I1
sa(dp285
g7
I101
sg17
VC0398648
p286
sg10
I3
sg11
VPTP
p287
sg13
I1
sasa(dp288
g2
S'Simulating the presence of hyperglycemia, hypercholesterolemia and hypertension, this in vitro study investigated the effect of glucose, angiotensin II, and nLDL treatments on IL-6, ET-1 and NO in HMEC-1.\n'
p289
sg4
(lp290
(dp291
g7
I176
sg8
VP05231
p292
sg10
I4
sg11
VIL-6
p293
sg13
I1
sa(dp294
g7
I182
sg8
VP05305
p295
sg10
I4
sg11
VET-1
p296
sg13
I1
sa(dp297
g7
I137
sg8
VP01019
p298
sg10
I14
sg11
Vangiotensin II
p299
sg13
I2
sasg14
(lp300
(dp301
g7
I27
sg17
VC0020456
p302
sg10
I13
sg11
Vhyperglycemia
p303
sg13
I1
sa(dp304
g7
I67
sg17
VC0020538
p305
sg10
I12
sg11
Vhypertension
p306
sg13
I1
sa(dp307
g7
I42
sg17
VC0020443
p308
sg10
I20
sg11
Vhypercholesterolemia
p309
sg13
I1
sasa(dp310
g2
S'HMEC-1 cells (a human microvascular endothelial cell line) were exposed to control (5 mM), 30 mM (high), fluctuating (5/30 mM) and 11.2 mM glucose (approximate glycaemic criteria for the diagnosis of diabetes mellitus) for 72 h. Cells were assessed for TLR2, 4, high mobility group box -1 (HMGB1), NF-KB, monocyte chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1).\n'
p311
sg4
(lp312
(dp313
g7
I406
sg8
VP05362
p314
sg10
I6
sg11
VICAM-1
p315
sg13
I1
sa(dp316
g7
I349
sg8
VP60568
p317
sg10
I13
sg11
Vinterleukin-8
p318
sg13
I1
sa(dp319
g7
I253
sg8
g49
sg10
I35
sg11
VTLR2, 4, high mobility group box -1
p320
sg13
I7
sa(dp321
g7
I341
sg8
VP41597
p322
sg10
I5
sg11
VMCP-1
p323
sg13
I1
sa(dp324
g7
I371
sg8
VP05362
p325
sg10
I33
sg11
Vintercellular adhesion molecule-1
p326
sg13
I3
sa(dp327
g7
I364
sg8
VP60568
p328
sg10
I4
sg11
VIL-8
p329
sg13
I1
sa(dp330
g7
I290
sg8
VP09429
p331
sg10
I5
sg11
VHMGB1
p332
sg13
I1
sa(dp333
g7
I453
sg8
VP19320
p334
sg10
I6
sg11
VVCAM-1
p335
sg13
I1
sa(dp336
g7
I418
sg8
VP19320
p337
sg10
I33
sg11
Vvascular cell adhesion molecule-1
p338
sg13
I4
sa(dp339
g7
I298
sg8
VP13500
p340
sg10
I41
sg11
VNF-KB, monocyte chemoattractant protein-1
p341
sg13
I4
sasg14
(lp342
(dp343
g7
I200
sg17
VC0011849
p344
sg10
I17
sg11
Vdiabetes mellitus
p345
sg13
I2
sa(dp346
g7
I385
sg17
VC0001511
p347
sg10
I8
sg11
Vadhesion
p348
sg13
I1
sa(dp349
g7
I385
sg17
VC0001511
p350
sg10
I8
sg11
Vadhesion
p351
sg13
I1
sasa(dp352
g2
S'In an exploratory pilot study; blood and ascitic fluid from 34 patients with liver cirrhosis of different etiology were analyzed for pattern recognition molecules (ficolin-1, ficolin-2, ficolin-3 and MBL) and complement proteins (C4 and C3).\n'
p353
sg4
(lp354
(dp355
g7
I175
sg8
g49
sg10
I9
sg11
Vficolin-2
p356
sg13
I1
sa(dp357
g7
I164
sg8
g49
sg10
I9
sg11
Vficolin-1
p358
sg13
I1
sa(dp359
g7
I209
sg8
g49
sg10
I19
sg11
Vcomplement proteins
p360
sg13
I2
sa(dp361
g7
I200
sg8
VP11226
p362
sg10
I3
sg11
VMBL
p363
sg13
I1
sa(dp364
g7
I133
sg8
g49
sg10
I29
sg11
Vpattern recognition molecules
p365
sg13
I3
sa(dp366
g7
I186
sg8
g49
sg10
I9
sg11
Vficolin-3
p367
sg13
I1
sasg14
(lp368
(dp369
g7
I77
sg17
VC0023890
p370
sg10
I15
sg11
Vliver cirrhosis
p371
sg13
I2
sasa(dp372
g2
S'Ficolin-1, ficolin-2, MBL, C4 and C3 in ascitic fluid and ficolin-1, C4 and C3 in blood were significantly (p = .001-.027) lower in patients with Child-Pugh stage C (n = 16, 47%) compared to Child-Pugh stage B cirrhosis (n = 18, 53%).\n'
p373
sg4
(lp374
(dp375
g7
I58
sg8
g49
sg10
I9
sg11
Vficolin-1
p376
sg13
I1
sa(dp377
g7
I11
sg8
g49
sg10
I9
sg11
Vficolin-2
p378
sg13
I1
sa(dp379
g7
I22
sg8
VP11226
p380
sg10
I3
sg11
VMBL
p381
sg13
I1
sa(dp382
g7
I0
sg8
g49
sg10
I9
sg11
VFicolin-1
p383
sg13
I1
sasg14
(lp384
(dp385
g7
I210
sg17
VC0023890
p386
sg10
I9
sg11
Vcirrhosis
p387
sg13
I1
sasa(dp388
g2
S'Low C4 and C3 in serum and C3 and ficolin-1 in ascitic fluid are risk factors for all-cause mortality or liver transplantation independently of liver function in patients with cirrhosis and ascites.\n'
p389
sg4
(lp390
(dp391
g7
I34
sg8
g49
sg10
I9
sg11
Vficolin-1
p392
sg13
I1
sasg14
(lp393
(dp394
g7
I176
sg17
VC0023890
p395
sg10
I9
sg11
Vcirrhosis
p396
sg13
I1
sasa(dp397
g2
S'The purpose of current study was to determine the association of three complement activators, namely Pentraxin-3 (PTX3),M-ficolin, and Surfactant protein A (SPA) with the severity of ischemic stroke.\n'
p398
sg4
(lp399
(dp400
g7
I157
sg8
g49
sg10
I3
sg11
VSPA
p401
sg13
I1
sa(dp402
g7
I114
sg8
VP26022
p403
sg10
I4
sg11
VPTX3
p404
sg13
I1
sa(dp405
g7
I120
sg8
g49
sg10
I9
sg11
VM-ficolin
p406
sg13
I1
sa(dp407
g7
I71
sg8
g49
sg10
I41
sg11
Vcomplement activators, namely Pentraxin-3
p408
sg13
I4
sa(dp409
g7
I135
sg8
VP02810
p410
sg10
I20
sg11
VSurfactant protein A
p411
sg13
I3
sasg14
(lp412
(dp413
g7
I183
sg17
VC3272363
p414
sg10
I15
sg11
Vischemic stroke
p415
sg13
I2
sasa(dp416
g2
S'The correlation of serum level of PTX3, M-ficolin, and SPA with stroke severity was 0.732, 0.736, and 0.731, respectively.\n'
p417
sg4
(lp418
(dp419
g7
I34
sg8
VP26022
p420
sg10
I4
sg11
VPTX3
p421
sg13
I1
sa(dp422
g7
I40
sg8
g49
sg10
I9
sg11
VM-ficolin
p423
sg13
I1
sasg14
(lp424
(dp425
g7
I64
sg17
VC0038454
p426
sg10
I6
sg11
Vstroke
p427
sg13
I1
sasa(dp428
g2
S'There is a strong association between serum levels of PTX3, M-ficolin, and SPA with the severity of ischemic stroke.\n'
p429
sg4
(lp430
(dp431
g7
I54
sg8
VP26022
p432
sg10
I4
sg11
VPTX3
p433
sg13
I1
sa(dp434
g7
I60
sg8
g49
sg10
I9
sg11
VM-ficolin
p435
sg13
I1
sasg14
(lp436
(dp437
g7
I100
sg17
VC3272363
p438
sg10
I15
sg11
Vischemic stroke
p439
sg13
I2
sasa(dp440
g2
S'Various immunological and inflammatory biomarkers have been associated with cancer, including soluble urokinase plasminogen activator receptor (suPAR) and the pattern recognition receptors (PRRs) pentraxin-3, mannose-binding lectin, ficolin-1, ficolin-2 and ficolin-3.\n'
p441
sg4
(lp442
(dp443
g7
I94
sg8
VP00747
p444
sg10
I48
sg11
Vsoluble urokinase plasminogen activator receptor
p445
sg13
I5
sa(dp446
g7
I209
sg8
VP11226
p447
sg10
I22
sg11
Vmannose-binding lectin
p448
sg13
I2
sa(dp449
g7
I233
sg8
g49
sg10
I9
sg11
Vficolin-1
p450
sg13
I1
sa(dp451
g7
I244
sg8
g49
sg10
I9
sg11
Vficolin-2
p452
sg13
I1
sa(dp453
g7
I144
sg8
VP00747
p454
sg10
I5
sg11
VsuPAR
p455
sg13
I1
sa(dp456
g7
I258
sg8
g49
sg10
I9
sg11
Vficolin-3
p457
sg13
I1
sasg14
(lp458
(dp459
g7
I159
sg17
VC0376538
p460
sg10
I29
sg11
Vpattern recognition receptors
p461
sg13
I3
sa(dp462
g7
I190
sg17
VC0376538
p463
sg10
I4
sg11
VPRRs
p464
sg13
I1
sa(dp465
g7
I76
sg17
VC0006826
p466
sg10
I6
sg11
Vcancer
p467
sg13
I1
sasa(dp468
g2
S'Ficolin-1-3, MBL and pentraxin-3 were not associated with cancer.\n'
p469
sg4
(lp470
(dp471
g7
I21
sg8
VP26022
p472
sg10
I11
sg11
Vpentraxin-3
p473
sg13
I1
sa(dp474
g7
I0
sg8
g49
sg10
I11
sg11
VFicolin-1-3
p475
sg13
I1
sa(dp476
g7
I13
sg8
VP11226
p477
sg10
I3
sg11
VMBL
p478
sg13
I1
sasg14
(lp479
(dp480
g7
I58
sg17
VC0006826
p481
sg10
I6
sg11
Vcancer
p482
sg13
I1
sasa(dp483
g2
S'Symptomatic patients experiencing a transient ischemic attack had lower plasma levels of ficolin-1.\n'
p484
sg4
(lp485
(dp486
g7
I89
sg8
g49
sg10
I9
sg11
Vficolin-1
p487
sg13
I1
sasg14
(lp488
(dp489
g7
I36
sg17
VC0007787
p490
sg10
I25
sg11
Vtransient ischemic attack
p491
sg13
I3
sasa(dp492
g2
S'Among the genes in the turquoise module, COL5A2 (collagen, type V, alpha 2) could be regulated by PBX (pre-B-cell leukemia homeobox 1)1/2 and HOXB1(homeobox B1) transcription factors to be involved in the focal adhesion pathway; CENP-E (centromere protein E, 312kDa) by E2F4 (E2F transcription factor 4, p107/p130-binding); MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived [avian]) by PAX5 (paired box 5); and BCL-2 (B-cell CLL/ lymphoma 2) and IGFBP-6 (insulin-like growth factor binding protein 6) by GLI1.\n'
p493
sg4
(lp494
(dp495
g7
I529
sg8
VP08151
p496
sg10
I4
sg11
VGLI1
p497
sg13
I1
sa(dp498
g7
I237
sg8
g49
sg10
I20
sg11
Vcentromere protein E
p499
sg13
I3
sa(dp500
g7
I229
sg8
g49
sg10
I6
sg11
VCENP-E
p501
sg13
I1
sa(dp502
g7
I411
sg8
g49
sg10
I4
sg11
VPAX5
p503
sg13
I1
sa(dp504
g7
I142
sg8
VP14653
p505
sg10
I5
sg11
VHOXB1
p506
sg13
I1
sa(dp507
g7
I276
sg8
VP15884
p508
sg10
I26
sg11
VE2F transcription factor 4
p509
sg13
I4
sa(dp510
g7
I471
sg8
VP24592
p511
sg10
I7
sg11
VIGFBP-6
p512
sg13
I1
sa(dp513
g7
I330
sg8
VP12524
p514
sg10
I5
sg11
Vv-myc
p515
sg13
I1
sa(dp516
g7
I480
sg8
VP01308
p517
sg10
I44
sg11
Vinsulin-like growth factor binding protein 6
p518
sg13
I6
sa(dp519
g7
I304
sg8
VP28749
p520
sg10
I4
sg11
Vp107
p521
sg13
I1
sa(dp522
g7
I336
sg8
VP35125
p523
sg10
I39
sg11
Vmyelocytomatosis viral related oncogene
p524
sg13
I4
sa(dp525
g7
I324
sg8
VP04198
p526
sg10
I4
sg11
VMYCN
p527
sg13
I1
sa(dp528
g7
I270
sg8
g49
sg10
I4
sg11
VE2F4
p529
sg13
I1
sa(dp530
g7
I309
sg8
g49
sg10
I4
sg11
Vp130
p531
sg13
I1
sa(dp532
g7
I417
sg8
g49
sg10
I12
sg11
Vpaired box 5
p533
sg13
I3
sasg14
(lp534
(dp535
g7
I455
sg17
VC0024299
p536
sg10
I8
sg11
Vlymphoma
p537
sg13
I1
sa(dp538
g7
I211
sg17
VC0001511
p539
sg10
I8
sg11
Vadhesion
p540
sg13
I1
sa(dp541
g7
I103
sg17
VC0023485
p542
sg10
I19
sg11
Vpre-B-cell leukemia
p543
sg13
I2
sa(dp544
g7
I377
sg17
VC0027819
p545
sg10
I13
sg11
Vneuroblastoma
p546
sg13
I1
sa(dp547
g7
I443
sg17
VC0023434
p548
sg10
I10
sg11
VB-cell CLL
p549
sg13
I2
sasa(dp550
g2
S"The PAX5 gene is involved in medulloblastoma, non-Hodgkin's lymphoma, transitional cell carcinoma of the bladder, neuroblastoma, breast cancer and SCC.\n"
p551
sg4
(lp552
(dp553
g7
I4
sg8
g49
sg10
I9
sg11
VPAX5 gene
p554
sg13
I2
sasg14
(lp555
(dp556
g7
I46
sg17
VC0024305
p557
sg10
I22
sg11
Vnon-Hodgkin's lymphoma
p558
sg13
I2
sa(dp559
g7
I114
sg17
VC0027819
p560
sg10
I13
sg11
Vneuroblastoma
p561
sg13
I1
sa(dp562
g7
I129
sg17
VC0678222
p563
sg10
I13
sg11
Vbreast cancer
p564
sg13
I2
sa(dp565
g7
I29
sg17
VC0025149
p566
sg10
I15
sg11
Vmedulloblastoma
p567
sg13
I1
sa(dp568
g7
I70
sg17
VC0279680
p569
sg10
I42
sg11
Vtransitional cell carcinoma of the bladder
p570
sg13
I6
sasa(dp571
g2
S"Screening of neuroblastoma cell lines revealed PAX5 expression in a malignant subset of neuroblastoma cells, so-called 'N-type' cells, but not in the more benign 'S-type' neuroblastoma cells.\n"
p572
sg4
(lp573
(dp574
g7
I47
sg8
g49
sg10
I4
sg11
VPAX5
p575
sg13
I1
sasg14
(lp576
(dp577
g7
I13
sg17
VC0027819
p578
sg10
I13
sg11
Vneuroblastoma
p579
sg13
I1
sa(dp580
g7
I13
sg17
VC0027819
p581
sg10
I13
sg11
Vneuroblastoma
p582
sg13
I1
sa(dp583
g7
I13
sg17
VC0027819
p584
sg10
I13
sg11
Vneuroblastoma
p585
sg13
I1
sasa(dp586
g2
S'Taken together we propose PAX5 as an important factor for the maintenance of the proliferative and tumorigenic phenotype of neuroblastoma.\n'
p587
sg4
(lp588
(dp589
g7
I26
sg8
g49
sg10
I4
sg11
VPAX5
p590
sg13
I1
sasg14
(lp591
(dp592
g7
I124
sg17
VC0027819
p593
sg10
I13
sg11
Vneuroblastoma
p594
sg13
I1
sa(dp595
g7
I81
sg17
VC0334094
p596
sg10
I13
sg11
Vproliferative
p597
sg13
I1
sasa(dp598
g2
S'Pancreatitis and adverse events consistent with sphincter of Oddi spasm were uncommon.\n'
p599
sg4
(lp600
sg14
(lp601
(dp602
g7
I0
sg17
VC0030305
p603
sg10
I12
sg11
VPancreatitis
p604
sg13
I1
sa(dp605
g7
I48
sg17
VC0152168
p606
sg10
I23
sg11
Vsphincter of Oddi spasm
p607
sg13
I4
sasa(dp608
g2
S"Expert commentary: The efficacy and safety of eluxadoline in treating bowel habit alterations and pain, both in the short and long-term, make the drug a welcome addition to our therapeutic alternatives in IBS-D. Its positioning in any IBS algorithm will depend on the 'real world' prevalence of the small risk of sphincter of Oddi spasm and mild pancreatitis.\n"
p609
sg4
(lp610
sg14
(lp611
(dp612
g7
I205
sg17
VC0022104
p613
sg10
I3
sg11
VIBS
p614
sg13
I1
sa(dp615
g7
I346
sg17
VC0030305
p616
sg10
I12
sg11
Vpancreatitis
p617
sg13
I1
sa(dp618
g7
I205
sg17
VC0022104
p619
sg10
I3
sg11
VIBS
p620
sg13
I1
sa(dp621
g7
I313
sg17
VC0152168
p622
sg10
I23
sg11
Vsphincter of Oddi spasm
p623
sg13
I4
sasa(dp624
g2
S'It is caused by vasospasm, but the mechanism of spasm is unknown but has been linked with hyperthyroidism in some studies.\n'
p625
sg4
(lp626
sg14
(lp627
(dp628
g7
I16
sg17
VC0085616
p629
sg10
I9
sg11
Vvasospasm
p630
sg13
I1
sa(dp631
g7
I20
sg17
VC0037763
p632
sg10
I5
sg11
Vspasm
p633
sg13
I1
sa(dp634
g7
I90
sg17
VC0020550
p635
sg10
I15
sg11
Vhyperthyroidism
p636
sg13
I1
sasa(dp637
g2
S'Overall, the prognosis for hyperthyroidism-associated coronary vasospasm is good.\n'
p638
sg4
(lp639
sg14
(lp640
(dp641
g7
I54
sg17
VC0010073
p642
sg10
I18
sg11
Vcoronary vasospasm
p643
sg13
I2
sa(dp644
g7
I27
sg17
VC0020550
p645
sg10
I15
sg11
Vhyperthyroidism
p646
sg13
I1
sasa(dp647
g2
S'We describe a very rare case of an acute myocardial infarction in a 27-year-old female, at 9 weeks of gestation due to right coronary artery spasm secondary to gestational hyperthyroidism with free thyroxine of 7.7 ng/dL and TSH &lt;0.07 IU/L.\n'
p648
sg4
(lp649
(dp650
g7
I225
sg8
VP01222
p651
sg10
I3
sg11
VTSH
p652
sg13
I1
sasg14
(lp653
(dp654
g7
I172
sg17
VC0020550
p655
sg10
I15
sg11
Vhyperthyroidism
p656
sg13
I1
sa(dp657
g7
I35
sg17
VC0155626
p658
sg10
I27
sg11
Vacute myocardial infarction
p659
sg13
I3
sa(dp660
g7
I125
sg17
VC0010073
p661
sg10
I21
sg11
Vcoronary artery spasm
p662
sg13
I3
sasa(dp663
g2
S'Adrenal haemorrhage is a rare cause of hypoadrenalism, and thus requires prompt diagnosis and management to prevent death from primary adrenocortical insufficiency.Mechanisms of adrenal haemorrhage include reduced adrenal vascular bed capillary resistance, adrenal vein thrombosis, catecholamine-related increased adrenal blood flow and adrenal vein spasm.Standard diagnostic assessment is a non-contrast CT abdomen.Intravenous hydrocortisone and intravenous substitution of fluids are the initial management.A formal diagnosis of primary adrenal insufficiency should never delay treatment, but should be made afterwards.\n'
p664
sg4
(lp665
sg14
(lp666
(dp667
g7
I178
sg17
VC0151693
p668
sg10
I19
sg11
Vadrenal haemorrhage
p669
sg13
I2
sa(dp670
g7
I39
sg17
VC0001623
p671
sg10
I14
sg11
Vhypoadrenalism
p672
sg13
I1
sa(dp673
g7
I127
sg17
VC0001403
p674
sg10
I36
sg11
Vprimary adrenocortical insufficiency
p675
sg13
I3
sa(dp676
g7
I531
sg17
VC0001403
p677
sg10
I29
sg11
Vprimary adrenal insufficiency
p678
sg13
I3
sa(dp679
g7
I0
sg17
VC0151693
p680
sg10
I19
sg11
VAdrenal haemorrhage
p681
sg13
I2
sa(dp682
g7
I265
sg17
VC0042487
p683
sg10
I15
sg11
Vvein thrombosis
p684
sg13
I2
sa(dp685
g7
I350
sg17
VC0037763
p686
sg10
I5
sg11
Vspasm
p687
sg13
I1
sa(dp688
g7
I231
sg17
VC3159311
p689
sg10
I3
sg11
Vbed
p690
sg13
I1
sasa(dp691
g2
S'Results: The predominant features of the hypoparathyroidism were carpopedal spasm (89.3%, 108/121) and seizures (66.1%, 84/127).\n'
p692
sg4
(lp693
sg14
(lp694
(dp695
g7
I41
sg17
VC0020626
p696
sg10
I18
sg11
Vhypoparathyroidism
p697
sg13
I1
sa(dp698
g7
I103
sg17
VC0036572
p699
sg10
I8
sg11
Vseizures
p700
sg13
I1
sa(dp701
g7
I65
sg17
VC0231785
p702
sg10
I16
sg11
Vcarpopedal spasm
p703
sg13
I2
sasa(dp704
g2
S'Conclusions: Carpopedal spasm and seizures were the main manifestations of childhood- and adolescent- onset hypoparathyroidism.\n'
p705
sg4
(lp706
sg14
(lp707
(dp708
g7
I13
sg17
VC0231785
p709
sg10
I16
sg11
VCarpopedal spasm
p710
sg13
I2
sa(dp711
g7
I34
sg17
VC0036572
p712
sg10
I8
sg11
Vseizures
p713
sg13
I1
sa(dp714
g7
I108
sg17
VC0020626
p715
sg10
I18
sg11
Vhypoparathyroidism
p716
sg13
I1
sasa(dp717
g2
S'Eluxadoline was associated with increased occurrence of sphincter of Oddi spasm and biliary pancreatitis.\n'
p718
sg4
(lp719
sg14
(lp720
(dp721
g7
I56
sg17
VC0152168
p722
sg10
I23
sg11
Vsphincter of Oddi spasm
p723
sg13
I4
sa(dp724
g7
I84
sg17
VC0747195
p725
sg10
I20
sg11
Vbiliary pancreatitis
p726
sg13
I2
sasa(dp727
g2
S'In this single-centre prospective study, blood samples for analysis of CTCs were obtained from 102 patients with Stage I-IIIA NSCLC both before (CTC1) and 1 month after (CTC2) radical resection.\n'
p728
sg4
(lp729
sg14
(lp730
(dp731
g7
I126
sg17
VC0007131
p732
sg10
I5
sg11
VNSCLC
p733
sg13
I1
sasa(dp734
g2
S'Recent studies have shown that the human CTC1/STN1/TEN1 complex (CST) plays a multi-faceted role in telomere maintenance in telomerase-expressing cancer cells.\n'
p735
sg4
(lp736
(dp737
g7
I35
sg8
g49
sg10
I10
sg11
Vhuman CTC1
p738
sg13
I2
sa(dp739
g7
I51
sg8
g49
sg10
I4
sg11
VTEN1
p740
sg13
I1
sa(dp741
g7
I46
sg8
VP16949
p742
sg10
I4
sg11
VSTN1
p743
sg13
I1
sasg14
(lp744
(dp745
g7
I146
sg17
VC0006826
p746
sg10
I6
sg11
Vcancer
p747
sg13
I1
sasa(dp748
g2
S'Using case-control comparisons, we analyzed eight single nucleotide polymorphisms (SNPs) in genes definitively associated with interindividual variation in leukocyte telomere length (LTL) in prior genome-wide association studies: ACYP2, TERC, NAF1, TERT, OBFC1, CTC1, ZNF208 and RTEL1 Six of these SNPs were associated (P &lt; 0.05) with neuroblastoma risk, one with leukemia risk and one with osteosarcoma risk.\n'
p749
sg4
(lp750
(dp751
g7
I249
sg8
g49
sg10
I4
sg11
VTERT
p752
sg13
I1
sa(dp753
g7
I230
sg8
VP14621
p754
sg10
I5
sg11
VACYP2
p755
sg13
I1
sa(dp756
g7
I255
sg8
g49
sg10
I5
sg11
VOBFC1
p757
sg13
I1
sa(dp758
g7
I262
sg8
g49
sg10
I4
sg11
VCTC1
p759
sg13
I1
sa(dp760
g7
I243
sg8
g49
sg10
I4
sg11
VNAF1
p761
sg13
I1
sa(dp762
g7
I268
sg8
g49
sg10
I6
sg11
VZNF208
p763
sg13
I1
sa(dp764
g7
I279
sg8
g49
sg10
I9
sg11
VRTEL1 Six
p765
sg13
I2
sasg14
(lp766
(dp767
g7
I338
sg17
VC0027819
p768
sg10
I13
sg11
Vneuroblastoma
p769
sg13
I1
sa(dp770
g7
I367
sg17
VC0023418
p771
sg10
I8
sg11
Vleukemia
p772
sg13
I1
sa(dp773
g7
I394
sg17
VC0029463
p774
sg10
I12
sg11
Vosteosarcoma
p775
sg13
I1
sasa(dp776
g2
S'In search of the gene for progressive epilepsy with mental retardation (EPMR) we identified DLGAP2, the human homolog of the gene encoding the rat PSD-95/SAP90-associated protein-2 (Dlgap2).\n'
p777
sg4
(lp778
(dp779
g7
I92
sg8
g49
sg10
I6
sg11
VDLGAP2
p780
sg13
I1
sa(dp781
g7
I182
sg8
g49
sg10
I6
sg11
VDlgap2
p782
sg13
I1
sa(dp783
g7
I154
sg8
VP78352
p784
sg10
I26
sg11
VSAP90-associated protein-2
p785
sg13
I2
sa(dp786
g7
I143
sg8
VP78352
p787
sg10
I10
sg11
Vrat PSD-95
p788
sg13
I2
sasg14
(lp789
(dp790
g7
I38
sg17
VC1864923
p791
sg10
I32
sg11
Vepilepsy with mental retardation
p792
sg13
I4
sa(dp793
g7
I72
sg17
VC1864923
p794
sg10
I4
sg11
VEPMR
p795
sg13
I1
sasa(dp796
g2
S'DLGAP2 was excluded as the gene responsible for EPMR.\n'
p797
sg4
(lp798
(dp799
g7
I0
sg8
g49
sg10
I6
sg11
VDLGAP2
p800
sg13
I1
sasg14
(lp801
(dp802
g7
I48
sg17
VC1864923
p803
sg10
I4
sg11
VEPMR
p804
sg13
I1
sasa(dp805
g2
S'PERP (p53 apoptosis effector related to PMP-22), a transcriptional target of p53, is downregulated and contributes to the impairment of apoptosis in uveal melanoma (UM).\n'
p806
sg4
(lp807
(dp808
g7
I6
sg8
g49
sg10
I40
sg11
Vp53 apoptosis effector related to PMP-22
p809
sg13
I6
sa(dp810
g7
I6
sg8
VP42771
p811
sg10
I3
sg11
Vp53
p812
sg13
I1
sa(dp813
g7
I0
sg8
g49
sg10
I4
sg11
VPERP
p814
sg13
I1
sasg14
(lp815
(dp816
g7
I165
sg17
VC0220633
p817
sg10
I2
sg11
VUM
p818
sg13
I1
sa(dp819
g7
I122
sg17
VC0684336
p820
sg10
I10
sg11
Vimpairment
p821
sg13
I1
sa(dp822
g7
I149
sg17
VC0220633
p823
sg10
I14
sg11
Vuveal melanoma
p824
sg13
I2
sasa(dp825
g2
S'Downregulation of PERP is associated with the aggressive, monosomy 3-type of uveal melanoma (UM), the most common primary intraocular tumour in adults, and increased PERP expression has a pro-apoptotic effect in UM cells.\n'
p826
sg4
(lp827
(dp828
g7
I18
sg8
g49
sg10
I4
sg11
VPERP
p829
sg13
I1
sa(dp830
g7
I18
sg8
g49
sg10
I4
sg11
VPERP
p831
sg13
I1
sasg14
(lp832
(dp833
g7
I58
sg17
VC1709071
p834
sg10
I10
sg11
Vmonosomy 3
p835
sg13
I2
sa(dp836
g7
I93
sg17
VC0220633
p837
sg10
I2
sg11
VUM
p838
sg13
I1
sa(dp839
g7
I46
sg17
VC0001807
p840
sg10
I10
sg11
Vaggressive
p841
sg13
I1
sa(dp842
g7
I134
sg17
VC0027651
p843
sg10
I6
sg11
Vtumour
p844
sg13
I1
sa(dp845
g7
I93
sg17
VC0220633
p846
sg10
I2
sg11
VUM
p847
sg13
I1
sa(dp848
g7
I77
sg17
VC0220633
p849
sg10
I14
sg11
Vuveal melanoma
p850
sg13
I2
sasa(dp851
g2
S'In primary uveal melanoma (UM), the most common intraocular malignancy in adults that has a reportedly unaffected signalling pathway upstream of and including p53, PERP expression is down-regulated in the metastatic monosomy 3-type tumours, compared with the less aggressive disomy 3-type tumours.\n'
p852
sg4
(lp853
(dp854
g7
I164
sg8
g49
sg10
I4
sg11
VPERP
p855
sg13
I1
sa(dp856
g7
I159
sg8
VP42771
p857
sg10
I3
sg11
Vp53
p858
sg13
I1
sa(dp859
g7
I205
sg8
VP41162
p860
sg10
I26
sg11
Vmetastatic monosomy 3-type
p861
sg13
I3
sasg14
(lp862
(dp863
g7
I264
sg17
VC0001807
p864
sg10
I10
sg11
Vaggressive
p865
sg13
I1
sa(dp866
g7
I216
sg17
VC1709071
p867
sg10
I10
sg11
Vmonosomy 3
p868
sg13
I2
sa(dp869
g7
I11
sg17
VC0220633
p870
sg10
I14
sg11
Vuveal melanoma
p871
sg13
I2
sa(dp872
g7
I232
sg17
VC0027651
p873
sg10
I7
sg11
Vtumours
p874
sg13
I1
sa(dp875
g7
I27
sg17
VC0220633
p876
sg10
I2
sg11
VUM
p877
sg13
I1
sa(dp878
g7
I232
sg17
VC0027651
p879
sg10
I7
sg11
Vtumours
p880
sg13
I1
sa(dp881
g7
I60
sg17
VC0006826
p882
sg10
I10
sg11
Vmalignancy
p883
sg13
I1
sasa(dp884
g2
S'Expression of PERP (p53 apoptosis effector related to PMP-22) was investigated in primary uveal melanomas and its variation was analyzed in relation to clinico-pathological and cytogenetical characteristics of these tumors.\n'
p885
sg4
(lp886
(dp887
g7
I20
sg8
g49
sg10
I40
sg11
Vp53 apoptosis effector related to PMP-22
p888
sg13
I6
sa(dp889
g7
I14
sg8
g49
sg10
I4
sg11
VPERP
p890
sg13
I1
sasg14
(lp891
(dp892
g7
I216
sg17
VC0027651
p893
sg10
I6
sg11
Vtumors
p894
sg13
I1
sa(dp895
g7
I96
sg17
VC0025202
p896
sg10
I9
sg11
Vmelanomas
p897
sg13
I1
sasa(dp898
g2
S'The transcriptional level of PERP gene was measured by quantitative real-time RT-PCR in 26 uveal melanomas with known chromosomes 3 and 8 status.\n'
p899
sg4
(lp900
(dp901
g7
I29
sg8
g49
sg10
I9
sg11
VPERP gene
p902
sg13
I2
sasg14
(lp903
(dp904
g7
I97
sg17
VC0025202
p905
sg10
I9
sg11
Vmelanomas
p906
sg13
I1
sasa(dp907
g2
S'The altered expression of PERP highlighted this apoptosis-specific target of p53 as a possible contributor to apoptosis in uveal melanoma with PERP downregulation being particularly relevant to the aggressive (monosomy 3) type of uveal melanoma.\n'
p908
sg4
(lp909
(dp910
g7
I26
sg8
g49
sg10
I4
sg11
VPERP
p911
sg13
I1
sa(dp912
g7
I77
sg8
VP42771
p913
sg10
I3
sg11
Vp53
p914
sg13
I1
sasg14
(lp915
(dp916
g7
I123
sg17
VC0220633
p917
sg10
I14
sg11
Vuveal melanoma
p918
sg13
I2
sa(dp919
g7
I198
sg17
VC0001807
p920
sg10
I10
sg11
Vaggressive
p921
sg13
I1
sa(dp922
g7
I123
sg17
VC0220633
p923
sg10
I14
sg11
Vuveal melanoma
p924
sg13
I2
sa(dp925
g7
I210
sg17
VC1709071
p926
sg10
I10
sg11
Vmonosomy 3
p927
sg13
I2
sasa(dp928
g2
S'As PERP is a novel type of p53 effector that is likely to stimulate apoptosis through a mechanism distinct from that of Bcl-2-related mitochondrial effectors, further elucidation of its role in uveal melanoma pathogenesis will assist in the design of novel therapeutic approaches aimed at increasing the rate of apoptosis in this tumor.\n'
p929
sg4
(lp930
(dp931
g7
I120
sg8
VP10415
p932
sg10
I5
sg11
VBcl-2
p933
sg13
I1
sa(dp934
g7
I3
sg8
g49
sg10
I4
sg11
VPERP
p935
sg13
I1
sa(dp936
g7
I27
sg8
VP42771
p937
sg10
I3
sg11
Vp53
p938
sg13
I1
sasg14
(lp939
(dp940
g7
I194
sg17
VC0220633
p941
sg10
I14
sg11
Vuveal melanoma
p942
sg13
I2
sa(dp943
g7
I209
sg17
VC0699748
p944
sg10
I12
sg11
Vpathogenesis
p945
sg13
I1
sa(dp946
g7
I330
sg17
VC0027651
p947
sg10
I5
sg11
Vtumor
p948
sg13
I1
sasa(dp949
g2
S'In human acquired cholesteatoma, the expression of proinflammatory cytokines (IL-1Beta, TNF-Alfa and IL-6) and matrix metalloproteinases (MMP-2, MMP-8 and MMP-9) were up-regulated, and their expression levels were positively correlated with TREM-2 expression.\n'
p950
sg4
(lp951
(dp952
g7
I145
sg8
VP22894
p953
sg10
I5
sg11
VMMP-8
p954
sg13
I1
sa(dp955
g7
I101
sg8
VP05231
p956
sg10
I4
sg11
VIL-6
p957
sg13
I1
sa(dp958
g7
I78
sg8
VP01584
p959
sg10
I8
sg11
VIL-1Beta
p960
sg13
I1
sa(dp961
g7
I155
sg8
VP14780
p962
sg10
I5
sg11
VMMP-9
p963
sg13
I1
sa(dp964
g7
I88
sg8
VP01375
p965
sg10
I8
sg11
VTNF-Alfa
p966
sg13
I1
sa(dp967
g7
I241
sg8
g49
sg10
I6
sg11
VTREM-2
p968
sg13
I1
sasg14
(lp969
(dp970
g7
I18
sg17
VC0008373
p971
sg10
I13
sg11
Vcholesteatoma
p972
sg13
I1
sasa(dp973
g2
S'Additional data showed that TREM-2 up-regulated IL-1Beta and IL-6 expression via TLR4 instead of the TLR2 signaling pathway and promoted MMP-2 and MMP-8 secretion and osteoclast activation in experimentally acquired cholesteatoma.\n'
p974
sg4
(lp975
(dp976
g7
I101
sg8
g49
sg10
I4
sg11
VTLR2
p977
sg13
I1
sa(dp978
g7
I137
sg8
VP08253
p979
sg10
I5
sg11
VMMP-2
p980
sg13
I1
sa(dp981
g7
I61
sg8
VP05231
p982
sg10
I4
sg11
VIL-6
p983
sg13
I1
sa(dp984
g7
I147
sg8
VP22894
p985
sg10
I5
sg11
VMMP-8
p986
sg13
I1
sa(dp987
g7
I28
sg8
g49
sg10
I28
sg11
VTREM-2 up-regulated IL-1Beta
p988
sg13
I3
sasg14
(lp989
(dp990
g7
I216
sg17
VC0008373
p991
sg10
I13
sg11
Vcholesteatoma
p992
sg13
I1
sasa(dp993
g2
S'However, the expression and function of TLRs in cholesteatoma remain unclear.We observed inflammatory cell infiltration of the matrix and prematrix of human acquired cholesteatoma, as well as dramatically increased expression of TLR4 and the pro-inflammatory cytokines TNF-Alfa and IL-1Beta.\n'
p994
sg4
(lp995
(dp996
g7
I282
sg8
VP01584
p997
sg10
I8
sg11
VIL-1Beta
p998
sg13
I1
sa(dp999
g7
I259
sg8
VP01375
p1000
sg10
I18
sg11
Vcytokines TNF-Alfa
p1001
sg13
I2
sasg14
(lp1002
(dp1003
g7
I89
sg17
VC0302158
p1004
sg10
I30
sg11
Vinflammatory cell infiltration
p1005
sg13
I3
sa(dp1006
g7
I48
sg17
VC0008373
p1007
sg10
I13
sg11
Vcholesteatoma
p1008
sg13
I1
sa(dp1009
g7
I48
sg17
VC0008373
p1010
sg10
I13
sg11
Vcholesteatoma
p1011
sg13
I1
sasa(dp1012
g2
S'Moreover, TLR4 deficiency was protective against experimental acquired cholesteatoma-driven bone destruction and hearing loss, as it reduced local TNF-Alfa and IL-1Beta expression and impaired osteoclast formation by decreasing expression of the osteoclast effectors receptor activator of nuclear factor (NF)-KB ligand (RANKL) and tartrate-resistant acid phosphatase (TRAP).\n'
p1013
sg4
(lp1014
(dp1015
g7
I160
sg8
VP01584
p1016
sg10
I8
sg11
VIL-1Beta
p1017
sg13
I1
sa(dp1018
g7
I320
sg8
g49
sg10
I5
sg11
VRANKL
p1019
sg13
I1
sa(dp1020
g7
I246
sg8
g49
sg10
I39
sg11
Vosteoclast effectors receptor activator
p1021
sg13
I4
sa(dp1022
g7
I289
sg8
VP01160
p1023
sg10
I29
sg11
Vnuclear factor (NF)-KB ligand
p1024
sg13
I4
sa(dp1025
g7
I368
sg8
VP13686
p1026
sg10
I4
sg11
VTRAP
p1027
sg13
I1
sa(dp1028
g7
I331
sg8
VP13686
p1029
sg10
I35
sg11
Vtartrate-resistant acid phosphatase
p1030
sg13
I3
sa(dp1031
g7
I147
sg8
VP01375
p1032
sg10
I8
sg11
VTNF-Alfa
p1033
sg13
I1
sasg14
(lp1034
(dp1035
g7
I113
sg17
VC0011053
p1036
sg10
I12
sg11
Vhearing loss
p1037
sg13
I2
sa(dp1038
g7
I184
sg17
VC0684336
p1039
sg10
I8
sg11
Vimpaired
p1040
sg13
I1
sa(dp1041
g7
I92
sg17
VC0238790
p1042
sg10
I16
sg11
Vbone destruction
p1043
sg13
I2
sa(dp1044
g7
I71
sg17
VC0008373
p1045
sg10
I13
sg11
Vcholesteatoma
p1046
sg13
I1
sasa(dp1047
g2
S'TNF-Alfa and IL-1Beta can be induced by purified HMGB-1 combined with CpG-DNA in the cholesteatoma keratinocytes.\n'
p1048
sg4
(lp1049
(dp1050
g7
I49
sg8
VP09429
p1051
sg10
I6
sg11
VHMGB-1
p1052
sg13
I1
sa(dp1053
g7
I13
sg8
VP01584
p1054
sg10
I8
sg11
VIL-1Beta
p1055
sg13
I1
sa(dp1056
g7
I0
sg8
VP01375
p1057
sg10
I8
sg11
VTNF-Alfa
p1058
sg13
I1
sasg14
(lp1059
(dp1060
g7
I85
sg17
VC0008373
p1061
sg10
I13
sg11
Vcholesteatoma
p1062
sg13
I1
sasa(dp1063
g2
S'This study suggested that persistent expression of extracellular HMGB-1 and DNA fragments in cholesteatoma leads to TNF-Alfa and IL-1Beta production, causing bone resorption and destruction.\n'
p1064
sg4
(lp1065
(dp1066
g7
I116
sg8
VP01375
p1067
sg10
I8
sg11
VTNF-Alfa
p1068
sg13
I1
sa(dp1069
g7
I51
sg8
VP09429
p1070
sg10
I20
sg11
Vextracellular HMGB-1
p1071
sg13
I2
sa(dp1072
g7
I129
sg8
VP01584
p1073
sg10
I8
sg11
VIL-1Beta
p1074
sg13
I1
sasg14
(lp1075
(dp1076
g7
I93
sg17
VC0008373
p1077
sg10
I13
sg11
Vcholesteatoma
p1078
sg13
I1
sasa(dp1079
g2
S'The Luminex Multiplex xMAP bead-based antibody assay was applied to measure the concentrations of 44 cytokines, chemokines, and growth factors (BIRC5, CCL11, CCL2, CCL3, CCL4, CCL5, CCL7, CD40LG, CSF2, CSF3, CX3CL1, CXCL10, CXCL9, EGF, HGF, ICAM1, IFNA2, IFNG, IL10, IL12*, IL12B, IL13, IL15, IL17A, IL17F, IL1A, IL1B, IL1R1, IL2, IL20, IL21, IL22, IL23A, IL4, IL5, IL6, IL7, IL8, LTA, MIF, TGFA, TGFB1, TNF, VEGFA) in human biopsies from cholesteatoma, neck of cholesteatoma (the transition zone from tympanic membrane), tympanic membrane, external auditory canal skin, and middle ear mucosa.\n'
p1080
sg4
(lp1081
(dp1082
g7
I300
sg8
g49
sg10
I5
sg11
VIL17F
p1083
sg13
I1
sa(dp1084
g7
I208
sg8
VP78423
p1085
sg10
I6
sg11
VCX3CL1
p1086
sg13
I1
sa(dp1087
g7
I170
sg8
VP13236
p1088
sg10
I4
sg11
VCCL4
p1089
sg13
I1
sa(dp1090
g7
I202
sg8
VP09919
p1091
sg10
I4
sg11
VCSF3
p1092
sg13
I1
sa(dp1093
g7
I176
sg8
VP13501
p1094
sg10
I4
sg11
VCCL5
p1095
sg13
I1
sa(dp1096
g7
I224
sg8
g49
sg10
I5
sg11
VCXCL9
p1097
sg13
I1
sa(dp1098
g7
I361
sg8
VP05113
p1099
sg10
I3
sg11
VIL5
p1100
sg13
I1
sa(dp1101
g7
I381
sg8
VP10515
p1102
sg10
I3
sg11
VLTA
p1103
sg13
I1
sa(dp1104
g7
I241
sg8
VP05362
p1105
sg10
I5
sg11
VICAM1
p1106
sg13
I1
sa(dp1107
g7
I164
sg8
VP10147
p1108
sg10
I4
sg11
VCCL3
p1109
sg13
I1
sa(dp1110
g7
I287
sg8
VP40933
p1111
sg10
I4
sg11
VIL15
p1112
sg13
I1
sa(dp1113
g7
I151
sg8
VP51671
p1114
sg10
I5
sg11
VCCL11
p1115
sg13
I1
sa(dp1116
g7
I371
sg8
VP13232
p1117
sg10
I3
sg11
VIL7
p1118
sg13
I1
sa(dp1119
g7
I281
sg8
VP35225
p1120
sg10
I4
sg11
VIL13
p1121
sg13
I1
sa(dp1122
g7
I386
sg8
VP05109
p1123
sg10
I3
sg11
VMIF
p1124
sg13
I1
sa(dp1125
g7
I313
sg8
VP01584
p1126
sg10
I4
sg11
VIL1B
p1127
sg13
I1
sa(dp1128
g7
I182
sg8
VP80098
p1129
sg10
I4
sg11
VCCL7
p1130
sg13
I1
sa(dp1131
g7
I231
sg8
VP01133
p1132
sg10
I3
sg11
VEGF
p1133
sg13
I1
sa(dp1134
g7
I158
sg8
VP13500
p1135
sg10
I4
sg11
VCCL2
p1136
sg13
I1
sa(dp1137
g7
I404
sg8
VP01375
p1138
sg10
I3
sg11
VTNF
p1139
sg13
I1
sa(dp1140
g7
I236
sg8
VP05231
p1141
sg10
I3
sg11
VHGF
p1142
sg13
I1
sa(dp1143
g7
I274
sg8
VP29460
p1144
sg10
I5
sg11
VIL12B
p1145
sg13
I1
sa(dp1146
g7
I326
sg8
VP60568
p1147
sg10
I3
sg11
VIL2
p1148
sg13
I1
sa(dp1149
g7
I337
sg8
g49
sg10
I4
sg11
VIL21
p1150
sg13
I1
sa(dp1151
g7
I307
sg8
VP01584
p1152
sg10
I4
sg11
VIL1A
p1153
sg13
I1
sa(dp1154
g7
I397
sg8
VP01137
p1155
sg10
I5
sg11
VTGFB1
p1156
sg13
I1
sa(dp1157
g7
I343
sg8
g49
sg10
I4
sg11
VIL22
p1158
sg13
I1
sa(dp1159
g7
I261
sg8
VP22301
p1160
sg10
I4
sg11
VIL10
p1161
sg13
I1
sa(dp1162
g7
I366
sg8
VP05231
p1163
sg10
I3
sg11
VIL6
p1164
sg13
I1
sa(dp1165
g7
I356
sg8
VP05112
p1166
sg10
I3
sg11
VIL4
p1167
sg13
I1
sa(dp1168
g7
I188
sg8
VP29965
p1169
sg10
I6
sg11
VCD40LG
p1170
sg13
I1
sa(dp1171
g7
I248
sg8
VP01563
p1172
sg10
I5
sg11
VIFNA2
p1173
sg13
I1
sa(dp1174
g7
I349
sg8
g49
sg10
I5
sg11
VIL23A
p1175
sg13
I1
sa(dp1176
g7
I391
sg8
VP01135
p1177
sg10
I4
sg11
VTGFA
p1178
sg13
I1
sa(dp1179
g7
I196
sg8
VP09603
p1180
sg10
I4
sg11
VCSF2
p1181
sg13
I1
sa(dp1182
g7
I255
sg8
VP01579
p1183
sg10
I4
sg11
VIFNG
p1184
sg13
I1
sa(dp1185
g7
I331
sg8
g49
sg10
I4
sg11
VIL20
p1186
sg13
I1
sa(dp1187
g7
I319
sg8
VP14778
p1188
sg10
I5
sg11
VIL1R1
p1189
sg13
I1
sa(dp1190
g7
I216
sg8
VP02778
p1191
sg10
I6
sg11
VCXCL10
p1192
sg13
I1
sa(dp1193
g7
I293
sg8
g49
sg10
I5
sg11
VIL17A
p1194
sg13
I1
sasg14
(lp1195
(dp1196
g7
I481
sg17
VC0599156
p1197
sg10
I10
sg11
Vtransition
p1198
sg13
I1
sa(dp1199
g7
I439
sg17
VC0008373
p1200
sg10
I13
sg11
Vcholesteatoma
p1201
sg13
I1
sa(dp1202
g7
I236
sg17
VC0399440
p1203
sg10
I3
sg11
VHGF
p1204
sg13
I1
sa(dp1205
g7
I439
sg17
VC0008373
p1206
sg10
I13
sg11
Vcholesteatoma
p1207
sg13
I1
sasa(dp1208
g2
S'All mice with experimentally induced cholesteatoma showed hearing impairment and an upregulated expression of TNF-Alfa, IL-1Beta, and IL-6.\n'
p1209
sg4
(lp1210
(dp1211
g7
I134
sg8
VP05231
p1212
sg10
I4
sg11
VIL-6
p1213
sg13
I1
sa(dp1214
g7
I120
sg8
VP01584
p1215
sg10
I8
sg11
VIL-1Beta
p1216
sg13
I1
sa(dp1217
g7
I110
sg8
VP01375
p1218
sg10
I8
sg11
VTNF-Alfa
p1219
sg13
I1
sasg14
(lp1220
(dp1221
g7
I66
sg17
VC0684336
p1222
sg10
I10
sg11
Vimpairment
p1223
sg13
I1
sa(dp1224
g7
I37
sg17
VC0008373
p1225
sg10
I13
sg11
Vcholesteatoma
p1226
sg13
I1
sasa(dp1227
g2
S'The levels of IL-1beta in cholesteatoma and EACS were 0.41+/-0.06 and 0.24+/-0.02, respectively.\n'
p1228
sg4
(lp1229
(dp1230
g7
I14
sg8
VP01584
p1231
sg10
I8
sg11
VIL-1beta
p1232
sg13
I1
sasg14
(lp1233
(dp1234
g7
I26
sg17
VC0008373
p1235
sg10
I13
sg11
Vcholesteatoma
p1236
sg13
I1
sasa(dp1237
g2
S'The ratio of IL-1 beta and IL-8 of aural cholesteatoma was significantly higher than that of EACS and PAS.\n'
p1238
sg4
(lp1239
(dp1240
g7
I13
sg8
VP01584
p1241
sg10
I9
sg11
VIL-1 beta
p1242
sg13
I2
sasg14
(lp1243
(dp1244
g7
I35
sg17
VC0155490
p1245
sg10
I19
sg11
Vaural cholesteatoma
p1246
sg13
I2
sasa(dp1247
g2
S'We suggest that both of IL-1 alpha and IL-1 beta may play a role in the pathological changes, and that IL-8, which is mainly produced from cholesteatomatous epithelium, may have an important role in the pathological changes of cholesteatomas.\n'
p1248
sg4
(lp1249
(dp1250
g7
I24
sg8
VP01583
p1251
sg10
I10
sg11
VIL-1 alpha
p1252
sg13
I2
sa(dp1253
g7
I39
sg8
VP01584
p1254
sg10
I9
sg11
VIL-1 beta
p1255
sg13
I2
sasg14
(lp1256
(dp1257
g7
I227
sg17
VC0008373
p1258
sg10
I14
sg11
Vcholesteatomas
p1259
sg13
I1
sasa(dp1260
g2
S'Two years later, both T2DM and eCCl &lt;60 mL/min were associated with poorer cognitive scores, and 19.7% of the participants developed cognitive decline (mild cognitive impairment or dementia).\n'
p1261
sg4
(lp1262
sg14
(lp1263
(dp1264
g7
I136
sg17
VC0338656
p1265
sg10
I17
sg11
Vcognitive decline
p1266
sg13
I2
sa(dp1267
g7
I184
sg17
VC0497327
p1268
sg10
I8
sg11
Vdementia
p1269
sg13
I1
sa(dp1270
g7
I31
sg17
VC0406612
p1271
sg10
I4
sg11
VeCCl
p1272
sg13
I1
sa(dp1273
g7
I155
sg17
VC1270972
p1274
sg10
I25
sg11
Vmild cognitive impairment
p1275
sg13
I3
sasa(dp1276
g2
S'ChiPseq revealed that the nuclear (n) form of FGFR1, a pan-ontogenic regulator, is overexpressed in schizophrenia NCCs and overtargets dysregulated mRNA and miRNA genes.\n'
p1277
sg4
(lp1278
(dp1279
g7
I46
sg8
VP20930
p1280
sg10
I5
sg11
VFGFR1
p1281
sg13
I1
sasg14
(lp1282
(dp1283
g7
I100
sg17
VC0036341
p1284
sg10
I13
sg11
Vschizophrenia
p1285
sg13
I1
sasa(dp1286
g2
S'The nFGFR1 targeted 54% of all human gene promoters and 84.4% of schizophrenia dysregulated genes.\n'
p1287
sg4
(lp1288
sg14
(lp1289
(dp1290
g7
I65
sg17
VC0036341
p1291
sg10
I13
sg11
Vschizophrenia
p1292
sg13
I1
sasa(dp1293
g2
S'Our results indicate (i) an early (preneuronal) genomic etiology of schizophrenia, (ii) dysregulated genes and new coordinated gene networks are common to unrelated cases of schizophrenia, (iii) gene dysregulations are accompanied by increased nFGFR1-genome interactions, and (iv) modeling of increased nFGFR1 by an overexpression of a nFGFR1 lead to up or downregulation of selected genes as observed in schizophrenia NCCs.\n'
p1294
sg4
(lp1295
sg14
(lp1296
(dp1297
g7
I68
sg17
VC0036341
p1298
sg10
I13
sg11
Vschizophrenia
p1299
sg13
I1
sa(dp1300
g7
I68
sg17
VC0036341
p1301
sg10
I13
sg11
Vschizophrenia
p1302
sg13
I1
sa(dp1303
g7
I68
sg17
VC0036341
p1304
sg10
I13
sg11
Vschizophrenia
p1305
sg13
I1
sasa(dp1306
g2
S'Together our results designate nFGFR1 signaling as a potential common dysregulated mechanism in investigated patients and potential therapeutic target in schizophrenia.\n'
p1307
sg4
(lp1308
sg14
(lp1309
(dp1310
g7
I154
sg17
VC0036341
p1311
sg10
I13
sg11
Vschizophrenia
p1312
sg13
I1
sasa(dp1313
g2
S'Relative to unaffected comparison subjects, subjects with schizophrenia exhibited elevated mRNA levels for 1) the transcription factor MafB, which is expressed by parvalbumin and somatostatin neurons as they migrate from the medial ganglionic eminence to the cortex, 2) the transcriptional coactivator PGC-1Alfa, which is expressed postnatally by parvalbumin neurons to maintain parvalbumin levels and inhibitory function, and 3) FgfR1, which is required for the migration and phenotypic specification of parvalbumin and somatostatin neurons.\n'
p1314
sg4
(lp1315
(dp1316
g7
I163
sg8
VP20472
p1317
sg10
I11
sg11
Vparvalbumin
p1318
sg13
I1
sa(dp1319
g7
I430
sg8
VP20930
p1320
sg10
I5
sg11
VFgfR1
p1321
sg13
I1
sa(dp1322
g7
I179
sg8
VP61278
p1323
sg10
I12
sg11
Vsomatostatin
p1324
sg13
I1
sa(dp1325
g7
I135
sg8
g49
sg10
I4
sg11
VMafB
p1326
sg13
I1
sa(dp1327
g7
I163
sg8
VP20472
p1328
sg10
I11
sg11
Vparvalbumin
p1329
sg13
I1
sa(dp1330
g7
I302
sg8
VP20142
p1331
sg10
I9
sg11
VPGC-1Alfa
p1332
sg13
I1
sa(dp1333
g7
I179
sg8
VP61278
p1334
sg10
I12
sg11
Vsomatostatin
p1335
sg13
I1
sa(dp1336
g7
I163
sg8
VP20472
p1337
sg10
I11
sg11
Vparvalbumin
p1338
sg13
I1
sasg14
(lp1339
(dp1340
g7
I58
sg17
VC0036341
p1341
sg10
I13
sg11
Vschizophrenia
p1342
sg13
I1
sasa(dp1343
g2
S'This assignment excludes Pon1 as a candidate for the atherosclerosis susceptibility genes Ath1, Ath2, and Ath3.\n'
p1344
sg4
(lp1345
(dp1346
g7
I25
sg8
VP27169
p1347
sg10
I4
sg11
VPon1
p1348
sg13
I1
sa(dp1349
g7
I90
sg8
g49
sg10
I4
sg11
VAth1
p1350
sg13
I1
sa(dp1351
g7
I106
sg8
g49
sg10
I4
sg11
VAth3
p1352
sg13
I1
sasg14
(lp1353
(dp1354
g7
I53
sg17
VC0004153
p1355
sg10
I15
sg11
Vatherosclerosis
p1356
sg13
I1
sasa(dp1357
g2
S'The expression level of Robo4 increases gradually along with the development of diabetic retinopathy (DR).\n'
p1358
sg4
(lp1359
(dp1360
g7
I24
sg8
g49
sg10
I5
sg11
VRobo4
p1361
sg13
I1
sasg14
(lp1362
(dp1363
g7
I102
sg17
VC0011884
p1364
sg10
I2
sg11
VDR
p1365
sg13
I1
sa(dp1366
g7
I80
sg17
VC0011884
p1367
sg10
I20
sg11
Vdiabetic retinopathy
p1368
sg13
I2
sasa(dp1369
g2
S'We conclude that Robo4 inhibits angiogenesis and vessel permeability independently of its cytoplasmic domain, while activating VEGFR2-Y951 via ROBO4 inhibition might accelerate tissue revascularization in retinopathy of prematurity and in diabetic patients.\n'
p1370
sg4
(lp1371
(dp1372
g7
I143
sg8
g49
sg10
I5
sg11
VROBO4
p1373
sg13
I1
sa(dp1374
g7
I116
sg8
VP35968
p1375
sg10
I22
sg11
Vactivating VEGFR2-Y951
p1376
sg13
I2
sasg14
(lp1377
(dp1378
g7
I205
sg17
VC0035344
p1379
sg10
I26
sg11
Vretinopathy of prematurity
p1380
sg13
I3
sasa(dp1381
g2
S'We determined if hypoxia-inducible factor-1Alfa (HIF-1Alfa) and Roundabout4 (Robo4) colocalized in fibrovascular membranes (FVM) from patients with proliferative diabetic retinopathy (PDR), and investigated the regulation of HIF-1Alfa on Robo4 in microvascular endothelial cells under normoxic and hypoxic conditions in vitro.\n'
p1382
sg4
(lp1383
(dp1384
g7
I17
sg8
g49
sg10
I30
sg11
Vhypoxia-inducible factor-1Alfa
p1385
sg13
I2
sa(dp1386
g7
I77
sg8
g49
sg10
I5
sg11
VRobo4
p1387
sg13
I1
sa(dp1388
g7
I64
sg8
g49
sg10
I11
sg11
VRoundabout4
p1389
sg13
I1
sa(dp1390
g7
I49
sg8
g49
sg10
I9
sg11
VHIF-1Alfa
p1391
sg13
I1
sa(dp1392
g7
I49
sg8
g49
sg10
I9
sg11
VHIF-1Alfa
p1393
sg13
I1
sasg14
(lp1394
(dp1395
g7
I184
sg17
VC0154830
p1396
sg10
I3
sg11
VPDR
p1397
sg13
I1
sa(dp1398
g7
I298
sg17
VC0242184
p1399
sg10
I7
sg11
Vhypoxic
p1400
sg13
I1
sa(dp1401
g7
I148
sg17
VC0154830
p1402
sg10
I34
sg11
Vproliferative diabetic retinopathy
p1403
sg13
I3
sa(dp1404
g7
I17
sg17
VC0242184
p1405
sg10
I7
sg11
Vhypoxia
p1406
sg13
I1
sasa(dp1407
g2
S'To determine if hypoxia-inducible factor-1Alfa (HIF-1Alfa) and Robo4 colocalized in fibrovascular membranes (FVM) from patients with proliferative diabetic retinopathy and to investigate the regulation of HIF-1Alfa on Robo4 in microvascular endothelial cells under normoxic and hypoxic conditions in vitro.\n'
p1408
sg4
(lp1409
(dp1410
g7
I63
sg8
g49
sg10
I5
sg11
VRobo4
p1411
sg13
I1
sa(dp1412
g7
I16
sg8
g49
sg10
I30
sg11
Vhypoxia-inducible factor-1Alfa
p1413
sg13
I2
sa(dp1414
g7
I48
sg8
g49
sg10
I9
sg11
VHIF-1Alfa
p1415
sg13
I1
sa(dp1416
g7
I48
sg8
g49
sg10
I9
sg11
VHIF-1Alfa
p1417
sg13
I1
sa(dp1418
g7
I63
sg8
g49
sg10
I5
sg11
VRobo4
p1419
sg13
I1
sasg14
(lp1420
(dp1421
g7
I133
sg17
VC0154830
p1422
sg10
I34
sg11
Vproliferative diabetic retinopathy
p1423
sg13
I3
sa(dp1424
g7
I278
sg17
VC0242184
p1425
sg10
I7
sg11
Vhypoxic
p1426
sg13
I1
sa(dp1427
g7
I16
sg17
VC0242184
p1428
sg10
I7
sg11
Vhypoxia
p1429
sg13
I1
sasa(dp1430
g2
S'Our results indicate that augmenting the host Robo4/Slit2 system could provide a useful therapeutic approach to control pathological angiogenesis associated with HSV induced stromal keratitis.\n'
p1431
sg4
(lp1432
(dp1433
g7
I52
sg8
g49
sg10
I5
sg11
VSlit2
p1434
sg13
I1
sa(dp1435
g7
I46
sg8
g49
sg10
I5
sg11
VRobo4
p1436
sg13
I1
sasg14
(lp1437
(dp1438
g7
I120
sg17
VC0027686
p1439
sg10
I25
sg11
Vpathological angiogenesis
p1440
sg13
I2
sa(dp1441
g7
I174
sg17
VC1318020
p1442
sg10
I17
sg11
Vstromal keratitis
p1443
sg13
I2
sasa(dp1444
g2
S'Consistent with these in vitro studies, inhibition of Arf6 activity in vivo phenocopies Robo4 activation by reducing pathologic angiogenesis in choroidal and retinal vascular disease and VEGF-165 (vascular endothelial growth factor-165)-induced retinal hyperpermeability.\n'
p1445
sg4
(lp1446
(dp1447
g7
I197
sg8
g49
sg10
I38
sg11
Vvascular endothelial growth factor-165
p1448
sg13
I4
sa(dp1449
g7
I54
sg8
VP62330
p1450
sg10
I4
sg11
VArf6
p1451
sg13
I1
sa(dp1452
g7
I187
sg8
g49
sg10
I8
sg11
VVEGF-165
p1453
sg13
I1
sasg14
(lp1454
(dp1455
g7
I166
sg17
VC0042373
p1456
sg10
I16
sg11
Vvascular disease
p1457
sg13
I2
sa(dp1458
g7
I158
sg17
VC0549652
p1459
sg10
I16
sg11
Vretinal vascular
p1460
sg13
I2
sa(dp1461
g7
I117
sg17
VC0027686
p1462
sg10
I23
sg11
Vpathologic angiogenesis
p1463
sg13
I2
sasa(dp1464
g2
S'This study investigated the effect of Robo4 on the formation of fibrovascular membranes (FVMs) from patients with proliferative diabetic retinopathy and its roles in choroid-retina endothelial (RF/6A) and human retinal pigment epithelial (RPE) cells.\n'
p1465
sg4
(lp1466
(dp1467
g7
I38
sg8
g49
sg10
I5
sg11
VRobo4
p1468
sg13
I1
sasg14
(lp1469
(dp1470
g7
I114
sg17
VC0154830
p1471
sg10
I34
sg11
Vproliferative diabetic retinopathy
p1472
sg13
I3
sasa(dp1473
g2
S'Immunohistochemical stains for markers which have known variable specificity for sex cord-stromal lineage [inhibin, calretinin, MART-1/melan-A, CD99, steroidogenic factor 1 (SF-1, adrenal 4-binding protein), and WT1], were performed in 127 cases of 5 different types of ovarian sex cord-stromal tumors: adult granulosa cell tumor (n=32), Sertoli cell tumor (n=27), Sertoli-Leydig cell tumor (n=18), steroid cell tumor (n=25), and fibroma/fibrothecoma (n=25).\n'
p1474
sg4
(lp1475
(dp1476
g7
I144
sg8
VP14209
p1477
sg10
I4
sg11
VCD99
p1478
sg13
I1
sa(dp1479
g7
I174
sg8
g49
sg10
I31
sg11
VSF-1, adrenal 4-binding protein
p1480
sg13
I4
sa(dp1481
g7
I128
sg8
g49
sg10
I14
sg11
VMART-1/melan-A
p1482
sg13
I1
sa(dp1483
g7
I150
sg8
g49
sg10
I22
sg11
Vsteroidogenic factor 1
p1484
sg13
I3
sa(dp1485
g7
I212
sg8
g49
sg10
I3
sg11
VWT1
p1486
sg13
I1
sa(dp1487
g7
I116
sg8
VP22676
p1488
sg10
I10
sg11
Vcalretinin
p1489
sg13
I1
sasg14
(lp1490
(dp1491
g7
I399
sg17
VC0334412
p1492
sg10
I18
sg11
Vsteroid cell tumor
p1493
sg13
I3
sa(dp1494
g7
I338
sg17
VC0036769
p1495
sg10
I18
sg11
VSertoli cell tumor
p1496
sg13
I3
sa(dp1497
g7
I438
sg17
VC0039747
p1498
sg10
I12
sg11
Vfibrothecoma
p1499
sg13
I1
sa(dp1500
g7
I278
sg17
VC0206724
p1501
sg10
I23
sg11
Vsex cord-stromal tumors
p1502
sg13
I3
sa(dp1503
g7
I85
sg17
VC0035334
p1504
sg10
I4
sg11
Vcord
p1505
sg13
I1
sa(dp1506
g7
I309
sg17
VC0018206
p1507
sg10
I20
sg11
Vgranulosa cell tumor
p1508
sg13
I3
sa(dp1509
g7
I430
sg17
VC0016045
p1510
sg10
I7
sg11
Vfibroma
p1511
sg13
I1
sa(dp1512
g7
I365
sg17
VC1318541
p1513
sg10
I25
sg11
VSertoli-Leydig cell tumor
p1514
sg13
I3
sa(dp1515
g7
I212
sg17
VC0027708
p1516
sg10
I3
sg11
VWT1
p1517
sg13
I1
sasa(dp1518
g2
S'Although each of the different types of sex cord-stromal tumors has a slightly unique immunoprofile in terms of frequency and extent of expression, these differences are relatively minor for most types of tumors with certain exceptions (eg, WT1 is not diagnostically useful in steroid cell tumor; CD99 is not diagnostically useful in fibroma/fibrothecoma; the only sex cord-stromal tumor for which MART-1 is diagnostically useful is steroid cell tumor; inhibin and calretinin are less diagnostically useful in fibroma/fibrothecoma than in the other types of tumors, but expression in fibrothecoma was higher than in fibroma).\n'
p1519
sg4
(lp1520
(dp1521
g7
I398
sg8
g49
sg10
I6
sg11
VMART-1
p1522
sg13
I1
sa(dp1523
g7
I465
sg8
VP22676
p1524
sg10
I10
sg11
Vcalretinin
p1525
sg13
I1
sa(dp1526
g7
I297
sg8
VP14209
p1527
sg10
I4
sg11
VCD99
p1528
sg13
I1
sa(dp1529
g7
I241
sg8
g49
sg10
I3
sg11
VWT1
p1530
sg13
I1
sasg14
(lp1531
(dp1532
g7
I334
sg17
VC0016045
p1533
sg10
I7
sg11
Vfibroma
p1534
sg13
I1
sa(dp1535
g7
I334
sg17
VC0016045
p1536
sg10
I7
sg11
Vfibroma
p1537
sg13
I1
sa(dp1538
g7
I57
sg17
VC0027651
p1539
sg10
I6
sg11
Vtumors
p1540
sg13
I1
sa(dp1541
g7
I40
sg17
VC0206724
p1542
sg10
I23
sg11
Vsex cord-stromal tumors
p1543
sg13
I3
sa(dp1544
g7
I342
sg17
VC0039747
p1545
sg10
I12
sg11
Vfibrothecoma
p1546
sg13
I1
sa(dp1547
g7
I277
sg17
VC0334412
p1548
sg10
I18
sg11
Vsteroid cell tumor
p1549
sg13
I3
sa(dp1550
g7
I342
sg17
VC0039747
p1551
sg10
I12
sg11
Vfibrothecoma
p1552
sg13
I1
sa(dp1553
g7
I334
sg17
VC0016045
p1554
sg10
I7
sg11
Vfibroma
p1555
sg13
I1
sa(dp1556
g7
I57
sg17
VC0027651
p1557
sg10
I6
sg11
Vtumors
p1558
sg13
I1
sa(dp1559
g7
I241
sg17
VC0027708
p1560
sg10
I3
sg11
VWT1
p1561
sg13
I1
sa(dp1562
g7
I277
sg17
VC0334412
p1563
sg10
I18
sg11
Vsteroid cell tumor
p1564
sg13
I3
sa(dp1565
g7
I40
sg17
VC0206724
p1566
sg10
I22
sg11
Vsex cord-stromal tumor
p1567
sg13
I3
sa(dp1568
g7
I342
sg17
VC0039747
p1569
sg10
I12
sg11
Vfibrothecoma
p1570
sg13
I1
sasa(dp1571
g2
S'The AKNA gene is part of the 9q32 susceptibility locus for cervical cancer.\n'
p1572
sg4
(lp1573
sg14
(lp1574
(dp1575
g7
I59
sg17
VC0302592
p1576
sg10
I15
sg11
Vcervical cancer
p1577
sg13
I2
sasa(dp1578
g2
S'Therefore, AKNA appears to be an important genetic factor associated with the risk cervical cancer.\n'
p1579
sg4
(lp1580
sg14
(lp1581
(dp1582
g7
I83
sg17
VC0302592
p1583
sg10
I15
sg11
Vcervical cancer
p1584
sg13
I2
sasa(dp1585
g2
S'Here we report on CNS MRI findings from two female individuals with BFLS due to a de novo duplication in PHF6 who presented with typical BFLS and epilepsy.\n'
p1586
sg4
(lp1587
(dp1588
g7
I105
sg8
g49
sg10
I4
sg11
VPHF6
p1589
sg13
I1
sasg14
(lp1590
(dp1591
g7
I68
sg17
VC0265339
p1592
sg10
I4
sg11
VBFLS
p1593
sg13
I1
sa(dp1594
g7
I90
sg17
VC1705960
p1595
sg10
I11
sg11
Vduplication
p1596
sg13
I1
sa(dp1597
g7
I68
sg17
VC0265339
p1598
sg10
I4
sg11
VBFLS
p1599
sg13
I1
sa(dp1600
g7
I146
sg17
VC0014544
p1601
sg10
I8
sg11
Vepilepsy
p1602
sg13
I1
sasa(dp1603
g2
S'Furthermore, two CSS patients were reported to have a PHF6 abnormality, which can also cause Borjeson-Forssman-Lehmann syndrome (OMIM#301900), an X-linked intellectual disability syndrome with epilepsy and endocrine abnormalities.\n'
p1604
sg4
(lp1605
(dp1606
g7
I54
sg8
g49
sg10
I4
sg11
VPHF6
p1607
sg13
I1
sasg14
(lp1608
(dp1609
g7
I119
sg17
VC0039082
p1610
sg10
I8
sg11
Vsyndrome
p1611
sg13
I1
sa(dp1612
g7
I17
sg17
VC0265338
p1613
sg10
I3
sg11
VCSS
p1614
sg13
I1
sa(dp1615
g7
I155
sg17
VC0025362
p1616
sg10
I23
sg11
Vintellectual disability
p1617
sg13
I2
sa(dp1618
g7
I193
sg17
VC0014544
p1619
sg10
I8
sg11
Vepilepsy
p1620
sg13
I1
sa(dp1621
g7
I93
sg17
VC0265339
p1622
sg10
I34
sg11
VBorjeson-Forssman-Lehmann syndrome
p1623
sg13
I2
sasa(dp1624
g2
S'Eight-week-old CCR9-deficient mice were injected with a collagen II monoclonal antibody cocktail to create a rheumatoid arthritis model.\n'
p1625
sg4
(lp1626
(dp1627
g7
I15
sg8
VP51686
p1628
sg10
I4
sg11
VCCR9
p1629
sg13
I1
sasg14
(lp1630
(dp1631
g7
I109
sg17
VC0003873
p1632
sg10
I20
sg11
Vrheumatoid arthritis
p1633
sg13
I2
sasa(dp1634
g2
S'To address the question of B cell migration into the inflamed synovial tissue of patients with rheumatoid arthritis (RA), peripheral blood naive B cells, memory B cells and plasma cells were analyzed for cell surface expression of the chemokine receptors CXCR3, CXCR4, CXCR5, CCR5, CCR6, CCR7 and CCR9.\n'
p1635
sg4
(lp1636
(dp1637
g7
I276
sg8
VP32302
p1638
sg10
I4
sg11
VCCR5
p1639
sg13
I1
sa(dp1640
g7
I262
sg8
VP61073
p1641
sg10
I5
sg11
VCXCR4
p1642
sg13
I1
sa(dp1643
g7
I282
sg8
VP51684
p1644
sg10
I4
sg11
VCCR6
p1645
sg13
I1
sa(dp1646
g7
I255
sg8
VP49682
p1647
sg10
I5
sg11
VCXCR3
p1648
sg13
I1
sa(dp1649
g7
I269
sg8
VP32302
p1650
sg10
I5
sg11
VCXCR5
p1651
sg13
I1
sa(dp1652
g7
I288
sg8
VP32248
p1653
sg10
I4
sg11
VCCR7
p1654
sg13
I1
sa(dp1655
g7
I297
sg8
VP51686
p1656
sg10
I4
sg11
VCCR9
p1657
sg13
I1
sasg14
(lp1658
(dp1659
g7
I95
sg17
VC0003873
p1660
sg10
I20
sg11
Vrheumatoid arthritis
p1661
sg13
I2
sa(dp1662
g7
I117
sg17
VC0003873
p1663
sg10
I2
sg11
VRA
p1664
sg13
I1
sasa(dp1665
g2
S'Candida-associated lesions (CALs) and burning mouth syndrome (BMS) may induce glossodynia without objective manifestations.\n'
p1666
sg4
(lp1667
sg14
(lp1668
(dp1669
g7
I78
sg17
VC0017672
p1670
sg10
I11
sg11
Vglossodynia
p1671
sg13
I1
sa(dp1672
g7
I62
sg17
VC0006430
p1673
sg10
I3
sg11
VBMS
p1674
sg13
I1
sa(dp1675
g7
I38
sg17
VC0006430
p1676
sg10
I22
sg11
Vburning mouth syndrome
p1677
sg13
I3
sasa(dp1678
g2
S'We divided stroke-prone spontaneously hypertensive rats (SHRSPs), as hypertensive and vascular dementia model rats, into five groups, telmisartan-treated (TLM), TLM+GW9662, a PPAR-gamma inhibitor, -treated (T+G), GW9662-treated (GW), TLM+ANA-12, a TrkB antagonist, -treated (T+A), and vehicle-treated SHRSPs (VEH).\n'
p1679
sg4
(lp1680
(dp1681
g7
I175
sg8
g49
sg10
I10
sg11
VPPAR-gamma
p1682
sg13
I1
sa(dp1683
g7
I248
sg8
g49
sg10
I4
sg11
VTrkB
p1684
sg13
I1
sasg14
(lp1685
(dp1686
g7
I86
sg17
VC0011269
p1687
sg10
I17
sg11
Vvascular dementia
p1688
sg13
I2
sa(dp1689
g7
I11
sg17
VC0038454
p1690
sg10
I6
sg11
Vstroke
p1691
sg13
I1
sasa(dp1692
g2
S'The purpose of this study was to investigate the effects of MCM4 in laryngeal squamous cell carcinoma (LSCC) cell growth and apoptosis.\n'
p1693
sg4
(lp1694
(dp1695
g7
I60
sg8
VP33991
p1696
sg10
I4
sg11
VMCM4
p1697
sg13
I1
sasg14
(lp1698
(dp1699
g7
I68
sg17
VC0280324
p1700
sg10
I33
sg11
Vlaryngeal squamous cell carcinoma
p1701
sg13
I4
sa(dp1702
g7
I103
sg17
VC0280324
p1703
sg10
I4
sg11
VLSCC
p1704
sg13
I1
sasa(dp1705
g2
S'The results showed that siRNA of MCM4 could significantly inhibit LSCC cell line UMSCC 5 proliferation and induce apoptosis.\n'
p1706
sg4
(lp1707
(dp1708
g7
I33
sg8
VP33991
p1709
sg10
I4
sg11
VMCM4
p1710
sg13
I1
sasg14
(lp1711
(dp1712
g7
I89
sg17
VC0334094
p1713
sg10
I13
sg11
Vproliferation
p1714
sg13
I1
sasa(dp1715
g2
S'MCM4 mRNA was higher expressed in carcinoma tissues than in adjacent normal tissues.\n'
p1716
sg4
(lp1717
(dp1718
g7
I0
sg8
VP33991
p1719
sg10
I9
sg11
VMCM4 mRNA
p1720
sg13
I2
sasg14
(lp1721
(dp1722
g7
I34
sg17
VC0007097
p1723
sg10
I9
sg11
Vcarcinoma
p1724
sg13
I1
sasa(dp1725
g2
S'We noticed a significant role for MCM4 overexpression in human LSCC tissues and their corresponding adjacent non-neoplastic tissues and found that siRNA of MCM4 can significantly decrease the proliferation of cancer cells.\n'
p1726
sg4
(lp1727
(dp1728
g7
I34
sg8
VP33991
p1729
sg10
I4
sg11
VMCM4
p1730
sg13
I1
sa(dp1731
g7
I34
sg8
VP33991
p1732
sg10
I4
sg11
VMCM4
p1733
sg13
I1
sasg14
(lp1734
(dp1735
g7
I192
sg17
VC0334094
p1736
sg10
I13
sg11
Vproliferation
p1737
sg13
I1
sa(dp1738
g7
I209
sg17
VC0006826
p1739
sg10
I6
sg11
Vcancer
p1740
sg13
I1
sasa(dp1741
g2
S'It is suggested that MCM4 profiling could potentially be used to predict response to treatment and prognosis in LSCC.\n'
p1742
sg4
(lp1743
(dp1744
g7
I21
sg8
VP33991
p1745
sg10
I4
sg11
VMCM4
p1746
sg13
I1
sasg14
(lp1747
sa(dp1748
g2
S'Furthermore, we identified some potential lung cancer driver genes, such as TBX2, MCM4, SLC2A1, BIRC5, and CDC20, whose expression is significantly upregulated in lung cancer, and the copy number of these genes is amplified in the genome of patients with lung cancer.\n'
p1749
sg4
(lp1750
(dp1751
g7
I82
sg8
VP33991
p1752
sg10
I4
sg11
VMCM4
p1753
sg13
I1
sa(dp1754
g7
I76
sg8
g49
sg10
I4
sg11
VTBX2
p1755
sg13
I1
sa(dp1756
g7
I88
sg8
VP11166
p1757
sg10
I6
sg11
VSLC2A1
p1758
sg13
I1
sa(dp1759
g7
I107
sg8
g49
sg10
I5
sg11
VCDC20
p1760
sg13
I1
sasg14
(lp1761
(dp1762
g7
I42
sg17
VC0684249
p1763
sg10
I11
sg11
Vlung cancer
p1764
sg13
I2
sa(dp1765
g7
I42
sg17
VC0684249
p1766
sg10
I11
sg11
Vlung cancer
p1767
sg13
I2
sa(dp1768
g7
I42
sg17
VC0684249
p1769
sg10
I11
sg11
Vlung cancer
p1770
sg13
I2
sasa(dp1771
g2
S'An analysis of gene regulatory networks showed that replicative helicase proteins (MCM2, MCM4, MCM5, MCM6, and MCM10) and DNA polymerases (PLOA1/E2/E3/Q) have enhanced DNA replication in cervical cancer.\n'
p1772
sg4
(lp1773
(dp1774
g7
I95
sg8
VP33992
p1775
sg10
I4
sg11
VMCM5
p1776
sg13
I1
sa(dp1777
g7
I89
sg8
VP33991
p1778
sg10
I4
sg11
VMCM4
p1779
sg13
I1
sa(dp1780
g7
I83
sg8
VP33993
p1781
sg10
I4
sg11
VMCM2
p1782
sg13
I1
sa(dp1783
g7
I101
sg8
g49
sg10
I4
sg11
VMCM6
p1784
sg13
I1
sa(dp1785
g7
I122
sg8
g49
sg10
I15
sg11
VDNA polymerases
p1786
sg13
I2
sa(dp1787
g7
I64
sg8
g49
sg10
I17
sg11
Vhelicase proteins
p1788
sg13
I2
sasg14
(lp1789
(dp1790
g7
I187
sg17
VC0302592
p1791
sg10
I15
sg11
Vcervical cancer
p1792
sg13
I2
sasa(dp1793
g2
S'The association between E2F2, MCM4, CCNE2 and WHSC1 and overall survival (OS) and recurrence-free survival (RFS) in ovarian cancer patients were assessed using Kaplan-Meier plotter.\n'
p1794
sg4
(lp1795
(dp1796
g7
I36
sg8
g49
sg10
I5
sg11
VCCNE2
p1797
sg13
I1
sa(dp1798
g7
I24
sg8
g49
sg10
I4
sg11
VE2F2
p1799
sg13
I1
sa(dp1800
g7
I30
sg8
VP33991
p1801
sg10
I4
sg11
VMCM4
p1802
sg13
I1
sasg14
(lp1803
(dp1804
g7
I108
sg17
VC0015624
p1805
sg10
I3
sg11
VRFS
p1806
sg13
I1
sa(dp1807
g7
I82
sg17
VC0015624
p1808
sg10
I24
sg11
Vrecurrence-free survival
p1809
sg13
I2
sa(dp1810
g7
I116
sg17
VC1140680
p1811
sg10
I14
sg11
Vovarian cancer
p1812
sg13
I2
sasa(dp1813
g2
S"MCM4, CCNE2, and WHSC1 are co-upregulated with E2F2 among the 308 ovarian cancer samples (Pearson's r=0.5159, 0.3963 and 0.4941 respectively).\n"
p1814
sg4
(lp1815
(dp1816
g7
I6
sg8
g49
sg10
I5
sg11
VCCNE2
p1817
sg13
I1
sa(dp1818
g7
I47
sg8
g49
sg10
I4
sg11
VE2F2
p1819
sg13
I1
sa(dp1820
g7
I0
sg8
VP33991
p1821
sg10
I4
sg11
VMCM4
p1822
sg13
I1
sasg14
(lp1823
(dp1824
g7
I66
sg17
VC1140680
p1825
sg10
I14
sg11
Vovarian cancer
p1826
sg13
I2
sasa(dp1827
g2
S'MCM4, CCNE2, and WHSC1 are co-upregulated with E2F2 in ovarian cancer.\n'
p1828
sg4
(lp1829
(dp1830
g7
I6
sg8
g49
sg10
I5
sg11
VCCNE2
p1831
sg13
I1
sa(dp1832
g7
I47
sg8
g49
sg10
I4
sg11
VE2F2
p1833
sg13
I1
sa(dp1834
g7
I0
sg8
VP33991
p1835
sg10
I4
sg11
VMCM4
p1836
sg13
I1
sasg14
(lp1837
(dp1838
g7
I55
sg17
VC1140680
p1839
sg10
I14
sg11
Vovarian cancer
p1840
sg13
I2
sasa(dp1841
g2
S'Enforced E2F2 expression significantly increased MCM4, CCNE2, and WHSC1 expression in ovarian cancer cells.\n'
p1842
sg4
(lp1843
(dp1844
g7
I55
sg8
g49
sg10
I5
sg11
VCCNE2
p1845
sg13
I1
sa(dp1846
g7
I9
sg8
g49
sg10
I4
sg11
VE2F2
p1847
sg13
I1
sa(dp1848
g7
I49
sg8
VP33991
p1849
sg10
I4
sg11
VMCM4
p1850
sg13
I1
sasg14
(lp1851
(dp1852
g7
I86
sg17
VC1140680
p1853
sg10
I14
sg11
Vovarian cancer
p1854
sg13
I2
sasa(dp1855
g2
S'The quantitative reverse transcriptase-polymerase chain reaction analysis verified the upregulation of ASAH1, PCBP2, DDX5, MCM5, TAGLN2, hnRNPA1, ENO1, TYPH, CYC, and MCM4 in squamous cell carcinoma compared to normal cervix ( p &lt; 0.05).\n'
p1856
sg4
(lp1857
(dp1858
g7
I123
sg8
VP33992
p1859
sg10
I4
sg11
VMCM5
p1860
sg13
I1
sa(dp1861
g7
I103
sg8
g49
sg10
I5
sg11
VASAH1
p1862
sg13
I1
sa(dp1863
g7
I129
sg8
VP37802
p1864
sg10
I6
sg11
VTAGLN2
p1865
sg13
I1
sa(dp1866
g7
I17
sg8
VP63136
p1867
sg10
I21
sg11
Vreverse transcriptase
p1868
sg13
I2
sa(dp1869
g7
I158
sg8
VP99999
p1870
sg10
I3
sg11
VCYC
p1871
sg13
I1
sa(dp1872
g7
I117
sg8
VP17844
p1873
sg10
I4
sg11
VDDX5
p1874
sg13
I1
sa(dp1875
g7
I110
sg8
g49
sg10
I5
sg11
VPCBP2
p1876
sg13
I1
sa(dp1877
g7
I167
sg8
VP33991
p1878
sg10
I4
sg11
VMCM4
p1879
sg13
I1
sa(dp1880
g7
I137
sg8
VP09651
p1881
sg10
I7
sg11
VhnRNPA1
p1882
sg13
I1
sasg14
(lp1883
(dp1884
g7
I175
sg17
VC0007137
p1885
sg10
I23
sg11
Vsquamous cell carcinoma
p1886
sg13
I3
sasa(dp1887
g2
S'Seven core transcription factors (MCM4, VWF, ECT2, RBMS3, LIMCH1, MYBL2 and FBXL7) are detected, and have been reported to contribute to tumorigenesis of lung adenocarcinoma.\n'
p1888
sg4
(lp1889
(dp1890
g7
I40
sg8
VP04275
p1891
sg10
I3
sg11
VVWF
p1892
sg13
I1
sa(dp1893
g7
I66
sg8
VP10244
p1894
sg10
I5
sg11
VMYBL2
p1895
sg13
I1
sa(dp1896
g7
I51
sg8
g49
sg10
I5
sg11
VRBMS3
p1897
sg13
I1
sa(dp1898
g7
I34
sg8
VP33991
p1899
sg10
I4
sg11
VMCM4
p1900
sg13
I1
sa(dp1901
g7
I45
sg8
g49
sg10
I4
sg11
VECT2
p1902
sg13
I1
sa(dp1903
g7
I76
sg8
g49
sg10
I5
sg11
VFBXL7
p1904
sg13
I1
sasg14
(lp1905
(dp1906
g7
I154
sg17
VC0152013
p1907
sg10
I19
sg11
Vlung adenocarcinoma
p1908
sg13
I2
sa(dp1909
g7
I137
sg17
VC0007621
p1910
sg10
I13
sg11
Vtumorigenesis
p1911
sg13
I1
sasa(dp1912
g2
S'The objective of this study is to determine the efficiency of YKL-40, HE-4 and DKK-3 levels in early diagnosis of patients with endometrial cancer and in the pre-operative estimation of the prognostic parameters such as stage, grade and the extension of the disease.\n'
p1913
sg4
(lp1914
(dp1915
g7
I79
sg8
g49
sg10
I5
sg11
VDKK-3
p1916
sg13
I1
sa(dp1917
g7
I62
sg8
VP36222
p1918
sg10
I6
sg11
VYKL-40
p1919
sg13
I1
sasg14
(lp1920
(dp1921
g7
I128
sg17
VC0476089
p1922
sg10
I18
sg11
Vendometrial cancer
p1923
sg13
I2
sasa(dp1924
g2
S'The aim of the study was to determine the differential expression patterns of the wingless-type (Wnt) pathway inhibitors Dkk3 (Dickkopf 3), SFRP1 (secreted frizzled-related protein 1), and SFRP4 in normal mullerian tissue and endometrial endometrioid adenocarcinoma specimens.\n'
p1925
sg4
(lp1926
(dp1927
g7
I189
sg8
g49
sg10
I5
sg11
VSFRP4
p1928
sg13
I1
sa(dp1929
g7
I147
sg8
g49
sg10
I35
sg11
Vsecreted frizzled-related protein 1
p1930
sg13
I4
sa(dp1931
g7
I121
sg8
g49
sg10
I4
sg11
VDkk3
p1932
sg13
I1
sa(dp1933
g7
I140
sg8
g49
sg10
I5
sg11
VSFRP1
p1934
sg13
I1
sa(dp1935
g7
I127
sg8
g49
sg10
I10
sg11
VDickkopf 3
p1936
sg13
I2
sasg14
(lp1937
(dp1938
g7
I226
sg17
VC1336905
p1939
sg10
I39
sg11
Vendometrial endometrioid adenocarcinoma
p1940
sg13
I3
sasa(dp1941
g2
S'There was a difference in Dkk3 protein expression between normal mullerian tissues and primary endometrial endometrioid adenocarcinoma samples (P = 0.05).\n'
p1942
sg4
(lp1943
(dp1944
g7
I26
sg8
g49
sg10
I12
sg11
VDkk3 protein
p1945
sg13
I2
sasg14
(lp1946
(dp1947
g7
I95
sg17
VC1336905
p1948
sg10
I39
sg11
Vendometrial endometrioid adenocarcinoma
p1949
sg13
I3
sasa(dp1950
g2
S'We investigated whether Dkk3 plays an important role in the carcinogenesis of endometrial cancer (EC).\n'
p1951
sg4
(lp1952
(dp1953
g7
I24
sg8
g49
sg10
I4
sg11
VDkk3
p1954
sg13
I1
sasg14
(lp1955
(dp1956
g7
I78
sg17
VC0476089
p1957
sg10
I18
sg11
Vendometrial cancer
p1958
sg13
I2
sa(dp1959
g7
I98
sg17
VC0476089
p1960
sg10
I2
sg11
VEC
p1961
sg13
I1
sa(dp1962
g7
I60
sg17
VC0596263
p1963
sg10
I14
sg11
Vcarcinogenesis
p1964
sg13
I1
sasa(dp1965
g2
S'Dkk3 gene expression is frequently downregulated in endometrial cancer, and is associated with poor prognostic clinicopathologic markers.\n'
p1966
sg4
(lp1967
(dp1968
g7
I0
sg8
g49
sg10
I9
sg11
VDkk3 gene
p1969
sg13
I2
sasg14
(lp1970
(dp1971
g7
I52
sg17
VC0476089
p1972
sg10
I18
sg11
Vendometrial cancer
p1973
sg13
I2
sasa(dp1974
g2
S'The levels of Dkk-3 protein were assessed by enzyme-linked immunosorbent assay in the sera of 104 patients with gynecological cancer: 36 with ovarian, 40 with cervical and 28 with endometrial cancers.\n'
p1975
sg4
(lp1976
(dp1977
g7
I14
sg8
g49
sg10
I13
sg11
VDkk-3 protein
p1978
sg13
I2
sasg14
(lp1979
(dp1980
g7
I180
sg17
VC0476089
p1981
sg10
I19
sg11
Vendometrial cancers
p1982
sg13
I2
sa(dp1983
g7
I126
sg17
VC0006826
p1984
sg10
I6
sg11
Vcancer
p1985
sg13
I1
sasa(dp1986
g2
S'But serum levels of Dkk-3 protein in patients with cervical [166.39 (300.68) pg/mL] (P = 0.013) and endometrial cancers [73.64 (23.36) pg/mL] (P = 0.000) were higher than in normal individuals.\n'
p1987
sg4
(lp1988
(dp1989
g7
I20
sg8
g49
sg10
I13
sg11
VDkk-3 protein
p1990
sg13
I2
sasg14
(lp1991
(dp1992
g7
I100
sg17
VC0476089
p1993
sg10
I19
sg11
Vendometrial cancers
p1994
sg13
I2
sasa(dp1995
g2
S'The serum levels of Dkk-3 protein were associated with clinical stage in patients with cervical and endometrial cancers.\n'
p1996
sg4
(lp1997
(dp1998
g7
I20
sg8
g49
sg10
I13
sg11
VDkk-3 protein
p1999
sg13
I2
sasg14
(lp2000
(dp2001
g7
I100
sg17
VC0476089
p2002
sg10
I19
sg11
Vendometrial cancers
p2003
sg13
I2
sasa(dp2004
g2
S'Dkk-3 protein detection using enzyme-linked immunosorbent assay as molecular markers can contribute to detection and diagnosis of gynecological cancer, especially for ovarian cancer and endometrial cancer.\n'
p2005
sg4
(lp2006
(dp2007
g7
I0
sg8
g49
sg10
I13
sg11
VDkk-3 protein
p2008
sg13
I2
sasg14
(lp2009
(dp2010
g7
I167
sg17
VC1140680
p2011
sg10
I14
sg11
Vovarian cancer
p2012
sg13
I2
sa(dp2013
g7
I186
sg17
VC0476089
p2014
sg10
I18
sg11
Vendometrial cancer
p2015
sg13
I2
sa(dp2016
g7
I144
sg17
VC0006826
p2017
sg10
I6
sg11
Vcancer
p2018
sg13
I1
sasa(dp2019
g2
S'Gene expressions of ARG1, CTSL, COX2, and IL6 were higher in tumor-infiltrating CD11b(+)CD11c(+) cells compared with PBMCs isolated from colorectal cancer patients.\n'
p2020
sg4
(lp2021
(dp2022
g7
I26
sg8
VP07711
p2023
sg10
I4
sg11
VCTSL
p2024
sg13
I1
sa(dp2025
g7
I32
sg8
VP35354
p2026
sg10
I4
sg11
VCOX2
p2027
sg13
I1
sa(dp2028
g7
I42
sg8
VP05231
p2029
sg10
I3
sg11
VIL6
p2030
sg13
I1
sa(dp2031
g7
I20
sg8
VP05089
p2032
sg10
I4
sg11
VARG1
p2033
sg13
I1
sa(dp2034
g7
I80
sg8
VP11215
p2035
sg10
I13
sg11
VCD11b(+)CD11c
p2036
sg13
I1
sasg14
(lp2037
(dp2038
g7
I137
sg17
VC1527249
p2039
sg10
I17
sg11
Vcolorectal cancer
p2040
sg13
I2
sa(dp2041
g7
I61
sg17
VC0027651
p2042
sg10
I5
sg11
Vtumor
p2043
sg13
I1
sa(dp2044
g7
I67
sg17
VC0332448
p2045
sg10
I12
sg11
Vinfiltrating
p2046
sg13
I1
sasa(dp2047
g2
S'Expression of surface HLA-DR and CD86 on CD11b(+)CD11c(+) cells was down-regulated, and T cell-stimulating ability was attenuated compared with PBMCs, suggesting that an immunosuppressive phenotype might be induced by IL-6, ARG1, CTSL, and COX2 in tumor sites of colorectal cancer patients.\n'
p2048
sg4
(lp2049
(dp2050
g7
I41
sg8
VP11215
p2051
sg10
I13
sg11
VCD11b(+)CD11c
p2052
sg13
I1
sa(dp2053
g7
I14
sg8
VP30486
p2054
sg10
I14
sg11
Vsurface HLA-DR
p2055
sg13
I2
sa(dp2056
g7
I224
sg8
VP05089
p2057
sg10
I4
sg11
VARG1
p2058
sg13
I1
sa(dp2059
g7
I218
sg8
VP05231
p2060
sg10
I4
sg11
VIL-6
p2061
sg13
I1
sa(dp2062
g7
I240
sg8
VP35354
p2063
sg10
I4
sg11
VCOX2
p2064
sg13
I1
sa(dp2065
g7
I33
sg8
VP42081
p2066
sg10
I4
sg11
VCD86
p2067
sg13
I1
sa(dp2068
g7
I230
sg8
VP07711
p2069
sg10
I4
sg11
VCTSL
p2070
sg13
I1
sasg14
(lp2071
(dp2072
g7
I263
sg17
VC1527249
p2073
sg10
I17
sg11
Vcolorectal cancer
p2074
sg13
I2
sa(dp2075
g7
I248
sg17
VC0027651
p2076
sg10
I5
sg11
Vtumor
p2077
sg13
I1
sasa(dp2078
g2
S'Tumor-infiltrating CD11c(+) DCs in human colon cancer specimens were shown to produce CCL5.\n'
p2079
sg4
(lp2080
(dp2081
g7
I19
sg8
VP20702
p2082
sg10
I12
sg11
VCD11c(+) DCs
p2083
sg13
I2
sa(dp2084
g7
I86
sg8
VP13501
p2085
sg10
I4
sg11
VCCL5
p2086
sg13
I1
sasg14
(lp2087
(dp2088
g7
I6
sg17
VC0332448
p2089
sg10
I12
sg11
Vinfiltrating
p2090
sg13
I1
sa(dp2091
g7
I28
sg17
VC0268238
p2092
sg10
I3
sg11
VDCs
p2093
sg13
I1
sa(dp2094
g7
I0
sg17
VC0027651
p2095
sg10
I5
sg11
VTumor
p2096
sg13
I1
sa(dp2097
g7
I41
sg17
VC0699790
p2098
sg10
I12
sg11
Vcolon cancer
p2099
sg13
I2
sasa(dp2100
g2
S'To assess and compare cAIx in patients with peripheral arterial disease (PAD) and / or abdominal aortic aneurysm (AAA).\n'
p2101
sg4
(lp2102
sg14
(lp2103
(dp2104
g7
I73
sg17
VC1704436
p2105
sg10
I3
sg11
VPAD
p2106
sg13
I1
sa(dp2107
g7
I87
sg17
VC0162871
p2108
sg10
I25
sg11
Vabdominal aortic aneurysm
p2109
sg13
I3
sa(dp2110
g7
I44
sg17
VC1704436
p2111
sg10
I27
sg11
Vperipheral arterial disease
p2112
sg13
I3
sa(dp2113
g7
I114
sg17
VC0162871
p2114
sg10
I3
sg11
VAAA
p2115
sg13
I1
sasa(dp2116
g2
S'Differences in cAIx measurements between the three patient groups were tested by non-parametric tests and stepwise multivariate linear regression analysis to investigate associations with obstructive or aneurysmatic patterns of vascular disease.\n'
p2117
sg4
(lp2118
sg14
(lp2119
(dp2120
g7
I228
sg17
VC0042373
p2121
sg10
I16
sg11
Vvascular disease
p2122
sg13
I2
sasa(dp2123
g2
S'Non-invasive assessment of arterial stiffness in high-risk patients indicates that cAIx differs according to the pattern of vascular disease.\n'
p2124
sg4
(lp2125
(dp2126
g7
I83
sg8
g49
sg10
I4
sg11
VcAIx
p2127
sg13
I1
sasg14
(lp2128
(dp2129
g7
I36
sg17
VC0427008
p2130
sg10
I9
sg11
Vstiffness
p2131
sg13
I1
sa(dp2132
g7
I124
sg17
VC0042373
p2133
sg10
I16
sg11
Vvascular disease
p2134
sg13
I2
sasa(dp2135
g2
S'In the present study, we investigated the prevalence of rs2424913 single nucleotide polymorphism located in DNMT3B gene Promotor by restriction fragment length polymorphism (PCR-RFLP) in Egyptian pediatric chronic immune thrombocytopenia (ITP) patients and controls.\n'
p2136
sg4
(lp2137
(dp2138
g7
I108
sg8
g49
sg10
I11
sg11
VDNMT3B gene
p2139
sg13
I2
sasg14
(lp2140
(dp2141
g7
I214
sg17
VC0272286
p2142
sg10
I23
sg11
Vimmune thrombocytopenia
p2143
sg13
I2
sa(dp2144
g7
I239
sg17
VC0043117
p2145
sg10
I3
sg11
VITP
p2146
sg13
I1
sasa(dp2147
g2
S'The current study investigated the association between DNMT3B 579G&gt;T and the risk for idiopathic thrombocytopenic purpura (ITP).\n'
p2148
sg4
(lp2149
(dp2150
g7
I55
sg8
g49
sg10
I11
sg11
VDNMT3B 579G
p2151
sg13
I2
sasg14
(lp2152
(dp2153
g7
I89
sg17
VC0043117
p2154
sg10
I35
sg11
Vidiopathic thrombocytopenic purpura
p2155
sg13
I3
sa(dp2156
g7
I126
sg17
VC0043117
p2157
sg10
I3
sg11
VITP
p2158
sg13
I1
sasa(dp2159
g2
S'The purpose of this study was to investigate the association between the single nucleotide polymorphism (SNP) in promoter of the DNMT3B gene and the risk for development of idiopathic thrombocytopenic purpura (ITP).\n'
p2160
sg4
(lp2161
(dp2162
g7
I129
sg8
g49
sg10
I11
sg11
VDNMT3B gene
p2163
sg13
I2
sasg14
(lp2164
(dp2165
g7
I173
sg17
VC0043117
p2166
sg10
I35
sg11
Vidiopathic thrombocytopenic purpura
p2167
sg13
I3
sa(dp2168
g7
I210
sg17
VC0043117
p2169
sg10
I3
sg11
VITP
p2170
sg13
I1
sasa(dp2171
g2
S'18F-fluorodeoxyglucose (FDG) positron emission tomography-(PET)/computed tomography (CT) imaging is used for staging and treatment planning of patients with anal cancer.\n'
p2172
sg4
(lp2173
sg14
(lp2174
(dp2175
g7
I157
sg17
VC0153446
p2176
sg10
I11
sg11
Vanal cancer
p2177
sg13
I2
sasa(dp2178
g2
S'The aim of this study was to evaluate the relevance of PET/CT and 18F-FDG as a strategy for response evaluation after chemoradiotherapy for anal cancer.\n'
p2179
sg4
(lp2180
sg14
(lp2181
(dp2182
g7
I140
sg17
VC0153446
p2183
sg10
I11
sg11
Vanal cancer
p2184
sg13
I2
sasa(dp2185
g2
S'Conclusion:18F-FDG PET/CT shows good accuracy in posttreatment evaluation of anal cancer and has a relevant impact on patient management.\n'
p2186
sg4
(lp2187
sg14
(lp2188
(dp2189
g7
I77
sg17
VC0153446
p2190
sg10
I11
sg11
Vanal cancer
p2191
sg13
I2
sasa(dp2192
g2
S'Thus, 18F-FDG PET/CT may play a significant role during posttreatment follow-up of anal cancer.\n'
p2193
sg4
(lp2194
sg14
(lp2195
(dp2196
g7
I83
sg17
VC0153446
p2197
sg10
I11
sg11
Vanal cancer
p2198
sg13
I2
sasa(dp2199
g2
S'FDG-PET/CT is considered to be a crucial tool in pretherapeutic assessment of esophageal, localized pancreatic and anal cancer.\n'
p2200
sg4
(lp2201
sg14
(lp2202
(dp2203
g7
I115
sg17
VC0153446
p2204
sg10
I11
sg11
Vanal cancer
p2205
sg13
I2
sasa(dp2206
g2
S'to determine whether [(18)F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography and X-ray computed tomography (PET/CT) findings and metabolic parameters before combined chemo- and radiotherapy (CRT) have a prognostic value in patients with anal carcinoma.\n'
p2207
sg4
(lp2208
sg14
(lp2209
(dp2210
g7
I247
sg17
VC0349534
p2211
sg10
I14
sg11
Vanal carcinoma
p2212
sg13
I2
sasa(dp2213
g2
S'45 patients with anal cancer who underwent pre-treatment FDG-PET/CT were included.\n'
p2214
sg4
(lp2215
sg14
(lp2216
(dp2217
g7
I17
sg17
VC0153446
p2218
sg10
I11
sg11
Vanal cancer
p2219
sg13
I2
sasa(dp2220
g2
S'the extent of disease on FDG PET/CT before combined radio-chemotherapy is strongly predictive of prognosis in anal cancer.\n'
p2221
sg4
(lp2222
sg14
(lp2223
(dp2224
g7
I110
sg17
VC0153446
p2225
sg10
I11
sg11
Vanal cancer
p2226
sg13
I2
sasa(dp2227
g2
S'Fluorine-18 fluorodeoxyglucose (F-FDG) PET-computed tomography (CT) is used in the assessment of anal cancer, but its routine use is not established.\n'
p2228
sg4
(lp2229
sg14
(lp2230
(dp2231
g7
I97
sg17
VC0153446
p2232
sg10
I11
sg11
Vanal cancer
p2233
sg13
I2
sasa(dp2234
g2
S'The aim of this study was to assess the value of F-FDG-PET-CT in staging and post-treatment assessment in anal cancer and to determine its impact on management.\n'
p2235
sg4
(lp2236
sg14
(lp2237
(dp2238
g7
I106
sg17
VC0153446
p2239
sg10
I11
sg11
Vanal cancer
p2240
sg13
I2
sasa(dp2241
g2
S'To test the hypothesis that irradiated volume of specific subregions of pelvic active bone marrow as detected by (18)FDG-PET may be a predictor of decreased blood cells nadirs in anal cancer patients undergoing concurrent chemoradiation, we analyzed 44 patients submitted to IMRT and concurrent chemotherapy.\n'
p2242
sg4
(lp2243
sg14
(lp2244
(dp2245
g7
I179
sg17
VC0153446
p2246
sg10
I11
sg11
Vanal cancer
p2247
sg13
I2
sasa(dp2248
g2
S'The cohort included 45 patients with nonmetastatic anal cancer who underwent FDG-PET imaging prior to definitive chemoradiation with mitomycin-C and 5-fluorouracil.\n'
p2249
sg4
(lp2250
sg14
(lp2251
(dp2252
g7
I51
sg17
VC0153446
p2253
sg10
I11
sg11
Vanal cancer
p2254
sg13
I2
sasa(dp2255
g2
S'We hypothesize that posttreatment F-18 fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) metabolic response predicts clinical outcomes in patients with anal cancer treated with chemoradiation.\n'
p2256
sg4
(lp2257
sg14
(lp2258
(dp2259
g7
I183
sg17
VC0153446
p2260
sg10
I11
sg11
Vanal cancer
p2261
sg13
I2
sasa(dp2262
g2
S'Complete metabolic response on posttreatment FDG PET-CT is highly predictive of increased PFS and OS in patients treated with chemoradiation for anal carcinoma.\n'
p2263
sg4
(lp2264
sg14
(lp2265
(dp2266
g7
I145
sg17
VC0349534
p2267
sg10
I14
sg11
Vanal carcinoma
p2268
sg13
I2
sasa(dp2269
g2
S'The present work studies the correlation of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) standardized uptake value (SUV) with tumor characteristics, clinical response and prognosis in a series of anal canal cancer patients treated with chemo-radiotherapy.\n'
p2270
sg4
(lp2271
sg14
(lp2272
(dp2273
g7
I169
sg17
VC0027651
p2274
sg10
I5
sg11
Vtumor
p2275
sg13
I1
sa(dp2276
g7
I239
sg17
VC0563211
p2277
sg10
I17
sg11
Vanal canal cancer
p2278
sg13
I3
sasa(dp2279
g2
S'Our data suggest that pre-treatment FDG-PET/CT SUVmax cannot directly predict tumor response and survival, but it is strongly associated with tumor characteristics such as primary tumor stage and histology, being the first one of the most important and validated prognostic factors for anal cancer.\n'
p2280
sg4
(lp2281
sg14
(lp2282
(dp2283
g7
I172
sg17
VC0677930
p2284
sg10
I13
sg11
Vprimary tumor
p2285
sg13
I2
sa(dp2286
g7
I78
sg17
VC0027651
p2287
sg10
I5
sg11
Vtumor
p2288
sg13
I1
sa(dp2289
g7
I286
sg17
VC0153446
p2290
sg10
I11
sg11
Vanal cancer
p2291
sg13
I2
sa(dp2292
g7
I78
sg17
VC0027651
p2293
sg10
I5
sg11
Vtumor
p2294
sg13
I1
sasa(dp2295
g2
S'All patients experienced at least one grade &gt;= 3 treatment-related adverse event, most commonly fatigue, elevated GGT, and lymphopenia.\n'
p2296
sg4
(lp2297
(dp2298
g7
I117
sg8
VP36268
p2299
sg10
I3
sg11
VGGT
p2300
sg13
I1
sasg14
(lp2301
(dp2302
g7
I99
sg17
VC0015672
p2303
sg10
I7
sg11
Vfatigue
p2304
sg13
I1
sa(dp2305
g7
I126
sg17
VC0024312
p2306
sg10
I11
sg11
Vlymphopenia
p2307
sg13
I1
sasa(dp2308
g2
S'PHC patients with hypersplenism who displayed elevated levels of alanine transaminase (ALT), aspartate transaminase (AST), Gamma-glutamyltransferase (GGT), ALK, phosphatase, and prolonged prothrombin time (PT) had a significantly increased risk of HCC.\n'
p2309
sg4
(lp2310
(dp2311
g7
I87
sg8
VP13716
p2312
sg10
I3
sg11
VALT
p2313
sg13
I1
sa(dp2314
g7
I117
sg8
VP51689
p2315
sg10
I3
sg11
VAST
p2316
sg13
I1
sa(dp2317
g7
I150
sg8
VP36268
p2318
sg10
I3
sg11
VGGT
p2319
sg13
I1
sa(dp2320
g7
I188
sg8
VP00734
p2321
sg10
I11
sg11
Vprothrombin
p2322
sg13
I1
sa(dp2323
g7
I65
sg8
VP24298
p2324
sg10
I20
sg11
Valanine transaminase
p2325
sg13
I2
sa(dp2326
g7
I123
sg8
VP36268
p2327
sg10
I25
sg11
VGamma-glutamyltransferase
p2328
sg13
I1
sa(dp2329
g7
I156
sg8
g49
sg10
I3
sg11
VALK
p2330
sg13
I1
sa(dp2331
g7
I93
sg8
VP17174
p2332
sg10
I22
sg11
Vaspartate transaminase
p2333
sg13
I2
sasg14
(lp2334
(dp2335
g7
I18
sg17
VC0020532
p2336
sg10
I13
sg11
Vhypersplenism
p2337
sg13
I1
sa(dp2338
g7
I248
sg17
VC2239176
p2339
sg10
I3
sg11
VHCC
p2340
sg13
I1
sasa(dp2341
g2
S'In patients with PHC and hypersplenism, abnormal levels of ALT, AST, ALP, and GGT and prolonged PT are risk factors of HCC.\n'
p2342
sg4
(lp2343
(dp2344
g7
I64
sg8
VP51689
p2345
sg10
I3
sg11
VAST
p2346
sg13
I1
sa(dp2347
g7
I69
sg8
VP03973
p2348
sg10
I3
sg11
VALP
p2349
sg13
I1
sa(dp2350
g7
I78
sg8
VP36268
p2351
sg10
I3
sg11
VGGT
p2352
sg13
I1
sa(dp2353
g7
I59
sg8
VP13716
p2354
sg10
I3
sg11
VALT
p2355
sg13
I1
sasg14
(lp2356
(dp2357
g7
I119
sg17
VC2239176
p2358
sg10
I3
sg11
VHCC
p2359
sg13
I1
sa(dp2360
g7
I25
sg17
VC0020532
p2361
sg10
I13
sg11
Vhypersplenism
p2362
sg13
I1
sasa(dp2363
g2
S'Two years later, laboratory findings revealed high levels of aminotransferases and Gamma-glutamyltransferase (GGT), thrombocytopenia, and neutropenia.\n'
p2364
sg4
(lp2365
(dp2366
g7
I110
sg8
VP36268
p2367
sg10
I3
sg11
VGGT
p2368
sg13
I1
sa(dp2369
g7
I83
sg8
VP36268
p2370
sg10
I25
sg11
VGamma-glutamyltransferase
p2371
sg13
I1
sasg14
(lp2372
sa(dp2373
g2
S'Cancer-selective tetra-branched peptides, named NT4, can be coupled to different functional units for cancer cell imaging or therapy.\n'
p2374
sg4
(lp2375
(dp2376
g7
I48
sg8
VP34130
p2377
sg10
I3
sg11
VNT4
p2378
sg13
I1
sasg14
(lp2379
(dp2380
g7
I0
sg17
VC0006826
p2381
sg10
I6
sg11
VCancer
p2382
sg13
I1
sa(dp2383
g7
I102
sg17
VC0006826
p2384
sg10
I6
sg11
Vcancer
p2385
sg13
I1
sasa(dp2386
g2
S'NT4 peptides specifically bind to lipoprotein receptor-related proteins (LRP) receptors and to heparan sulfate chains on membrane proteoglycans and can be efficiently internalized by cancer cells expressing these membrane targets.\n'
p2387
sg4
(lp2388
(dp2389
g7
I34
sg8
g49
sg10
I37
sg11
Vlipoprotein receptor-related proteins
p2390
sg13
I3
sa(dp2391
g7
I73
sg8
g49
sg10
I3
sg11
VLRP
p2392
sg13
I1
sa(dp2393
g7
I0
sg8
VP34130
p2394
sg10
I3
sg11
VNT4
p2395
sg13
I1
sasg14
(lp2396
(dp2397
g7
I183
sg17
VC0006826
p2398
sg10
I6
sg11
Vcancer
p2399
sg13
I1
sasa(dp2400
g2
S'Since binding and internalization of NT4 peptides is mediated by specific NT4 receptors on cancer cell membranes and this may allow drug resistance produced by drug membrane transporters to be by-passed, we tested the ability of drug-armed NT4 to by-pass drug resistance in cancer cell lines.\n'
p2401
sg4
(lp2402
(dp2403
g7
I74
sg8
VP34130
p2404
sg10
I13
sg11
VNT4 receptors
p2405
sg13
I2
sa(dp2406
g7
I37
sg8
VP34130
p2407
sg10
I12
sg11
VNT4 peptides
p2408
sg13
I2
sasg14
(lp2409
(dp2410
g7
I91
sg17
VC0006826
p2411
sg10
I6
sg11
Vcancer
p2412
sg13
I1
sa(dp2413
g7
I91
sg17
VC0006826
p2414
sg10
I6
sg11
Vcancer
p2415
sg13
I1
sasa(dp2416
g2
S'We found that MTX-conjugated NT4 allows drug resistance to be by-passed in MTX-resistant human breast cancer cells lacking expression of folate reduced carrier.\n'
p2417
sg4
(lp2418
sg14
(lp2419
(dp2420
g7
I95
sg17
VC0678222
p2421
sg10
I13
sg11
Vbreast cancer
p2422
sg13
I2
sasa(dp2423
g2
S'NT4 peptides appear to be extremely promising cancer-selective targeting agents that can be exploited as theranostics in personalized oncological applications.\n'
p2424
sg4
(lp2425
(dp2426
g7
I0
sg8
VP34130
p2427
sg10
I3
sg11
VNT4
p2428
sg13
I1
sasg14
(lp2429
(dp2430
g7
I46
sg17
VC0006826
p2431
sg10
I6
sg11
Vcancer
p2432
sg13
I1
sasa(dp2433
g2
S'However, the accurate implication of the two specific ligands of tropomyosin kinase B receptor, BDNF and neurotrophic factor 4 (NT4/5), has not been studied in colorectal cancer (CRC) patients.\n'
p2434
sg4
(lp2435
(dp2436
g7
I128
sg8
VP34130
p2437
sg10
I5
sg11
VNT4/5
p2438
sg13
I1
sa(dp2439
g7
I96
sg8
VP34130
p2440
sg10
I30
sg11
VBDNF and neurotrophic factor 4
p2441
sg13
I5
sa(dp2442
g7
I65
sg8
VP07951
p2443
sg10
I29
sg11
Vtropomyosin kinase B receptor
p2444
sg13
I4
sasg14
(lp2445
(dp2446
g7
I179
sg17
VC1527249
p2447
sg10
I3
sg11
VCRC
p2448
sg13
I1
sa(dp2449
g7
I160
sg17
VC1527249
p2450
sg10
I17
sg11
Vcolorectal cancer
p2451
sg13
I2
sasa(dp2452
g2
S'As BDNF and NT4/5 are implicated in the response of psychoactive treatments applied to manage depression, which frequently occurs in cancer patients, they cannot be used as prognostic or diagnostic markers for CRC in these patients.\n'
p2453
sg4
(lp2454
(dp2455
g7
I12
sg8
VP34130
p2456
sg10
I5
sg11
VNT4/5
p2457
sg13
I1
sasg14
(lp2458
(dp2459
g7
I210
sg17
VC1527249
p2460
sg10
I3
sg11
VCRC
p2461
sg13
I1
sa(dp2462
g7
I94
sg17
VC0011581
p2463
sg10
I10
sg11
Vdepression
p2464
sg13
I1
sa(dp2465
g7
I133
sg17
VC0006826
p2466
sg10
I6
sg11
Vcancer
p2467
sg13
I1
sasa(dp2468
g2
S'Finally, the cortical spinal tract regeneration was detected by DBA tracing at 4 weeks post operation, and the expression of nerve growth factor (NGF), BDNF, neurotrophic factor (NT)-3, NT-4, fibroblast growth factor (FGF-2)-2, B cell lymphoma 2 (BCL-2) assaciated X protein (BAX) and BCL-2 in the caudal cord tissues was assessed by reverse transcription-PCR.\n'
p2469
sg4
(lp2470
(dp2471
g7
I146
sg8
VP01138
p2472
sg10
I3
sg11
VNGF
p2473
sg13
I1
sa(dp2474
g7
I247
sg8
VP10415
p2475
sg10
I5
sg11
VBCL-2
p2476
sg13
I1
sa(dp2477
g7
I125
sg8
VP01138
p2478
sg10
I19
sg11
Vnerve growth factor
p2479
sg13
I3
sa(dp2480
g7
I192
sg8
g49
sg10
I24
sg11
Vfibroblast growth factor
p2481
sg13
I3
sa(dp2482
g7
I152
sg8
VP20783
p2483
sg10
I32
sg11
VBDNF, neurotrophic factor (NT)-3
p2484
sg13
I4
sa(dp2485
g7
I247
sg8
VP10415
p2486
sg10
I5
sg11
VBCL-2
p2487
sg13
I1
sa(dp2488
g7
I228
sg8
VP10415
p2489
sg10
I17
sg11
VB cell lymphoma 2
p2490
sg13
I4
sasg14
(lp2491
(dp2492
g7
I64
sg17
VC0398550
p2493
sg10
I3
sg11
VDBA
p2494
sg13
I1
sa(dp2495
g7
I305
sg17
VC0035334
p2496
sg10
I4
sg11
Vcord
p2497
sg13
I1
sa(dp2498
g7
I228
sg17
VC0079731
p2499
sg10
I15
sg11
VB cell lymphoma
p2500
sg13
I3
sasa(dp2501
g2
S'The tetra-branched peptide NT4 selectively binds to different human cancer cells and tissues.\n'
p2502
sg4
(lp2503
sg14
(lp2504
(dp2505
g7
I68
sg17
VC0006826
p2506
sg10
I6
sg11
Vcancer
p2507
sg13
I1
sasa(dp2508
g2
S'NT4 specifically binds to sulfated glycosaminoglycans on cancer cell membranes.\n'
p2509
sg4
(lp2510
(dp2511
g7
I0
sg8
VP34130
p2512
sg10
I3
sg11
VNT4
p2513
sg13
I1
sasg14
(lp2514
(dp2515
g7
I57
sg17
VC0006826
p2516
sg10
I6
sg11
Vcancer
p2517
sg13
I1
sasa(dp2518
g2
S'Since sulfated glycosaminoglycans are involved in cancer cell interaction with the extracellular matrix, we evaluated the effect of NT4 on cancer cell adhesion and migration.\n'
p2519
sg4
(lp2520
(dp2521
g7
I132
sg8
VP34130
p2522
sg10
I3
sg11
VNT4
p2523
sg13
I1
sasg14
(lp2524
(dp2525
g7
I50
sg17
VC0006826
p2526
sg10
I6
sg11
Vcancer
p2527
sg13
I1
sa(dp2528
g7
I151
sg17
VC0001511
p2529
sg10
I8
sg11
Vadhesion
p2530
sg13
I1
sa(dp2531
g7
I50
sg17
VC0006826
p2532
sg10
I6
sg11
Vcancer
p2533
sg13
I1
sasa(dp2534
g2
S'NT4 inhibits cancer cell adhesion and migration on different proteins, without modifying cancer cell morphology or their ability to produce protrusions, but dramatically affecting the directionality and polarity of cell movement.\n'
p2535
sg4
(lp2536
(dp2537
g7
I0
sg8
VP34130
p2538
sg10
I3
sg11
VNT4
p2539
sg13
I1
sasg14
(lp2540
(dp2541
g7
I140
sg17
VC0333056
p2542
sg10
I11
sg11
Vprotrusions
p2543
sg13
I1
sa(dp2544
g7
I25
sg17
VC0001511
p2545
sg10
I8
sg11
Vadhesion
p2546
sg13
I1
sa(dp2547
g7
I13
sg17
VC0006826
p2548
sg10
I6
sg11
Vcancer
p2549
sg13
I1
sa(dp2550
g7
I13
sg17
VC0006826
p2551
sg10
I6
sg11
Vcancer
p2552
sg13
I1
sasa(dp2553
g2
S'Results obtained by taking advantage of the selective targeting of glycosaminoglycans chains by NT4, provide insights into the role of heparan sulfate proteoglycans in cancer cell adhesion and migration and suggest a determinant role of sulfated glycosaminoglycans in the control of cancer cell directional migration.\n'
p2554
sg4
(lp2555
sg14
(lp2556
(dp2557
g7
I180
sg17
VC0001511
p2558
sg10
I8
sg11
Vadhesion
p2559
sg13
I1
sa(dp2560
g7
I168
sg17
VC0006826
p2561
sg10
I6
sg11
Vcancer
p2562
sg13
I1
sa(dp2563
g7
I168
sg17
VC0006826
p2564
sg10
I6
sg11
Vcancer
p2565
sg13
I1
sasa(dp2566
g2
S'Biological activity of NT4-paclitaxel was tested in vitro on MDA-MB 231 and SKOV-3 cell lines, representing breast and ovarian cancer, respectively, and in vivo in an orthotopic mouse model of human breast cancer.\n'
p2567
sg4
(lp2568
sg14
(lp2569
(dp2570
g7
I119
sg17
VC1140680
p2571
sg10
I14
sg11
Vovarian cancer
p2572
sg13
I2
sa(dp2573
g7
I199
sg17
VC0678222
p2574
sg10
I13
sg11
Vbreast cancer
p2575
sg13
I2
sasa(dp2576
g2
S'To evaluate novel clinical markers of endometriosis including the neurotrophins brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin 4/5 (NT4/5) and compare them to others previously reported in the literature including cancer antigen 125 (CA-125) and C-reactive protein (CRP).\n'
p2577
sg4
(lp2578
(dp2579
g7
I143
sg8
VP01138
p2580
sg10
I3
sg11
VNGF
p2581
sg13
I1
sa(dp2582
g7
I253
sg8
VP14209
p2583
sg10
I18
sg11
Vcancer antigen 125
p2584
sg13
I3
sa(dp2585
g7
I153
sg8
VP34130
p2586
sg10
I16
sg11
Vneurotrophin 4/5
p2587
sg13
I2
sa(dp2588
g7
I122
sg8
VP01138
p2589
sg10
I19
sg11
Vnerve growth factor
p2590
sg13
I3
sa(dp2591
g7
I273
sg8
g49
sg10
I6
sg11
VCA-125
p2592
sg13
I1
sa(dp2593
g7
I66
sg8
g49
sg10
I54
sg11
Vneurotrophins brain-derived neurotrophic factor (BDNF)
p2594
sg13
I5
sa(dp2595
g7
I305
sg8
VP02741
p2596
sg10
I3
sg11
VCRP
p2597
sg13
I1
sa(dp2598
g7
I285
sg8
VP02741
p2599
sg10
I18
sg11
VC-reactive protein
p2600
sg13
I2
sa(dp2601
g7
I171
sg8
VP34130
p2602
sg10
I5
sg11
VNT4/5
p2603
sg13
I1
sasg14
(lp2604
(dp2605
g7
I38
sg17
VC0014175
p2606
sg10
I13
sg11
Vendometriosis
p2607
sg13
I1
sa(dp2608
g7
I253
sg17
VC0006826
p2609
sg10
I6
sg11
Vcancer
p2610
sg13
I1
sasa(dp2611
g2
S'These results indicated that rAAV-NT4-TAT-6His-Shepherdin may be considered a novel therapeutic strategy in the gene therapy for gallbladder carcinoma.\n'
p2612
sg4
(lp2613
(dp2614
g7
I29
sg8
VP17735
p2615
sg10
I28
sg11
VrAAV-NT4-TAT-6His-Shepherdin
p2616
sg13
I1
sasg14
(lp2617
(dp2618
g7
I129
sg17
VC0235782
p2619
sg10
I21
sg11
Vgallbladder carcinoma
p2620
sg13
I2
sasa(dp2621
g2
S'In the present study, the tetrabranched neurotensin peptide NT4 was conjugated with functional units for cancer-cell imaging or therapy and was tested on bladder cancer cell lines and specimens from bladder cancer surgical resections, in order to evaluate its potential for targeted personalized therapy of bladder cancer.\n'
p2622
sg4
(lp2623
(dp2624
g7
I26
sg8
VP30990
p2625
sg10
I37
sg11
Vtetrabranched neurotensin peptide NT4
p2626
sg13
I4
sasg14
(lp2627
(dp2628
g7
I105
sg17
VC0006826
p2629
sg10
I6
sg11
Vcancer
p2630
sg13
I1
sa(dp2631
g7
I154
sg17
VC0699885
p2632
sg10
I14
sg11
Vbladder cancer
p2633
sg13
I2
sa(dp2634
g7
I154
sg17
VC0699885
p2635
sg10
I14
sg11
Vbladder cancer
p2636
sg13
I2
sa(dp2637
g7
I154
sg17
VC0699885
p2638
sg10
I14
sg11
Vbladder cancer
p2639
sg13
I2
sasa(dp2640
g2
S'Fluorophore-conjugated NT4 distinguished healthy and cancer tissues with good statistical significance (P &lt; 0.05).\n'
p2641
sg4
(lp2642
sg14
(lp2643
(dp2644
g7
I53
sg17
VC0006826
p2645
sg10
I6
sg11
Vcancer
p2646
sg13
I1
sasa(dp2647
g2
S'NT4 conjugated to methotrexate or gemcitabine was cytotoxic for human bladder cancer cell lines at micromolar concentrations.\n'
p2648
sg4
(lp2649
(dp2650
g7
I0
sg8
VP34130
p2651
sg10
I3
sg11
VNT4
p2652
sg13
I1
sasg14
(lp2653
(dp2654
g7
I70
sg17
VC0699885
p2655
sg10
I14
sg11
Vbladder cancer
p2656
sg13
I2
sasa(dp2657
g2
S'Their selectivity for bladder cancer tissue and capacity to carry tracers or drugs make NT4 peptides candidate tumor targeting agents for tracing cancer cells and for personalized therapy of human bladder cancer.\n'
p2658
sg4
(lp2659
sg14
(lp2660
(dp2661
g7
I111
sg17
VC0027651
p2662
sg10
I5
sg11
Vtumor
p2663
sg13
I1
sa(dp2664
g7
I22
sg17
VC0699885
p2665
sg10
I14
sg11
Vbladder cancer
p2666
sg13
I2
sa(dp2667
g7
I30
sg17
VC0006826
p2668
sg10
I6
sg11
Vcancer
p2669
sg13
I1
sa(dp2670
g7
I22
sg17
VC0699885
p2671
sg10
I14
sg11
Vbladder cancer
p2672
sg13
I2
sasa(dp2673
g2
S'The phenotype is the result of haploinsufficiency of at least two regions on 10p, the HDR1 region associated with hypoparathyroidism, sensorineural deafness, and renal defects (HDR syndrome) and the more proximal region DGCR2 responsible for heart defects and thymus hypoplasia/aplasia.\n'
p2674
sg4
(lp2675
(dp2676
g7
I86
sg8
g49
sg10
I11
sg11
VHDR1 region
p2677
sg13
I2
sasg14
(lp2678
(dp2679
g7
I114
sg17
VC0020626
p2680
sg10
I18
sg11
Vhypoparathyroidism
p2681
sg13
I1
sa(dp2682
g7
I278
sg17
VC0243065
p2683
sg10
I7
sg11
Vaplasia
p2684
sg13
I1
sa(dp2685
g7
I134
sg17
VC0018784
p2686
sg10
I22
sg11
Vsensorineural deafness
p2687
sg13
I2
sa(dp2688
g7
I260
sg17
VC0685891
p2689
sg10
I17
sg11
Vthymus hypoplasia
p2690
sg13
I2
sa(dp2691
g7
I177
sg17
VC1840333
p2692
sg10
I12
sg11
VHDR syndrome
p2693
sg13
I2
sa(dp2694
g7
I242
sg17
VC0018798
p2695
sg10
I13
sg11
Vheart defects
p2696
sg13
I2
sasa(dp2697
g2
S'Six miRNAs previously identified as prognostic markers in Asian patients (miR-21-5p, miR-20a-5p, miR-103a-3p, miR-106b-5p, miR-143-5p, and miR-215) were studied in tumor samples from 71 white patients with stage II colon cancer.\n'
p2698
sg4
(lp2699
(dp2700
g7
I110
sg8
g49
sg10
I11
sg11
VmiR-106b-5p
p2701
sg13
I1
sa(dp2702
g7
I85
sg8
g49
sg10
I10
sg11
VmiR-20a-5p
p2703
sg13
I1
sa(dp2704
g7
I123
sg8
g49
sg10
I10
sg11
VmiR-143-5p
p2705
sg13
I1
sa(dp2706
g7
I97
sg8
g49
sg10
I11
sg11
VmiR-103a-3p
p2707
sg13
I1
sasg14
(lp2708
(dp2709
g7
I206
sg17
VC0278479
p2710
sg10
I21
sg11
Vstage II colon cancer
p2711
sg13
I4
sa(dp2712
g7
I164
sg17
VC0027651
p2713
sg10
I5
sg11
Vtumor
p2714
sg13
I1
sasa(dp2715
g2
S'The 6 circulating miRNAs most frequently found to be dysregulated in colorectal cancer are miR-18a-5p, miR-21-5p, miR-29a-5p, miR-92a-5p, miR-143-5p and miR-378-5p.\n'
p2716
sg4
(lp2717
(dp2718
g7
I114
sg8
g49
sg10
I10
sg11
VmiR-29a-5p
p2719
sg13
I1
sa(dp2720
g7
I103
sg8
g49
sg10
I9
sg11
VmiR-21-5p
p2721
sg13
I1
sa(dp2722
g7
I153
sg8
g49
sg10
I10
sg11
VmiR-378-5p
p2723
sg13
I1
sa(dp2724
g7
I138
sg8
g49
sg10
I10
sg11
VmiR-143-5p
p2725
sg13
I1
sa(dp2726
g7
I91
sg8
g49
sg10
I10
sg11
VmiR-18a-5p
p2727
sg13
I1
sa(dp2728
g7
I126
sg8
g49
sg10
I10
sg11
VmiR-92a-5p
p2729
sg13
I1
sasg14
(lp2730
(dp2731
g7
I69
sg17
VC1527249
p2732
sg10
I17
sg11
Vcolorectal cancer
p2733
sg13
I2
sasa(dp2734
g2
S'We transfected HCT-116, a highly invasive colon cancer cell line, with corresponding downregulated miRNA and demonstrated that overexpression of three miRNA (miR200c*, miR143*, and miR424*) significantly abrogated invasive potential.\n'
p2735
sg4
(lp2736
sg14
(lp2737
(dp2738
g7
I42
sg17
VC0699790
p2739
sg10
I12
sg11
Vcolon cancer
p2740
sg13
I2
sasa(dp2741
g2
S'This study demonstrated that the TRI-HFT is a reliable and sensitive measure to assess unilateral hand gross motor function in persons with tetraplegia, with moderate to strong construct validity.\n'
p2742
sg4
(lp2743
(dp2744
g7
I33
sg8
g49
sg10
I7
sg11
VTRI-HFT
p2745
sg13
I1
sasg14
(lp2746
(dp2747
g7
I140
sg17
VC0034372
p2748
sg10
I11
sg11
Vtetraplegia
p2749
sg13
I1
sasa(dp2750
g2
S"For the patients with RD without anti-inflammatory optimization, those with mutant XIAP and FOXP3 died of Crohn's-like colitis and electrolyte exhaustion in awaiting transplantation, while transplantation cured the STAT1 patient.\n"
p2751
sg4
(lp2752
(dp2753
g7
I92
sg8
g49
sg10
I5
sg11
VFOXP3
p2754
sg13
I1
sa(dp2755
g7
I83
sg8
VP98170
p2756
sg10
I4
sg11
VXIAP
p2757
sg13
I1
sa(dp2758
g7
I215
sg8
VP42224
p2759
sg10
I5
sg11
VSTAT1
p2760
sg13
I1
sasg14
(lp2761
(dp2762
g7
I143
sg17
VC0392674
p2763
sg10
I10
sg11
Vexhaustion
p2764
sg13
I1
sa(dp2765
g7
I76
sg17
VC0596988
p2766
sg10
I6
sg11
Vmutant
p2767
sg13
I1
sa(dp2768
g7
I106
sg17
VC0010346
p2769
sg10
I7
sg11
VCrohn's
p2770
sg13
I1
sa(dp2771
g7
I119
sg17
VC0009319
p2772
sg10
I7
sg11
Vcolitis
p2773
sg13
I1
sasa(dp2774
g2
S'Our results show that alliin ameliorates DSS-induced ulcerative colitis and inhibits the inflammatory responses in LPS-stimulated RAW264.7 cells partly through inhibiting ERK1/2-, JNK-/PPAR-Gamma-stimulated NF-KB/AP-1/STAT-1 activations.\n'
p2775
sg4
(lp2776
(dp2777
g7
I213
sg8
VP01100
p2778
sg10
I4
sg11
VAP-1
p2779
sg13
I1
sa(dp2780
g7
I171
sg8
VP27361
p2781
sg10
I24
sg11
VERK1/2-, JNK-/PPAR-Gamma
p2782
sg13
I2
sa(dp2783
g7
I218
sg8
g49
sg10
I6
sg11
VSTAT-1
p2784
sg13
I1
sasg14
(lp2785
(dp2786
g7
I53
sg17
VC0009324
p2787
sg10
I18
sg11
Vulcerative colitis
p2788
sg13
I2
sa(dp2789
g7
I89
sg17
VC1155266
p2790
sg10
I22
sg11
Vinflammatory responses
p2791
sg13
I2
sa(dp2792
g7
I41
sg17
VC0011195
p2793
sg10
I3
sg11
VDSS
p2794
sg13
I1
sa(dp2795
g7
I115
sg17
VC0175697
p2796
sg10
I3
sg11
VLPS
p2797
sg13
I1
sasa(dp2798
g2
S'These data support a role for endogenous IFN-1 as a context-dependent modulator of T-cell function that promotes regulatory activity in healthy human intestine, but indicate that the IFN-1/STAT1 pathway is dysregulated in inflammatory bowel disease.\n'
p2799
sg4
(lp2800
(dp2801
g7
I41
sg8
VP01562
p2802
sg10
I5
sg11
VIFN-1
p2803
sg13
I1
sa(dp2804
g7
I41
sg8
VP01562
p2805
sg10
I5
sg11
VIFN-1
p2806
sg13
I1
sa(dp2807
g7
I189
sg8
VP42224
p2808
sg10
I5
sg11
VSTAT1
p2809
sg13
I1
sasg14
(lp2810
(dp2811
g7
I222
sg17
VC0021390
p2812
sg10
I26
sg11
Vinflammatory bowel disease
p2813
sg13
I3
sasa(dp2814
g2
S'In this study, we report an alternative mechanism by which integrin-linked kinase (ILK) post-transcriptionally modulates the expression of MUC1-C by maintaining its protein stability in pancreatic cancer cells.\n'
p2815
sg4
(lp2816
(dp2817
g7
I83
sg8
g49
sg10
I3
sg11
VILK
p2818
sg13
I1
sa(dp2819
g7
I59
sg8
g49
sg10
I22
sg11
Vintegrin-linked kinase
p2820
sg13
I2
sasg14
(lp2821
(dp2822
g7
I186
sg17
VC0235974
p2823
sg10
I17
sg11
Vpancreatic cancer
p2824
sg13
I2
sasa(dp2825
g2
S'From a mechanistic perspective, the present finding, together with our recent report that ILK controls the expression of oncogenic KRAS through a regulatory loop, underscores the pivotal role of ILK in promoting pancreatic cancer progression.\n'
p2826
sg4
(lp2827
(dp2828
g7
I90
sg8
g49
sg10
I3
sg11
VILK
p2829
sg13
I1
sa(dp2830
g7
I90
sg8
g49
sg10
I3
sg11
VILK
p2831
sg13
I1
sasg14
(lp2832
(dp2833
g7
I223
sg17
VC0178874
p2834
sg10
I18
sg11
Vcancer progression
p2835
sg13
I2
sasa(dp2836
g2
S'Our recent work demonstrated a KRAS-integrin-linked kinase (ILK) regulatory feedback loop that allows pancreatic cancer cells to regulate KRAS expression and to interact with the tumor microenvironment to promote aggressive phenotype.\n'
p2837
sg4
(lp2838
(dp2839
g7
I60
sg8
g49
sg10
I3
sg11
VILK
p2840
sg13
I1
sa(dp2841
g7
I31
sg8
VP01116
p2842
sg10
I4
sg11
VKRAS
p2843
sg13
I1
sa(dp2844
g7
I31
sg8
VP01116
p2845
sg10
I27
sg11
VKRAS-integrin-linked kinase
p2846
sg13
I2
sasg14
(lp2847
(dp2848
g7
I102
sg17
VC0235974
p2849
sg10
I17
sg11
Vpancreatic cancer
p2850
sg13
I2
sa(dp2851
g7
I213
sg17
VC0001807
p2852
sg10
I10
sg11
Vaggressive
p2853
sg13
I1
sa(dp2854
g7
I179
sg17
VC0027651
p2855
sg10
I5
sg11
Vtumor
p2856
sg13
I1
sasa(dp2857
g2
S"This regulatory loop, however, was not noted in KRAS mutant colorectal and lung cancer cells examined as knockdown of KRAS or ILK did not affect each other's expression, suggesting that this KRAS-ILK feedback regulation is specific for pancreatic cancer.\n"
p2858
sg4
(lp2859
(dp2860
g7
I126
sg8
g49
sg10
I3
sg11
VILK
p2861
sg13
I1
sa(dp2862
g7
I48
sg8
VP01116
p2863
sg10
I4
sg11
VKRAS
p2864
sg13
I1
sa(dp2865
g7
I48
sg8
VP01116
p2866
sg10
I11
sg11
VKRAS mutant
p2867
sg13
I2
sa(dp2868
g7
I48
sg8
VP01116
p2869
sg10
I4
sg11
VKRAS
p2870
sg13
I1
sa(dp2871
g7
I126
sg8
g49
sg10
I3
sg11
VILK
p2872
sg13
I1
sasg14
(lp2873
(dp2874
g7
I236
sg17
VC0235974
p2875
sg10
I17
sg11
Vpancreatic cancer
p2876
sg13
I2
sa(dp2877
g7
I75
sg17
VC0684249
p2878
sg10
I11
sg11
Vlung cancer
p2879
sg13
I2
sa(dp2880
g7
I53
sg17
VC0596988
p2881
sg10
I6
sg11
Vmutant
p2882
sg13
I1
sasa(dp2883
g2
S'In sum, this regulatory loop provides a strong mechanistic rationale for suppressing oncogenic KRAS signaling through targeting ILK, and this creating a potential new therapeutic strategy for pancreatic cancer.\n'
p2884
sg4
(lp2885
(dp2886
g7
I95
sg8
VP01116
p2887
sg10
I4
sg11
VKRAS
p2888
sg13
I1
sa(dp2889
g7
I128
sg8
g49
sg10
I3
sg11
VILK
p2890
sg13
I1
sasg14
(lp2891
(dp2892
g7
I192
sg17
VC0235974
p2893
sg10
I17
sg11
Vpancreatic cancer
p2894
sg13
I2
sasa(dp2895
g2
S'Recent data have revealed that KRAS is interconnected to ILK and hnRNP A1 in a circuitry that enables pancreatic cancer cells to maintain an aggressive phenotype.\n'
p2896
sg4
(lp2897
(dp2898
g7
I65
sg8
VP09651
p2899
sg10
I8
sg11
VhnRNP A1
p2900
sg13
I2
sa(dp2901
g7
I31
sg8
VP01116
p2902
sg10
I4
sg11
VKRAS
p2903
sg13
I1
sa(dp2904
g7
I57
sg8
g49
sg10
I3
sg11
VILK
p2905
sg13
I1
sasg14
(lp2906
(dp2907
g7
I102
sg17
VC0235974
p2908
sg10
I17
sg11
Vpancreatic cancer
p2909
sg13
I2
sa(dp2910
g7
I141
sg17
VC0001807
p2911
sg10
I10
sg11
Vaggressive
p2912
sg13
I1
sasa(dp2913
g2
S'Integrin-linked kinase (ILK) is a mediator of aggressive phenotype in pancreatic cancer.\n'
p2914
sg4
(lp2915
(dp2916
g7
I24
sg8
g49
sg10
I3
sg11
VILK
p2917
sg13
I1
sa(dp2918
g7
I0
sg8
g49
sg10
I22
sg11
VIntegrin-linked kinase
p2919
sg13
I2
sasg14
(lp2920
(dp2921
g7
I46
sg17
VC0001807
p2922
sg10
I10
sg11
Vaggressive
p2923
sg13
I1
sa(dp2924
g7
I70
sg17
VC0235974
p2925
sg10
I17
sg11
Vpancreatic cancer
p2926
sg13
I2
sasa(dp2927
g2
S"On the basis of our finding that knockdown of either KRAS or ILK has a reciprocal effect on the other's expression, we hypothesized the presence of an ILK-KRAS regulatory loop that enables pancreatic cancer cells to regulate KRAS expression.\n"
p2928
sg4
(lp2929
(dp2930
g7
I53
sg8
VP01116
p2931
sg10
I4
sg11
VKRAS
p2932
sg13
I1
sa(dp2933
g7
I53
sg8
VP01116
p2934
sg10
I4
sg11
VKRAS
p2935
sg13
I1
sa(dp2936
g7
I61
sg8
g49
sg10
I3
sg11
VILK
p2937
sg13
I1
sa(dp2938
g7
I61
sg8
g49
sg10
I3
sg11
VILK
p2939
sg13
I1
sa(dp2940
g7
I53
sg8
VP01116
p2941
sg10
I4
sg11
VKRAS
p2942
sg13
I1
sasg14
(lp2943
(dp2944
g7
I189
sg17
VC0235974
p2945
sg10
I17
sg11
Vpancreatic cancer
p2946
sg13
I2
sasa(dp2947
g2
S'This study aimed to elucidate the mechanism by which this regulatory circuitry is regulated and to investigate the translational potential of targeting ILK to suppress oncogenic KRAS signaling in pancreatic cancer.\n'
p2948
sg4
(lp2949
(dp2950
g7
I152
sg8
g49
sg10
I3
sg11
VILK
p2951
sg13
I1
sa(dp2952
g7
I168
sg8
VP01116
p2953
sg10
I14
sg11
Voncogenic KRAS
p2954
sg13
I2
sasg14
(lp2955
(dp2956
g7
I196
sg17
VC0235974
p2957
sg10
I17
sg11
Vpancreatic cancer
p2958
sg13
I2
sasa(dp2959
g2
S'The knockdown or pharmacological inhibition of ILK suppressed pancreatic tumor growth, in part, by suppressing KRAS signaling.\n'
p2960
sg4
(lp2961
(dp2962
g7
I111
sg8
VP01116
p2963
sg10
I4
sg11
VKRAS
p2964
sg13
I1
sa(dp2965
g7
I47
sg8
g49
sg10
I3
sg11
VILK
p2966
sg13
I1
sasg14
(lp2967
(dp2968
g7
I62
sg17
VC0030297
p2969
sg10
I16
sg11
Vpancreatic tumor
p2970
sg13
I2
sasa(dp2971
g2
S'These studies suggest that this KRAS-E2F1-ILK-hnRNPA1 regulatory loop enables pancreatic cancer cells to promote oncogenic KRAS signaling and to interact with the tumor microenvironment to promote aggressive phenotypes.\n'
p2972
sg4
(lp2973
(dp2974
g7
I46
sg8
VP09651
p2975
sg10
I7
sg11
VhnRNPA1
p2976
sg13
I1
sa(dp2977
g7
I32
sg8
VP01116
p2978
sg10
I4
sg11
VKRAS
p2979
sg13
I1
sa(dp2980
g7
I113
sg8
VP01116
p2981
sg10
I14
sg11
Voncogenic KRAS
p2982
sg13
I2
sa(dp2983
g7
I42
sg8
g49
sg10
I3
sg11
VILK
p2984
sg13
I1
sa(dp2985
g7
I37
sg8
g49
sg10
I4
sg11
VE2F1
p2986
sg13
I1
sasg14
(lp2987
(dp2988
g7
I163
sg17
VC0027651
p2989
sg10
I5
sg11
Vtumor
p2990
sg13
I1
sa(dp2991
g7
I197
sg17
VC0001807
p2992
sg10
I10
sg11
Vaggressive
p2993
sg13
I1
sa(dp2994
g7
I78
sg17
VC0235974
p2995
sg10
I17
sg11
Vpancreatic cancer
p2996
sg13
I2
sasa(dp2997
g2
S'This regulatory loop provides a mechanistic rationale for targeting ILK to suppress oncogenic KRAS signaling, which might foster new therapeutic strategies for pancreatic cancer.\n'
p2998
sg4
(lp2999
(dp3000
g7
I68
sg8
g49
sg10
I3
sg11
VILK
p3001
sg13
I1
sa(dp3002
g7
I84
sg8
VP01116
p3003
sg10
I14
sg11
Voncogenic KRAS
p3004
sg13
I2
sasg14
(lp3005
(dp3006
g7
I160
sg17
VC0235974
p3007
sg10
I17
sg11
Vpancreatic cancer
p3008
sg13
I2
sasa(dp3009
g2
S'In conclusion, the activation of PAR-2 signaling induced human pancreatic cancer progression through the induction of TGF-Alfa expression by ILK/HIFs-Alfa, as well as through MEK/VEGF-A-mediated angiogenesis, and it plays a role in the interaction between cancer progression and cancer-related thrombosis.\n'
p3010
sg4
(lp3011
(dp3012
g7
I141
sg8
g49
sg10
I3
sg11
VILK
p3013
sg13
I1
sa(dp3014
g7
I118
sg8
g49
sg10
I8
sg11
VTGF-Alfa
p3015
sg13
I1
sa(dp3016
g7
I33
sg8
VP55085
p3017
sg10
I5
sg11
VPAR-2
p3018
sg13
I1
sa(dp3019
g7
I175
sg8
VP45985
p3020
sg10
I3
sg11
VMEK
p3021
sg13
I1
sasg14
(lp3022
(dp3023
g7
I74
sg17
VC0006826
p3024
sg10
I6
sg11
Vcancer
p3025
sg13
I1
sa(dp3026
g7
I74
sg17
VC0178874
p3027
sg10
I18
sg11
Vcancer progression
p3028
sg13
I2
sa(dp3029
g7
I74
sg17
VC0178874
p3030
sg10
I18
sg11
Vcancer progression
p3031
sg13
I2
sa(dp3032
g7
I294
sg17
VC0040053
p3033
sg10
I10
sg11
Vthrombosis
p3034
sg13
I1
sasa(dp3035
g2
S'In this study, we examined the effect of a lentivirus-mediated knockdown of ILK on the proliferation, migration and invasion of pancreatic cancer (Panc-1) cells.\n'
p3036
sg4
(lp3037
(dp3038
g7
I76
sg8
g49
sg10
I3
sg11
VILK
p3039
sg13
I1
sasg14
(lp3040
(dp3041
g7
I87
sg17
VC0334094
p3042
sg10
I13
sg11
Vproliferation
p3043
sg13
I1
sa(dp3044
g7
I128
sg17
VC0235974
p3045
sg10
I17
sg11
Vpancreatic cancer
p3046
sg13
I2
sa(dp3047
g7
I116
sg17
VC2699153
p3048
sg10
I8
sg11
Vinvasion
p3049
sg13
I1
sasa(dp3050
g2
S'Immunohistochemical staining showed that ILK expression was enhanced in pancreatic cancer tissue.\n'
p3051
sg4
(lp3052
(dp3053
g7
I41
sg8
g49
sg10
I3
sg11
VILK
p3054
sg13
I1
sasg14
(lp3055
(dp3056
g7
I72
sg17
VC0235974
p3057
sg10
I17
sg11
Vpancreatic cancer
p3058
sg13
I2
sasa(dp3059
g2
S'These findings indicate that ILK may be a new diagnostic marker for pancreatic cancer and that silencing ILK could be a potentially useful therapeutic approach for treating pancreatic cancer.\n'
p3060
sg4
(lp3061
(dp3062
g7
I29
sg8
g49
sg10
I3
sg11
VILK
p3063
sg13
I1
sa(dp3064
g7
I29
sg8
g49
sg10
I3
sg11
VILK
p3065
sg13
I1
sasg14
(lp3066
(dp3067
g7
I68
sg17
VC0235974
p3068
sg10
I17
sg11
Vpancreatic cancer
p3069
sg13
I2
sa(dp3070
g7
I68
sg17
VC0235974
p3071
sg10
I17
sg11
Vpancreatic cancer
p3072
sg13
I2
sasa(dp3073
g2
S'In the previous study, we have shown that metabotropic glutamate receptor 7 (mGluR7) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling may be involved in the developmental sevoflurane neurotoxicity.\n'
p3074
sg4
(lp3075
(dp3076
g7
I77
sg8
g49
sg10
I6
sg11
VmGluR7
p3077
sg13
I1
sa(dp3078
g7
I136
sg8
VP27361
p3079
sg10
I6
sg11
VERK1/2
p3080
sg13
I1
sa(dp3081
g7
I89
sg8
VP27361
p3082
sg10
I45
sg11
Vextracellular signal-regulated kinase 1 and 2
p3083
sg13
I6
sa(dp3084
g7
I42
sg8
g49
sg10
I33
sg11
Vmetabotropic glutamate receptor 7
p3085
sg13
I4
sasg14
(lp3086
sa(dp3087
g2
S'These results suggested that Beta-arr1 and 2 may differently modulate mGluR7 signaling in developmental sevoflurane neurotoxicity.\n'
p3088
sg4
(lp3089
(dp3090
g7
I70
sg8
g49
sg10
I6
sg11
VmGluR7
p3091
sg13
I1
sa(dp3092
g7
I29
sg8
VP49407
p3093
sg10
I15
sg11
VBeta-arr1 and 2
p3094
sg13
I3
sasg14
(lp3095
sa(dp3096
g2
S'In both models of neurotoxicity, namely OGD- and KA-induced injury, the neuroprotective effects of AMN082 (1 myM) were reversed by the selective mGlu7 antagonist, 6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridinyl)-isoxazolo[4,5-c]pyridin-4(5H)-one hydrochloride (MMPIP, 1 myM), suggesting the mGlu7-dependent mechanism of neuroprotective effects of AMN082.\n'
p3097
sg4
(lp3098
(dp3099
g7
I145
sg8
g49
sg10
I5
sg11
VmGlu7
p3100
sg13
I1
sa(dp3101
g7
I145
sg8
g49
sg10
I5
sg11
VmGlu7
p3102
sg13
I1
sasg14
(lp3103
(dp3104
g7
I40
sg17
VC0432283
p3105
sg10
I3
sg11
VOGD
p3106
sg13
I1
sasa(dp3107
g2
S"The present study was designed to evaluate the possible neuroprotective effects of metabotropic glutamate receptor (mGluR7) allosteric agonist N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082) on developmental sevoflurane neurotoxicity.\n"
p3108
sg4
(lp3109
(dp3110
g7
I116
sg8
g49
sg10
I6
sg11
VmGluR7
p3111
sg13
I1
sa(dp3112
g7
I96
sg8
VP39086
p3113
sg10
I18
sg11
Vglutamate receptor
p3114
sg13
I2
sasg14
(lp3115
sa(dp3116
g2
S'Further studies are needed to fully assess the neuroprotective role of mGluR7 agonist AMN082 in developmental anesthetic neurotoxicity.\n'
p3117
sg4
(lp3118
(dp3119
g7
I71
sg8
g49
sg10
I6
sg11
VmGluR7
p3120
sg13
I1
sasg14
(lp3121
sa(dp3122
g2
S'The present study aimed to examine the role of mGluR3/mGluR7 in lead-induced neurotoxicity.\n'
p3123
sg4
(lp3124
(dp3125
g7
I54
sg8
g49
sg10
I6
sg11
VmGluR7
p3126
sg13
I1
sa(dp3127
g7
I47
sg8
g49
sg10
I6
sg11
VmGluR3
p3128
sg13
I1
sasg14
(lp3129
sa(dp3130
g2
S'The impact of lead exposure on mGluR3 and mGluR7 mRNA expression in hippocampal tissue of pups were investigated by quantitative real-time polymerase chain reaction and its potential role in lead neurotoxicity were discussed.\n'
p3131
sg4
(lp3132
(dp3133
g7
I31
sg8
g49
sg10
I6
sg11
VmGluR3
p3134
sg13
I1
sa(dp3135
g7
I42
sg8
g49
sg10
I11
sg11
VmGluR7 mRNA
p3136
sg13
I2
sasg14
(lp3137
sa(dp3138
g2
S'However, the current study does not provide evidence that the expression of rat hippocampal mGluR3 and mGluR7 can be altered by systemic administration of lead during gestation and lactation, which are informative for the field of lead-induced developmental neurotoxicity noting that it seems not to be worthwhile to include mGluR3 and mGluR7 in future studies.\n'
p3139
sg4
(lp3140
(dp3141
g7
I103
sg8
g49
sg10
I6
sg11
VmGluR7
p3142
sg13
I1
sa(dp3143
g7
I92
sg8
g49
sg10
I6
sg11
VmGluR3
p3144
sg13
I1
sa(dp3145
g7
I92
sg8
g49
sg10
I6
sg11
VmGluR3
p3146
sg13
I1
sa(dp3147
g7
I103
sg8
g49
sg10
I6
sg11
VmGluR7
p3148
sg13
I1
sasg14
(lp3149
sa(dp3150
g2
S'We determined whether mGluRs subtypes 1, 3, and 7 (mGluR1, mGluR3, and mGluR7) were involved in developmental neurotoxicity due to lead.\n'
p3151
sg4
(lp3152
(dp3153
g7
I59
sg8
g49
sg10
I6
sg11
VmGluR3
p3154
sg13
I1
sa(dp3155
g7
I71
sg8
g49
sg10
I6
sg11
VmGluR7
p3156
sg13
I1
sasg14
(lp3157
sa(dp3158
g2
S'Flow cytometry effectively identifies major forms of PIDs, including severe combined immunodeficiency, X-linked agammaglobulinemia, hyper IgM syndromes, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome, familial hemophagocytic lymphohistiocytosis, autoimmune lymphoproliferative syndrome, IPEX syndrome, CTLA 4 haploinsufficiency and LRBA deficiency, IRAK4 and MyD88 deficiencies, Mendelian susceptibility to mycobacterial disease, chronic mucocuneous candidiasis, and chronic granulomatous disease.\n'
p3159
sg4
(lp3160
(dp3161
g7
I366
sg8
g49
sg10
I5
sg11
VIRAK4
p3162
sg13
I1
sa(dp3163
g7
I319
sg8
VP08311
p3164
sg10
I6
sg11
VCTLA 4
p3165
sg13
I2
sa(dp3166
g7
I349
sg8
VP50851
p3167
sg10
I4
sg11
VLRBA
p3168
sg13
I1
sa(dp3169
g7
I376
sg8
g49
sg10
I5
sg11
VMyD88
p3170
sg13
I1
sasg14
(lp3171
(dp3172
g7
I484
sg17
VC0018203
p3173
sg10
I29
sg11
Vchronic granulomatous disease
p3174
sg13
I3
sa(dp3175
g7
I112
sg17
VC0001768
p3176
sg10
I18
sg11
Vagammaglobulinemia
p3177
sg13
I1
sa(dp3178
g7
I169
sg17
VC0549463
p3179
sg10
I38
sg11
Vsyndrome, X-linked lymphoproliferative
p3180
sg13
I3
sa(dp3181
g7
I304
sg17
VC0342288
p3182
sg10
I4
sg11
VIPEX
p3183
sg13
I1
sa(dp3184
g7
I467
sg17
VC0006840
p3185
sg10
I11
sg11
Vcandidiasis
p3186
sg13
I1
sa(dp3187
g7
I142
sg17
VC0039082
p3188
sg10
I9
sg11
Vsyndromes
p3189
sg13
I1
sa(dp3190
g7
I153
sg17
VC0043194
p3191
sg10
I24
sg11
VWiskott-Aldrich syndrome
p3192
sg13
I2
sa(dp3193
g7
I69
sg17
VC2931540
p3194
sg10
I42
sg11
Vsevere combined immunodeficiency, X-linked
p3195
sg13
I4
sa(dp3196
g7
I424
sg17
VC0026918
p3197
sg10
I21
sg11
Vmycobacterial disease
p3198
sg13
I2
sa(dp3199
g7
I142
sg17
VC0039082
p3200
sg10
I8
sg11
Vsyndrome
p3201
sg13
I1
sa(dp3202
g7
I263
sg17
VC1328840
p3203
sg10
I39
sg11
Vautoimmune lymphoproliferative syndrome
p3204
sg13
I3
sa(dp3205
g7
I218
sg17
VC0272199
p3206
sg10
I43
sg11
Vfamilial hemophagocytic lymphohistiocytosis
p3207
sg13
I3
sa(dp3208
g7
I142
sg17
VC0039082
p3209
sg10
I8
sg11
Vsyndrome
p3210
sg13
I1
sasa(dp3211
g2
S'OGR1 deficiency reduced insulin secretion induced by glucose administered ip, although it was not associated with glucose intolerance in vivo.\n'
p3212
sg4
(lp3213
(dp3214
g7
I24
sg8
VP01308
p3215
sg10
I7
sg11
Vinsulin
p3216
sg13
I1
sa(dp3217
g7
I0
sg8
g49
sg10
I4
sg11
VOGR1
p3218
sg13
I1
sasg14
(lp3219
(dp3220
g7
I114
sg17
VC0271650
p3221
sg10
I19
sg11
Vglucose intolerance
p3222
sg13
I2
sasa(dp3223
g2
S'Objective: To summarize the clinical characteristics of the diffuse parenchymal lung diseases in a child caused by a novel compound heterozygous ABCA3 mutation and explore the association between the phenotype and ABCA3 mutation.\n'
p3224
sg4
(lp3225
(dp3226
g7
I145
sg8
g49
sg10
I14
sg11
VABCA3 mutation
p3227
sg13
I2
sa(dp3228
g7
I145
sg8
g49
sg10
I5
sg11
VABCA3
p3229
sg13
I1
sasg14
(lp3230
(dp3231
g7
I60
sg17
VC0206062
p3232
sg10
I33
sg11
Vdiffuse parenchymal lung diseases
p3233
sg13
I4
sasa(dp3234
g2
S"Method: The clinical material of a patient diagnosed with diffuse parenchymal lung disease with ABCA3 mutation in December 2016 in Shenzhen Children's Hospital was analyzed.\n"
p3235
sg4
(lp3236
(dp3237
g7
I96
sg8
g49
sg10
I14
sg11
VABCA3 mutation
p3238
sg13
I2
sasg14
(lp3239
(dp3240
g7
I78
sg17
VC0024115
p3241
sg10
I12
sg11
Vlung disease
p3242
sg13
I2
sasa(dp3243
g2
S"Conclusion: c.1755delC+c.2890G&gt;A is a new kind of compound heterozygous mutation in ABCA3, which can cause children's diffuse parenchymal lung disease.\n"
p3244
sg4
(lp3245
(dp3246
g7
I87
sg8
g49
sg10
I5
sg11
VABCA3
p3247
sg13
I1
sasg14
(lp3248
(dp3249
g7
I141
sg17
VC0024115
p3250
sg10
I12
sg11
Vlung disease
p3251
sg13
I2
sasa(dp3252
g2
S'However, interstitial lung diseases have also been observed in full-term infants with mutations in the SFTPC, SFTPB, NKX2-1, or ABCA3 genes, involved in the surfactant metabolism.\n'
p3253
sg4
(lp3254
(dp3255
g7
I110
sg8
VP07988
p3256
sg10
I5
sg11
VSFTPB
p3257
sg13
I1
sa(dp3258
g7
I128
sg8
g49
sg10
I11
sg11
VABCA3 genes
p3259
sg13
I2
sa(dp3260
g7
I103
sg8
VP11686
p3261
sg10
I5
sg11
VSFTPC
p3262
sg13
I1
sa(dp3263
g7
I117
sg8
VP43699
p3264
sg10
I6
sg11
VNKX2-1
p3265
sg13
I1
sasg14
(lp3266
(dp3267
g7
I9
sg17
VC0206062
p3268
sg10
I26
sg11
Vinterstitial lung diseases
p3269
sg13
I3
sasa(dp3270
g2
S'Herein, we report a newborn baby with neonatal respiratory distress and diffuse lung disease caused by ABCA3 mutation.\n'
p3271
sg4
(lp3272
(dp3273
g7
I103
sg8
g49
sg10
I14
sg11
VABCA3 mutation
p3274
sg13
I2
sasg14
(lp3275
(dp3276
g7
I80
sg17
VC0024115
p3277
sg10
I12
sg11
Vlung disease
p3278
sg13
I2
sa(dp3279
g7
I38
sg17
VC0852283
p3280
sg10
I29
sg11
Vneonatal respiratory distress
p3281
sg13
I3
sasa(dp3282
g2
S'Genomic DNA was analyzed for four genes involved in surfactant metabolism out of which the c. 4545C&gt;G (p.Tyr1515*) homozygous mutation in exon 29 of ABCA3 was identified which is one of the most frequent mutation causing lethal neonatal respiratory failure in a term neonate.\n'
p3283
sg4
(lp3284
(dp3285
g7
I152
sg8
g49
sg10
I5
sg11
VABCA3
p3286
sg13
I1
sasg14
(lp3287
(dp3288
g7
I231
sg17
VC0521648
p3289
sg10
I28
sg11
Vneonatal respiratory failure
p3290
sg13
I3
sasa(dp3291
g2
S'Biallelic mutations of ABCA3 has been associated with fatal respiratory distress syndrome and interstitial lung disease (ILD) in children.\n'
p3292
sg4
(lp3293
(dp3294
g7
I23
sg8
g49
sg10
I5
sg11
VABCA3
p3295
sg13
I1
sasg14
(lp3296
(dp3297
g7
I121
sg17
VC0206062
p3298
sg10
I3
sg11
VILD
p3299
sg13
I1
sa(dp3300
g7
I60
sg17
VC0035220
p3301
sg10
I29
sg11
Vrespiratory distress syndrome
p3302
sg13
I3
sa(dp3303
g7
I94
sg17
VC0206062
p3304
sg10
I25
sg11
Vinterstitial lung disease
p3305
sg13
I3
sasa(dp3306
g2
S'However, whether variations in ABCA3 have a role in the development of adult ILD, including idiopathic pulmonary fibrosis (IPF), remains to be addressed.\n'
p3307
sg4
(lp3308
(dp3309
g7
I31
sg8
g49
sg10
I5
sg11
VABCA3
p3310
sg13
I1
sasg14
(lp3311
(dp3312
g7
I123
sg17
VC3161101
p3313
sg10
I3
sg11
VIPF
p3314
sg13
I1
sa(dp3315
g7
I92
sg17
VC3161101
p3316
sg10
I29
sg11
Vidiopathic pulmonary fibrosis
p3317
sg13
I3
sasa(dp3318
g2
S'Airway cells expressing surfactant protein (SP)-C and ATP binding cassette subfamily A member 3, alveolar pod cells expressing keratin (KRT) 5, and pulmonary fibrosis were observed when these mice were infected with a sublethal dose of HKx31, H3N2 influenza A virus.\n'
p3319
sg4
(lp3320
(dp3321
g7
I136
sg8
VP02533
p3322
sg10
I3
sg11
VKRT
p3323
sg13
I1
sa(dp3324
g7
I243
sg8
g49
sg10
I16
sg11
VH3N2 influenza A
p3325
sg13
I3
sa(dp3326
g7
I127
sg8
VP02533
p3327
sg10
I7
sg11
Vkeratin
p3328
sg13
I1
sasg14
(lp3329
(dp3330
g7
I248
sg17
VC0021400
p3331
sg10
I9
sg11
Vinfluenza
p3332
sg13
I1
sa(dp3333
g7
I148
sg17
VC0034069
p3334
sg10
I18
sg11
Vpulmonary fibrosis
p3335
sg13
I2
sasa(dp3336
g2
S"Antitumor activity of saffron (Crocus sativus) extract a commonly used spice in India was studied against intraperitoneally transplanted sarcoma-180 (S-180), Ehrlich ascites Carcinoma (EAC) and Dalton's lymphoma ascites (DLA) tumours in mice.\n"
p3337
sg4
(lp3338
sg14
(lp3339
(dp3340
g7
I158
sg17
VC1275122
p3341
sg10
I25
sg11
VEhrlich ascites Carcinoma
p3342
sg13
I3
sa(dp3343
g7
I137
sg17
VC1261473
p3344
sg10
I7
sg11
Vsarcoma
p3345
sg13
I1
sa(dp3346
g7
I203
sg17
VC0024299
p3347
sg10
I8
sg11
Vlymphoma
p3348
sg13
I1
sa(dp3349
g7
I185
sg17
VC1275122
p3350
sg10
I3
sg11
VEAC
p3351
sg13
I1
sa(dp3352
g7
I226
sg17
VC0027651
p3353
sg10
I7
sg11
Vtumours
p3354
sg13
I1
sasa(dp3355
g2
S'Our results suggest that obesity can be produced in BARs by feeding HFD.\n'
p3356
sg4
(lp3357
sg14
(lp3358
(dp3359
g7
I25
sg17
VC0028754
p3360
sg10
I7
sg11
Vobesity
p3361
sg13
I1
sasa(dp3362
g2
S'cEDS can be caused by heterozygosity for missense mutations in genes COL5A2 and COL5A1, which encode the Alfa2(V) and Alfa1(V) chains, respectively, of collagen V, and is most often caused by COL5A1 null alleles.\n'
p3363
sg4
(lp3364
(dp3365
g7
I192
sg8
VP20908
p3366
sg10
I19
sg11
VCOL5A1 null alleles
p3367
sg13
I3
sa(dp3368
g7
I80
sg8
VP20908
p3369
sg10
I6
sg11
VCOL5A1
p3370
sg13
I1
sasg14
(lp3371
(dp3372
g7
I0
sg17
VC1846545
p3373
sg10
I4
sg11
VcEDS
p3374
sg13
I1
sasa(dp3375
g2
S'On the whole, our findings indicate that the Kras, Col5a1 and Furin genes may play essential roles in the molecular mechanisms of SMCD, which warrants further investigation.\n'
p3376
sg4
(lp3377
(dp3378
g7
I45
sg8
VP01116
p3379
sg10
I4
sg11
VKras
p3380
sg13
I1
sa(dp3381
g7
I51
sg8
VP20908
p3382
sg10
I6
sg11
VCol5a1
p3383
sg13
I1
sa(dp3384
g7
I62
sg8
VP09958
p3385
sg10
I11
sg11
VFurin genes
p3386
sg13
I2
sasg14
(lp3387
(dp3388
g7
I130
sg17
VC2748503
p3389
sg10
I4
sg11
VSMCD
p3390
sg13
I1
sasa(dp3391
g2
S'Gene expression of transforming growth factor beta 1, various asthma-related collagen types [collagen, type I, alpha 1; collagen, type II, alpha 1; collagen, type III, alpha 1; collagen, type V, alpha 1 (COL5A1) and collagen, type V, alpha 2], and ATG5 were measured using mRNA isolated from bronchial biopsies of refractory asthmatic subjects and assessed for pairwise associations.\n'
p3392
sg4
(lp3393
(dp3394
g7
I111
sg8
VP25100
p3395
sg10
I7
sg11
Valpha 1
p3396
sg13
I2
sa(dp3397
g7
I111
sg8
VP25100
p3398
sg10
I7
sg11
Valpha 1
p3399
sg13
I2
sa(dp3400
g7
I204
sg8
VP20908
p3401
sg10
I6
sg11
VCOL5A1
p3402
sg13
I1
sa(dp3403
g7
I111
sg8
VP25100
p3404
sg10
I7
sg11
Valpha 1
p3405
sg13
I2
sa(dp3406
g7
I177
sg8
VP20908
p3407
sg10
I25
sg11
Vcollagen, type V, alpha 1
p3408
sg13
I5
sa(dp3409
g7
I130
sg8
VP27037
p3410
sg10
I7
sg11
Vtype II
p3411
sg13
I2
sa(dp3412
g7
I248
sg8
g49
sg10
I4
sg11
VATG5
p3413
sg13
I1
sa(dp3414
g7
I19
sg8
VP01137
p3415
sg10
I33
sg11
Vtransforming growth factor beta 1
p3416
sg13
I5
sasg14
(lp3417
(dp3418
g7
I62
sg17
VC0004096
p3419
sg10
I6
sg11
Vasthma
p3420
sg13
I1
sa(dp3421
g7
I325
sg17
VC0004096
p3422
sg10
I9
sg11
Vasthmatic
p3423
sg13
I1
sasa(dp3424
g2
S'In refractory asthmatic individuals, gene expression of ATG5 was positively associated with COL5A1 in the airways.\n'
p3425
sg4
(lp3426
(dp3427
g7
I92
sg8
VP20908
p3428
sg10
I6
sg11
VCOL5A1
p3429
sg13
I1
sa(dp3430
g7
I56
sg8
g49
sg10
I4
sg11
VATG5
p3431
sg13
I1
sasg14
(lp3432
(dp3433
g7
I14
sg17
VC0004096
p3434
sg10
I9
sg11
Vasthmatic
p3435
sg13
I1
sasa(dp3436
g2
S'Positive correlation between the gene expression patterns of ATG5 and COL5A1 suggests that dysregulated autophagy may contribute to subepithelial fibrosis in the airways of refractory asthmatic individuals.\n'
p3437
sg4
(lp3438
(dp3439
g7
I70
sg8
VP20908
p3440
sg10
I6
sg11
VCOL5A1
p3441
sg13
I1
sa(dp3442
g7
I61
sg8
g49
sg10
I4
sg11
VATG5
p3443
sg13
I1
sasg14
(lp3444
(dp3445
g7
I184
sg17
VC0004096
p3446
sg10
I9
sg11
Vasthmatic
p3447
sg13
I1
sa(dp3448
g7
I146
sg17
VC0016059
p3449
sg10
I8
sg11
Vfibrosis
p3450
sg13
I1
sasa(dp3451
g2
S'Recently, we observed regulator roles of selenium (Se) on apoptosis and Ca2+ entry through transient receptor potential vanilloid 1 (TRPV1) channels in the cancer cell lines.\n'
p3452
sg4
(lp3453
(dp3454
g7
I91
sg8
g49
sg10
I40
sg11
Vtransient receptor potential vanilloid 1
p3455
sg13
I5
sa(dp3456
g7
I133
sg8
g49
sg10
I5
sg11
VTRPV1
p3457
sg13
I1
sasg14
(lp3458
(dp3459
g7
I156
sg17
VC0006826
p3460
sg10
I6
sg11
Vcancer
p3461
sg13
I1
sasa(dp3462
g2
S'We investigated the effects of JWH-133 (CB2 agonist) and RTX (TRPV1 agonist) in six human Osteosarcoma cell lines: MG-63, U-2OS, MNNG/HOS, Saos-2, KHOS/NP, Hs888Lu, by Apoptosis and Migration-Assay.\n'
p3463
sg4
(lp3464
(dp3465
g7
I62
sg8
g49
sg10
I5
sg11
VTRPV1
p3466
sg13
I1
sa(dp3467
g7
I57
sg8
g49
sg10
I3
sg11
VRTX
p3468
sg13
I1
sa(dp3469
g7
I134
sg8
g49
sg10
I3
sg11
VHOS
p3470
sg13
I1
sasg14
(lp3471
(dp3472
g7
I90
sg17
VC0029463
p3473
sg10
I12
sg11
VOsteosarcoma
p3474
sg13
I1
sa(dp3475
g7
I134
sg17
VC0265264
p3476
sg10
I3
sg11
VHOS
p3477
sg13
I1
sasa(dp3478
g2
S'Our results show that both CB2 stimulation and TRPV1 activation, in different Osteosarcoma cell lines, can act on the same pathways to obtain the same effect, indicating the Endocannabinoid/Endovanilloid system as a new therapeutic target in Osteosarcoma.\n'
p3479
sg4
(lp3480
(dp3481
g7
I47
sg8
g49
sg10
I5
sg11
VTRPV1
p3482
sg13
I1
sasg14
(lp3483
(dp3484
g7
I78
sg17
VC0029463
p3485
sg10
I12
sg11
VOsteosarcoma
p3486
sg13
I1
sa(dp3487
g7
I78
sg17
VC0029463
p3488
sg10
I12
sg11
VOsteosarcoma
p3489
sg13
I1
sasa(dp3490
g2
S'Whether coadministration of a CB2 receptor agonist and morphine could reduce TRPV1 expression in morphine-induced antinociception and tolerance in cancer pain is unclear.\n'
p3491
sg4
(lp3492
(dp3493
g7
I77
sg8
g49
sg10
I5
sg11
VTRPV1
p3494
sg13
I1
sa(dp3495
g7
I30
sg8
VP34972
p3496
sg10
I12
sg11
VCB2 receptor
p3497
sg13
I2
sasg14
(lp3498
(dp3499
g7
I134
sg17
VC0020963
p3500
sg10
I9
sg11
Vtolerance
p3501
sg13
I1
sa(dp3502
g7
I147
sg17
VC0596240
p3503
sg10
I11
sg11
Vcancer pain
p3504
sg13
I2
sasa(dp3505
g2
S'Therefore, we investigated the effects of coadministration of a CB2 receptor agonist AM1241 and morphine on TRPV1 expression and tolerance in cancer pain.\n'
p3506
sg4
(lp3507
(dp3508
g7
I64
sg8
VP34972
p3509
sg10
I12
sg11
VCB2 receptor
p3510
sg13
I2
sa(dp3511
g7
I108
sg8
g49
sg10
I5
sg11
VTRPV1
p3512
sg13
I1
sasg14
(lp3513
(dp3514
g7
I129
sg17
VC0020963
p3515
sg10
I9
sg11
Vtolerance
p3516
sg13
I1
sa(dp3517
g7
I142
sg17
VC0596240
p3518
sg10
I11
sg11
Vcancer pain
p3519
sg13
I2
sasa(dp3520
g2
S'Our findings suggest that coadministration of a CB2 receptor agonist AM1241 and morphine reduced morphine tolerance possibly through regulation of TRPV1 protein expression in the DRG in cancer pain.\n'
p3521
sg4
(lp3522
(dp3523
g7
I147
sg8
g49
sg10
I13
sg11
VTRPV1 protein
p3524
sg13
I2
sa(dp3525
g7
I48
sg8
VP34972
p3526
sg10
I12
sg11
VCB2 receptor
p3527
sg13
I2
sasg14
(lp3528
(dp3529
g7
I106
sg17
VC0020963
p3530
sg10
I9
sg11
Vtolerance
p3531
sg13
I1
sa(dp3532
g7
I186
sg17
VC0596240
p3533
sg10
I11
sg11
Vcancer pain
p3534
sg13
I2
sasa(dp3535
g2
S'Clinical trial of resiniferatoxin from Euphorbia species is successfully aimed at TRPV1 in cancer pain management and heading toward new selective painkiller status that further validates this target for drug discovery efforts.\n'
p3536
sg4
(lp3537
(dp3538
g7
I82
sg8
g49
sg10
I5
sg11
VTRPV1
p3539
sg13
I1
sasg14
(lp3540
(dp3541
g7
I91
sg17
VC0596240
p3542
sg10
I11
sg11
Vcancer pain
p3543
sg13
I2
sasa(dp3544
g2
S'In erosive gastritis, increased proliferation (MET) and transport (UCP2, SCFD1, KPNA4) were found, while genes associated with adhesion (SIGLEC11), transcription regulation (ESRRG), and electron and ion transport (ACADM, CLIC6) were down-regulated.\n'
p3545
sg4
(lp3546
(dp3547
g7
I73
sg8
g49
sg10
I5
sg11
VSCFD1
p3548
sg13
I1
sa(dp3549
g7
I67
sg8
VP55851
p3550
sg10
I4
sg11
VUCP2
p3551
sg13
I1
sa(dp3552
g7
I137
sg8
g49
sg10
I8
sg11
VSIGLEC11
p3553
sg13
I1
sa(dp3554
g7
I80
sg8
g49
sg10
I5
sg11
VKPNA4
p3555
sg13
I1
sa(dp3556
g7
I221
sg8
g49
sg10
I5
sg11
VCLIC6
p3557
sg13
I1
sasg14
(lp3558
(dp3559
g7
I32
sg17
VC0334094
p3560
sg10
I13
sg11
Vproliferation
p3561
sg13
I1
sa(dp3562
g7
I3
sg17
VC2243088
p3563
sg10
I17
sg11
Verosive gastritis
p3564
sg13
I2
sa(dp3565
g7
I127
sg17
VC0001511
p3566
sg10
I8
sg11
Vadhesion
p3567
sg13
I1
sasa(dp3568
g2
S"In addition, EphA4 has been found to play a role in cancer biology as well as in the pathogenesis of several neurological disorders such as stroke, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.\n"
p3569
sg4
(lp3570
(dp3571
g7
I13
sg8
VP54764
p3572
sg10
I5
sg11
VEphA4
p3573
sg13
I1
sasg14
(lp3574
(dp3575
g7
I177
sg17
VC0002736
p3576
sg10
I30
sg11
Vsclerosis, amyotrophic lateral
p3577
sg13
I3
sa(dp3578
g7
I219
sg17
VC0002736
p3579
sg10
I3
sg11
VALS
p3580
sg13
I1
sa(dp3581
g7
I140
sg17
VC0038454
p3582
sg10
I6
sg11
Vstroke
p3583
sg13
I1
sa(dp3584
g7
I85
sg17
VC0699748
p3585
sg10
I12
sg11
Vpathogenesis
p3586
sg13
I1
sa(dp3587
g7
I109
sg17
VC0027765
p3588
sg10
I22
sg11
Vneurological disorders
p3589
sg13
I2
sa(dp3590
g7
I52
sg17
VC0006826
p3591
sg10
I6
sg11
Vcancer
p3592
sg13
I1
sa(dp3593
g7
I188
sg17
VC0002736
p3594
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p3595
sg13
I3
sa(dp3596
g7
I229
sg17
VC1521724
p3597
sg10
I19
sg11
VAlzheimer's disease
p3598
sg13
I2
sa(dp3599
g7
I155
sg17
VC0035334
p3600
sg10
I4
sg11
Vcord
p3601
sg13
I1
sasa(dp3602
g2
S"However, aberrant EphA4 activity can inhibit neural repair after injury and exacerbate neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer's.\n"
p3603
sg4
(lp3604
(dp3605
g7
I18
sg8
VP54764
p3606
sg10
I5
sg11
VEphA4
p3607
sg13
I1
sasg14
(lp3608
(dp3609
g7
I153
sg17
VC0002736
p3610
sg10
I3
sg11
VALS
p3611
sg13
I1
sa(dp3612
g7
I87
sg17
VC0524851
p3613
sg10
I26
sg11
Vneurodegenerative diseases
p3614
sg13
I2
sa(dp3615
g7
I122
sg17
VC0002736
p3616
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p3617
sg13
I3
sasa(dp3618
g2
S'Additional to involvement in diverse physiological and pathological processes such as axon regeneration, synaptic plasticity, and cancers, EphA4 receptor has been recently identified as the only amyotrophic lateral sclerosis (ALS) modifier.\n'
p3619
sg4
(lp3620
(dp3621
g7
I139
sg8
VP54764
p3622
sg10
I14
sg11
VEphA4 receptor
p3623
sg13
I2
sasg14
(lp3624
(dp3625
g7
I130
sg17
VC0006826
p3626
sg10
I7
sg11
Vcancers
p3627
sg13
I1
sa(dp3628
g7
I195
sg17
VC0002736
p3629
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p3630
sg13
I3
sa(dp3631
g7
I55
sg17
VC0030660
p3632
sg10
I22
sg11
Vpathological processes
p3633
sg13
I2
sa(dp3634
g7
I226
sg17
VC0002736
p3635
sg10
I3
sg11
VALS
p3636
sg13
I1
sasa(dp3637
g2
S'In conclusion, our results strongly suggest a role for Acrp30 oligomerization in OSAS; in fact, the down-regulation of Acpr30 and its HMW oligomers seems to be correlated to illness status independently of concomitant presence of obesity.\n'
p3638
sg4
(lp3639
(dp3640
g7
I55
sg8
g49
sg10
I6
sg11
VAcrp30
p3641
sg13
I1
sasg14
(lp3642
(dp3643
g7
I81
sg17
VC0520679
p3644
sg10
I4
sg11
VOSAS
p3645
sg13
I1
sa(dp3646
g7
I230
sg17
VC0028754
p3647
sg10
I7
sg11
Vobesity
p3648
sg13
I1
sasa(dp3649
g2
S'SOM-14 and HMW-SOM are depleted in cortical tissue from cases of pre-senile Alzheimer-type dementia (ATD), but there is a disproportionate reduction in HMW-SOM.\n'
p3650
sg4
(lp3651
(dp3652
g7
I11
sg8
VP61278
p3653
sg10
I7
sg11
VHMW-SOM
p3654
sg13
I1
sa(dp3655
g7
I0
sg8
VP61278
p3656
sg10
I6
sg11
VSOM-14
p3657
sg13
I1
sasg14
(lp3658
(dp3659
g7
I91
sg17
VC0497327
p3660
sg10
I8
sg11
Vdementia
p3661
sg13
I1
sasa(dp3662
g2
S'Data on plasma acylated ghrelin (AG) and unacylated ghrelin (UAG) levels in acromegaly are limited.\n'
p3663
sg4
(lp3664
(dp3665
g7
I24
sg8
g49
sg10
I7
sg11
Vghrelin
p3666
sg13
I1
sasg14
(lp3667
(dp3668
g7
I76
sg17
VC0001206
p3669
sg10
I10
sg11
Vacromegaly
p3670
sg13
I1
sasa(dp3671
g2
S'We studied the ACTH and cortisol response to acylated ghrelin in 49 patients with history of pituitary disease.\n'
p3672
sg4
(lp3673
(dp3674
g7
I15
sg8
VP01189
p3675
sg10
I4
sg11
VACTH
p3676
sg13
I1
sasg14
(lp3677
(dp3678
g7
I93
sg17
VC0032002
p3679
sg10
I17
sg11
Vpituitary disease
p3680
sg13
I2
sasa(dp3681
g2
S'Our data show that testing with acylated ghrelin is not a useful diagnostic tool for the diagnosis of central hypocortisolism; particularly ghrelin test adds no more information that basal cortisol evaluation in the diagnosis of ACTH deficiency in patients with hypothalamus-pituitary disease.\n'
p3682
sg4
(lp3683
(dp3684
g7
I41
sg8
g49
sg10
I7
sg11
Vghrelin
p3685
sg13
I1
sa(dp3686
g7
I229
sg8
VP01189
p3687
sg10
I4
sg11
VACTH
p3688
sg13
I1
sasg14
(lp3689
(dp3690
g7
I110
sg17
VC0001403
p3691
sg10
I15
sg11
Vhypocortisolism
p3692
sg13
I1
sa(dp3693
g7
I275
sg17
VC0032002
p3694
sg10
I17
sg11
Vpituitary disease
p3695
sg13
I2
sa(dp3696
g7
I229
sg17
VC0342388
p3697
sg10
I15
sg11
VACTH deficiency
p3698
sg13
I2
sasa(dp3699
g2
S'The objective of the study was to test the hypothesis that remission of acromegaly after surgical therapy increases weight and adiposity and some CV risk markers and these changes are paralleled by a rise in ghrelin.\n'
p3700
sg4
(lp3701
(dp3702
g7
I208
sg8
g49
sg10
I7
sg11
Vghrelin
p3703
sg13
I1
sasg14
(lp3704
(dp3705
g7
I127
sg17
VC0028754
p3706
sg10
I9
sg11
Vadiposity
p3707
sg13
I1
sa(dp3708
g7
I72
sg17
VC0001206
p3709
sg10
I10
sg11
Vacromegaly
p3710
sg13
I1
sa(dp3711
g7
I59
sg17
VC0687702
p3712
sg10
I9
sg11
Vremission
p3713
sg13
I1
sasa(dp3714
g2
S'Weight, waist circumference, and ghrelin did not increase significantly in the persistent active acromegaly group.\n'
p3715
sg4
(lp3716
sg14
(lp3717
(dp3718
g7
I97
sg17
VC0001206
p3719
sg10
I10
sg11
Vacromegaly
p3720
sg13
I1
sasa(dp3721
g2
S'Although most markers of CV risk improve with acromegaly remission after surgery, some markers and adiposity increase and are paralleled by a rise in total ghrelin, suggesting that these changes may be related.\n'
p3722
sg4
(lp3723
sg14
(lp3724
(dp3725
g7
I99
sg17
VC0028754
p3726
sg10
I9
sg11
Vadiposity
p3727
sg13
I1
sa(dp3728
g7
I57
sg17
VC0687702
p3729
sg10
I9
sg11
Vremission
p3730
sg13
I1
sa(dp3731
g7
I46
sg17
VC0001206
p3732
sg10
I10
sg11
Vacromegaly
p3733
sg13
I1
sasa(dp3734
g2
S'Ghrelin has been administered as an infusion or a bolus in a variety of doses to 1850 study participants, including healthy participants and patients with obesity, prior gastrectomy, cancer, pituitary disease, diabetes mellitus, eating disorders, and other conditions.\n'
p3735
sg4
(lp3736
(dp3737
g7
I0
sg8
g49
sg10
I7
sg11
VGhrelin
p3738
sg13
I1
sasg14
(lp3739
(dp3740
g7
I229
sg17
VC0013473
p3741
sg10
I16
sg11
Veating disorders
p3742
sg13
I2
sa(dp3743
g7
I155
sg17
VC0028754
p3744
sg10
I7
sg11
Vobesity
p3745
sg13
I1
sa(dp3746
g7
I210
sg17
VC0011849
p3747
sg10
I17
sg11
Vdiabetes mellitus
p3748
sg13
I2
sa(dp3749
g7
I183
sg17
VC0346300
p3750
sg10
I17
sg11
Vcancer, pituitary
p3751
sg13
I2
sa(dp3752
g7
I191
sg17
VC0032002
p3753
sg10
I17
sg11
Vpituitary disease
p3754
sg13
I2
sasa(dp3755
g2
S'The cation cotransporters Na(+)-K(+)-2Cl(-) cotransporter 1 and 2 (NKCC1 and NKCC2) and Na(+)-Cl cotransporter (NCC) are phosphorylated and activated by the kinases Ste20-related proline alanine-rich kinase (SPAK) and oxidative stress-responsive kinase (OSR1), and their targeted disruption in mice causes phenotypes resembling the human disorders Bartter syndrome and Gitelman syndrome, reflecting reduced NKCC2 and NCC activity, respectively.\n'
p3756
sg4
(lp3757
(dp3758
g7
I67
sg8
VP55011
p3759
sg10
I5
sg11
VNKCC1
p3760
sg13
I1
sa(dp3761
g7
I228
sg8
VP33981
p3762
sg10
I24
sg11
Vstress-responsive kinase
p3763
sg13
I2
sa(dp3764
g7
I208
sg8
g49
sg10
I4
sg11
VSPAK
p3765
sg13
I1
sa(dp3766
g7
I77
sg8
g49
sg10
I5
sg11
VNKCC2
p3767
sg13
I1
sa(dp3768
g7
I77
sg8
g49
sg10
I5
sg11
VNKCC2
p3769
sg13
I1
sa(dp3770
g7
I165
sg8
g49
sg10
I41
sg11
VSte20-related proline alanine-rich kinase
p3771
sg13
I4
sa(dp3772
g7
I254
sg8
g49
sg10
I4
sg11
VOSR1
p3773
sg13
I1
sasg14
(lp3774
(dp3775
g7
I348
sg17
VC0004775
p3776
sg10
I16
sg11
VBartter syndrome
p3777
sg13
I2
sa(dp3778
g7
I218
sg17
VC0242606
p3779
sg10
I16
sg11
Voxidative stress
p3780
sg13
I2
sa(dp3781
g7
I369
sg17
VC0268450
p3782
sg10
I17
sg11
VGitelman syndrome
p3783
sg13
I2
sasa(dp3784
g2
S'Keeping this in mind, attenuation of MT might be a mechanism underlying the prevalence of end-stage renal disease documented in hypertensive African-Americans with decreased NKCC1 activity and in hypertensive patients subjected to chronic HCD treatment.\n'
p3785
sg4
(lp3786
(dp3787
g7
I174
sg8
VP55011
p3788
sg10
I5
sg11
VNKCC1
p3789
sg13
I1
sasg14
(lp3790
(dp3791
g7
I239
sg17
VC0235833
p3792
sg10
I3
sg11
VHCD
p3793
sg13
I1
sa(dp3794
g7
I90
sg17
VC0022661
p3795
sg10
I23
sg11
Vend-stage renal disease
p3796
sg13
I3
sasa(dp3797
g2
S"Association of the HLA class I region, independent of known HLA class II effects, has now been detected for several AIDs, including strong association of HLA-B with type 1 diabetes and HLA-C with multiple sclerosis and Graves' disease.\n"
p3798
sg4
(lp3799
(dp3800
g7
I60
sg8
VP30486
p3801
sg10
I12
sg11
VHLA class II
p3802
sg13
I3
sa(dp3803
g7
I19
sg8
g49
sg10
I18
sg11
VHLA class I region
p3804
sg13
I4
sa(dp3805
g7
I185
sg8
VP30499
p3806
sg10
I5
sg11
VHLA-C
p3807
sg13
I1
sa(dp3808
g7
I154
sg8
VP30461
p3809
sg10
I5
sg11
VHLA-B
p3810
sg13
I1
sasg14
(lp3811
(dp3812
g7
I219
sg17
VC0018213
p3813
sg10
I15
sg11
VGraves' disease
p3814
sg13
I2
sa(dp3815
g7
I165
sg17
VC0011854
p3816
sg10
I15
sg11
Vtype 1 diabetes
p3817
sg13
I3
sa(dp3818
g7
I196
sg17
VC0026769
p3819
sg10
I18
sg11
Vmultiple sclerosis
p3820
sg13
I2
sasa(dp3821
g2
S"The present study was undertaken in 117 new patients with Graves' disease, typed for HLA-A, HLA-B, HLA-C and DR antigens and IgG heavy chain markers, to determine whether these characteristics could be used to segregate patients into clinically relevant subsets.\n"
p3822
sg4
(lp3823
(dp3824
g7
I92
sg8
VP30461
p3825
sg10
I5
sg11
VHLA-B
p3826
sg13
I1
sa(dp3827
g7
I85
sg8
VP30447
p3828
sg10
I5
sg11
VHLA-A
p3829
sg13
I1
sa(dp3830
g7
I99
sg8
VP30499
p3831
sg10
I21
sg11
VHLA-C and DR antigens
p3832
sg13
I4
sasg14
(lp3833
(dp3834
g7
I58
sg17
VC0018213
p3835
sg10
I15
sg11
VGraves' disease
p3836
sg13
I2
sasa(dp3837
g2
S"The study aimed at: 1) assessing occurrence of HLA-A, HLA-B and HLA-C antigens in patients with Graves' disease in comparison with control group of healthy individuals; 2) determining relationship between circulating serum antimicrosomal and antithyroglobulin antibodies and selected HLA complex antigens.\n"
p3838
sg4
(lp3839
(dp3840
g7
I47
sg8
VP30486
p3841
sg10
I3
sg11
VHLA
p3842
sg13
I1
sa(dp3843
g7
I64
sg8
VP30499
p3844
sg10
I14
sg11
VHLA-C antigens
p3845
sg13
I2
sa(dp3846
g7
I47
sg8
VP30447
p3847
sg10
I5
sg11
VHLA-A
p3848
sg13
I1
sa(dp3849
g7
I54
sg8
VP30461
p3850
sg10
I5
sg11
VHLA-B
p3851
sg13
I1
sa(dp3852
g7
I217
sg8
g49
sg10
I53
sg11
Vserum antimicrosomal and antithyroglobulin antibodies
p3853
sg13
I5
sasg14
(lp3854
(dp3855
g7
I96
sg17
VC0018213
p3856
sg10
I15
sg11
VGraves' disease
p3857
sg13
I2
sasa(dp3858
g2
S"HLA-B8, HLA-B15, HLA-B35, and HLA-Cw3 antibodies were detected more frequently in patients with Graves' disease than in the healthy individuals.\n"
p3859
sg4
(lp3860
(dp3861
g7
I0
sg8
VP30486
p3862
sg10
I6
sg11
VHLA-B8
p3863
sg13
I1
sa(dp3864
g7
I17
sg8
VP30486
p3865
sg10
I7
sg11
VHLA-B35
p3866
sg13
I1
sa(dp3867
g7
I30
sg8
VP30486
p3868
sg10
I18
sg11
VHLA-Cw3 antibodies
p3869
sg13
I2
sa(dp3870
g7
I8
sg8
VP30486
p3871
sg10
I7
sg11
VHLA-B15
p3872
sg13
I1
sasg14
(lp3873
(dp3874
g7
I96
sg17
VC0018213
p3875
sg10
I15
sg11
VGraves' disease
p3876
sg13
I2
sasa(dp3877
g2
S'The role of caspase-12 and caspase-4 in inflammation associated with cerebral ischemia, a condition that results from a transient or permanent reduction of cerebral blood flow, is still unknown.\n'
p3878
sg4
(lp3879
(dp3880
g7
I12
sg8
VP39880
p3881
sg10
I10
sg11
Vcaspase-12
p3882
sg13
I1
sa(dp3883
g7
I27
sg8
VP49662
p3884
sg10
I9
sg11
Vcaspase-4
p3885
sg13
I1
sasg14
(lp3886
(dp3887
g7
I69
sg17
VC0917798
p3888
sg10
I17
sg11
Vcerebral ischemia
p3889
sg13
I2
sa(dp3890
g7
I90
sg17
VC0012634
p3891
sg10
I9
sg11
Vcondition
p3892
sg13
I1
sa(dp3893
g7
I40
sg17
VC0021368
p3894
sg10
I12
sg11
Vinflammation
p3895
sg13
I1
sasa(dp3896
g2
S'Fyn(-/-) mice developed prediabetes after 16-wk high-fat diet treatment and exhibited thermal hypoalgesia, without showing tactile allodynia or altered expression and activation of NR2B subunit, relative to normal diet-fed Fyn(-/-) mice.\n'
p3897
sg4
(lp3898
(dp3899
g7
I0
sg8
VP06241
p3900
sg10
I8
sg11
VFyn(-/-)
p3901
sg13
I1
sa(dp3902
g7
I181
sg8
g49
sg10
I12
sg11
VNR2B subunit
p3903
sg13
I2
sa(dp3904
g7
I0
sg8
VP06241
p3905
sg10
I8
sg11
VFyn(-/-)
p3906
sg13
I1
sasg14
(lp3907
(dp3908
g7
I94
sg17
VC0085625
p3909
sg10
I11
sg11
Vhypoalgesia
p3910
sg13
I1
sa(dp3911
g7
I24
sg17
VC0362046
p3912
sg10
I11
sg11
Vprediabetes
p3913
sg13
I1
sa(dp3914
g7
I123
sg17
VC0751213
p3915
sg10
I17
sg11
Vtactile allodynia
p3916
sg13
I2
sasa(dp3917
g2
S'Our results suggested that Fyn-mediated NR2B signaling plays a critical role in regulation of prediabetic neuropathy and that the increased expression/function of NR2B subunit-containing NMDARs may contribute to the progression of neuropathy in type 2 diabetes.\n'
p3918
sg4
(lp3919
(dp3920
g7
I27
sg8
VP06241
p3921
sg10
I3
sg11
VFyn
p3922
sg13
I1
sa(dp3923
g7
I40
sg8
g49
sg10
I4
sg11
VNR2B
p3924
sg13
I1
sa(dp3925
g7
I40
sg8
g49
sg10
I4
sg11
VNR2B
p3926
sg13
I1
sasg14
(lp3927
(dp3928
g7
I106
sg17
VC0442874
p3929
sg10
I10
sg11
Vneuropathy
p3930
sg13
I1
sa(dp3931
g7
I106
sg17
VC0442874
p3932
sg10
I10
sg11
Vneuropathy
p3933
sg13
I1
sa(dp3934
g7
I245
sg17
VC0011860
p3935
sg10
I15
sg11
Vtype 2 diabetes
p3936
sg13
I3
sasa(dp3937
g2
S'In addition, loss of GluN2B in AgRP neurons of the morbidly obese and severely diabetic leptin-deficient Lep (ob/ob) mice does not affect body weight and food intake but, remarkably, leads to full correction of hyperglycemia.\n'
p3938
sg4
(lp3939
(dp3940
g7
I31
sg8
g49
sg10
I4
sg11
VAgRP
p3941
sg13
I1
sa(dp3942
g7
I105
sg8
VP41159
p3943
sg10
I3
sg11
VLep
p3944
sg13
I1
sa(dp3945
g7
I88
sg8
VP41159
p3946
sg10
I6
sg11
Vleptin
p3947
sg13
I1
sasg14
(lp3948
(dp3949
g7
I60
sg17
VC0028754
p3950
sg10
I5
sg11
Vobese
p3951
sg13
I1
sa(dp3952
g7
I211
sg17
VC0020456
p3953
sg10
I13
sg11
Vhyperglycemia
p3954
sg13
I1
sasa(dp3955
g2
S'The study aimed to investigate the role of NR2B in cognitive dysfunction in the rats with type 1 diabetes and define the protective effects of L-NBP on cognition.\n'
p3956
sg4
(lp3957
(dp3958
g7
I43
sg8
g49
sg10
I4
sg11
VNR2B
p3959
sg13
I1
sa(dp3960
g7
I143
sg8
VP53384
p3961
sg10
I5
sg11
VL-NBP
p3962
sg13
I1
sasg14
(lp3963
(dp3964
g7
I90
sg17
VC0011854
p3965
sg10
I15
sg11
Vtype 1 diabetes
p3966
sg13
I3
sa(dp3967
g7
I51
sg17
VC0338656
p3968
sg10
I21
sg11
Vcognitive dysfunction
p3969
sg13
I2
sasa(dp3970
g2
S'To evaluate the role of three-dimensional constructive interference in steady state (3D-CISS) sequences and phase-contrast magnetic resonance imaging (PC-MRI) in patients with arrested hydrocephalus.\n'
p3971
sg4
(lp3972
sg14
(lp3973
(dp3974
g7
I176
sg17
VC0270718
p3975
sg10
I22
sg11
Varrested hydrocephalus
p3976
sg13
I2
sasa(dp3977
g2
S'We concluded that 3D-CISS and PC-MRI are noninvasive sequences for diagnosis of the level and cause of arrested hydrocephalus.\n'
p3978
sg4
(lp3979
sg14
(lp3980
(dp3981
g7
I103
sg17
VC0270718
p3982
sg10
I22
sg11
Varrested hydrocephalus
p3983
sg13
I2
sasa(dp3984
g2
S'To evaluate efficacy of three-dimensional (3D) heavily T2-weighted (W) MRI sequences in assessment of cerebrospinal fluid (CSF) pathways and to compare two different types of 3D heavily T2W MRI sequences (CISS and SPACE) with two-dimensional (2D) T2W turbo spin echo (TSE) sequences for hydrocephalus with intraventricular obstruction.\n'
p3985
sg4
(lp3986
sg14
(lp3987
(dp3988
g7
I287
sg17
VC0020255
p3989
sg10
I13
sg11
Vhydrocephalus
p3990
sg13
I1
sa(dp3991
g7
I323
sg17
VC0028778
p3992
sg10
I11
sg11
Vobstruction
p3993
sg13
I1
sasa(dp3994
g2
S'Therefore, the article focuses mainly on the effective usage of various MRI sequences in both diagnosis and follow-up of pediatric hydrocephalus, such as 3D CISS, cine PC, TSE, and GRE T2* sequences, to be able to investigate all possible obstructive pathology through the CSF pathway and to assess the efficiency of treatment in a standardized way.\n'
p3995
sg4
(lp3996
(dp3997
g7
I273
sg8
VP04141
p3998
sg10
I3
sg11
VCSF
p3999
sg13
I1
sasg14
(lp4000
(dp4001
g7
I251
sg17
VC0677042
p4002
sg10
I9
sg11
Vpathology
p4003
sg13
I1
sa(dp4004
g7
I131
sg17
VC0020255
p4005
sg10
I13
sg11
Vhydrocephalus
p4006
sg13
I1
sasa(dp4007
g2
S'We will consider mtDNA based syndromes such as LHON/dystonia/Mitochondrial Encephalomyopahty Lactic Acidosis Stroke-like (MELAS)/Leigh overlapping syndrome, or nuclear based diseases such as Friedreich ataxia (mutations in FXN gene), deafness-dystonia-optic atrophy (Mohr-Tranebjerg) syndrome (mutations in TIMM8A), complicated hereditary spastic paraplegia (mutations in SPG7), DOA "plus" syndromes (mutations in OPA1), Charcot-Marie-Tooth type 2A (CMT2A) with optic atrophy or hereditary motor and sensory neuropathy type VI (HMSN VI) (mutations in MFN2), and Costeff syndrome and DOA with cataract (mutations in OPA3).\n'
p4008
sg4
(lp4009
(dp4010
g7
I307
sg8
g49
sg10
I6
sg11
VTIMM8A
p4011
sg13
I1
sa(dp4012
g7
I372
sg8
g49
sg10
I4
sg11
VSPG7
p4013
sg13
I1
sa(dp4014
g7
I223
sg8
VP51587
p4015
sg10
I8
sg11
VFXN gene
p4016
sg13
I2
sa(dp4017
g7
I551
sg8
g49
sg10
I4
sg11
VMFN2
p4018
sg13
I1
sa(dp4019
g7
I414
sg8
g49
sg10
I4
sg11
VOPA1
p4020
sg13
I1
sa(dp4021
g7
I615
sg8
g49
sg10
I4
sg11
VOPA3
p4022
sg13
I1
sasg14
(lp4023
(dp4024
g7
I234
sg17
VC0011053
p4025
sg10
I8
sg11
Vdeafness
p4026
sg13
I1
sa(dp4027
g7
I135
sg17
VC0410000
p4028
sg10
I20
sg11
Voverlapping syndrome
p4029
sg13
I2
sa(dp4030
g7
I52
sg17
VC0393593
p4031
sg10
I8
sg11
Vdystonia
p4032
sg13
I1
sa(dp4033
g7
I47
sg17
VC0162671
p4034
sg10
I73
sg11
VLHON/dystonia/Mitochondrial Encephalomyopahty Lactic Acidosis Stroke-like
p4035
sg13
I5
sa(dp4036
g7
I592
sg17
VC0086543
p4037
sg10
I8
sg11
Vcataract
p4038
sg13
I1
sa(dp4039
g7
I252
sg17
VC0029124
p4040
sg10
I13
sg11
Voptic atrophy
p4041
sg13
I2
sa(dp4042
g7
I29
sg17
VC0039082
p4043
sg10
I8
sg11
Vsyndrome
p4044
sg13
I1
sa(dp4045
g7
I562
sg17
VC0574084
p4046
sg10
I16
sg11
VCosteff syndrome
p4047
sg13
I2
sa(dp4048
g7
I29
sg17
VC0039082
p4049
sg10
I9
sg11
Vsyndromes
p4050
sg13
I1
sa(dp4051
g7
I316
sg17
VC0393556
p4052
sg10
I41
sg11
Vcomplicated hereditary spastic paraplegia
p4053
sg13
I4
sa(dp4054
g7
I29
sg17
VC0039082
p4055
sg10
I9
sg11
Vsyndromes
p4056
sg13
I1
sa(dp4057
g7
I372
sg17
VC1846564
p4058
sg10
I4
sg11
VSPG7
p4059
sg13
I1
sa(dp4060
g7
I528
sg17
VC0393807
p4061
sg10
I7
sg11
VHMSN VI
p4062
sg13
I2
sa(dp4063
g7
I122
sg17
VC0162671
p4064
sg10
I5
sg11
VMELAS
p4065
sg13
I1
sa(dp4066
g7
I414
sg17
VC0338508
p4067
sg10
I4
sg11
VOPA1
p4068
sg13
I1
sa(dp4069
g7
I191
sg17
VC0016719
p4070
sg10
I17
sg11
VFriedreich ataxia
p4071
sg13
I2
sa(dp4072
g7
I252
sg17
VC0029124
p4073
sg10
I13
sg11
Voptic atrophy
p4074
sg13
I2
sa(dp4075
g7
I479
sg17
VC0393807
p4076
sg10
I47
sg11
Vhereditary motor and sensory neuropathy type VI
p4077
sg13
I7
sasa(dp4078
g2
S'This rare X-linked progressive neurodegenerative disorder, named Mohr-Tranebjaerg (MT syndrome), is caused by mutations in the DDP1 gene and includes sensorineural deafness, blindness, mental retardation and a complex movement disorder.\n'
p4079
sg4
(lp4080
(dp4081
g7
I127
sg8
g49
sg10
I9
sg11
VDDP1 gene
p4082
sg13
I2
sasg14
(lp4083
(dp4084
g7
I174
sg17
VC0456909
p4085
sg10
I9
sg11
Vblindness
p4086
sg13
I1
sa(dp4087
g7
I86
sg17
VC0039082
p4088
sg10
I8
sg11
Vsyndrome
p4089
sg13
I1
sa(dp4090
g7
I218
sg17
VC0026650
p4091
sg10
I17
sg11
Vmovement disorder
p4092
sg13
I2
sa(dp4093
g7
I150
sg17
VC0018784
p4094
sg10
I22
sg11
Vsensorineural deafness
p4095
sg13
I2
sa(dp4096
g7
I185
sg17
VC0025362
p4097
sg10
I18
sg11
Vmental retardation
p4098
sg13
I2
sa(dp4099
g7
I31
sg17
VC0524851
p4100
sg10
I26
sg11
Vneurodegenerative disorder
p4101
sg13
I2
sasa(dp4102
g2
S'More recently, it was shown that this original DFN-1 family represented a new type of recessive neurodegenerative syndrome characterized by postlingual progressive sensorineural deafness as the first presenting symptom in early childhood, followed by progressive dystonia, spasticity, dysphagia, mental deterioration, paranoia and cortical blindness.\n'
p4103
sg4
(lp4104
sg14
(lp4105
(dp4106
g7
I331
sg17
VC0155320
p4107
sg10
I18
sg11
Vcortical blindness
p4108
sg13
I2
sa(dp4109
g7
I211
sg17
VC1457887
p4110
sg10
I7
sg11
Vsymptom
p4111
sg13
I1
sa(dp4112
g7
I114
sg17
VC0039082
p4113
sg10
I8
sg11
Vsyndrome
p4114
sg13
I1
sa(dp4115
g7
I285
sg17
VC0011168
p4116
sg10
I9
sg11
Vdysphagia
p4117
sg13
I1
sa(dp4118
g7
I164
sg17
VC0018784
p4119
sg10
I22
sg11
Vsensorineural deafness
p4120
sg13
I2
sa(dp4121
g7
I296
sg17
VC0234985
p4122
sg10
I20
sg11
Vmental deterioration
p4123
sg13
I2
sa(dp4124
g7
I318
sg17
VC1456784
p4125
sg10
I8
sg11
Vparanoia
p4126
sg13
I1
sa(dp4127
g7
I263
sg17
VC0393593
p4128
sg10
I8
sg11
Vdystonia
p4129
sg13
I1
sa(dp4130
g7
I273
sg17
VC0026838
p4131
sg10
I10
sg11
Vspasticity
p4132
sg13
I1
sasa(dp4133
g2
S'We now report small deletions in this candidate gene in the original DFN-1/MTS family, and in a family with deafness, dystonia and mental deficiency but not blindness.\n'
p4134
sg4
(lp4135
(dp4136
g7
I75
sg8
VP40692
p4137
sg10
I10
sg11
VMTS family
p4138
sg13
I2
sasg14
(lp4139
(dp4140
g7
I75
sg17
VC0796074
p4141
sg10
I3
sg11
VMTS
p4142
sg13
I1
sa(dp4143
g7
I108
sg17
VC0011053
p4144
sg10
I8
sg11
Vdeafness
p4145
sg13
I1
sa(dp4146
g7
I118
sg17
VC0393593
p4147
sg10
I8
sg11
Vdystonia
p4148
sg13
I1
sa(dp4149
g7
I157
sg17
VC0456909
p4150
sg10
I9
sg11
Vblindness
p4151
sg13
I1
sa(dp4152
g7
I131
sg17
VC0917816
p4153
sg10
I17
sg11
Vmental deficiency
p4154
sg13
I2
sasa(dp4155
g2
S'Restudy of the original DFN-1 family showed that the deafness is part of a progressive X linked recessive syndrome, which includes visual disability leading to cortical blindness, dystonia, fractures, and mental deficiency.\n'
p4156
sg4
(lp4157
sg14
(lp4158
(dp4159
g7
I53
sg17
VC0011053
p4160
sg10
I8
sg11
Vdeafness
p4161
sg13
I1
sa(dp4162
g7
I180
sg17
VC0393593
p4163
sg10
I8
sg11
Vdystonia
p4164
sg13
I1
sa(dp4165
g7
I106
sg17
VC0039082
p4166
sg10
I8
sg11
Vsyndrome
p4167
sg13
I1
sa(dp4168
g7
I205
sg17
VC0917816
p4169
sg10
I17
sg11
Vmental deficiency
p4170
sg13
I2
sa(dp4171
g7
I160
sg17
VC0155320
p4172
sg10
I18
sg11
Vcortical blindness
p4173
sg13
I2
sasa(dp4174
g2
S'The aim of this study was to investigate tissue factor (TF) expression, fibrin/fibrinogen and D-dimer deposition, as well as the occurrence of intravascular thrombosis (IVT) in canine intracranial meningiomas using immunohistochemistry.\n'
p4175
sg4
(lp4176
(dp4177
g7
I94
sg8
g49
sg10
I7
sg11
VD-dimer
p4178
sg13
I1
sa(dp4179
g7
I56
sg8
VP13726
p4180
sg10
I2
sg11
VTF
p4181
sg13
I1
sa(dp4182
g7
I72
sg8
VP22087
p4183
sg10
I6
sg11
Vfibrin
p4184
sg13
I1
sa(dp4185
g7
I79
sg8
VP22087
p4186
sg10
I10
sg11
Vfibrinogen
p4187
sg13
I1
sa(dp4188
g7
I41
sg8
VP13726
p4189
sg10
I13
sg11
Vtissue factor
p4190
sg13
I2
sasg14
(lp4191
(dp4192
g7
I143
sg17
VC0442860
p4193
sg10
I24
sg11
Vintravascular thrombosis
p4194
sg13
I2
sa(dp4195
g7
I169
sg17
VC0442860
p4196
sg10
I3
sg11
VIVT
p4197
sg13
I1
sa(dp4198
g7
I184
sg17
VC0349604
p4199
sg10
I24
sg11
Vintracranial meningiomas
p4200
sg13
I2
sasa(dp4201
g2
S'Five patients (4 girls and 1 boy) with AT/RT were treated in our hospital.\n'
p4202
sg4
(lp4203
sg14
(lp4204
(dp4205
g7
I39
sg17
VC1266184
p4206
sg10
I5
sg11
VAT/RT
p4207
sg13
I1
sasa(dp4208
g2
S'Ucn3 mRNA expression was lower in pPROM with and without chorioamnionitis than in PTD.\n'
p4209
sg4
(lp4210
(dp4211
g7
I0
sg8
g49
sg10
I9
sg11
VUcn3 mRNA
p4212
sg13
I2
sa(dp4213
g7
I34
sg8
VP50454
p4214
sg10
I5
sg11
VpPROM
p4215
sg13
I1
sasg14
(lp4216
(dp4217
g7
I82
sg17
VC0266006
p4218
sg10
I3
sg11
VPTD
p4219
sg13
I1
sa(dp4220
g7
I57
sg17
VC0008495
p4221
sg10
I16
sg11
Vchorioamnionitis
p4222
sg13
I1
sa(dp4223
g7
I34
sg17
VC0729264
p4224
sg10
I5
sg11
VpPROM
p4225
sg13
I1
sasa(dp4226
g2
S'The aim of the present study was to determine whether the expression of A disintegrin and metallproteinase 15 (ADAM15) affected the inflammatory conditions and cell migration in human fibroblast-like synoviocytes (FLSs) in a rat model of rheumatoid arthritis (RA).\n'
p4227
sg4
(lp4228
(dp4229
g7
I111
sg8
g49
sg10
I6
sg11
VADAM15
p4230
sg13
I1
sa(dp4231
g7
I72
sg8
g49
sg10
I37
sg11
VA disintegrin and metallproteinase 15
p4232
sg13
I5
sasg14
(lp4233
(dp4234
g7
I260
sg17
VC0003873
p4235
sg10
I2
sg11
VRA
p4236
sg13
I1
sa(dp4237
g7
I238
sg17
VC0003873
p4238
sg10
I20
sg11
Vrheumatoid arthritis
p4239
sg13
I2
sasa(dp4240
g2
S'The therapeutic effects and side effects of ADAM15 in a rat model of collagen-induced arthritis (CIA) were examined in vivo.\n'
p4241
sg4
(lp4242
(dp4243
g7
I44
sg8
g49
sg10
I6
sg11
VADAM15
p4244
sg13
I1
sasg14
(lp4245
(dp4246
g7
I86
sg17
VC0003864
p4247
sg10
I9
sg11
Varthritis
p4248
sg13
I1
sasa(dp4249
g2
S'In addition, treatment of CIA rats using siADAM15 significantly reduced the arthritis score and extent of joint damage in the rats.\n'
p4250
sg4
(lp4251
sg14
(lp4252
(dp4253
g7
I76
sg17
VC0003864
p4254
sg10
I9
sg11
Varthritis
p4255
sg13
I1
sasa(dp4256
g2
S'To study the contribution of ADAM15, a disintegrin metalloproteinase that is up-regulated in the rheumatoid arthritis (RA) synovial membrane, to the characteristic resistance of RA synovial fibroblasts (RASFs) to apoptosis induction by genotoxic stress or stimulation with proapoptotic FasL, which is present at high concentrations in RA synovial fluid.\n'
p4257
sg4
(lp4258
(dp4259
g7
I39
sg8
VP52888
p4260
sg10
I29
sg11
Vdisintegrin metalloproteinase
p4261
sg13
I2
sa(dp4262
g7
I286
sg8
VP48023
p4263
sg10
I4
sg11
VFasL
p4264
sg13
I1
sa(dp4265
g7
I29
sg8
g49
sg10
I6
sg11
VADAM15
p4266
sg13
I1
sasg14
(lp4267
(dp4268
g7
I119
sg17
VC0003873
p4269
sg10
I2
sg11
VRA
p4270
sg13
I1
sa(dp4271
g7
I119
sg17
VC0003873
p4272
sg10
I2
sg11
VRA
p4273
sg13
I1
sa(dp4274
g7
I97
sg17
VC0003873
p4275
sg10
I20
sg11
Vrheumatoid arthritis
p4276
sg13
I2
sa(dp4277
g7
I236
sg17
VC1257899
p4278
sg10
I16
sg11
Vgenotoxic stress
p4279
sg13
I2
sa(dp4280
g7
I119
sg17
VC0003873
p4281
sg10
I2
sg11
VRA
p4282
sg13
I1
sasa(dp4283
g2
S'To investigate the regulation of the proteins ADAM-15 and ADAM-17 in intrauterine adhesions (IUA).\n'
p4284
sg4
(lp4285
(dp4286
g7
I46
sg8
g49
sg10
I7
sg11
VADAM-15
p4287
sg13
I1
sa(dp4288
g7
I58
sg8
VP78536
p4289
sg10
I7
sg11
VADAM-17
p4290
sg13
I1
sasg14
(lp4291
(dp4292
g7
I69
sg17
VC0241593
p4293
sg10
I22
sg11
Vintrauterine adhesions
p4294
sg13
I2
sa(dp4295
g7
I93
sg17
VC0241593
p4296
sg10
I3
sg11
VIUA
p4297
sg13
I1
sasa(dp4298
g2
S'The development of IUA is associated with regulation of ADAM15 and ADAM-17, which may be potential biological markers for evaluating the severity of intrauterine adhesions.\n'
p4299
sg4
(lp4300
(dp4301
g7
I56
sg8
g49
sg10
I6
sg11
VADAM15
p4302
sg13
I1
sa(dp4303
g7
I67
sg8
VP78536
p4304
sg10
I7
sg11
VADAM-17
p4305
sg13
I1
sasg14
(lp4306
(dp4307
g7
I149
sg17
VC0241593
p4308
sg10
I22
sg11
Vintrauterine adhesions
p4309
sg13
I2
sasa(dp4310
g2
S'In a mouse model of acute lung injury induced by lipopolysaccharide (LPS), upregulation of ADAM15 was observed in association with pulmonary edema and neutrophil infiltration.\n'
p4311
sg4
(lp4312
(dp4313
g7
I91
sg8
g49
sg10
I6
sg11
VADAM15
p4314
sg13
I1
sasg14
(lp4315
(dp4316
g7
I69
sg17
VC0175697
p4317
sg10
I3
sg11
VLPS
p4318
sg13
I1
sa(dp4319
g7
I131
sg17
VC0034063
p4320
sg10
I15
sg11
Vpulmonary edema
p4321
sg13
I2
sa(dp4322
g7
I162
sg17
VC0332448
p4323
sg10
I12
sg11
Vinfiltration
p4324
sg13
I1
sa(dp4325
g7
I49
sg17
VC0175697
p4326
sg10
I18
sg11
Vlipopolysaccharide
p4327
sg13
I1
sasa(dp4328
g2
S'However, whether and how ADAM15 contributes to atherosclerosis remains unknown.\n'
p4329
sg4
(lp4330
(dp4331
g7
I25
sg8
g49
sg10
I6
sg11
VADAM15
p4332
sg13
I1
sasg14
(lp4333
(dp4334
g7
I47
sg17
VC0004153
p4335
sg10
I15
sg11
Vatherosclerosis
p4336
sg13
I1
sasa(dp4337
g2
S'HuR is an RNA-binding protein implicated in immune homeostasis and various cancers, including colorectal cancer.\n'
p4338
sg4
(lp4339
(dp4340
g7
I0
sg8
g49
sg10
I3
sg11
VHuR
p4341
sg13
I1
sasg14
(lp4342
(dp4343
g7
I94
sg17
VC1527249
p4344
sg10
I17
sg11
Vcolorectal cancer
p4345
sg13
I2
sa(dp4346
g7
I75
sg17
VC0006826
p4347
sg10
I7
sg11
Vcancers
p4348
sg13
I1
sasa(dp4349
g2
S'In this study, we evaluated HuR as a small-molecule target for preventing colorectal cancer in high-risk groups such as those with familial adenomatosis polyposis (FAP) or inflammatory bowel disease (IBD).\n'
p4350
sg4
(lp4351
sg14
(lp4352
(dp4353
g7
I200
sg17
VC0021390
p4354
sg10
I3
sg11
VIBD
p4355
sg13
I1
sa(dp4356
g7
I131
sg17
VC0032580
p4357
sg10
I31
sg11
Vfamilial adenomatosis polyposis
p4358
sg13
I3
sa(dp4359
g7
I74
sg17
VC1527249
p4360
sg10
I17
sg11
Vcolorectal cancer
p4361
sg13
I2
sa(dp4362
g7
I172
sg17
VC0021390
p4363
sg10
I26
sg11
Vinflammatory bowel disease
p4364
sg13
I3
sa(dp4365
g7
I164
sg17
VC0032580
p4366
sg10
I3
sg11
VFAP
p4367
sg13
I1
sasa(dp4368
g2
S'In human specimens, levels of cytoplasmic HuR were increased in colonic epithelial cells from patients with IBD, IBD-cancer, FAP-adenoma, and colorectal cancer, but not in patients with IBD-dysplasia.\n'
p4369
sg4
(lp4370
sg14
(lp4371
(dp4372
g7
I129
sg17
VC0001430
p4373
sg10
I7
sg11
Vadenoma
p4374
sg13
I1
sa(dp4375
g7
I117
sg17
VC0006826
p4376
sg10
I6
sg11
Vcancer
p4377
sg13
I1
sa(dp4378
g7
I125
sg17
VC0032580
p4379
sg10
I3
sg11
VFAP
p4380
sg13
I1
sa(dp4381
g7
I108
sg17
VC0021390
p4382
sg10
I3
sg11
VIBD
p4383
sg13
I1
sa(dp4384
g7
I108
sg17
VC0021390
p4385
sg10
I3
sg11
VIBD
p4386
sg13
I1
sa(dp4387
g7
I142
sg17
VC1527249
p4388
sg10
I17
sg11
Vcolorectal cancer
p4389
sg13
I2
sa(dp4390
g7
I190
sg17
VC0334044
p4391
sg10
I9
sg11
Vdysplasia
p4392
sg13
I1
sa(dp4393
g7
I108
sg17
VC0021390
p4394
sg10
I3
sg11
VIBD
p4395
sg13
I1
sasa(dp4396
g2
S'Intraperitoneal injection of the HuR small-molecule inhibitor MS-444 in AOM/DSS mice, a model of IBD and inflammatory colon cancer, augmented DSS-induced weight loss and increased tumor multiplicity, size, and invasiveness.\n'
p4397
sg4
(lp4398
(dp4399
g7
I33
sg8
g49
sg10
I18
sg11
VHuR small-molecule
p4400
sg13
I2
sasg14
(lp4401
(dp4402
g7
I180
sg17
VC0027651
p4403
sg10
I5
sg11
Vtumor
p4404
sg13
I1
sa(dp4405
g7
I76
sg17
VC0011195
p4406
sg10
I3
sg11
VDSS
p4407
sg13
I1
sa(dp4408
g7
I97
sg17
VC0021390
p4409
sg10
I3
sg11
VIBD
p4410
sg13
I1
sa(dp4411
g7
I72
sg17
VC0265253
p4412
sg10
I3
sg11
VAOM
p4413
sg13
I1
sa(dp4414
g7
I118
sg17
VC0699790
p4415
sg10
I12
sg11
Vcolon cancer
p4416
sg13
I2
sa(dp4417
g7
I76
sg17
VC0011195
p4418
sg10
I3
sg11
VDSS
p4419
sg13
I1
sasa(dp4420
g2
S'In contrast, HuR inhibition in APCMin mice, a model of FAP and colon cancer, diminished the number of small intestinal tumors generated.\n'
p4421
sg4
(lp4422
(dp4423
g7
I55
sg8
VP25054
p4424
sg10
I3
sg11
VFAP
p4425
sg13
I1
sa(dp4426
g7
I13
sg8
g49
sg10
I3
sg11
VHuR
p4427
sg13
I1
sasg14
(lp4428
(dp4429
g7
I108
sg17
VC0021841
p4430
sg10
I17
sg11
Vintestinal tumors
p4431
sg13
I2
sa(dp4432
g7
I55
sg17
VC0032580
p4433
sg10
I3
sg11
VFAP
p4434
sg13
I1
sa(dp4435
g7
I63
sg17
VC0699790
p4436
sg10
I12
sg11
Vcolon cancer
p4437
sg13
I2
sasa(dp4438
g2
S'Using a publically available database, HuR expression levels were determined to be increased in primary PDA and colorectal cancer tumor cohorts as compared with normal pancreas and colon tissues, respectively.\n'
p4439
sg4
(lp4440
(dp4441
g7
I39
sg8
g49
sg10
I3
sg11
VHuR
p4442
sg13
I1
sasg14
(lp4443
(dp4444
g7
I130
sg17
VC0027651
p4445
sg10
I5
sg11
Vtumor
p4446
sg13
I1
sa(dp4447
g7
I112
sg17
VC1527249
p4448
sg10
I17
sg11
Vcolorectal cancer
p4449
sg13
I2
sa(dp4450
g7
I104
sg17
VC0013274
p4451
sg10
I3
sg11
VPDA
p4452
sg13
I1
sasa(dp4453
g2
S'CRISPR/Cas9 technology was successfully used to delete the HuR gene in both PDA (MIA PaCa-2 and Hs 766T) and colorectal cancer (HCT116) cell lines.\n'
p4454
sg4
(lp4455
(dp4456
g7
I59
sg8
g49
sg10
I8
sg11
VHuR gene
p4457
sg13
I2
sa(dp4458
g7
I81
sg8
g49
sg10
I10
sg11
VMIA PaCa-2
p4459
sg13
I2
sasg14
(lp4460
(dp4461
g7
I76
sg17
VC0013274
p4462
sg10
I3
sg11
VPDA
p4463
sg13
I1
sa(dp4464
g7
I85
sg17
VC1836780
p4465
sg10
I4
sg11
VPaCa
p4466
sg13
I1
sa(dp4467
g7
I109
sg17
VC1527249
p4468
sg10
I17
sg11
Vcolorectal cancer
p4469
sg13
I2
sasa(dp4470
g2
S'Although not as a dramatic phenotype, CRISPR knockout HuR HCT116 colon cancer cells (HCT.HuR-KO(-/-)) showed significantly reduced in vivo tumor growth compared with controls (HCT.HuR-WT(+/+)).\n'
p4471
sg4
(lp4472
sg14
(lp4473
(dp4474
g7
I65
sg17
VC0699790
p4475
sg10
I12
sg11
Vcolon cancer
p4476
sg13
I2
sa(dp4477
g7
I139
sg17
VC0598934
p4478
sg10
I12
sg11
Vtumor growth
p4479
sg13
I2
sasa(dp4480
g2
S'Collectively, sensitization of colon carcinoma cells to radiation-induced cell death and DNA-damage by HuR knockdown critically depends on caspase-2 and may represent a valuable approach to intervene with therapy resistance of colorectal cancer (CRC).\n'
p4481
sg4
(lp4482
(dp4483
g7
I139
sg8
VP42575
p4484
sg10
I9
sg11
Vcaspase-2
p4485
sg13
I1
sasg14
(lp4486
(dp4487
g7
I246
sg17
VC1527249
p4488
sg10
I3
sg11
VCRC
p4489
sg13
I1
sa(dp4490
g7
I227
sg17
VC1527249
p4491
sg10
I17
sg11
Vcolorectal cancer
p4492
sg13
I2
sa(dp4493
g7
I31
sg17
VC0699790
p4494
sg10
I15
sg11
Vcolon carcinoma
p4495
sg13
I2
sasa(dp4496
g2
S'And importantly, HuR levels were found to be highly representative in liver and colon cancer.\n'
p4497
sg4
(lp4498
(dp4499
g7
I17
sg8
g49
sg10
I3
sg11
VHuR
p4500
sg13
I1
sasg14
(lp4501
(dp4502
g7
I80
sg17
VC0699790
p4503
sg10
I12
sg11
Vcolon cancer
p4504
sg13
I2
sasa(dp4505
g2
S'In summary, we report that HuR and TTP are the critical regulators of the posttranscriptional regulation of claudin-1 expression in colon cancer cells.\n'
p4506
sg4
(lp4507
(dp4508
g7
I27
sg8
g49
sg10
I3
sg11
VHuR
p4509
sg13
I1
sa(dp4510
g7
I108
sg8
g49
sg10
I9
sg11
Vclaudin-1
p4511
sg13
I1
sa(dp4512
g7
I35
sg8
g49
sg10
I3
sg11
VTTP
p4513
sg13
I1
sasg14
(lp4514
(dp4515
g7
I132
sg17
VC0699790
p4516
sg10
I12
sg11
Vcolon cancer
p4517
sg13
I2
sa(dp4518
g7
I35
sg17
VC1268935
p4519
sg10
I3
sg11
VTTP
p4520
sg13
I1
sasa(dp4521
g2
S'Four genes showed inverse correlation between methylation and gene expression; ROR1, GXYLT2, FOXA2, and, notably, RARB, a gene previously identified as a tumor suppressor in colorectal adenocarcinoma as well as breast, lung and prostate cancer.\n'
p4522
sg4
(lp4523
(dp4524
g7
I85
sg8
g49
sg10
I6
sg11
VGXYLT2
p4525
sg13
I1
sa(dp4526
g7
I114
sg8
VP10826
p4527
sg10
I4
sg11
VRARB
p4528
sg13
I1
sa(dp4529
g7
I93
sg8
g49
sg10
I5
sg11
VFOXA2
p4530
sg13
I1
sa(dp4531
g7
I79
sg8
VP35398
p4532
sg10
I4
sg11
VROR1
p4533
sg13
I1
sasg14
(lp4534
(dp4535
g7
I154
sg17
VC0027651
p4536
sg10
I5
sg11
Vtumor
p4537
sg13
I1
sa(dp4538
g7
I174
sg17
VC1319315
p4539
sg10
I25
sg11
Vcolorectal adenocarcinoma
p4540
sg13
I2
sa(dp4541
g7
I228
sg17
VC0600139
p4542
sg10
I15
sg11
Vprostate cancer
p4543
sg13
I2
sasa(dp4544
g2
S'Head and neck cancer (HNC) is the seventh most common malignancy in the world and its prevailing form, the head and neck squamous cell carcinoma (HNSCC), is characterized as aggressive and invasive cancer type.\n'
p4545
sg4
(lp4546
sg14
(lp4547
(dp4548
g7
I54
sg17
VC0006826
p4549
sg10
I10
sg11
Vmalignancy
p4550
sg13
I1
sa(dp4551
g7
I174
sg17
VC0001807
p4552
sg10
I10
sg11
Vaggressive
p4553
sg13
I1
sa(dp4554
g7
I107
sg17
VC1168401
p4555
sg10
I37
sg11
Vhead and neck squamous cell carcinoma
p4556
sg13
I6
sa(dp4557
g7
I189
sg17
VC0677898
p4558
sg10
I15
sg11
Vinvasive cancer
p4559
sg13
I2
sa(dp4560
g7
I146
sg17
VC1168401
p4561
sg10
I5
sg11
VHNSCC
p4562
sg13
I1
sa(dp4563
g7
I0
sg17
VC0278996
p4564
sg10
I20
sg11
VHead and neck cancer
p4565
sg13
I4
sa(dp4566
g7
I22
sg17
VC0278996
p4567
sg10
I3
sg11
VHNC
p4568
sg13
I1
sasa(dp4569
g2
S'Head and neck squamous cell carcinoma (HNSCC), the most common form of HNC, develops in the oral cavity, pharynx, and larynx and is associated with tobacco exposure, alcohol abuse, and infection with oncogenic viruses.\n'
p4570
sg4
(lp4571
(dp4572
g7
I71
sg8
VP22894
p4573
sg10
I3
sg11
VHNC
p4574
sg13
I1
sasg14
(lp4575
(dp4576
g7
I0
sg17
VC1168401
p4577
sg10
I37
sg11
VHead and neck squamous cell carcinoma
p4578
sg13
I6
sa(dp4579
g7
I39
sg17
VC1168401
p4580
sg10
I5
sg11
VHNSCC
p4581
sg13
I1
sa(dp4582
g7
I185
sg17
VC0009450
p4583
sg10
I9
sg11
Vinfection
p4584
sg13
I1
sa(dp4585
g7
I97
sg17
VC0011334
p4586
sg10
I6
sg11
Vcavity
p4587
sg13
I1
sa(dp4588
g7
I166
sg17
VC0085762
p4589
sg10
I13
sg11
Valcohol abuse
p4590
sg13
I2
sa(dp4591
g7
I118
sg17
VC0023051
p4592
sg10
I6
sg11
Vlarynx
p4593
sg13
I1
sasa(dp4594
g2
S'We attempted to assess MMP-8 function in oral tongue squamous cell carcinoma (OTSCC).\n'
p4595
sg4
(lp4596
(dp4597
g7
I23
sg8
VP22894
p4598
sg10
I5
sg11
VMMP-8
p4599
sg13
I1
sasg14
(lp4600
(dp4601
g7
I46
sg17
VC0349566
p4602
sg10
I30
sg11
Vtongue squamous cell carcinoma
p4603
sg13
I4
sasa(dp4604
g2
S'We investigated the immunohistochemical expression profiles of cytokeratins (CAM5.2, AE1/AE3, CK7, CK8, CK18, and CK20), epithelial membrane antigen, SRY (sex-determining region Y)-box 9, type II collagen, runt-related transcription factor 2, and osteocalcin in clear cell chondrosarcoma and compared them with those in chondroblastoma, conventional chondrosarcoma, and osteosarcoma.\n'
p4605
sg4
(lp4606
(dp4607
g7
I150
sg8
g49
sg10
I3
sg11
VSRY
p4608
sg13
I1
sa(dp4609
g7
I85
sg8
VP02730
p4610
sg10
I3
sg11
VAE1
p4611
sg13
I1
sa(dp4612
g7
I247
sg8
VP02818
p4613
sg10
I11
sg11
Vosteocalcin
p4614
sg13
I1
sa(dp4615
g7
I121
sg8
VP12830
p4616
sg10
I27
sg11
Vepithelial membrane antigen
p4617
sg13
I3
sa(dp4618
g7
I94
sg8
VP08729
p4619
sg10
I3
sg11
VCK7
p4620
sg13
I1
sa(dp4621
g7
I89
sg8
VP48751
p4622
sg10
I3
sg11
VAE3
p4623
sg13
I1
sa(dp4624
g7
I155
sg8
g49
sg10
I24
sg11
Vsex-determining region Y
p4625
sg13
I3
sa(dp4626
g7
I114
sg8
VP35900
p4627
sg10
I4
sg11
VCK20
p4628
sg13
I1
sasg14
(lp4629
(dp4630
g7
I206
sg17
VC0013336
p4631
sg10
I4
sg11
Vrunt
p4632
sg13
I1
sa(dp4633
g7
I370
sg17
VC0029463
p4634
sg10
I12
sg11
Vosteosarcoma
p4635
sg13
I1
sa(dp4636
g7
I337
sg17
VC1335473
p4637
sg10
I27
sg11
Vconventional chondrosarcoma
p4638
sg13
I2
sa(dp4639
g7
I320
sg17
VC0008441
p4640
sg10
I15
sg11
Vchondroblastoma
p4641
sg13
I1
sa(dp4642
g7
I262
sg17
VC1266167
p4643
sg10
I25
sg11
Vclear cell chondrosarcoma
p4644
sg13
I3
sasa(dp4645
g2
S'In this study we investigated the functional role of FAP-1 as a potential inhibitor of CD95 (Fas, APO-1)-mediated apoptosis in pancreatic cancer cells.\n'
p4646
sg4
(lp4647
(dp4648
g7
I93
sg8
VP48023
p4649
sg10
I3
sg11
VFas
p4650
sg13
I1
sa(dp4651
g7
I87
sg8
VP48023
p4652
sg10
I4
sg11
VCD95
p4653
sg13
I1
sa(dp4654
g7
I98
sg8
VP48023
p4655
sg10
I5
sg11
VAPO-1
p4656
sg13
I1
sa(dp4657
g7
I53
sg8
VP25054
p4658
sg10
I5
sg11
VFAP-1
p4659
sg13
I1
sasg14
(lp4660
(dp4661
g7
I93
sg17
VC0015923
p4662
sg10
I3
sg11
VFas
p4663
sg13
I1
sa(dp4664
g7
I53
sg17
VC0032580
p4665
sg10
I3
sg11
VFAP
p4666
sg13
I1
sa(dp4667
g7
I127
sg17
VC0235974
p4668
sg10
I17
sg11
Vpancreatic cancer
p4669
sg13
I2
sasa(dp4670
g2
S'Finally, we demonstrate by immunohistochemistry that FAP-1 is strongly expressed in tumor cells from pancreatic carcinoma tissues.\n'
p4671
sg4
(lp4672
(dp4673
g7
I53
sg8
VP25054
p4674
sg10
I5
sg11
VFAP-1
p4675
sg13
I1
sasg14
(lp4676
(dp4677
g7
I101
sg17
VC0235974
p4678
sg10
I20
sg11
Vpancreatic carcinoma
p4679
sg13
I2
sa(dp4680
g7
I53
sg17
VC0032580
p4681
sg10
I3
sg11
VFAP
p4682
sg13
I1
sa(dp4683
g7
I84
sg17
VC0027651
p4684
sg10
I5
sg11
Vtumor
p4685
sg13
I1
sasa(dp4686
g2
S'Taken together, these results show that FAP-1 can protect pancreatic carcinoma cells from CD95-mediated apoptosis, probably by preventing anti-CD95-induced translocation of CD95 from intracellular stores to the cell surface.\n'
p4687
sg4
(lp4688
(dp4689
g7
I90
sg8
VP48023
p4690
sg10
I4
sg11
VCD95
p4691
sg13
I1
sa(dp4692
g7
I40
sg8
VP25054
p4693
sg10
I5
sg11
VFAP-1
p4694
sg13
I1
sa(dp4695
g7
I138
sg8
VP48023
p4696
sg10
I9
sg11
Vanti-CD95
p4697
sg13
I1
sa(dp4698
g7
I90
sg8
VP48023
p4699
sg10
I4
sg11
VCD95
p4700
sg13
I1
sasg14
(lp4701
(dp4702
g7
I156
sg17
VC0040715
p4703
sg10
I13
sg11
Vtranslocation
p4704
sg13
I1
sa(dp4705
g7
I58
sg17
VC0235974
p4706
sg10
I20
sg11
Vpancreatic carcinoma
p4707
sg13
I2
sa(dp4708
g7
I40
sg17
VC0032580
p4709
sg10
I3
sg11
VFAP
p4710
sg13
I1
sasa(dp4711
g2
S'The most striking findings were the overexpression of Fas decoy receptors (DcR3), Fas associated phosphatase-1 (FAP-1), and FLICE-inhibitory protein (c-FLIP) in the resistant cell lines as well as in pancreatic cancer surgical specimens.\n'
p4712
sg4
(lp4713
(dp4714
g7
I82
sg8
VP48023
p4715
sg10
I28
sg11
VFas associated phosphatase-1
p4716
sg13
I3
sa(dp4717
g7
I54
sg8
VP48023
p4718
sg10
I19
sg11
VFas decoy receptors
p4719
sg13
I3
sa(dp4720
g7
I112
sg8
VP25054
p4721
sg10
I5
sg11
VFAP-1
p4722
sg13
I1
sa(dp4723
g7
I75
sg8
g49
sg10
I4
sg11
VDcR3
p4724
sg13
I1
sasg14
(lp4725
(dp4726
g7
I112
sg17
VC0032580
p4727
sg10
I3
sg11
VFAP
p4728
sg13
I1
sa(dp4729
g7
I54
sg17
VC0015923
p4730
sg10
I3
sg11
VFas
p4731
sg13
I1
sa(dp4732
g7
I200
sg17
VC0235974
p4733
sg10
I17
sg11
Vpancreatic cancer
p4734
sg13
I2
sa(dp4735
g7
I54
sg17
VC0015923
p4736
sg10
I3
sg11
VFas
p4737
sg13
I1
sasa(dp4738
g2
S'This resistance correlated with high levels in pancreatic tumor cells of mRNA for FAP-1, a Fas-associated phosphatase that can block the apoptotic function of Fas.\n'
p4739
sg4
(lp4740
(dp4741
g7
I91
sg8
VP48023
p4742
sg10
I3
sg11
VFas
p4743
sg13
I1
sa(dp4744
g7
I91
sg8
VP48023
p4745
sg10
I26
sg11
VFas-associated phosphatase
p4746
sg13
I2
sa(dp4747
g7
I82
sg8
VP25054
p4748
sg10
I5
sg11
VFAP-1
p4749
sg13
I1
sasg14
(lp4750
(dp4751
g7
I91
sg17
VC0015923
p4752
sg10
I3
sg11
VFas
p4753
sg13
I1
sa(dp4754
g7
I47
sg17
VC0030297
p4755
sg10
I16
sg11
Vpancreatic tumor
p4756
sg13
I2
sa(dp4757
g7
I91
sg17
VC0015923
p4758
sg10
I3
sg11
VFas
p4759
sg13
I1
sa(dp4760
g7
I82
sg17
VC0032580
p4761
sg10
I3
sg11
VFAP
p4762
sg13
I1
sasa(dp4763
g2
S'The delineation of the phenotypic spectrum associated with mutations in ATP1A3, FOXG1, GNAO1, GRIN1, FRRS1L, and TBC1D24 is revealing an expanding genetic overlap between epileptic encephalopathies, developmental delay/intellectual disability, and hyperkinetic movement disorders,.\n'
p4764
sg4
(lp4765
(dp4766
g7
I72
sg8
VP13637
p4767
sg10
I6
sg11
VATP1A3
p4768
sg13
I1
sa(dp4769
g7
I80
sg8
VP55316
p4770
sg10
I5
sg11
VFOXG1
p4771
sg13
I1
sa(dp4772
g7
I94
sg8
g49
sg10
I5
sg11
VGRIN1
p4773
sg13
I1
sa(dp4774
g7
I113
sg8
g49
sg10
I7
sg11
VTBC1D24
p4775
sg13
I1
sa(dp4776
g7
I87
sg8
VP09471
p4777
sg10
I5
sg11
VGNAO1
p4778
sg13
I1
sasg14
(lp4779
(dp4780
g7
I171
sg17
VC0014544
p4781
sg10
I9
sg11
Vepileptic
p4782
sg13
I1
sa(dp4783
g7
I219
sg17
VC0025362
p4784
sg10
I23
sg11
Vintellectual disability
p4785
sg13
I2
sa(dp4786
g7
I261
sg17
VC0026650
p4787
sg10
I18
sg11
Vmovement disorders
p4788
sg13
I2
sa(dp4789
g7
I199
sg17
VC0424605
p4790
sg10
I19
sg11
Vdevelopmental delay
p4791
sg13
I2
sa(dp4792
g7
I181
sg17
VC0085584
p4793
sg10
I16
sg11
Vencephalopathies
p4794
sg13
I1
sasa(dp4795
g2
S'We confirmed a genetic diagnosis in five patients (36%): epileptic encephalopathy associated with autosomal dominant de novo variants in SCN2A (p.Met1545Val), KCNQ2 (p.Asp212Tyr), and GNAO1 (p.Gly40Arg); lipoic acid synthetase deficiency due to compound heterozygous variants in LIAS (p.Ala253Pro and p.His236Gln); and encephalopathy associated with an X-linked variant in CUL4B (p.Asn211Ser).ConclusionWES is helpful at arriving genetic diagnoses in neonatal encephalopathy and/or seizures and brain damage.\n'
p4796
sg4
(lp4797
(dp4798
g7
I184
sg8
VP09471
p4799
sg10
I5
sg11
VGNAO1
p4800
sg13
I1
sa(dp4801
g7
I204
sg8
g49
sg10
I22
sg11
Vlipoic acid synthetase
p4802
sg13
I3
sa(dp4803
g7
I137
sg8
g49
sg10
I5
sg11
VSCN2A
p4804
sg13
I1
sa(dp4805
g7
I159
sg8
g49
sg10
I5
sg11
VKCNQ2
p4806
sg13
I1
sa(dp4807
g7
I353
sg8
VP26640
p4808
sg10
I16
sg11
VX-linked variant
p4809
sg13
I2
sa(dp4810
g7
I279
sg8
g49
sg10
I4
sg11
VLIAS
p4811
sg13
I1
sasg14
(lp4812
(dp4813
g7
I451
sg17
VC0235820
p4814
sg10
I23
sg11
Vneonatal encephalopathy
p4815
sg13
I2
sa(dp4816
g7
I57
sg17
VC0543888
p4817
sg10
I24
sg11
Vepileptic encephalopathy
p4818
sg13
I2
sa(dp4819
g7
I67
sg17
VC0085584
p4820
sg10
I14
sg11
Vencephalopathy
p4821
sg13
I1
sa(dp4822
g7
I482
sg17
VC0036572
p4823
sg10
I8
sg11
Vseizures
p4824
sg13
I1
sa(dp4825
g7
I216
sg17
VC1291575
p4826
sg10
I21
sg11
Vsynthetase deficiency
p4827
sg13
I2
sasa(dp4828
g2
S'The results suggest that signaling proteins affected by EGCG in breast cancer, which include JUN, FADD, NFKB1, Bcl-2, GNAO1, and MMP14, are involved primarily in cell death and survival; DNA replication, recombination and repair; and the cell cycle.\n'
p4829
sg4
(lp4830
(dp4831
g7
I93
sg8
VP05412
p4832
sg10
I3
sg11
VJUN
p4833
sg13
I1
sa(dp4834
g7
I129
sg8
VP50281
p4835
sg10
I5
sg11
VMMP14
p4836
sg13
I1
sa(dp4837
g7
I111
sg8
VP10415
p4838
sg10
I5
sg11
VBcl-2
p4839
sg13
I1
sa(dp4840
g7
I104
sg8
VP19838
p4841
sg10
I5
sg11
VNFKB1
p4842
sg13
I1
sa(dp4843
g7
I98
sg8
g49
sg10
I4
sg11
VFADD
p4844
sg13
I1
sa(dp4845
g7
I118
sg8
VP09471
p4846
sg10
I5
sg11
VGNAO1
p4847
sg13
I1
sasg14
(lp4848
(dp4849
g7
I64
sg17
VC0678222
p4850
sg10
I13
sg11
Vbreast cancer
p4851
sg13
I2
sasa(dp4852
g2
S'We describe a case of GNAO1-associated epilepsy and chorea in a patient with a de novo pathogenic mutation.\n'
p4853
sg4
(lp4854
(dp4855
g7
I22
sg8
VP09471
p4856
sg10
I5
sg11
VGNAO1
p4857
sg13
I1
sasg14
(lp4858
(dp4859
g7
I52
sg17
VC0008489
p4860
sg10
I6
sg11
Vchorea
p4861
sg13
I1
sa(dp4862
g7
I39
sg17
VC0014544
p4863
sg10
I8
sg11
Vepilepsy
p4864
sg13
I1
sasa(dp4865
g2
S'The neurological phenotypes associated with GNAO1 mutations appear to lie on a spectrum, and it is possible that the c.607G&gt;A (p.Gly203Arg) variant characterizes a phenotype with both severe epilepsy and chorea.\n'
p4866
sg4
(lp4867
(dp4868
g7
I44
sg8
VP09471
p4869
sg10
I15
sg11
VGNAO1 mutations
p4870
sg13
I2
sasg14
(lp4871
(dp4872
g7
I207
sg17
VC0008489
p4873
sg10
I6
sg11
Vchorea
p4874
sg13
I1
sa(dp4875
g7
I194
sg17
VC0014544
p4876
sg10
I8
sg11
Vepilepsy
p4877
sg13
I1
sasa(dp4878
g2
S'We report the case of a 19-year-old female patient who had progressive chorea associated with a GNAO1 mutation.\n'
p4879
sg4
(lp4880
(dp4881
g7
I96
sg8
VP09471
p4882
sg10
I14
sg11
VGNAO1 mutation
p4883
sg13
I2
sasg14
(lp4884
(dp4885
g7
I59
sg17
VC0699734
p4886
sg10
I18
sg11
Vprogressive chorea
p4887
sg13
I2
sasa(dp4888
g2
S'After identification of a GNAO1 missense mutation at the age of 18years, topiramate treatment was initiated and the frequency of chorea decreased dramatically.\n'
p4889
sg4
(lp4890
(dp4891
g7
I26
sg8
VP09471
p4892
sg10
I5
sg11
VGNAO1
p4893
sg13
I1
sasg14
(lp4894
(dp4895
g7
I129
sg17
VC0008489
p4896
sg10
I6
sg11
Vchorea
p4897
sg13
I1
sasa(dp4898
g2
S'Given the side effects and complications associated with neuroleptics and deep brain stimulation, respectively, topiramate is recommended for the first-line management of severe chorea associated with a GNAO1 mutation.\n'
p4899
sg4
(lp4900
(dp4901
g7
I203
sg8
VP09471
p4902
sg10
I14
sg11
VGNAO1 mutation
p4903
sg13
I2
sasg14
(lp4904
(dp4905
g7
I178
sg17
VC0008489
p4906
sg10
I6
sg11
Vchorea
p4907
sg13
I1
sasa(dp4908
g2
S'In 2 unrelated patients with axial hypotonia, developmental delay and a hyperkinetic movement disorder, a missense mutation was found in codon 209 of the GNAO1 gene.\n'
p4909
sg4
(lp4910
(dp4911
g7
I154
sg8
VP09471
p4912
sg10
I10
sg11
VGNAO1 gene
p4913
sg13
I2
sasg14
(lp4914
(dp4915
g7
I35
sg17
VC0026827
p4916
sg10
I9
sg11
Vhypotonia
p4917
sg13
I1
sa(dp4918
g7
I46
sg17
VC0424605
p4919
sg10
I19
sg11
Vdevelopmental delay
p4920
sg13
I2
sa(dp4921
g7
I85
sg17
VC0026650
p4922
sg10
I17
sg11
Vmovement disorder
p4923
sg13
I2
sasa(dp4924
g2
S'Here we report the smallest deletion involving SNURF/SNRPN that causes major symptoms of Prader-Willi syndrome (PWS), including hypotonia, dysmorphic features, intellectual disability, and obesity.\n'
p4925
sg4
(lp4926
(dp4927
g7
I53
sg8
VP63162
p4928
sg10
I5
sg11
VSNRPN
p4929
sg13
I1
sa(dp4930
g7
I47
sg8
VP78317
p4931
sg10
I5
sg11
VSNURF
p4932
sg13
I1
sasg14
(lp4933
(dp4934
g7
I128
sg17
VC0026827
p4935
sg10
I9
sg11
Vhypotonia
p4936
sg13
I1
sa(dp4937
g7
I189
sg17
VC0028754
p4938
sg10
I7
sg11
Vobesity
p4939
sg13
I1
sa(dp4940
g7
I160
sg17
VC0025362
p4941
sg10
I23
sg11
Vintellectual disability
p4942
sg13
I2
sa(dp4943
g7
I89
sg17
VC0032897
p4944
sg10
I21
sg11
VPrader-Willi syndrome
p4945
sg13
I2
sa(dp4946
g7
I112
sg17
VC0032897
p4947
sg10
I3
sg11
VPWS
p4948
sg13
I1
sa(dp4949
g7
I139
sg17
VC0432072
p4950
sg10
I19
sg11
Vdysmorphic features
p4951
sg13
I2
sasa(dp4952
g2
S'An eight-gene (C9orf64, OSMR, MDK, MARVELD1, PTRF, MYD88, BIRC3, RPP25) signature was established to divide GBM patients into two groups based on the cut-off point (27.24).\n'
p4953
sg4
(lp4954
(dp4955
g7
I30
sg8
VP21741
p4956
sg10
I3
sg11
VMDK
p4957
sg13
I1
sa(dp4958
g7
I15
sg8
g49
sg10
I7
sg11
VC9orf64
p4959
sg13
I1
sa(dp4960
g7
I51
sg8
g49
sg10
I5
sg11
VMYD88
p4961
sg13
I1
sa(dp4962
g7
I58
sg8
g49
sg10
I5
sg11
VBIRC3
p4963
sg13
I1
sa(dp4964
g7
I65
sg8
g49
sg10
I5
sg11
VRPP25
p4965
sg13
I1
sa(dp4966
g7
I45
sg8
g49
sg10
I4
sg11
VPTRF
p4967
sg13
I1
sa(dp4968
g7
I24
sg8
g49
sg10
I4
sg11
VOSMR
p4969
sg13
I1
sa(dp4970
g7
I35
sg8
g49
sg10
I8
sg11
VMARVELD1
p4971
sg13
I1
sasg14
(lp4972
(dp4973
g7
I30
sg17
VC1835009
p4974
sg10
I3
sg11
VMDK
p4975
sg13
I1
sa(dp4976
g7
I108
sg17
VC0017636
p4977
sg10
I3
sg11
VGBM
p4978
sg13
I1
sasa(dp4979
g2
S'This result was associated with a reduction in the protein abundance of the lipodystrophy gene polymerase I and transcript release factor (Ptrf; Cavin) in gonadal adipose tissue.\n'
p4980
sg4
(lp4981
(dp4982
g7
I139
sg8
g49
sg10
I4
sg11
VPtrf
p4983
sg13
I1
sa(dp4984
g7
I145
sg8
g49
sg10
I5
sg11
VCavin
p4985
sg13
I1
sa(dp4986
g7
I90
sg8
g49
sg10
I47
sg11
Vgene polymerase I and transcript release factor
p4987
sg13
I7
sasg14
(lp4988
(dp4989
g7
I76
sg17
VC0023787
p4990
sg10
I13
sg11
Vlipodystrophy
p4991
sg13
I1
sasa(dp4992
g2
S'Polymerase I and transcript release factor (PTRF) was identified as a direct target of miR-187 in the promotion of the migration of NSCLC cells.\n'
p4993
sg4
(lp4994
(dp4995
g7
I44
sg8
g49
sg10
I4
sg11
VPTRF
p4996
sg13
I1
sa(dp4997
g7
I0
sg8
g49
sg10
I42
sg11
VPolymerase I and transcript release factor
p4998
sg13
I6
sasg14
(lp4999
(dp5000
g7
I132
sg17
VC0007131
p5001
sg10
I5
sg11
VNSCLC
p5002
sg13
I1
sasa(dp5003
g2
S'Restored expression of PTRF neutralized the promoting effect of miR-187 on cell migration and EMT of NSCLC cells.\n'
p5004
sg4
(lp5005
(dp5006
g7
I23
sg8
g49
sg10
I4
sg11
VPTRF
p5007
sg13
I1
sa(dp5008
g7
I94
sg8
g49
sg10
I3
sg11
VEMT
p5009
sg13
I1
sasg14
(lp5010
(dp5011
g7
I101
sg17
VC0007131
p5012
sg10
I5
sg11
VNSCLC
p5013
sg13
I1
sasa(dp5014
g2
S'ice and humans lacking the caveolae component polymerase I transcription release factor (PTRF, also known as cavin-1) exhibit lipo- and muscular dystrophy.\n'
p5015
sg4
(lp5016
(dp5017
g7
I27
sg8
g49
sg10
I60
sg11
Vcaveolae component polymerase I transcription release factor
p5018
sg13
I7
sa(dp5019
g7
I109
sg8
g49
sg10
I7
sg11
Vcavin-1
p5020
sg13
I1
sa(dp5021
g7
I89
sg8
g49
sg10
I4
sg11
VPTRF
p5022
sg13
I1
sasg14
(lp5023
(dp5024
g7
I136
sg17
VC0026850
p5025
sg10
I18
sg11
Vmuscular dystrophy
p5026
sg13
I2
sa(dp5027
g7
I126
sg17
VC3489413
p5028
sg10
I4
sg11
Vlipo
p5029
sg13
I1
sasa(dp5030
g2
S'Thus, in addition to compromised adipocyte-related physiology, the absence of PTRF/cavin-1 in mice caused a unique form of muscular dystrophy with a phenotype similar or identical to that seen in humans lacking this protein.\n'
p5031
sg4
(lp5032
(dp5033
g7
I78
sg8
g49
sg10
I4
sg11
VPTRF
p5034
sg13
I1
sa(dp5035
g7
I83
sg8
g49
sg10
I7
sg11
Vcavin-1
p5036
sg13
I1
sasg14
(lp5037
(dp5038
g7
I123
sg17
VC0026850
p5039
sg10
I18
sg11
Vmuscular dystrophy
p5040
sg13
I2
sasa(dp5041
g2
S'All four MoAbs, PAL-M2, NK1/C3, IND-1, and MAAMA against cutaneous melanoma-associated antigens stained positively all melanoma cell lines as well as the melanocytic cell line, suggesting that in vitro proliferation of melanocytes could modify their antigenic expression.\n'
p5042
sg4
(lp5043
(dp5044
g7
I24
sg8
g49
sg10
I3
sg11
VNK1
p5045
sg13
I1
sa(dp5046
g7
I16
sg8
g49
sg10
I3
sg11
VPAL
p5047
sg13
I1
sasg14
(lp5048
(dp5049
g7
I202
sg17
VC0334094
p5050
sg10
I13
sg11
Vproliferation
p5051
sg13
I1
sa(dp5052
g7
I67
sg17
VC0025202
p5053
sg10
I8
sg11
Vmelanoma
p5054
sg13
I1
sa(dp5055
g7
I57
sg17
VC0025202
p5056
sg10
I18
sg11
Vcutaneous melanoma
p5057
sg13
I2
sasa(dp5058
g2
S'On the whole, our findings indicate that the Kras, Col5a1 and Furin genes may play essential roles in the molecular mechanisms of SMCD, which warrants further investigation.\n'
p5059
sg4
(lp5060
(dp5061
g7
I45
sg8
VP01116
p5062
sg10
I4
sg11
VKras
p5063
sg13
I1
sa(dp5064
g7
I51
sg8
VP20908
p5065
sg10
I6
sg11
VCol5a1
p5066
sg13
I1
sa(dp5067
g7
I62
sg8
VP09958
p5068
sg10
I11
sg11
VFurin genes
p5069
sg13
I2
sasg14
(lp5070
(dp5071
g7
I130
sg17
VC2748503
p5072
sg10
I4
sg11
VSMCD
p5073
sg13
I1
sasa(dp5074
g2
S"The results suggest that PKCDelta plays a role in the regulation of Nox1-mediated oxidative stress elicited by PQ and could have a role in the pathogenesis of Parkinson's disease.\n"
p5075
sg4
(lp5076
(dp5077
g7
I25
sg8
g49
sg10
I8
sg11
VPKCDelta
p5078
sg13
I1
sa(dp5079
g7
I68
sg8
g49
sg10
I4
sg11
VNox1
p5080
sg13
I1
sasg14
(lp5081
(dp5082
g7
I143
sg17
VC0699748
p5083
sg10
I12
sg11
Vpathogenesis
p5084
sg13
I1
sa(dp5085
g7
I82
sg17
VC0242606
p5086
sg10
I16
sg11
Voxidative stress
p5087
sg13
I2
sa(dp5088
g7
I159
sg17
VC0030567
p5089
sg10
I19
sg11
VParkinson's disease
p5090
sg13
I2
sasa(dp5091
g2
S'Recently, it was discovered that levels of CGB-derived peptides are decreased in the cerebrospinal fluid of multiple sclerosis (MS) patients.\n'
p5092
sg4
(lp5093
(dp5094
g7
I43
sg8
VP05060
p5095
sg10
I20
sg11
VCGB-derived peptides
p5096
sg13
I2
sasg14
(lp5097
(dp5098
g7
I108
sg17
VC0026769
p5099
sg10
I18
sg11
Vmultiple sclerosis
p5100
sg13
I2
sa(dp5101
g7
I128
sg17
VC0026769
p5102
sg10
I2
sg11
VMS
p5103
sg13
I1
sasa(dp5104
g2
S'Recent studies provided evidence that chromogranins can interact with mutant superoxide dismutase 1 (SOD1) and that chromogranin B (CgB) may act as a susceptibility gene and modifier of onset in amyotrophic lateral sclerosis (ALS).\n'
p5105
sg4
(lp5106
(dp5107
g7
I132
sg8
VP05060
p5108
sg10
I3
sg11
VCgB
p5109
sg13
I1
sa(dp5110
g7
I70
sg8
VP00441
p5111
sg10
I29
sg11
Vmutant superoxide dismutase 1
p5112
sg13
I4
sa(dp5113
g7
I38
sg8
VP08311
p5114
sg10
I13
sg11
Vchromogranins
p5115
sg13
I1
sa(dp5116
g7
I116
sg8
VP08311
p5117
sg10
I14
sg11
Vchromogranin B
p5118
sg13
I2
sa(dp5119
g7
I101
sg8
VP00441
p5120
sg10
I4
sg11
VSOD1
p5121
sg13
I1
sasg14
(lp5122
(dp5123
g7
I195
sg17
VC0002736
p5124
sg10
I29
sg11
Vamyotrophic lateral sclerosis
p5125
sg13
I3
sa(dp5126
g7
I70
sg17
VC0596988
p5127
sg10
I6
sg11
Vmutant
p5128
sg13
I1
sa(dp5129
g7
I226
sg17
VC0002736
p5130
sg10
I3
sg11
VALS
p5131
sg13
I1
sasa(dp5132
g2
S"The immunoreactive patterns of CgA and CgB were investigated in CJD and compared to those observed in Alzheimer's disease.\n"
p5133
sg4
(lp5134
(dp5135
g7
I39
sg8
VP05060
p5136
sg10
I3
sg11
VCgB
p5137
sg13
I1
sa(dp5138
g7
I31
sg8
VP10645
p5139
sg10
I3
sg11
VCgA
p5140
sg13
I1
sasg14
(lp5141
(dp5142
g7
I102
sg17
VC1521724
p5143
sg10
I19
sg11
VAlzheimer's disease
p5144
sg13
I2
sa(dp5145
g7
I64
sg17
VC0022336
p5146
sg10
I3
sg11
VCJD
p5147
sg13
I1
sasa(dp5148
g2
S'Detection of the expression of these proteins and genes encoding these proteins in human gastric cancer tissues by real-time PCR (RT-qPCR) and western blot revealed that the expression of Beta-ACTIN, LDH, DLD, PRPF19 and CaM genes were up-regulated and RanGAP was down-regulated in gastric cancer tissues and/or metastatic lymph nodes compared to peri-cancerous tissues.\n'
p5149
sg4
(lp5150
(dp5151
g7
I205
sg8
VP98173
p5152
sg10
I3
sg11
VDLD
p5153
sg13
I1
sa(dp5154
g7
I200
sg8
g49
sg10
I3
sg11
VLDH
p5155
sg13
I1
sa(dp5156
g7
I188
sg8
VP63261
p5157
sg10
I10
sg11
VBeta-ACTIN
p5158
sg13
I1
sa(dp5159
g7
I221
sg8
VP01768
p5160
sg10
I9
sg11
VCaM genes
p5161
sg13
I2
sa(dp5162
g7
I210
sg8
g49
sg10
I6
sg11
VPRPF19
p5163
sg13
I1
sasg14
(lp5164
(dp5165
g7
I89
sg17
VC0024623
p5166
sg10
I14
sg11
Vgastric cancer
p5167
sg13
I2
sa(dp5168
g7
I89
sg17
VC0024623
p5169
sg10
I14
sg11
Vgastric cancer
p5170
sg13
I2
sa(dp5171
g7
I221
sg17
VC1861821
p5172
sg10
I3
sg11
VCaM
p5173
sg13
I1
sasa(dp5174
g2
S'Together, these studies add a new dimension to our understanding of hPrp19, and we have reason to believe that continuing excavation of this multi-faceted protein may shed light on its roles in human diseases, especially in cancer.\n'
p5175
sg4
(lp5176
sg14
(lp5177
(dp5178
g7
I224
sg17
VC0006826
p5179
sg10
I6
sg11
Vcancer
p5180
sg13
I1
sa(dp5181
g7
I24
sg17
VC0004269
p5182
sg10
I3
sg11
Vadd
p5183
sg13
I1
sasa(dp5184
g2
S'The mRNA and protein expression of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 subtypes in 40 specimens of HCC and 40 specimens of liver cirrhosis were detected by reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC), respectively.\n'
p5185
sg4
(lp5186
(dp5187
g7
I42
sg8
VP30874
p5188
sg10
I5
sg11
VSSTR2
p5189
sg13
I1
sa(dp5190
g7
I35
sg8
VP30872
p5191
sg10
I5
sg11
VSSTR1
p5192
sg13
I1
sa(dp5193
g7
I49
sg8
VP32745
p5194
sg10
I5
sg11
VSSTR3
p5195
sg13
I1
sa(dp5196
g7
I56
sg8
VP31391
p5197
sg10
I5
sg11
VSSTR4
p5198
sg13
I1
sa(dp5199
g7
I67
sg8
VP35346
p5200
sg10
I14
sg11
VSSTR5 subtypes
p5201
sg13
I2
sasg14
(lp5202
(dp5203
g7
I101
sg17
VC2239176
p5204
sg10
I3
sg11
VHCC
p5205
sg13
I1
sa(dp5206
g7
I125
sg17
VC0023890
p5207
sg10
I15
sg11
Vliver cirrhosis
p5208
sg13
I2
sasa(dp5209
g2
S'The positive rates of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 proteins were 47.5%, 70.0%, 50.0%, 65.0%, and 67.5% in HCC, and 55.0%, 67.5%, 52.5%, 60.0%, and 47.5% in liver cirrhosis tissues, respectively.\n'
p5210
sg4
(lp5211
(dp5212
g7
I29
sg8
VP30874
p5213
sg10
I5
sg11
VSSTR2
p5214
sg13
I1
sa(dp5215
g7
I22
sg8
VP30872
p5216
sg10
I5
sg11
VSSTR1
p5217
sg13
I1
sa(dp5218
g7
I43
sg8
VP31391
p5219
sg10
I5
sg11
VSSTR4
p5220
sg13
I1
sa(dp5221
g7
I36
sg8
VP32745
p5222
sg10
I5
sg11
VSSTR3
p5223
sg13
I1
sa(dp5224
g7
I54
sg8
VP35346
p5225
sg10
I14
sg11
VSSTR5 proteins
p5226
sg13
I2
sasg14
(lp5227
(dp5228
g7
I165
sg17
VC0023890
p5229
sg10
I15
sg11
Vliver cirrhosis
p5230
sg13
I2
sa(dp5231
g7
I115
sg17
VC2239176
p5232
sg10
I3
sg11
VHCC
p5233
sg13
I1
sasa(dp5234
g2
S'The protein levels of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 were markedly higher in HCC than in liver cirrhosis tissues.\n'
p5235
sg4
(lp5236
(dp5237
g7
I29
sg8
VP30874
p5238
sg10
I5
sg11
VSSTR2
p5239
sg13
I1
sa(dp5240
g7
I22
sg8
VP30872
p5241
sg10
I5
sg11
VSSTR1
p5242
sg13
I1
sa(dp5243
g7
I54
sg8
VP35346
p5244
sg10
I5
sg11
VSSTR5
p5245
sg13
I1
sa(dp5246
g7
I43
sg8
VP31391
p5247
sg10
I5
sg11
VSSTR4
p5248
sg13
I1
sa(dp5249
g7
I36
sg8
VP32745
p5250
sg10
I5
sg11
VSSTR3
p5251
sg13
I1
sasg14
(lp5252
(dp5253
g7
I84
sg17
VC2239176
p5254
sg10
I3
sg11
VHCC
p5255
sg13
I1
sa(dp5256
g7
I96
sg17
VC0023890
p5257
sg10
I15
sg11
Vliver cirrhosis
p5258
sg13
I2
sasa(dp5259
g2
S'Flow cytometry effectively identifies major forms of PIDs, including severe combined immunodeficiency, X-linked agammaglobulinemia, hyper IgM syndromes, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome, familial hemophagocytic lymphohistiocytosis, autoimmune lymphoproliferative syndrome, IPEX syndrome, CTLA 4 haploinsufficiency and LRBA deficiency, IRAK4 and MyD88 deficiencies, Mendelian susceptibility to mycobacterial disease, chronic mucocuneous candidiasis, and chronic granulomatous disease.\n'
p5260
sg4
(lp5261
(dp5262
g7
I366
sg8
g49
sg10
I5
sg11
VIRAK4
p5263
sg13
I1
sa(dp5264
g7
I319
sg8
VP08311
p5265
sg10
I6
sg11
VCTLA 4
p5266
sg13
I2
sa(dp5267
g7
I349
sg8
VP50851
p5268
sg10
I4
sg11
VLRBA
p5269
sg13
I1
sa(dp5270
g7
I376
sg8
g49
sg10
I5
sg11
VMyD88
p5271
sg13
I1
sasg14
(lp5272
(dp5273
g7
I484
sg17
VC0018203
p5274
sg10
I29
sg11
Vchronic granulomatous disease
p5275
sg13
I3
sa(dp5276
g7
I112
sg17
VC0001768
p5277
sg10
I18
sg11
Vagammaglobulinemia
p5278
sg13
I1
sa(dp5279
g7
I169
sg17
VC0549463
p5280
sg10
I38
sg11
Vsyndrome, X-linked lymphoproliferative
p5281
sg13
I3
sa(dp5282
g7
I304
sg17
VC0342288
p5283
sg10
I4
sg11
VIPEX
p5284
sg13
I1
sa(dp5285
g7
I467
sg17
VC0006840
p5286
sg10
I11
sg11
Vcandidiasis
p5287
sg13
I1
sa(dp5288
g7
I142
sg17
VC0039082
p5289
sg10
I9
sg11
Vsyndromes
p5290
sg13
I1
sa(dp5291
g7
I153
sg17
VC0043194
p5292
sg10
I24
sg11
VWiskott-Aldrich syndrome
p5293
sg13
I2
sa(dp5294
g7
I69
sg17
VC2931540
p5295
sg10
I42
sg11
Vsevere combined immunodeficiency, X-linked
p5296
sg13
I4
sa(dp5297
g7
I424
sg17
VC0026918
p5298
sg10
I21
sg11
Vmycobacterial disease
p5299
sg13
I2
sa(dp5300
g7
I142
sg17
VC0039082
p5301
sg10
I8
sg11
Vsyndrome
p5302
sg13
I1
sa(dp5303
g7
I263
sg17
VC1328840
p5304
sg10
I39
sg11
Vautoimmune lymphoproliferative syndrome
p5305
sg13
I3
sa(dp5306
g7
I218
sg17
VC0272199
p5307
sg10
I43
sg11
Vfamilial hemophagocytic lymphohistiocytosis
p5308
sg13
I3
sa(dp5309
g7
I142
sg17
VC0039082
p5310
sg10
I8
sg11
Vsyndrome
p5311
sg13
I1
sasa(dp5312
g2
S'The association of moderate to severe eczema and elevated plasma levels of immunoglobulin E is a characteristic not only of atopic dermatitis but also of various genodermatoses: hyperimmunoglobulin E syndromes, Omenn syndrome, Netherton syndrome, peeling skin syndrome type B, severe dermatitis, multiple allergies, and metabolic wasting syndrome, Wiskott-Aldrich syndrome, prolidase deficiency, Loeys-Dietz syndrome, IPEX syndrome, STAT5B deficiency, and pentasomy X.\n'
p5313
sg4
(lp5314
(dp5315
g7
I374
sg8
VP12955
p5316
sg10
I9
sg11
Vprolidase
p5317
sg13
I1
sa(dp5318
g7
I178
sg8
VP40763
p5319
sg10
I21
sg11
Vhyperimmunoglobulin E
p5320
sg13
I2
sa(dp5321
g7
I433
sg8
VP51692
p5322
sg10
I6
sg11
VSTAT5B
p5323
sg13
I1
sa(dp5324
g7
I75
sg8
VP01854
p5325
sg10
I16
sg11
Vimmunoglobulin E
p5326
sg13
I2
sasg14
(lp5327
(dp5328
g7
I396
sg17
VC2697932
p5329
sg10
I20
sg11
VLoeys-Dietz syndrome
p5330
sg13
I2
sa(dp5331
g7
I456
sg17
VC2937419
p5332
sg10
I11
sg11
Vpentasomy X
p5333
sg13
I2
sa(dp5334
g7
I131
sg17
VC0011603
p5335
sg10
I10
sg11
Vdermatitis
p5336
sg13
I1
sa(dp5337
g7
I200
sg17
VC0039082
p5338
sg10
I8
sg11
Vsyndrome
p5339
sg13
I1
sa(dp5340
g7
I374
sg17
VC0268532
p5341
sg10
I20
sg11
Vprolidase deficiency
p5342
sg13
I2
sa(dp5343
g7
I38
sg17
VC0013595
p5344
sg10
I6
sg11
Veczema
p5345
sg13
I1
sa(dp5346
g7
I296
sg17
VC0740281
p5347
sg10
I18
sg11
Vmultiple allergies
p5348
sg13
I2
sa(dp5349
g7
I247
sg17
VC1849193
p5350
sg10
I21
sg11
Vpeeling skin syndrome
p5351
sg13
I3
sa(dp5352
g7
I217
sg17
VC0265962
p5353
sg10
I19
sg11
Vsyndrome, Netherton
p5354
sg13
I2
sa(dp5355
g7
I200
sg17
VC0039082
p5356
sg10
I8
sg11
Vsyndrome
p5357
sg13
I1
sa(dp5358
g7
I200
sg17
VC0039082
p5359
sg10
I8
sg11
Vsyndrome
p5360
sg13
I1
sa(dp5361
g7
I418
sg17
VC0342288
p5362
sg10
I4
sg11
VIPEX
p5363
sg13
I1
sa(dp5364
g7
I211
sg17
VC1801959
p5365
sg10
I14
sg11
VOmenn syndrome
p5366
sg13
I2
sa(dp5367
g7
I338
sg17
VC0043194
p5368
sg10
I25
sg11
Vsyndrome, Wiskott-Aldrich
p5369
sg13
I2
sa(dp5370
g7
I200
sg17
VC0039082
p5371
sg10
I9
sg11
Vsyndromes
p5372
sg13
I1
sa(dp5373
g7
I124
sg17
VC0011615
p5374
sg10
I17
sg11
Vatopic dermatitis
p5375
sg13
I2
sasa(dp5376
g2
S'In this review, we describe the recent advancements achieved both in vitro and at preclinical level with LVVs for the treatment of Wiskott-Aldrich syndrome (WAS), chronic granulomatous disease (CGD), ADA deficiency (ADA-SCID), Artemis deficiency, RAG1/2 deficiency, X-linked severe combined immunodeficiency (Gammachain deficiency, SCIDX1), X-linked lymphoproliferative disease (XLP) and immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome.\n'
p5377
sg4
(lp5378
(dp5379
g7
I332
sg8
VP31785
p5380
sg10
I6
sg11
VSCIDX1
p5381
sg13
I1
sa(dp5382
g7
I247
sg8
VP15918
p5383
sg10
I6
sg11
VRAG1/2
p5384
sg13
I1
sa(dp5385
g7
I200
sg8
VP00813
p5386
sg10
I3
sg11
VADA
p5387
sg13
I1
sa(dp5388
g7
I216
sg8
VP00813
p5389
sg10
I8
sg11
VADA-SCID
p5390
sg13
I1
sasg14
(lp5391
(dp5392
g7
I163
sg17
VC0018203
p5393
sg10
I29
sg11
Vchronic granulomatous disease
p5394
sg13
I3
sa(dp5395
g7
I194
sg17
VC0018203
p5396
sg10
I3
sg11
VCGD
p5397
sg13
I1
sa(dp5398
g7
I453
sg17
VC0342288
p5399
sg10
I4
sg11
VIPEX
p5400
sg13
I1
sa(dp5401
g7
I430
sg17
VC0021831
p5402
sg10
I11
sg11
Venteropathy
p5403
sg13
I1
sa(dp5404
g7
I200
sg17
VC0268124
p5405
sg10
I14
sg11
VADA deficiency
p5406
sg13
I2
sa(dp5407
g7
I266
sg17
VC2931540
p5408
sg10
I41
sg11
VX-linked severe combined immunodeficiency
p5409
sg13
I4
sa(dp5410
g7
I131
sg17
VC0043194
p5411
sg10
I24
sg11
VWiskott-Aldrich syndrome
p5412
sg13
I2
sa(dp5413
g7
I157
sg17
VC0043194
p5414
sg10
I3
sg11
VWAS
p5415
sg13
I1
sa(dp5416
g7
I332
sg17
VC2931540
p5417
sg10
I6
sg11
VSCIDX1
p5418
sg13
I1
sa(dp5419
g7
I341
sg17
VC0549463
p5420
sg10
I36
sg11
VX-linked lymphoproliferative disease
p5421
sg13
I3
sa(dp5422
g7
I379
sg17
VC1868674
p5423
sg10
I3
sg11
VXLP
p5424
sg13
I1
sa(dp5425
g7
I147
sg17
VC0039082
p5426
sg10
I8
sg11
Vsyndrome
p5427
sg13
I1
sa(dp5428
g7
I216
sg17
VC1863236
p5429
sg10
I8
sg11
VADA-SCID
p5430
sg13
I1
sasa(dp5431
g2
S'The common duplicated region in those three patients and the presented case comprises 12 disease-associated genes including the FOXP3 (Forkhead Box P3) and WAS (Wiskott-Aldrich syndrome) gene, both implicated in immune function.\n'
p5432
sg4
(lp5433
(dp5434
g7
I128
sg8
g49
sg10
I5
sg11
VFOXP3
p5435
sg13
I1
sa(dp5436
g7
I135
sg8
g49
sg10
I15
sg11
VForkhead Box P3
p5437
sg13
I3
sasg14
(lp5438
(dp5439
g7
I156
sg17
VC0043194
p5440
sg10
I3
sg11
VWAS
p5441
sg13
I1
sa(dp5442
g7
I161
sg17
VC0043194
p5443
sg10
I24
sg11
VWiskott-Aldrich syndrome
p5444
sg13
I2
sasa(dp5445
g2
S'This theory has been supported by observations in patients with primary immunodeficiencies such as the Wiskott-Aldrich syndrome and IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome).\n'
p5446
sg4
(lp5447
sg14
(lp5448
(dp5449
g7
I72
sg17
VC0021051
p5450
sg10
I18
sg11
Vimmunodeficiencies
p5451
sg13
I1
sa(dp5452
g7
I132
sg17
VC0342288
p5453
sg10
I4
sg11
VIPEX
p5454
sg13
I1
sa(dp5455
g7
I179
sg17
VC0021831
p5456
sg10
I11
sg11
Venteropathy
p5457
sg13
I1
sa(dp5458
g7
I103
sg17
VC0043194
p5459
sg10
I24
sg11
VWiskott-Aldrich syndrome
p5460
sg13
I2
sa(dp5461
g7
I119
sg17
VC0039082
p5462
sg10
I8
sg11
Vsyndrome
p5463
sg13
I1
sasa(dp5464
g2
S'Hyper-IgE syndrome; Wiskott-Aldrich syndrome; immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX); Omenn syndrome; and atypical complete DiGeorge syndrome are primary immune deficiencies that are associated with elevated serum IgE levels.\n'
p5465
sg4
(lp5466
(dp5467
g7
I0
sg8
VP01854
p5468
sg10
I9
sg11
VHyper-IgE
p5469
sg13
I1
sa(dp5470
g7
I239
sg8
VP01854
p5471
sg10
I9
sg11
Vserum IgE
p5472
sg13
I2
sasg14
(lp5473
(dp5474
g7
I0
sg17
VC0022398
p5475
sg10
I18
sg11
VHyper-IgE syndrome
p5476
sg13
I2
sa(dp5477
g7
I87
sg17
VC0021831
p5478
sg10
I11
sg11
Venteropathy
p5479
sg13
I1
sa(dp5480
g7
I6
sg17
VC0270850
p5481
sg10
I3
sg11
VIgE
p5482
sg13
I1
sa(dp5483
g7
I117
sg17
VC1801959
p5484
sg10
I14
sg11
VOmenn syndrome
p5485
sg13
I2
sa(dp5486
g7
I155
sg17
VC0012236
p5487
sg10
I17
sg11
VDiGeorge syndrome
p5488
sg13
I2
sa(dp5489
g7
I20
sg17
VC0043194
p5490
sg10
I24
sg11
VWiskott-Aldrich syndrome
p5491
sg13
I2
sa(dp5492
g7
I110
sg17
VC0342288
p5493
sg10
I4
sg11
VIPEX
p5494
sg13
I1
sasa(dp5495
g2
S'Increased IgE levels in IPEX, Wiskott-Aldrich syndrome and Omenn syndrome are likely related to increased T(H)2 cytokine production caused by decreased a number or function of CD4(+)CD25(+)forkhead box protein P3(+) regulatory T cells.\n'
p5496
sg4
(lp5497
(dp5498
g7
I10
sg8
VP01854
p5499
sg10
I3
sg11
VIgE
p5500
sg13
I1
sa(dp5501
g7
I176
sg8
g49
sg10
I36
sg11
VCD4(+)CD25(+)forkhead box protein P3
p5502
sg13
I4
sasg14
(lp5503
(dp5504
g7
I30
sg17
VC0043194
p5505
sg10
I24
sg11
VWiskott-Aldrich syndrome
p5506
sg13
I2
sa(dp5507
g7
I10
sg17
VC0270850
p5508
sg10
I3
sg11
VIgE
p5509
sg13
I1
sa(dp5510
g7
I24
sg17
VC0342288
p5511
sg10
I4
sg11
VIPEX
p5512
sg13
I1
sa(dp5513
g7
I59
sg17
VC1801959
p5514
sg10
I14
sg11
VOmenn syndrome
p5515
sg13
I2
sasa(dp5516
g2
S'The aim of the present study was to clarify the clinical implication and functional role of tripartite motif-59 (TRIM59) in colorectal carcinoma (CRC) and explore the underlying mechanism of aberrant high expression of TRIM59 in cancer.\n'
p5517
sg4
(lp5518
(dp5519
g7
I113
sg8
g49
sg10
I6
sg11
VTRIM59
p5520
sg13
I1
sa(dp5521
g7
I113
sg8
g49
sg10
I6
sg11
VTRIM59
p5522
sg13
I1
sa(dp5523
g7
I92
sg8
g49
sg10
I19
sg11
Vtripartite motif-59
p5524
sg13
I2
sasg14
(lp5525
(dp5526
g7
I146
sg17
VC1527249
p5527
sg10
I3
sg11
VCRC
p5528
sg13
I1
sa(dp5529
g7
I229
sg17
VC0006826
p5530
sg10
I6
sg11
Vcancer
p5531
sg13
I1
sa(dp5532
g7
I124
sg17
VC0009402
p5533
sg10
I20
sg11
Vcolorectal carcinoma
p5534
sg13
I2
sasa(dp5535
g2
S'Tripartite motif 59 (TRIM59) was identified from a microarray dataset of matched-samples and was verified as an aberrantly upregulated gene in NSCLC tissue.\n'
p5536
sg4
(lp5537
(dp5538
g7
I21
sg8
g49
sg10
I6
sg11
VTRIM59
p5539
sg13
I1
sa(dp5540
g7
I0
sg8
g49
sg10
I19
sg11
VTripartite motif 59
p5541
sg13
I3
sasg14
(lp5542
(dp5543
g7
I143
sg17
VC0007131
p5544
sg10
I5
sg11
VNSCLC
p5545
sg13
I1
sasa(dp5546
g2
S'The expression level of TRIM59 in NSCLC subtypes was observed to be significantly increased in large cell lung carcinoma and squamous cell carcinoma as compared with that in adenocarcinoma.\n'
p5547
sg4
(lp5548
(dp5549
g7
I24
sg8
g49
sg10
I6
sg11
VTRIM59
p5550
sg13
I1
sasg14
(lp5551
(dp5552
g7
I174
sg17
VC0001418
p5553
sg10
I14
sg11
Vadenocarcinoma
p5554
sg13
I1
sa(dp5555
g7
I125
sg17
VC0007137
p5556
sg10
I23
sg11
Vsquamous cell carcinoma
p5557
sg13
I3
sa(dp5558
g7
I34
sg17
VC0007131
p5559
sg10
I5
sg11
VNSCLC
p5560
sg13
I1
sa(dp5561
g7
I95
sg17
VC0345958
p5562
sg10
I25
sg11
Vlarge cell lung carcinoma
p5563
sg13
I4
sasa(dp5564
g2
S'Notably, TRIM59 demonstrated a negative correlation with survival time and its overexpression indicated a poor prognosis in NSCLC.\n'
p5565
sg4
(lp5566
(dp5567
g7
I9
sg8
g49
sg10
I6
sg11
VTRIM59
p5568
sg13
I1
sasg14
(lp5569
(dp5570
g7
I124
sg17
VC0007131
p5571
sg10
I5
sg11
VNSCLC
p5572
sg13
I1
sasa(dp5573
g2
S'In conclusion, it was revealed that TRIM59 is a novel prognostic biomarker modulating oncogenic MTOR and EIF4E signaling pathways in NSCLC.\n'
p5574
sg4
(lp5575
(dp5576
g7
I36
sg8
g49
sg10
I6
sg11
VTRIM59
p5577
sg13
I1
sa(dp5578
g7
I105
sg8
VP06730
p5579
sg10
I5
sg11
VEIF4E
p5580
sg13
I1
sa(dp5581
g7
I96
sg8
VP42345
p5582
sg10
I4
sg11
VMTOR
p5583
sg13
I1
sasg14
(lp5584
(dp5585
g7
I133
sg17
VC0007131
p5586
sg10
I5
sg11
VNSCLC
p5587
sg13
I1
sasa(dp5588
g2
S'Therefore, TRIM59 may serve as an independent predictor for prognosis and a potential therapeutic target for NSCLC.\n'
p5589
sg4
(lp5590
(dp5591
g7
I11
sg8
g49
sg10
I6
sg11
VTRIM59
p5592
sg13
I1
sasg14
(lp5593
(dp5594
g7
I109
sg17
VC0007131
p5595
sg10
I5
sg11
VNSCLC
p5596
sg13
I1
sasa(dp5597
g2
S'Our data showed that the mRNA level of TRIM59 in cancerous tissues was 2-fold increased as compared with non-cancerous tissues.\n'
p5598
sg4
(lp5599
(dp5600
g7
I39
sg8
g49
sg10
I6
sg11
VTRIM59
p5601
sg13
I1
sasg14
(lp5602
sa(dp5603
g2
S'One member of this protein family, Trim59, has been reported as a novel biomarker for the occurrence and progression of multiple human carcinomas, such as lung cancer, gastric cancer, cervical cancer, and osteosarcoma.\n'
p5604
sg4
(lp5605
(dp5606
g7
I35
sg8
g49
sg10
I6
sg11
VTrim59
p5607
sg13
I1
sasg14
(lp5608
(dp5609
g7
I135
sg17
VC0007097
p5610
sg10
I10
sg11
Vcarcinomas
p5611
sg13
I1
sa(dp5612
g7
I160
sg17
VC0006826
p5613
sg10
I6
sg11
Vcancer
p5614
sg13
I1
sa(dp5615
g7
I160
sg17
VC0024623
p5616
sg10
I15
sg11
Vcancer, gastric
p5617
sg13
I2
sa(dp5618
g7
I184
sg17
VC0302592
p5619
sg10
I15
sg11
Vcervical cancer
p5620
sg13
I2
sa(dp5621
g7
I205
sg17
VC0029463
p5622
sg10
I12
sg11
Vosteosarcoma
p5623
sg13
I1
sasa(dp5624
g2
S'In this study, we examined the expression of Trim59 in bladder cancer (Bca) specimens and cell lines, and investigated its biological roles in Bca cell lines.\n'
p5625
sg4
(lp5626
(dp5627
g7
I45
sg8
g49
sg10
I6
sg11
VTrim59
p5628
sg13
I1
sasg14
(lp5629
(dp5630
g7
I71
sg17
VC0699885
p5631
sg10
I3
sg11
VBca
p5632
sg13
I1
sa(dp5633
g7
I55
sg17
VC0699885
p5634
sg10
I14
sg11
Vbladder cancer
p5635
sg13
I2
sa(dp5636
g7
I71
sg17
VC0699885
p5637
sg10
I3
sg11
VBca
p5638
sg13
I1
sasa(dp5639
g2
S'Our findings also revealed that Trim59 can present oncogenic activity, and may serve as a novel candidate target for bladder carcinoma treatment.\n'
p5640
sg4
(lp5641
(dp5642
g7
I32
sg8
g49
sg10
I6
sg11
VTrim59
p5643
sg13
I1
sasg14
(lp5644
(dp5645
g7
I117
sg17
VC0699885
p5646
sg10
I17
sg11
Vbladder carcinoma
p5647
sg13
I2
sasa(dp5648
g2
S'Recently, TRIM59 has been described in multiple cancers such as gastric, prostatic and lung cancer.\n'
p5649
sg4
(lp5650
(dp5651
g7
I10
sg8
g49
sg10
I6
sg11
VTRIM59
p5652
sg13
I1
sasg14
(lp5653
(dp5654
g7
I48
sg17
VC0006826
p5655
sg10
I7
sg11
Vcancers
p5656
sg13
I1
sa(dp5657
g7
I87
sg17
VC0684249
p5658
sg10
I11
sg11
Vlung cancer
p5659
sg13
I2
sasa(dp5660
g2
S'In this study, we elucidated the biological roles of TRIM59 in breast cancer.\n'
p5661
sg4
(lp5662
(dp5663
g7
I53
sg8
g49
sg10
I6
sg11
VTRIM59
p5664
sg13
I1
sasg14
(lp5665
(dp5666
g7
I63
sg17
VC0678222
p5667
sg10
I13
sg11
Vbreast cancer
p5668
sg13
I2
sasa(dp5669
g2
S'We found that TRIM59 was up-regulated in breast cancer cells.\n'
p5670
sg4
(lp5671
(dp5672
g7
I14
sg8
g49
sg10
I6
sg11
VTRIM59
p5673
sg13
I1
sasg14
(lp5674
(dp5675
g7
I41
sg17
VC0678222
p5676
sg10
I13
sg11
Vbreast cancer
p5677
sg13
I2
sasa(dp5678
g2
S'Down-regulation of TRIM59 inhibited breast cancer cell proliferation, migration and invasion in vitro as well as tumor growth in vivo.\n'
p5679
sg4
(lp5680
(dp5681
g7
I19
sg8
g49
sg10
I6
sg11
VTRIM59
p5682
sg13
I1
sasg14
(lp5683
(dp5684
g7
I55
sg17
VC0334094
p5685
sg10
I13
sg11
Vproliferation
p5686
sg13
I1
sa(dp5687
g7
I84
sg17
VC2699153
p5688
sg10
I8
sg11
Vinvasion
p5689
sg13
I1
sa(dp5690
g7
I36
sg17
VC0678222
p5691
sg10
I13
sg11
Vbreast cancer
p5692
sg13
I2
sa(dp5693
g7
I113
sg17
VC0598934
p5694
sg10
I12
sg11
Vtumor growth
p5695
sg13
I2
sasa(dp5696
g2
S'Taken together, our study results provided new evidence showing that TRIM59 may be considered as a promising therapeutic target for breast cancer.\n'
p5697
sg4
(lp5698
(dp5699
g7
I69
sg8
g49
sg10
I6
sg11
VTRIM59
p5700
sg13
I1
sasg14
(lp5701
(dp5702
g7
I132
sg17
VC0678222
p5703
sg10
I13
sg11
Vbreast cancer
p5704
sg13
I2
sasa(dp5705
g2
S'Tripartite motif 59 (TRIM59) is a novel oncogenic driver in gastric cancer (GC) that is implicated in disease progression as well as dismal survival.\n'
p5706
sg4
(lp5707
(dp5708
g7
I21
sg8
g49
sg10
I6
sg11
VTRIM59
p5709
sg13
I1
sa(dp5710
g7
I0
sg8
g49
sg10
I19
sg11
VTripartite motif 59
p5711
sg13
I3
sasg14
(lp5712
(dp5713
g7
I76
sg17
VC0024623
p5714
sg10
I2
sg11
VGC
p5715
sg13
I1
sa(dp5716
g7
I60
sg17
VC0024623
p5717
sg10
I14
sg11
Vgastric cancer
p5718
sg13
I2
sa(dp5719
g7
I102
sg17
VC0242656
p5720
sg10
I19
sg11
Vdisease progression
p5721
sg13
I2
sasa(dp5722
g2
S'In this study, the effects of TRIM59 expression on tumor growth were investigated in prostate cancer.\n'
p5723
sg4
(lp5724
(dp5725
g7
I30
sg8
g49
sg10
I6
sg11
VTRIM59
p5726
sg13
I1
sasg14
(lp5727
(dp5728
g7
I85
sg17
VC0600139
p5729
sg10
I15
sg11
Vprostate cancer
p5730
sg13
I2
sa(dp5731
g7
I51
sg17
VC0598934
p5732
sg10
I12
sg11
Vtumor growth
p5733
sg13
I2
sasa(dp5734
g2
S'The expression of TRIM59 in prostate cancer tissues (n = 15) and prostate cancer cell lines was determined by quantitative reverse transcriptase-PCR (qRT-PCR), Western blotting, and immunohistochemistry.\n'
p5735
sg4
(lp5736
(dp5737
g7
I123
sg8
VP63136
p5738
sg10
I21
sg11
Vreverse transcriptase
p5739
sg13
I2
sa(dp5740
g7
I18
sg8
g49
sg10
I6
sg11
VTRIM59
p5741
sg13
I1
sasg14
(lp5742
(dp5743
g7
I28
sg17
VC0600139
p5744
sg10
I15
sg11
Vprostate cancer
p5745
sg13
I2
sa(dp5746
g7
I28
sg17
VC0600139
p5747
sg10
I15
sg11
Vprostate cancer
p5748
sg13
I2
sasa(dp5749
g2
S'A specific shRNA targeting TRIM59 was employed to knockdown TRIM59 expression in the prostate cancer cell lines PC3 and DU145.\n'
p5750
sg4
(lp5751
(dp5752
g7
I27
sg8
g49
sg10
I6
sg11
VTRIM59
p5753
sg13
I1
sa(dp5754
g7
I27
sg8
g49
sg10
I6
sg11
VTRIM59
p5755
sg13
I1
sasg14
(lp5756
(dp5757
g7
I85
sg17
VC0600139
p5758
sg10
I15
sg11
Vprostate cancer
p5759
sg13
I2
sasa(dp5760
g2
S'The effects on cell cycle progression were determined by flow cytometry, and a xenograft mouse model of prostate cancer was generated to determine the in vivo effects of TRIM59 knockdown.\n'
p5761
sg4
(lp5762
(dp5763
g7
I170
sg8
g49
sg10
I6
sg11
VTRIM59
p5764
sg13
I1
sasg14
(lp5765
(dp5766
g7
I104
sg17
VC0600139
p5767
sg10
I15
sg11
Vprostate cancer
p5768
sg13
I2
sasa(dp5769
g2
S'TRIM59 was highly expressed in prostate cancer tissues.\n'
p5770
sg4
(lp5771
(dp5772
g7
I0
sg8
g49
sg10
I6
sg11
VTRIM59
p5773
sg13
I1
sasg14
(lp5774
(dp5775
g7
I31
sg17
VC0600139
p5776
sg10
I15
sg11
Vprostate cancer
p5777
sg13
I2
sasa(dp5778
g2
S'Our study suggests that TRIM59 promotes prostate cancer cell proliferation, possibly through its effects on cell cycle progression.\n'
p5779
sg4
(lp5780
(dp5781
g7
I24
sg8
g49
sg10
I6
sg11
VTRIM59
p5782
sg13
I1
sasg14
(lp5783
(dp5784
g7
I61
sg17
VC0334094
p5785
sg10
I13
sg11
Vproliferation
p5786
sg13
I1
sa(dp5787
g7
I40
sg17
VC0600139
p5788
sg10
I15
sg11
Vprostate cancer
p5789
sg13
I2
sasa(dp5790
g2
S'In this study, the effects of TRIM59 expression on cell proliferation and migration were investigated in human cervical cancer cells.\n'
p5791
sg4
(lp5792
(dp5793
g7
I30
sg8
g49
sg10
I6
sg11
VTRIM59
p5794
sg13
I1
sasg14
(lp5795
(dp5796
g7
I56
sg17
VC0334094
p5797
sg10
I13
sg11
Vproliferation
p5798
sg13
I1
sa(dp5799
g7
I111
sg17
VC0302592
p5800
sg10
I15
sg11
Vcervical cancer
p5801
sg13
I2
sasa(dp5802
g2
S'The expression of TRIM59 in clinical cervical cancer tissues and cervical cancer cells was initially determined by RT-PCR and Western blot.\n'
p5803
sg4
(lp5804
(dp5805
g7
I18
sg8
g49
sg10
I6
sg11
VTRIM59
p5806
sg13
I1
sasg14
(lp5807
(dp5808
g7
I37
sg17
VC0302592
p5809
sg10
I15
sg11
Vcervical cancer
p5810
sg13
I2
sa(dp5811
g7
I37
sg17
VC0302592
p5812
sg10
I15
sg11
Vcervical cancer
p5813
sg13
I2
sasa(dp5814
g2
S'Specific shRNA against TRIM59 was then employed to knock down the expression of TRIM59 in cervical cancer lines HeLa and SiHa.\n'
p5815
sg4
(lp5816
(dp5817
g7
I23
sg8
g49
sg10
I6
sg11
VTRIM59
p5818
sg13
I1
sa(dp5819
g7
I23
sg8
g49
sg10
I6
sg11
VTRIM59
p5820
sg13
I1
sasg14
(lp5821
(dp5822
g7
I90
sg17
VC0302592
p5823
sg10
I15
sg11
Vcervical cancer
p5824
sg13
I2
sasa(dp5825
g2
S'Our results showed that the expression of TRIM59 was significantly elevated in cervical cancers.\n'
p5826
sg4
(lp5827
(dp5828
g7
I42
sg8
g49
sg10
I6
sg11
VTRIM59
p5829
sg13
I1
sasg14
(lp5830
(dp5831
g7
I79
sg17
VC0007847
p5832
sg10
I16
sg11
Vcervical cancers
p5833
sg13
I2
sasa(dp5834
g2
S'Knockdown of TRIM59 significantly inhibited cell proliferation and colony formation as well as cell migration and invasion abilities in cervical cancer HeLa and SiHa cells.\n'
p5835
sg4
(lp5836
(dp5837
g7
I13
sg8
g49
sg10
I6
sg11
VTRIM59
p5838
sg13
I1
sasg14
(lp5839
(dp5840
g7
I136
sg17
VC0302592
p5841
sg10
I15
sg11
Vcervical cancer
p5842
sg13
I2
sa(dp5843
g7
I49
sg17
VC0334094
p5844
sg10
I13
sg11
Vproliferation
p5845
sg13
I1
sa(dp5846
g7
I114
sg17
VC2699153
p5847
sg10
I8
sg11
Vinvasion
p5848
sg13
I1
sasa(dp5849
g2
S'These data suggest that TRIM59 is a potential target that promotes the progression of cervical cancer.\n'
p5850
sg4
(lp5851
(dp5852
g7
I24
sg8
g49
sg10
I6
sg11
VTRIM59
p5853
sg13
I1
sasg14
(lp5854
(dp5855
g7
I86
sg17
VC0302592
p5856
sg10
I15
sg11
Vcervical cancer
p5857
sg13
I2
sasa(dp5858
g2
S'In order to assess the risk of complete AV block in patients with intraventricular conduction disturbances who undergo general anesthesia, 20 patients with various conduction defects (7 LBBB, 1 RBBB and 1st degree AV block, 1 incomplete RBBB, 9 RBBB + LAH and 2 RBBB + LPH) were studied by means of His bundle recording and corrected sinus node recovery time (CSNRT) before and after the subministration of thiopental (0.2 g I.V.\n'
p5859
sg4
(lp5860
sg14
(lp5861
(dp5862
g7
I186
sg17
VC0023211
p5863
sg10
I4
sg11
VLBBB
p5864
sg13
I1
sa(dp5865
g7
I194
sg17
VC0085615
p5866
sg10
I4
sg11
VRBBB
p5867
sg13
I1
sa(dp5868
g7
I194
sg17
VC0085615
p5869
sg10
I4
sg11
VRBBB
p5870
sg13
I1
sa(dp5871
g7
I203
sg17
VC0085614
p5872
sg10
I19
sg11
V1st degree AV block
p5873
sg13
I4
sa(dp5874
g7
I164
sg17
VC0264886
p5875
sg10
I18
sg11
Vconduction defects
p5876
sg13
I2
sa(dp5877
g7
I31
sg17
VC0151517
p5878
sg10
I17
sg11
Vcomplete AV block
p5879
sg13
I3
sa(dp5880
g7
I127
sg17
VC0278134
p5881
sg10
I10
sg11
Vanesthesia
p5882
sg13
I1
sa(dp5883
g7
I194
sg17
VC0085615
p5884
sg10
I4
sg11
VRBBB
p5885
sg13
I1
sa(dp5886
g7
I334
sg17
VC0016169
p5887
sg10
I5
sg11
Vsinus
p5888
sg13
I1
sa(dp5889
g7
I194
sg17
VC0085615
p5890
sg10
I4
sg11
VRBBB
p5891
sg13
I1
sa(dp5892
g7
I252
sg17
VC1842839
p5893
sg10
I3
sg11
VLAH
p5894
sg13
I1
sasa(dp5895
g2
S'The preoperative investigation showed prolonged HV-time in three cases and Wenckebach block at 110 ppm in one case, while six patients had LAH-block, five RBB-block and two first degree AV-block.\n'
p5896
sg4
(lp5897
sg14
(lp5898
(dp5899
g7
I139
sg17
VC1842839
p5900
sg10
I3
sg11
VLAH
p5901
sg13
I1
sasa(dp5902
g2
S'The most frequent electrographic abnormalities included: decrease in ST, LAH and atrio-ventricular block of the I degree.\n'
p5903
sg4
(lp5904
sg14
(lp5905
(dp5906
g7
I73
sg17
VC1842839
p5907
sg10
I3
sg11
VLAH
p5908
sg13
I1
sasa(dp5909
g2
S'Isolated RBBB was present in 6,3% of cases; both RBBB and LAH or LPH in 3,4%; isolated LAH in 5,8%; LBBB in 3%; suspect blocks of the three brances [RBBB+LAH+first degree atrio-ventricular block (AVB), or LBBB+first degree AVB] in 2,9% of cases.\n'
p5910
sg4
(lp5911
sg14
(lp5912
(dp5913
g7
I58
sg17
VC1842839
p5914
sg10
I3
sg11
VLAH
p5915
sg13
I1
sa(dp5916
g7
I9
sg17
VC0085615
p5917
sg10
I4
sg11
VRBBB
p5918
sg13
I1
sa(dp5919
g7
I58
sg17
VC1842839
p5920
sg10
I3
sg11
VLAH
p5921
sg13
I1
sa(dp5922
g7
I9
sg17
VC0085615
p5923
sg10
I4
sg11
VRBBB
p5924
sg13
I1
sa(dp5925
g7
I100
sg17
VC0023211
p5926
sg10
I4
sg11
VLBBB
p5927
sg13
I1
sasa(dp5928
g2
S'The overall prevalence of RBBB+LAH was 3.3% compared to 1.6% for RBBB+LPH, and complete atrioventricular block was seen in 36% of the former and 66% of the latter.\n'
p5929
sg4
(lp5930
sg14
(lp5931
(dp5932
g7
I26
sg17
VC1842839
p5933
sg10
I8
sg11
VRBBB+LAH
p5934
sg13
I1
sa(dp5935
g7
I79
sg17
VC0151517
p5936
sg10
I31
sg11
Vcomplete atrioventricular block
p5937
sg13
I3
sasa(dp5938
g2
S'All presented advanced RBBB and sinus rhythm; in the immediate postoperative period, one presented complete transitory A-V block which required a stand by pacemaker; in 2 cases there was a first degree AV block; in two other, LAH and LPH.\n'
p5939
sg4
(lp5940
sg14
(lp5941
(dp5942
g7
I32
sg17
VC0016169
p5943
sg10
I5
sg11
Vsinus
p5944
sg13
I1
sa(dp5945
g7
I226
sg17
VC1842839
p5946
sg10
I3
sg11
VLAH
p5947
sg13
I1
sa(dp5948
g7
I23
sg17
VC0085615
p5949
sg10
I4
sg11
VRBBB
p5950
sg13
I1
sa(dp5951
g7
I189
sg17
VC0085614
p5952
sg10
I21
sg11
Vfirst degree AV block
p5953
sg13
I4
sasa(dp5954
g2
S'In the LAH + RBBB group, there was a higher mortality rate and frequent evolution toward complete A-V block.\n'
p5955
sg4
(lp5956
sg14
(lp5957
(dp5958
g7
I7
sg17
VC1842839
p5959
sg10
I3
sg11
VLAH
p5960
sg13
I1
sa(dp5961
g7
I13
sg17
VC0085615
p5962
sg10
I4
sg11
VRBBB
p5963
sg13
I1
sasa(dp5964
g2
S'S100 calcium-binding protein A9, annexin A3, nicotinamide phosphoribosyltransferase, carboxylesterase 2 and calcium activated chloride channel A1 were probably potential biomarkers of colorectal cancer.\n'
p5965
sg4
(lp5966
(dp5967
g7
I33
sg8
VP12429
p5968
sg10
I10
sg11
Vannexin A3
p5969
sg13
I2
sa(dp5970
g7
I45
sg8
g49
sg10
I58
sg11
Vnicotinamide phosphoribosyltransferase, carboxylesterase 2
p5971
sg13
I4
sa(dp5972
g7
I0
sg8
VP06702
p5973
sg10
I31
sg11
VS100 calcium-binding protein A9
p5974
sg13
I4
sasg14
(lp5975
(dp5976
g7
I184
sg17
VC1527249
p5977
sg10
I17
sg11
Vcolorectal cancer
p5978
sg13
I2
sasa(dp5979
g2
S'We previously showed that calgranulin B levels are increased in the stools of colorectal cancer patients.\n'
p5980
sg4
(lp5981
(dp5982
g7
I26
sg8
VP06702
p5983
sg10
I13
sg11
Vcalgranulin B
p5984
sg13
I2
sasg14
(lp5985
(dp5986
g7
I78
sg17
VC1527249
p5987
sg10
I17
sg11
Vcolorectal cancer
p5988
sg13
I2
sasa(dp5989
g2
S'In patient tumor tissues, calgranulin B protein levels correlated with the presence of stromal inflammatory cells surrounding tumor cells, and calgranulin B promoter methylation was observed in both paired human tissues and colon cancer cell lines.\n'
p5990
sg4
(lp5991
(dp5992
g7
I26
sg8
VP06702
p5993
sg10
I21
sg11
Vcalgranulin B protein
p5994
sg13
I3
sa(dp5995
g7
I143
sg8
VP06702
p5996
sg10
I22
sg11
Vcalgranulin B promoter
p5997
sg13
I3
sasg14
(lp5998
(dp5999
g7
I11
sg17
VC0027651
p6000
sg10
I5
sg11
Vtumor
p6001
sg13
I1
sa(dp6002
g7
I224
sg17
VC0699790
p6003
sg10
I12
sg11
Vcolon cancer
p6004
sg13
I2
sa(dp6005
g7
I11
sg17
VC0027651
p6006
sg10
I5
sg11
Vtumor
p6007
sg13
I1
sasa(dp6008
g2
S'Cell lines did not express calgranulin B, but in vitro studies showed that colon cancer cells internalized extracellular calgranulin B, while other types of cancer cells did not.\n'
p6009
sg4
(lp6010
(dp6011
g7
I27
sg8
VP06702
p6012
sg10
I13
sg11
Vcalgranulin B
p6013
sg13
I2
sa(dp6014
g7
I107
sg8
VP06702
p6015
sg10
I27
sg11
Vextracellular calgranulin B
p6016
sg13
I3
sasg14
(lp6017
(dp6018
g7
I75
sg17
VC0699790
p6019
sg10
I12
sg11
Vcolon cancer
p6020
sg13
I2
sa(dp6021
g7
I81
sg17
VC0006826
p6022
sg10
I6
sg11
Vcancer
p6023
sg13
I1
sasa(dp6024
g2
S'Our findings demonstrate the antitumor effects of calgranulin B in the inflammatory microenvironment and suggest that calgranulin B could be potentially efficacious in the treatment of colon cancer.\n'
p6025
sg4
(lp6026
(dp6027
g7
I50
sg8
VP06702
p6028
sg10
I13
sg11
Vcalgranulin B
p6029
sg13
I2
sa(dp6030
g7
I50
sg8
VP06702
p6031
sg10
I13
sg11
Vcalgranulin B
p6032
sg13
I2
sasg14
(lp6033
(dp6034
g7
I185
sg17
VC0699790
p6035
sg10
I12
sg11
Vcolon cancer
p6036
sg13
I2
sasa(dp6037
g2
S'We assessed the clinical usefulness of calgranulin B as a stool marker for colorectal cancer in a pilot study of patients with colorectal cancer.\n'
p6038
sg4
(lp6039
(dp6040
g7
I39
sg8
VP06702
p6041
sg10
I13
sg11
Vcalgranulin B
p6042
sg13
I2
sasg14
(lp6043
(dp6044
g7
I75
sg17
VC1527249
p6045
sg10
I17
sg11
Vcolorectal cancer
p6046
sg13
I2
sa(dp6047
g7
I75
sg17
VC1527249
p6048
sg10
I17
sg11
Vcolorectal cancer
p6049
sg13
I2
sasa(dp6050
g2
S'We checked the calgranulin B in stools from 77 colorectal cancer patients and from 75 controls by western blot and enzyme-linked immunosorbent assay.\n'
p6051
sg4
(lp6052
(dp6053
g7
I15
sg8
VP06702
p6054
sg10
I13
sg11
Vcalgranulin B
p6055
sg13
I2
sasg14
(lp6056
(dp6057
g7
I47
sg17
VC1527249
p6058
sg10
I17
sg11
Vcolorectal cancer
p6059
sg13
I2
sasa(dp6060
g2
S'Fecal calgranulin A did not show any difference, but stool calgranulin B of colorectal cancer patients was significantly higher than controls [50.6 ng/mg stool protein (SD, 34.8) vs. 20.2 ng/mg stool protein (SD,24.0), respectively, P &lt; 0.001).\n'
p6061
sg4
(lp6062
(dp6063
g7
I6
sg8
VP05109
p6064
sg10
I13
sg11
Vcalgranulin A
p6065
sg13
I2
sasg14
(lp6066
(dp6067
g7
I76
sg17
VC1527249
p6068
sg10
I17
sg11
Vcolorectal cancer
p6069
sg13
I2
sasa(dp6070
g2
S'Calgranulin B was increased in stools of colorectal cancer patients but our results suggest that colorectal cancer screening by determination of stool calgranulin B would not be better than conventional fecal occult blood test.\n'
p6071
sg4
(lp6072
(dp6073
g7
I145
sg8
VP06702
p6074
sg10
I19
sg11
Vstool calgranulin B
p6075
sg13
I3
sa(dp6076
g7
I0
sg8
VP06702
p6077
sg10
I13
sg11
VCalgranulin B
p6078
sg13
I2
sasg14
(lp6079
(dp6080
g7
I41
sg17
VC1527249
p6081
sg10
I17
sg11
Vcolorectal cancer
p6082
sg13
I2
sa(dp6083
g7
I41
sg17
VC1527249
p6084
sg10
I17
sg11
Vcolorectal cancer
p6085
sg13
I2
sasa(dp6086
g2
S'Calgranulin B was upregulated in colorectal cancer, and hepatoma-derived aldose reductase-like protein was reexpressed in a rat model during hepatocarcinogenesis.\n'
p6087
sg4
(lp6088
(dp6089
g7
I0
sg8
VP06702
p6090
sg10
I13
sg11
VCalgranulin B
p6091
sg13
I2
sa(dp6092
g7
I73
sg8
VP15121
p6093
sg10
I29
sg11
Valdose reductase-like protein
p6094
sg13
I3
sasg14
(lp6095
(dp6096
g7
I141
sg17
VC1512409
p6097
sg10
I20
sg11
Vhepatocarcinogenesis
p6098
sg13
I1
sa(dp6099
g7
I56
sg17
VC0023903
p6100
sg10
I8
sg11
Vhepatoma
p6101
sg13
I1
sa(dp6102
g7
I33
sg17
VC1527249
p6103
sg10
I17
sg11
Vcolorectal cancer
p6104
sg13
I2
sasa(dp6105
g2
S'The most interesting new members of the chromo superfamily are Drosophila male-specific lethal (MSL-3) protein involved in the X chromosome gene dosage compensation in the males and human retinoblastoma-binding protein RBP-1.\n'
p6106
sg4
(lp6107
(dp6108
g7
I188
sg8
g49
sg10
I36
sg11
Vretinoblastoma-binding protein RBP-1
p6109
sg13
I3
sasg14
(lp6110
(dp6111
g7
I188
sg17
VC0035335
p6112
sg10
I14
sg11
Vretinoblastoma
p6113
sg13
I1
sa(dp6114
g7
I96
sg17
VC0023804
p6115
sg10
I3
sg11
VMSL
p6116
sg13
I1
sasa(dp6117
g2
S'To evaluate variants in the LRPAP1, CTSH, LEPREL1, ZNF644, SLC39A5, and SCO2 genes in 298 unrelated patients with early-onset high myopia (eoHM).\n'
p6118
sg4
(lp6119
(dp6120
g7
I36
sg8
VP09668
p6121
sg10
I4
sg11
VCTSH
p6122
sg13
I1
sa(dp6123
g7
I28
sg8
VP30533
p6124
sg10
I6
sg11
VLRPAP1
p6125
sg13
I1
sa(dp6126
g7
I59
sg8
g49
sg10
I7
sg11
VSLC39A5
p6127
sg13
I1
sa(dp6128
g7
I42
sg8
g49
sg10
I7
sg11
VLEPREL1
p6129
sg13
I1
sa(dp6130
g7
I72
sg8
g49
sg10
I10
sg11
VSCO2 genes
p6131
sg13
I2
sasg14
(lp6132
(dp6133
g7
I126
sg17
VC0271183
p6134
sg10
I11
sg11
Vhigh myopia
p6135
sg13
I2
sasa(dp6136
g2
S'The ZNF644 gene showed five heterozygous missense mutations (c.1106A&gt;T, p.K369M; c.1648G&gt;A, p.A550T; c.2014A&gt;G, p.S672G; c.2048G&gt;C, p.R683T, and c.2551G&gt;C, p.D851H) in five families, but the c.1106A&gt;T, (p.K369M) and c.1648G&gt;A, (p.A550T) in ZNF644 did not co-segregated with high myopia in the families and should be excluded as causative mutations.\n'
p6137
sg4
(lp6138
sg14
(lp6139
(dp6140
g7
I295
sg17
VC0271183
p6141
sg10
I11
sg11
Vhigh myopia
p6142
sg13
I2
sasa(dp6143
g2
S'To investigate the association of ZNF644, GRM6 and CTNND2 genes with high myopia in Jiangsu Chinese population.\n'
p6144
sg4
(lp6145
(dp6146
g7
I51
sg8
VP01893
p6147
sg10
I12
sg11
VCTNND2 genes
p6148
sg13
I2
sa(dp6149
g7
I42
sg8
g49
sg10
I4
sg11
VGRM6
p6150
sg13
I1
sasg14
(lp6151
(dp6152
g7
I69
sg17
VC0271183
p6153
sg10
I11
sg11
Vhigh myopia
p6154
sg13
I2
sasa(dp6155
g2
S'ZNF644-rs358695 was associated with high myopia (P = 0.03).\n'
p6156
sg4
(lp6157
sg14
(lp6158
(dp6159
g7
I36
sg17
VC0271183
p6160
sg10
I11
sg11
Vhigh myopia
p6161
sg13
I2
sasa(dp6162
g2
S'ZNF644 gene mutation was associated with high myopia.\n'
p6163
sg4
(lp6164
sg14
(lp6165
(dp6166
g7
I41
sg17
VC0271183
p6167
sg10
I11
sg11
Vhigh myopia
p6168
sg13
I2
sasa(dp6169
g2
S'ZNF644 gene may play a role in the development of high myopia.\n'
p6170
sg4
(lp6171
sg14
(lp6172
(dp6173
g7
I50
sg17
VC0271183
p6174
sg10
I11
sg11
Vhigh myopia
p6175
sg13
I2
sasa(dp6176
g2
S'In this study, we investigated the mutation spectrum of ZNF644, a causative gene for autosomal dominant high myopia, in a high-myopia cohort from a Chinese population.\n'
p6177
sg4
(lp6178
sg14
(lp6179
(dp6180
g7
I109
sg17
VC0027092
p6181
sg10
I6
sg11
Vmyopia
p6182
sg13
I1
sa(dp6183
g7
I104
sg17
VC0271183
p6184
sg10
I11
sg11
Vhigh myopia
p6185
sg13
I2
sasa(dp6186
g2
S'ZNF644 is associated with high myopia in a cohort from a Chinese population.\n'
p6187
sg4
(lp6188
sg14
(lp6189
(dp6190
g7
I26
sg17
VC0271183
p6191
sg10
I11
sg11
Vhigh myopia
p6192
sg13
I2
sasa(dp6193
g2
S'ZNF644 mutations have a minor contribution to the genetic etiology of high myopia.\n'
p6194
sg4
(lp6195
sg14
(lp6196
(dp6197
g7
I70
sg17
VC0271183
p6198
sg10
I11
sg11
Vhigh myopia
p6199
sg13
I2
sasa(dp6200
g2
S'Recent advances in whole exome sequencing technology show promise for further elucidation of disease causing variants as in the recent identification of rare variants within ZNF644 segregating with pathological myopia.\n'
p6201
sg4
(lp6202
sg14
(lp6203
(dp6204
g7
I198
sg17
VC0154778
p6205
sg10
I19
sg11
Vpathological myopia
p6206
sg13
I2
sasa(dp6207
g2
S'A recent study implicated zinc finger protein 644 isoform 1 (ZNF644) variants with non-syndromic high-grade myopia in a Chinese-Asian population.\n'
p6208
sg4
(lp6209
(dp6210
g7
I61
sg8
VP13682
p6211
sg10
I6
sg11
VZNF644
p6212
sg13
I1
sa(dp6213
g7
I26
sg8
VP13682
p6214
sg10
I33
sg11
Vzinc finger protein 644 isoform 1
p6215
sg13
I6
sasg14
(lp6216
(dp6217
g7
I108
sg17
VC0027092
p6218
sg10
I6
sg11
Vmyopia
p6219
sg13
I1
sasa(dp6220
g2
S'Herein we focused on investigating the role for ZNF644 variants in high-grade myopia in a United States (US) cohort.\n'
p6221
sg4
(lp6222
(dp6223
g7
I48
sg8
VP26640
p6224
sg10
I15
sg11
VZNF644 variants
p6225
sg13
I2
sasg14
(lp6226
(dp6227
g7
I78
sg17
VC0027092
p6228
sg10
I6
sg11
Vmyopia
p6229
sg13
I1
sasa(dp6230
g2
S'DNA from a case cohort of 131 subject participants diagnosed with high-grade myopia was screened for ZNF644 variants.\n'
p6231
sg4
(lp6232
(dp6233
g7
I101
sg8
VP26640
p6234
sg10
I15
sg11
VZNF644 variants
p6235
sg13
I2
sasg14
(lp6236
(dp6237
g7
I77
sg17
VC0027092
p6238
sg10
I6
sg11
Vmyopia
p6239
sg13
I1
sasa(dp6240
g2
S'Our study has identified two novel variants in ZNF644 associated with high-grade myopia in a US cohort.\n'
p6241
sg4
(lp6242
sg14
(lp6243
(dp6244
g7
I81
sg17
VC0027092
p6245
sg10
I6
sg11
Vmyopia
p6246
sg13
I1
sasa(dp6247
g2
S'Our results suggest that ZNF644 may play a role in myopia development.\n'
p6248
sg4
(lp6249
sg14
(lp6250
(dp6251
g7
I51
sg17
VC0027092
p6252
sg10
I6
sg11
Vmyopia
p6253
sg13
I1
sasa(dp6254
g2
S"After we performed sequencing analysis of the exons in the ZNF644 gene in 300 sporadic cases of high myopia, we identified an additional five mutations (I587V, R680G, C699Y, 3'UTR+12 C&gt;G, and 3'UTR+592 G&gt;A) in 11 different patients.\n"
p6255
sg4
(lp6256
sg14
(lp6257
(dp6258
g7
I96
sg17
VC0271183
p6259
sg10
I11
sg11
Vhigh myopia
p6260
sg13
I2
sasa(dp6261
g2
S'Given that ZNF644 is predicted to be a transcription factor that may regulate genes involved in eye development, mutation may cause the axial elongation of eyeball found in high myopia patients.\n'
p6262
sg4
(lp6263
sg14
(lp6264
(dp6265
g7
I173
sg17
VC0271183
p6266
sg10
I11
sg11
Vhigh myopia
p6267
sg13
I2
sasa(dp6268
g2
S'Our results suggest that ZNF644 might be a causal gene for high myopia in a monogenic form.\n'
p6269
sg4
(lp6270
sg14
(lp6271
(dp6272
g7
I59
sg17
VC0271183
p6273
sg10
I11
sg11
Vhigh myopia
p6274
sg13
I2
sasa(dp6275
g2
S'We hypothesized that Nrf2 modulates progression from acute tubular damage to renal fibrosis.\n'
p6276
sg4
(lp6277
(dp6278
g7
I21
sg8
g49
sg10
I4
sg11
VNrf2
p6279
sg13
I1
sasg14
(lp6280
(dp6281
g7
I77
sg17
VC0151650
p6282
sg10
I14
sg11
Vrenal fibrosis
p6283
sg13
I2
sasa(dp6284
g2
S'We asked whether Nrf2 deletion increases renal injury in mice following unilateral ureteral obstruction (UUO).\n'
p6285
sg4
(lp6286
(dp6287
g7
I17
sg8
g49
sg10
I4
sg11
VNrf2
p6288
sg13
I1
sasg14
(lp6289
(dp6290
g7
I83
sg17
VC0041956
p6291
sg10
I20
sg11
Vureteral obstruction
p6292
sg13
I2
sa(dp6293
g7
I105
sg17
VC0041956
p6294
sg10
I3
sg11
VUUO
p6295
sg13
I1
sasa(dp6296
g2
S'We studied Nrf2 in renal biopsies of patients with acute, subacute and chronic tubulointerstitial nephritis (TIN).\n'
p6297
sg4
(lp6298
sg14
(lp6299
(dp6300
g7
I71
sg17
VC0238304
p6301
sg10
I36
sg11
Vchronic tubulointerstitial nephritis
p6302
sg13
I3
sasa(dp6303
g2
S'The aim of this study was to evaluate the effects of resistance exercise programs on the expression of transcription factors Nrf2 and nuclear factor KB (NF-KB) in CKD patients on hemodialysis (HD).\n'
p6304
sg4
(lp6305
(dp6306
g7
I125
sg8
g49
sg10
I4
sg11
VNrf2
p6307
sg13
I1
sa(dp6308
g7
I134
sg8
VP01160
p6309
sg10
I17
sg11
Vnuclear factor KB
p6310
sg13
I3
sa(dp6311
g7
I153
sg8
VP01160
p6312
sg10
I5
sg11
VNF-KB
p6313
sg13
I1
sasg14
(lp6314
sa(dp6315
g2
S'In conclusion, these data suggest that resistance exercises seem to be capable of inducing Nrf2 activation in CKD patients on HD.\n'
p6316
sg4
(lp6317
(dp6318
g7
I91
sg8
g49
sg10
I4
sg11
VNrf2
p6319
sg13
I1
sasg14
(lp6320
sa(dp6321
g2
S'Activate Nrf2 could inhibit the activation of NLRP3 inflammasome in acute liver injury and severe lupus nephritis.\n'
p6322
sg4
(lp6323
(dp6324
g7
I9
sg8
g49
sg10
I4
sg11
VNrf2
p6325
sg13
I1
sasg14
(lp6326
(dp6327
g7
I98
sg17
VC0024143
p6328
sg10
I15
sg11
Vlupus nephritis
p6329
sg13
I2
sasa(dp6330
g2
S'Here, we show that the loss of Nrf2 suppresses fibrosis and inflammation in a unilateral ureter obstruction (UUO) model of CKD in mice.\n'
p6331
sg4
(lp6332
(dp6333
g7
I31
sg8
g49
sg10
I4
sg11
VNrf2
p6334
sg13
I1
sasg14
(lp6335
(dp6336
g7
I89
sg17
VC0041956
p6337
sg10
I18
sg11
Vureter obstruction
p6338
sg13
I2
sa(dp6339
g7
I109
sg17
VC0041956
p6340
sg10
I3
sg11
VUUO
p6341
sg13
I1
sa(dp6342
g7
I47
sg17
VC0016059
p6343
sg10
I8
sg11
Vfibrosis
p6344
sg13
I1
sa(dp6345
g7
I60
sg17
VC0021368
p6346
sg10
I12
sg11
Vinflammation
p6347
sg13
I1
sasa(dp6348
g2
S'These results demonstrate that Nrf2-related inflammasome activation can promote CKD symptoms via infiltration of M1 macrophages.\n'
p6349
sg4
(lp6350
(dp6351
g7
I31
sg8
g49
sg10
I4
sg11
VNrf2
p6352
sg13
I1
sasg14
(lp6353
(dp6354
g7
I97
sg17
VC0332448
p6355
sg10
I12
sg11
Vinfiltration
p6356
sg13
I1
sasa(dp6357
g2
S'Thus, we have identified the Nrf2 pathway as a promising therapeutic target for CKD.\n'
p6358
sg4
(lp6359
(dp6360
g7
I29
sg8
g49
sg10
I4
sg11
VNrf2
p6361
sg13
I1
sasg14
(lp6362
sa(dp6363
g2
S'Reduced nuclear factor erythroid 2-related factor 2 (NRF2) pathway activity was reported in models of chronic kidney disease (CKD).\n'
p6364
sg4
(lp6365
(dp6366
g7
I53
sg8
g49
sg10
I4
sg11
VNRF2
p6367
sg13
I1
sa(dp6368
g7
I8
sg8
g49
sg10
I43
sg11
Vnuclear factor erythroid 2-related factor 2
p6369
sg13
I6
sasg14
(lp6370
(dp6371
g7
I102
sg17
VC1561643
p6372
sg10
I22
sg11
Vchronic kidney disease
p6373
sg13
I3
sa(dp6374
g7
I126
sg17
VC1561643
p6375
sg10
I3
sg11
VCKD
p6376
sg13
I1
sasa(dp6377
g2
S'[Purpose] The aim of this study was to examine the agreement between physiotherapists (PTs) and mothers (Ms) about the treatment of children with cerebral palsy (CP) who received treatment in special education and rehabilitation centers.\n'
p6378
sg4
(lp6379
sg14
(lp6380
(dp6381
g7
I146
sg17
VC0007789
p6382
sg10
I14
sg11
Vcerebral palsy
p6383
sg13
I2
sasa(dp6384
g2
S'The purpose of this study was to evaluate the impact of a multifaceted knowledge translation intervention, using PTs as knowledge brokers (KBs) to facilitate the use in clinical practice of four evidence-based measurement tools designed to evaluate and understand motor function in children with cerebral palsy (CP).\n'
p6385
sg4
(lp6386
sg14
(lp6387
(dp6388
g7
I312
sg17
VC0007789
p6389
sg10
I2
sg11
VCP
p6390
sg13
I1
sa(dp6391
g7
I296
sg17
VC0007789
p6392
sg10
I14
sg11
Vcerebral palsy
p6393
sg13
I2
sasa(dp6394
g2
S'In this study, interaction between eight Swedish children with cerebral palsy, mean age 8.6 years, and their physiotherapists (PTs) and speech-language therapists (SLTs) was analysed during intervention across 16 dyads.\n'
p6395
sg4
(lp6396
sg14
(lp6397
(dp6398
g7
I63
sg17
VC0007789
p6399
sg10
I14
sg11
Vcerebral palsy
p6400
sg13
I2
sasa(dp6401
g2
S'A case of inherited homozygous complement C3 deficiency (C3D) in a patient with systemic lupus erythematosus (SLE) and the molecular basis for this deficiency are reported.\n'
p6402
sg4
(lp6403
(dp6404
g7
I31
sg8
VP01024
p6405
sg10
I13
sg11
Vcomplement C3
p6406
sg13
I2
sasg14
(lp6407
(dp6408
g7
I57
sg17
VC3151071
p6409
sg10
I3
sg11
VC3D
p6410
sg13
I1
sa(dp6411
g7
I42
sg17
VC1332655
p6412
sg10
I13
sg11
VC3 deficiency
p6413
sg13
I2
sa(dp6414
g7
I110
sg17
VC0024141
p6415
sg10
I3
sg11
VSLE
p6416
sg13
I1
sa(dp6417
g7
I80
sg17
VC0024141
p6418
sg10
I28
sg11
Vsystemic lupus erythematosus
p6419
sg13
I3
sasa(dp6420
g2
S'Our previous studies indicate that uPA and uPAR expression increase in the ischemic brain during the recovery phase from an acute ischemic injury and that uPA binding to uPAR promotes neurological recovery after an acute ischemic stroke.\n'
p6421
sg4
(lp6422
(dp6423
g7
I35
sg8
VP00749
p6424
sg10
I3
sg11
VuPA
p6425
sg13
I1
sa(dp6426
g7
I35
sg8
VP00749
p6427
sg10
I3
sg11
VuPA
p6428
sg13
I1
sasg14
(lp6429
(dp6430
g7
I221
sg17
VC3272363
p6431
sg10
I15
sg11
Vischemic stroke
p6432
sg13
I2
sasa(dp6433
g2
S'The data reviewed here indicate that the uPA-uPAR-LRP1 system is a potential target for the development of therapeutic strategies to promote neurological recovery in acute ischemic stroke patients.\n'
p6434
sg4
(lp6435
(dp6436
g7
I41
sg8
VP00749
p6437
sg10
I3
sg11
VuPA
p6438
sg13
I1
sa(dp6439
g7
I50
sg8
g49
sg10
I4
sg11
VLRP1
p6440
sg13
I1
sasg14
(lp6441
(dp6442
g7
I172
sg17
VC3272363
p6443
sg10
I15
sg11
Vischemic stroke
p6444
sg13
I2
sasa(dp6445
g2
S'We report that cerebral cortical neurons release uPA during the recovery phase from ischemic stroke in vivo or hypoxia in vitro.\n'
p6446
sg4
(lp6447
(dp6448
g7
I49
sg8
VP00749
p6449
sg10
I3
sg11
VuPA
p6450
sg13
I1
sasg14
(lp6451
(dp6452
g7
I111
sg17
VC0242184
p6453
sg10
I7
sg11
Vhypoxia
p6454
sg13
I1
sa(dp6455
g7
I84
sg17
VC3272363
p6456
sg10
I15
sg11
Vischemic stroke
p6457
sg13
I2
sasa(dp6458
g2
S'Treatment with recombinant uPA after ischemic stroke induces neurological recovery in wild-type and uPA(-/-) but not in uPAR(-/-) mice.\n'
p6459
sg4
(lp6460
(dp6461
g7
I27
sg8
VP00749
p6462
sg10
I3
sg11
VuPA
p6463
sg13
I1
sa(dp6464
g7
I27
sg8
VP00749
p6465
sg10
I3
sg11
VuPA
p6466
sg13
I1
sasg14
(lp6467
(dp6468
g7
I37
sg17
VC3272363
p6469
sg10
I15
sg11
Vischemic stroke
p6470
sg13
I2
sasa(dp6471
g2
S'This study reports of the Interactive Learning and Action (ILA) approach, a methodology for agricultural innovation which has been adapted to the context of HIV/AIDS.\n'
p6472
sg4
(lp6473
sg14
(lp6474
(dp6475
g7
I157
sg17
VC0497169
p6476
sg10
I8
sg11
VHIV/AIDS
p6477
sg13
I1
sasa(dp6478
g2
S'Interference with the 4-1BB-4-1BBL pathway may be of therapeutic use in the treatment of HIV infection.\n'
p6479
sg4
(lp6480
(dp6481
g7
I22
sg8
g49
sg10
I7
sg11
V4-1BB-4
p6482
sg13
I1
sasg14
(lp6483
(dp6484
g7
I89
sg17
VC0019693
p6485
sg10
I13
sg11
VHIV infection
p6486
sg13
I2
sasa(dp6487
g2
S'A negative correlation between the WHO degree of malignancy and the strength of expression was identified on both transcriptional and translational level for AOX1, GSTM3 and GSTP1, although the results could have been biased by the prevalence of meningiomas and glioblastomas in the inevitably bipolar distribution of the WHO grades.\n'
p6488
sg4
(lp6489
(dp6490
g7
I164
sg8
VP21266
p6491
sg10
I5
sg11
VGSTM3
p6492
sg13
I1
sa(dp6493
g7
I174
sg8
VP09211
p6494
sg10
I5
sg11
VGSTP1
p6495
sg13
I1
sa(dp6496
g7
I158
sg8
g49
sg10
I4
sg11
VAOX1
p6497
sg13
I1
sasg14
(lp6498
(dp6499
g7
I262
sg17
VC0017636
p6500
sg10
I13
sg11
Vglioblastomas
p6501
sg13
I1
sa(dp6502
g7
I246
sg17
VC0025286
p6503
sg10
I11
sg11
Vmeningiomas
p6504
sg13
I1
sa(dp6505
g7
I49
sg17
VC0006826
p6506
sg10
I10
sg11
Vmalignancy
p6507
sg13
I1
sasa(dp6508
g2
S'A correlation between the gene expression and the protein product was observed for AOX1, GSTP1 and GSTM3 in astrocytomas.\n'
p6509
sg4
(lp6510
(dp6511
g7
I89
sg8
VP09211
p6512
sg10
I5
sg11
VGSTP1
p6513
sg13
I1
sa(dp6514
g7
I99
sg8
VP21266
p6515
sg10
I5
sg11
VGSTM3
p6516
sg13
I1
sa(dp6517
g7
I83
sg8
g49
sg10
I4
sg11
VAOX1
p6518
sg13
I1
sasg14
(lp6519
(dp6520
g7
I108
sg17
VC0004114
p6521
sg10
I12
sg11
Vastrocytomas
p6522
sg13
I1
sasa(dp6523
g2
S'In addition, 5 features, including the expression of the putative biomarkers SNTN and AOX1, were selected to differentiate between normal, SBOT, and serous ovarian carcinoma groups.\n'
p6524
sg4
(lp6525
(dp6526
g7
I77
sg8
g49
sg10
I4
sg11
VSNTN
p6527
sg13
I1
sa(dp6528
g7
I86
sg8
g49
sg10
I4
sg11
VAOX1
p6529
sg13
I1
sasg14
(lp6530
(dp6531
g7
I156
sg17
VC0029925
p6532
sg10
I17
sg11
Vovarian carcinoma
p6533
sg13
I2
sasa(dp6534
g2
S'We previously reported that upregulation of NAD(P)H:quinone oxidoreductase 1 (NQO1) in cholangiocarcinoma (CCA; a fatal bile duct cancer) was associated with poor prognosis.\n'
p6535
sg4
(lp6536
(dp6537
g7
I44
sg8
g49
sg10
I32
sg11
VNAD(P)H:quinone oxidoreductase 1
p6538
sg13
I3
sa(dp6539
g7
I78
sg8
VP15559
p6540
sg10
I4
sg11
VNQO1
p6541
sg13
I1
sasg14
(lp6542
(dp6543
g7
I107
sg17
VC0220668
p6544
sg10
I3
sg11
VCCA
p6545
sg13
I1
sa(dp6546
g7
I44
sg17
VC1850380
p6547
sg10
I3
sg11
VNAD
p6548
sg13
I1
sa(dp6549
g7
I120
sg17
VC0740277
p6550
sg10
I16
sg11
Vbile duct cancer
p6551
sg13
I3
sa(dp6552
g7
I87
sg17
VC0206698
p6553
sg10
I18
sg11
Vcholangiocarcinoma
p6554
sg13
I1
sasa(dp6555
g2
S'This study aimed to evaluate the association between the immunohistochemical expression of NAD(P) H:quinone oxidoreductase-1 (NQO1) and nuclear factor erythroid 2-related factor 2 (Nrf2) in resected specimens of intrahepatic cholangiocarcinoma (ICC) and to elucidate the prognostic value of NQO1 and Nrf2 expression.\n'
p6556
sg4
(lp6557
(dp6558
g7
I181
sg8
g49
sg10
I4
sg11
VNrf2
p6559
sg13
I1
sa(dp6560
g7
I91
sg8
g49
sg10
I33
sg11
VNAD(P) H:quinone oxidoreductase-1
p6561
sg13
I3
sa(dp6562
g7
I181
sg8
g49
sg10
I4
sg11
VNrf2
p6563
sg13
I1
sa(dp6564
g7
I136
sg8
g49
sg10
I43
sg11
Vnuclear factor erythroid 2-related factor 2
p6565
sg13
I6
sa(dp6566
g7
I126
sg8
VP15559
p6567
sg10
I4
sg11
VNQO1
p6568
sg13
I1
sa(dp6569
g7
I126
sg8
VP15559
p6570
sg10
I4
sg11
VNQO1
p6571
sg13
I1
sasg14
(lp6572
(dp6573
g7
I245
sg17
VC0268074
p6574
sg10
I3
sg11
VICC
p6575
sg13
I1
sa(dp6576
g7
I212
sg17
VC0345905
p6577
sg10
I31
sg11
Vintrahepatic cholangiocarcinoma
p6578
sg13
I2
sa(dp6579
g7
I91
sg17
VC1850380
p6580
sg10
I3
sg11
VNAD
p6581
sg13
I1
sasa(dp6582
g2
S'The aim of this study was to evaluate the effect of inflammation on NAD(P)H: quinone oxidoreductase-1 (NQO1), the xenobiotic metabolizing and antioxidant enzyme protecting cells against electrophiles and reactive oxygen species in biliary cancer (cholangiocarcinoma) cells.\n'
p6583
sg4
(lp6584
(dp6585
g7
I68
sg8
g49
sg10
I33
sg11
VNAD(P)H: quinone oxidoreductase-1
p6586
sg13
I3
sa(dp6587
g7
I103
sg8
VP15559
p6588
sg10
I4
sg11
VNQO1
p6589
sg13
I1
sasg14
(lp6590
(dp6591
g7
I247
sg17
VC0206698
p6592
sg10
I18
sg11
Vcholangiocarcinoma
p6593
sg13
I1
sa(dp6594
g7
I68
sg17
VC1850380
p6595
sg10
I3
sg11
VNAD
p6596
sg13
I1
sa(dp6597
g7
I231
sg17
VC0750952
p6598
sg10
I14
sg11
Vbiliary cancer
p6599
sg13
I2
sa(dp6600
g7
I52
sg17
VC0021368
p6601
sg10
I12
sg11
Vinflammation
p6602
sg13
I1
sasa(dp6603
g2
S'Human cholangiocarcinoma cell line, KKU-OCA17 and HeLa Chang liver cells were treated with inflammatory cytokine combinations (interferon-gamma, interleukin-1beta and tumor necrosis factor-alpha) for 48 h before NQO1 activity was assayed.\n'
p6604
sg4
(lp6605
(dp6606
g7
I212
sg8
VP15559
p6607
sg10
I4
sg11
VNQO1
p6608
sg13
I1
sa(dp6609
g7
I145
sg8
VP01584
p6610
sg10
I17
sg11
Vinterleukin-1beta
p6611
sg13
I1
sa(dp6612
g7
I167
sg8
VP01375
p6613
sg10
I27
sg11
Vtumor necrosis factor-alpha
p6614
sg13
I3
sa(dp6615
g7
I127
sg8
VP01579
p6616
sg10
I16
sg11
Vinterferon-gamma
p6617
sg13
I1
sasg14
(lp6618
(dp6619
g7
I167
sg17
VC0333516
p6620
sg10
I14
sg11
Vtumor necrosis
p6621
sg13
I2
sa(dp6622
g7
I6
sg17
VC0206698
p6623
sg10
I18
sg11
Vcholangiocarcinoma
p6624
sg13
I1
sasa(dp6625
g2
S'Building on these investigations, the present study had two goals: first, to develop a method for inducing voluntary ethanol intake in individual zebrafish, which can be used as a model in future studies to examine how this behavior is affected by various manipulations, and second, to characterize the effects of this ethanol intake on different behaviors and the expression of hypothalamic orexigenic peptides, galanin (GAL) and orexin (OX), which are known in rodents to stimulate consumption of ethanol and alter behaviors associated with alcohol abuse.\n'
p6626
sg4
(lp6627
(dp6628
g7
I439
sg8
g49
sg10
I2
sg11
VOX
p6629
sg13
I1
sa(dp6630
g7
I431
sg8
g49
sg10
I6
sg11
Vorexin
p6631
sg13
I1
sa(dp6632
g7
I422
sg8
VP16278
p6633
sg10
I3
sg11
VGAL
p6634
sg13
I1
sa(dp6635
g7
I413
sg8
VP22466
p6636
sg10
I7
sg11
Vgalanin
p6637
sg13
I1
sasg14
(lp6638
(dp6639
g7
I543
sg17
VC0085762
p6640
sg10
I13
sg11
Valcohol abuse
p6641
sg13
I2
sasa(dp6642
g2
S'The neuropeptide galanin has been shown to modulate opiate dependence and withdrawal.\n'
p6643
sg4
(lp6644
sg14
(lp6645
(dp6646
g7
I74
sg17
VC2825032
p6647
sg10
I10
sg11
Vwithdrawal
p6648
sg13
I1
sa(dp6649
g7
I52
sg17
VC0524662
p6650
sg10
I17
sg11
Vopiate dependence
p6651
sg13
I2
sasa(dp6652
g2
S'In this study, we used several transgenic mouse lines to further define the mechanisms underlying the role played by galanin and its receptors in the modulation of morphine dependence.\n'
p6653
sg4
(lp6654
(dp6655
g7
I117
sg8
VP22466
p6656
sg10
I7
sg11
Vgalanin
p6657
sg13
I1
sasg14
(lp6658
(dp6659
g7
I164
sg17
VC0026552
p6660
sg10
I19
sg11
Vmorphine dependence
p6661
sg13
I2
sasa(dp6662
g2
S'Galanin opposes the actions of morphine which leads to opiate dependence and withdrawal, an effect that is mediated via GalR1.\n'
p6663
sg4
(lp6664
(dp6665
g7
I0
sg8
VP22466
p6666
sg10
I7
sg11
VGalanin
p6667
sg13
I1
sa(dp6668
g7
I120
sg8
VP47211
p6669
sg10
I5
sg11
VGalR1
p6670
sg13
I1
sasg14
(lp6671
(dp6672
g7
I77
sg17
VC2825032
p6673
sg10
I10
sg11
Vwithdrawal
p6674
sg13
I1
sa(dp6675
g7
I55
sg17
VC0524662
p6676
sg10
I17
sg11
Vopiate dependence
p6677
sg13
I2
sasa(dp6678
g2
S'The neuropeptide galanin and its three receptor subtypes (GalR1-3) are expressed in the central amygdala (CeA), a brain region involved in stress- and anxiety-related behaviors, as well as alcohol dependence.\n'
p6679
sg4
(lp6680
(dp6681
g7
I106
sg8
VP40198
p6682
sg10
I3
sg11
VCeA
p6683
sg13
I1
sa(dp6684
g7
I88
sg8
VP40198
p6685
sg10
I16
sg11
Vcentral amygdala
p6686
sg13
I2
sa(dp6687
g7
I58
sg8
VP47211
p6688
sg10
I7
sg11
VGalR1-3
p6689
sg13
I1
sasg14
(lp6690
(dp6691
g7
I189
sg17
VC0001973
p6692
sg10
I18
sg11
Valcohol dependence
p6693
sg13
I2
sasa(dp6694
g2
S'Galanin also has been suggested to play a role in alcohol intake and alcohol dependence.\n'
p6695
sg4
(lp6696
(dp6697
g7
I0
sg8
VP22466
p6698
sg10
I7
sg11
VGalanin
p6699
sg13
I1
sasg14
(lp6700
(dp6701
g7
I69
sg17
VC0001973
p6702
sg10
I18
sg11
Valcohol dependence
p6703
sg13
I2
sasa(dp6704
g2
S'Therefore, niacin was effective against iodoacetamide-induced colitis through ameliorating pathologic angiogenesis and inflammatory changes in a GPR109A-dependent manner.\n'
p6705
sg4
(lp6706
(dp6707
g7
I145
sg8
g49
sg10
I7
sg11
VGPR109A
p6708
sg13
I1
sasg14
(lp6709
(dp6710
g7
I62
sg17
VC0009319
p6711
sg10
I7
sg11
Vcolitis
p6712
sg13
I1
sa(dp6713
g7
I91
sg17
VC0027686
p6714
sg10
I23
sg11
Vpathologic angiogenesis
p6715
sg13
I2
sasa(dp6716
g2
S'Reversely, AA alleviates obesity-related disorders via rescuing anti-inflammatory and butyrate-producing microbiota, up-regulating GPR41 and GPR109A and controlling hypothalamic inflammation in female.\n'
p6717
sg4
(lp6718
(dp6719
g7
I131
sg8
g49
sg10
I5
sg11
VGPR41
p6720
sg13
I1
sa(dp6721
g7
I141
sg8
g49
sg10
I7
sg11
VGPR109A
p6722
sg13
I1
sasg14
(lp6723
(dp6724
g7
I178
sg17
VC0021368
p6725
sg10
I12
sg11
Vinflammation
p6726
sg13
I1
sa(dp6727
g7
I25
sg17
VC0028754
p6728
sg10
I7
sg11
Vobesity
p6729
sg13
I1
sasa(dp6730
g2
S'As such, these three metabolite receptors play a critical role in cancer and represent a new class of drug targets with selective antagonists of GPR81 and GPR91 for cancer treatment and agonists of GPR109A for cancer prevention.\n'
p6731
sg4
(lp6732
(dp6733
g7
I145
sg8
g49
sg10
I5
sg11
VGPR81
p6734
sg13
I1
sa(dp6735
g7
I198
sg8
g49
sg10
I7
sg11
VGPR109A
p6736
sg13
I1
sa(dp6737
g7
I155
sg8
g49
sg10
I5
sg11
VGPR91
p6738
sg13
I1
sasg14
(lp6739
(dp6740
g7
I66
sg17
VC0006826
p6741
sg10
I6
sg11
Vcancer
p6742
sg13
I1
sa(dp6743
g7
I66
sg17
VC0006826
p6744
sg10
I6
sg11
Vcancer
p6745
sg13
I1
sa(dp6746
g7
I66
sg17
VC0006826
p6747
sg10
I6
sg11
Vcancer
p6748
sg13
I1
sasa(dp6749
g2
S'In present study, global metabolic profiling with ultra-high-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS) combined with pattern recognition method was performed to discover the underlying hematopoietic regulation mechanisms of DG, CX and GX on hemolytic and aplastic anemia rats (HAA) induced by acetyl phenylhydrazine (APH) and cyclophosphamide (CP).\n'
p6750
sg4
(lp6751
sg14
(lp6752
(dp6753
g7
I318
sg17
VC0002874
p6754
sg10
I15
sg11
Vaplastic anemia
p6755
sg13
I2
sasa(dp6756
g2
S'We demonstrate the utility of these PET-SERRS nanoparticles in several proof-of-concept studies including lymph node (LN) tracking, intraoperative guidance for LN resection, and cancer imaging after intravenous injection.\n'
p6757
sg4
(lp6758
sg14
(lp6759
(dp6760
g7
I178
sg17
VC0006826
p6761
sg10
I6
sg11
Vcancer
p6762
sg13
I1
sasa(dp6763
g2
S'Background: Synovial sarcoma (SyS) is a rare malignancy that typically invades the extremities and occurs predominantly in adolescents.\n'
p6764
sg4
(lp6765
sg14
(lp6766
(dp6767
g7
I30
sg17
VC0039101
p6768
sg10
I3
sg11
VSyS
p6769
sg13
I1
sa(dp6770
g7
I45
sg17
VC0006826
p6771
sg10
I10
sg11
Vmalignancy
p6772
sg13
I1
sa(dp6773
g7
I12
sg17
VC0039101
p6774
sg10
I16
sg11
VSynovial sarcoma
p6775
sg13
I2
sasa(dp6776
g2
S'The unique spectral signatures and biologically inert compositions of surface-enhanced resonance Raman scattering (SERRS) nanoparticles make them promising contrast agents for in vivo cancer imaging.\n'
p6777
sg4
(lp6778
sg14
(lp6779
(dp6780
g7
I184
sg17
VC0006826
p6781
sg10
I6
sg11
Vcancer
p6782
sg13
I1
sasa(dp6783
g2
S'administration of SERRS nanoparticles such that delineation of cancerous lesions can be achieved in vivo and ex vivo on resected tissues without the need for specific biomarker targeting.\n'
p6784
sg4
(lp6785
sg14
(lp6786
sa(dp6787
g2
S'The sensitization enhancement ratios (SERs) calculated by a multitarget single-hit model were 1.62, 1.37, and 1.21 corresponding to the treatments of GNPs, GNSs, and GNRs, respectively, demonstrating that the GNPs showed a higher anticancer efficiency than both GNSs and GNRs upon X-ray irradiation.\n'
p6788
sg4
(lp6789
sg14
(lp6790
sa(dp6791
g2
S'We demonstrated the performance of the PB-based SERRS tags for high-sensitivity immunoassay and cancer cell imaging.\n'
p6792
sg4
(lp6793
sg14
(lp6794
(dp6795
g7
I96
sg17
VC0006826
p6796
sg10
I6
sg11
Vcancer
p6797
sg13
I1
sasa(dp6798
g2
S'We devised a method that employs folate receptor (FR)-targeted surface-enhanced resonance Raman scattering (SERRS) nanoparticles (NPs), as folate receptors are typically overexpressed in ovarian cancer.\n'
p6799
sg4
(lp6800
(dp6801
g7
I33
sg8
VP15328
p6802
sg10
I15
sg11
Vfolate receptor
p6803
sg13
I2
sa(dp6804
g7
I50
sg8
VP15328
p6805
sg10
I2
sg11
VFR
p6806
sg13
I1
sa(dp6807
g7
I139
sg8
VP14207
p6808
sg10
I16
sg11
Vfolate receptors
p6809
sg13
I2
sasg14
(lp6810
(dp6811
g7
I187
sg17
VC1140680
p6812
sg10
I14
sg11
Vovarian cancer
p6813
sg13
I2
sa(dp6814
g7
I115
sg17
VC0027341
p6815
sg10
I13
sg11
Vnanoparticles
p6816
sg13
I1
sa(dp6817
g7
I130
sg17
VC0027341
p6818
sg10
I3
sg11
VNPs
p6819
sg13
I1
sasa(dp6820
g2
S"Here we demonstrate a novel application of 'surface enhanced resonance Raman scattering nanoparticles' (SERRS NPs) for imaging breast cancer lung metastases with much higher precision than currently feasible.\n"
p6821
sg4
(lp6822
sg14
(lp6823
(dp6824
g7
I127
sg17
VC0678222
p6825
sg10
I13
sg11
Vbreast cancer
p6826
sg13
I2
sa(dp6827
g7
I110
sg17
VC0027341
p6828
sg10
I3
sg11
VNPs
p6829
sg13
I1
sa(dp6830
g7
I141
sg17
VC0153676
p6831
sg10
I15
sg11
Vlung metastases
p6832
sg13
I2
sasa(dp6833
g2
S'Successful detection and delineation of pulmonary micrometastatic lesions as small as 200 mym, corroborated by histology, immunohistochemistry, and bioluminescence imaging confirmed the suitability of both TF as a target and AlfaTF-SERRS-NPs as an effective contrast agent for imaging breast cancer lung metastases.\n'
p6834
sg4
(lp6835
(dp6836
g7
I238
sg8
VP0C0P6
p6837
sg10
I3
sg11
VNPs
p6838
sg13
I1
sa(dp6839
g7
I232
sg8
VP49591
p6840
sg10
I5
sg11
VSERRS
p6841
sg13
I1
sasg14
(lp6842
(dp6843
g7
I238
sg17
VC0027341
p6844
sg10
I3
sg11
VNPs
p6845
sg13
I1
sa(dp6846
g7
I285
sg17
VC0678222
p6847
sg10
I13
sg11
Vbreast cancer
p6848
sg13
I2
sa(dp6849
g7
I299
sg17
VC0153676
p6850
sg10
I15
sg11
Vlung metastases
p6851
sg13
I2
sasa(dp6852
g2
S'Six process and intermediate outcome indicators, representing screening for breast and colorectal cancer and care for patients with diabetes and cardiovascular disease, were selected and analyzed for change over time (2003-2009) in overall performance, as well as the difference between the lowest and the highest socio-economic ranks (SERs) and Arab and non-Arab members.\n'
p6853
sg4
(lp6854
sg14
(lp6855
(dp6856
g7
I132
sg17
VC0011849
p6857
sg10
I8
sg11
Vdiabetes
p6858
sg13
I1
sa(dp6859
g7
I87
sg17
VC1527249
p6860
sg10
I17
sg11
Vcolorectal cancer
p6861
sg13
I2
sa(dp6862
g7
I145
sg17
VC0007222
p6863
sg10
I22
sg11
Vcardiovascular disease
p6864
sg13
I2
sasa(dp6865
g2
S'Here we explored the ability of integrin-targeted surface-enhanced resonance Raman spectroscopy (SERRS) nanoparticles to depict the true tumor extent in a GBM mouse model that closely mimics the pathology in humans.\n'
p6866
sg4
(lp6867
sg14
(lp6868
(dp6869
g7
I195
sg17
VC0677042
p6870
sg10
I9
sg11
Vpathology
p6871
sg13
I1
sa(dp6872
g7
I155
sg17
VC0017636
p6873
sg10
I3
sg11
VGBM
p6874
sg13
I1
sa(dp6875
g7
I137
sg17
VC0027651
p6876
sg10
I5
sg11
Vtumor
p6877
sg13
I1
sasa(dp6878
g2
S'The oxytocin receptor (OXTR) is a key regulator of stress and anxiety and may be regulated by both psychosocial risk factors and gonadal hormones, making it an attractive candidate for study in postpartum depression (PPD).\n'
p6879
sg4
(lp6880
(dp6881
g7
I4
sg8
VP30559
p6882
sg10
I17
sg11
Voxytocin receptor
p6883
sg13
I2
sa(dp6884
g7
I23
sg8
VP30559
p6885
sg10
I4
sg11
VOXTR
p6886
sg13
I1
sasg14
(lp6887
(dp6888
g7
I217
sg17
VC0432215
p6889
sg10
I3
sg11
VPPD
p6890
sg13
I1
sa(dp6891
g7
I194
sg17
VC0221074
p6892
sg10
I21
sg11
Vpostpartum depression
p6893
sg13
I2
sasa(dp6894
g2
S"Maternal history of major depressive disorder during children's lives was associated with children's sensitivity in detecting emotional faces among children homozygous for the OXTR rs53576 G allele, but not among carriers of the A allele.\n"
p6895
sg4
(lp6896
(dp6897
g7
I176
sg8
VP30559
p6898
sg10
I21
sg11
VOXTR rs53576 G allele
p6899
sg13
I4
sasg14
(lp6900
(dp6901
g7
I20
sg17
VC1269683
p6902
sg10
I25
sg11
Vmajor depressive disorder
p6903
sg13
I3
sasa(dp6904
g2
S'In sum, HPS2 is the result of the absence of the entire AP-3 complex, which results in severe neutropenia with a defect in granule formation as the major hematological finding.\n'
p6905
sg4
(lp6906
(dp6907
g7
I8
sg8
VP04155
p6908
sg10
I4
sg11
VHPS2
p6909
sg13
I1
sa(dp6910
g7
I56
sg8
g49
sg10
I12
sg11
VAP-3 complex
p6911
sg13
I2
sasg14
(lp6912
(dp6913
g7
I8
sg17
VC1842362
p6914
sg10
I4
sg11
VHPS2
p6915
sg13
I1
sasa(dp6916
g2
S'Syndromic variants of congenital neutropenia may be due to mutations in genes controlling glucose metabolism (SLC37A4, G6PC3) or lysosomal function (LYST, RAB27A, ROBLD3/p14, AP3B1, VPS13B).\n'
p6917
sg4
(lp6918
(dp6919
g7
I163
sg8
g49
sg10
I6
sg11
VROBLD3
p6920
sg13
I1
sa(dp6921
g7
I110
sg8
g49
sg10
I7
sg11
VSLC37A4
p6922
sg13
I1
sa(dp6923
g7
I129
sg8
g49
sg10
I18
sg11
Vlysosomal function
p6924
sg13
I2
sa(dp6925
g7
I149
sg8
g49
sg10
I4
sg11
VLYST
p6926
sg13
I1
sa(dp6927
g7
I175
sg8
g49
sg10
I5
sg11
VAP3B1
p6928
sg13
I1
sa(dp6929
g7
I119
sg8
g49
sg10
I5
sg11
VG6PC3
p6930
sg13
I1
sa(dp6931
g7
I170
sg8
VP03971
p6932
sg10
I3
sg11
Vp14
p6933
sg13
I1
sa(dp6934
g7
I155
sg8
VP51159
p6935
sg10
I6
sg11
VRAB27A
p6936
sg13
I1
sasg14
(lp6937
(dp6938
g7
I22
sg17
VC0340970
p6939
sg10
I22
sg11
Vcongenital neutropenia
p6940
sg13
I2
sasa(dp6941
g2
S'We now report 2 unrelated subjects with HPS2 who show a characteristic clinical phenotype of oculocutaneous albinism, platelet and T-lymphocyte dysfunction and neutropenia.\n'
p6942
sg4
(lp6943
(dp6944
g7
I40
sg8
VP04155
p6945
sg10
I4
sg11
VHPS2
p6946
sg13
I1
sasg14
(lp6947
(dp6948
g7
I93
sg17
VC0078918
p6949
sg10
I23
sg11
Voculocutaneous albinism
p6950
sg13
I2
sa(dp6951
g7
I40
sg17
VC1842362
p6952
sg10
I4
sg11
VHPS2
p6953
sg13
I1
sasa(dp6954
g2
S'A canine form of cyclic neutropenia corresponds to human Hermansky-Pudlak syndrome type 2 (HPS2) and results from mutations in AP3B1 encoding a subunit of a complex involved in the subcellular trafficking of vesicular cargo proteins (among which NE appears to be one).\n'
p6955
sg4
(lp6956
(dp6957
g7
I127
sg8
g49
sg10
I5
sg11
VAP3B1
p6958
sg13
I1
sa(dp6959
g7
I91
sg8
VP04155
p6960
sg10
I4
sg11
VHPS2
p6961
sg13
I1
sa(dp6962
g7
I51
sg8
g49
sg10
I38
sg11
Vhuman Hermansky-Pudlak syndrome type 2
p6963
sg13
I5
sasg14
(lp6964
(dp6965
g7
I17
sg17
VC0221023
p6966
sg10
I18
sg11
Vcyclic neutropenia
p6967
sg13
I2
sa(dp6968
g7
I91
sg17
VC1842362
p6969
sg10
I4
sg11
VHPS2
p6970
sg13
I1
sa(dp6971
g7
I57
sg17
VC1842362
p6972
sg10
I32
sg11
VHermansky-Pudlak syndrome type 2
p6973
sg13
I4
sasa(dp6974
g2
S'To clarify the functions of S. cerevisiae Sgs1 and to get an insight into the functions of Blm, Wrn and Rts, in this study, we analyzed the phenotype of sgs1 disruptant and in detail the cause of the poor sporulation phenotype of sgs1 disruptants in relation to meiotic processes including meiotic recombination.\n'
p6975
sg4
(lp6976
(dp6977
g7
I96
sg8
VP02545
p6978
sg10
I3
sg11
VWrn
p6979
sg13
I1
sa(dp6980
g7
I104
sg8
VP04000
p6981
sg10
I3
sg11
VRts
p6982
sg13
I1
sa(dp6983
g7
I91
sg8
VP54132
p6984
sg10
I3
sg11
VBlm
p6985
sg13
I1
sa(dp6986
g7
I28
sg8
VP61009
p6987
sg10
I18
sg11
VS. cerevisiae Sgs1
p6988
sg13
I3
sasg14
(lp6989
(dp6990
g7
I96
sg17
VC0043119
p6991
sg10
I3
sg11
VWrn
p6992
sg13
I1
sa(dp6993
g7
I104
sg17
VC0035372
p6994
sg10
I3
sg11
VRts
p6995
sg13
I1
sa(dp6996
g7
I91
sg17
VC0005859
p6997
sg10
I3
sg11
VBlm
p6998
sg13
I1
sasa(dp6999
g2
S"In this study, using colon cancer as an example, we provide both in vitro (cell culture) and in vivo (chemically induced mouse model of colon cancer) evidence that this profound antineoplastic action may be associated with aspirin's ability to irreversibly inhibit COX-1-mediated platelet activation, thereby blocking platelet-cancer cell interactions, which promote cancer cell number and invasive potential.\n"
p7000
sg4
(lp7001
(dp7002
g7
I265
sg8
VP00395
p7003
sg10
I5
sg11
VCOX-1
p7004
sg13
I1
sasg14
(lp7005
(dp7006
g7
I27
sg17
VC0006826
p7007
sg10
I6
sg11
Vcancer
p7008
sg13
I1
sa(dp7009
g7
I102
sg17
VC0007994
p7010
sg10
I18
sg11
Vchemically induced
p7011
sg13
I2
sa(dp7012
g7
I21
sg17
VC0699790
p7013
sg10
I12
sg11
Vcolon cancer
p7014
sg13
I2
sa(dp7015
g7
I309
sg17
VC0233660
p7016
sg10
I8
sg11
Vblocking
p7017
sg13
I1
sa(dp7018
g7
I27
sg17
VC0006826
p7019
sg10
I6
sg11
Vcancer
p7020
sg13
I1
sa(dp7021
g7
I21
sg17
VC0699790
p7022
sg10
I12
sg11
Vcolon cancer
p7023
sg13
I2
sasa(dp7024
g2
S'Data clearly showed that COX-1 was required for maintenance of malignant characteristics of colon cancer cells or tumor promoter-induced transformation of preneoplastic cells.\n'
p7025
sg4
(lp7026
(dp7027
g7
I25
sg8
VP00395
p7028
sg10
I5
sg11
VCOX-1
p7029
sg13
I1
sasg14
(lp7030
(dp7031
g7
I137
sg17
VC1510411
p7032
sg10
I14
sg11
Vtransformation
p7033
sg13
I1
sa(dp7034
g7
I114
sg17
VC0027651
p7035
sg10
I5
sg11
Vtumor
p7036
sg13
I1
sa(dp7037
g7
I92
sg17
VC0699790
p7038
sg10
I12
sg11
Vcolon cancer
p7039
sg13
I2
sasa(dp7040
g2
S'We genotyped candidate polymorphisms and tag SNPs in PTGS1 (COX-1) and PTGS2 (COX-2) in a population-based case-control study (Diet, Activity and Lifestyle Study, DALS) of colon cancer (n = 1,470 cases/1,837 controls) and rectal cancer (n = 583/775), and independently among cases and controls from the Colon Cancer Family Registry (CCFR; colon n = 959/1,535, rectal n = 505/839).\n'
p7041
sg4
(lp7042
(dp7043
g7
I78
sg8
VP35354
p7044
sg10
I5
sg11
VCOX-2
p7045
sg13
I1
sa(dp7046
g7
I53
sg8
VP23219
p7047
sg10
I5
sg11
VPTGS1
p7048
sg13
I1
sa(dp7049
g7
I71
sg8
VP35354
p7050
sg10
I5
sg11
VPTGS2
p7051
sg13
I1
sa(dp7052
g7
I60
sg8
VP00395
p7053
sg10
I5
sg11
VCOX-1
p7054
sg13
I1
sa(dp7055
g7
I41
sg8
g49
sg10
I8
sg11
Vtag SNPs
p7056
sg13
I2
sasg14
(lp7057
(dp7058
g7
I303
sg17
VC0699790
p7059
sg10
I12
sg11
VColon Cancer
p7060
sg13
I2
sa(dp7061
g7
I222
sg17
VC0007113
p7062
sg10
I13
sg11
Vrectal cancer
p7063
sg13
I2
sa(dp7064
g7
I172
sg17
VC0699790
p7065
sg10
I12
sg11
Vcolon cancer
p7066
sg13
I2
sa(dp7067
g7
I41
sg17
VC0037293
p7068
sg10
I3
sg11
Vtag
p7069
sg13
I1
sasa(dp7070
g2
S'Genotype-NSAID interactions were observed in the DALS for PTGS1 and rectal cancer risk and for PTGS2 and colon cancer risk, but were no longer significant after correcting for multiple comparisons and did not replicate in the CCFR.\n'
p7071
sg4
(lp7072
(dp7073
g7
I58
sg8
VP23219
p7074
sg10
I5
sg11
VPTGS1
p7075
sg13
I1
sa(dp7076
g7
I95
sg8
VP35354
p7077
sg10
I5
sg11
VPTGS2
p7078
sg13
I1
sasg14
(lp7079
(dp7080
g7
I105
sg17
VC0699790
p7081
sg10
I12
sg11
Vcolon cancer
p7082
sg13
I2
sa(dp7083
g7
I68
sg17
VC0007113
p7084
sg10
I13
sg11
Vrectal cancer
p7085
sg13
I2
sasa(dp7086
g2
S'We observed interactions and statistically significant increases in colon cancer risk for low docosahexaenoic acid intake among those with the PTGS1 rs10306110 (-1,053 A &gt; G) variant genotypes (OR = 1.6, 95 % confidence interval = 1.1-2.3, adj.\n'
p7087
sg4
(lp7088
sg14
(lp7089
(dp7090
g7
I68
sg17
VC0699790
p7091
sg10
I12
sg11
Vcolon cancer
p7092
sg13
I2
sasa(dp7093
g2
S'Analogous with cystic fibrosis CFTR p.Phe508del, screening for RSPH9 p.Lys268del (which lacks sentinel dextrocardia) in those at risk would help in early diagnosis, tailored clinical management, genetic counselling and primary prevention.\n'
p7094
sg4
(lp7095
(dp7096
g7
I63
sg8
g49
sg10
I7
sg11
VRSPH9 p
p7097
sg13
I2
sasg14
(lp7098
(dp7099
g7
I15
sg17
VC0010674
p7100
sg10
I15
sg11
Vcystic fibrosis
p7101
sg13
I2
sa(dp7102
g7
I103
sg17
VC0011813
p7103
sg10
I12
sg11
Vdextrocardia
p7104
sg13
I1
sasa(dp7105
g2
S'The HSPC069/HYPB gene was originally isolated from the human hematopoietic stem/progenitor cells (HSPCs), and it was also identified as a huntingtin interacting protein, implicated in the pathogenesis of Huntington disease (HD).\n'
p7106
sg4
(lp7107
(dp7108
g7
I138
sg8
VP42858
p7109
sg10
I30
sg11
Vhuntingtin interacting protein
p7110
sg13
I3
sasg14
(lp7111
(dp7112
g7
I224
sg17
VC0020179
p7113
sg10
I2
sg11
VHD
p7114
sg13
I1
sa(dp7115
g7
I204
sg17
VC0020179
p7116
sg10
I18
sg11
VHuntington disease
p7117
sg13
I2
sa(dp7118
g7
I188
sg17
VC0699748
p7119
sg10
I12
sg11
Vpathogenesis
p7120
sg13
I1
sasa(dp7121
g2
S'We also found that the nucleus PLAC2 bind with STAT1 and interact with RPL36 promoters but the cytoplasmic lncRNA PLAC2 inhibited STAT1 nuclear transfer, thereby decreasing RP36 expression, inhibiting cell proliferation and inducing cell cycle arrest.\n'
p7122
sg4
(lp7123
(dp7124
g7
I71
sg8
g49
sg10
I15
sg11
VRPL36 promoters
p7125
sg13
I2
sa(dp7126
g7
I173
sg8
g49
sg10
I4
sg11
VRP36
p7127
sg13
I1
sa(dp7128
g7
I47
sg8
VP42224
p7129
sg10
I5
sg11
VSTAT1
p7130
sg13
I1
sa(dp7131
g7
I31
sg8
g49
sg10
I5
sg11
VPLAC2
p7132
sg13
I1
sa(dp7133
g7
I95
sg8
g49
sg10
I24
sg11
Vcytoplasmic lncRNA PLAC2
p7134
sg13
I3
sa(dp7135
g7
I47
sg8
VP42224
p7136
sg10
I5
sg11
VSTAT1
p7137
sg13
I1
sasg14
(lp7138
(dp7139
g7
I173
sg17
VC1864621
p7140
sg10
I4
sg11
VRP36
p7141
sg13
I1
sa(dp7142
g7
I206
sg17
VC0334094
p7143
sg10
I13
sg11
Vproliferation
p7144
sg13
I1
sasa(dp7145
g2
S'Real-time RT-PCR results showed that the overall direction of differential expression was consistent except COL17A1.CXCL8 interacted with STAT1, CCL27, and IGF1R targeted by hsa-miR-375, and COL17A1 targeted by RP11-361L15.4 might function in the development and progression of melanoma, which should be verified by more detailed experiments.\n'
p7146
sg4
(lp7147
(dp7148
g7
I108
sg8
g49
sg10
I7
sg11
VCOL17A1
p7149
sg13
I1
sa(dp7150
g7
I174
sg8
g49
sg10
I7
sg11
Vhsa-miR
p7151
sg13
I1
sa(dp7152
g7
I156
sg8
VP08069
p7153
sg10
I5
sg11
VIGF1R
p7154
sg13
I1
sa(dp7155
g7
I108
sg8
g49
sg10
I7
sg11
VCOL17A1
p7156
sg13
I1
sa(dp7157
g7
I138
sg8
VP42224
p7158
sg10
I5
sg11
VSTAT1
p7159
sg13
I1
sa(dp7160
g7
I211
sg8
g49
sg10
I13
sg11
VRP11-361L15.4
p7161
sg13
I1
sa(dp7162
g7
I145
sg8
g49
sg10
I5
sg11
VCCL27
p7163
sg13
I1
sasg14
(lp7164
(dp7165
g7
I211
sg17
VC1838601
p7166
sg10
I4
sg11
VRP11
p7167
sg13
I1
sa(dp7168
g7
I174
sg17
VC0393754
p7169
sg10
I3
sg11
Vhsa
p7170
sg13
I1
sa(dp7171
g7
I278
sg17
VC0025202
p7172
sg10
I8
sg11
Vmelanoma
p7173
sg13
I1
sasa(dp7174
g2
S'We found that unconjugated lithocholic acid (LCA) impedes Th1 activation as measured by i) decreased production of the Th1 cytokines IFNGamma and TNFAlfaAlfa, ii) decreased expression of the Th1 genes T-box protein expressed in T cells (T-bet), Stat-1 and Stat4, and iii) decreased STAT1Alfa/Beta phosphorylation.\n'
p7175
sg4
(lp7176
(dp7177
g7
I119
sg8
VP01374
p7178
sg10
I13
sg11
VTh1 cytokines
p7179
sg13
I2
sa(dp7180
g7
I245
sg8
g49
sg10
I6
sg11
VStat-1
p7181
sg13
I1
sa(dp7182
g7
I256
sg8
g49
sg10
I5
sg11
VStat4
p7183
sg13
I1
sa(dp7184
g7
I191
sg8
VP01893
p7185
sg10
I23
sg11
VTh1 genes T-box protein
p7186
sg13
I4
sasg14
(lp7187
(dp7188
g7
I27
sg17
VC0339527
p7189
sg10
I16
sg11
Vlithocholic acid
p7190
sg13
I2
sa(dp7191
g7
I45
sg17
VC0339527
p7192
sg10
I3
sg11
VLCA
p7193
sg13
I1
sasa(dp7194
g2
S'Once internalized into pancreatic cancer cells, the elevated lysosomal cathepsin B could further promote the release of GEM.\n'
p7195
sg4
(lp7196
(dp7197
g7
I61
sg8
VP07858
p7198
sg10
I21
sg11
Vlysosomal cathepsin B
p7199
sg13
I3
sasg14
(lp7200
(dp7201
g7
I23
sg17
VC0235974
p7202
sg10
I17
sg11
Vpancreatic cancer
p7203
sg13
I2
sasa(dp7204
g2
S'These micelles afforded protection to gemcitabine from plasma metabolism as evident by negligible amount of gemcitabine and its metabolite dFdU detected in the plasma after 24 h. A controlled release of gemcitabine from the micelles was observed with 53.89% drug release in 10 days in the presence of protease enzyme Cathepsin B. Gemcitabine conjugated micelles were cytotoxic, showed internalization, and induced cell apoptosis in MIA PaCa-2 and L3.6pl pancreatic cancer cell lines.\n'
p7205
sg4
(lp7206
(dp7207
g7
I432
sg8
g49
sg10
I21
sg11
VMIA PaCa-2 and L3.6pl
p7208
sg13
I4
sa(dp7209
g7
I301
sg8
VP07858
p7210
sg10
I27
sg11
Vprotease enzyme Cathepsin B
p7211
sg13
I4
sasg14
(lp7212
(dp7213
g7
I454
sg17
VC0235974
p7214
sg10
I17
sg11
Vpancreatic cancer
p7215
sg13
I2
sa(dp7216
g7
I436
sg17
VC1836780
p7217
sg10
I4
sg11
VPaCa
p7218
sg13
I1
sasa(dp7219
g2
S'Further, our results showed that MUC1-c protects pancreatic cancer cells from cell death by stabilizing lysosomes and preventing release of Cathepsin B in the cytosol.\n'
p7220
sg4
(lp7221
(dp7222
g7
I140
sg8
VP07858
p7223
sg10
I11
sg11
VCathepsin B
p7224
sg13
I2
sasg14
(lp7225
(dp7226
g7
I49
sg17
VC0235974
p7227
sg10
I17
sg11
Vpancreatic cancer
p7228
sg13
I2
sasa(dp7229
g2
S'To observe the effects of electroacupuncture (EA) on cochlea morphology and expression of aquaporin 1 (AQP1) in guinea pigs with endolymphatic hydrops, so as to explore the possible mechanism of EA on endolymphatic hydrops.\n'
p7230
sg4
(lp7231
(dp7232
g7
I90
sg8
VP29972
p7233
sg10
I11
sg11
Vaquaporin 1
p7234
sg13
I2
sa(dp7235
g7
I103
sg8
VP29972
p7236
sg10
I4
sg11
VAQP1
p7237
sg13
I1
sasg14
(lp7238
(dp7239
g7
I129
sg17
VC0206586
p7240
sg10
I21
sg11
Vendolymphatic hydrops
p7241
sg13
I2
sa(dp7242
g7
I129
sg17
VC0206586
p7243
sg10
I21
sg11
Vendolymphatic hydrops
p7244
sg13
I2
sasa(dp7245
g2
S'EA could relieve the endolymphatic hydrops in guinea pigs; the mechanism is likely to be related with up-regulating the expression of AQP1 in cochlea and ion concentration might be an important factor involved.\n'
p7246
sg4
(lp7247
(dp7248
g7
I134
sg8
VP29972
p7249
sg10
I4
sg11
VAQP1
p7250
sg13
I1
sasg14
(lp7251
(dp7252
g7
I21
sg17
VC0206586
p7253
sg10
I21
sg11
Vendolymphatic hydrops
p7254
sg13
I2
sasa(dp7255
g2
S'The aim of this study was to explore the pathological changes in water homeostasis and the effects of glucocorticoids on aquaporin-1 (AQP1) in guinea pigs with otitis media with effusion (OME).\n'
p7256
sg4
(lp7257
(dp7258
g7
I121
sg8
VP29972
p7259
sg10
I11
sg11
Vaquaporin-1
p7260
sg13
I1
sa(dp7261
g7
I134
sg8
VP29972
p7262
sg10
I4
sg11
VAQP1
p7263
sg13
I1
sasg14
(lp7264
(dp7265
g7
I160
sg17
VC0029883
p7266
sg10
I26
sg11
Votitis media with effusion
p7267
sg13
I4
sa(dp7268
g7
I188
sg17
VC0029883
p7269
sg10
I3
sg11
VOME
p7270
sg13
I1
sasa(dp7271
g2
S"mRNA was extracted from the surgically acquired utricles from subjects with Meniere's disease and acoustic neuroma to conduct quantitative real-time reverse transcription with polymerase chain reaction for AQP1, AQP4, and AQP6.\n"
p7272
sg4
(lp7273
(dp7274
g7
I212
sg8
VP55087
p7275
sg10
I4
sg11
VAQP4
p7276
sg13
I1
sa(dp7277
g7
I206
sg8
VP29972
p7278
sg10
I4
sg11
VAQP1
p7279
sg13
I1
sa(dp7280
g7
I222
sg8
g49
sg10
I4
sg11
VAQP6
p7281
sg13
I1
sasg14
(lp7282
(dp7283
g7
I76
sg17
VC0025281
p7284
sg10
I17
sg11
VMeniere's disease
p7285
sg13
I2
sa(dp7286
g7
I98
sg17
VC0027859
p7287
sg10
I16
sg11
Vacoustic neuroma
p7288
sg13
I2
sasa(dp7289
g2
S"Expression of AQP1, AQP4, or AQP6 mRNA did not differ in vestibular endorgans from patients with Meniere's disease.\n"
p7290
sg4
(lp7291
(dp7292
g7
I14
sg8
VP29972
p7293
sg10
I4
sg11
VAQP1
p7294
sg13
I1
sa(dp7295
g7
I29
sg8
g49
sg10
I9
sg11
VAQP6 mRNA
p7296
sg13
I2
sa(dp7297
g7
I20
sg8
VP55087
p7298
sg10
I4
sg11
VAQP4
p7299
sg13
I1
sasg14
(lp7300
(dp7301
g7
I97
sg17
VC0025281
p7302
sg10
I17
sg11
VMeniere's disease
p7303
sg13
I2
sasa(dp7304
g2
S'To explore the pathological change of water homeostasis in the secretory otitis media (SOM) middle ear, we observed the expression and regulation of aquaporin 1 (AQP1) in the SOM middle ear cavity.\n'
p7305
sg4
(lp7306
(dp7307
g7
I149
sg8
VP29972
p7308
sg10
I11
sg11
Vaquaporin 1
p7309
sg13
I2
sa(dp7310
g7
I162
sg8
VP29972
p7311
sg10
I4
sg11
VAQP1
p7312
sg13
I1
sasg14
(lp7313
(dp7314
g7
I87
sg17
VC0029883
p7315
sg10
I3
sg11
VSOM
p7316
sg13
I1
sa(dp7317
g7
I87
sg17
VC0029883
p7318
sg10
I3
sg11
VSOM
p7319
sg13
I1
sa(dp7320
g7
I63
sg17
VC0029883
p7321
sg10
I22
sg11
Vsecretory otitis media
p7322
sg13
I3
sa(dp7323
g7
I190
sg17
VC0011334
p7324
sg10
I6
sg11
Vcavity
p7325
sg13
I1
sasa(dp7326
g2
S'Clinical, cytogenetic and molecular features of acute myeloid leukemia with a MLL-SEPT5 fusion gene are reviewed.\n'
p7327
sg4
(lp7328
(dp7329
g7
I82
sg8
g49
sg10
I5
sg11
VSEPT5
p7330
sg13
I1
sa(dp7331
g7
I78
sg8
g49
sg10
I3
sg11
VMLL
p7332
sg13
I1
sasg14
(lp7333
(dp7334
g7
I48
sg17
VC0023467
p7335
sg10
I22
sg11
Vacute myeloid leukemia
p7336
sg13
I3
sasa(dp7337
g2
S'We report on an adult patient with de novo acute myeloid leukemia (AML) with a t(11;22)(q23;q11.2) involving CDCREL1 and MLL genes.\n'
p7338
sg4
(lp7339
(dp7340
g7
I121
sg8
g49
sg10
I9
sg11
VMLL genes
p7341
sg13
I2
sa(dp7342
g7
I109
sg8
g49
sg10
I7
sg11
VCDCREL1
p7343
sg13
I1
sasg14
(lp7344
(dp7345
g7
I67
sg17
VC0023467
p7346
sg10
I3
sg11
VAML
p7347
sg13
I1
sa(dp7348
g7
I43
sg17
VC0023467
p7349
sg10
I22
sg11
Vacute myeloid leukemia
p7350
sg13
I3
sasa(dp7351
g2
S'Fifty-four individuals (17 normal-weight; 18 overweight; 19 individuals with obesity) completed two food-based go/no-go tasks (one with high- and one with low-calorie foods as no-go stimuli), once during ERP data acquisition and once during fMRI data acquisition.\n'
p7352
sg4
(lp7353
sg14
(lp7354
(dp7355
g7
I45
sg17
VC0497406
p7356
sg10
I10
sg11
Voverweight
p7357
sg13
I1
sa(dp7358
g7
I77
sg17
VC0028754
p7359
sg10
I7
sg11
Vobesity
p7360
sg13
I1
sasa(dp7361
g2
S'Interestingly, incubation of BSM cells with asthma-associated cytokines, such as interleukin-13 (IL-13), IL-17, and tumor necrosis factor-Alfa (TNF-Alfa), caused up-regulations of RhoA and CPI-17 in BSM cells of naive animals and cultured human BSM cells.\n'
p7362
sg4
(lp7363
(dp7364
g7
I97
sg8
VP35225
p7365
sg10
I5
sg11
VIL-13
p7366
sg13
I1
sa(dp7367
g7
I189
sg8
g49
sg10
I6
sg11
VCPI-17
p7368
sg13
I1
sa(dp7369
g7
I81
sg8
VP35225
p7370
sg10
I14
sg11
Vinterleukin-13
p7371
sg13
I1
sa(dp7372
g7
I180
sg8
VP61586
p7373
sg10
I4
sg11
VRhoA
p7374
sg13
I1
sa(dp7375
g7
I116
sg8
VP01375
p7376
sg10
I26
sg11
Vtumor necrosis factor-Alfa
p7377
sg13
I3
sa(dp7378
g7
I144
sg8
VP01375
p7379
sg10
I8
sg11
VTNF-Alfa
p7380
sg13
I1
sasg14
(lp7381
(dp7382
g7
I189
sg17
VC0008925
p7383
sg10
I3
sg11
VCPI
p7384
sg13
I1
sa(dp7385
g7
I44
sg17
VC0004096
p7386
sg10
I6
sg11
Vasthma
p7387
sg13
I1
sa(dp7388
g7
I116
sg17
VC0333516
p7389
sg10
I14
sg11
Vtumor necrosis
p7390
sg13
I2
sasa(dp7391
g2
S'Results also revealed an overexpression of CPI-17 protein in lung biopsies derived from patients with asthma.\n'
p7392
sg4
(lp7393
(dp7394
g7
I43
sg8
g49
sg10
I14
sg11
VCPI-17 protein
p7395
sg13
I2
sasg14
(lp7396
(dp7397
g7
I43
sg17
VC0008925
p7398
sg10
I3
sg11
VCPI
p7399
sg13
I1
sa(dp7400
g7
I102
sg17
VC0004096
p7401
sg10
I6
sg11
Vasthma
p7402
sg13
I1
sasa(dp7403
g2
S'Mutations in the ROMK1 potassium channel gene (KCNJ1) cause antenatal/neonatal Bartter syndrome type II (aBS II), a renal disorder that begins in utero, accounting for the polyhydramnios and premature delivery that is typical in affected infants, who develop massive renal salt wasting, hypokalaemic metabolic alkalosis, secondary hyperreninaemic hyperaldosteronism, hypercalciuria and nephrocalcinosis.\n'
p7404
sg4
(lp7405
(dp7406
g7
I47
sg8
VP48048
p7407
sg10
I5
sg11
VKCNJ1
p7408
sg13
I1
sa(dp7409
g7
I17
sg8
VP48048
p7410
sg10
I28
sg11
VROMK1 potassium channel gene
p7411
sg13
I4
sasg14
(lp7412
(dp7413
g7
I116
sg17
VC0022658
p7414
sg10
I14
sg11
Vrenal disorder
p7415
sg13
I2
sa(dp7416
g7
I172
sg17
VC0020224
p7417
sg10
I14
sg11
Vpolyhydramnios
p7418
sg13
I1
sa(dp7419
g7
I347
sg17
VC0020428
p7420
sg10
I18
sg11
Vhyperaldosteronism
p7421
sg13
I1
sa(dp7422
g7
I278
sg17
VC0235394
p7423
sg10
I7
sg11
Vwasting
p7424
sg13
I1
sa(dp7425
g7
I300
sg17
VC0220983
p7426
sg10
I19
sg11
Vmetabolic alkalosis
p7427
sg13
I2
sa(dp7428
g7
I79
sg17
VC0004775
p7429
sg10
I16
sg11
VBartter syndrome
p7430
sg13
I2
sa(dp7431
g7
I191
sg17
VC0151526
p7432
sg10
I18
sg11
Vpremature delivery
p7433
sg13
I2
sa(dp7434
g7
I367
sg17
VC0020438
p7435
sg10
I14
sg11
Vhypercalciuria
p7436
sg13
I1
sa(dp7437
g7
I386
sg17
VC0027709
p7438
sg10
I16
sg11
Vnephrocalcinosis
p7439
sg13
I1
sasa(dp7440
g2
S'The key symptoms, such as polyhydramnios secondary to fetal polyuria, postnatal volume depletion with hypotension, iso- or hyposthenuria, hyperprostaglandinuria and hypercalciuria followed by hypokalemic alkalosis secondary to hyperaldosteronism, are typical features of loop disorders that are restricted to TAL, such as in disorders with NKCC2 and ROMK mutations.\n'
p7441
sg4
(lp7442
(dp7443
g7
I340
sg8
g49
sg10
I5
sg11
VNKCC2
p7444
sg13
I1
sa(dp7445
g7
I350
sg8
VP48048
p7446
sg10
I4
sg11
VROMK
p7447
sg13
I1
sasg14
(lp7448
(dp7449
g7
I60
sg17
VC0032617
p7450
sg10
I8
sg11
Vpolyuria
p7451
sg13
I1
sa(dp7452
g7
I227
sg17
VC0020428
p7453
sg10
I18
sg11
Vhyperaldosteronism
p7454
sg13
I1
sa(dp7455
g7
I165
sg17
VC0020438
p7456
sg10
I14
sg11
Vhypercalciuria
p7457
sg13
I1
sa(dp7458
g7
I192
sg17
VC0085570
p7459
sg10
I21
sg11
Vhypokalemic alkalosis
p7460
sg13
I2
sa(dp7461
g7
I26
sg17
VC0020224
p7462
sg10
I14
sg11
Vpolyhydramnios
p7463
sg13
I1
sasa(dp7464
g2
S'Immunomorphological and biochemical study of the myoglobin in the myocardium of 118 males at the age of from 30 to 55 years who died suddenly from coronary insufficiency, chronic pulmonary-cardiac insufficiency and from alcoholic cardiomyopathy in Magadan and Moscow is described.\n'
p7465
sg4
(lp7466
(dp7467
g7
I49
sg8
VP02144
p7468
sg10
I9
sg11
Vmyoglobin
p7469
sg13
I1
sasg14
(lp7470
(dp7471
g7
I220
sg17
VC0007192
p7472
sg10
I24
sg11
Valcoholic cardiomyopathy
p7473
sg13
I2
sa(dp7474
g7
I147
sg17
VC0542052
p7475
sg10
I22
sg11
Vcoronary insufficiency
p7476
sg13
I2
sa(dp7477
g7
I189
sg17
VC0018801
p7478
sg10
I21
sg11
Vcardiac insufficiency
p7479
sg13
I2
sasa(dp7480
g2
S'Almost two-fold decrease of the myoglobin concentration in the left ventricle without its visible hypertrophy was observed in alcoholic cardiomyopathy, this may serve as a complementary test in the diagnosis of this disease.\n'
p7481
sg4
(lp7482
(dp7483
g7
I32
sg8
VP02144
p7484
sg10
I9
sg11
Vmyoglobin
p7485
sg13
I1
sasg14
(lp7486
(dp7487
g7
I126
sg17
VC0007192
p7488
sg10
I24
sg11
Valcoholic cardiomyopathy
p7489
sg13
I2
sa(dp7490
g7
I98
sg17
VC0020564
p7491
sg10
I11
sg11
Vhypertrophy
p7492
sg13
I1
sasa(dp7493
g2
S'To observe the effect of manual acupuncture intervention on serotonin transporter (5-HTT), 5-HT 1 A receptor (5-HT1AR), norepinephrine (NE) alpha receptor 2 (NEAlfa2R) protein of brain tissues in rats with post-stroke depression (PSD).\n'
p7494
sg4
(lp7495
(dp7496
g7
I206
sg8
g49
sg10
I22
sg11
Vpost-stroke depression
p7497
sg13
I2
sa(dp7498
g7
I83
sg8
VP31645
p7499
sg10
I34
sg11
V5-HTT), 5-HT 1 A receptor (5-HT1AR
p7500
sg13
I6
sa(dp7501
g7
I60
sg8
VP31645
p7502
sg10
I21
sg11
Vserotonin transporter
p7503
sg13
I2
sa(dp7504
g7
I230
sg8
g49
sg10
I3
sg11
VPSD
p7505
sg13
I1
sa(dp7506
g7
I140
sg8
g49
sg10
I16
sg11
Valpha receptor 2
p7507
sg13
I3
sasg14
(lp7508
(dp7509
g7
I218
sg17
VC0011581
p7510
sg10
I10
sg11
Vdepression
p7511
sg13
I1
sa(dp7512
g7
I211
sg17
VC0038454
p7513
sg10
I6
sg11
Vstroke
p7514
sg13
I1
sasa(dp7515
g2
S'Acupuncture can improve the locomotor function changes in stroke rats with depression after stroke, which may be associated with its effects in suppressing the up-regulated cortical ACh, GABA, Glu contents, the expression levels of 5-HT1AR and NEAlfa2R proteins in the hippocampus, raphe nucleus and LC, and the down-regulated 5-HT and NE contents in the cerebral cortex and 5-HTT protein expression levels in the hippocampus, raphe nucleus and LC.\n'
p7516
sg4
(lp7517
(dp7518
g7
I232
sg8
VP02649
p7519
sg10
I29
sg11
V5-HT1AR and NEAlfa2R proteins
p7520
sg13
I4
sa(dp7521
g7
I375
sg8
VP31645
p7522
sg10
I13
sg11
V5-HTT protein
p7523
sg13
I2
sasg14
(lp7524
(dp7525
g7
I58
sg17
VC0038454
p7526
sg10
I6
sg11
Vstroke
p7527
sg13
I1
sa(dp7528
g7
I182
sg17
VC0234238
p7529
sg10
I3
sg11
VACh
p7530
sg13
I1
sa(dp7531
g7
I75
sg17
VC0011581
p7532
sg10
I10
sg11
Vdepression
p7533
sg13
I1
sa(dp7534
g7
I58
sg17
VC0038454
p7535
sg10
I6
sg11
Vstroke
p7536
sg13
I1
sasa(dp7537
g2
S'In contrast to the effect in a transient ischemia model, the pretreatment effect did not depend on the 5HT1A receptor.\n'
p7538
sg4
(lp7539
(dp7540
g7
I103
sg8
VP08908
p7541
sg10
I14
sg11
V5HT1A receptor
p7542
sg13
I2
sasg14
(lp7543
(dp7544
g7
I31
sg17
VC0022118
p7545
sg10
I18
sg11
Vtransient ischemia
p7546
sg13
I2
sasa(dp7547
g2
S'Urapidil (Eupressyl((R))) an antihypertensive drug acting as an Alfa1 antagonist and a 5-HT1A agonist, may be of special interest in the treatment of hypertension associated with preeclamptic toxaemia and hypoxia-induced pulmonary arterial vasoconstriction.\n'
p7548
sg4
(lp7549
sg14
(lp7550
(dp7551
g7
I240
sg17
VC1456863
p7552
sg10
I16
sg11
Vvasoconstriction
p7553
sg13
I1
sa(dp7554
g7
I205
sg17
VC0242184
p7555
sg10
I7
sg11
Vhypoxia
p7556
sg13
I1
sa(dp7557
g7
I192
sg17
VC0040524
p7558
sg10
I8
sg11
Vtoxaemia
p7559
sg13
I1
sa(dp7560
g7
I150
sg17
VC0020538
p7561
sg10
I12
sg11
Vhypertension
p7562
sg13
I1
sasa(dp7563
g2
S'These data suggest that preventing permeability changes at the BBB could represent an as yet unrecognized mechanism of CBD-induced neuroprotection in ischaemic stroke, a mechanism mediated by activation of PPARGamma and 5-HT1A receptors.\n'
p7564
sg4
(lp7565
(dp7566
g7
I220
sg8
VP08908
p7567
sg10
I16
sg11
V5-HT1A receptors
p7568
sg13
I2
sasg14
(lp7569
(dp7570
g7
I150
sg17
VC0948008
p7571
sg10
I16
sg11
Vischaemic stroke
p7572
sg13
I2
sasa(dp7573
g2
S'The hypothermia as well as the suppression of the locomotion and the hypertension could be reversed by the blockade of 5-HT1A receptors with WAY 100635.\n'
p7574
sg4
(lp7575
(dp7576
g7
I119
sg8
VP08908
p7577
sg10
I16
sg11
V5-HT1A receptors
p7578
sg13
I2
sasg14
(lp7579
(dp7580
g7
I69
sg17
VC0020538
p7581
sg10
I12
sg11
Vhypertension
p7582
sg13
I1
sa(dp7583
g7
I31
sg17
VC0221103
p7584
sg10
I11
sg11
Vsuppression
p7585
sg13
I1
sasa(dp7586
g2
S'For NMP22, regardless of the exclusion criteria they were 72 and 34 % and after exclusion of urinary tract infection (UTI) or prior to manipulation 46 and 86 %, respectively.\n'
p7587
sg4
(lp7588
sg14
(lp7589
(dp7590
g7
I118
sg17
VC0042029
p7591
sg10
I3
sg11
VUTI
p7592
sg13
I1
sa(dp7593
g7
I93
sg17
VC0042029
p7594
sg10
I23
sg11
Vurinary tract infection
p7595
sg13
I3
sasa(dp7596
g2
S'There is evidence that nuclear matrix protein 22 (NMP22) is influenced by urinary tract infection and instrumented urinary sampling (IUS).\n'
p7597
sg4
(lp7598
(dp7599
g7
I50
sg8
VP63145
p7600
sg10
I5
sg11
VNMP22
p7601
sg13
I1
sa(dp7602
g7
I23
sg8
VP63145
p7603
sg10
I25
sg11
Vnuclear matrix protein 22
p7604
sg13
I4
sasg14
(lp7605
(dp7606
g7
I74
sg17
VC0042029
p7607
sg10
I23
sg11
Vurinary tract infection
p7608
sg13
I3
sasa(dp7609
g2
S'Further, we evaluated the usefulness of Bladder Chek NMP22 in patients with benign diseases such as cystitis, urolithiasis, and benign prostate hyperplasia (BPH) and examined how blood cells in urine samples affect the results of Bladder Chek NMP22.\n'
p7610
sg4
(lp7611
sg14
(lp7612
(dp7613
g7
I157
sg17
VC0005001
p7614
sg10
I3
sg11
VBPH
p7615
sg13
I1
sa(dp7616
g7
I100
sg17
VC0010692
p7617
sg10
I8
sg11
Vcystitis
p7618
sg13
I1
sa(dp7619
g7
I110
sg17
VC0451641
p7620
sg10
I12
sg11
Vurolithiasis
p7621
sg13
I1
sa(dp7622
g7
I128
sg17
VC0005001
p7623
sg10
I27
sg11
Vbenign prostate hyperplasia
p7624
sg13
I3
sa(dp7625
g7
I185
sg17
VC0854148
p7626
sg10
I14
sg11
Vcells in urine
p7627
sg13
I3
sasa(dp7628
g2
S'In 36 cystitis, 20 urolithiasis, and 19 BPH patients, the positive rates of Bladder Chek NMP22 were 58.3, 25.0 and 5.5%, respectively.\n'
p7629
sg4
(lp7630
sg14
(lp7631
(dp7632
g7
I40
sg17
VC0005001
p7633
sg10
I3
sg11
VBPH
p7634
sg13
I1
sa(dp7635
g7
I6
sg17
VC0010692
p7636
sg10
I8
sg11
Vcystitis
p7637
sg13
I1
sa(dp7638
g7
I19
sg17
VC0451641
p7639
sg10
I12
sg11
Vurolithiasis
p7640
sg13
I1
sasa(dp7641
g2
S'Pristane-induced lupus (PIL) was aggravated in 2 mouse strains with impaired induction of NET formation, i.e., NOX2-deficient (Ncf1-mutated) and peptidyl arginine deiminase 4-deficient (PAD4-deficient) mice, as seen from elevated levels of antinuclear autoantibodies (ANAs) and exacerbated glomerulonephritis.\n'
p7642
sg4
(lp7643
(dp7644
g7
I186
sg8
g49
sg10
I4
sg11
VPAD4
p7645
sg13
I1
sa(dp7646
g7
I111
sg8
VP04839
p7647
sg10
I4
sg11
VNOX2
p7648
sg13
I1
sasg14
(lp7649
(dp7650
g7
I17
sg17
VC0024131
p7651
sg10
I5
sg11
Vlupus
p7652
sg13
I1
sa(dp7653
g7
I68
sg17
VC0684336
p7654
sg10
I8
sg11
Vimpaired
p7655
sg13
I1
sa(dp7656
g7
I290
sg17
VC0017658
p7657
sg10
I18
sg11
Vglomerulonephritis
p7658
sg13
I1
sasa(dp7659
g2
S"Areas covered: We will review animal studies on the biochemical and behavioral roles of DARPP-32 in drug addiction, schizophrenia and Parkinson's disease.\n"
p7660
sg4
(lp7661
(dp7662
g7
I88
sg8
g49
sg10
I8
sg11
VDARPP-32
p7663
sg13
I1
sasg14
(lp7664
(dp7665
g7
I116
sg17
VC0036341
p7666
sg10
I13
sg11
Vschizophrenia
p7667
sg13
I1
sa(dp7668
g7
I134
sg17
VC0030567
p7669
sg10
I19
sg11
VParkinson's disease
p7670
sg13
I2
sa(dp7671
g7
I100
sg17
VC1510472
p7672
sg10
I14
sg11
Vdrug addiction
p7673
sg13
I2
sasa(dp7674
g2
S'High fat diet-induced activation of insulin receptor substrate 1/Forkhead box protein O1 (IRS1/FOXO1), Janus kinase 2 gene/signal transducer and activator of transcription (JAK2/STAT3) and Protein Kinase B/Glycogen synthase kinase 3 beta (AKT/GSK3Beta) pathways in liver was inhibited by actein, a potential mechanism by which hyperinsulinemia, hyperleptindemia and dyslipidemia were attenuated.\n'
p7675
sg4
(lp7676
(dp7677
g7
I173
sg8
g49
sg10
I4
sg11
VJAK2
p7678
sg13
I1
sa(dp7679
g7
I36
sg8
VP35568
p7680
sg10
I52
sg11
Vinsulin receptor substrate 1/Forkhead box protein O1
p7681
sg13
I7
sa(dp7682
g7
I178
sg8
VP40763
p7683
sg10
I5
sg11
VSTAT3
p7684
sg13
I1
sa(dp7685
g7
I239
sg8
g49
sg10
I3
sg11
VAKT
p7686
sg13
I1
sa(dp7687
g7
I123
sg8
VP35555
p7688
sg10
I48
sg11
Vsignal transducer and activator of transcription
p7689
sg13
I6
sa(dp7690
g7
I90
sg8
VP35568
p7691
sg10
I10
sg11
VIRS1/FOXO1
p7692
sg13
I1
sa(dp7693
g7
I206
sg8
VP49841
p7694
sg10
I31
sg11
VGlycogen synthase kinase 3 beta
p7695
sg13
I5
sa(dp7696
g7
I189
sg8
VP31749
p7697
sg10
I16
sg11
VProtein Kinase B
p7698
sg13
I3
sa(dp7699
g7
I103
sg8
g49
sg10
I19
sg11
VJanus kinase 2 gene
p7700
sg13
I4
sasg14
(lp7701
(dp7702
g7
I103
sg17
VC0266700
p7703
sg10
I5
sg11
VJanus
p7704
sg13
I1
sa(dp7705
g7
I327
sg17
VC0020459
p7706
sg10
I16
sg11
Vhyperinsulinemia
p7707
sg13
I1
sa(dp7708
g7
I366
sg17
VC0242339
p7709
sg10
I12
sg11
Vdyslipidemia
p7710
sg13
I1
sasa(dp7711
g2
S'Furthermore, using the stimulus Poly(I: C), ODN2006, R848, and lipopolysaccharide (LPS) as well as the viral pathogens DTMUV, H9N2 avian influenza virus (AIV), and gosling plague virus (GPV) to treat goose peripheral blood mononuclear cells (PBMCs) for 6 h, goOASL transcripts level was significantly upregulated in all treated groups.\n'
p7712
sg4
(lp7713
sg14
(lp7714
(dp7715
g7
I131
sg17
VC0016627
p7716
sg10
I15
sg11
Vavian influenza
p7717
sg13
I2
sa(dp7718
g7
I83
sg17
VC0175697
p7719
sg10
I3
sg11
VLPS
p7720
sg13
I1
sa(dp7721
g7
I172
sg17
VC0032064
p7722
sg10
I6
sg11
Vplague
p7723
sg13
I1
sa(dp7724
g7
I63
sg17
VC0175697
p7725
sg10
I18
sg11
Vlipopolysaccharide
p7726
sg13
I1
sasa(dp7727
g2
S"Among them, the gene encoding 2'-5' oligoadenylate synthetase-like (OASL) underwent the greatest upregulation and was also shown to be upregulated in M. leprae-infected human macrophage cell lineages, primary monocytes, and skin lesion specimens from patients with a disseminated form of leprosy.\n"
p7728
sg4
(lp7729
(dp7730
g7
I16
sg8
g49
sg10
I50
sg11
Vgene encoding 2'-5' oligoadenylate synthetase-like
p7731
sg13
I5
sa(dp7732
g7
I68
sg8
g49
sg10
I4
sg11
VOASL
p7733
sg13
I1
sasg14
(lp7734
(dp7735
g7
I224
sg17
VC0037284
p7736
sg10
I11
sg11
Vskin lesion
p7737
sg13
I2
sa(dp7738
g7
I288
sg17
VC0023343
p7739
sg10
I7
sg11
Vleprosy
p7740
sg13
I1
sasa(dp7741
g2
S'In addition, transduced DCs inhibited CD8+ T response to ChgA stimulation, and ameliorated the severity of diabetes.\n'
p7742
sg4
(lp7743
(dp7744
g7
I57
sg8
VP10645
p7745
sg10
I4
sg11
VChgA
p7746
sg13
I1
sa(dp7747
g7
I38
sg8
VP01732
p7748
sg10
I4
sg11
VCD8+
p7749
sg13
I1
sasg14
(lp7750
(dp7751
g7
I107
sg17
VC0011849
p7752
sg10
I8
sg11
Vdiabetes
p7753
sg13
I1
sa(dp7754
g7
I24
sg17
VC0268238
p7755
sg10
I3
sg11
VDCs
p7756
sg13
I1
sasa(dp7757
g2
S'To compare blood pressure readings obtained with two commonly used oscillometric monitors: Omron HEM 711 AC (OM) and Welch-Allyn 52000 series NIBP/oximeter (WA) with mercury sphygmomanometers (Merc) in subjects with atrial fibrillation.\n'
p7758
sg4
(lp7759
(dp7760
g7
I109
sg8
VP0CE72
p7761
sg10
I2
sg11
VOM
p7762
sg13
I1
sa(dp7763
g7
I91
sg8
g49
sg10
I16
sg11
VOmron HEM 711 AC
p7764
sg13
I4
sasg14
(lp7765
(dp7766
g7
I216
sg17
VC0004238
p7767
sg10
I19
sg11
Vatrial fibrillation
p7768
sg13
I2
sasa(dp7769
g2
S'Dysregulation of orexin signaling may contribute to behavioral problems and hyperphagia seen in PWS and we sought to assess orexin A levels in PWS relative to controls children.\n'
p7770
sg4
(lp7771
(dp7772
g7
I124
sg8
g49
sg10
I8
sg11
Vorexin A
p7773
sg13
I2
sa(dp7774
g7
I17
sg8
g49
sg10
I6
sg11
Vorexin
p7775
sg13
I1
sasg14
(lp7776
(dp7777
g7
I76
sg17
VC0020505
p7778
sg10
I11
sg11
Vhyperphagia
p7779
sg13
I1
sa(dp7780
g7
I96
sg17
VC0032897
p7781
sg10
I3
sg11
VPWS
p7782
sg13
I1
sa(dp7783
g7
I52
sg17
VC0260653
p7784
sg10
I19
sg11
Vbehavioral problems
p7785
sg13
I2
sa(dp7786
g7
I96
sg17
VC0032897
p7787
sg10
I3
sg11
VPWS
p7788
sg13
I1
sasa(dp7789
g2
S'Morning fasting plasma orexin A levels were analyzed in 23 children (aged 5-11 years) with genetically confirmed PWS and 18 age and gender matched healthy unrelated siblings without PWS.\n'
p7790
sg4
(lp7791
(dp7792
g7
I16
sg8
g49
sg10
I15
sg11
Vplasma orexin A
p7793
sg13
I3
sasg14
(lp7794
(dp7795
g7
I113
sg17
VC0032897
p7796
sg10
I3
sg11
VPWS
p7797
sg13
I1
sa(dp7798
g7
I113
sg17
VC0032897
p7799
sg10
I3
sg11
VPWS
p7800
sg13
I1
sasa(dp7801
g2
S'Plasma orexin A levels were significantly higher (P &lt; 0.006) in children with PWS (average +/-SD = 1,028 pg/ml +/- 358) compared with unrelated siblings (average +/-SD = 609 pg/ml +/- 351; P &lt; 0.001).\n'
p7802
sg4
(lp7803
(dp7804
g7
I0
sg8
g49
sg10
I15
sg11
VPlasma orexin A
p7805
sg13
I3
sasg14
(lp7806
(dp7807
g7
I81
sg17
VC0032897
p7808
sg10
I3
sg11
VPWS
p7809
sg13
I1
sasa(dp7810
g2
S'Orexin A levels correlated with age in females and were significantly elevated in PWS even after these effects were controlled.\n'
p7811
sg4
(lp7812
(dp7813
g7
I0
sg8
g49
sg10
I8
sg11
VOrexin A
p7814
sg13
I2
sasg14
(lp7815
(dp7816
g7
I82
sg17
VC0032897
p7817
sg10
I3
sg11
VPWS
p7818
sg13
I1
sasa(dp7819
g2
S'These findings support the hypothesis that dysregulation of orexin signaling may contribute to behavioral problems and hyperphagia in PWS.\n'
p7820
sg4
(lp7821
(dp7822
g7
I60
sg8
g49
sg10
I6
sg11
Vorexin
p7823
sg13
I1
sasg14
(lp7824
(dp7825
g7
I119
sg17
VC0020505
p7826
sg10
I11
sg11
Vhyperphagia
p7827
sg13
I1
sa(dp7828
g7
I95
sg17
VC0260653
p7829
sg10
I19
sg11
Vbehavioral problems
p7830
sg13
I2
sa(dp7831
g7
I134
sg17
VC0032897
p7832
sg10
I3
sg11
VPWS
p7833
sg13
I1
sasa(dp7834
g2
S'Further studies are warranted to better understand the complex relationship between orexin A levels and the problematic behaviors consistently found in individuals with PWS.\n'
p7835
sg4
(lp7836
(dp7837
g7
I84
sg8
g49
sg10
I8
sg11
Vorexin A
p7838
sg13
I2
sasg14
(lp7839
(dp7840
g7
I169
sg17
VC0032897
p7841
sg10
I3
sg11
VPWS
p7842
sg13
I1
sasa(dp7843
g2
S'Dysregulation of orexin signaling may contribute to behavioral problems and hyperphagia seen in PWS and we sought to assess orexin A levels in PWS relative to controls children.\n'
p7844
sg4
(lp7845
(dp7846
g7
I124
sg8
g49
sg10
I8
sg11
Vorexin A
p7847
sg13
I2
sa(dp7848
g7
I17
sg8
g49
sg10
I6
sg11
Vorexin
p7849
sg13
I1
sasg14
(lp7850
(dp7851
g7
I76
sg17
VC0020505
p7852
sg10
I11
sg11
Vhyperphagia
p7853
sg13
I1
sa(dp7854
g7
I96
sg17
VC0032897
p7855
sg10
I3
sg11
VPWS
p7856
sg13
I1
sa(dp7857
g7
I52
sg17
VC0260653
p7858
sg10
I19
sg11
Vbehavioral problems
p7859
sg13
I2
sa(dp7860
g7
I96
sg17
VC0032897
p7861
sg10
I3
sg11
VPWS
p7862
sg13
I1
sasa(dp7863
g2
S'Morning fasting plasma orexin A levels were analyzed in 23 children (aged 5-11 years) with genetically confirmed PWS and 18 age and gender matched healthy unrelated siblings without PWS.\n'
p7864
sg4
(lp7865
(dp7866
g7
I16
sg8
g49
sg10
I15
sg11
Vplasma orexin A
p7867
sg13
I3
sasg14
(lp7868
(dp7869
g7
I113
sg17
VC0032897
p7870
sg10
I3
sg11
VPWS
p7871
sg13
I1
sa(dp7872
g7
I113
sg17
VC0032897
p7873
sg10
I3
sg11
VPWS
p7874
sg13
I1
sasa(dp7875
g2
S'Plasma orexin A levels were significantly higher (P &lt; 0.006) in children with PWS (average +/-SD = 1028 pg/ml +/- 358) compared with unrelated siblings (average +/-SD = 609 pg/ml +/- 351; P &lt; 0.001).\n'
p7876
sg4
(lp7877
(dp7878
g7
I0
sg8
g49
sg10
I15
sg11
VPlasma orexin A
p7879
sg13
I3
sasg14
(lp7880
(dp7881
g7
I81
sg17
VC0032897
p7882
sg10
I3
sg11
VPWS
p7883
sg13
I1
sasa(dp7884
g2
S'Orexin A levels correlated with age in females and were significantly elevated in PWS even after these effects were controlled.\n'
p7885
sg4
(lp7886
(dp7887
g7
I0
sg8
g49
sg10
I8
sg11
VOrexin A
p7888
sg13
I2
sasg14
(lp7889
(dp7890
g7
I82
sg17
VC0032897
p7891
sg10
I3
sg11
VPWS
p7892
sg13
I1
sasa(dp7893
g2
S'These findings support the hypothesis that dysregulation of orexin signaling may contribute to behavioral problems and hyperphagia in PWS.\n'
p7894
sg4
(lp7895
(dp7896
g7
I60
sg8
g49
sg10
I6
sg11
Vorexin
p7897
sg13
I1
sasg14
(lp7898
(dp7899
g7
I119
sg17
VC0020505
p7900
sg10
I11
sg11
Vhyperphagia
p7901
sg13
I1
sa(dp7902
g7
I95
sg17
VC0260653
p7903
sg10
I19
sg11
Vbehavioral problems
p7904
sg13
I2
sa(dp7905
g7
I134
sg17
VC0032897
p7906
sg10
I3
sg11
VPWS
p7907
sg13
I1
sasa(dp7908
g2
S'Further studies are warranted to better understand the complex relationship between orexin A levels and the problematic behaviors consistently found in individuals with PWS.\n'
p7909
sg4
(lp7910
(dp7911
g7
I84
sg8
g49
sg10
I8
sg11
Vorexin A
p7912
sg13
I2
sasg14
(lp7913
(dp7914
g7
I169
sg17
VC0032897
p7915
sg10
I3
sg11
VPWS
p7916
sg13
I1
sasa(dp7917
g2
S'However, reports showing cerebrospinal fluid orexin levels in Prader-Willi syndrome patients have been limited.\n'
p7918
sg4
(lp7919
sg14
(lp7920
(dp7921
g7
I62
sg17
VC0032897
p7922
sg10
I21
sg11
VPrader-Willi syndrome
p7923
sg13
I2
sasa(dp7924
g2
S'The aim of this study was to examine the relationship between the characteristic symptoms of Prader-Willi syndrome and cerebrospinal fluid orexin levels.\n'
p7925
sg4
(lp7926
sg14
(lp7927
(dp7928
g7
I93
sg17
VC0032897
p7929
sg10
I21
sg11
VPrader-Willi syndrome
p7930
sg13
I2
sasa(dp7931
g2
S'We clinically identified 14 Prader-Willi syndrome patients and examined their cerebrospinal fluid orexin levels.\n'
p7932
sg4
(lp7933
sg14
(lp7934
(dp7935
g7
I28
sg17
VC0032897
p7936
sg10
I21
sg11
VPrader-Willi syndrome
p7937
sg13
I2
sasa(dp7938
g2
S'Cerebrospinal fluid orexin levels (median [25-75 percentiles]) in the 14 Prader-Willi syndrome patients were intermediate (192 [161-234.5] pg/ml), higher than in the narcoleptic patients, but lower than in the idiopathic hypersomnia patients.\n'
p7939
sg4
(lp7940
(dp7941
g7
I0
sg8
g49
sg10
I26
sg11
VCerebrospinal fluid orexin
p7942
sg13
I3
sasg14
(lp7943
(dp7944
g7
I210
sg17
VC0751757
p7945
sg10
I22
sg11
Vidiopathic hypersomnia
p7946
sg13
I2
sa(dp7947
g7
I73
sg17
VC0032897
p7948
sg10
I21
sg11
VPrader-Willi syndrome
p7949
sg13
I2
sasa(dp7950
g2
S'There was also a negative correlation between Epworth sleepiness scale scores and orexin levels in Prader-Willi syndrome patients.\n'
p7951
sg4
(lp7952
sg14
(lp7953
(dp7954
g7
I99
sg17
VC0032897
p7955
sg10
I21
sg11
VPrader-Willi syndrome
p7956
sg13
I2
sasa(dp7957
g2
S'Decreased cerebrospinal fluid orexin levels in Prader-Willi syndrome may play an important role in severity of obesity and excessive daytime sleepiness.\n'
p7958
sg4
(lp7959
(dp7960
g7
I10
sg8
g49
sg10
I26
sg11
Vcerebrospinal fluid orexin
p7961
sg13
I3
sasg14
(lp7962
(dp7963
g7
I111
sg17
VC0028754
p7964
sg10
I7
sg11
Vobesity
p7965
sg13
I1
sa(dp7966
g7
I123
sg17
VC0694563
p7967
sg10
I28
sg11
Vexcessive daytime sleepiness
p7968
sg13
I3
sa(dp7969
g7
I47
sg17
VC0032897
p7970
sg10
I21
sg11
VPrader-Willi syndrome
p7971
sg13
I2
sasa(dp7972
g2
S'Further research is needed to evaluate the contribution of the upper airway resistance syndrome in the pathogenesis of EDS, the role of the alterations of sleep microstructure, the relationships between PWS and narcoleptic phenotype, the involvement of orexin/hypocretin, and the effects of drugs acting on REM sleep and/or wakefulness.\n'
p7973
sg4
(lp7974
(dp7975
g7
I260
sg8
VP50336
p7976
sg10
I10
sg11
Vhypocretin
p7977
sg13
I1
sa(dp7978
g7
I253
sg8
g49
sg10
I6
sg11
Vorexin
p7979
sg13
I1
sasg14
(lp7980
(dp7981
g7
I203
sg17
VC0032897
p7982
sg10
I3
sg11
VPWS
p7983
sg13
I1
sa(dp7984
g7
I119
sg17
VC0013720
p7985
sg10
I3
sg11
VEDS
p7986
sg13
I1
sa(dp7987
g7
I103
sg17
VC0699748
p7988
sg10
I12
sg11
Vpathogenesis
p7989
sg13
I1
sa(dp7990
g7
I63
sg17
VC1319384
p7991
sg10
I32
sg11
Vupper airway resistance syndrome
p7992
sg13
I4
sasa(dp7993
g2
S'Quantitative RT-PCR for SAG, OXTR, STAR, HCRT, and HTR2B using RNA isolated from their lymphoblastoid cells and available brain tissue (frontal cortex) from separate individuals with PWS and control subjects and normalized to GAPD gene expression levels validated our microarray gene expression data.\n'
p7994
sg4
(lp7995
(dp7996
g7
I35
sg8
VP49675
p7997
sg10
I4
sg11
VSTAR
p7998
sg13
I1
sa(dp7999
g7
I41
sg8
VP50336
p8000
sg10
I4
sg11
VHCRT
p8001
sg13
I1
sa(dp8002
g7
I226
sg8
VP04406
p8003
sg10
I9
sg11
VGAPD gene
p8004
sg13
I2
sa(dp8005
g7
I24
sg8
VP10523
p8006
sg10
I3
sg11
VSAG
p8007
sg13
I1
sa(dp8008
g7
I29
sg8
VP30559
p8009
sg10
I4
sg11
VOXTR
p8010
sg13
I1
sa(dp8011
g7
I51
sg8
VP41595
p8012
sg10
I5
sg11
VHTR2B
p8013
sg13
I1
sasg14
(lp8014
(dp8015
g7
I183
sg17
VC0032897
p8016
sg10
I3
sg11
VPWS
p8017
sg13
I1
sa(dp8018
g7
I35
sg17
VC2678045
p8019
sg10
I4
sg11
VSTAR
p8020
sg13
I1
sasa(dp8021
g2
S'In addition to excessive daytime sleepiness, Prader-Willi syndrome (PWS) patients may show narcolepsy-like symptoms, such as sleep-onset rapid eye movement sleep and cataplexy, independent of obesity-related sleep disturbances, which suggests a disorder of the hypocretin neurons.\n'
p8022
sg4
(lp8023
sg14
(lp8024
(dp8025
g7
I192
sg17
VC0028754
p8026
sg10
I7
sg11
Vobesity
p8027
sg13
I1
sa(dp8028
g7
I208
sg17
VC0037317
p8029
sg10
I18
sg11
Vsleep disturbances
p8030
sg13
I2
sa(dp8031
g7
I68
sg17
VC0032897
p8032
sg10
I3
sg11
VPWS
p8033
sg13
I1
sa(dp8034
g7
I45
sg17
VC0032897
p8035
sg10
I21
sg11
VPrader-Willi syndrome
p8036
sg13
I2
sa(dp8037
g7
I166
sg17
VC0007384
p8038
sg10
I9
sg11
Vcataplexy
p8039
sg13
I1
sa(dp8040
g7
I91
sg17
VC0027404
p8041
sg10
I10
sg11
Vnarcolepsy
p8042
sg13
I1
sa(dp8043
g7
I15
sg17
VC0694563
p8044
sg10
I28
sg11
Vexcessive daytime sleepiness
p8045
sg13
I3
sasa(dp8046
g2
S'We hypothesized that the narcolepsy-like symptoms in PWS are caused by a decline in the number of hypocretin neurons.\n'
p8047
sg4
(lp8048
sg14
(lp8049
(dp8050
g7
I53
sg17
VC0032897
p8051
sg10
I3
sg11
VPWS
p8052
sg13
I1
sa(dp8053
g7
I25
sg17
VC0027404
p8054
sg10
I10
sg11
Vnarcolepsy
p8055
sg13
I1
sasa(dp8056
g2
S'There was no significant difference in the total number of hypocretin-containing neurons among the seven PWS patients (in whom sufficient hypothalamic material was available to quantify total cell number) and seven age-matched controls, either in adults or in infants.\n'
p8057
sg4
(lp8058
(dp8059
g7
I59
sg8
VP50336
p8060
sg10
I10
sg11
Vhypocretin
p8061
sg13
I1
sasg14
(lp8062
(dp8063
g7
I105
sg17
VC0032897
p8064
sg10
I3
sg11
VPWS
p8065
sg13
I1
sasa(dp8066
g2
S'We conclude that a decrease in the number of hypocretin neurons does not play a major role in the occurrence of narcolepsy-like symptoms in PWS.\n'
p8067
sg4
(lp8068
sg14
(lp8069
(dp8070
g7
I140
sg17
VC0032897
p8071
sg10
I3
sg11
VPWS
p8072
sg13
I1
sa(dp8073
g7
I112
sg17
VC0027404
p8074
sg10
I10
sg11
Vnarcolepsy
p8075
sg13
I1
sasa(dp8076
g2
S'Four patients with clinically and genetically confirmed Prader-Willi syndrome (PWS) underwent nocturnal polysomnograpy (PSG), multiple sleep latency test (MSLT), human leukocyte antigens (HLA) typing and estimation of cerebrospinal fluid (CSF) hypocretin-1 (Hcrt-1) level to investigate if a role of hypothalamic dysfunction and sleep disturbance might be functionally connected through the hypocretin (orexin) system.\n'
p8077
sg4
(lp8078
(dp8079
g7
I258
sg8
VP50336
p8080
sg10
I6
sg11
VHcrt-1
p8081
sg13
I1
sa(dp8082
g7
I188
sg8
VP30486
p8083
sg10
I3
sg11
VHLA
p8084
sg13
I1
sa(dp8085
g7
I244
sg8
VP50336
p8086
sg10
I10
sg11
Vhypocretin
p8087
sg13
I1
sa(dp8088
g7
I162
sg8
VP05534
p8089
sg10
I24
sg11
Vhuman leukocyte antigens
p8090
sg13
I3
sa(dp8091
g7
I403
sg8
g49
sg10
I6
sg11
Vorexin
p8092
sg13
I1
sa(dp8093
g7
I244
sg8
g49
sg10
I12
sg11
Vhypocretin-1
p8094
sg13
I1
sasg14
(lp8095
(dp8096
g7
I56
sg17
VC0032897
p8097
sg10
I21
sg11
VPrader-Willi syndrome
p8098
sg13
I2
sa(dp8099
g7
I79
sg17
VC0032897
p8100
sg10
I3
sg11
VPWS
p8101
sg13
I1
sa(dp8102
g7
I300
sg17
VC0751230
p8103
sg10
I24
sg11
Vhypothalamic dysfunction
p8104
sg13
I2
sa(dp8105
g7
I329
sg17
VC0700201
p8106
sg10
I17
sg11
Vsleep disturbance
p8107
sg13
I2
sasa(dp8108
g2
S'Furthermore, the cell-matrix Rho GTPase-encoding ARHGAP26 gene, and MAN1C1, a gene encoding a Golgi mannosidase involved in the maturation of procollagens, emerged as new candidate uterine leiomyoma genes affecting both risk and tumor size.\n'
p8109
sg4
(lp8110
(dp8111
g7
I49
sg8
g49
sg10
I13
sg11
VARHGAP26 gene
p8112
sg13
I2
sa(dp8113
g7
I29
sg8
VP08100
p8114
sg10
I10
sg11
VRho GTPase
p8115
sg13
I2
sa(dp8116
g7
I68
sg8
g49
sg10
I6
sg11
VMAN1C1
p8117
sg13
I1
sasg14
(lp8118
(dp8119
g7
I229
sg17
VC0027651
p8120
sg10
I5
sg11
Vtumor
p8121
sg13
I1
sa(dp8122
g7
I181
sg17
VC0042133
p8123
sg10
I17
sg11
Vuterine leiomyoma
p8124
sg13
I2
sasa(dp8125
g2
S'Despite their clinical activity in many patients with CML, the BCR-ABL kinase inhibitors (BCR-ABL-KIs) imatinib, dasatinib, and nilotinib provide only transient leukemia reduction in patients with Ph+ ALL.\n'
p8126
sg4
(lp8127
(dp8128
g7
I63
sg8
VP11274
p8129
sg10
I14
sg11
VBCR-ABL kinase
p8130
sg13
I2
sa(dp8131
g7
I98
sg8
g49
sg10
I3
sg11
VKIs
p8132
sg13
I1
sa(dp8133
g7
I67
sg8
VP55157
p8134
sg10
I3
sg11
VABL
p8135
sg13
I1
sa(dp8136
g7
I63
sg8
VP11274
p8137
sg10
I3
sg11
VBCR
p8138
sg13
I1
sasg14
(lp8139
(dp8140
g7
I197
sg17
VC1960397
p8141
sg10
I7
sg11
VPh+ ALL
p8142
sg13
I2
sa(dp8143
g7
I54
sg17
VC0023473
p8144
sg10
I3
sg11
VCML
p8145
sg13
I1
sa(dp8146
g7
I67
sg17
VC0000744
p8147
sg10
I3
sg11
VABL
p8148
sg13
I1
sa(dp8149
g7
I67
sg17
VC0000744
p8150
sg10
I3
sg11
VABL
p8151
sg13
I1
sa(dp8152
g7
I161
sg17
VC0023418
p8153
sg10
I8
sg11
Vleukemia
p8154
sg13
I1
sasa(dp8155
g2
S'Here, we have interrogated the expression of PIP4K2B in a cohort (489) of patients with breast tumor using immunohistochemical staining and by a meta-analysis of gene expression profiles from 2,999 breast tumors, both with associated clinical outcome data.\n'
p8156
sg4
(lp8157
(dp8158
g7
I45
sg8
VP78356
p8159
sg10
I7
sg11
VPIP4K2B
p8160
sg13
I1
sasg14
(lp8161
(dp8162
g7
I198
sg17
VC1458155
p8163
sg10
I13
sg11
Vbreast tumors
p8164
sg13
I2
sa(dp8165
g7
I88
sg17
VC1458155
p8166
sg10
I12
sg11
Vbreast tumor
p8167
sg13
I2
sasa(dp8168
g2
S'High expression of TCN1 have been reported in neoplasms such as breast cancer and hepatocellular carcinoma.\n'
p8169
sg4
(lp8170
(dp8171
g7
I19
sg8
VP20061
p8172
sg10
I4
sg11
VTCN1
p8173
sg13
I1
sasg14
(lp8174
(dp8175
g7
I82
sg17
VC1512411
p8176
sg10
I24
sg11
Vhepatocellular carcinoma
p8177
sg13
I2
sa(dp8178
g7
I46
sg17
VC0027651
p8179
sg10
I9
sg11
Vneoplasms
p8180
sg13
I1
sa(dp8181
g7
I64
sg17
VC0678222
p8182
sg10
I13
sg11
Vbreast cancer
p8183
sg13
I2
sasa(dp8184
g2
S'The vitamin B12 (B12)-binding protein haptocorrin (HC) has proven to be a potentially useful biomarker in patients with fibrolamellar hepatocellular carcinoma (HCC).\n'
p8185
sg4
(lp8186
(dp8187
g7
I38
sg8
VP27352
p8188
sg10
I11
sg11
Vhaptocorrin
p8189
sg13
I1
sa(dp8190
g7
I51
sg8
VP27352
p8191
sg10
I2
sg11
VHC
p8192
sg13
I1
sasg14
(lp8193
(dp8194
g7
I120
sg17
VC0334287
p8195
sg10
I38
sg11
Vfibrolamellar hepatocellular carcinoma
p8196
sg13
I3
sa(dp8197
g7
I160
sg17
VC2239176
p8198
sg10
I3
sg11
VHCC
p8199
sg13
I1
sasa(dp8200
g2
S'Of 37 patients with histologically verified hepatocellular carcinoma (HCC) from Bangkok, Thailand, 34 had raised values of plasma cobalamin, and 1 presented with a markedly increased value of plasma transcobalamin I (TC I).\n'
p8201
sg4
(lp8202
(dp8203
g7
I192
sg8
VP20061
p8204
sg10
I23
sg11
Vplasma transcobalamin I
p8205
sg13
I3
sa(dp8206
g7
I217
sg8
VP20061
p8207
sg10
I4
sg11
VTC I
p8208
sg13
I2
sasg14
(lp8209
(dp8210
g7
I44
sg17
VC2239176
p8211
sg10
I24
sg11
Vhepatocellular carcinoma
p8212
sg13
I2
sa(dp8213
g7
I70
sg17
VC2239176
p8214
sg10
I3
sg11
VHCC
p8215
sg13
I1
sasa(dp8216
g2
S'A 12 year old girl with a localised fibrolamellar hepatoma had a raised serum unsaturated vitamin B12 binding capacity (UBBC) and transcobalamin I (TCI) prior to complete resection and chemotherapy.\n'
p8217
sg4
(lp8218
sg14
(lp8219
(dp8220
g7
I50
sg17
VC0023903
p8221
sg10
I8
sg11
Vhepatoma
p8222
sg13
I1
sasa(dp8223
g2
S'These findings suggest that determination of R-binder in liver tumours may be of some value in differentiating hepatocellular carcinomas and cholangiocarcinoma, and that synthesis of R-binder by tumour cells causes an increase in serum transcobalamin I.\n'
p8224
sg4
(lp8225
sg14
(lp8226
(dp8227
g7
I111
sg17
VC2239176
p8228
sg10
I25
sg11
Vhepatocellular carcinomas
p8229
sg13
I2
sa(dp8230
g7
I63
sg17
VC0027651
p8231
sg10
I6
sg11
Vtumour
p8232
sg13
I1
sa(dp8233
g7
I57
sg17
VC0023903
p8234
sg10
I13
sg11
Vliver tumours
p8235
sg13
I2
sa(dp8236
g7
I141
sg17
VC0206698
p8237
sg10
I18
sg11
Vcholangiocarcinoma
p8238
sg13
I1
sasa(dp8239
g2
S'Bilateral phaeochromocytoma was histologically recorded from a primigravida and primipara, 22 years of ager, who had died 13 hours after precipitate spontaneous birth of a living mature child.\n'
p8240
sg4
(lp8241
sg14
(lp8242
(dp8243
g7
I10
sg17
VC0031511
p8244
sg10
I17
sg11
Vphaeochromocytoma
p8245
sg13
I1
sasa(dp8246
g2
S'We discovered a new spontaneous recessive microphthalmos mouse mutant in the Japanese wild-derived inbred strain KOR1/Stm.\n'
p8247
sg4
(lp8248
(dp8249
g7
I118
sg8
g49
sg10
I3
sg11
VStm
p8250
sg13
I1
sasg14
(lp8251
(dp8252
g7
I42
sg17
VC0026010
p8253
sg10
I14
sg11
Vmicrophthalmos
p8254
sg13
I1
sa(dp8255
g7
I63
sg17
VC0596988
p8256
sg10
I6
sg11
Vmutant
p8257
sg13
I1
sasa(dp8258
g2
S"While the Lupus antigen (La)-related protein 7 (LARP7) is a constitutive component, the methylphosphate capping enzyme (MePCE) associates secondarily to phosphorylate the 5' end of 7SK snRNA.\n"
p8259
sg4
(lp8260
(dp8261
g7
I120
sg8
g49
sg10
I5
sg11
VMePCE
p8262
sg13
I1
sa(dp8263
g7
I10
sg8
VP14209
p8264
sg10
I36
sg11
VLupus antigen (La)-related protein 7
p8265
sg13
I5
sa(dp8266
g7
I88
sg8
g49
sg10
I30
sg11
Vmethylphosphate capping enzyme
p8267
sg13
I3
sa(dp8268
g7
I48
sg8
g49
sg10
I5
sg11
VLARP7
p8269
sg13
I1
sasg14
(lp8270
(dp8271
g7
I10
sg17
VC0024131
p8272
sg10
I5
sg11
VLupus
p8273
sg13
I1
sasa(dp8274
g2
S'As a result, a novel heterozygous HAND2 mutation, p.L47P, was identified in a patient with tetralogy of Fallot (TOF).\n'
p8275
sg4
(lp8276
(dp8277
g7
I34
sg8
VP61296
p8278
sg10
I14
sg11
VHAND2 mutation
p8279
sg13
I2
sasg14
(lp8280
(dp8281
g7
I91
sg17
VC0039685
p8282
sg10
I19
sg11
Vtetralogy of Fallot
p8283
sg13
I3
sa(dp8284
g7
I112
sg17
VC0039685
p8285
sg10
I3
sg11
VTOF
p8286
sg13
I1
sasa(dp8287
g2
S'The persistence of new enhancing T1 hypointense lesions (acute black holes, ABHs) in multiple sclerosis (MS) cannot be predicted visually at lesion onset.\n'
p8288
sg4
(lp8289
sg14
(lp8290
(dp8291
g7
I76
sg17
VC0740342
p8292
sg10
I4
sg11
VABHs
p8293
sg13
I1
sa(dp8294
g7
I105
sg17
VC0026769
p8295
sg10
I2
sg11
VMS
p8296
sg13
I1
sa(dp8297
g7
I85
sg17
VC0026769
p8298
sg10
I18
sg11
Vmultiple sclerosis
p8299
sg13
I2
sasa(dp8300
g2
S'In an infant patient with sensorineural hearing loss, psychomotor retardation, and epilepsy, WES resulted in identification of a novel homozygous CLPP frameshift mutation (c.21delA).\n'
p8301
sg4
(lp8302
(dp8303
g7
I146
sg8
g49
sg10
I24
sg11
VCLPP frameshift mutation
p8304
sg13
I3
sasg14
(lp8305
(dp8306
g7
I151
sg17
VC0079380
p8307
sg10
I19
sg11
Vframeshift mutation
p8308
sg13
I2
sa(dp8309
g7
I26
sg17
VC0018784
p8310
sg10
I26
sg11
Vsensorineural hearing loss
p8311
sg13
I3
sa(dp8312
g7
I83
sg17
VC0014544
p8313
sg10
I8
sg11
Vepilepsy
p8314
sg13
I1
sasa(dp8315
g2
S'The three examples of clinical and genetic complexities are drawn from studies of (i) Pendred syndrome/DFNB4 (PDS, OMIM 274600), (ii) Perrault syndrome (deafness and infertility) due to mutations of CLPP (PRTLS3, OMIM 614129), and (iii) the unexplained extensive clinical variability associated with TBC1D24 mutations.\n'
p8316
sg4
(lp8317
(dp8318
g7
I86
sg8
VP41222
p8319
sg10
I22
sg11
VPendred syndrome/DFNB4
p8320
sg13
I2
sa(dp8321
g7
I110
sg8
VP41222
p8322
sg10
I3
sg11
VPDS
p8323
sg13
I1
sa(dp8324
g7
I300
sg8
g49
sg10
I7
sg11
VTBC1D24
p8325
sg13
I1
sa(dp8326
g7
I199
sg8
g49
sg10
I4
sg11
VCLPP
p8327
sg13
I1
sasg14
(lp8328
(dp8329
g7
I86
sg17
VC0271829
p8330
sg10
I22
sg11
VPendred syndrome/DFNB4
p8331
sg13
I2
sa(dp8332
g7
I110
sg17
VC0271829
p8333
sg10
I3
sg11
VPDS
p8334
sg13
I1
sa(dp8335
g7
I166
sg17
VC0021359
p8336
sg10
I11
sg11
Vinfertility
p8337
sg13
I1
sa(dp8338
g7
I153
sg17
VC0011053
p8339
sg10
I8
sg11
Vdeafness
p8340
sg13
I1
sa(dp8341
g7
I134
sg17
VC0685838
p8342
sg10
I17
sg11
VPerrault syndrome
p8343
sg13
I2
sasa(dp8344
g2
S'Recessive CLPP mutations were recently observed in the human Perrault variant of ovarian failure and sensorineural hearing loss.\n'
p8345
sg4
(lp8346
sg14
(lp8347
(dp8348
g7
I101
sg17
VC0018784
p8349
sg10
I26
sg11
Vsensorineural hearing loss
p8350
sg13
I3
sa(dp8351
g7
I81
sg17
VC0025322
p8352
sg10
I15
sg11
Vovarian failure
p8353
sg13
I2
sasa(dp8354
g2
S'This closely linked but distinct nonsyndromic hearing loss locus was designated DFNB81.\n'
p8355
sg4
(lp8356
sg14
(lp8357
(dp8358
g7
I46
sg17
VC0011053
p8359
sg10
I12
sg11
Vhearing loss
p8360
sg13
I2
sasa(dp8361
g2
S'Both the bloodstream and procyclic forms of T. brucei showed a several-fold greater sensitivity than the mammalian cells to GA and also to 17-AAG, a less toxic derivative of GA, suggesting that Hsp90 could be a potential chemotherapeuric target for African trypanosomiasis.\n'
p8362
sg4
(lp8363
(dp8364
g7
I194
sg8
VP07900
p8365
sg10
I5
sg11
VHsp90
p8366
sg13
I1
sasg14
(lp8367
(dp8368
g7
I249
sg17
VC0041228
p8369
sg10
I23
sg11
VAfrican trypanosomiasis
p8370
sg13
I2
sasa(dp8371
g2
S'In the period from 1999 till 2009 there were 18 patients (14 women and 4 men) with adenomas of the parathyroid gland (PTG).\n'
p8372
sg4
(lp8373
sg14
(lp8374
(dp8375
g7
I83
sg17
VC0001430
p8376
sg10
I8
sg11
Vadenomas
p8377
sg13
I1
sasa(dp8378
g2
S'One adenoma of PTG was found in 17 patients, in one woman there were two adenomas on both sides of the trachea, but they were diagnosed not at once.\n'
p8379
sg4
(lp8380
sg14
(lp8381
(dp8382
g7
I103
sg17
VC0040580
p8383
sg10
I7
sg11
Vtrachea
p8384
sg13
I1
sa(dp8385
g7
I4
sg17
VC0001430
p8386
sg10
I7
sg11
Vadenoma
p8387
sg13
I1
sa(dp8388
g7
I73
sg17
VC0001430
p8389
sg10
I8
sg11
Vadenomas
p8390
sg13
I1
sasa(dp8391
g2
S'The histopathologic result showed hyperplasia or an adenoma of the reimplanted parathyroid gland (PTG) particles.\n'
p8392
sg4
(lp8393
sg14
(lp8394
(dp8395
g7
I52
sg17
VC0001430
p8396
sg10
I7
sg11
Vadenoma
p8397
sg13
I1
sa(dp8398
g7
I34
sg17
VC0020507
p8399
sg10
I11
sg11
Vhyperplasia
p8400
sg13
I1
sasa(dp8401
g2
S'In 6 patients persistent PHPT was associated with hyperplasia of parathyroid glands (PTG), in 1 -- with adenoma of PTG missed during the first surgery.\n'
p8402
sg4
(lp8403
sg14
(lp8404
(dp8405
g7
I50
sg17
VC0271844
p8406
sg10
I26
sg11
Vhyperplasia of parathyroid
p8407
sg13
I3
sa(dp8408
g7
I104
sg17
VC0001430
p8409
sg10
I7
sg11
Vadenoma
p8410
sg13
I1
sasa(dp8411
g2
S'Using immunohistochemistry for CD34, LYVE-1 (specific markers for vascular and lymphatic endothelium, respectively), vascular endothelial growth factor (VEGF)-A, VEGF-C, and fibroblast growth factor (FGF)-2, this study analyzes microvascular density (MVD), lymphatic vascular density (LVD), and expression of angiogenic and lymphangiogenic growth factors in 13 normal PTG, 77 parathyroid adenomas (PTA), and 17 primary parathyroid hyperplasia (PPH).\n'
p8412
sg4
(lp8413
(dp8414
g7
I117
sg8
g49
sg10
I43
sg11
Vvascular endothelial growth factor (VEGF)-A
p8415
sg13
I5
sa(dp8416
g7
I408
sg8
g49
sg10
I34
sg11
V17 primary parathyroid hyperplasia
p8417
sg13
I4
sa(dp8418
g7
I31
sg8
VP28906
p8419
sg10
I4
sg11
VCD34
p8420
sg13
I1
sa(dp8421
g7
I37
sg8
g49
sg10
I6
sg11
VLYVE-1
p8422
sg13
I1
sa(dp8423
g7
I174
sg8
g49
sg10
I32
sg11
Vfibroblast growth factor (FGF)-2
p8424
sg13
I4
sa(dp8425
g7
I162
sg8
VP49767
p8426
sg10
I6
sg11
VVEGF-C
p8427
sg13
I1
sasg14
(lp8428
(dp8429
g7
I419
sg17
VC0271844
p8430
sg10
I23
sg11
Vparathyroid hyperplasia
p8431
sg13
I2
sa(dp8432
g7
I398
sg17
VC0041207
p8433
sg10
I3
sg11
VPTA
p8434
sg13
I1
sa(dp8435
g7
I376
sg17
VC0262587
p8436
sg10
I20
sg11
Vparathyroid adenomas
p8437
sg13
I2
sasa(dp8438
g2
S'In PT adenomas, scores of VDR and CaSR were markedly lower than in normal PTGs (P&lt;0.01), while the proportion of Ki67-positive cells in PT adenomas was significantly higher than in normal PTGs (P&lt;0.01).\n'
p8439
sg4
(lp8440
(dp8441
g7
I26
sg8
VP11473
p8442
sg10
I3
sg11
VVDR
p8443
sg13
I1
sa(dp8444
g7
I34
sg8
VP41180
p8445
sg10
I4
sg11
VCaSR
p8446
sg13
I1
sasg14
(lp8447
(dp8448
g7
I6
sg17
VC0001430
p8449
sg10
I8
sg11
Vadenomas
p8450
sg13
I1
sa(dp8451
g7
I6
sg17
VC0001430
p8452
sg10
I8
sg11
Vadenomas
p8453
sg13
I1
sasa(dp8454
g2
S'We compared the degrees of cell maturity, antigenicity and secretory function of parathyroid tissues (PTG) from cadavers (C-PTG), 20-28 week fetuses (F-PTG) and PTG adenomas (A-PTG).\n'
p8455
sg4
(lp8456
sg14
(lp8457
(dp8458
g7
I165
sg17
VC0001430
p8459
sg10
I8
sg11
Vadenomas
p8460
sg13
I1
sasa(dp8461
g2
S'The authors compared the degrees of cell maturity, antigenicity and secretory function of parathyroid (PTG) tissues from cadavers (C-PTG), 20-28 wk fetus (F-PTG) and PTG adenoma (A-PTG).\n'
p8462
sg4
(lp8463
sg14
(lp8464
(dp8465
g7
I170
sg17
VC0001430
p8466
sg10
I7
sg11
Vadenoma
p8467
sg13
I1
sasa(dp8468
g2
S'IL-32 is increasingly recognized to be an important host-protective molecule against tuberculosis.\n'
p8469
sg4
(lp8470
sg14
(lp8471
(dp8472
g7
I85
sg17
VC0041296
p8473
sg10
I12
sg11
Vtuberculosis
p8474
sg13
I1
sasa(dp8475
g2
S'Silencing of interleukin-32 (IL-32) in a differentiated human promonocytic cell line impairs killing of Mycobacterium tuberculosis (MTB) but the role of IL-32 in vivo against MTB remains unknown.\n'
p8476
sg4
(lp8477
(dp8478
g7
I13
sg8
VP24001
p8479
sg10
I14
sg11
Vinterleukin-32
p8480
sg13
I1
sa(dp8481
g7
I29
sg8
VP24001
p8482
sg10
I5
sg11
VIL-32
p8483
sg13
I1
sa(dp8484
g7
I29
sg8
VP24001
p8485
sg10
I5
sg11
VIL-32
p8486
sg13
I1
sasg14
(lp8487
(dp8488
g7
I132
sg17
VC0041296
p8489
sg10
I3
sg11
VMTB
p8490
sg13
I1
sa(dp8491
g7
I132
sg17
VC0041296
p8492
sg10
I3
sg11
VMTB
p8493
sg13
I1
sa(dp8494
g7
I104
sg17
VC0041296
p8495
sg10
I26
sg11
VMycobacterium tuberculosis
p8496
sg13
I2
sasa(dp8497
g2
S'The lungs of patients with tuberculosis showed increased IL-32 expression, particularly in macrophages of granulomas and airway epithelial cells but also B cells and T cells.\n'
p8498
sg4
(lp8499
sg14
(lp8500
(dp8501
g7
I106
sg17
VC0018188
p8502
sg10
I10
sg11
Vgranulomas
p8503
sg13
I1
sa(dp8504
g7
I27
sg17
VC0041296
p8505
sg10
I12
sg11
Vtuberculosis
p8506
sg13
I1
sasa(dp8507
g2
S'IL-32 induced the vitamin D-dependent antimicrobial peptides cathelicidin and DEFB4 and to generate antimicrobial activity in vitro, dependent on the presence of adequate 25-hydroxyvitamin D. In addition, the IL-15-induced defense response macrophage gene network was integrated with ranked pairwise comparisons of gene expression from five different clinical data sets of latent compared with active tuberculosis or healthy controls and a coexpression network derived from gene expression in patients with tuberculosis undergoing chemotherapy.\n'
p8508
sg4
(lp8509
(dp8510
g7
I78
sg8
g49
sg10
I5
sg11
VDEFB4
p8511
sg13
I1
sa(dp8512
g7
I209
sg8
VP40933
p8513
sg10
I5
sg11
VIL-15
p8514
sg13
I1
sasg14
(lp8515
(dp8516
g7
I394
sg17
VC0151332
p8517
sg10
I19
sg11
Vactive tuberculosis
p8518
sg13
I2
sa(dp8519
g7
I401
sg17
VC0041296
p8520
sg10
I12
sg11
Vtuberculosis
p8521
sg13
I1
sasa(dp8522
g2
S'Together, these analyses identified eight common genes, including IL-32, as molecular markers of latent tuberculosis and the IL-15-induced gene network.\n'
p8523
sg4
(lp8524
(dp8525
g7
I125
sg8
VP40933
p8526
sg10
I5
sg11
VIL-15
p8527
sg13
I1
sasg14
(lp8528
(dp8529
g7
I97
sg17
VC1609538
p8530
sg10
I19
sg11
Vlatent tuberculosis
p8531
sg13
I2
sasa(dp8532
g2
S'As maintaining M. tuberculosis in a latent state and preventing transition to active disease may represent a form of host resistance, these results identify IL-32 as one functional marker and potential correlate of protection against active tuberculosis.\n'
p8533
sg4
(lp8534
sg14
(lp8535
(dp8536
g7
I64
sg17
VC0599156
p8537
sg10
I10
sg11
Vtransition
p8538
sg13
I1
sa(dp8539
g7
I18
sg17
VC0041296
p8540
sg10
I12
sg11
Vtuberculosis
p8541
sg13
I1
sa(dp8542
g7
I234
sg17
VC0151332
p8543
sg10
I19
sg11
Vactive tuberculosis
p8544
sg13
I2
sasa(dp8545
g2
S'CFs-CoPc/PMS system could effectively decolorize azo dyes such as Acid Red 1 (AR1) with almost 100% decolorization efficiency in 35 min, suggesting that the CFs-CoPc/PMS system was a highly efficient oxidation process.\n'
p8546
sg4
(lp8547
(dp8548
g7
I66
sg8
VP16435
p8549
sg10
I10
sg11
VAcid Red 1
p8550
sg13
I3
sa(dp8551
g7
I78
sg8
g49
sg10
I3
sg11
VAR1
p8552
sg13
I1
sasg14
(lp8553
(dp8554
g7
I0
sg17
VC0015674
p8555
sg10
I3
sg11
VCFs
p8556
sg13
I1
sa(dp8557
g7
I9
sg17
VC0033046
p8558
sg10
I3
sg11
VPMS
p8559
sg13
I1
sa(dp8560
g7
I9
sg17
VC0033046
p8561
sg10
I3
sg11
VPMS
p8562
sg13
I1
sa(dp8563
g7
I0
sg17
VC0015674
p8564
sg10
I3
sg11
VCFs
p8565
sg13
I1
sasa(dp8566
g2
S'In addition to raised creatinine phosphokinase (CPK) levels, his biochemical profile showed hypothyroidism.\n'
p8567
sg4
(lp8568
(dp8569
g7
I22
sg8
VP22676
p8570
sg10
I24
sg11
Vcreatinine phosphokinase
p8571
sg13
I2
sa(dp8572
g7
I48
sg8
g49
sg10
I3
sg11
VCPK
p8573
sg13
I1
sasg14
(lp8574
(dp8575
g7
I92
sg17
VC0020676
p8576
sg10
I14
sg11
Vhypothyroidism
p8577
sg13
I1
sasa(dp8578
g2
S'Myopathy is a known complication of hypothyroidism, commonly characterized by an elevation in Creatine Kinase (CPK) due to increase capillary permeability proportional to the hypothyroid state.\n'
p8579
sg4
(lp8580
(dp8581
g7
I94
sg8
VP12532
p8582
sg10
I15
sg11
VCreatine Kinase
p8583
sg13
I2
sa(dp8584
g7
I111
sg8
g49
sg10
I3
sg11
VCPK
p8585
sg13
I1
sasg14
(lp8586
(dp8587
g7
I36
sg17
VC0020676
p8588
sg10
I14
sg11
Vhypothyroidism
p8589
sg13
I1
sa(dp8590
g7
I20
sg17
VC0009566
p8591
sg10
I12
sg11
Vcomplication
p8592
sg13
I1
sa(dp8593
g7
I36
sg17
VC0020676
p8594
sg10
I11
sg11
Vhypothyroid
p8595
sg13
I1
sa(dp8596
g7
I0
sg17
VC0026848
p8597
sg10
I8
sg11
VMyopathy
p8598
sg13
I1
sasa(dp8599
g2
S'The decreased serum levels of triiodothyroinine (T3) and thyroxine (T4) in hypothyroid patients is well established but whether there is any correlation of creatinephosphokinase (CPK) with hypothyroidism is not well established.\n'
p8600
sg4
(lp8601
(dp8602
g7
I156
sg8
g49
sg10
I27
sg11
Vcreatinephosphokinase (CPK)
p8603
sg13
I2
sasg14
(lp8604
(dp8605
g7
I189
sg17
VC0020676
p8606
sg10
I14
sg11
Vhypothyroidism
p8607
sg13
I1
sa(dp8608
g7
I75
sg17
VC0020676
p8609
sg10
I11
sg11
Vhypothyroid
p8610
sg13
I1
sasa(dp8611
g2
S'To determine serum CPK variation based on TSH e free T4 (FT4), and to assess serum CPK in pathological states of the thyroid (hyperthyroidism and hypothyroidism), in relation to the euthyroidism.\n'
p8612
sg4
(lp8613
(dp8614
g7
I13
sg8
g49
sg10
I9
sg11
Vserum CPK
p8615
sg13
I2
sa(dp8616
g7
I13
sg8
g49
sg10
I9
sg11
Vserum CPK
p8617
sg13
I2
sa(dp8618
g7
I42
sg8
VP01222
p8619
sg10
I3
sg11
VTSH
p8620
sg13
I1
sasg14
(lp8621
(dp8622
g7
I126
sg17
VC0020550
p8623
sg10
I15
sg11
Vhyperthyroidism
p8624
sg13
I1
sa(dp8625
g7
I146
sg17
VC0020676
p8626
sg10
I14
sg11
Vhypothyroidism
p8627
sg13
I1
sasa(dp8628
g2
S'From the total of results analyzed, 586 (9.4%) were measures of hyperthyroidism, with a median (range) of CPK of 98 U/L (27 to 1,113), and 556 (8.9%) were of hypothyroidism, with CPK of 114 U/L (25-4,182).\n'
p8629
sg4
(lp8630
sg14
(lp8631
(dp8632
g7
I158
sg17
VC0020676
p8633
sg10
I14
sg11
Vhypothyroidism
p8634
sg13
I1
sa(dp8635
g7
I64
sg17
VC0020550
p8636
sg10
I15
sg11
Vhyperthyroidism
p8637
sg13
I1
sasa(dp8638
g2
S'CPK was lower in the group with hyperthyroidism, and greater in that with hypothyroidism.\n'
p8639
sg4
(lp8640
(dp8641
g7
I0
sg8
g49
sg10
I3
sg11
VCPK
p8642
sg13
I1
sasg14
(lp8643
(dp8644
g7
I74
sg17
VC0020676
p8645
sg10
I14
sg11
Vhypothyroidism
p8646
sg13
I1
sa(dp8647
g7
I32
sg17
VC0020550
p8648
sg10
I15
sg11
Vhyperthyroidism
p8649
sg13
I1
sasa(dp8650
g2
S'We have previously shown that ablation of sarcolipin (SLN), a regulatory protein and uncoupler of sarco(endo)plasmic reticulum Ca2+-ATPases, leads to excessive diet-induced obesity and glucose intolerance in mice.\n'
p8651
sg4
(lp8652
(dp8653
g7
I117
sg8
VP00918
p8654
sg10
I22
sg11
Vreticulum Ca2+-ATPases
p8655
sg13
I2
sa(dp8656
g7
I42
sg8
g49
sg10
I10
sg11
Vsarcolipin
p8657
sg13
I1
sa(dp8658
g7
I54
sg8
g49
sg10
I3
sg11
VSLN
p8659
sg13
I1
sasg14
(lp8660
(dp8661
g7
I104
sg17
VC0014175
p8662
sg10
I4
sg11
Vendo
p8663
sg13
I1
sa(dp8664
g7
I173
sg17
VC0028754
p8665
sg10
I7
sg11
Vobesity
p8666
sg13
I1
sa(dp8667
g7
I185
sg17
VC0271650
p8668
sg10
I19
sg11
Vglucose intolerance
p8669
sg13
I2
sasa(dp8670
g2
S'We have previously shown that mice lacking the sarco(endo)plasmic reticulum Ca(2+)-ATPase pump regulatory protein sarcolipin (Sln(-/-)), an uncoupler of Ca(2+) uptake, develop excessive diet-induced obesity under standard housing conditions.\n'
p8671
sg4
(lp8672
(dp8673
g7
I126
sg8
g49
sg10
I3
sg11
VSln
p8674
sg13
I1
sa(dp8675
g7
I76
sg8
g49
sg10
I48
sg11
VCa(2+)-ATPase pump regulatory protein sarcolipin
p8676
sg13
I5
sasg14
(lp8677
(dp8678
g7
I199
sg17
VC0028754
p8679
sg10
I7
sg11
Vobesity
p8680
sg13
I1
sa(dp8681
g7
I53
sg17
VC0014175
p8682
sg10
I4
sg11
Vendo
p8683
sg13
I1
sasa(dp8684
g2
S'However, Sln(-/-) mice developed excessive obesity (P &lt; 0.05) and glucose intolerance (P &lt; 0.05) with high-fat feeding relative to wild-type controls.\n'
p8685
sg4
(lp8686
(dp8687
g7
I9
sg8
g49
sg10
I8
sg11
VSln(-/-)
p8688
sg13
I1
sasg14
(lp8689
(dp8690
g7
I69
sg17
VC0271650
p8691
sg10
I19
sg11
Vglucose intolerance
p8692
sg13
I2
sa(dp8693
g7
I43
sg17
VC0028754
p8694
sg10
I7
sg11
Vobesity
p8695
sg13
I1
sasa(dp8696
g2
S'Overall, our results suggest that SR membrane DHA content and unsaturation, and, in part, sarcolipin expression may contribute to SR Ca(2+) permeability and, in turn, may have implications in muscle-based metabolism and diet-induced obesity.\n'
p8697
sg4
(lp8698
(dp8699
g7
I90
sg8
g49
sg10
I10
sg11
Vsarcolipin
p8700
sg13
I1
sasg14
(lp8701
(dp8702
g7
I233
sg17
VC0028754
p8703
sg10
I7
sg11
Vobesity
p8704
sg13
I1
sasa(dp8705
g2
S'In situ hybridization for two selected transcripts (CA7, CXCL1) was performed on NAT (n = 3), adenoma (n = 3) and CRC (n = 3) FFPE samples.\n'
p8706
sg4
(lp8707
(dp8708
g7
I57
sg8
VP09341
p8709
sg10
I5
sg11
VCXCL1
p8710
sg13
I1
sa(dp8711
g7
I52
sg8
VP43166
p8712
sg10
I3
sg11
VCA7
p8713
sg13
I1
sasg14
(lp8714
(dp8715
g7
I94
sg17
VC0001430
p8716
sg10
I7
sg11
Vadenoma
p8717
sg13
I1
sa(dp8718
g7
I114
sg17
VC1527249
p8719
sg10
I3
sg11
VCRC
p8720
sg13
I1
sasa(dp8721
g2
S'In situ hybridization could confirm the upregulation of CXCL1 and downregulation of CA7 in colorectal adenomas and tumors compared to healthy controls.\n'
p8722
sg4
(lp8723
(dp8724
g7
I56
sg8
VP09341
p8725
sg10
I5
sg11
VCXCL1
p8726
sg13
I1
sa(dp8727
g7
I84
sg8
VP43166
p8728
sg10
I3
sg11
VCA7
p8729
sg13
I1
sasg14
(lp8730
(dp8731
g7
I115
sg17
VC0027651
p8732
sg10
I6
sg11
Vtumors
p8733
sg13
I1
sa(dp8734
g7
I91
sg17
VC1302401
p8735
sg10
I19
sg11
Vcolorectal adenomas
p8736
sg13
I2
sasa(dp8737
g2
S'A set of 26 transcripts [including matrix metalloproteinase-3 (MMP3) and chemokine (C-X-C motif) ligand 1 (CXCL1)] has been determined recently, indicating a linear expression correlation with the adenoma-dysplasia-carcinoma sequence, thereby having the potential to discriminate between dysplasia and early malignancy.\n'
p8738
sg4
(lp8739
(dp8740
g7
I35
sg8
VP08254
p8741
sg10
I26
sg11
Vmatrix metalloproteinase-3
p8742
sg13
I2
sa(dp8743
g7
I63
sg8
VP08254
p8744
sg10
I4
sg11
VMMP3
p8745
sg13
I1
sasg14
(lp8746
(dp8747
g7
I215
sg17
VC0007097
p8748
sg10
I9
sg11
Vcarcinoma
p8749
sg13
I1
sa(dp8750
g7
I197
sg17
VC0001430
p8751
sg10
I7
sg11
Vadenoma
p8752
sg13
I1
sa(dp8753
g7
I205
sg17
VC0334044
p8754
sg10
I9
sg11
Vdysplasia
p8755
sg13
I1
sa(dp8756
g7
I308
sg17
VC0006826
p8757
sg10
I10
sg11
Vmalignancy
p8758
sg13
I1
sa(dp8759
g7
I205
sg17
VC0334044
p8760
sg10
I9
sg11
Vdysplasia
p8761
sg13
I1
sasa(dp8762
g2
S'Currently, we find that high-grade dysplastic sessile adenomatous-stage and early-stage colorectal cancer conditions can be differentiated correctly by the stromal expression of MMP3 and CXCL1, respectively, on tissue microarray-based analysis.\n'
p8763
sg4
(lp8764
(dp8765
g7
I178
sg8
VP08254
p8766
sg10
I4
sg11
VMMP3
p8767
sg13
I1
sa(dp8768
g7
I187
sg8
VP09341
p8769
sg10
I5
sg11
VCXCL1
p8770
sg13
I1
sasg14
(lp8771
(dp8772
g7
I35
sg17
VC0334044
p8773
sg10
I10
sg11
Vdysplastic
p8774
sg13
I1
sa(dp8775
g7
I88
sg17
VC1527249
p8776
sg10
I17
sg11
Vcolorectal cancer
p8777
sg13
I2
sasa(dp8778
g2
S'A set of 11 transcripts (including CXCL1, CHI3L1 and GREM1) was determined which could correctly discriminate between high-grade dysplastic adenoma and CRC samples by 100% sensitivity and 88.9% specificity.\n'
p8779
sg4
(lp8780
(dp8781
g7
I42
sg8
VP36222
p8782
sg10
I6
sg11
VCHI3L1
p8783
sg13
I1
sa(dp8784
g7
I35
sg8
VP09341
p8785
sg10
I5
sg11
VCXCL1
p8786
sg13
I1
sa(dp8787
g7
I53
sg8
g49
sg10
I5
sg11
VGREM1
p8788
sg13
I1
sasg14
(lp8789
(dp8790
g7
I129
sg17
VC0334044
p8791
sg10
I10
sg11
Vdysplastic
p8792
sg13
I1
sa(dp8793
g7
I140
sg17
VC0001430
p8794
sg10
I7
sg11
Vadenoma
p8795
sg13
I1
sa(dp8796
g7
I152
sg17
VC1527249
p8797
sg10
I3
sg11
VCRC
p8798
sg13
I1
sasa(dp8799
g2
S'We assessed gene expression profiles of a list of 10 candidate genes (MMP-1, MMP-3, MMP-7, DEFA 1, DEFA-5, DEFA-6, IL-8, CXCL-1, SPP-1, CTHRC-1) by quantitative real time PCR in triplets of colonic mucosa (normal, adenoma, tumoral tissue) collected from the same patient during surgery for a group of 20 patients.\n'
p8800
sg4
(lp8801
(dp8802
g7
I77
sg8
VP08254
p8803
sg10
I5
sg11
VMMP-3
p8804
sg13
I1
sa(dp8805
g7
I129
sg8
VP10451
p8806
sg10
I5
sg11
VSPP-1
p8807
sg13
I1
sa(dp8808
g7
I70
sg8
VP03956
p8809
sg10
I5
sg11
VMMP-1
p8810
sg13
I1
sa(dp8811
g7
I84
sg8
VP09237
p8812
sg10
I5
sg11
VMMP-7
p8813
sg13
I1
sasg14
(lp8814
(dp8815
g7
I214
sg17
VC0001430
p8816
sg10
I7
sg11
Vadenoma
p8817
sg13
I1
sasa(dp8818
g2
S'Several inflammatory cytokine genes (CXCL1, CXCL2, CXCL3, CCL20, IL8, CCL23, CCL19, CCL21, CCL5) are dysregulated in adenomas.\n'
p8819
sg4
(lp8820
(dp8821
g7
I37
sg8
VP09341
p8822
sg10
I5
sg11
VCXCL1
p8823
sg13
I1
sa(dp8824
g7
I77
sg8
g49
sg10
I5
sg11
VCCL19
p8825
sg13
I1
sa(dp8826
g7
I70
sg8
VP55773
p8827
sg10
I5
sg11
VCCL23
p8828
sg13
I1
sa(dp8829
g7
I44
sg8
VP19875
p8830
sg10
I5
sg11
VCXCL2
p8831
sg13
I1
sa(dp8832
g7
I84
sg8
g49
sg10
I5
sg11
VCCL21
p8833
sg13
I1
sa(dp8834
g7
I51
sg8
VP19876
p8835
sg10
I5
sg11
VCXCL3
p8836
sg13
I1
sa(dp8837
g7
I58
sg8
VP78556
p8838
sg10
I5
sg11
VCCL20
p8839
sg13
I1
sa(dp8840
g7
I91
sg8
VP13501
p8841
sg10
I4
sg11
VCCL5
p8842
sg13
I1
sasg14
(lp8843
(dp8844
g7
I117
sg17
VC0001430
p8845
sg10
I8
sg11
Vadenomas
p8846
sg13
I1
sasa(dp8847
g2
S'Expression of GROalpha mRNA was higher in primary adenocarcinomas (n = 132), adenomas (n = 32), and metastases (n = 52) than in normal colon epithelium (P &lt; 0.001).\n'
p8848
sg4
(lp8849
(dp8850
g7
I14
sg8
VP09341
p8851
sg10
I13
sg11
VGROalpha mRNA
p8852
sg13
I2
sasg14
(lp8853
(dp8854
g7
I100
sg17
VC0027627
p8855
sg10
I10
sg11
Vmetastases
p8856
sg13
I1
sa(dp8857
g7
I77
sg17
VC0001430
p8858
sg10
I8
sg11
Vadenomas
p8859
sg13
I1
sa(dp8860
g7
I50
sg17
VC0001418
p8861
sg10
I15
sg11
Vadenocarcinomas
p8862
sg13
I1
sasa(dp8863
g2
S'Finally, Kibra complexes with Wts and kibra depletion in tissue culture cells induces a marked reduction in Yki phosphorylation without affecting the Yki/Wts interaction.\n'
p8864
sg4
(lp8865
(dp8866
g7
I30
sg8
g49
sg10
I3
sg11
VWts
p8867
sg13
I1
sa(dp8868
g7
I108
sg8
VP46937
p8869
sg10
I3
sg11
VYki
p8870
sg13
I1
sa(dp8871
g7
I30
sg8
g49
sg10
I3
sg11
VWts
p8872
sg13
I1
sasg14
(lp8873
(dp8874
g7
I30
sg17
VC1839736
p8875
sg10
I3
sg11
VWts
p8876
sg13
I1
sa(dp8877
g7
I30
sg17
VC1839736
p8878
sg10
I3
sg11
VWts
p8879
sg13
I1
sasa(dp8880
g2
S'A targeted analysis of the PCCA and PCCB genes using available WES data from 157 further DCM patients subsequently identified another patient with propionic acidemia.\n'
p8881
sg4
(lp8882
(dp8883
g7
I27
sg8
VP05165
p8884
sg10
I4
sg11
VPCCA
p8885
sg13
I1
sa(dp8886
g7
I36
sg8
VP05166
p8887
sg10
I10
sg11
VPCCB genes
p8888
sg13
I2
sasg14
(lp8889
(dp8890
g7
I147
sg17
VC0268579
p8891
sg10
I18
sg11
Vpropionic acidemia
p8892
sg13
I2
sa(dp8893
g7
I27
sg17
VC3151140
p8894
sg10
I4
sg11
VPCCA
p8895
sg13
I1
sasa(dp8896
g2
S'A regulatory region within the PCCB gene, a gene previously associated with schizophrenia, exhibited a suggestive association.\n'
p8897
sg4
(lp8898
(dp8899
g7
I31
sg8
VP05166
p8900
sg10
I9
sg11
VPCCB gene
p8901
sg13
I2
sasg14
(lp8902
(dp8903
g7
I76
sg17
VC0036341
p8904
sg10
I13
sg11
Vschizophrenia
p8905
sg13
I1
sasa(dp8906
g2
S'We report three patients with elevations of propionylcarnitine (C3), one without elevations of 2-methylcitrate and 3-hydroxypropionate in urine organic acid analysis, and the other two showing only mild elevations, all of whom were subsequently confirmed to have propionic acidemia by molecular analysis of PCCA and PCCB genes.\n'
p8907
sg4
(lp8908
(dp8909
g7
I316
sg8
VP05166
p8910
sg10
I10
sg11
VPCCB genes
p8911
sg13
I2
sa(dp8912
g7
I307
sg8
VP05165
p8913
sg10
I4
sg11
VPCCA
p8914
sg13
I1
sasg14
(lp8915
(dp8916
g7
I263
sg17
VC0268579
p8917
sg10
I18
sg11
Vpropionic acidemia
p8918
sg13
I2
sa(dp8919
g7
I307
sg17
VC3151140
p8920
sg10
I4
sg11
VPCCA
p8921
sg13
I1
sasa(dp8922
g2
S'Five of the eight patients were diagnosed with Autism Spectrum Disorder, four of them had pathogenic variants in PCCB.\n'
p8923
sg4
(lp8924
sg14
(lp8925
(dp8926
g7
I47
sg17
VC1510586
p8927
sg10
I24
sg11
VAutism Spectrum Disorder
p8928
sg13
I3
sasa(dp8929
g2
S'Propionic acidemia (PA) is an inborn error of metabolism, caused by mutations in either the PCCA or PCCB gene, leading to mitochondrial accumulation of propionyl-CoA and its by-products.\n'
p8930
sg4
(lp8931
(dp8932
g7
I92
sg8
VP05165
p8933
sg10
I4
sg11
VPCCA
p8934
sg13
I1
sa(dp8935
g7
I100
sg8
VP05166
p8936
sg10
I9
sg11
VPCCB gene
p8937
sg13
I2
sasg14
(lp8938
(dp8939
g7
I20
sg17
VC0268579
p8940
sg10
I2
sg11
VPA
p8941
sg13
I1
sa(dp8942
g7
I162
sg17
VC2678439
p8943
sg10
I3
sg11
VCoA
p8944
sg13
I1
sa(dp8945
g7
I0
sg17
VC0268579
p8946
sg10
I18
sg11
VPropionic acidemia
p8947
sg13
I2
sa(dp8948
g7
I92
sg17
VC3151140
p8949
sg10
I4
sg11
VPCCA
p8950
sg13
I1
sa(dp8951
g7
I30
sg17
VC0025521
p8952
sg10
I26
sg11
Vinborn error of metabolism
p8953
sg13
I4
sasa(dp8954
g2
S'Propionic acidemia (PA) is a disorder of intermediary metabolism with defects in the alpha or beta subunits of propionyl CoA carboxylase (PCCA and PCCB respectively) enzyme.\n'
p8955
sg4
(lp8956
(dp8957
g7
I147
sg8
VP05166
p8958
sg10
I4
sg11
VPCCB
p8959
sg13
I1
sa(dp8960
g7
I111
sg8
VP50747
p8961
sg10
I25
sg11
Vpropionyl CoA carboxylase
p8962
sg13
I3
sa(dp8963
g7
I138
sg8
VP05165
p8964
sg10
I4
sg11
VPCCA
p8965
sg13
I1
sasg14
(lp8966
(dp8967
g7
I20
sg17
VC0268579
p8968
sg10
I2
sg11
VPA
p8969
sg13
I1
sa(dp8970
g7
I0
sg17
VC0268579
p8971
sg10
I18
sg11
VPropionic acidemia
p8972
sg13
I2
sa(dp8973
g7
I121
sg17
VC2678439
p8974
sg10
I3
sg11
VCoA
p8975
sg13
I1
sa(dp8976
g7
I138
sg17
VC3151140
p8977
sg10
I4
sg11
VPCCA
p8978
sg13
I1
sasa(dp8979
g2
S'This study aimed to investigate the association of two single nucleotide polymorphism (SNPs), one in the HLA-DPB1 (rs9277535) and one in the HLA-DQB2 (rs7453920), with chronic hepatitis B infection in a southern Brazilian sample.\n'
p8980
sg4
(lp8981
(dp8982
g7
I141
sg8
VP05538
p8983
sg10
I8
sg11
VHLA-DQB2
p8984
sg13
I1
sa(dp8985
g7
I105
sg8
VP30486
p8986
sg10
I8
sg11
VHLA-DPB1
p8987
sg13
I1
sasg14
(lp8988
(dp8989
g7
I176
sg17
VC0019163
p8990
sg10
I21
sg11
Vhepatitis B infection
p8991
sg13
I3
sasa(dp8992
g2
S'Genotyping and expression analysis in HLA class II gene revealed that two SNPs of HLA-DPB1 (rs2071025 and rs3116996) were significantly correlated to RNA expression and progression of HCV-related liver diseases.\n'
p8993
sg4
(lp8994
(dp8995
g7
I38
sg8
VP30486
p8996
sg10
I17
sg11
VHLA class II gene
p8997
sg13
I4
sa(dp8998
g7
I38
sg8
VP30486
p8999
sg10
I3
sg11
VHLA
p9000
sg13
I1
sasg14
(lp9001
(dp9002
g7
I196
sg17
VC0023895
p9003
sg10
I14
sg11
Vliver diseases
p9004
sg13
I2
sasa(dp9005
g2
S'To investigate the influence of HLA-DP variants on the outcome of HBV infection in an Indonesian population where it has the third-highest prevalence of HBV infection worldwide, we performed a case-control study of 686 participants, including patients with HBV-related advanced or nonadvanced liver disease, patients with spontaneously resolved HBV, and healthy controls.\n'
p9006
sg4
(lp9007
(dp9008
g7
I32
sg8
VP30486
p9009
sg10
I15
sg11
VHLA-DP variants
p9010
sg13
I2
sasg14
(lp9011
(dp9012
g7
I66
sg17
VC0019163
p9013
sg10
I3
sg11
VHBV
p9014
sg13
I1
sa(dp9015
g7
I66
sg17
VC0019163
p9016
sg10
I3
sg11
VHBV
p9017
sg13
I1
sa(dp9018
g7
I66
sg17
VC0019163
p9019
sg10
I3
sg11
VHBV
p9020
sg13
I1
sa(dp9021
g7
I70
sg17
VC0009450
p9022
sg10
I9
sg11
Vinfection
p9023
sg13
I1
sa(dp9024
g7
I66
sg17
VC0019163
p9025
sg10
I3
sg11
VHBV
p9026
sg13
I1
sa(dp9027
g7
I70
sg17
VC0009450
p9028
sg10
I9
sg11
Vinfection
p9029
sg13
I1
sa(dp9030
g7
I293
sg17
VC0023895
p9031
sg10
I13
sg11
Vliver disease
p9032
sg13
I2
sasa(dp9033
g2
S"We also found that the SNPs in the 3'-UTR region of HLA-DPB1 were significant between the subgroups of inactive HBV carrier, chronic hepatitis B, or hepatic cirrhosis from the case group and the spontaneous HBV-clearance subgroup from the control group.\n"
p9034
sg4
(lp9035
(dp9036
g7
I52
sg8
VP30486
p9037
sg10
I8
sg11
VHLA-DPB1
p9038
sg13
I1
sasg14
(lp9039
(dp9040
g7
I125
sg17
VC0524909
p9041
sg10
I19
sg11
Vchronic hepatitis B
p9042
sg13
I3
sa(dp9043
g7
I149
sg17
VC0023890
p9044
sg10
I17
sg11
Vhepatic cirrhosis
p9045
sg13
I2
sa(dp9046
g7
I112
sg17
VC0019163
p9047
sg10
I3
sg11
VHBV
p9048
sg13
I1
sa(dp9049
g7
I112
sg17
VC0019163
p9050
sg10
I3
sg11
VHBV
p9051
sg13
I1
sasa(dp9052
g2
S'To investigate the genetic association between cirrhosis and polymorphisms in the genes encoding major histocompatibility complex, class II (HLA)-DR beta 1 (DRB1) and HLA-DP beta 1 (DPB1).\n'
p9053
sg4
(lp9054
(dp9055
g7
I182
sg8
VP30486
p9056
sg10
I4
sg11
VDPB1
p9057
sg13
I1
sa(dp9058
g7
I167
sg8
VP30486
p9059
sg10
I13
sg11
VHLA-DP beta 1
p9060
sg13
I3
sa(dp9061
g7
I97
sg8
VP18464
p9062
sg10
I58
sg11
Vmajor histocompatibility complex, class II (HLA)-DR beta 1
p9063
sg13
I8
sa(dp9064
g7
I157
sg8
g49
sg10
I4
sg11
VDRB1
p9065
sg13
I1
sasg14
(lp9066
(dp9067
g7
I47
sg17
VC0023890
p9068
sg10
I9
sg11
Vcirrhosis
p9069
sg13
I1
sasa(dp9070
g2
S'A population of 168 parent/offspring trios, in which the proband had a diagnosis of hepatitis B virus infection with clinical signs of cirrhosis.The HLA-DRB1 and DPB 1 gene polymorphisms of rs24755213 and rs202176660 were detected by PCR and single nucleotide polymorphism (SNP) genotyping.Correlation analysis and haplotype relative risk analysis were carried out.\n'
p9071
sg4
(lp9072
(dp9073
g7
I149
sg8
VP20039
p9074
sg10
I8
sg11
VHLA-DRB1
p9075
sg13
I1
sasg14
(lp9076
(dp9077
g7
I162
sg17
VC0878555
p9078
sg10
I3
sg11
VDPB
p9079
sg13
I1
sa(dp9080
g7
I94
sg17
VC0037140
p9081
sg10
I17
sg11
VB virus infection
p9082
sg13
I3
sa(dp9083
g7
I135
sg17
VC0023890
p9084
sg10
I9
sg11
Vcirrhosis
p9085
sg13
I1
sasa(dp9086
g2
S'A/G genotypes were detected in rs24755213 of HLA-DRB1 and C/T genotypes were detected in rs202176660 of DPB1.The rs24755213 allele was associated with cirrhosis (P=0.014), with the G allele identified as a protective factor (Z=-2.33) and the A allele identified as a hazard factor (Z=2.33).The rs202176660 allele was also associated with cirrhosis (P =0.026), with the T allele identified as a protective factor (Z=-2.06) and the C allele identified as a hazard factor (Z=2.06).The haplotypes of G/T and A/C in rs24755213 and rs202176660 respectively were associated with cirrhosis (P =0.037 and 0.002, Z=-2.12 and 2.09 respectively).\n'
p9087
sg4
(lp9088
(dp9089
g7
I45
sg8
VP30486
p9090
sg10
I3
sg11
VHLA
p9091
sg13
I1
sa(dp9092
g7
I49
sg8
g49
sg10
I4
sg11
VDRB1
p9093
sg13
I1
sasg14
(lp9094
(dp9095
g7
I151
sg17
VC0023890
p9096
sg10
I9
sg11
Vcirrhosis
p9097
sg13
I1
sa(dp9098
g7
I151
sg17
VC0023890
p9099
sg10
I9
sg11
Vcirrhosis
p9100
sg13
I1
sa(dp9101
g7
I151
sg17
VC0023890
p9102
sg10
I9
sg11
Vcirrhosis
p9103
sg13
I1
sasa(dp9104
g2
S'In this group of Chinese patients with hepatitis B virus-related cirrhosis, polymorphisms in the HLA-DRB 1 and DPB1 genes were associated with cimhosis.\n'
p9105
sg4
(lp9106
(dp9107
g7
I111
sg8
VP01893
p9108
sg10
I10
sg11
VDPB1 genes
p9109
sg13
I2
sa(dp9110
g7
I97
sg8
g49
sg10
I9
sg11
VHLA-DRB 1
p9111
sg13
I2
sasg14
(lp9112
(dp9113
g7
I39
sg17
VC0019163
p9114
sg10
I11
sg11
Vhepatitis B
p9115
sg13
I2
sa(dp9116
g7
I65
sg17
VC0023890
p9117
sg10
I9
sg11
Vcirrhosis
p9118
sg13
I1
sasa(dp9119
g2
S'Previous studies have shown that genetic variants in HLA-DP genes affect disease progression in hepatitis B virus (HBV) infection.\n'
p9120
sg4
(lp9121
(dp9122
g7
I53
sg8
VP30486
p9123
sg10
I12
sg11
VHLA-DP genes
p9124
sg13
I2
sasg14
(lp9125
(dp9126
g7
I115
sg17
VC0019163
p9127
sg10
I3
sg11
VHBV
p9128
sg13
I1
sa(dp9129
g7
I73
sg17
VC0242656
p9130
sg10
I19
sg11
Vdisease progression
p9131
sg13
I2
sa(dp9132
g7
I120
sg17
VC0009450
p9133
sg10
I9
sg11
Vinfection
p9134
sg13
I1
sa(dp9135
g7
I96
sg17
VC0019163
p9136
sg10
I17
sg11
Vhepatitis B virus
p9137
sg13
I3
sasa(dp9138
g2
S'We aimed to evaluate possible association between HLA-DPB1 rs9277534 polymorphism and different clinical complications of hepatitis B virus (HBV) infection.\n'
p9139
sg4
(lp9140
(dp9141
g7
I50
sg8
VP30486
p9142
sg10
I18
sg11
VHLA-DPB1 rs9277534
p9143
sg13
I2
sasg14
(lp9144
(dp9145
g7
I122
sg17
VC0019163
p9146
sg10
I17
sg11
Vhepatitis B virus
p9147
sg13
I3
sa(dp9148
g7
I146
sg17
VC0009450
p9149
sg10
I9
sg11
Vinfection
p9150
sg13
I1
sa(dp9151
g7
I141
sg17
VC0019163
p9152
sg10
I3
sg11
VHBV
p9153
sg13
I1
sasa(dp9154
g2
S'Gamma-glutamylcysteine synthetase deficiency is also associated with hemolytic anemia, and some patients with this disorder show defects of neuromuscular function and generalized aminoaciduria.\n'
p9155
sg4
(lp9156
(dp9157
g7
I0
sg8
VP48507
p9158
sg10
I33
sg11
VGamma-glutamylcysteine synthetase
p9159
sg13
I2
sasg14
(lp9160
(dp9161
g7
I179
sg17
VC0238621
p9162
sg10
I13
sg11
Vaminoaciduria
p9163
sg13
I1
sa(dp9164
g7
I69
sg17
VC0002878
p9165
sg10
I16
sg11
Vhemolytic anemia
p9166
sg13
I2
sa(dp9167
g7
I0
sg17
VC0268523
p9168
sg10
I44
sg11
VGamma-glutamylcysteine synthetase deficiency
p9169
sg13
I3
sasa(dp9170
g2
S'miR-193b-3p was found to be downregulated and contributed to ovarian cancer (OC) progression.\n'
p9171
sg4
(lp9172
(dp9173
g7
I0
sg8
g49
sg10
I11
sg11
VmiR-193b-3p
p9174
sg13
I1
sasg14
(lp9175
(dp9176
g7
I61
sg17
VC1140680
p9177
sg10
I14
sg11
Vovarian cancer
p9178
sg13
I2
sasa(dp9179
g2
S'We reported that oncogene SNHG7 predicted a poor clinical outcome and functioned as competitive endogenous RNA (ceRNA) antagonized microRNA-193b (miR-193b) to up-regulate the FAIM2 level in NSCLC.\n'
p9180
sg4
(lp9181
(dp9182
g7
I175
sg8
g49
sg10
I5
sg11
VFAIM2
p9183
sg13
I1
sasg14
(lp9184
(dp9185
g7
I190
sg17
VC0007131
p9186
sg10
I5
sg11
VNSCLC
p9187
sg13
I1
sasa(dp9188
g2
S'Bioinformatic analysis predicted that SNHG7 harboured miR-193b-binding sites, and we found decreased miR-193b levels in NSCLC tissues when compared to relative normal tissues.\n'
p9189
sg4
(lp9190
(dp9191
g7
I54
sg8
g49
sg10
I22
sg11
VmiR-193b-binding sites
p9192
sg13
I2
sasg14
(lp9193
(dp9194
g7
I120
sg17
VC0007131
p9195
sg10
I5
sg11
VNSCLC
p9196
sg13
I1
sasa(dp9197
g2
S'The restoration of miR-193b levels in NSCLC cell lines A549 and H125 suppressed the expression of FAIM2 and related tumour proliferation, metastasis and induced apoptosis.\n'
p9198
sg4
(lp9199
(dp9200
g7
I98
sg8
g49
sg10
I5
sg11
VFAIM2
p9201
sg13
I1
sasg14
(lp9202
(dp9203
g7
I38
sg17
VC0007131
p9204
sg10
I5
sg11
VNSCLC
p9205
sg13
I1
sa(dp9206
g7
I138
sg17
VC0027627
p9207
sg10
I10
sg11
Vmetastasis
p9208
sg13
I1
sa(dp9209
g7
I116
sg17
VC0027651
p9210
sg10
I6
sg11
Vtumour
p9211
sg13
I1
sa(dp9212
g7
I123
sg17
VC0334094
p9213
sg10
I13
sg11
Vproliferation
p9214
sg13
I1
sasa(dp9215
g2
S'The results indicated that miR-193b is indispensible for the ceRNA role of SNHG7 in FAIM2-supported tumourigenesis of lung cancer.\n'
p9216
sg4
(lp9217
(dp9218
g7
I27
sg8
g49
sg10
I8
sg11
VmiR-193b
p9219
sg13
I1
sa(dp9220
g7
I84
sg8
g49
sg10
I5
sg11
VFAIM2
p9221
sg13
I1
sasg14
(lp9222
(dp9223
g7
I118
sg17
VC0684249
p9224
sg10
I11
sg11
Vlung cancer
p9225
sg13
I2
sasa(dp9226
g2
S'In this study, we evaluated the functions of miRNA (miR-193b) in liposarcoma in vitro and in vivo Deep RNA sequencing on 93 WDLS, 145 DDLS, and 12 normal fat samples demonstrated that miR-193b was significantly underexpressed in DDLS compared with normal fat.\n'
p9227
sg4
(lp9228
(dp9229
g7
I52
sg8
g49
sg10
I8
sg11
VmiR-193b
p9230
sg13
I1
sa(dp9231
g7
I52
sg8
g49
sg10
I8
sg11
VmiR-193b
p9232
sg13
I1
sasg14
(lp9233
(dp9234
g7
I65
sg17
VC0023827
p9235
sg10
I11
sg11
Vliposarcoma
p9236
sg13
I1
sasa(dp9237
g2
S'Reintroduction of miR-193b induced apoptosis in liposarcoma cells and promoted adipogenesis in human adipose-derived stem cells (ASC).\n'
p9238
sg4
(lp9239
(dp9240
g7
I18
sg8
g49
sg10
I8
sg11
VmiR-193b
p9241
sg13
I1
sasg14
(lp9242
(dp9243
g7
I48
sg17
VC0023827
p9244
sg10
I11
sg11
Vliposarcoma
p9245
sg13
I1
sasa(dp9246
g2
S'miR-193b also stimulated reactive oxygen species signaling by targeting the antioxidant methionine sulfoxide reductase A to modulate liposarcoma cell survival and ASC differentiation state.\n'
p9247
sg4
(lp9248
(dp9249
g7
I0
sg8
g49
sg10
I8
sg11
VmiR-193b
p9250
sg13
I1
sa(dp9251
g7
I88
sg8
g49
sg10
I32
sg11
Vmethionine sulfoxide reductase A
p9252
sg13
I4
sasg14
(lp9253
(dp9254
g7
I133
sg17
VC0023827
p9255
sg10
I11
sg11
Vliposarcoma
p9256
sg13
I1
sasa(dp9257
g2
S'Expression of miR-193b in liposarcoma cells was downregulated by promoter methylation, resulting at least in part from increased expression of the DNA methyltransferase DNMT1 in WDLS/DDLS.\n'
p9258
sg4
(lp9259
(dp9260
g7
I14
sg8
g49
sg10
I8
sg11
VmiR-193b
p9261
sg13
I1
sa(dp9262
g7
I147
sg8
VP26358
p9263
sg10
I27
sg11
VDNA methyltransferase DNMT1
p9264
sg13
I3
sasg14
(lp9265
(dp9266
g7
I26
sg17
VC0023827
p9267
sg10
I11
sg11
Vliposarcoma
p9268
sg13
I1
sasa(dp9269
g2
S'In vivo, miR-193b mimetics and FAK inhibitor (PF-562271) each inhibited liposarcoma xenograft growth.\n'
p9270
sg4
(lp9271
(dp9272
g7
I31
sg8
g49
sg10
I3
sg11
VFAK
p9273
sg13
I1
sasg14
(lp9274
(dp9275
g7
I72
sg17
VC0023827
p9276
sg10
I11
sg11
Vliposarcoma
p9277
sg13
I1
sasa(dp9278
g2
S'In summary, miR-193b not only functions as a tumor suppressor in liposarcoma but also promotes adipogenesis in ASC.\n'
p9279
sg4
(lp9280
(dp9281
g7
I12
sg8
g49
sg10
I8
sg11
VmiR-193b
p9282
sg13
I1
sasg14
(lp9283
(dp9284
g7
I65
sg17
VC0023827
p9285
sg10
I11
sg11
Vliposarcoma
p9286
sg13
I1
sa(dp9287
g7
I45
sg17
VC0027651
p9288
sg10
I5
sg11
Vtumor
p9289
sg13
I1
sasa(dp9290
g2
S'The miRNA signature consists of the 18 miRNAs which strongly correlates with lung adenocarcinoma: hsa-let-7f-1, hsa-miR-16-1, hsa-miR-152, hsa-miR-217, hsa-miR-18a, hsa-miR-193b, hsa-miR-3136, hsa-let-7g, hsa-miR-155, hsa-miR-3199-1, hsa-miR-219-2, hsa-miR-1254, hsa-miR-1291, hsa-miR-192, hsa-miR-3653, hsa-miR-3934, hsa-miR-342, and hsa-miR-141.\n'
p9291
sg4
(lp9292
(dp9293
g7
I193
sg8
g49
sg10
I10
sg11
Vhsa-let-7g
p9294
sg13
I1
sa(dp9295
g7
I98
sg8
g49
sg10
I3
sg11
Vhsa
p9296
sg13
I1
sa(dp9297
g7
I277
sg8
g49
sg10
I11
sg11
Vhsa-miR-192
p9298
sg13
I1
sa(dp9299
g7
I139
sg8
g49
sg10
I11
sg11
Vhsa-miR-217
p9300
sg13
I1
sa(dp9301
g7
I126
sg8
g49
sg10
I11
sg11
Vhsa-miR-152
p9302
sg13
I1
sa(dp9303
g7
I112
sg8
g49
sg10
I12
sg11
Vhsa-miR-16-1
p9304
sg13
I1
sa(dp9305
g7
I179
sg8
g49
sg10
I12
sg11
Vhsa-miR-3136
p9306
sg13
I1
sa(dp9307
g7
I98
sg8
g49
sg10
I12
sg11
Vhsa-let-7f-1
p9308
sg13
I1
sa(dp9309
g7
I304
sg8
g49
sg10
I12
sg11
Vhsa-miR-3934
p9310
sg13
I1
sa(dp9311
g7
I218
sg8
g49
sg10
I14
sg11
Vhsa-miR-3199-1
p9312
sg13
I1
sa(dp9313
g7
I318
sg8
g49
sg10
I11
sg11
Vhsa-miR-342
p9314
sg13
I1
sa(dp9315
g7
I205
sg8
g49
sg10
I11
sg11
Vhsa-miR-155
p9316
sg13
I1
sa(dp9317
g7
I263
sg8
g49
sg10
I12
sg11
Vhsa-miR-1291
p9318
sg13
I1
sa(dp9319
g7
I249
sg8
g49
sg10
I12
sg11
Vhsa-miR-1254
p9320
sg13
I1
sa(dp9321
g7
I165
sg8
g49
sg10
I12
sg11
Vhsa-miR-193b
p9322
sg13
I1
sa(dp9323
g7
I290
sg8
g49
sg10
I12
sg11
Vhsa-miR-3653
p9324
sg13
I1
sa(dp9325
g7
I152
sg8
g49
sg10
I11
sg11
Vhsa-miR-18a
p9326
sg13
I1
sa(dp9327
g7
I234
sg8
g49
sg10
I13
sg11
Vhsa-miR-219-2
p9328
sg13
I1
sasg14
(lp9329
(dp9330
g7
I98
sg17
VC0393754
p9331
sg10
I3
sg11
Vhsa
p9332
sg13
I1
sa(dp9333
g7
I98
sg17
VC0393754
p9334
sg10
I3
sg11
Vhsa
p9335
sg13
I1
sa(dp9336
g7
I98
sg17
VC0393754
p9337
sg10
I3
sg11
Vhsa
p9338
sg13
I1
sa(dp9339
g7
I98
sg17
VC0393754
p9340
sg10
I3
sg11
Vhsa
p9341
sg13
I1
sa(dp9342
g7
I98
sg17
VC0393754
p9343
sg10
I3
sg11
Vhsa
p9344
sg13
I1
sa(dp9345
g7
I98
sg17
VC0393754
p9346
sg10
I3
sg11
Vhsa
p9347
sg13
I1
sa(dp9348
g7
I98
sg17
VC0393754
p9349
sg10
I3
sg11
Vhsa
p9350
sg13
I1
sa(dp9351
g7
I98
sg17
VC0393754
p9352
sg10
I3
sg11
Vhsa
p9353
sg13
I1
sa(dp9354
g7
I98
sg17
VC0393754
p9355
sg10
I3
sg11
Vhsa
p9356
sg13
I1
sa(dp9357
g7
I77
sg17
VC0152013
p9358
sg10
I19
sg11
Vlung adenocarcinoma
p9359
sg13
I2
sa(dp9360
g7
I98
sg17
VC0393754
p9361
sg10
I3
sg11
Vhsa
p9362
sg13
I1
sa(dp9363
g7
I98
sg17
VC0393754
p9364
sg10
I3
sg11
Vhsa
p9365
sg13
I1
sa(dp9366
g7
I98
sg17
VC0393754
p9367
sg10
I3
sg11
Vhsa
p9368
sg13
I1
sa(dp9369
g7
I98
sg17
VC0393754
p9370
sg10
I3
sg11
Vhsa
p9371
sg13
I1
sa(dp9372
g7
I98
sg17
VC0393754
p9373
sg10
I3
sg11
Vhsa
p9374
sg13
I1
sa(dp9375
g7
I98
sg17
VC0393754
p9376
sg10
I3
sg11
Vhsa
p9377
sg13
I1
sa(dp9378
g7
I98
sg17
VC0393754
p9379
sg10
I3
sg11
Vhsa
p9380
sg13
I1
sa(dp9381
g7
I98
sg17
VC0393754
p9382
sg10
I3
sg11
Vhsa
p9383
sg13
I1
sa(dp9384
g7
I98
sg17
VC0393754
p9385
sg10
I3
sg11
Vhsa
p9386
sg13
I1
sasa(dp9387
g2
S'Together, our studies show that the EWS/Fli1-repressed miR-193b is growth suppressive in Ewing Sarcoma, and identify ErbB4 as a target gene and candidate mediator of this growth suppression.\n'
p9388
sg4
(lp9389
(dp9390
g7
I55
sg8
g49
sg10
I8
sg11
VmiR-193b
p9391
sg13
I1
sa(dp9392
g7
I117
sg8
g49
sg10
I5
sg11
VErbB4
p9393
sg13
I1
sa(dp9394
g7
I36
sg8
g49
sg10
I3
sg11
VEWS
p9395
sg13
I1
sa(dp9396
g7
I40
sg8
g49
sg10
I4
sg11
VFli1
p9397
sg13
I1
sasg14
(lp9398
(dp9399
g7
I171
sg17
VC0151686
p9400
sg10
I18
sg11
Vgrowth suppression
p9401
sg13
I2
sa(dp9402
g7
I89
sg17
VC0553580
p9403
sg10
I13
sg11
VEwing Sarcoma
p9404
sg13
I2
sasa(dp9405
g2
S'Most notably, we demonstrate that the C77G polymorphism, which correlates with autoimmune disease susceptibility in humans, disrupts exon silencing by preventing the redundant activity of hnRNPs K and E2 to compensate for the weakened function of hnRNP L. Therefore, these studies provide an important example of the functional relevance of combinatorial function in splicing regulation and suggest that additional polymorphisms may similarly disrupt function of the ESS1 silencer.\n'
p9406
sg4
(lp9407
(dp9408
g7
I247
sg8
VP14866
p9409
sg10
I7
sg11
VhnRNP L
p9410
sg13
I2
sa(dp9411
g7
I79
sg8
g49
sg10
I33
sg11
Vautoimmune disease susceptibility
p9412
sg13
I3
sa(dp9413
g7
I188
sg8
g49
sg10
I8
sg11
VhnRNPs K
p9414
sg13
I2
sasg14
(lp9415
(dp9416
g7
I79
sg17
VC0004364
p9417
sg10
I18
sg11
Vautoimmune disease
p9418
sg13
I2
sasa(dp9419
g2
S"Closely related sets of lacZ mRNAs, carrying 5'-leaders from the PYK1, PGK1, RpL3, Rp29, HSP12, HSP26 or THI4 mRNAs, were studied.\n"
p9420
sg4
(lp9421
(dp9422
g7
I77
sg8
VP09001
p9423
sg10
I4
sg11
VRpL3
p9424
sg13
I1
sa(dp9425
g7
I71
sg8
VP00558
p9426
sg10
I4
sg11
VPGK1
p9427
sg13
I1
sasg14
(lp9428
(dp9429
g7
I83
sg17
VC2677325
p9430
sg10
I4
sg11
VRp29
p9431
sg13
I1
sasa(dp9432
g2
S'RNA blot hybridization analysis showed that the steady-state level of the SUP45+ transcript is less than 10% of that for ribosomal protein L3 or rp59 transcripts.\n'
p9433
sg4
(lp9434
(dp9435
g7
I121
sg8
VP39023
p9436
sg10
I20
sg11
Vribosomal protein L3
p9437
sg13
I3
sasg14
(lp9438
(dp9439
g7
I145
sg17
VC3151227
p9440
sg10
I4
sg11
Vrp59
p9441
sg13
I1
sasa(dp9442
g2
S"We assessed the therapeutic efficacy of NMN and the role of SIRT3 in the Friedreich's ataxia cardiomyopathy mouse model (FXN-KO).\n"
p9443
sg4
(lp9444
(dp9445
g7
I121
sg8
VP51587
p9446
sg10
I6
sg11
VFXN-KO
p9447
sg13
I1
sa(dp9448
g7
I60
sg8
g49
sg10
I5
sg11
VSIRT3
p9449
sg13
I1
sasg14
(lp9450
(dp9451
g7
I93
sg17
VC0878544
p9452
sg10
I14
sg11
Vcardiomyopathy
p9453
sg13
I1
sa(dp9454
g7
I73
sg17
VC0016719
p9455
sg10
I19
sg11
VFriedreich's ataxia
p9456
sg13
I2
sasa(dp9457
g2
S"Taken together, these results serve as important preclinical data for NMN supplementation or SIRT3 activator therapy in Friedreich's ataxia patients.\n"
p9458
sg4
(lp9459
(dp9460
g7
I93
sg8
g49
sg10
I15
sg11
VSIRT3 activator
p9461
sg13
I2
sasg14
(lp9462
(dp9463
g7
I120
sg17
VC0016719
p9464
sg10
I19
sg11
VFriedreich's ataxia
p9465
sg13
I2
sasa(dp9466
g2
S'This case suggests that 3D-FLAIR-VISTA images are useful for the visualisation of acute vestibular neuritis.\n'
p9467
sg4
(lp9468
sg14
(lp9469
(dp9470
g7
I82
sg17
VC0153113
p9471
sg10
I25
sg11
Vacute vestibular neuritis
p9472
sg13
I3
sasa(dp9473
g2
S'To evaluate the neurovascular compression (NVC) in patients with trigeminal neuralgia (TN) using T2 VISTA and FLAIR VISTA fusion imaging.\n'
p9474
sg4
(lp9475
sg14
(lp9476
(dp9477
g7
I87
sg17
VC0040997
p9478
sg10
I2
sg11
VTN
p9479
sg13
I1
sa(dp9480
g7
I65
sg17
VC0040997
p9481
sg10
I20
sg11
Vtrigeminal neuralgia
p9482
sg13
I2
sasa(dp9483
g2
S'BTB/POZ domain-containing protein 7 (Btbd7) has been found in various cancers, including lung cancer and liver cancer, but the role of Btbd7 in non-small cell lung cancer (NSCLC), CSC self-renewal, and chemoresistance is still unknown.\n'
p9484
sg4
(lp9485
(dp9486
g7
I0
sg8
g49
sg10
I35
sg11
VBTB/POZ domain-containing protein 7
p9487
sg13
I4
sa(dp9488
g7
I37
sg8
g49
sg10
I5
sg11
VBtbd7
p9489
sg13
I1
sa(dp9490
g7
I37
sg8
g49
sg10
I5
sg11
VBtbd7
p9491
sg13
I1
sasg14
(lp9492
(dp9493
g7
I105
sg17
VC0345904
p9494
sg10
I12
sg11
Vliver cancer
p9495
sg13
I2
sa(dp9496
g7
I172
sg17
VC0007131
p9497
sg10
I5
sg11
VNSCLC
p9498
sg13
I1
sa(dp9499
g7
I70
sg17
VC0006826
p9500
sg10
I7
sg11
Vcancers
p9501
sg13
I1
sa(dp9502
g7
I89
sg17
VC0684249
p9503
sg10
I11
sg11
Vlung cancer
p9504
sg13
I2
sa(dp9505
g7
I144
sg17
VC0007131
p9506
sg10
I26
sg11
Vnon-small cell lung cancer
p9507
sg13
I4
sasa(dp9508
g2
S'In conclusion, our results suggest that Btbd7 is a promising agent for the inhibition of survival and chemoresistance of cancer stem-like cells of NSCLC, which may act as an important therapeutic target in NSCLC.\n'
p9509
sg4
(lp9510
(dp9511
g7
I40
sg8
g49
sg10
I5
sg11
VBtbd7
p9512
sg13
I1
sasg14
(lp9513
(dp9514
g7
I147
sg17
VC0007131
p9515
sg10
I5
sg11
VNSCLC
p9516
sg13
I1
sa(dp9517
g7
I121
sg17
VC0006826
p9518
sg10
I6
sg11
Vcancer
p9519
sg13
I1
sa(dp9520
g7
I147
sg17
VC0007131
p9521
sg10
I5
sg11
VNSCLC
p9522
sg13
I1
sasa(dp9523
g2
S'In present study, we examined BTBD7 expression status and its association with unfavorable clinical features in non-small-cell lung cancer (NSCLC).\n'
p9524
sg4
(lp9525
(dp9526
g7
I30
sg8
g49
sg10
I5
sg11
VBTBD7
p9527
sg13
I1
sasg14
(lp9528
(dp9529
g7
I112
sg17
VC0007131
p9530
sg10
I26
sg11
Vnon-small-cell lung cancer
p9531
sg13
I3
sa(dp9532
g7
I140
sg17
VC0007131
p9533
sg10
I5
sg11
VNSCLC
p9534
sg13
I1
sasa(dp9535
g2
S'Firstly, we studied the fresh specimens, and found that both mRNA and protein expression levels of BTBD7 in NSCLC tissue were significantly increased compared with the adjacent nontumorous lung tissue.\n'
p9536
sg4
(lp9537
(dp9538
g7
I99
sg8
g49
sg10
I5
sg11
VBTBD7
p9539
sg13
I1
sasg14
(lp9540
(dp9541
g7
I108
sg17
VC0007131
p9542
sg10
I5
sg11
VNSCLC
p9543
sg13
I1
sasa(dp9544
g2
S'Then, we determined BTBD7 protein expressions in the paraffin-embedded samples from NSCLC patients, and analyzed the relations of BTBD7 expression with clinicopathologic features of the patients.\n'
p9545
sg4
(lp9546
(dp9547
g7
I20
sg8
g49
sg10
I13
sg11
VBTBD7 protein
p9548
sg13
I2
sa(dp9549
g7
I20
sg8
g49
sg10
I5
sg11
VBTBD7
p9550
sg13
I1
sasg14
(lp9551
(dp9552
g7
I84
sg17
VC0007131
p9553
sg10
I5
sg11
VNSCLC
p9554
sg13
I1
sasa(dp9555
g2
S'The results showed that incidence of metastasis in patients with positive BTBD7 expression was significantly higher than that in those with negative BTBD7 expression, and the positive BTBD7 expression rate in metastatic cases was significantly higher than that in non-metastatic ones; furthermore, Cox regression analyses revealed that BTBD7 was an independent risk factor for either metastasis or survival in NSCLC patients.\n'
p9556
sg4
(lp9557
(dp9558
g7
I74
sg8
g49
sg10
I5
sg11
VBTBD7
p9559
sg13
I1
sa(dp9560
g7
I74
sg8
g49
sg10
I5
sg11
VBTBD7
p9561
sg13
I1
sa(dp9562
g7
I74
sg8
g49
sg10
I5
sg11
VBTBD7
p9563
sg13
I1
sa(dp9564
g7
I74
sg8
g49
sg10
I5
sg11
VBTBD7
p9565
sg13
I1
sasg14
(lp9566
(dp9567
g7
I37
sg17
VC0027627
p9568
sg10
I10
sg11
Vmetastasis
p9569
sg13
I1
sa(dp9570
g7
I37
sg17
VC0027627
p9571
sg10
I10
sg11
Vmetastasis
p9572
sg13
I1
sa(dp9573
g7
I410
sg17
VC0007131
p9574
sg10
I5
sg11
VNSCLC
p9575
sg13
I1
sasa(dp9576
g2
S'Thus, we conclude that BTBD7 contributes to metastasis of NSCLC and BTBD7-positive NSCLC may have a high potential for metastasis and thereby a poor prognosis.\n'
p9577
sg4
(lp9578
(dp9579
g7
I23
sg8
g49
sg10
I5
sg11
VBTBD7
p9580
sg13
I1
sa(dp9581
g7
I23
sg8
g49
sg10
I5
sg11
VBTBD7
p9582
sg13
I1
sasg14
(lp9583
(dp9584
g7
I58
sg17
VC0007131
p9585
sg10
I5
sg11
VNSCLC
p9586
sg13
I1
sa(dp9587
g7
I44
sg17
VC0027627
p9588
sg10
I10
sg11
Vmetastasis
p9589
sg13
I1
sa(dp9590
g7
I58
sg17
VC0007131
p9591
sg10
I5
sg11
VNSCLC
p9592
sg13
I1
sa(dp9593
g7
I44
sg17
VC0027627
p9594
sg10
I10
sg11
Vmetastasis
p9595
sg13
I1
sasa(dp9596
g2
S'Mutations in Nesprin-1 and 2 (also called Syne-1 and 2) are associated with numerous diseases including autism, cerebellar ataxia, cancer, and Emery-Dreifuss muscular dystrophy.\n'
p9597
sg4
(lp9598
sg14
(lp9599
(dp9600
g7
I104
sg17
VC0004352
p9601
sg10
I6
sg11
Vautism
p9602
sg13
I1
sa(dp9603
g7
I143
sg17
VC0410189
p9604
sg10
I33
sg11
VEmery-Dreifuss muscular dystrophy
p9605
sg13
I3
sa(dp9606
g7
I112
sg17
VC0007758
p9607
sg10
I17
sg11
Vcerebellar ataxia
p9608
sg13
I2
sa(dp9609
g7
I131
sg17
VC0006826
p9610
sg10
I6
sg11
Vcancer
p9611
sg13
I1
sasa(dp9612
g2
S'We present a bioinformatical approach to accurate definition of the boundaries of each SR by comparison with canonical SR structures, allowing for a large-scale homology modelling of the 74 nesprin-1 and 56 nesprin-2 SRs.\n'
p9613
sg4
(lp9614
sg14
(lp9615
(dp9616
g7
I217
sg17
VC0175693
p9617
sg10
I3
sg11
VSRs
p9618
sg13
I1
sasa(dp9619
g2
S'This review briefly describes the discovery of each of the HRASLS enzymes and their role in cancer, and discusses the biochemical function of each enzyme, as well as the biological role, if known.\n'
p9620
sg4
(lp9621
sg14
(lp9622
(dp9623
g7
I92
sg17
VC0006826
p9624
sg10
I6
sg11
Vcancer
p9625
sg13
I1
sasa(dp9626
g2
S'Furthermore, when H-rev107 was expressed in human NT2/D1 testicular cancer cells, cell migration and invasion were inhibited.\n'
p9627
sg4
(lp9628
sg14
(lp9629
(dp9630
g7
I101
sg17
VC2699153
p9631
sg10
I8
sg11
Vinvasion
p9632
sg13
I1
sa(dp9633
g7
I57
sg17
VC0153594
p9634
sg10
I17
sg11
Vtesticular cancer
p9635
sg13
I2
sasa(dp9636
g2
S'Our data suggest that the PGD2-cAMP-SOX9 signal pathway might play an important role in H-rev107-mediated cancer cell invasion in testes.\n'
p9637
sg4
(lp9638
(dp9639
g7
I26
sg8
VP41222
p9640
sg10
I14
sg11
VPGD2-cAMP-SOX9
p9641
sg13
I1
sasg14
(lp9642
(dp9643
g7
I106
sg17
VC0006826
p9644
sg10
I6
sg11
Vcancer
p9645
sg13
I1
sa(dp9646
g7
I113
sg17
VC2699153
p9647
sg10
I13
sg11
Vcell invasion
p9648
sg13
I2
sasa(dp9649
g2
S'In the present study, we used methylation-specific PCR (MSP) to analyze promoter methylation of 9 gastric cancer-associated genes, including MLF1, MGMT, p16, RASSF2, hMLH1, HAND1, HRASLS, TM, and FLNc, and their association with clinicopathological characteristics and clinical outcome in a large cohort of gastric cancers.\n'
p9650
sg4
(lp9651
(dp9652
g7
I173
sg8
g49
sg10
I5
sg11
VHAND1
p9653
sg13
I1
sa(dp9654
g7
I153
sg8
VP42771
p9655
sg10
I3
sg11
Vp16
p9656
sg13
I1
sa(dp9657
g7
I158
sg8
VP50749
p9658
sg10
I6
sg11
VRASSF2
p9659
sg13
I1
sa(dp9660
g7
I180
sg8
g49
sg10
I6
sg11
VHRASLS
p9661
sg13
I1
sa(dp9662
g7
I196
sg8
g49
sg10
I4
sg11
VFLNc
p9663
sg13
I1
sa(dp9664
g7
I147
sg8
VP16455
p9665
sg10
I4
sg11
VMGMT
p9666
sg13
I1
sa(dp9667
g7
I141
sg8
VP58340
p9668
sg10
I4
sg11
VMLF1
p9669
sg13
I1
sa(dp9670
g7
I166
sg8
VP40692
p9671
sg10
I5
sg11
VhMLH1
p9672
sg13
I1
sasg14
(lp9673
(dp9674
g7
I307
sg17
VC0024623
p9675
sg10
I15
sg11
Vgastric cancers
p9676
sg13
I2
sa(dp9677
g7
I98
sg17
VC0024623
p9678
sg10
I14
sg11
Vgastric cancer
p9679
sg13
I2
sasa(dp9680
g2
S'Tarzarotene-induced gene 3 (TIG3) and HRAS-like suppressor (HRASLS3) are members of the HREV107 family of class II tumor suppressors, which are down-regulated in various cancer cells.\n'
p9681
sg4
(lp9682
(dp9683
g7
I28
sg8
g49
sg10
I4
sg11
VTIG3
p9684
sg13
I1
sa(dp9685
g7
I0
sg8
g49
sg10
I26
sg11
VTarzarotene-induced gene 3
p9686
sg13
I3
sa(dp9687
g7
I88
sg8
VP53816
p9688
sg10
I7
sg11
VHREV107
p9689
sg13
I1
sa(dp9690
g7
I38
sg8
g49
sg10
I30
sg11
VHRAS-like suppressor (HRASLS3)
p9691
sg13
I3
sasg14
(lp9692
(dp9693
g7
I170
sg17
VC0006826
p9694
sg10
I6
sg11
Vcancer
p9695
sg13
I1
sa(dp9696
g7
I115
sg17
VC0027651
p9697
sg10
I5
sg11
Vtumor
p9698
sg13
I1
sasa(dp9699
g2
S'Our previous research suggested that the P2X4 receptor (P2X4R) expression in microglia was involved in the activation of toll-like receptor-4 (TLR4) in the dorsal horn in the rat model of cancer induced bone pain (CIBP).\n'
p9700
sg4
(lp9701
(dp9702
g7
I143
sg8
g49
sg10
I4
sg11
VTLR4
p9703
sg13
I1
sa(dp9704
g7
I121
sg8
g49
sg10
I20
sg11
Vtoll-like receptor-4
p9705
sg13
I2
sa(dp9706
g7
I41
sg8
g49
sg10
I13
sg11
VP2X4 receptor
p9707
sg13
I2
sa(dp9708
g7
I56
sg8
g49
sg10
I5
sg11
VP2X4R
p9709
sg13
I1
sasg14
(lp9710
(dp9711
g7
I203
sg17
VC0151825
p9712
sg10
I9
sg11
Vbone pain
p9713
sg13
I2
sa(dp9714
g7
I188
sg17
VC0006826
p9715
sg10
I6
sg11
Vcancer
p9716
sg13
I1
sasa(dp9717
g2
S'Using an FDA-approved anti-parasitic agent Ivermectin as a prototype agent to allosterically modulate P2X4 receptors, we can switch the balance between the dual pro-survival and cytotoxic functions of purinergic signaling in breast cancer cells.\n'
p9718
sg4
(lp9719
(dp9720
g7
I102
sg8
g49
sg10
I14
sg11
VP2X4 receptors
p9721
sg13
I2
sasg14
(lp9722
(dp9723
g7
I225
sg17
VC0678222
p9724
sg10
I13
sg11
Vbreast cancer
p9725
sg13
I2
sasa(dp9726
g2
S'Potentiated P2X4/P2X7 signaling can be further linked to the ATP rich tumor microenvironment providing a mechanistic explanation for the tumor selectivity of purinergic receptors modulation and its potential to be used as a platform for integrated cancer immunotherapy.\n'
p9727
sg4
(lp9728
(dp9729
g7
I17
sg8
g49
sg10
I4
sg11
VP2X7
p9730
sg13
I1
sa(dp9731
g7
I158
sg8
VP47900
p9732
sg10
I20
sg11
Vpurinergic receptors
p9733
sg13
I2
sasg14
(lp9734
(dp9735
g7
I248
sg17
VC0006826
p9736
sg10
I6
sg11
Vcancer
p9737
sg13
I1
sa(dp9738
g7
I70
sg17
VC0027651
p9739
sg10
I5
sg11
Vtumor
p9740
sg13
I1
sa(dp9741
g7
I70
sg17
VC0027651
p9742
sg10
I5
sg11
Vtumor
p9743
sg13
I1
sasa(dp9744
g2
S'We investigated the association of high myopia with the common single nucleotide polymorphisms (SNPs) of five candidate genes - early growth response 1 (EGR1), v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS), jun oncogene (JUN), vasoactive intestinal peptide (VIP), and vasoactive intestinal peptide receptor 2 (VIPR2).\n'
p9745
sg4
(lp9746
(dp9747
g7
I153
sg8
VP18146
p9748
sg10
I4
sg11
VEGR1
p9749
sg13
I1
sa(dp9750
g7
I234
sg8
VP05412
p9751
sg10
I3
sg11
VJUN
p9752
sg13
I1
sa(dp9753
g7
I160
sg8
VP01100
p9754
sg10
I52
sg11
Vv-fos FBJ murine osteosarcoma viral oncogene homolog
p9755
sg13
I7
sa(dp9756
g7
I220
sg8
VP05412
p9757
sg10
I12
sg11
Vjun oncogene
p9758
sg13
I2
sa(dp9759
g7
I128
sg8
VP18146
p9760
sg10
I23
sg11
Vearly growth response 1
p9761
sg13
I4
sa(dp9762
g7
I281
sg8
VP41587
p9763
sg10
I40
sg11
Vvasoactive intestinal peptide receptor 2
p9764
sg13
I5
sa(dp9765
g7
I262
sg8
VP01282
p9766
sg10
I13
sg11
Vpeptide (VIP)
p9767
sg13
I2
sa(dp9768
g7
I323
sg8
VP41587
p9769
sg10
I5
sg11
VVIPR2
p9770
sg13
I1
sa(dp9771
g7
I214
sg8
VP01100
p9772
sg10
I3
sg11
VFOS
p9773
sg13
I1
sasg14
(lp9774
(dp9775
g7
I35
sg17
VC0271183
p9776
sg10
I11
sg11
Vhigh myopia
p9777
sg13
I2
sa(dp9778
g7
I177
sg17
VC0029463
p9779
sg10
I12
sg11
Vosteosarcoma
p9780
sg13
I1
sasa(dp9781
g2
S'In the discovery phase, EGR1, JUN and VIP did not show any significant association while FOS and VIPR2 demonstrated significant haplotype association with high myopia.\n'
p9782
sg4
(lp9783
(dp9784
g7
I24
sg8
VP18146
p9785
sg10
I4
sg11
VEGR1
p9786
sg13
I1
sa(dp9787
g7
I38
sg8
VP01282
p9788
sg10
I3
sg11
VVIP
p9789
sg13
I1
sa(dp9790
g7
I30
sg8
VP05412
p9791
sg10
I3
sg11
VJUN
p9792
sg13
I1
sasg14
(lp9793
(dp9794
g7
I155
sg17
VC0271183
p9795
sg10
I11
sg11
Vhigh myopia
p9796
sg13
I2
sasa(dp9797
g2
S'This is the first study to suggest a role of VIPR2 in the genetic susceptibility to high myopia.\n'
p9798
sg4
(lp9799
(dp9800
g7
I45
sg8
VP41587
p9801
sg10
I5
sg11
VVIPR2
p9802
sg13
I1
sasg14
(lp9803
(dp9804
g7
I84
sg17
VC0271183
p9805
sg10
I11
sg11
Vhigh myopia
p9806
sg13
I2
sasa(dp9807
g2
S'The VIPR2 and SNTB1 genes are expressed in the retina and the retinal pigment epithelium and have been previously reported to have potential functions for the pathogenesis of myopia.\n'
p9808
sg4
(lp9809
(dp9810
g7
I14
sg8
g49
sg10
I11
sg11
VSNTB1 genes
p9811
sg13
I2
sa(dp9812
g7
I4
sg8
VP41587
p9813
sg10
I5
sg11
VVIPR2
p9814
sg13
I1
sasg14
(lp9815
(dp9816
g7
I159
sg17
VC0699748
p9817
sg10
I12
sg11
Vpathogenesis
p9818
sg13
I1
sa(dp9819
g7
I175
sg17
VC0027092
p9820
sg10
I6
sg11
Vmyopia
p9821
sg13
I1
sasa(dp9822
g2
S'Our results suggest that variants of the VIPR2 and SNTB1 genes increase susceptibility to high myopia in Han Chinese.\n'
p9823
sg4
(lp9824
(dp9825
g7
I51
sg8
g49
sg10
I11
sg11
VSNTB1 genes
p9826
sg13
I2
sa(dp9827
g7
I41
sg8
VP41587
p9828
sg10
I5
sg11
VVIPR2
p9829
sg13
I1
sasg14
(lp9830
(dp9831
g7
I90
sg17
VC0271183
p9832
sg10
I11
sg11
Vhigh myopia
p9833
sg13
I2
sasa(dp9834
g2
S'To investigate the dynamic expression and significance of vasoactive intestinal peptide receptor 2 (VIPR2) on retina-choroid-clera in high myopia.\n'
p9835
sg4
(lp9836
(dp9837
g7
I58
sg8
VP41587
p9838
sg10
I40
sg11
Vvasoactive intestinal peptide receptor 2
p9839
sg13
I5
sa(dp9840
g7
I100
sg8
VP41587
p9841
sg10
I5
sg11
VVIPR2
p9842
sg13
I1
sasg14
(lp9843
(dp9844
g7
I134
sg17
VC0271183
p9845
sg10
I11
sg11
Vhigh myopia
p9846
sg13
I2
sasa(dp9847
g2
S'VIPR2 may play an important role on the formation and development of myopia.\n'
p9848
sg4
(lp9849
(dp9850
g7
I0
sg8
VP41587
p9851
sg10
I5
sg11
VVIPR2
p9852
sg13
I1
sasg14
(lp9853
(dp9854
g7
I69
sg17
VC0027092
p9855
sg10
I6
sg11
Vmyopia
p9856
sg13
I1
sasa(dp9857
g2
S"The presence of a dysregulated NF-KB/Snail/YY1/RKIP loop was recently established in metastatic prostate cancer cells and non-Hodgkin's lymphoma; however, its involvement in multiple myeloma (MM) has yet to be investigated.\n"
p9858
sg4
(lp9859
(dp9860
g7
I43
sg8
VP25490
p9861
sg10
I3
sg11
VYY1
p9862
sg13
I1
sa(dp9863
g7
I37
sg8
g49
sg10
I5
sg11
VSnail
p9864
sg13
I1
sa(dp9865
g7
I47
sg8
VP30086
p9866
sg10
I4
sg11
VRKIP
p9867
sg13
I1
sasg14
(lp9868
(dp9869
g7
I174
sg17
VC0026764
p9870
sg10
I16
sg11
Vmultiple myeloma
p9871
sg13
I2
sa(dp9872
g7
I122
sg17
VC0024305
p9873
sg10
I22
sg11
Vnon-Hodgkin's lymphoma
p9874
sg13
I2
sa(dp9875
g7
I85
sg17
VC0936223
p9876
sg10
I26
sg11
Vmetastatic prostate cancer
p9877
sg13
I3
sasa(dp9878
g2
S'Compound 6a showed the highest inhibitory activity with IC50 - 0.99 myM to human liver carcinoma HepG2 cells and low cytotoxicity towards Lep3 (IC50 = 191 myM).\n'
p9879
sg4
(lp9880
(dp9881
g7
I138
sg8
g49
sg10
I4
sg11
VLep3
p9882
sg13
I1
sa(dp9883
g7
I56
sg8
g49
sg10
I15
sg11
VIC50 - 0.99 myM
p9884
sg13
I4
sasg14
(lp9885
(dp9886
g7
I81
sg17
VC2239176
p9887
sg10
I15
sg11
Vliver carcinoma
p9888
sg13
I2
sa(dp9889
g7
I117
sg17
VC0596402
p9890
sg10
I12
sg11
Vcytotoxicity
p9891
sg13
I1
sasa(dp9892
g2
S'The results obtained revealed that: (1) UDCA and its metal complexes in the tested concentrations decreased (to a varying degree) the viability and proliferation of the treated cells in a time- and concentration-dependent manner; (2) chicken hepatoma (LSCC-SF-Mc29) cells were most sensitive to the cytotoxic and antiproliferative action of the compounds tested, followed by rat sarcoma (LSR-SF-SR) cells; (3) Cu-UDCA and Ni-UDCA were more effective against animal LSCC-SF-Mc29 and LSR-SF-SR cells, while Zn-UDCA significantly decreased the viability and proliferation of human tumour cell lines; (4) applied independently, UDCA expressed lower cytotoxic/cytostatic activity as compared to metal complexes; and (5) the sensitivity of the non-tumour embryonic Lep-3 cells to the effects of UDCA and its metal complexes was comparable or even higher than those of the human tumour cells.\n'
p9893
sg4
(lp9894
(dp9895
g7
I759
sg8
VP41159
p9896
sg10
I5
sg11
VLep-3
p9897
sg13
I1
sasg14
(lp9898
(dp9899
g7
I242
sg17
VC0023903
p9900
sg10
I8
sg11
Vhepatoma
p9901
sg13
I1
sa(dp9902
g7
I148
sg17
VC0334094
p9903
sg10
I13
sg11
Vproliferation
p9904
sg13
I1
sa(dp9905
g7
I148
sg17
VC0334094
p9906
sg10
I13
sg11
Vproliferation
p9907
sg13
I1
sa(dp9908
g7
I578
sg17
VC0027651
p9909
sg10
I6
sg11
Vtumour
p9910
sg13
I1
sa(dp9911
g7
I375
sg17
VC1882848
p9912
sg10
I11
sg11
Vrat sarcoma
p9913
sg13
I2
sa(dp9914
g7
I578
sg17
VC0027651
p9915
sg10
I6
sg11
Vtumour
p9916
sg13
I1
sa(dp9917
g7
I578
sg17
VC0027651
p9918
sg10
I6
sg11
Vtumour
p9919
sg13
I1
sasa(dp9920
g2
S'Compounds 5, 7-8 and 10-18 were evaluated for their cytotoxical effect on four cancer cell lines: human colorectal cancer cell line HT-29, breast cancer cells MDA-MB-231, cervical cancer cells HeLa, human liver carcinoma HepG2 and human normal diploid cell line Lep3.\n'
p9921
sg4
(lp9922
(dp9923
g7
I262
sg8
g49
sg10
I4
sg11
VLep3
p9924
sg13
I1
sasg14
(lp9925
(dp9926
g7
I104
sg17
VC1527249
p9927
sg10
I17
sg11
Vcolorectal cancer
p9928
sg13
I2
sa(dp9929
g7
I79
sg17
VC0006826
p9930
sg10
I6
sg11
Vcancer
p9931
sg13
I1
sa(dp9932
g7
I171
sg17
VC0302592
p9933
sg10
I15
sg11
Vcervical cancer
p9934
sg13
I2
sa(dp9935
g7
I139
sg17
VC0678222
p9936
sg10
I13
sg11
Vbreast cancer
p9937
sg13
I2
sa(dp9938
g7
I205
sg17
VC2239176
p9939
sg10
I15
sg11
Vliver carcinoma
p9940
sg13
I2
sasa(dp9941
g2
S'The positive emotions program for schizophrenia (PEPS) is a new method that specifically aims to reduce the syndrome of a diminished capacity to experience.\n'
p9942
sg4
(lp9943
sg14
(lp9944
(dp9945
g7
I108
sg17
VC0039082
p9946
sg10
I8
sg11
Vsyndrome
p9947
sg13
I1
sa(dp9948
g7
I49
sg17
VC1846609
p9949
sg10
I4
sg11
VPEPS
p9950
sg13
I1
sa(dp9951
g7
I4
sg17
VC1846609
p9952
sg10
I43
sg11
Vpositive emotions program for schizophrenia
p9953
sg13
I5
sasa(dp9954
g2
S'PEPS is a specific, short, easy to use, group-based intervention to improve pleasure, and motivation in schizophrenia.\n'
p9955
sg4
(lp9956
(dp9957
g7
I0
sg8
VP28838
p9958
sg10
I4
sg11
VPEPS
p9959
sg13
I1
sasg14
(lp9960
(dp9961
g7
I0
sg17
VC1846609
p9962
sg10
I4
sg11
VPEPS
p9963
sg13
I1
sa(dp9964
g7
I104
sg17
VC0036341
p9965
sg10
I13
sg11
Vschizophrenia
p9966
sg13
I1
sasa(dp9967
g2
S'They took part in eight sessions of the Positive Emotions Program for Schizophrenia (PEPS)--an intervention that teaches participants skills to help overcome defeatist thinking and to increase the anticipation and maintenance of positive emotions.\n'
p9968
sg4
(lp9969
sg14
(lp9970
(dp9971
g7
I85
sg17
VC1846609
p9972
sg10
I4
sg11
VPEPS
p9973
sg13
I1
sa(dp9974
g7
I40
sg17
VC1846609
p9975
sg10
I43
sg11
VPositive Emotions Program for Schizophrenia
p9976
sg13
I5
sasa(dp9977
g2
S"Although renal involvement is uncommon in primary Sjoegren's syndrome (pSS), patients may experience renal tubular acidosis type I (RTA I), tubulointerstitial nephritis, diabetes insipidus (DI), nephrolithiasis, and Fanconi syndrome.\n"
p9978
sg4
(lp9979
sg14
(lp9980
(dp9981
g7
I195
sg17
VC0392525
p9982
sg10
I15
sg11
Vnephrolithiasis
p9983
sg13
I1
sa(dp9984
g7
I132
sg17
VC0259810
p9985
sg10
I5
sg11
VRTA I
p9986
sg13
I2
sa(dp9987
g7
I216
sg17
VC0015624
p9988
sg10
I16
sg11
VFanconi syndrome
p9989
sg13
I2
sa(dp9990
g7
I42
sg17
VC1832588
p9991
sg10
I27
sg11
Vprimary Sjoegren's syndrome
p9992
sg13
I3
sa(dp9993
g7
I71
sg17
VC1832588
p9994
sg10
I3
sg11
VpSS
p9995
sg13
I1
sa(dp9996
g7
I170
sg17
VC0687720
p9997
sg10
I18
sg11
Vdiabetes insipidus
p9998
sg13
I2
sa(dp9999
g7
I101
sg17
VC0259810
p10000
sg10
I29
sg11
Vrenal tubular acidosis type I
p10001
sg13
I5
sa(dp10002
g7
I140
sg17
VC0041349
p10003
sg10
I28
sg11
Vtubulointerstitial nephritis
p10004
sg13
I2
sa(dp10005
g7
I190
sg17
VC0687720
p10006
sg10
I2
sg11
VDI
p10007
sg13
I1
sasa(dp10008
g2
S'CONCLUSIONS This was a pSS patient with tubulointerstitial nephritis, diabetes insipidus, renal tubular acidosis, hypokalemia, and nephrolithiasis, who was receiving symptomatic treatment for diabetes insipidus.\n'
p10009
sg4
(lp10010
sg14
(lp10011
(dp10012
g7
I70
sg17
VC0687720
p10013
sg10
I18
sg11
Vdiabetes insipidus
p10014
sg13
I2
sa(dp10015
g7
I90
sg17
VC0001126
p10016
sg10
I22
sg11
Vrenal tubular acidosis
p10017
sg13
I3
sa(dp10018
g7
I131
sg17
VC0392525
p10019
sg10
I15
sg11
Vnephrolithiasis
p10020
sg13
I1
sa(dp10021
g7
I70
sg17
VC0687720
p10022
sg10
I18
sg11
Vdiabetes insipidus
p10023
sg13
I2
sa(dp10024
g7
I23
sg17
VC1832588
p10025
sg10
I3
sg11
VpSS
p10026
sg13
I1
sa(dp10027
g7
I40
sg17
VC0041349
p10028
sg10
I28
sg11
Vtubulointerstitial nephritis
p10029
sg13
I2
sasa(dp10030
g2
S'pSS should be considered as one of the differential diagnoses in patients with diabetes insipidus and renal tubular acidosis.\n'
p10031
sg4
(lp10032
(dp10033
g7
I0
sg8
g49
sg10
I3
sg11
VpSS
p10034
sg13
I1
sasg14
(lp10035
(dp10036
g7
I79
sg17
VC0687720
p10037
sg10
I18
sg11
Vdiabetes insipidus
p10038
sg13
I2
sa(dp10039
g7
I102
sg17
VC0001126
p10040
sg10
I22
sg11
Vrenal tubular acidosis
p10041
sg13
I3
sa(dp10042
g7
I0
sg17
VC1832588
p10043
sg10
I3
sg11
VpSS
p10044
sg13
I1
sasa(dp10045
g2
S'However, we cannot exclude the possibility that a higher PWV in pSS patients is caused, not by pSS itself, but by the use of steroids, hypertension and dyslipidemia.\n'
p10046
sg4
(lp10047
(dp10048
g7
I64
sg8
g49
sg10
I3
sg11
VpSS
p10049
sg13
I1
sasg14
(lp10050
(dp10051
g7
I135
sg17
VC0020538
p10052
sg10
I12
sg11
Vhypertension
p10053
sg13
I1
sa(dp10054
g7
I64
sg17
VC1832588
p10055
sg10
I3
sg11
VpSS
p10056
sg13
I1
sa(dp10057
g7
I152
sg17
VC0242339
p10058
sg10
I12
sg11
Vdyslipidemia
p10059
sg13
I1
sa(dp10060
g7
I64
sg17
VC1832588
p10061
sg10
I3
sg11
VpSS
p10062
sg13
I1
sasa(dp10063
g2
S'This study examined how patients with chronic obstructive pulmonary disease (COPD) and their physiotherapists (PHTs) value an eHealth self-management intervention following a period of use.\n'
p10064
sg4
(lp10065
sg14
(lp10066
(dp10067
g7
I77
sg17
VC0024117
p10068
sg10
I4
sg11
VCOPD
p10069
sg13
I1
sa(dp10070
g7
I38
sg17
VC0024117
p10071
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p10072
sg13
I4
sasa(dp10073
g2
S'These disorders include adenomatous polyposis syndromes (APC and MUTYH), juvenile polyposis coli (BMPR1A and SMAD4), Peutz-Jeghers Syndrome (STK11/LKB1), and PTEN hamartoma tumor syndrome (PHTS; PTEN), which can present with a more limited juvenile polyposis phenotype.\n'
p10074
sg4
(lp10075
(dp10076
g7
I109
sg8
g49
sg10
I5
sg11
VSMAD4
p10077
sg13
I1
sa(dp10078
g7
I189
sg8
g49
sg10
I4
sg11
VPHTS
p10079
sg13
I1
sa(dp10080
g7
I98
sg8
VP36894
p10081
sg10
I6
sg11
VBMPR1A
p10082
sg13
I1
sa(dp10083
g7
I158
sg8
g49
sg10
I29
sg11
VPTEN hamartoma tumor syndrome
p10084
sg13
I4
sa(dp10085
g7
I158
sg8
VP60484
p10086
sg10
I4
sg11
VPTEN
p10087
sg13
I1
sa(dp10088
g7
I147
sg8
g49
sg10
I4
sg11
VLKB1
p10089
sg13
I1
sa(dp10090
g7
I141
sg8
g49
sg10
I5
sg11
VSTK11
p10091
sg13
I1
sasg14
(lp10092
(dp10093
g7
I189
sg17
VC1959582
p10094
sg10
I4
sg11
VPHTS
p10095
sg13
I1
sa(dp10096
g7
I46
sg17
VC0039082
p10097
sg10
I9
sg11
Vsyndromes
p10098
sg13
I1
sa(dp10099
g7
I158
sg17
VC1959582
p10100
sg10
I29
sg11
VPTEN hamartoma tumor syndrome
p10101
sg13
I4
sa(dp10102
g7
I117
sg17
VC0031269
p10103
sg10
I22
sg11
VPeutz-Jeghers Syndrome
p10104
sg13
I2
sa(dp10105
g7
I73
sg17
VC1868081
p10106
sg10
I23
sg11
Vjuvenile polyposis coli
p10107
sg13
I3
sa(dp10108
g7
I57
sg17
VC0033036
p10109
sg10
I3
sg11
VAPC
p10110
sg13
I1
sa(dp10111
g7
I24
sg17
VC0032580
p10112
sg10
I21
sg11
Vadenomatous polyposis
p10113
sg13
I2
sa(dp10114
g7
I73
sg17
VC0345893
p10115
sg10
I18
sg11
Vjuvenile polyposis
p10116
sg13
I2
sasa(dp10117
g2
S'PTEN hamartoma tumor syndrome (PHTS), DICER1 syndrome, and hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome are pleiotropic tumor predisposition syndromes that include benign and malignant neoplasms affecting adults and children.\n'
p10118
sg4
(lp10119
(dp10120
g7
I0
sg8
VP60484
p10121
sg10
I4
sg11
VPTEN
p10122
sg13
I1
sasg14
(lp10123
(dp10124
g7
I0
sg17
VC1959582
p10125
sg10
I29
sg11
VPTEN hamartoma tumor syndrome
p10126
sg13
I4
sa(dp10127
g7
I195
sg17
VC0006826
p10128
sg10
I19
sg11
Vmalignant neoplasms
p10129
sg13
I2
sa(dp10130
g7
I21
sg17
VC0039082
p10131
sg10
I8
sg11
Vsyndrome
p10132
sg13
I1
sa(dp10133
g7
I15
sg17
VC0027651
p10134
sg10
I5
sg11
Vtumor
p10135
sg13
I1
sa(dp10136
g7
I31
sg17
VC1959582
p10137
sg10
I4
sg11
VPHTS
p10138
sg13
I1
sa(dp10139
g7
I21
sg17
VC0039082
p10140
sg10
I8
sg11
Vsyndrome
p10141
sg13
I1
sa(dp10142
g7
I59
sg17
VC1708350
p10143
sg10
I47
sg11
Vhereditary leiomyomatosis and renal cell cancer
p10144
sg13
I6
sa(dp10145
g7
I161
sg17
VC0039082
p10146
sg10
I9
sg11
Vsyndromes
p10147
sg13
I1
sa(dp10148
g7
I108
sg17
VC1708350
p10149
sg10
I5
sg11
VHLRCC
p10150
sg13
I1
sasa(dp10151
g2
S'The resulting differential diagnosis includes (attenuated) familial adenomatous polyposis ([a]FAP), MUTYH-associated polyposis (MAP), polymerase proofreading-associated polyposis (PPAP), phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS), Peutz-Jeghers syndrome and juvenile polyposis, each with a specific genetic background.\n'
p10152
sg4
(lp10153
(dp10154
g7
I219
sg8
VP60484
p10155
sg10
I4
sg11
VPTEN
p10156
sg13
I1
sa(dp10157
g7
I187
sg8
VP60484
p10158
sg10
I30
sg11
Vphosphatase and tensin homolog
p10159
sg13
I4
sasg14
(lp10160
(dp10161
g7
I285
sg17
VC0345893
p10162
sg10
I18
sg11
Vjuvenile polyposis
p10163
sg13
I2
sa(dp10164
g7
I225
sg17
VC0018552
p10165
sg10
I9
sg11
Vhamartoma
p10166
sg13
I1
sa(dp10167
g7
I241
sg17
VC0039082
p10168
sg10
I8
sg11
Vsyndrome
p10169
sg13
I1
sa(dp10170
g7
I80
sg17
VC0334108
p10171
sg10
I9
sg11
Vpolyposis
p10172
sg13
I1
sa(dp10173
g7
I80
sg17
VC0334108
p10174
sg10
I9
sg11
Vpolyposis
p10175
sg13
I1
sa(dp10176
g7
I59
sg17
VC0032580
p10177
sg10
I30
sg11
Vfamilial adenomatous polyposis
p10178
sg13
I3
sa(dp10179
g7
I258
sg17
VC0031269
p10180
sg10
I22
sg11
VPeutz-Jeghers syndrome
p10181
sg13
I2
sa(dp10182
g7
I94
sg17
VC0032580
p10183
sg10
I3
sg11
VFAP
p10184
sg13
I1
sa(dp10185
g7
I235
sg17
VC0027651
p10186
sg10
I5
sg11
Vtumor
p10187
sg13
I1
sasa(dp10188
g2
S'Immune dysregulation in patients with PHTS included lymphopenia, CD4+ T-cell reduction, and changes in T- and B-cell subsets.\n'
p10189
sg4
(lp10190
(dp10191
g7
I65
sg8
VP01730
p10192
sg10
I4
sg11
VCD4+
p10193
sg13
I1
sasg14
(lp10194
(dp10195
g7
I52
sg17
VC0024312
p10196
sg10
I11
sg11
Vlymphopenia
p10197
sg13
I1
sasa(dp10198
g2
S'Combined homozygous deficiency for Rbbp1/Arid4a and heterozygous deficiency for Rbbp1l1/Arid4b altered epigenetic modifications at the PWS-IC with reduced trimethylation of histone H4K20 and H3K9 and reduced DNA methylation, changing the maternal allele toward a more paternal epigenotype.\n'
p10199
sg4
(lp10200
(dp10201
g7
I80
sg8
VP42696
p10202
sg10
I7
sg11
VRbbp1l1
p10203
sg13
I1
sa(dp10204
g7
I135
sg8
g49
sg10
I6
sg11
VPWS-IC
p10205
sg13
I1
sa(dp10206
g7
I173
sg8
VP62805
p10207
sg10
I13
sg11
Vhistone H4K20
p10208
sg13
I2
sa(dp10209
g7
I35
sg8
VP29374
p10210
sg10
I5
sg11
VRbbp1
p10211
sg13
I1
sa(dp10212
g7
I41
sg8
VP29374
p10213
sg10
I6
sg11
VArid4a
p10214
sg13
I1
sasg14
(lp10215
(dp10216
g7
I135
sg17
VC0032897
p10217
sg10
I3
sg11
VPWS
p10218
sg13
I1
sasa(dp10219
g2
S'These data identify Rbbp1/Arid4a and Rbbp1l1/Arid4b as new members of epigenetic complexes regulating genomic imprinting at the PWS/AS domain.\n'
p10220
sg4
(lp10221
(dp10222
g7
I37
sg8
VP42696
p10223
sg10
I7
sg11
VRbbp1l1
p10224
sg13
I1
sa(dp10225
g7
I20
sg8
VP29374
p10226
sg10
I5
sg11
VRbbp1
p10227
sg13
I1
sa(dp10228
g7
I26
sg8
VP29374
p10229
sg10
I6
sg11
VArid4a
p10230
sg13
I1
sasg14
(lp10231
(dp10232
g7
I128
sg17
VC0032897
p10233
sg10
I3
sg11
VPWS
p10234
sg13
I1
sasa(dp10235
g2
S'We report here for the first time that chorea-acanthocytosis red cells are characterized by impaired autophagy, with cytoplasmic accumulation of active Lyn and of autophagy-related proteins Ulk1 and Atg7.\n'
p10236
sg4
(lp10237
(dp10238
g7
I163
sg8
VP02649
p10239
sg10
I26
sg11
Vautophagy-related proteins
p10240
sg13
I2
sa(dp10241
g7
I190
sg8
g49
sg10
I4
sg11
VUlk1
p10242
sg13
I1
sa(dp10243
g7
I199
sg8
g49
sg10
I4
sg11
VAtg7
p10244
sg13
I1
sasg14
(lp10245
(dp10246
g7
I117
sg17
VC0544951
p10247
sg10
I24
sg11
Vcytoplasmic accumulation
p10248
sg13
I2
sa(dp10249
g7
I39
sg17
VC0393576
p10250
sg10
I21
sg11
Vchorea-acanthocytosis
p10251
sg13
I1
sa(dp10252
g7
I92
sg17
VC0684336
p10253
sg10
I8
sg11
Vimpaired
p10254
sg13
I1
sasa(dp10255
g2
S'In chorea-acanthocytosis erythrocytes, active Lyn is sequestered by HSP90-70 to form high-molecular-weight complexes that stabilize and protect Lyn from its proteasomal degradation, contributing to toxic Lyn accumulation.\n'
p10256
sg4
(lp10257
(dp10258
g7
I46
sg8
VP07948
p10259
sg10
I3
sg11
VLyn
p10260
sg13
I1
sa(dp10261
g7
I46
sg8
VP07948
p10262
sg10
I3
sg11
VLyn
p10263
sg13
I1
sa(dp10264
g7
I46
sg8
VP07948
p10265
sg10
I3
sg11
VLyn
p10266
sg13
I1
sa(dp10267
g7
I68
sg8
VP07900
p10268
sg10
I8
sg11
VHSP90-70
p10269
sg13
I1
sasg14
(lp10270
(dp10271
g7
I3
sg17
VC0393576
p10272
sg10
I21
sg11
Vchorea-acanthocytosis
p10273
sg13
I1
sasa(dp10274
g2
S'An interplay between accumulation of active Lyn and autophagy was found in chorea-acanthocytosis based on Lyn coimmunoprecipitation with Ulk1 and Atg7 and on the presence of Ulk1 in Lyn-containing high-molecular-weight complexes.\n'
p10275
sg4
(lp10276
(dp10277
g7
I137
sg8
g49
sg10
I4
sg11
VUlk1
p10278
sg13
I1
sa(dp10279
g7
I44
sg8
VP07948
p10280
sg10
I3
sg11
VLyn
p10281
sg13
I1
sa(dp10282
g7
I44
sg8
VP07948
p10283
sg10
I3
sg11
VLyn
p10284
sg13
I1
sa(dp10285
g7
I146
sg8
g49
sg10
I4
sg11
VAtg7
p10286
sg13
I1
sa(dp10287
g7
I137
sg8
g49
sg10
I4
sg11
VUlk1
p10288
sg13
I1
sasg14
(lp10289
(dp10290
g7
I75
sg17
VC0393576
p10291
sg10
I21
sg11
Vchorea-acanthocytosis
p10292
sg13
I1
sasa(dp10293
g2
S'In chorea-acanthocytosis, we found (1) dyserythropoiesis; (2) increased active Lyn; (3) accumulation of a marker of autophagic flux and autolysososme degradation; (4) accumlation of Lamp1, a lysosmal membrane protein, and LAMP1-positive aggregates; and (5) reduced clearance of lysosomes and mitochondria.\n'
p10294
sg4
(lp10295
(dp10296
g7
I191
sg8
VP35968
p10297
sg10
I25
sg11
Vlysosmal membrane protein
p10298
sg13
I3
sa(dp10299
g7
I222
sg8
VP11279
p10300
sg10
I5
sg11
VLAMP1
p10301
sg13
I1
sa(dp10302
g7
I182
sg8
VP11279
p10303
sg10
I5
sg11
VLamp1
p10304
sg13
I1
sasg14
(lp10305
(dp10306
g7
I39
sg17
VC0221143
p10307
sg10
I17
sg11
Vdyserythropoiesis
p10308
sg13
I1
sa(dp10309
g7
I3
sg17
VC0393576
p10310
sg10
I21
sg11
Vchorea-acanthocytosis
p10311
sg13
I1
sasa(dp10312
g2
S'Our results uncover in chorea-acanthocytosis erythroid cells an association between accumulation of active Lyn and impaired autophagy, suggesting a link between chorein and autophagic vesicle trafficking in erythroid maturation.\n'
p10313
sg4
(lp10314
(dp10315
g7
I107
sg8
VP07948
p10316
sg10
I3
sg11
VLyn
p10317
sg13
I1
sasg14
(lp10318
(dp10319
g7
I184
sg17
VC0333262
p10320
sg10
I7
sg11
Vvesicle
p10321
sg13
I1
sa(dp10322
g7
I23
sg17
VC0393576
p10323
sg10
I21
sg11
Vchorea-acanthocytosis
p10324
sg13
I1
sa(dp10325
g7
I115
sg17
VC0684336
p10326
sg10
I8
sg11
Vimpaired
p10327
sg13
I1
sasa(dp10328
g2
S'Adult Lyn(up/up) mice were anemic, with dysmorphic red cells (spherocyte-like, acanthocytes) in their circulation, indicative of hemolytic anemia and resembling the human disorder chorea acanthocytosis.\n'
p10329
sg4
(lp10330
sg14
(lp10331
(dp10332
g7
I180
sg17
VC0393576
p10333
sg10
I21
sg11
Vchorea acanthocytosis
p10334
sg13
I2
sa(dp10335
g7
I129
sg17
VC0002878
p10336
sg10
I16
sg11
Vhemolytic anemia
p10337
sg13
I2
sasa(dp10338
g2
S'The IHC results demonstrated significant increases of protein expressions of FGF19, FGFR4 and EpCAM in specimens with fatty liver, NASH, cirrhosis, and HCC compared to healthy liver tissue.\n'
p10339
sg4
(lp10340
(dp10341
g7
I77
sg8
g49
sg10
I5
sg11
VFGF19
p10342
sg13
I1
sa(dp10343
g7
I84
sg8
VP22455
p10344
sg10
I5
sg11
VFGFR4
p10345
sg13
I1
sa(dp10346
g7
I94
sg8
VP16422
p10347
sg10
I5
sg11
VEpCAM
p10348
sg13
I1
sasg14
(lp10349
(dp10350
g7
I137
sg17
VC0023890
p10351
sg10
I9
sg11
Vcirrhosis
p10352
sg13
I1
sa(dp10353
g7
I118
sg17
VC0015695
p10354
sg10
I11
sg11
Vfatty liver
p10355
sg13
I2
sa(dp10356
g7
I152
sg17
VC2239176
p10357
sg10
I3
sg11
VHCC
p10358
sg13
I1
sasa(dp10359
g2
S'FGF19, FGFR4 and EpCAM expressions between the different histologic stages of fatty liver steatohepatitis-cirrhosis-HCC carcinogenesis sequence were compared to healthy hepatic tissue.\n'
p10360
sg4
(lp10361
(dp10362
g7
I17
sg8
VP16422
p10363
sg10
I5
sg11
VEpCAM
p10364
sg13
I1
sa(dp10365
g7
I7
sg8
VP22455
p10366
sg10
I5
sg11
VFGFR4
p10367
sg13
I1
sa(dp10368
g7
I0
sg8
g49
sg10
I5
sg11
VFGF19
p10369
sg13
I1
sasg14
(lp10370
(dp10371
g7
I90
sg17
VC2711227
p10372
sg10
I15
sg11
Vsteatohepatitis
p10373
sg13
I1
sa(dp10374
g7
I106
sg17
VC0023890
p10375
sg10
I9
sg11
Vcirrhosis
p10376
sg13
I1
sa(dp10377
g7
I116
sg17
VC2239176
p10378
sg10
I3
sg11
VHCC
p10379
sg13
I1
sa(dp10380
g7
I120
sg17
VC0596263
p10381
sg10
I14
sg11
Vcarcinogenesis
p10382
sg13
I1
sa(dp10383
g7
I78
sg17
VC0015695
p10384
sg10
I11
sg11
Vfatty liver
p10385
sg13
I2
sasa(dp10386
g2
S'Overexpression of FGF19/FGFR4 significantly correlated with EpCAM as a marker of hepatic cancer stem cells within the fatty liver-steatosis-cirrhosis-HCC sequence.\n'
p10387
sg4
(lp10388
(dp10389
g7
I60
sg8
VP16422
p10390
sg10
I5
sg11
VEpCAM
p10391
sg13
I1
sa(dp10392
g7
I18
sg8
g49
sg10
I5
sg11
VFGF19
p10393
sg13
I1
sa(dp10394
g7
I24
sg8
VP22455
p10395
sg10
I5
sg11
VFGFR4
p10396
sg13
I1
sasg14
(lp10397
(dp10398
g7
I130
sg17
VC0152254
p10399
sg10
I9
sg11
Vsteatosis
p10400
sg13
I1
sa(dp10401
g7
I150
sg17
VC2239176
p10402
sg10
I3
sg11
VHCC
p10403
sg13
I1
sa(dp10404
g7
I81
sg17
VC0345904
p10405
sg10
I14
sg11
Vhepatic cancer
p10406
sg13
I2
sa(dp10407
g7
I118
sg17
VC0015695
p10408
sg10
I11
sg11
Vfatty liver
p10409
sg13
I2
sa(dp10410
g7
I140
sg17
VC0023890
p10411
sg10
I9
sg11
Vcirrhosis
p10412
sg13
I1
sasa(dp10413
g2
S'Our findings suggest that genetic polymorphism in FGFR4 rs351855 may be associated with the risk of HCC coupled with liver cirrhosis and may markedly increase the AFP level in Taiwanese patients with HCC.\n'
p10414
sg4
(lp10415
(dp10416
g7
I100
sg8
g49
sg10
I3
sg11
VHCC
p10417
sg13
I1
sa(dp10418
g7
I50
sg8
VP22455
p10419
sg10
I14
sg11
VFGFR4 rs351855
p10420
sg13
I2
sa(dp10421
g7
I163
sg8
VP02771
p10422
sg10
I3
sg11
VAFP
p10423
sg13
I1
sasg14
(lp10424
(dp10425
g7
I100
sg17
VC2239176
p10426
sg10
I3
sg11
VHCC
p10427
sg13
I1
sa(dp10428
g7
I100
sg17
VC2239176
p10429
sg10
I3
sg11
VHCC
p10430
sg13
I1
sa(dp10431
g7
I117
sg17
VC0023890
p10432
sg10
I15
sg11
Vliver cirrhosis
p10433
sg13
I2
sasa(dp10434
g2
S'This study examined the BCAR1-CFDP1-TMEM170A locus on chromosome 16, associated with carotid IMT and coronary artery disease in the IMT and IMT-Progression as Predictors of Vascular Events (IMPROVE) cohort, to identify the functional variant.\n'
p10435
sg4
(lp10436
(dp10437
g7
I24
sg8
VP56945
p10438
sg10
I5
sg11
VBCAR1
p10439
sg13
I1
sa(dp10440
g7
I36
sg8
g49
sg10
I8
sg11
VTMEM170A
p10441
sg13
I1
sa(dp10442
g7
I30
sg8
g49
sg10
I5
sg11
VCFDP1
p10443
sg13
I1
sasg14
(lp10444
(dp10445
g7
I101
sg17
VC1956346
p10446
sg10
I23
sg11
Vcoronary artery disease
p10447
sg13
I3
sasa(dp10448
g2
S'This study identified rs4888378 in the BCAR1-CFDP1-TMEM170A locus as a novel genetic determinant of cIMT and coronary artery disease risk in individuals of European descent.\n'
p10449
sg4
(lp10450
(dp10451
g7
I39
sg8
VP56945
p10452
sg10
I5
sg11
VBCAR1
p10453
sg13
I1
sa(dp10454
g7
I51
sg8
g49
sg10
I8
sg11
VTMEM170A
p10455
sg13
I1
sa(dp10456
g7
I45
sg8
g49
sg10
I5
sg11
VCFDP1
p10457
sg13
I1
sasg14
(lp10458
(dp10459
g7
I109
sg17
VC1956346
p10460
sg10
I23
sg11
Vcoronary artery disease
p10461
sg13
I3
sasa(dp10462
g2
S'We previously demonstrated that treatment of diabetic peripheral neuropathy with the short (4 hours) half-life phosphodiesterase 5 (PDE5) inhibitor, sildenafil, improved functional outcome in diabetic db/db mice.\n'
p10463
sg4
(lp10464
(dp10465
g7
I111
sg8
VP22413
p10466
sg10
I26
sg11
Vphosphodiesterase 5 (PDE5)
p10467
sg13
I3
sasg14
(lp10468
(dp10469
g7
I45
sg17
VC0740447
p10470
sg10
I30
sg11
Vdiabetic peripheral neuropathy
p10471
sg13
I3
sasa(dp10472
g2
S'To further examine the effect of PDE5 inhibition on diabetic peripheral neuropathy, we investigated the effect of another potent PDE5 inhibitor, tadalafil, on diabetic peripheral neuropathy.\n'
p10473
sg4
(lp10474
(dp10475
g7
I33
sg8
g49
sg10
I4
sg11
VPDE5
p10476
sg13
I1
sa(dp10477
g7
I33
sg8
g49
sg10
I4
sg11
VPDE5
p10478
sg13
I1
sasg14
(lp10479
(dp10480
g7
I52
sg17
VC0740447
p10481
sg10
I30
sg11
Vdiabetic peripheral neuropathy
p10482
sg13
I3
sa(dp10483
g7
I52
sg17
VC0740447
p10484
sg10
I30
sg11
Vdiabetic peripheral neuropathy
p10485
sg13
I3
sasa(dp10486
g2
S'Use of phosphodiesterase-5 (PDE-5) inhibitors has been reported to be a risk factor for development of nonarteritic anterior ischemic optic neuropathy (NAION) in males, based largely on a number of case reports.\n'
p10487
sg4
(lp10488
(dp10489
g7
I28
sg8
VP22413
p10490
sg10
I5
sg11
VPDE-5
p10491
sg13
I1
sa(dp10492
g7
I7
sg8
VP22413
p10493
sg10
I19
sg11
Vphosphodiesterase-5
p10494
sg13
I1
sasg14
(lp10495
(dp10496
g7
I103
sg17
VC1852242
p10497
sg10
I47
sg11
Vnonarteritic anterior ischemic optic neuropathy
p10498
sg13
I5
sa(dp10499
g7
I28
sg17
VC1849508
p10500
sg10
I3
sg11
VPDE
p10501
sg13
I1
sa(dp10502
g7
I152
sg17
VC1852242
p10503
sg10
I5
sg11
VNAION
p10504
sg13
I1
sasa(dp10505
g2
S'To present a summary of 10 cases of non-arteritic anterior ischemic optic neuropathy (NAION) in patients who received phosphodiesterase type 5 (PDE-5) inhibitors.\n'
p10506
sg4
(lp10507
(dp10508
g7
I118
sg8
VP22413
p10509
sg10
I32
sg11
Vphosphodiesterase type 5 (PDE-5)
p10510
sg13
I4
sasg14
(lp10511
(dp10512
g7
I36
sg17
VC1852242
p10513
sg10
I48
sg11
Vnon-arteritic anterior ischemic optic neuropathy
p10514
sg13
I5
sa(dp10515
g7
I144
sg17
VC1849508
p10516
sg10
I3
sg11
VPDE
p10517
sg13
I1
sa(dp10518
g7
I86
sg17
VC1852242
p10519
sg10
I5
sg11
VNAION
p10520
sg13
I1
sasa(dp10521
g2
S'We looked at alpha-blockers and intraoperative floppy iris syndrome (IFIS), phosphodiesterase type 5 (PDE5) inhibitors and non-arteritic ischemic optic neuropathy (NAION) and lastly anticholinergic medications and glaucoma.\n'
p10522
sg4
(lp10523
(dp10524
g7
I76
sg8
VP22413
p10525
sg10
I31
sg11
Vphosphodiesterase type 5 (PDE5)
p10526
sg13
I4
sasg14
(lp10527
(dp10528
g7
I164
sg17
VC1852242
p10529
sg10
I5
sg11
VNAION
p10530
sg13
I1
sa(dp10531
g7
I32
sg17
VC1688637
p10532
sg10
I35
sg11
Vintraoperative floppy iris syndrome
p10533
sg13
I4
sa(dp10534
g7
I123
sg17
VC0338507
p10535
sg10
I39
sg11
Vnon-arteritic ischemic optic neuropathy
p10536
sg13
I4
sa(dp10537
g7
I214
sg17
VC0017601
p10538
sg10
I8
sg11
Vglaucoma
p10539
sg13
I1
sa(dp10540
g7
I69
sg17
VC1688637
p10541
sg10
I4
sg11
VIFIS
p10542
sg13
I1
sasa(dp10543
g2
S'There is no convincing evidence that PDE5 inhibitors cause non-arteritic anterior ischemic optic neuropathy (NAION), but patients should be advised of the possible risk of visual loss, especially in patients with risk factors of ischemic heart disease.\n'
p10544
sg4
(lp10545
(dp10546
g7
I37
sg8
g49
sg10
I4
sg11
VPDE5
p10547
sg13
I1
sasg14
(lp10548
(dp10549
g7
I59
sg17
VC1852242
p10550
sg10
I48
sg11
Vnon-arteritic anterior ischemic optic neuropathy
p10551
sg13
I5
sa(dp10552
g7
I172
sg17
VC0042798
p10553
sg10
I11
sg11
Vvisual loss
p10554
sg13
I2
sa(dp10555
g7
I229
sg17
VC0151744
p10556
sg10
I22
sg11
Vischemic heart disease
p10557
sg13
I3
sa(dp10558
g7
I109
sg17
VC1852242
p10559
sg10
I5
sg11
VNAION
p10560
sg13
I1
sasa(dp10561
g2
S'In prostate adenocarcinoma, besides mutations in BRCA1 and BRCA2 genes that are known to increase the incidence of high-risk cancer in young patients, new studies have shown mutation in other gene such as HOXB13 and also polymorphisms in MYC, MSMB, KLK2 and KLK3 that can be related to hereditary prostate cancer.\n'
p10562
sg4
(lp10563
(dp10564
g7
I205
sg8
g49
sg10
I6
sg11
VHOXB13
p10565
sg13
I1
sa(dp10566
g7
I243
sg8
VP08118
p10567
sg10
I4
sg11
VMSMB
p10568
sg13
I1
sa(dp10569
g7
I59
sg8
VP51587
p10570
sg10
I11
sg11
VBRCA2 genes
p10571
sg13
I2
sa(dp10572
g7
I258
sg8
VP03952
p10573
sg10
I4
sg11
VKLK3
p10574
sg13
I1
sa(dp10575
g7
I249
sg8
VP20151
p10576
sg10
I4
sg11
VKLK2
p10577
sg13
I1
sa(dp10578
g7
I49
sg8
VP38398
p10579
sg10
I5
sg11
VBRCA1
p10580
sg13
I1
sa(dp10581
g7
I238
sg8
VP12524
p10582
sg10
I3
sg11
VMYC
p10583
sg13
I1
sasg14
(lp10584
(dp10585
g7
I3
sg17
VC0007112
p10586
sg10
I23
sg11
Vprostate adenocarcinoma
p10587
sg13
I2
sa(dp10588
g7
I286
sg17
VC2931456
p10589
sg10
I26
sg11
Vhereditary prostate cancer
p10590
sg13
I3
sa(dp10591
g7
I115
sg17
VC1512441
p10592
sg10
I16
sg11
Vhigh-risk cancer
p10593
sg13
I2
sasa(dp10594
g2
S'Immortalized human prostate basal epithelial EP156T cells and progeny cells that underwent epithelial to mesenchymal transition (EMT), primary prostate epithelial cells (PrECs) and prostate cancer cell lines LNCaP, VCaP and 22Rv1 were used to examine context dependent restriction and activation of the AR and classical target genes, such as KLK3.\n'
p10595
sg4
(lp10596
(dp10597
g7
I342
sg8
VP03952
p10598
sg10
I4
sg11
VKLK3
p10599
sg13
I1
sasg14
(lp10600
(dp10601
g7
I181
sg17
VC0600139
p10602
sg10
I15
sg11
Vprostate cancer
p10603
sg13
I2
sa(dp10604
g7
I117
sg17
VC0599156
p10605
sg10
I10
sg11
Vtransition
p10606
sg13
I1
sasa(dp10607
g2
S'Across 66 meta-analyses, a total of 20 genetic variants involving 584,100 subjects in 19 different genes (KLK3, IGFBP3, ESR1, SOD2, CAT, CYP1B1, VDR, RFX6, HNF1B, SRD5A2, FGFR4, LEP, HOXB13, FAS, FOXP4, SLC22A3, LMTK2, EHBP1 and MSMB) exhibited significant association with prostate cancer.\n'
p10608
sg4
(lp10609
(dp10610
g7
I191
sg8
VP48023
p10611
sg10
I3
sg11
VFAS
p10612
sg13
I1
sa(dp10613
g7
I145
sg8
VP11473
p10614
sg10
I3
sg11
VVDR
p10615
sg13
I1
sa(dp10616
g7
I106
sg8
VP03952
p10617
sg10
I4
sg11
VKLK3
p10618
sg13
I1
sa(dp10619
g7
I112
sg8
VP17936
p10620
sg10
I6
sg11
VIGFBP3
p10621
sg13
I1
sa(dp10622
g7
I196
sg8
g49
sg10
I5
sg11
VFOXP4
p10623
sg13
I1
sa(dp10624
g7
I156
sg8
VP35680
p10625
sg10
I5
sg11
VHNF1B
p10626
sg13
I1
sa(dp10627
g7
I126
sg8
VP04179
p10628
sg10
I4
sg11
VSOD2
p10629
sg13
I1
sa(dp10630
g7
I203
sg8
g49
sg10
I7
sg11
VSLC22A3
p10631
sg13
I1
sa(dp10632
g7
I120
sg8
VP03372
p10633
sg10
I4
sg11
VESR1
p10634
sg13
I1
sa(dp10635
g7
I212
sg8
g49
sg10
I5
sg11
VLMTK2
p10636
sg13
I1
sa(dp10637
g7
I229
sg8
VP08118
p10638
sg10
I4
sg11
VMSMB
p10639
sg13
I1
sa(dp10640
g7
I183
sg8
g49
sg10
I6
sg11
VHOXB13
p10641
sg13
I1
sa(dp10642
g7
I137
sg8
g49
sg10
I6
sg11
VCYP1B1
p10643
sg13
I1
sa(dp10644
g7
I178
sg8
VP41159
p10645
sg10
I3
sg11
VLEP
p10646
sg13
I1
sa(dp10647
g7
I163
sg8
VP31213
p10648
sg10
I6
sg11
VSRD5A2
p10649
sg13
I1
sa(dp10650
g7
I171
sg8
VP22455
p10651
sg10
I5
sg11
VFGFR4
p10652
sg13
I1
sa(dp10653
g7
I150
sg8
g49
sg10
I4
sg11
VRFX6
p10654
sg13
I1
sa(dp10655
g7
I132
sg8
VP04040
p10656
sg10
I3
sg11
VCAT
p10657
sg13
I1
sasg14
(lp10658
(dp10659
g7
I191
sg17
VC0015923
p10660
sg10
I3
sg11
VFAS
p10661
sg13
I1
sa(dp10662
g7
I274
sg17
VC0600139
p10663
sg10
I15
sg11
Vprostate cancer
p10664
sg13
I2
sasa(dp10665
g2
S'We hypothesized that EPOR signaling is important in pathological angiogenesis and tested this hypothesis using a rat model of oxygen-induced retinopathy that is representative of human retinopathy of prematurity.\n'
p10666
sg4
(lp10667
(dp10668
g7
I21
sg8
VP19235
p10669
sg10
I4
sg11
VEPOR
p10670
sg13
I1
sasg14
(lp10671
(dp10672
g7
I52
sg17
VC0027686
p10673
sg10
I25
sg11
Vpathological angiogenesis
p10674
sg13
I2
sa(dp10675
g7
I141
sg17
VC0035309
p10676
sg10
I11
sg11
Vretinopathy
p10677
sg13
I1
sa(dp10678
g7
I185
sg17
VC0035344
p10679
sg10
I26
sg11
Vretinopathy of prematurity
p10680
sg13
I3
sasa(dp10681
g2
S'Lentiviral-delivered shRNAs that knocked down Muller cell-expressed VEGF in the retinopathy of prematurity model also reduced phosphorylated EPOR (p-EPOR) and VEGFR2 (p-VEGFR2) in retinal ECs.\n'
p10682
sg4
(lp10683
(dp10684
g7
I147
sg8
VP19235
p10685
sg10
I6
sg11
Vp-EPOR
p10686
sg13
I1
sa(dp10687
g7
I126
sg8
VP19235
p10688
sg10
I19
sg11
Vphosphorylated EPOR
p10689
sg13
I2
sa(dp10690
g7
I167
sg8
VP35968
p10691
sg10
I8
sg11
Vp-VEGFR2
p10692
sg13
I1
sa(dp10693
g7
I159
sg8
VP35968
p10694
sg10
I6
sg11
VVEGFR2
p10695
sg13
I1
sasg14
(lp10696
(dp10697
g7
I80
sg17
VC0035344
p10698
sg10
I26
sg11
Vretinopathy of prematurity
p10699
sg13
I3
sasa(dp10700
g2
S'To evaluate the effects of intravitreal injection of soluble erythropoietin (EPO) receptor (sEPOR) on photoreceptor cell apoptosis in an animal model of retinal detachment (RD).\n'
p10701
sg4
(lp10702
(dp10703
g7
I61
sg8
VP01588
p10704
sg10
I29
sg11
Verythropoietin (EPO) receptor
p10705
sg13
I3
sasg14
(lp10706
(dp10707
g7
I153
sg17
VC0035305
p10708
sg10
I18
sg11
Vretinal detachment
p10709
sg13
I2
sa(dp10710
g7
I173
sg17
VC0035305
p10711
sg10
I2
sg11
VRD
p10712
sg13
I1
sasa(dp10713
g2
S'The aim of this study was to investigate the effects of supplemental erythropoietin (EPO) on its receptor (EPOR) and signal transduction pathways in rat model of retinal detachment (RD).\n'
p10714
sg4
(lp10715
(dp10716
g7
I85
sg8
VP01588
p10717
sg10
I3
sg11
VEPO
p10718
sg13
I1
sa(dp10719
g7
I69
sg8
VP01588
p10720
sg10
I14
sg11
Verythropoietin
p10721
sg13
I1
sa(dp10722
g7
I107
sg8
VP19235
p10723
sg10
I4
sg11
VEPOR
p10724
sg13
I1
sasg14
(lp10725
(dp10726
g7
I182
sg17
VC0035305
p10727
sg10
I2
sg11
VRD
p10728
sg13
I1
sa(dp10729
g7
I162
sg17
VC0035305
p10730
sg10
I18
sg11
Vretinal detachment
p10731
sg13
I2
sasa(dp10732
g2
S'To investigate the possible involvement of erythr opoietin (EPO)/erythropoietin receptor (EPOR) system in neovascularization and vascular regeneration in diabetic retinopathy (DR).\n'
p10733
sg4
(lp10734
(dp10735
g7
I43
sg8
VP01588
p10736
sg10
I15
sg11
Verythr opoietin
p10737
sg13
I2
sa(dp10738
g7
I64
sg8
VP19235
p10739
sg10
I24
sg11
V/erythropoietin receptor
p10740
sg13
I2
sa(dp10741
g7
I90
sg8
VP19235
p10742
sg10
I4
sg11
VEPOR
p10743
sg13
I1
sa(dp10744
g7
I60
sg8
VP01588
p10745
sg10
I3
sg11
VEPO
p10746
sg13
I1
sasg14
(lp10747
(dp10748
g7
I176
sg17
VC0011884
p10749
sg10
I2
sg11
VDR
p10750
sg13
I1
sa(dp10751
g7
I154
sg17
VC0011884
p10752
sg10
I20
sg11
Vdiabetic retinopathy
p10753
sg13
I2
sa(dp10754
g7
I106
sg17
VC0027686
p10755
sg10
I18
sg11
Vneovascularization
p10756
sg13
I1
sasa(dp10757
g2
S'Signaling pathways that are responsible for these Muller cell-mediated EPO/EpoR functions may be therapeutic targets for diabetic retinopathy.\n'
p10758
sg4
(lp10759
(dp10760
g7
I71
sg8
VP01588
p10761
sg10
I3
sg11
VEPO
p10762
sg13
I1
sa(dp10763
g7
I75
sg8
VP19235
p10764
sg10
I4
sg11
VEpoR
p10765
sg13
I1
sasg14
(lp10766
(dp10767
g7
I121
sg17
VC0011884
p10768
sg10
I20
sg11
Vdiabetic retinopathy
p10769
sg13
I2
sasa(dp10770
g2
S'The week of delivery was statistically significantly shorter in the study group and the levels of biochemical markers of inflammation (C-reactive protein and fibrinogen in the serum) were statistically significantly higher in women with bacterial vaginosis comparing to the control group.\n'
p10771
sg4
(lp10772
(dp10773
g7
I158
sg8
VP22087
p10774
sg10
I10
sg11
Vfibrinogen
p10775
sg13
I1
sa(dp10776
g7
I135
sg8
VP02741
p10777
sg10
I18
sg11
VC-reactive protein
p10778
sg13
I2
sasg14
(lp10779
(dp10780
g7
I237
sg17
VC0085166
p10781
sg10
I19
sg11
Vbacterial vaginosis
p10782
sg13
I2
sa(dp10783
g7
I121
sg17
VC0021368
p10784
sg10
I12
sg11
Vinflammation
p10785
sg13
I1
sasa(dp10786
g2
S'Biomeasure collection included height, weight, hip and waist circumference, blood pressure, heart rate, and preventricular contraction, timed walk and chair stands, smell, saliva collection using a Salivette (cortisol), saliva passive drool in a tube (dehydroepiandrosterone, estradiol, progesterone, testosterone), dried blood spots (Epstein-Barr virus antibody titers, C-reactive protein, glycosylated hemoglobin, hemoglobin, cholesterol, high-density lipoprotein), whole blood in a microtainer (cytokines), urine (creatinine, vasopressin, oxytocin), Oragene (genotype), respondent-administered vaginal swabs (bacterial vaginosis,yeast, and vaginal cell cytology), and Actiwatch (sleep patterns and activity).\n'
p10787
sg4
(lp10788
(dp10789
g7
I404
sg8
g49
sg10
I10
sg11
Vhemoglobin
p10790
sg13
I1
sa(dp10791
g7
I371
sg8
VP02741
p10792
sg10
I18
sg11
VC-reactive protein
p10793
sg13
I2
sa(dp10794
g7
I335
sg8
g49
sg10
I27
sg11
VEpstein-Barr virus antibody
p10795
sg13
I3
sa(dp10796
g7
I441
sg8
VP28845
p10797
sg10
I24
sg11
Vhigh-density lipoprotein
p10798
sg13
I2
sa(dp10799
g7
I542
sg8
VP01178
p10800
sg10
I8
sg11
Voxytocin
p10801
sg13
I1
sa(dp10802
g7
I529
sg8
VP01185
p10803
sg10
I11
sg11
Vvasopressin
p10804
sg13
I1
sa(dp10805
g7
I404
sg8
g49
sg10
I10
sg11
Vhemoglobin
p10806
sg13
I1
sasg14
(lp10807
(dp10808
g7
I612
sg17
VC0085166
p10809
sg10
I19
sg11
Vbacterial vaginosis
p10810
sg13
I2
sa(dp10811
g7
I235
sg17
VC0013132
p10812
sg10
I5
sg11
Vdrool
p10813
sg13
I1
sa(dp10814
g7
I328
sg17
VC0015230
p10815
sg10
I5
sg11
Vspots
p10816
sg13
I1
sa(dp10817
g7
I123
sg17
VC1140999
p10818
sg10
I11
sg11
Vcontraction
p10819
sg13
I1
sasa(dp10820
g2
S'Twenty variables were evaluated by univariate and logistic regression analysis: age, history of pregnancy/delivery, gynecological open/laparoscopic surgery, PID, oral contraceptives/intrauterine device use and intrauterine operation before onset, body temperature, signs of peritoneal irritation, vomiting/diarrhea, abnormal vaginal discharge, endometriosis/fibroid/adenomyosis/any cystic lesion detected by ultrasonography, white blood cell counts/C-reactive protein (CRP) levels .\n'
p10821
sg4
(lp10822
(dp10823
g7
I442
sg8
VP02741
p10824
sg10
I25
sg11
Vcounts/C-reactive protein
p10825
sg13
I2
sa(dp10826
g7
I469
sg8
VP02741
p10827
sg10
I3
sg11
VCRP
p10828
sg13
I1
sasg14
(lp10829
(dp10830
g7
I297
sg17
VC0042963
p10831
sg10
I8
sg11
Vvomiting
p10832
sg13
I1
sa(dp10833
g7
I157
sg17
VC0242172
p10834
sg10
I3
sg11
VPID
p10835
sg13
I1
sa(dp10836
g7
I358
sg17
VC0023267
p10837
sg10
I7
sg11
Vfibroid
p10838
sg13
I1
sa(dp10839
g7
I344
sg17
VC0014175
p10840
sg10
I13
sg11
Vendometriosis
p10841
sg13
I1
sa(dp10842
g7
I306
sg17
VC0011991
p10843
sg10
I8
sg11
Vdiarrhea
p10844
sg13
I1
sa(dp10845
g7
I366
sg17
VC0341858
p10846
sg10
I11
sg11
Vadenomyosis
p10847
sg13
I1
sasa(dp10848
g2
S'The study aim was to evaluate inflammation markers values (C-reactive protein (CRP), Erythrocite sedimentation (ES), White blood cells count (WBC)) in surgically treated pediatric patients with diagnosed developmental displasia of the hip or Perthes disease before and after operation.\n'
p10849
sg4
(lp10850
(dp10851
g7
I79
sg8
VP02741
p10852
sg10
I3
sg11
VCRP
p10853
sg13
I1
sa(dp10854
g7
I59
sg8
VP02741
p10855
sg10
I18
sg11
VC-reactive protein
p10856
sg13
I2
sasg14
(lp10857
(dp10858
g7
I242
sg17
VC1442965
p10859
sg10
I15
sg11
VPerthes disease
p10860
sg13
I2
sa(dp10861
g7
I30
sg17
VC0021368
p10862
sg10
I12
sg11
Vinflammation
p10863
sg13
I1
sasa(dp10864
g2
S'We investigated the levels of D-dimer and C-reactive protein (CRP) in a cohort of HIV-infected adults with and without osteonecrosis of the femoral head.\n'
p10865
sg4
(lp10866
(dp10867
g7
I42
sg8
VP02741
p10868
sg10
I18
sg11
VC-reactive protein
p10869
sg13
I2
sa(dp10870
g7
I62
sg8
VP02741
p10871
sg10
I3
sg11
VCRP
p10872
sg13
I1
sa(dp10873
g7
I30
sg8
g49
sg10
I7
sg11
VD-dimer
p10874
sg13
I1
sasg14
(lp10875
(dp10876
g7
I119
sg17
VC0029445
p10877
sg10
I13
sg11
Vosteonecrosis
p10878
sg13
I1
sa(dp10879
g7
I82
sg17
VC0019693
p10880
sg10
I3
sg11
VHIV
p10881
sg13
I1
sasa(dp10882
g2
S'D-dimer and CRP levels were measured prior to and at the time of diagnosis for osteonecrosis patients, at the time of negative MRI of the hips for controls, and at least 6 months later for both groups.\n'
p10883
sg4
(lp10884
(dp10885
g7
I12
sg8
VP02741
p10886
sg10
I3
sg11
VCRP
p10887
sg13
I1
sa(dp10888
g7
I0
sg8
g49
sg10
I7
sg11
VD-dimer
p10889
sg13
I1
sasg14
(lp10890
(dp10891
g7
I79
sg17
VC0029445
p10892
sg10
I13
sg11
Vosteonecrosis
p10893
sg13
I1
sasa(dp10894
g2
S'Postdiagnosis, D-dimer and CRP levels were also elevated in the osteonecrosis patients compared with controls.\n'
p10895
sg4
(lp10896
(dp10897
g7
I15
sg8
g49
sg10
I7
sg11
VD-dimer
p10898
sg13
I1
sa(dp10899
g7
I27
sg8
VP02741
p10900
sg10
I3
sg11
VCRP
p10901
sg13
I1
sasg14
(lp10902
(dp10903
g7
I64
sg17
VC0029445
p10904
sg10
I13
sg11
Vosteonecrosis
p10905
sg13
I1
sasa(dp10906
g2
S'Linear regression demonstrated a rise in D-dimer levels from prediagnosis to diagnosis in the osteonecrosis patients whereas CRP levels did not change significantly over time.\n'
p10907
sg4
(lp10908
(dp10909
g7
I125
sg8
VP02741
p10910
sg10
I3
sg11
VCRP
p10911
sg13
I1
sasg14
(lp10912
(dp10913
g7
I94
sg17
VC0029445
p10914
sg10
I13
sg11
Vosteonecrosis
p10915
sg13
I1
sasa(dp10916
g2
S'Compared to controls, patients who developed osteonecrosis had elevated levels of D-dimer and CRP at diagnosis.\n'
p10917
sg4
(lp10918
(dp10919
g7
I82
sg8
g49
sg10
I7
sg11
VD-dimer
p10920
sg13
I1
sa(dp10921
g7
I94
sg8
VP02741
p10922
sg10
I3
sg11
VCRP
p10923
sg13
I1
sasg14
(lp10924
(dp10925
g7
I45
sg17
VC0029445
p10926
sg10
I13
sg11
Vosteonecrosis
p10927
sg13
I1
sasa(dp10928
g2
S"Dental caries' GWAS identified significant signals in LYZL2, AJAp1, and KPNA4; and efforts are ongoing to identify genetic factors for multiple caries phenotypes.\n"
p10929
sg4
(lp10930
(dp10931
g7
I54
sg8
g49
sg10
I5
sg11
VLYZL2
p10932
sg13
I1
sa(dp10933
g7
I61
sg8
g49
sg10
I5
sg11
VAJAp1
p10934
sg13
I1
sa(dp10935
g7
I72
sg8
g49
sg10
I5
sg11
VKPNA4
p10936
sg13
I1
sasg14
(lp10937
(dp10938
g7
I7
sg17
VC0333519
p10939
sg10
I6
sg11
Vcaries
p10940
sg13
I1
sa(dp10941
g7
I0
sg17
VC0333519
p10942
sg10
I13
sg11
VDental caries
p10943
sg13
I2
sasa(dp10944
g2
S'In erosive gastritis, increased proliferation (MET) and transport (UCP2, SCFD1, KPNA4) were found, while genes associated with adhesion (SIGLEC11), transcription regulation (ESRRG), and electron and ion transport (ACADM, CLIC6) were down-regulated.\n'
p10945
sg4
(lp10946
(dp10947
g7
I73
sg8
g49
sg10
I5
sg11
VSCFD1
p10948
sg13
I1
sa(dp10949
g7
I67
sg8
VP55851
p10950
sg10
I4
sg11
VUCP2
p10951
sg13
I1
sa(dp10952
g7
I137
sg8
g49
sg10
I8
sg11
VSIGLEC11
p10953
sg13
I1
sa(dp10954
g7
I80
sg8
g49
sg10
I5
sg11
VKPNA4
p10955
sg13
I1
sa(dp10956
g7
I221
sg8
g49
sg10
I5
sg11
VCLIC6
p10957
sg13
I1
sasg14
(lp10958
(dp10959
g7
I32
sg17
VC0334094
p10960
sg10
I13
sg11
Vproliferation
p10961
sg13
I1
sa(dp10962
g7
I3
sg17
VC2243088
p10963
sg10
I17
sg11
Verosive gastritis
p10964
sg13
I2
sa(dp10965
g7
I127
sg17
VC0001511
p10966
sg10
I8
sg11
Vadhesion
p10967
sg13
I1
sasa(dp10968
g2
S'Mice bearing the MS-2 fibrosarcoma were administered 0.25, 0.5 or 1 mg kg(-1) body weight (b.w.)'
p10969
sg4
(lp10970
sg14
(lp10971
(dp10972
g7
I22
sg17
VC0016057
p10973
sg10
I12
sg11
Vfibrosarcoma
p10974
sg13
I1
sasa(dp10975
g2
S'MIP-1alpha, ADAM8, ADAM12 and CD68 were detected by immunohistochemistry in 24 paraffin-embedded specimens of central giant cell lesions of jaw and giant cell tumors respectively.\n'
p10976
sg4
(lp10977
(dp10978
g7
I12
sg8
VP78325
p10979
sg10
I5
sg11
VADAM8
p10980
sg13
I1
sa(dp10981
g7
I19
sg8
g49
sg10
I6
sg11
VADAM12
p10982
sg13
I1
sa(dp10983
g7
I0
sg8
g49
sg10
I10
sg11
VMIP-1alpha
p10984
sg13
I1
sa(dp10985
g7
I30
sg8
VP34810
p10986
sg10
I4
sg11
VCD68
p10987
sg13
I1
sasg14
(lp10988
(dp10989
g7
I0
sg17
VC1851100
p10990
sg10
I3
sg11
VMIP
p10991
sg13
I1
sa(dp10992
g7
I118
sg17
VC0017547
p10993
sg10
I5
sg11
Vgiant
p10994
sg13
I1
sa(dp10995
g7
I148
sg17
VC0017525
p10996
sg10
I17
sg11
Vgiant cell tumors
p10997
sg13
I3
sasa(dp10998
g2
S'Cells of the MS-2 fibrosarcoma were injected in mice in two compartments in order to cause the development of tumors in different host tissues.\n'
p10999
sg4
(lp11000
sg14
(lp11001
(dp11002
g7
I18
sg17
VC0016057
p11003
sg10
I12
sg11
Vfibrosarcoma
p11004
sg13
I1
sa(dp11005
g7
I110
sg17
VC0027651
p11006
sg10
I6
sg11
Vtumors
p11007
sg13
I1
sasa(dp11008
g2
S'MS-2 fibrosarcoma implanted in BALB-CDF1 mice was investigated by frequency and time domain measurements of the autofluorescence (AF) radiation emitted upon excitation by a N(2) laser beam (337.1 nm).\n'
p11009
sg4
(lp11010
sg14
(lp11011
(dp11012
g7
I5
sg17
VC0016057
p11013
sg10
I12
sg11
Vfibrosarcoma
p11014
sg13
I1
sasa(dp11015
g2
S'Zn(II)-phthalocyanines (ZnPc) and its octapentyl (ZnOPPc) and octadecyl (ZnODPc) derivatives have been intravenously injected at a dose of 1.46 mumol/kg into female Balb/c mice bearing an intramuscularly transplanted MS-2 fibrosarcoma.\n'
p11016
sg4
(lp11017
sg14
(lp11018
(dp11019
g7
I222
sg17
VC0016057
p11020
sg10
I12
sg11
Vfibrosarcoma
p11021
sg13
I1
sasa(dp11022
g2
S'to Balb/c mice bearing an intramuscularly implanted MS-2 fibrosarcoma.\n'
p11023
sg4
(lp11024
sg14
(lp11025
(dp11026
g7
I57
sg17
VC0016057
p11027
sg10
I12
sg11
Vfibrosarcoma
p11028
sg13
I1
sasa(dp11029
g2
S'The pharmacokinetic behavior and photodynamic properties of the dimer D1 were examined in Balb/c mice bearing an MS-2 fibrosarcoma.\n'
p11030
sg4
(lp11031
sg14
(lp11032
(dp11033
g7
I118
sg17
VC0016057
p11034
sg10
I12
sg11
Vfibrosarcoma
p11035
sg13
I1
sasa(dp11036
g2
S'Extensive experimental tests have been performed on mice bearing the MS-2 fibrosarcoma or the L1210 leukemia.\n'
p11037
sg4
(lp11038
sg14
(lp11039
(dp11040
g7
I74
sg17
VC0016057
p11041
sg10
I12
sg11
Vfibrosarcoma
p11042
sg13
I1
sa(dp11043
g7
I100
sg17
VC0023418
p11044
sg10
I8
sg11
Vleukemia
p11045
sg13
I1
sasa(dp11046
g2
S'Zn(II)-octapentyl-phthalocyanine (ZnOPPc), incorporated into a Cremophor oil emulsion, was found to be a highly selective tumour-targeting agent (50-fold larger concentration in the tumour than in the peritumoral tissue) when injected at a dose of 1.46 mumol (kg body weight)-1 in Balb/c mice bearing an intramuscularly transplanted MS-2 fibrosarcoma.\n'
p11047
sg4
(lp11048
sg14
(lp11049
(dp11050
g7
I122
sg17
VC0027651
p11051
sg10
I6
sg11
Vtumour
p11052
sg13
I1
sa(dp11053
g7
I338
sg17
VC0016057
p11054
sg10
I12
sg11
Vfibrosarcoma
p11055
sg13
I1
sa(dp11056
g7
I122
sg17
VC0027651
p11057
sg10
I6
sg11
Vtumour
p11058
sg13
I1
sasa(dp11059
g2
S'Additionally, we discovered that the sensitivity of Ewing sarcoma cells to inhibition or suppression of RNR is mediated, in part, by high levels of SLFN11, a protein that sensitizes cells to DNA damage.\n'
p11060
sg4
(lp11061
(dp11062
g7
I148
sg8
g49
sg10
I6
sg11
VSLFN11
p11063
sg13
I1
sa(dp11064
g7
I104
sg8
g49
sg10
I3
sg11
VRNR
p11065
sg13
I1
sasg14
(lp11066
(dp11067
g7
I191
sg17
VC0012860
p11068
sg10
I10
sg11
VDNA damage
p11069
sg13
I2
sa(dp11070
g7
I89
sg17
VC0221103
p11071
sg10
I11
sg11
Vsuppression
p11072
sg13
I1
sa(dp11073
g7
I52
sg17
VC0553580
p11074
sg10
I13
sg11
VEwing sarcoma
p11075
sg13
I2
sasa(dp11076
g2
S'Ewing sarcoma, which is characterized by the chimeric transcription factor EWS-FLI1, has notably high SLFN11 expression, leading us to investigate whether EWS-FLI1 drives SLFN11 expression and the role of SLFN11 in the drug response of Ewing sarcoma cells.\n'
p11077
sg4
(lp11078
(dp11079
g7
I102
sg8
g49
sg10
I6
sg11
VSLFN11
p11080
sg13
I1
sa(dp11081
g7
I75
sg8
g49
sg10
I3
sg11
VEWS
p11082
sg13
I1
sa(dp11083
g7
I75
sg8
g49
sg10
I3
sg11
VEWS
p11084
sg13
I1
sa(dp11085
g7
I79
sg8
g49
sg10
I4
sg11
VFLI1
p11086
sg13
I1
sa(dp11087
g7
I102
sg8
g49
sg10
I6
sg11
VSLFN11
p11088
sg13
I1
sa(dp11089
g7
I79
sg8
g49
sg10
I4
sg11
VFLI1
p11090
sg13
I1
sa(dp11091
g7
I102
sg8
g49
sg10
I6
sg11
VSLFN11
p11092
sg13
I1
sasg14
(lp11093
(dp11094
g7
I0
sg17
VC0553580
p11095
sg10
I13
sg11
VEwing sarcoma
p11096
sg13
I2
sa(dp11097
g7
I0
sg17
VC0553580
p11098
sg10
I13
sg11
VEwing sarcoma
p11099
sg13
I2
sasa(dp11100
g2
S'EWS-FLI1 binds near the transcription start site of SLFN11 promoter and acts as a positive regulator of SLFN11 expression in Ewing sarcoma cells.\n'
p11101
sg4
(lp11102
(dp11103
g7
I52
sg8
g49
sg10
I6
sg11
VSLFN11
p11104
sg13
I1
sa(dp11105
g7
I0
sg8
g49
sg10
I3
sg11
VEWS
p11106
sg13
I1
sa(dp11107
g7
I52
sg8
g49
sg10
I15
sg11
VSLFN11 promoter
p11108
sg13
I2
sa(dp11109
g7
I4
sg8
g49
sg10
I4
sg11
VFLI1
p11110
sg13
I1
sasg14
(lp11111
(dp11112
g7
I125
sg17
VC0553580
p11113
sg10
I13
sg11
VEwing sarcoma
p11114
sg13
I2
sasa(dp11115
g2
S'EWS-FLI1-mediated SLFN11 expression is responsible for high sensitivity of Ewing sarcoma to camptothecin and combinations of PARP inhibitors with temozolomide.\n'
p11116
sg4
(lp11117
(dp11118
g7
I0
sg8
g49
sg10
I3
sg11
VEWS
p11119
sg13
I1
sa(dp11120
g7
I18
sg8
g49
sg10
I6
sg11
VSLFN11
p11121
sg13
I1
sa(dp11122
g7
I125
sg8
VP09874
p11123
sg10
I4
sg11
VPARP
p11124
sg13
I1
sa(dp11125
g7
I4
sg8
g49
sg10
I4
sg11
VFLI1
p11126
sg13
I1
sasg14
(lp11127
(dp11128
g7
I75
sg17
VC0553580
p11129
sg10
I13
sg11
VEwing sarcoma
p11130
sg13
I2
sasa(dp11131
g2
S'Importantly, Ewing sarcoma patients with higher SLFN11 expression showed better tumor-free survival rate.\n'
p11132
sg4
(lp11133
(dp11134
g7
I48
sg8
g49
sg10
I6
sg11
VSLFN11
p11135
sg13
I1
sasg14
(lp11136
(dp11137
g7
I13
sg17
VC0553580
p11138
sg10
I13
sg11
VEwing sarcoma
p11139
sg13
I2
sa(dp11140
g7
I80
sg17
VC0027651
p11141
sg10
I5
sg11
Vtumor
p11142
sg13
I1
sasa(dp11143
g2
S'Overall, the strongest CDI-associated risk factors, which have significant contributions to the CDI burden as well, were the experience of gastroenteritis (OR=5.08, PAR%=17.09%) and use of antibiotics (OR=1.69, PAR%=19.00%), followed by the experiences of female pelvic infection, irritable bowel syndrome, inflammatory bowel disease, and pneumonia, and use of proton-pump inhibitors (OR=1.52-2.37, PAR%=1.95-2.90).\n'
p11144
sg4
(lp11145
sg14
(lp11146
(dp11147
g7
I307
sg17
VC0021390
p11148
sg10
I26
sg11
Vinflammatory bowel disease
p11149
sg13
I3
sa(dp11150
g7
I23
sg17
VC0687720
p11151
sg10
I3
sg11
VCDI
p11152
sg13
I1
sa(dp11153
g7
I263
sg17
VC0030790
p11154
sg10
I16
sg11
Vpelvic infection
p11155
sg13
I2
sa(dp11156
g7
I23
sg17
VC0687720
p11157
sg10
I3
sg11
VCDI
p11158
sg13
I1
sa(dp11159
g7
I139
sg17
VC0017160
p11160
sg10
I15
sg11
Vgastroenteritis
p11161
sg13
I1
sa(dp11162
g7
I339
sg17
VC0032285
p11163
sg10
I9
sg11
Vpneumonia
p11164
sg13
I1
sa(dp11165
g7
I281
sg17
VC0022104
p11166
sg10
I24
sg11
Virritable bowel syndrome
p11167
sg13
I3
sasa(dp11168
g2
S'We included patients over age 64 admitted to a tertiary care hospital between 2009-2010 with heart failure, pneumonia, or acute coronary syndrome who were taking a medication in any of six commonly-interchanged classes on admission: proton pump inhibitors (PPIs), histamine H2-receptor antagonists (H2 blockers), hydroxymethylglutaryl CoA reductase inhibitors (statins), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and inhaled corticosteroids (ICS).\n'
p11169
sg4
(lp11170
(dp11171
g7
I402
sg8
VP12821
p11172
sg10
I3
sg11
VACE
p11173
sg13
I1
sa(dp11174
g7
I371
sg8
VP12821
p11175
sg10
I29
sg11
Vangiotensin-converting enzyme
p11176
sg13
I2
sa(dp11177
g7
I264
sg8
g49
sg10
I21
sg11
Vhistamine H2-receptor
p11178
sg13
I2
sa(dp11179
g7
I313
sg8
g49
sg10
I35
sg11
Vhydroxymethylglutaryl CoA reductase
p11180
sg13
I3
sa(dp11181
g7
I419
sg8
VP04201
p11182
sg10
I20
sg11
Vangiotensin receptor
p11183
sg13
I2
sasg14
(lp11184
(dp11185
g7
I335
sg17
VC2678439
p11186
sg10
I3
sg11
VCoA
p11187
sg13
I1
sa(dp11188
g7
I108
sg17
VC0032285
p11189
sg10
I9
sg11
Vpneumonia
p11190
sg13
I1
sa(dp11191
g7
I486
sg17
VC0022521
p11192
sg10
I3
sg11
VICS
p11193
sg13
I1
sa(dp11194
g7
I461
sg17
VC0022521
p11195
sg10
I23
sg11
Vinhaled corticosteroids
p11196
sg13
I2
sa(dp11197
g7
I122
sg17
VC0948089
p11198
sg10
I23
sg11
Vacute coronary syndrome
p11199
sg13
I3
sa(dp11200
g7
I93
sg17
VC0018802
p11201
sg10
I13
sg11
Vheart failure
p11202
sg13
I2
sasa(dp11203
g2
S'CBG deficiency caused a fall of hepatic 11Beta-hydroxysteroid dehydrogenase type 2 expression and an increase in epidymal adipose tissue, particularly in HL mice.\n'
p11204
sg4
(lp11205
(dp11206
g7
I40
sg8
VP49366
p11207
sg10
I35
sg11
V11Beta-hydroxysteroid dehydrogenase
p11208
sg13
I2
sa(dp11209
g7
I0
sg8
VP08185
p11210
sg10
I3
sg11
VCBG
p11211
sg13
I1
sasg14
(lp11212
(dp11213
g7
I0
sg17
VC1852529
p11214
sg10
I14
sg11
VCBG deficiency
p11215
sg13
I2
sasa(dp11216
g2
S'This study was designed to evaluate the effects calcium fructoborate (CFB) and sodium tetraborate (NTB) as supplements in Iraqi patients with active rheumatoid arthritis (RA) maintained on etanercept.\n'
p11217
sg4
(lp11218
sg14
(lp11219
(dp11220
g7
I171
sg17
VC0003873
p11221
sg10
I2
sg11
VRA
p11222
sg13
I1
sa(dp11223
g7
I149
sg17
VC0003873
p11224
sg10
I20
sg11
Vrheumatoid arthritis
p11225
sg13
I2
sasa(dp11226
g2
S'Increased expression of endogenous Toll-like receptor 4 (TLR4) ligands (e.g., Tenascin-C, S100A8/A9, citrullinated fibrinogen (cFb) immune complexes) has been observed in patients with rheumatoid arthritis (RA).\n'
p11227
sg4
(lp11228
(dp11229
g7
I57
sg8
g49
sg10
I4
sg11
VTLR4
p11230
sg13
I1
sa(dp11231
g7
I90
sg8
VP05109
p11232
sg10
I6
sg11
VS100A8
p11233
sg13
I1
sa(dp11234
g7
I115
sg8
VP22087
p11235
sg10
I10
sg11
Vfibrinogen
p11236
sg13
I1
sa(dp11237
g7
I35
sg8
g49
sg10
I20
sg11
VToll-like receptor 4
p11238
sg13
I3
sa(dp11239
g7
I78
sg8
VP63316
p11240
sg10
I10
sg11
VTenascin-C
p11241
sg13
I1
sasg14
(lp11242
(dp11243
g7
I207
sg17
VC0003873
p11244
sg10
I2
sg11
VRA
p11245
sg13
I1
sa(dp11246
g7
I185
sg17
VC0003873
p11247
sg10
I20
sg11
Vrheumatoid arthritis
p11248
sg13
I2
sasa(dp11249
g2
S'The aim of the study was to investigate the allotypic variability of complement factor B (BF) in patients and relatives with rheumatoid arthritis (RA) and its association with serological biomarkers and clinical features of the disease.\n'
p11250
sg4
(lp11251
(dp11252
g7
I69
sg8
g49
sg10
I19
sg11
Vcomplement factor B
p11253
sg13
I3
sasg14
(lp11254
(dp11255
g7
I125
sg17
VC0003873
p11256
sg10
I20
sg11
Vrheumatoid arthritis
p11257
sg13
I2
sa(dp11258
g7
I147
sg17
VC0003873
p11259
sg10
I2
sg11
VRA
p11260
sg13
I1
sasa(dp11261
g2
S'Restoration of the expression of miR-499 in the mdx mouse model of Duchenne muscular dystrophy (DMD) reduced the severity of DMD Thus, we have identified a miR-499/Fnip1/AMPK circuit that can serve as a mechanism to couple muscle fiber type and mitochondrial function.\n'
p11262
sg4
(lp11263
(dp11264
g7
I164
sg8
g49
sg10
I5
sg11
VFnip1
p11265
sg13
I1
sa(dp11266
g7
I33
sg8
g49
sg10
I7
sg11
VmiR-499
p11267
sg13
I1
sa(dp11268
g7
I170
sg8
VP54646
p11269
sg10
I4
sg11
VAMPK
p11270
sg13
I1
sa(dp11271
g7
I33
sg8
g49
sg10
I7
sg11
VmiR-499
p11272
sg13
I1
sasg14
(lp11273
(dp11274
g7
I67
sg17
VC0013264
p11275
sg10
I27
sg11
VDuchenne muscular dystrophy
p11276
sg13
I3
sa(dp11277
g7
I48
sg17
VC1839839
p11278
sg10
I3
sg11
Vmdx
p11279
sg13
I1
sa(dp11280
g7
I96
sg17
VC0026850
p11281
sg10
I3
sg11
VDMD
p11282
sg13
I1
sa(dp11283
g7
I96
sg17
VC0026850
p11284
sg10
I3
sg11
VDMD
p11285
sg13
I1
sasa(dp11286
g2
S'The direct quantitative relation between microvascular leakage and kidney (dys)function may provide a missing link between near-normal tissue morphology and septic shock-related renal failure, thus further highlighting the important role of vascular integrity in septic shock-related renal failure.\n'
p11287
sg4
(lp11288
sg14
(lp11289
(dp11290
g7
I157
sg17
VC0036983
p11291
sg10
I12
sg11
Vseptic shock
p11292
sg13
I2
sa(dp11293
g7
I178
sg17
VC0035078
p11294
sg10
I13
sg11
Vrenal failure
p11295
sg13
I2
sa(dp11296
g7
I178
sg17
VC0035078
p11297
sg10
I13
sg11
Vrenal failure
p11298
sg13
I2
sa(dp11299
g7
I75
sg17
VC0013364
p11300
sg10
I3
sg11
Vdys
p11301
sg13
I1
sa(dp11302
g7
I157
sg17
VC0036983
p11303
sg10
I12
sg11
Vseptic shock
p11304
sg13
I2
sa(dp11305
g7
I55
sg17
VC0015376
p11306
sg10
I7
sg11
Vleakage
p11307
sg13
I1
sasa(dp11308
g2
S'Endothelial dysfunction is involved in the pathogenesis of atherosclerosis and cardiovascular complications in chronic kidney disease (CKD).\n'
p11309
sg4
(lp11310
sg14
(lp11311
(dp11312
g7
I135
sg17
VC1561643
p11313
sg10
I3
sg11
VCKD
p11314
sg13
I1
sa(dp11315
g7
I59
sg17
VC0004153
p11316
sg10
I15
sg11
Vatherosclerosis
p11317
sg13
I1
sa(dp11318
g7
I43
sg17
VC0699748
p11319
sg10
I12
sg11
Vpathogenesis
p11320
sg13
I1
sa(dp11321
g7
I0
sg17
VC0856169
p11322
sg10
I23
sg11
VEndothelial dysfunction
p11323
sg13
I2
sa(dp11324
g7
I111
sg17
VC1561643
p11325
sg10
I22
sg11
Vchronic kidney disease
p11326
sg13
I3
sasa(dp11327
g2
S'Our results supports the presence of endothelial dysfunction in CKD patients.\n'
p11328
sg4
(lp11329
sg14
(lp11330
(dp11331
g7
I37
sg17
VC0856169
p11332
sg10
I23
sg11
Vendothelial dysfunction
p11333
sg13
I2
sasa(dp11334
g2
S'Correlation between elevated serum AMDA concentration and disadvantageous changes in left ventricular structure and function may indicate an important role of endothelial dysfunction in cardiovascular complications in CKD patients.\n'
p11335
sg4
(lp11336
sg14
(lp11337
(dp11338
g7
I159
sg17
VC0856169
p11339
sg10
I23
sg11
Vendothelial dysfunction
p11340
sg13
I2
sasa(dp11341
g2
S'This is why it is opportune to review the response of the renal MC to sepsis and discuss the determinants of its (dys)function and how it contributes to the pathogenesis of renal failure.\n'
p11342
sg4
(lp11343
sg14
(lp11344
(dp11345
g7
I173
sg17
VC0035078
p11346
sg10
I13
sg11
Vrenal failure
p11347
sg13
I2
sa(dp11348
g7
I157
sg17
VC0699748
p11349
sg10
I12
sg11
Vpathogenesis
p11350
sg13
I1
sa(dp11351
g7
I70
sg17
VC0243026
p11352
sg10
I6
sg11
Vsepsis
p11353
sg13
I1
sa(dp11354
g7
I114
sg17
VC0013364
p11355
sg10
I3
sg11
Vdys
p11356
sg13
I1
sasa(dp11357
g2
S'The aim of this work was to assess the effect of statin therapy on inflammatory and fibrinolytic/endothelial (dys)function markers in end-stage renal disease (ESRD) patients under hemodialysis (HD), according to the type of vascular access.\n'
p11358
sg4
(lp11359
sg14
(lp11360
(dp11361
g7
I110
sg17
VC0013364
p11362
sg10
I3
sg11
Vdys
p11363
sg13
I1
sa(dp11364
g7
I159
sg17
VC0022661
p11365
sg10
I4
sg11
VESRD
p11366
sg13
I1
sa(dp11367
g7
I134
sg17
VC0022661
p11368
sg10
I23
sg11
Vend-stage renal disease
p11369
sg13
I3
sasa(dp11370
g2
S'This study was carried out to immuno-localize and estimate the levels of cyclooxygenase 1 and 2 in human gingival tissue samples from healthy individuals, chronic periodontitis patients and patients with cyclosporine induced gingival overgrowth.\n'
p11371
sg4
(lp11372
(dp11373
g7
I73
sg8
VP23219
p11374
sg10
I22
sg11
Vcyclooxygenase 1 and 2
p11375
sg13
I4
sasg14
(lp11376
(dp11377
g7
I155
sg17
VC0266929
p11378
sg10
I21
sg11
Vchronic periodontitis
p11379
sg13
I2
sasa(dp11380
g2
S'The study results demonstrated a significantly higher mean levels of COX-1 and 2 in drug induced gingival overgrowth samples (p&lt;0.05).\n'
p11381
sg4
(lp11382
(dp11383
g7
I69
sg8
VP00395
p11384
sg10
I5
sg11
VCOX-1
p11385
sg13
I1
sasg14
(lp11386
sa(dp11387
g2
S'COX-1 and COX-2 was localized to epithelium and connective tissue in human gingival tissue sections from cyclosporine induced gingival overgrowth.\n'
p11388
sg4
(lp11389
(dp11390
g7
I10
sg8
VP35354
p11391
sg10
I5
sg11
VCOX-2
p11392
sg13
I1
sa(dp11393
g7
I0
sg8
VP00395
p11394
sg10
I5
sg11
VCOX-1
p11395
sg13
I1
sasg14
(lp11396
sa(dp11397
g2
S'This study investigated the role of inhibitors of cyclo-oxygenases (COX-1 and COX-2) in a model of periodontal disease in rats.\n'
p11398
sg4
(lp11399
(dp11400
g7
I78
sg8
VP35354
p11401
sg10
I5
sg11
VCOX-2
p11402
sg13
I1
sa(dp11403
g7
I50
sg8
VP23219
p11404
sg10
I16
sg11
Vcyclo-oxygenases
p11405
sg13
I1
sa(dp11406
g7
I68
sg8
VP00395
p11407
sg10
I5
sg11
VCOX-1
p11408
sg13
I1
sasg14
(lp11409
(dp11410
g7
I99
sg17
VC0031090
p11411
sg10
I19
sg11
Vperiodontal disease
p11412
sg13
I2
sasa(dp11413
g2
S'Our results provide evidence for participation of COX-1 and COX-2 in early stages of periodontal disease in rats.\n'
p11414
sg4
(lp11415
(dp11416
g7
I60
sg8
VP35354
p11417
sg10
I5
sg11
VCOX-2
p11418
sg13
I1
sa(dp11419
g7
I50
sg8
VP00395
p11420
sg10
I5
sg11
VCOX-1
p11421
sg13
I1
sasg14
(lp11422
(dp11423
g7
I85
sg17
VC0031090
p11424
sg10
I19
sg11
Vperiodontal disease
p11425
sg13
I2
sasa(dp11426
g2
S'Following experimental gingivitis, cyclooxygenase-1 and microsomal prostaglandin E synthase-1 expression did not change.\n'
p11427
sg4
(lp11428
(dp11429
g7
I56
sg8
g49
sg10
I37
sg11
Vmicrosomal prostaglandin E synthase-1
p11430
sg13
I4
sa(dp11431
g7
I35
sg8
VP23219
p11432
sg10
I16
sg11
Vcyclooxygenase-1
p11433
sg13
I1
sasg14
(lp11434
(dp11435
g7
I23
sg17
VC0017574
p11436
sg10
I10
sg11
Vgingivitis
p11437
sg13
I1
sasa(dp11438
g2
S'miR-27a, miR-181a, and miR-570 genetic variants have been found to play an important role in many cancers, but their contribution in gallbladder carcinoma (GBC) has not been explored.\n'
p11439
sg4
(lp11440
(dp11441
g7
I9
sg8
g49
sg10
I8
sg11
VmiR-181a
p11442
sg13
I1
sa(dp11443
g7
I0
sg8
g49
sg10
I7
sg11
VmiR-27a
p11444
sg13
I1
sa(dp11445
g7
I23
sg8
g49
sg10
I24
sg11
VmiR-570 genetic variants
p11446
sg13
I3
sasg14
(lp11447
(dp11448
g7
I98
sg17
VC0006826
p11449
sg10
I7
sg11
Vcancers
p11450
sg13
I1
sa(dp11451
g7
I133
sg17
VC0235782
p11452
sg10
I21
sg11
Vgallbladder carcinoma
p11453
sg13
I2
sasa(dp11454
g2
S'We performed chip-based matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry using the MassARRAY system and multiplexed genotyping assays to investigate the association between 10 single nucleotide polymorphisms (SNPs) in the ADAM33 gene (F_+1, Q_-1, S_1, ST_+4, ST_+7, V_-2, V_-1, V_2, V_4, V_5) and asthma and asthma severity in a large Australian Caucasian population of nonasthmatic controls (n = 473), and patients with mild (n = 292), moderate (n = 238) and severe (n = 82) asthma.\n'
p11455
sg4
(lp11456
sg14
(lp11457
(dp11458
g7
I90
sg17
VC0039685
p11459
sg10
I3
sg11
VTOF
p11460
sg13
I1
sa(dp11461
g7
I337
sg17
VC0004096
p11462
sg10
I6
sg11
Vasthma
p11463
sg13
I1
sa(dp11464
g7
I337
sg17
VC0004096
p11465
sg10
I6
sg11
Vasthma
p11466
sg13
I1
sa(dp11467
g7
I337
sg17
VC0004096
p11468
sg10
I6
sg11
Vasthma
p11469
sg13
I1
sasa(dp11470
g2
S'However, the role of TRIM11 in hepatocellular carcinoma (HCC) is unknown.\n'
p11471
sg4
(lp11472
(dp11473
g7
I21
sg8
g49
sg10
I6
sg11
VTRIM11
p11474
sg13
I1
sasg14
(lp11475
(dp11476
g7
I57
sg17
VC2239176
p11477
sg10
I3
sg11
VHCC
p11478
sg13
I1
sa(dp11479
g7
I31
sg17
VC2239176
p11480
sg10
I24
sg11
Vhepatocellular carcinoma
p11481
sg13
I2
sasa(dp11482
g2
S'Foxp3 expression was lower in lesional vitiligo skin specimens compared to controls; it was also lower in lesional vitiligo specimens than nonlesional vitiligo specimens.\n'
p11483
sg4
(lp11484
(dp11485
g7
I0
sg8
g49
sg10
I5
sg11
VFoxp3
p11486
sg13
I1
sasg14
(lp11487
(dp11488
g7
I39
sg17
VC0042900
p11489
sg10
I8
sg11
Vvitiligo
p11490
sg13
I1
sa(dp11491
g7
I39
sg17
VC0042900
p11492
sg10
I8
sg11
Vvitiligo
p11493
sg13
I1
sa(dp11494
g7
I39
sg17
VC0042900
p11495
sg10
I8
sg11
Vvitiligo
p11496
sg13
I1
sasa(dp11497
g2
S'In addition, there was no significant correlation between Foxp3 expression with TGF-Beta and IL-10 expressions in lesional skin specimens in the vitiligo group.\n'
p11498
sg4
(lp11499
(dp11500
g7
I80
sg8
VP18075
p11501
sg10
I8
sg11
VTGF-Beta
p11502
sg13
I1
sa(dp11503
g7
I58
sg8
g49
sg10
I5
sg11
VFoxp3
p11504
sg13
I1
sasg14
(lp11505
(dp11506
g7
I145
sg17
VC0042900
p11507
sg10
I8
sg11
Vvitiligo
p11508
sg13
I1
sasa(dp11509
g2
S'In order to sustain the role of Tregs in pathogenesis and disease activity of vitiligo, surface markers for CD4(+)CD25(+) and FoxP3(+) peripheral Tregs were evaluated by flow cytometry in 80 Egyptian patients with nonsegmental vitiligo in addition to 60 healthy control subjects and correlated with clinical findings.\n'
p11510
sg4
(lp11511
(dp11512
g7
I108
sg8
VP01730
p11513
sg10
I3
sg11
VCD4
p11514
sg13
I1
sasg14
(lp11515
(dp11516
g7
I41
sg17
VC0699748
p11517
sg10
I12
sg11
Vpathogenesis
p11518
sg13
I1
sa(dp11519
g7
I78
sg17
VC0042900
p11520
sg10
I8
sg11
Vvitiligo
p11521
sg13
I1
sa(dp11522
g7
I78
sg17
VC0042900
p11523
sg10
I8
sg11
Vvitiligo
p11524
sg13
I1
sa(dp11525
g7
I299
sg17
VC0037088
p11526
sg10
I17
sg11
Vclinical findings
p11527
sg13
I2
sasa(dp11528
g2
S'Vitiligo patients had significantly decreased numbers of both peripheral CD4(+)CD25(+) and FoxP3(+) T cells compared to control subjects (11.49%  +/- 8.58% of CD4(+) T cells versus 21.20%  +/- 3.08%, and 1.09%  +/- 0.96% versus 1.44%  +/- 0.24%, resp., P &lt; 0.05 for both).\n'
p11529
sg4
(lp11530
(dp11531
g7
I73
sg8
VP01730
p11532
sg10
I10
sg11
VCD4(+)CD25
p11533
sg13
I1
sa(dp11534
g7
I73
sg8
VP01730
p11535
sg10
I3
sg11
VCD4
p11536
sg13
I1
sasg14
(lp11537
(dp11538
g7
I0
sg17
VC0042900
p11539
sg10
I8
sg11
VVitiligo
p11540
sg13
I1
sasa(dp11541
g2
S'(3) We replicated a previous association of FOXP3, a transcription factor that regulates T-cell development and function, with vitiligo; and (4) we discovered that C1GALT1C1 exhibits sex-specific effect on disease risk in both IBDs.\n'
p11542
sg4
(lp11543
(dp11544
g7
I44
sg8
g49
sg10
I5
sg11
VFOXP3
p11545
sg13
I1
sasg14
(lp11546
(dp11547
g7
I127
sg17
VC0042900
p11548
sg10
I8
sg11
Vvitiligo
p11549
sg13
I1
sasa(dp11550
g2
S'Its influence on the expression of IL-17, IL- 22 and FoxP3 as markers for the Th17 and Tregs lineages has not been studied before in the context of non-segmental vitiligo (NSV).\n'
p11551
sg4
(lp11552
sg14
(lp11553
(dp11554
g7
I152
sg17
VC1274648
p11555
sg10
I18
sg11
Vsegmental vitiligo
p11556
sg13
I2
sasa(dp11557
g2
S'Clinical evaluation Vitiligo Area Scoring Index (VASI) and determination of tissue expression of IL-17, IL-22 and FoxP3 by qRT-PCR (lesional, perilesional) were carried out before and after therapy.\n'
p11558
sg4
(lp11559
(dp11560
g7
I104
sg8
g49
sg10
I15
sg11
VIL-22 and FoxP3
p11561
sg13
I3
sasg14
(lp11562
(dp11563
g7
I20
sg17
VC0042900
p11564
sg10
I8
sg11
VVitiligo
p11565
sg13
I1
sasa(dp11566
g2
S'The aim of this study is to assess tissue FoxP3+ natural regulatory T-cells (Tregs), as well as CD4+ and CD8+ T-cells in active vs. stable nonsegmental vitiligo.\n'
p11567
sg4
(lp11568
(dp11569
g7
I96
sg8
VP01730
p11570
sg10
I4
sg11
VCD4+
p11571
sg13
I1
sa(dp11572
g7
I105
sg8
VP01732
p11573
sg10
I4
sg11
VCD8+
p11574
sg13
I1
sasg14
(lp11575
(dp11576
g7
I152
sg17
VC0042900
p11577
sg10
I8
sg11
Vvitiligo
p11578
sg13
I1
sasa(dp11579
g2
S'Immunohistochemical double-staining for expression of CD4+ and CD8+ T-cells with immunostaining for expression of FoxP3 in lesional, marginal, and nonlesional skin of nonsegmental vitiligo was used to evaluate the abundance of Tregs among CD4+ and CD8+ T-cells in active and stable cases of vitiligo.\n'
p11580
sg4
(lp11581
(dp11582
g7
I63
sg8
VP01732
p11583
sg10
I4
sg11
VCD8+
p11584
sg13
I1
sa(dp11585
g7
I63
sg8
VP01732
p11586
sg10
I4
sg11
VCD8+
p11587
sg13
I1
sa(dp11588
g7
I54
sg8
VP01730
p11589
sg10
I4
sg11
VCD4+
p11590
sg13
I1
sa(dp11591
g7
I114
sg8
g49
sg10
I5
sg11
VFoxP3
p11592
sg13
I1
sa(dp11593
g7
I54
sg8
VP01730
p11594
sg10
I4
sg11
VCD4+
p11595
sg13
I1
sasg14
(lp11596
(dp11597
g7
I180
sg17
VC0042900
p11598
sg10
I8
sg11
Vvitiligo
p11599
sg13
I1
sa(dp11600
g7
I180
sg17
VC0042900
p11601
sg10
I8
sg11
Vvitiligo
p11602
sg13
I1
sasa(dp11603
g2
S'A significant increase in the number of CD4+ and CD8+ T-cells and a highly significant reduction in the number of FoxP3-expressing Tregs were detected in marginal skin in both stable and active vitiligo cases.\n'
p11604
sg4
(lp11605
(dp11606
g7
I40
sg8
VP01730
p11607
sg10
I4
sg11
VCD4+
p11608
sg13
I1
sa(dp11609
g7
I114
sg8
g49
sg10
I5
sg11
VFoxP3
p11610
sg13
I1
sa(dp11611
g7
I49
sg8
VP01732
p11612
sg10
I4
sg11
VCD8+
p11613
sg13
I1
sasg14
(lp11614
(dp11615
g7
I194
sg17
VC0042900
p11616
sg10
I8
sg11
Vvitiligo
p11617
sg13
I1
sasa(dp11618
g2
S'FoxP3+ cells were decreased in tissue of patients with vitiligo compared with healthy controls.\n'
p11619
sg4
(lp11620
sg14
(lp11621
(dp11622
g7
I55
sg17
VC0042900
p11623
sg10
I8
sg11
Vvitiligo
p11624
sg13
I1
sasa(dp11625
g2
S'To evaluate the effect of NB-UVB on circulating CD4(+) CD25(high) FoxP3(+) regulatory T cells (FoxP3(+) Tregs) in vitiligo.\n'
p11626
sg4
(lp11627
(dp11628
g7
I48
sg8
VP01730
p11629
sg10
I3
sg11
VCD4
p11630
sg13
I1
sasg14
(lp11631
(dp11632
g7
I114
sg17
VC0042900
p11633
sg10
I8
sg11
Vvitiligo
p11634
sg13
I1
sasa(dp11635
g2
S'The CD4(+) CD25(high) Tregs% and FoxP3(+) Tregs% were significantly higher in vitiligo patients compared with controls.\n'
p11636
sg4
(lp11637
(dp11638
g7
I4
sg8
VP01730
p11639
sg10
I11
sg11
VCD4(+) CD25
p11640
sg13
I2
sasg14
(lp11641
(dp11642
g7
I78
sg17
VC0042900
p11643
sg10
I8
sg11
Vvitiligo
p11644
sg13
I1
sasa(dp11645
g2
S"Each of circulating CD4(+) CD25(high) Tregs% and FoxP3(+) Tregs% didn't correlate with either extent or activity of vitiligo before or after NB-UVB.\n"
p11646
sg4
(lp11647
(dp11648
g7
I20
sg8
VP01730
p11649
sg10
I3
sg11
VCD4
p11650
sg13
I1
sasg14
(lp11651
(dp11652
g7
I116
sg17
VC0042900
p11653
sg10
I8
sg11
Vvitiligo
p11654
sg13
I1
sasa(dp11655
g2
S'Phospholipase A2-associated neurodegeneration (PLAN), a syndrome of Neurodegeneration with Brain Iron Accumulation (NBIA), is an autosomal recessive disorder caused by mutations in PLA2G6 gene.\n'
p11656
sg4
(lp11657
(dp11658
g7
I181
sg8
g49
sg10
I11
sg11
VPLA2G6 gene
p11659
sg13
I2
sa(dp11660
g7
I0
sg8
VP04054
p11661
sg10
I13
sg11
VPhospholipase
p11662
sg13
I1
sasg14
(lp11663
(dp11664
g7
I0
sg17
VC0270724
p11665
sg10
I45
sg11
VPhospholipase A2-associated neurodegeneration
p11666
sg13
I3
sa(dp11667
g7
I56
sg17
VC0039082
p11668
sg10
I8
sg11
Vsyndrome
p11669
sg13
I1
sa(dp11670
g7
I47
sg17
VC0270724
p11671
sg10
I4
sg11
VPLAN
p11672
sg13
I1
sa(dp11673
g7
I68
sg17
VC0027746
p11674
sg10
I17
sg11
VNeurodegeneration
p11675
sg13
I1
sasa(dp11676
g2
S'The aim of this study was to investigate the association of a migraine without aura and Ala379Val polymorphism of lipoprotein-associated phospholipase A2 (Lp-PLA2) gene in the Iranian population.\n'
p11677
sg4
(lp11678
(dp11679
g7
I155
sg8
VP04054
p11680
sg10
I7
sg11
VLp-PLA2
p11681
sg13
I1
sa(dp11682
g7
I114
sg8
VP04054
p11683
sg10
I39
sg11
Vlipoprotein-associated phospholipase A2
p11684
sg13
I3
sasg14
(lp11685
(dp11686
g7
I62
sg17
VC0338480
p11687
sg10
I21
sg11
Vmigraine without aura
p11688
sg13
I3
sasa(dp11689
g2
S'We investigated the significance of lymphatic count, vascular count and angiogenic growth factors using immunohistochemistry in 108 tumour specimens of epithelial ovarian cancer with antibodies to lymphatic vessel endothelial hyaluronan receptor (LYVE-1), platelet endothelial cell adhesion molecule CD31, vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) in epithelial ovarian cancer to understand the pathogenesis of metastasis in ovarian cancer.\n'
p11690
sg4
(lp11691
(dp11692
g7
I377
sg8
VP19971
p11693
sg10
I2
sg11
VTP
p11694
sg13
I1
sa(dp11695
g7
I214
sg8
g49
sg10
I31
sg11
Vendothelial hyaluronan receptor
p11696
sg13
I3
sa(dp11697
g7
I342
sg8
g49
sg10
I4
sg11
VVEGF
p11698
sg13
I1
sa(dp11699
g7
I306
sg8
g49
sg10
I34
sg11
Vvascular endothelial growth factor
p11700
sg13
I4
sa(dp11701
g7
I247
sg8
g49
sg10
I6
sg11
VLYVE-1
p11702
sg13
I1
sa(dp11703
g7
I256
sg8
VP14770
p11704
sg10
I43
sg11
Vplatelet endothelial cell adhesion molecule
p11705
sg13
I5
sa(dp11706
g7
I72
sg8
VP19883
p11707
sg10
I25
sg11
Vangiogenic growth factors
p11708
sg13
I3
sa(dp11709
g7
I300
sg8
VP69905
p11710
sg10
I4
sg11
VCD31
p11711
sg13
I1
sa(dp11712
g7
I352
sg8
VP19971
p11713
sg10
I23
sg11
Vthymidine phosphorylase
p11714
sg13
I2
sasg14
(lp11715
(dp11716
g7
I163
sg17
VC1140680
p11717
sg10
I14
sg11
Vovarian cancer
p11718
sg13
I2
sa(dp11719
g7
I132
sg17
VC0027651
p11720
sg10
I6
sg11
Vtumour
p11721
sg13
I1
sa(dp11722
g7
I282
sg17
VC0001511
p11723
sg10
I8
sg11
Vadhesion
p11724
sg13
I1
sa(dp11725
g7
I152
sg17
VC0677886
p11726
sg10
I25
sg11
Vepithelial ovarian cancer
p11727
sg13
I3
sa(dp11728
g7
I444
sg17
VC0027627
p11729
sg10
I10
sg11
Vmetastasis
p11730
sg13
I1
sa(dp11731
g7
I152
sg17
VC0677886
p11732
sg10
I25
sg11
Vepithelial ovarian cancer
p11733
sg13
I3
sa(dp11734
g7
I428
sg17
VC0699748
p11735
sg10
I12
sg11
Vpathogenesis
p11736
sg13
I1
sasa(dp11737
g2
S'Immunohistochemical staining of patient samples revealed that a significant perivascular infiltration of M1, but not M2, macrophages coincides with endothelial expression of the critical EndMT transcription factors Snail/Slug in involuting hemangiomas.\n'
p11738
sg4
(lp11739
(dp11740
g7
I221
sg8
g49
sg10
I4
sg11
VSlug
p11741
sg13
I1
sa(dp11742
g7
I187
sg8
VP19883
p11743
sg10
I27
sg11
VEndMT transcription factors
p11744
sg13
I3
sa(dp11745
g7
I215
sg8
g49
sg10
I5
sg11
VSnail
p11746
sg13
I1
sasg14
(lp11747
(dp11748
g7
I240
sg17
VC0018916
p11749
sg10
I11
sg11
Vhemangiomas
p11750
sg13
I1
sa(dp11751
g7
I89
sg17
VC0332448
p11752
sg10
I12
sg11
Vinfiltration
p11753
sg13
I1
sasa(dp11754
g2
S'Thirty-seven ameloblastoma cases were evaluated for the involvement of EMT by immunohistochemical staining and western blotting using antibodies against Slug, Snail, Twist, TGF-Beta, and E-cadherin.\n'
p11755
sg4
(lp11756
(dp11757
g7
I153
sg8
g49
sg10
I4
sg11
VSlug
p11758
sg13
I1
sa(dp11759
g7
I187
sg8
VP12830
p11760
sg10
I10
sg11
VE-cadherin
p11761
sg13
I1
sa(dp11762
g7
I173
sg8
VP18075
p11763
sg10
I8
sg11
VTGF-Beta
p11764
sg13
I1
sa(dp11765
g7
I71
sg8
g49
sg10
I3
sg11
VEMT
p11766
sg13
I1
sa(dp11767
g7
I159
sg8
g49
sg10
I5
sg11
VSnail
p11768
sg13
I1
sa(dp11769
g7
I166
sg8
g49
sg10
I5
sg11
VTwist
p11770
sg13
I1
sasg14
(lp11771
(dp11772
g7
I13
sg17
VC0002448
p11773
sg10
I13
sg11
Vameloblastoma
p11774
sg13
I1
sasa(dp11775
g2
S'Slug and TGF-Beta were expressed in the nuclei of peripheral and stellate reticulum cells of ameloblastoma nests.\n'
p11776
sg4
(lp11777
(dp11778
g7
I9
sg8
VP18075
p11779
sg10
I8
sg11
VTGF-Beta
p11780
sg13
I1
sa(dp11781
g7
I0
sg8
g49
sg10
I4
sg11
VSlug
p11782
sg13
I1
sasg14
(lp11783
(dp11784
g7
I93
sg17
VC0002448
p11785
sg10
I13
sg11
Vameloblastoma
p11786
sg13
I1
sasa(dp11787
g2
S'Thus, strong expression of Slug and TGF-Beta and reduced expression of E-cadherin might be related to the local invasiveness of ameloblastoma.\n'
p11788
sg4
(lp11789
(dp11790
g7
I71
sg8
VP12830
p11791
sg10
I10
sg11
VE-cadherin
p11792
sg13
I1
sa(dp11793
g7
I27
sg8
g49
sg10
I4
sg11
VSlug
p11794
sg13
I1
sa(dp11795
g7
I36
sg8
VP18075
p11796
sg10
I8
sg11
VTGF-Beta
p11797
sg13
I1
sasg14
(lp11798
(dp11799
g7
I128
sg17
VC0002448
p11800
sg10
I13
sg11
Vameloblastoma
p11801
sg13
I1
sasa(dp11802
g2
S'Immunohistochemical method was used to examine the expression of EMT-related proteins: Slug, E-cadherin and fibronectin, in 41 cases of sinonasal inverted papilloma (SIP), 33 cases of sinonasal squamous cell carcinoma (SNC), and 22 cases of normal mucosa as a control.\n'
p11803
sg4
(lp11804
(dp11805
g7
I93
sg8
VP12830
p11806
sg10
I10
sg11
VE-cadherin
p11807
sg13
I1
sa(dp11808
g7
I65
sg8
g49
sg10
I20
sg11
VEMT-related proteins
p11809
sg13
I2
sa(dp11810
g7
I87
sg8
g49
sg10
I4
sg11
VSlug
p11811
sg13
I1
sasg14
(lp11812
(dp11813
g7
I194
sg17
VC0007137
p11814
sg10
I23
sg11
Vsquamous cell carcinoma
p11815
sg13
I3
sa(dp11816
g7
I146
sg17
VC1881254
p11817
sg10
I18
sg11
Vinverted papilloma
p11818
sg13
I2
sasa(dp11819
g2
S'In this study, we accessed the expression and correlation of p-STAT3 with Survivin, Cyclin D1, CD147, Slug and Ki67 by immunohistochemical staining of human tissue microarray which contains 72 adenoid cystic carcinoma (AdCC), 12 pleomorphic adenoma (PMA) and 18 normal salivary gland (NSG) using digital pathological scanner and scoring system.\n'
p11820
sg4
(lp11821
(dp11822
g7
I63
sg8
VP40763
p11823
sg10
I5
sg11
VSTAT3
p11824
sg13
I1
sa(dp11825
g7
I111
sg8
VP46013
p11826
sg10
I4
sg11
VKi67
p11827
sg13
I1
sa(dp11828
g7
I95
sg8
VP35613
p11829
sg10
I5
sg11
VCD147
p11830
sg13
I1
sa(dp11831
g7
I102
sg8
g49
sg10
I4
sg11
VSlug
p11832
sg13
I1
sa(dp11833
g7
I84
sg8
VP24385
p11834
sg10
I9
sg11
VCyclin D1
p11835
sg13
I2
sasg14
(lp11836
(dp11837
g7
I229
sg17
VC0026277
p11838
sg10
I19
sg11
Vpleomorphic adenoma
p11839
sg13
I2
sa(dp11840
g7
I250
sg17
VC0026277
p11841
sg10
I3
sg11
VPMA
p11842
sg13
I1
sa(dp11843
g7
I193
sg17
VC0010606
p11844
sg10
I24
sg11
Vadenoid cystic carcinoma
p11845
sg13
I3
sa(dp11846
g7
I219
sg17
VC1859972
p11847
sg10
I4
sg11
VAdCC
p11848
sg13
I1
sasa(dp11849
g2
S'In the present study, we investigated the expression of a panel of EMT markers, namely E-cadherin, N-cadherin, SLUG, SNA1 and TWIST in a cohort of human pituitary adenomas.\n'
p11850
sg4
(lp11851
(dp11852
g7
I117
sg8
g49
sg10
I4
sg11
VSNA1
p11853
sg13
I1
sa(dp11854
g7
I87
sg8
VP12830
p11855
sg10
I10
sg11
VE-cadherin
p11856
sg13
I1
sa(dp11857
g7
I111
sg8
g49
sg10
I4
sg11
VSLUG
p11858
sg13
I1
sa(dp11859
g7
I99
sg8
VP19022
p11860
sg10
I10
sg11
VN-cadherin
p11861
sg13
I1
sa(dp11862
g7
I126
sg8
g49
sg10
I5
sg11
VTWIST
p11863
sg13
I1
sasg14
(lp11864
(dp11865
g7
I153
sg17
VC0032000
p11866
sg10
I18
sg11
Vpituitary adenomas
p11867
sg13
I2
sasa(dp11868
g2
S'The present study examined the effects of a GABA(C) receptor antagonist on the light-evoked responses of retinal ganglion cells (RGCs) in a rat model of retinitis pigmentosa.\n'
p11869
sg4
(lp11870
(dp11871
g7
I44
sg8
g49
sg10
I16
sg11
VGABA(C) receptor
p11872
sg13
I2
sasg14
(lp11873
(dp11874
g7
I113
sg17
VC1258666
p11875
sg10
I8
sg11
Vganglion
p11876
sg13
I1
sa(dp11877
g7
I153
sg17
VC0035334
p11878
sg10
I20
sg11
Vretinitis pigmentosa
p11879
sg13
I2
sasa(dp11880
g2
S'In conclusion, GABA(C) receptors may be novel targets for therapeutic interventions aimed at increasing light responsiveness in patients with retinitis pigmentosa or other diseases involving degeneration of photoreceptors.\n'
p11881
sg4
(lp11882
(dp11883
g7
I15
sg8
g49
sg10
I17
sg11
VGABA(C) receptors
p11884
sg13
I2
sasg14
(lp11885
(dp11886
g7
I191
sg17
VC0011164
p11887
sg10
I12
sg11
Vdegeneration
p11888
sg13
I1
sa(dp11889
g7
I142
sg17
VC0035334
p11890
sg10
I20
sg11
Vretinitis pigmentosa
p11891
sg13
I2
sasa(dp11892
g2
S'This interval encompasses several retinal dystrophy loci, including the ELOVL4 gene, mutated in autosomal dominant Stargardt disease, and the RIM1 gene, mutated in autosomal dominant cone-rod dystrophy, as well as the retinally expressed GABRR1 and -2 genes.\n'
p11893
sg4
(lp11894
(dp11895
g7
I72
sg8
g49
sg10
I11
sg11
VELOVL4 gene
p11896
sg13
I2
sa(dp11897
g7
I238
sg8
VP24046
p11898
sg10
I6
sg11
VGABRR1
p11899
sg13
I1
sa(dp11900
g7
I34
sg8
VP55283
p11901
sg10
I22
sg11
Vretinal dystrophy loci
p11902
sg13
I3
sasg14
(lp11903
(dp11904
g7
I115
sg17
VC0271093
p11905
sg10
I17
sg11
VStargardt disease
p11906
sg13
I2
sa(dp11907
g7
I34
sg17
VC0854723
p11908
sg10
I17
sg11
Vretinal dystrophy
p11909
sg13
I2
sa(dp11910
g7
I183
sg17
VC0035334
p11911
sg10
I18
sg11
Vcone-rod dystrophy
p11912
sg13
I2
sasa(dp11913
g2
S'We proposed to assess serum antioxidant vitamins and magnesium (Mg) levels in patients with fibromyalgia (FM) in comparison to healthy controls.\n'
p11914
sg4
(lp11915
sg14
(lp11916
(dp11917
g7
I92
sg17
VC0016053
p11918
sg10
I12
sg11
Vfibromyalgia
p11919
sg13
I1
sa(dp11920
g7
I106
sg17
VC0016053
p11921
sg10
I2
sg11
VFM
p11922
sg13
I1
sasa(dp11923
g2
S'There were no significant differences in the levels of vitamins A, C, and E and Mg between control subjects and patients with fibromyalgia (p &gt; 0.05).\n'
p11924
sg4
(lp11925
sg14
(lp11926
(dp11927
g7
I126
sg17
VC0016053
p11928
sg10
I12
sg11
Vfibromyalgia
p11929
sg13
I1
sasa(dp11930
g2
S'Finally we show that high expression of LTBP3 and SNED1 correlates with poor outcome for ER(-)/PR(-)breast cancer patients.\n'
p11931
sg4
(lp11932
(dp11933
g7
I40
sg8
g49
sg10
I5
sg11
VLTBP3
p11934
sg13
I1
sa(dp11935
g7
I50
sg8
g49
sg10
I5
sg11
VSNED1
p11936
sg13
I1
sasg14
(lp11937
(dp11938
g7
I100
sg17
VC0678222
p11939
sg10
I13
sg11
Vbreast cancer
p11940
sg13
I2
sasa(dp11941
g2
S'sst3 receptors were present in 38% of DA, 40% of AA, and 84% of GBM.\n'
p11942
sg4
(lp11943
(dp11944
g7
I0
sg8
g49
sg10
I14
sg11
Vsst3 receptors
p11945
sg13
I2
sasg14
(lp11946
(dp11947
g7
I64
sg17
VC0017636
p11948
sg10
I3
sg11
VGBM
p11949
sg13
I1
sasa(dp11950
g2
S'Deletion of a phenylalanine at position 1617 (delF1617) in the extracellular linker between segments S3 and S4 in domain IV of the human heart Na(+) channel (hH1a) has been tentatively associated with long QT syndrome type 3 (LQT3).\n'
p11951
sg4
(lp11952
sg14
(lp11953
(dp11954
g7
I226
sg17
VC1859062
p11955
sg10
I4
sg11
VLQT3
p11956
sg13
I1
sa(dp11957
g7
I201
sg17
VC2931401
p11958
sg10
I23
sg11
Vlong QT syndrome type 3
p11959
sg13
I5
sasa(dp11960
g2
S'More dramatically, when the LQT3 mutation M1766L was introduced into the different clones, Na current was markedly reduced in the hH1 and hH1a backgrounds, whereas in hH1b the Na current was not reduced.\n'
p11961
sg4
(lp11962
sg14
(lp11963
(dp11964
g7
I28
sg17
VC1859062
p11965
sg10
I4
sg11
VLQT3
p11966
sg13
I1
sasa(dp11967
g2
S'Several studies have begun to elucidate the roles of TRPV1, TRPV6, TRPM8, and TRPC1 in cancer progression; however, no study has examined the expression profiles of human TRP channels in breast cancer on a large scale.\n'
p11968
sg4
(lp11969
(dp11970
g7
I165
sg8
VP13686
p11971
sg10
I18
sg11
Vhuman TRP channels
p11972
sg13
I3
sa(dp11973
g7
I53
sg8
g49
sg10
I5
sg11
VTRPV1
p11974
sg13
I1
sa(dp11975
g7
I60
sg8
g49
sg10
I5
sg11
VTRPV6
p11976
sg13
I1
sa(dp11977
g7
I67
sg8
g49
sg10
I5
sg11
VTRPM8
p11978
sg13
I1
sa(dp11979
g7
I78
sg8
VP48995
p11980
sg10
I5
sg11
VTRPC1
p11981
sg13
I1
sasg14
(lp11982
(dp11983
g7
I87
sg17
VC0178874
p11984
sg10
I18
sg11
Vcancer progression
p11985
sg13
I2
sa(dp11986
g7
I187
sg17
VC0678222
p11987
sg10
I13
sg11
Vbreast cancer
p11988
sg13
I2
sasa(dp11989
g2
S'(4) The Trpv6 gene expression is significantly upregulated in several human malignancies including the most common cancers, prostate and breast cancer (Wissenbach et al.\n'
p11990
sg4
(lp11991
(dp11992
g7
I8
sg8
g49
sg10
I10
sg11
VTrpv6 gene
p11993
sg13
I2
sasg14
(lp11994
(dp11995
g7
I137
sg17
VC0678222
p11996
sg10
I13
sg11
Vbreast cancer
p11997
sg13
I2
sa(dp11998
g7
I115
sg17
VC0376358
p11999
sg10
I17
sg11
Vcancers, prostate
p12000
sg13
I2
sa(dp12001
g7
I76
sg17
VC0006826
p12002
sg10
I12
sg11
Vmalignancies
p12003
sg13
I1
sasa(dp12004
g2
S'We show that the plasma membrane calcium channel TRPV6, which is highly selective for Ca(2+), is overexpressed in some breast cancer cell lines.\n'
p12005
sg4
(lp12006
(dp12007
g7
I49
sg8
g49
sg10
I5
sg11
VTRPV6
p12008
sg13
I1
sasg14
(lp12009
(dp12010
g7
I119
sg17
VC0678222
p12011
sg10
I13
sg11
Vbreast cancer
p12012
sg13
I2
sasa(dp12013
g2
S'Silencing of TRPV6 expression in a breast cancer cell line with increased endogenous TRPV6 expression leads to a reduction in basal calcium influx and cellular proliferation associated with a reduction in DNA synthesis.\n'
p12014
sg4
(lp12015
(dp12016
g7
I13
sg8
g49
sg10
I5
sg11
VTRPV6
p12017
sg13
I1
sa(dp12018
g7
I13
sg8
g49
sg10
I5
sg11
VTRPV6
p12019
sg13
I1
sasg14
(lp12020
(dp12021
g7
I151
sg17
VC0020507
p12022
sg10
I22
sg11
Vcellular proliferation
p12023
sg13
I2
sa(dp12024
g7
I35
sg17
VC0678222
p12025
sg10
I13
sg11
Vbreast cancer
p12026
sg13
I2
sasa(dp12027
g2
S'TRPV6 gene amplification was identified as one mechanism of TRPV6 overexpression in a subset of breast cancer cell lines and breast tumor samples.\n'
p12028
sg4
(lp12029
(dp12030
g7
I0
sg8
g49
sg10
I10
sg11
VTRPV6 gene
p12031
sg13
I2
sa(dp12032
g7
I0
sg8
g49
sg10
I5
sg11
VTRPV6
p12033
sg13
I1
sasg14
(lp12034
(dp12035
g7
I125
sg17
VC1458155
p12036
sg10
I12
sg11
Vbreast tumor
p12037
sg13
I2
sa(dp12038
g7
I96
sg17
VC0678222
p12039
sg10
I13
sg11
Vbreast cancer
p12040
sg13
I2
sa(dp12041
g7
I6
sg17
VC1705759
p12042
sg10
I18
sg11
Vgene amplification
p12043
sg13
I2
sasa(dp12044
g2
S'Analysis of two independent microarray expression datasets from breast tumor samples showed that increased TRPV6 expression is a feature of estrogen receptor (ER)-negative breast tumors encompassing the basal-like molecular subtype, as well as HER2-positive tumors.\n'
p12045
sg4
(lp12046
(dp12047
g7
I159
sg8
VP03372
p12048
sg10
I2
sg11
VER
p12049
sg13
I1
sa(dp12050
g7
I140
sg8
VP03372
p12051
sg10
I17
sg11
Vestrogen receptor
p12052
sg13
I2
sa(dp12053
g7
I107
sg8
g49
sg10
I5
sg11
VTRPV6
p12054
sg13
I1
sa(dp12055
g7
I244
sg8
VP04626
p12056
sg10
I4
sg11
VHER2
p12057
sg13
I1
sasg14
(lp12058
(dp12059
g7
I179
sg17
VC0027651
p12060
sg10
I6
sg11
Vtumors
p12061
sg13
I1
sa(dp12062
g7
I64
sg17
VC1458155
p12063
sg10
I12
sg11
Vbreast tumor
p12064
sg13
I2
sa(dp12065
g7
I172
sg17
VC1458155
p12066
sg10
I13
sg11
Vbreast tumors
p12067
sg13
I2
sasa(dp12068
g2
S'Breast cancer patients with high TRPV6 levels had decreased survival compared with patients with low or intermediate TRPV6 expression.\n'
p12069
sg4
(lp12070
(dp12071
g7
I33
sg8
g49
sg10
I5
sg11
VTRPV6
p12072
sg13
I1
sa(dp12073
g7
I33
sg8
g49
sg10
I5
sg11
VTRPV6
p12074
sg13
I1
sasg14
(lp12075
(dp12076
g7
I0
sg17
VC0678222
p12077
sg10
I13
sg11
VBreast cancer
p12078
sg13
I2
sasa(dp12079
g2
S'Our findings suggest that inhibitors of TRPV6 may offer a novel therapeutic strategy for the treatment of ER-negative breast cancers.\n'
p12080
sg4
(lp12081
(dp12082
g7
I40
sg8
g49
sg10
I5
sg11
VTRPV6
p12083
sg13
I1
sasg14
(lp12084
(dp12085
g7
I118
sg17
VC0006142
p12086
sg10
I14
sg11
Vbreast cancers
p12087
sg13
I2
sasa(dp12088
g2
S'Most interestingly, TRPC1, TRPM7 and TRPM8 expression strongly correlated with proliferative parameters (SBR grade, Ki67 proliferation index, and tumor size), and TRPV6 was mainly overexpressed in the invasive breast cancer cells.\n'
p12089
sg4
(lp12090
(dp12091
g7
I20
sg8
VP48995
p12092
sg10
I5
sg11
VTRPC1
p12093
sg13
I1
sa(dp12094
g7
I163
sg8
g49
sg10
I5
sg11
VTRPV6
p12095
sg13
I1
sa(dp12096
g7
I37
sg8
g49
sg10
I5
sg11
VTRPM8
p12097
sg13
I1
sa(dp12098
g7
I27
sg8
g49
sg10
I5
sg11
VTRPM7
p12099
sg13
I1
sasg14
(lp12100
(dp12101
g7
I121
sg17
VC0334094
p12102
sg10
I13
sg11
Vproliferation
p12103
sg13
I1
sa(dp12104
g7
I146
sg17
VC0027651
p12105
sg10
I5
sg11
Vtumor
p12106
sg13
I1
sa(dp12107
g7
I201
sg17
VC0853879
p12108
sg10
I22
sg11
Vinvasive breast cancer
p12109
sg13
I3
sa(dp12110
g7
I79
sg17
VC0334094
p12111
sg10
I13
sg11
Vproliferative
p12112
sg13
I1
sasa(dp12113
g2
S'The epithelial calcium channel TRPV6 is upregulated in breast carcinoma compared with normal mammary gland tissue.\n'
p12114
sg4
(lp12115
(dp12116
g7
I4
sg8
g49
sg10
I32
sg11
Vepithelial calcium channel TRPV6
p12117
sg13
I4
sasg14
(lp12118
(dp12119
g7
I55
sg17
VC0678222
p12120
sg10
I16
sg11
Vbreast carcinoma
p12121
sg13
I2
sasa(dp12122
g2
S'In this study, we examined the effect of tamoxifen on TRPV6 function and intracellular calcium homeostasis in MCF-7 breast cancer cells transiently transfected with EYFP-C1-TRPV6.\n'
p12123
sg4
(lp12124
(dp12125
g7
I54
sg8
g49
sg10
I5
sg11
VTRPV6
p12126
sg13
I1
sa(dp12127
g7
I54
sg8
g49
sg10
I5
sg11
VTRPV6
p12128
sg13
I1
sasg14
(lp12129
(dp12130
g7
I116
sg17
VC0678222
p12131
sg10
I13
sg11
Vbreast cancer
p12132
sg13
I2
sasa(dp12133
g2
S'These findings illustrate how tamoxifen might be effective in estrogen receptor-negative breast carcinomas and suggest that the therapeutic effect of tamoxifen and protein kinase C inhibitors used in breast cancer therapy might involve TRPV6-mediated calcium entry.\n'
p12134
sg4
(lp12135
(dp12136
g7
I62
sg8
VP03372
p12137
sg10
I17
sg11
Vestrogen receptor
p12138
sg13
I2
sa(dp12139
g7
I164
sg8
VP17252
p12140
sg10
I16
sg11
Vprotein kinase C
p12141
sg13
I3
sa(dp12142
g7
I236
sg8
g49
sg10
I5
sg11
VTRPV6
p12143
sg13
I1
sasg14
(lp12144
(dp12145
g7
I89
sg17
VC0678222
p12146
sg10
I17
sg11
Vbreast carcinomas
p12147
sg13
I2
sa(dp12148
g7
I200
sg17
VC0678222
p12149
sg10
I13
sg11
Vbreast cancer
p12150
sg13
I2
sasa(dp12151
g2
S'This study highlights a possible role of TRPV6 as therapeutic target in breast cancer therapy.\n'
p12152
sg4
(lp12153
(dp12154
g7
I41
sg8
g49
sg10
I5
sg11
VTRPV6
p12155
sg13
I1
sasg14
(lp12156
(dp12157
g7
I72
sg17
VC0678222
p12158
sg10
I13
sg11
Vbreast cancer
p12159
sg13
I2
sasa(dp12160
g2
S'TRPV6 is an endothelial calcium entry channel that is strongly expressed in breast adenocarcinoma tissue.\n'
p12161
sg4
(lp12162
(dp12163
g7
I0
sg8
g49
sg10
I5
sg11
VTRPV6
p12164
sg13
I1
sasg14
(lp12165
(dp12166
g7
I76
sg17
VC0858252
p12167
sg10
I21
sg11
Vbreast adenocarcinoma
p12168
sg13
I2
sasa(dp12169
g2
S'In this study, we further confirmed this observation by analysis of breast cancer tissues, which indicated that TRPV6 mRNA expression was up-regulated between 2-fold and 15-fold compared with the average in normal breast tissue.\n'
p12170
sg4
(lp12171
(dp12172
g7
I112
sg8
g49
sg10
I10
sg11
VTRPV6 mRNA
p12173
sg13
I2
sasg14
(lp12174
(dp12175
g7
I68
sg17
VC0678222
p12176
sg10
I13
sg11
Vbreast cancer
p12177
sg13
I2
sasa(dp12178
g2
S'Therefore, we investigated how TRPV6 affects the viability, apoptosis, and calcium transport in the breast cancer cell line T47D.\n'
p12179
sg4
(lp12180
(dp12181
g7
I31
sg8
g49
sg10
I5
sg11
VTRPV6
p12182
sg13
I1
sasg14
(lp12183
(dp12184
g7
I100
sg17
VC0678222
p12185
sg10
I13
sg11
Vbreast cancer
p12186
sg13
I2
sasa(dp12187
g2
S'The in vitro model showed that TRPV6 can be regulated by estrogen, progesterone, tamoxifen, and 1,25-vitamin D and has a large influence on breast cancer cell proliferation.\n'
p12188
sg4
(lp12189
(dp12190
g7
I31
sg8
g49
sg10
I5
sg11
VTRPV6
p12191
sg13
I1
sasg14
(lp12192
(dp12193
g7
I140
sg17
VC0678222
p12194
sg10
I13
sg11
Vbreast cancer
p12195
sg13
I2
sa(dp12196
g7
I159
sg17
VC0334094
p12197
sg10
I13
sg11
Vproliferation
p12198
sg13
I1
sasa(dp12199
g2
S'TRPV6 may be a novel target for the development of calcium channel inhibitors to treat breast adenocarcinoma expressing TRPV6.\n'
p12200
sg4
(lp12201
(dp12202
g7
I0
sg8
g49
sg10
I5
sg11
VTRPV6
p12203
sg13
I1
sa(dp12204
g7
I0
sg8
g49
sg10
I5
sg11
VTRPV6
p12205
sg13
I1
sasg14
(lp12206
(dp12207
g7
I87
sg17
VC0858252
p12208
sg10
I21
sg11
Vbreast adenocarcinoma
p12209
sg13
I2
sasa(dp12210
g2
S'Cervical cancer model showed cytokeratin 19 expression in different epithelial layers and weak or no expression for cytokeratin 5 and cytokeratin 10.\n'
p12211
sg4
(lp12212
(dp12213
g7
I29
sg8
g49
sg10
I11
sg11
Vcytokeratin
p12214
sg13
I1
sa(dp12215
g7
I116
sg8
VP02533
p12216
sg10
I32
sg11
Vcytokeratin 5 and cytokeratin 10
p12217
sg13
I5
sasg14
(lp12218
(dp12219
g7
I0
sg17
VC0302592
p12220
sg10
I15
sg11
VCervical cancer
p12221
sg13
I2
sasa(dp12222
g2
S'While Keratin, type II cytoskeletal 5, Peroxiredoxin-1 and 14-3-3 protein sigma showed a decrease in their protein expression level in cervical cancer in comparison with normal cervix cells.\n'
p12223
sg4
(lp12224
(dp12225
g7
I15
sg8
VP27037
p12226
sg10
I22
sg11
Vtype II cytoskeletal 5
p12227
sg13
I4
sa(dp12228
g7
I59
sg8
VP31947
p12229
sg10
I20
sg11
V14-3-3 protein sigma
p12230
sg13
I3
sa(dp12231
g7
I39
sg8
g49
sg10
I15
sg11
VPeroxiredoxin-1
p12232
sg13
I1
sa(dp12233
g7
I6
sg8
VP02533
p12234
sg10
I7
sg11
VKeratin
p12235
sg13
I1
sasg14
(lp12236
(dp12237
g7
I135
sg17
VC0302592
p12238
sg10
I15
sg11
Vcervical cancer
p12239
sg13
I2
sasa(dp12240
g2
S'To assess the role of Beta(7) integrins in chronic ileitis, we generated SAMP1/YitFc lacking Beta(7) integrins (SAMP1/YitFc Itgb7(-/-)) using a congenic strain developed via marker-assisted selection.\n'
p12241
sg4
(lp12242
(dp12243
g7
I118
sg8
VP26010
p12244
sg10
I11
sg11
VYitFc Itgb7
p12245
sg13
I2
sasg14
(lp12246
(dp12247
g7
I51
sg17
VC0020877
p12248
sg10
I7
sg11
Vileitis
p12249
sg13
I1
sasa(dp12250
g2
S'In both young (&lt;20 wk) and old (20-50 wk) SAMP1/YitFc Itgb7(-/-) mice, ileitis was reduced by 30-50% compared with SAMP1/YitFc mice.\n'
p12251
sg4
(lp12252
(dp12253
g7
I51
sg8
VP26010
p12254
sg10
I11
sg11
VYitFc Itgb7
p12255
sg13
I2
sasg14
(lp12256
(dp12257
g7
I74
sg17
VC0020877
p12258
sg10
I7
sg11
Vileitis
p12259
sg13
I1
sasa(dp12260
g2
S'Cotransfer of SAMP1/YitFc MLN B cells but not SAMP1/YitFc Itgb7(-/-) MLN B cells along with CD4(+) T cells resulted in exacerbated ileitis severity in SCID mice.\n'
p12261
sg4
(lp12262
(dp12263
g7
I52
sg8
VP26010
p12264
sg10
I11
sg11
VYitFc Itgb7
p12265
sg13
I2
sa(dp12266
g7
I92
sg8
VP01730
p12267
sg10
I3
sg11
VCD4
p12268
sg13
I1
sa(dp12269
g7
I20
sg8
VP12872
p12270
sg10
I11
sg11
VYitFc MLN B
p12271
sg13
I3
sasg14
(lp12272
(dp12273
g7
I151
sg17
VC0085110
p12274
sg10
I4
sg11
VSCID
p12275
sg13
I1
sa(dp12276
g7
I131
sg17
VC0020877
p12277
sg10
I7
sg11
Vileitis
p12278
sg13
I1
sasa(dp12279
g2
S'The prominent decreases in HDAC expression during status epilepticus are consistent with the previously demonstrated increased expression of numerous proteins and with the augmented acetylation of histone H4.\n'
p12280
sg4
(lp12281
(dp12282
g7
I27
sg8
VP56524
p12283
sg10
I4
sg11
VHDAC
p12284
sg13
I1
sa(dp12285
g7
I197
sg8
VP62805
p12286
sg10
I10
sg11
Vhistone H4
p12287
sg13
I2
sasg14
(lp12288
(dp12289
g7
I50
sg17
VC0038220
p12290
sg10
I18
sg11
Vstatus epilepticus
p12291
sg13
I2
sasa(dp12292
g2
S'To understand the molecular actions of status epilepticus at the chromatin level, we studied the effects of kainate-induced status epilepticus on two different histone modifications at amino terminal tails: histone H3 phosphorylation at serine 10 and histone H4 acetylation.\n'
p12293
sg4
(lp12294
(dp12295
g7
I160
sg8
VP62805
p12296
sg10
I7
sg11
Vhistone
p12297
sg13
I1
sa(dp12298
g7
I207
sg8
g49
sg10
I10
sg11
Vhistone H3
p12299
sg13
I2
sa(dp12300
g7
I251
sg8
VP62805
p12301
sg10
I10
sg11
Vhistone H4
p12302
sg13
I2
sa(dp12303
g7
I237
sg8
VP30740
p12304
sg10
I9
sg11
Vserine 10
p12305
sg13
I2
sasg14
(lp12306
(dp12307
g7
I39
sg17
VC0038220
p12308
sg10
I18
sg11
Vstatus epilepticus
p12309
sg13
I2
sa(dp12310
g7
I39
sg17
VC0038220
p12311
sg10
I18
sg11
Vstatus epilepticus
p12312
sg13
I2
sasa(dp12313
g2
S'Background L-acetylcarnitine, a drug marketed for the treatment of chronic pain, causes analgesia by epigenetically up-regulating type-2 metabotropic glutamate (mGlu2) receptors in the spinal cord.\n'
p12314
sg4
(lp12315
(dp12316
g7
I130
sg8
g49
sg10
I47
sg11
Vtype-2 metabotropic glutamate (mGlu2) receptors
p12317
sg13
I5
sasg14
(lp12318
(dp12319
g7
I88
sg17
VC0344307
p12320
sg10
I9
sg11
Vanalgesia
p12321
sg13
I1
sa(dp12322
g7
I67
sg17
VC0150055
p12323
sg10
I12
sg11
Vchronic pain
p12324
sg13
I2
sa(dp12325
g7
I192
sg17
VC0035334
p12326
sg10
I4
sg11
Vcord
p12327
sg13
I1
sasa(dp12328
g2
S'The serotonin 2A (5-HT2A) and metabotropic glutamate 2 (mGlu2) receptors regulate each other and are associated with schizophrenia.\n'
p12329
sg4
(lp12330
(dp12331
g7
I30
sg8
g49
sg10
I24
sg11
Vmetabotropic glutamate 2
p12332
sg13
I3
sa(dp12333
g7
I56
sg8
g49
sg10
I5
sg11
VmGlu2
p12334
sg13
I1
sa(dp12335
g7
I18
sg8
VP28223
p12336
sg10
I6
sg11
V5-HT2A
p12337
sg13
I1
sa(dp12338
g7
I4
sg8
g49
sg10
I12
sg11
Vserotonin 2A
p12339
sg13
I2
sasg14
(lp12340
(dp12341
g7
I117
sg17
VC0036341
p12342
sg10
I13
sg11
Vschizophrenia
p12343
sg13
I1
sasa(dp12344
g2
S'Brain metabotropic glutamate receptor 2 (mGluR2) has been proposed as a therapeutic target for the treatment of schizophrenia-like symptoms arising from increased glutamate transmission in the forebrain.\n'
p12345
sg4
(lp12346
(dp12347
g7
I41
sg8
g49
sg10
I6
sg11
VmGluR2
p12348
sg13
I1
sa(dp12349
g7
I0
sg8
VP42262
p12350
sg10
I39
sg11
VBrain metabotropic glutamate receptor 2
p12351
sg13
I5
sasg14
(lp12352
(dp12353
g7
I112
sg17
VC0036341
p12354
sg10
I13
sg11
Vschizophrenia
p12355
sg13
I1
sasa(dp12356
g2
S'Reduced SHOX gene expression has been demonstrated to be associated with all skeletal abnormalities in Turner syndrome, other than scoliosis (and kyphosis).\n'
p12357
sg4
(lp12358
(dp12359
g7
I8
sg8
g49
sg10
I9
sg11
VSHOX gene
p12360
sg13
I2
sasg14
(lp12361
(dp12362
g7
I146
sg17
VC0022821
p12363
sg10
I8
sg11
Vkyphosis
p12364
sg13
I1
sa(dp12365
g7
I131
sg17
VC0700208
p12366
sg10
I9
sg11
Vscoliosis
p12367
sg13
I1
sa(dp12368
g7
I103
sg17
VC0041408
p12369
sg10
I15
sg11
VTurner syndrome
p12370
sg13
I2
sasa(dp12371
g2
S'This pilot gene expression study used relative quantitative real-time PCR (qRT-PCR) of the SHOX (short stature on X) gene to determine whether it is expressed in vertebral body growth plates in idiopathic and congenital scoliosis.\n'
p12372
sg4
(lp12373
(dp12374
g7
I97
sg8
VP37268
p12375
sg10
I18
sg11
Vshort stature on X
p12376
sg13
I4
sa(dp12377
g7
I91
sg8
g49
sg10
I4
sg11
VSHOX
p12378
sg13
I1
sasg14
(lp12379
(dp12380
g7
I97
sg17
VC0013336
p12381
sg10
I13
sg11
Vshort stature
p12382
sg13
I2
sa(dp12383
g7
I209
sg17
VC0559260
p12384
sg10
I20
sg11
Vcongenital scoliosis
p12385
sg13
I2
sasa(dp12386
g2
S'SHOX abundance was demonstrated in congenital and idiopathic scoliosis vertebral body growth plates.\n'
p12387
sg4
(lp12388
(dp12389
g7
I0
sg8
g49
sg10
I4
sg11
VSHOX
p12390
sg13
I1
sasg14
(lp12391
(dp12392
g7
I50
sg17
VC0595995
p12393
sg10
I20
sg11
Vidiopathic scoliosis
p12394
sg13
I2
sasa(dp12395
g2
S'SHOX expression was 11-fold greater in idiopathic compared to congenital (n = 3) scoliosis (p = 0.027).\n'
p12396
sg4
(lp12397
(dp12398
g7
I0
sg8
g49
sg10
I4
sg11
VSHOX
p12399
sg13
I1
sasg14
(lp12400
(dp12401
g7
I81
sg17
VC0700208
p12402
sg10
I9
sg11
Vscoliosis
p12403
sg13
I1
sasa(dp12404
g2
S'This study confirmed that SHOX was expressed in vertebral body growth plates, which implies that its expression may also be associated with the scoliosis (and kyphosis) of Turner syndrome.\n'
p12405
sg4
(lp12406
(dp12407
g7
I26
sg8
g49
sg10
I4
sg11
VSHOX
p12408
sg13
I1
sasg14
(lp12409
(dp12410
g7
I172
sg17
VC0041408
p12411
sg10
I15
sg11
VTurner syndrome
p12412
sg13
I2
sa(dp12413
g7
I159
sg17
VC0022821
p12414
sg10
I8
sg11
Vkyphosis
p12415
sg13
I1
sa(dp12416
g7
I144
sg17
VC0700208
p12417
sg10
I9
sg11
Vscoliosis
p12418
sg13
I1
sasa(dp12419
g2
S'In this study, increased SHOX expression was demonstrated in idiopathic scoliosis (tall stature) and congenital scoliosis.\n'
p12420
sg4
(lp12421
(dp12422
g7
I25
sg8
g49
sg10
I4
sg11
VSHOX
p12423
sg13
I1
sasg14
(lp12424
(dp12425
g7
I61
sg17
VC0595995
p12426
sg10
I20
sg11
Vidiopathic scoliosis
p12427
sg13
I2
sa(dp12428
g7
I101
sg17
VC0559260
p12429
sg10
I20
sg11
Vcongenital scoliosis
p12430
sg13
I2
sasa(dp12431
g2
S'The GFM model segregates patients into 3 groups based on: age &gt;65 years, WBC &gt;15 x 10(9) /L, anemia, platelets &lt;100 x 10(9) /L, and ASXL1 mutation status, with respective median survivals of 56 (low), 27.4 (intermediate), and 9.2 (high) months.\n'
p12432
sg4
(lp12433
sg14
(lp12434
(dp12435
g7
I99
sg17
VC0002871
p12436
sg10
I6
sg11
Vanemia
p12437
sg13
I1
sasa(dp12438
g2
S'The Groupe Francophone des (GFM) score segregated CMML patients into three risk groups based on: age &gt;65 years, WBC &gt;15 x 109/L, anemia, platelets &lt;100 x 109/L, and ASXL1 mutation status.\n'
p12439
sg4
(lp12440
sg14
(lp12441
(dp12442
g7
I135
sg17
VC0002871
p12443
sg10
I6
sg11
Vanemia
p12444
sg13
I1
sa(dp12445
g7
I50
sg17
VC0023480
p12446
sg10
I4
sg11
VCMML
p12447
sg13
I1
sa(dp12448
g7
I23
sg17
VC0394006
p12449
sg10
I3
sg11
Vdes
p12450
sg13
I1
sasa(dp12451
g2
S'Egf1.5 also bound PAP1, PAP3 and serine proteinase homolog 2 (SPH2).\n'
p12452
sg4
(lp12453
(dp12454
g7
I18
sg8
g49
sg10
I4
sg11
VPAP1
p12455
sg13
I1
sa(dp12456
g7
I0
sg8
g49
sg10
I4
sg11
VEgf1
p12457
sg13
I1
sa(dp12458
g7
I62
sg8
VP11277
p12459
sg10
I4
sg11
VSPH2
p12460
sg13
I1
sa(dp12461
g7
I33
sg8
VP30740
p12462
sg10
I27
sg11
Vserine proteinase homolog 2
p12463
sg13
I4
sasg14
(lp12464
sa(dp12465
g2
S'Consistent with its PAP inhibitory activity, Egf1.0 also prevented processing of pro-phenoloxidase, serine proteinase homolog (SPH) 1, and SPH2.\n'
p12466
sg4
(lp12467
(dp12468
g7
I100
sg8
VP08247
p12469
sg10
I33
sg11
Vserine proteinase homolog (SPH) 1
p12470
sg13
I5
sa(dp12471
g7
I20
sg8
g49
sg10
I3
sg11
VPAP
p12472
sg13
I1
sa(dp12473
g7
I139
sg8
VP11277
p12474
sg10
I4
sg11
VSPH2
p12475
sg13
I1
sa(dp12476
g7
I45
sg8
g49
sg10
I6
sg11
VEgf1.0
p12477
sg13
I1
sa(dp12478
g7
I81
sg8
VP63125
p12479
sg10
I17
sg11
Vpro-phenoloxidase
p12480
sg13
I1
sasg14
(lp12481
(dp12482
g7
I127
sg17
VC2674218
p12483
sg10
I3
sg11
VSPH
p12484
sg13
I1
sa(dp12485
g7
I20
sg17
VC1863340
p12486
sg10
I3
sg11
VPAP
p12487
sg13
I1
sa(dp12488
g7
I100
sg17
VC2674218
p12489
sg10
I25
sg11
Vserine proteinase homolog
p12490
sg13
I3
sasa(dp12491
g2
S'Egf1.0 also potentially interacts with SPH2 and two other proteins, ferritin and gloverin, not previously associated with the phenoloxidase cascade.\n'
p12492
sg4
(lp12493
(dp12494
g7
I0
sg8
g49
sg10
I4
sg11
VEgf1
p12495
sg13
I1
sa(dp12496
g7
I39
sg8
VP11277
p12497
sg10
I4
sg11
VSPH2
p12498
sg13
I1
sa(dp12499
g7
I68
sg8
VP02794
p12500
sg10
I8
sg11
Vferritin
p12501
sg13
I1
sasg14
(lp12502
sa(dp12503
g2
S'B cells express CD1d, however, we show that CD1d expression is reduced on B cells from patients with chronic lymphocytic leukemia (CLL).\n'
p12504
sg4
(lp12505
(dp12506
g7
I16
sg8
VP15813
p12507
sg10
I4
sg11
VCD1d
p12508
sg13
I1
sa(dp12509
g7
I16
sg8
VP15813
p12510
sg10
I4
sg11
VCD1d
p12511
sg13
I1
sasg14
(lp12512
(dp12513
g7
I101
sg17
VC0023434
p12514
sg10
I28
sg11
Vchronic lymphocytic leukemia
p12515
sg13
I3
sa(dp12516
g7
I131
sg17
VC0023434
p12517
sg10
I3
sg11
VCLL
p12518
sg13
I1
sasa(dp12519
g2
S'Elevated CD1d expression is detected in CD5(+) IL10-producing B cells, called B10 B cells, and is correlated with poorer prognosis in chronic lymphocytic leukemia (CLL), a CD5(+) B cell malignancy with B10-like functional properties.\n'
p12520
sg4
(lp12521
(dp12522
g7
I40
sg8
VP06127
p12523
sg10
I11
sg11
VCD5(+) IL10
p12524
sg13
I2
sa(dp12525
g7
I40
sg8
VP06127
p12526
sg10
I3
sg11
VCD5
p12527
sg13
I1
sa(dp12528
g7
I78
sg8
g49
sg10
I5
sg11
VB10 B
p12529
sg13
I2
sa(dp12530
g7
I9
sg8
VP15813
p12531
sg10
I4
sg11
VCD1d
p12532
sg13
I1
sasg14
(lp12533
(dp12534
g7
I134
sg17
VC0023434
p12535
sg10
I28
sg11
Vchronic lymphocytic leukemia
p12536
sg13
I3
sa(dp12537
g7
I186
sg17
VC0006826
p12538
sg10
I10
sg11
Vmalignancy
p12539
sg13
I1
sa(dp12540
g7
I164
sg17
VC0023434
p12541
sg10
I3
sg11
VCLL
p12542
sg13
I1
sasa(dp12543
g2
S'A significant decrease was observed in the levels of CD1d on monocytes in the PB of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patients compared with the healthy controls.\n'
p12544
sg4
(lp12545
(dp12546
g7
I53
sg8
VP15813
p12547
sg10
I4
sg11
VCD1d
p12548
sg13
I1
sasg14
(lp12549
(dp12550
g7
I147
sg17
VC1961102
p12551
sg10
I3
sg11
VALL
p12552
sg13
I1
sa(dp12553
g7
I108
sg17
VC0023467
p12554
sg10
I3
sg11
VAML
p12555
sg13
I1
sa(dp12556
g7
I84
sg17
VC0023467
p12557
sg10
I22
sg11
Vacute myeloid leukemia
p12558
sg13
I3
sa(dp12559
g7
I117
sg17
VC1961102
p12560
sg10
I28
sg11
Vacute lymphoblastic leukemia
p12561
sg13
I3
sasa(dp12562
g2
S'We analyzed the expression of CD1d, an antigen-presenting molecule, on peripheral blood leukemic cells of cases of chronic lymphocytic leukemia (CLL) by flow cytometry.\n'
p12563
sg4
(lp12564
(dp12565
g7
I30
sg8
VP15813
p12566
sg10
I4
sg11
VCD1d
p12567
sg13
I1
sasg14
(lp12568
(dp12569
g7
I145
sg17
VC0023434
p12570
sg10
I3
sg11
VCLL
p12571
sg13
I1
sa(dp12572
g7
I115
sg17
VC0023434
p12573
sg10
I28
sg11
Vchronic lymphocytic leukemia
p12574
sg13
I3
sasa(dp12575
g2
S'The numbers of circulating invariant natural killer T cells and the expression of CD1d on antigen-presenting cells were evaluated in patients with chronic lymphocytic leukemia and age-matched controls.\n'
p12576
sg4
(lp12577
(dp12578
g7
I82
sg8
VP15813
p12579
sg10
I4
sg11
VCD1d
p12580
sg13
I1
sasg14
(lp12581
(dp12582
g7
I147
sg17
VC0023434
p12583
sg10
I28
sg11
Vchronic lymphocytic leukemia
p12584
sg13
I3
sasa(dp12585
g2
S'In conclusion, the invariant natural killer T-cell and CD1d axis is fundamentally intact in patients with early-stage chronic lymphocytic leukemia and, despite reduced circulating numbers, function is retained in fludarabine-treated patients.\n'
p12586
sg4
(lp12587
(dp12588
g7
I55
sg8
VP15813
p12589
sg10
I4
sg11
VCD1d
p12590
sg13
I1
sasg14
(lp12591
(dp12592
g7
I118
sg17
VC0023434
p12593
sg10
I28
sg11
Vchronic lymphocytic leukemia
p12594
sg13
I3
sasa(dp12595
g2
S'To study the change of endogenous hydrogen sulfide (hydrogen sulfide, H2S) and its rate-limiting enzyme Cystathionine-gamma-lyase (CSE) in allergic rhinitis through guinea pigs with intervention treatment.\n'
p12596
sg4
(lp12597
(dp12598
g7
I131
sg8
VP32929
p12599
sg10
I3
sg11
VCSE
p12600
sg13
I1
sa(dp12601
g7
I104
sg8
VP32929
p12602
sg10
I25
sg11
VCystathionine-gamma-lyase
p12603
sg13
I1
sasg14
(lp12604
(dp12605
g7
I139
sg17
VC2607914
p12606
sg10
I17
sg11
Vallergic rhinitis
p12607
sg13
I2
sa(dp12608
g7
I131
sg17
VC1832855
p12609
sg10
I3
sg11
VCSE
p12610
sg13
I1
sa(dp12611
g7
I104
sg17
VC1832855
p12612
sg10
I25
sg11
VCystathionine-gamma-lyase
p12613
sg13
I1
sasa(dp12614
g2
S'So far, potential immune-modulatory properties of PACAP have not been investigated in experimental ileitis.\n'
p12615
sg4
(lp12616
(dp12617
g7
I50
sg8
g49
sg10
I5
sg11
VPACAP
p12618
sg13
I1
sasg14
(lp12619
(dp12620
g7
I99
sg17
VC0020877
p12621
sg10
I7
sg11
Vileitis
p12622
sg13
I1
sasa(dp12623
g2
S'Mice were perorally infected with Toxoplasma (T.) gondii to induce acute ileitis (day 0) and treated daily with synthetic PACAP38 from day 1 to 6 post infection (p.i.\n'
p12624
sg4
(lp12625
sg14
(lp12626
(dp12627
g7
I73
sg17
VC0020877
p12628
sg10
I7
sg11
Vileitis
p12629
sg13
I1
sa(dp12630
g7
I151
sg17
VC0009450
p12631
sg10
I9
sg11
Vinfection
p12632
sg13
I1
sasa(dp12633
g2
S'Study 1 - Nerves in colonic resection specimens with either acute diverticulitis (AD, n = 16) or chronic diverticulitis (CD, n = 16) were assessed for neuropeptide expression recording % area staining with protein gene product (PGP9.5), substance P (SP), neuropeptide K (NPK), pituitary adenylate cyclase activating polypeptide (PACAP), vasoactive intestinal polypeptide (VIP) and galanin.\n'
p12634
sg4
(lp12635
(dp12636
g7
I381
sg8
VP22466
p12637
sg10
I7
sg11
Vgalanin
p12638
sg13
I1
sa(dp12639
g7
I329
sg8
g49
sg10
I5
sg11
VPACAP
p12640
sg13
I1
sa(dp12641
g7
I359
sg8
VP23468
p12642
sg10
I17
sg11
Vpolypeptide (VIP)
p12643
sg13
I2
sa(dp12644
g7
I277
sg8
VP18509
p12645
sg10
I50
sg11
Vpituitary adenylate cyclase activating polypeptide
p12646
sg13
I5
sasg14
(lp12647
(dp12648
g7
I121
sg17
VC0859969
p12649
sg10
I2
sg11
VCD
p12650
sg13
I1
sa(dp12651
g7
I97
sg17
VC0859969
p12652
sg10
I22
sg11
Vchronic diverticulitis
p12653
sg13
I2
sa(dp12654
g7
I60
sg17
VC0518989
p12655
sg10
I20
sg11
Vacute diverticulitis
p12656
sg13
I2
sa(dp12657
g7
I82
sg17
VC0518989
p12658
sg10
I2
sg11
VAD
p12659
sg13
I1
sasa(dp12660
g2
S'Our aim was to obtain insight in the role of PACAP in experimental colitis in mice and thus its possible role in inflammatory bowel disease.\n'
p12661
sg4
(lp12662
(dp12663
g7
I45
sg8
g49
sg10
I5
sg11
VPACAP
p12664
sg13
I1
sasg14
(lp12665
(dp12666
g7
I67
sg17
VC0009319
p12667
sg10
I7
sg11
Vcolitis
p12668
sg13
I1
sa(dp12669
g7
I113
sg17
VC0021390
p12670
sg10
I26
sg11
Vinflammatory bowel disease
p12671
sg13
I3
sasa(dp12672
g2
S'PACAP-deficient (PACAP-/-) mice and wild-type control mice were challenged by colitis-inducing agent, dextran sulfate sodium (DSS).\n'
p12673
sg4
(lp12674
(dp12675
g7
I0
sg8
g49
sg10
I5
sg11
VPACAP
p12676
sg13
I1
sasg14
(lp12677
(dp12678
g7
I126
sg17
VC0011195
p12679
sg10
I3
sg11
VDSS
p12680
sg13
I1
sa(dp12681
g7
I78
sg17
VC0009319
p12682
sg10
I7
sg11
Vcolitis
p12683
sg13
I1
sa(dp12684
g7
I102
sg17
VC0011195
p12685
sg10
I22
sg11
Vdextran sulfate sodium
p12686
sg13
I3
sasa(dp12687
g2
S'Our findings indicate that PACAP regulates the production of pro-inflammatory cytokine in the experimental colitis.\n'
p12688
sg4
(lp12689
(dp12690
g7
I27
sg8
g49
sg10
I5
sg11
VPACAP
p12691
sg13
I1
sasg14
(lp12692
(dp12693
g7
I107
sg17
VC0009319
p12694
sg10
I7
sg11
Vcolitis
p12695
sg13
I1
sasa(dp12696
g2
S"Therefore, VIP/PACAP and analogues have been recently proposed as very promising candidates, alternative to other existing treatments, for treating acute and chronic inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Parkinson's disease, Crohn disease, or autoimmune diabetes.\n"
p12697
sg4
(lp12698
(dp12699
g7
I11
sg8
VP01282
p12700
sg10
I3
sg11
VVIP
p12701
sg13
I1
sa(dp12702
g7
I15
sg8
g49
sg10
I5
sg11
VPACAP
p12703
sg13
I1
sasg14
(lp12704
(dp12705
g7
I212
sg17
VC0036983
p12706
sg10
I12
sg11
Vseptic shock
p12707
sg13
I2
sa(dp12708
g7
I307
sg17
VC0205734
p12709
sg10
I19
sg11
Vautoimmune diabetes
p12710
sg13
I2
sa(dp12711
g7
I183
sg17
VC0004364
p12712
sg10
I19
sg11
Vautoimmune diseases
p12713
sg13
I2
sa(dp12714
g7
I248
sg17
VC0026769
p12715
sg10
I18
sg11
Vmultiple sclerosis
p12716
sg13
I2
sa(dp12717
g7
I268
sg17
VC0030567
p12718
sg10
I19
sg11
VParkinson's disease
p12719
sg13
I2
sa(dp12720
g7
I289
sg17
VC0010346
p12721
sg10
I13
sg11
VCrohn disease
p12722
sg13
I2
sa(dp12723
g7
I226
sg17
VC0003873
p12724
sg10
I20
sg11
Vrheumatoid arthritis
p12725
sg13
I2
sasa(dp12726
g2
S"Therefore, PACAP and analogs have been proposed as very promising candidates, alternative to other existing treatments, for treating acute and chronic inflammatory and autoimmune diseases, such as septic shock, arthritis, multiple sclerosis, Crohn's disease, or autoimmune diabetes.\n"
p12727
sg4
(lp12728
(dp12729
g7
I11
sg8
g49
sg10
I5
sg11
VPACAP
p12730
sg13
I1
sasg14
(lp12731
(dp12732
g7
I211
sg17
VC0003864
p12733
sg10
I9
sg11
Varthritis
p12734
sg13
I1
sa(dp12735
g7
I197
sg17
VC0036983
p12736
sg10
I12
sg11
Vseptic shock
p12737
sg13
I2
sa(dp12738
g7
I242
sg17
VC0010346
p12739
sg10
I15
sg11
VCrohn's disease
p12740
sg13
I2
sa(dp12741
g7
I262
sg17
VC0205734
p12742
sg10
I19
sg11
Vautoimmune diabetes
p12743
sg13
I2
sa(dp12744
g7
I222
sg17
VC0026769
p12745
sg10
I18
sg11
Vmultiple sclerosis
p12746
sg13
I2
sa(dp12747
g7
I168
sg17
VC0004364
p12748
sg10
I19
sg11
Vautoimmune diseases
p12749
sg13
I2
sasa(dp12750
g2
S"The distribution of PACAP in ganglionic and aganglionic portions of the large intestine of patients with Hirschsprung's disease was examined by immunohistochemistry and radioimmunoassay.\n"
p12751
sg4
(lp12752
(dp12753
g7
I20
sg8
g49
sg10
I5
sg11
VPACAP
p12754
sg13
I1
sasg14
(lp12755
(dp12756
g7
I105
sg17
VC0019569
p12757
sg10
I22
sg11
VHirschsprung's disease
p12758
sg13
I2
sasa(dp12759
g2
S"The scarcer PACAP innervation of the aganglionic segment may contribute to the defect in intestinal relaxation seen in patients with Hirschsprung's disease.\n"
p12760
sg4
(lp12761
sg14
(lp12762
(dp12763
g7
I133
sg17
VC0019569
p12764
sg10
I22
sg11
VHirschsprung's disease
p12765
sg13
I2
sasa(dp12766
g2
S'We have determined the solution structures of the three quasi-RNA-recognition motifs (qRRMs) of hnRNP F in complex with G-tract RNA.\n'
p12767
sg4
(lp12768
(dp12769
g7
I96
sg8
VP52597
p12770
sg10
I7
sg11
VhnRNP F
p12771
sg13
I2
sasg14
(lp12772
sa(dp12773
g2
S'We also show that isolated qRRMs of hnRNP F are sufficient to regulate the alternative splicing of the Bcl-x pre-mRNA, suggesting that hnRNP F would act by remodeling RNA secondary and tertiary structures.\n'
p12774
sg4
(lp12775
(dp12776
g7
I36
sg8
VP52597
p12777
sg10
I7
sg11
VhnRNP F
p12778
sg13
I2
sa(dp12779
g7
I36
sg8
VP52597
p12780
sg10
I7
sg11
VhnRNP F
p12781
sg13
I2
sa(dp12782
g7
I103
sg8
g49
sg10
I14
sg11
VBcl-x pre-mRNA
p12783
sg13
I2
sasg14
(lp12784
sa(dp12785
g2
S'In order to gain insight into G-tract recognition by hnRNP H members, we initiated an NMR study of human hnRNP F. We present the solution structure of the three quasi RNA recognition motifs (qRRMs) of hnRNP F and identify the residues that are important for the interaction with the Bcl-x RNA by NMR chemical shift perturbation and mutagenesis experiments.\n'
p12786
sg4
(lp12787
(dp12788
g7
I105
sg8
VP52597
p12789
sg10
I7
sg11
VhnRNP F
p12790
sg13
I2
sa(dp12791
g7
I53
sg8
VP31943
p12792
sg10
I15
sg11
VhnRNP H members
p12793
sg13
I3
sa(dp12794
g7
I283
sg8
g49
sg10
I9
sg11
VBcl-x RNA
p12795
sg13
I2
sa(dp12796
g7
I99
sg8
VP52597
p12797
sg10
I13
sg11
Vhuman hnRNP F
p12798
sg13
I3
sasg14
(lp12799
sa(dp12800
g2
S'The three qRRMs exhibit the canonical betaalphabetabetaalphabeta RRM fold but additional secondary structure elements are present in the two N-terminal qRRMs of hnRNP F. We show that qRRM1 and qRRM2 but not qRRM3 are responsible for G-tract recognition and that the residues of qRRM1 and qRRM2 involved in G-tract interaction are not on the beta-sheet surface as observed for the classical RRM but are part of a short beta-hairpin and two adjacent loops.\n'
p12801
sg4
(lp12802
(dp12803
g7
I161
sg8
VP52597
p12804
sg10
I7
sg11
VhnRNP F
p12805
sg13
I2
sasg14
(lp12806
sa(dp12807
g2
S'Bipolar cell-related dystrophies were associated with the highest risk of SE high myopia 239.7; odds ratio (OR) mild hyperopia 263.2, both P &lt; .0001; SE -6.86 diopters (D) (standard deviation [SD] 6.38), followed by cone-dominated dystrophies (OR high myopia 19.5, P &lt; .0001; OR high hyperopia 10.7, P = .033; SE -3.10 D [SD 4.49]); rod dominated dystrophies (OR high myopia 10.1, P &lt; .0001; OR high hyperopia 9.7, P = .001; SE -2.27 D [SD 4.65]), and retinal pigment epithelium (RPE)-related dystrophies (OR low myopia 2.7; P = .001; OR high hyperopia 5.8; P = .025; SE -0.10 D [SD 3.09]).\n'
p12808
sg4
(lp12809
(dp12810
g7
I117
sg8
g49
sg10
I15
sg11
Vhyperopia 263.2
p12811
sg13
I2
sasg14
(lp12812
(dp12813
g7
I117
sg17
VC0020490
p12814
sg10
I9
sg11
Vhyperopia
p12815
sg13
I1
sa(dp12816
g7
I21
sg17
VC0333606
p12817
sg10
I11
sg11
Vdystrophies
p12818
sg13
I1
sa(dp12819
g7
I21
sg17
VC0333606
p12820
sg10
I11
sg11
Vdystrophies
p12821
sg13
I1
sa(dp12822
g7
I117
sg17
VC0020490
p12823
sg10
I9
sg11
Vhyperopia
p12824
sg13
I1
sa(dp12825
g7
I82
sg17
VC0027092
p12826
sg10
I6
sg11
Vmyopia
p12827
sg13
I1
sa(dp12828
g7
I77
sg17
VC0271183
p12829
sg10
I11
sg11
Vhigh myopia
p12830
sg13
I2
sa(dp12831
g7
I117
sg17
VC0020490
p12832
sg10
I9
sg11
Vhyperopia
p12833
sg13
I1
sa(dp12834
g7
I21
sg17
VC0333606
p12835
sg10
I11
sg11
Vdystrophies
p12836
sg13
I1
sa(dp12837
g7
I21
sg17
VC0333606
p12838
sg10
I11
sg11
Vdystrophies
p12839
sg13
I1
sa(dp12840
g7
I77
sg17
VC0271183
p12841
sg10
I11
sg11
Vhigh myopia
p12842
sg13
I2
sa(dp12843
g7
I117
sg17
VC0020490
p12844
sg10
I9
sg11
Vhyperopia
p12845
sg13
I1
sa(dp12846
g7
I77
sg17
VC0271183
p12847
sg10
I11
sg11
Vhigh myopia
p12848
sg13
I2
sasa(dp12849
g2
S'Two hundred fifty-eight eyes that had LASIK for low myopia were reviewed, and a subsequent control-matched comparative analysis of visual outcomes in highly myopic eyes (SE -7.54 +/- 1.43 D) versus low myopic eyes (SE -2.26 +/- 0.51 D) was performed after controlling for preoperative and surgical parameters.\n'
p12850
sg4
(lp12851
sg14
(lp12852
(dp12853
g7
I52
sg17
VC0027092
p12854
sg10
I6
sg11
Vmyopia
p12855
sg13
I1
sasa(dp12856
g2
S'Submucous cleft palate (SMCP) classically involves bifid uvula, zona pellucida, and notched hard palate.\n'
p12857
sg4
(lp12858
sg14
(lp12859
(dp12860
g7
I24
sg17
VC0432103
p12861
sg10
I4
sg11
VSMCP
p12862
sg13
I1
sa(dp12863
g7
I64
sg17
VC0019360
p12864
sg10
I4
sg11
Vzona
p12865
sg13
I1
sa(dp12866
g7
I51
sg17
VC0266122
p12867
sg10
I11
sg11
Vbifid uvula
p12868
sg13
I2
sa(dp12869
g7
I0
sg17
VC0432103
p12870
sg10
I22
sg11
VSubmucous cleft palate
p12871
sg13
I3
sasa(dp12872
g2
S'Validate an assessment protocol for diagnosis of occult submucous cleft palate (OSMCP) and identify physical examination features present in patients with OSMCP in the relaxed and activated palate positions.\n'
p12873
sg4
(lp12874
sg14
(lp12875
(dp12876
g7
I49
sg17
VC0432104
p12877
sg10
I29
sg11
Voccult submucous cleft palate
p12878
sg13
I4
sa(dp12879
g7
I80
sg17
VC0432104
p12880
sg10
I5
sg11
VOSMCP
p12881
sg13
I1
sa(dp12882
g7
I80
sg17
VC0432104
p12883
sg10
I5
sg11
VOSMCP
p12884
sg13
I1
sasa(dp12885
g2
S'This study aimed to evaluate the craniofacial morphology of unoperated adult submucous cleft palate (SMCP) patients and to explore the possible correlation between the intrinsic growth insufficiency of the maxillofacial complex and the severity of the cleft.\n'
p12886
sg4
(lp12887
sg14
(lp12888
(dp12889
g7
I101
sg17
VC0432103
p12890
sg10
I4
sg11
VSMCP
p12891
sg13
I1
sa(dp12892
g7
I77
sg17
VC0432103
p12893
sg10
I22
sg11
Vsubmucous cleft palate
p12894
sg13
I3
sasa(dp12895
g2
S'A total of 20 unoperated SMCP patients, 20 unoperated overt cleft palate (OCP) patients, and 32 normal controls, ages between 18 and 30, were included for cephalometric analysis.\n'
p12896
sg4
(lp12897
sg14
(lp12898
(dp12899
g7
I74
sg17
VC1282359
p12900
sg10
I3
sg11
VOCP
p12901
sg13
I1
sa(dp12902
g7
I54
sg17
VC1282359
p12903
sg10
I18
sg11
Vovert cleft palate
p12904
sg13
I3
sasa(dp12905
g2
S'Because some patients with submucous cleft palate (SMCP) are asymptomatic, surgical treatment is conventionally delayed until hypernasal resonance is identified during speech production.\n'
p12906
sg4
(lp12907
sg14
(lp12908
(dp12909
g7
I27
sg17
VC0432103
p12910
sg10
I22
sg11
Vsubmucous cleft palate
p12911
sg13
I3
sa(dp12912
g7
I51
sg17
VC0432103
p12913
sg10
I4
sg11
VSMCP
p12914
sg13
I1
sasa(dp12915
g2
S'Since 69% of individuals with 22q11.2 deletion have a palatal abnormality, we studied the prevalence of 22q11.2 deletion syndrome in 378 Iranian patients during a 5-year period, including 291 patients affected with cleft palate only without cleft lip (CPO) and 87 patients affected with velopharyngeal incompetence (VPI) and/or submucous cleft palate (SMCP).\n'
p12916
sg4
(lp12917
sg14
(lp12918
(dp12919
g7
I328
sg17
VC0432103
p12920
sg10
I22
sg11
Vsubmucous cleft palate
p12921
sg13
I3
sa(dp12922
g7
I352
sg17
VC0432103
p12923
sg10
I4
sg11
VSMCP
p12924
sg13
I1
sa(dp12925
g7
I287
sg17
VC0042454
p12926
sg10
I27
sg11
Vvelopharyngeal incompetence
p12927
sg13
I2
sa(dp12928
g7
I104
sg17
VC0220704
p12929
sg10
I25
sg11
V22q11.2 deletion syndrome
p12930
sg13
I3
sa(dp12931
g7
I215
sg17
VC0008925
p12932
sg10
I12
sg11
Vcleft palate
p12933
sg13
I2
sa(dp12934
g7
I316
sg17
VC0042454
p12935
sg10
I3
sg11
VVPI
p12936
sg13
I1
sa(dp12937
g7
I241
sg17
VC0008924
p12938
sg10
I9
sg11
Vcleft lip
p12939
sg13
I2
sasa(dp12940
g2
S'Submucous cleft palate (SMCP) is a relatively rare variant of the common pathology of cleft palate with specific anatomic and clinical features.\n'
p12941
sg4
(lp12942
sg14
(lp12943
(dp12944
g7
I24
sg17
VC0432103
p12945
sg10
I4
sg11
VSMCP
p12946
sg13
I1
sa(dp12947
g7
I73
sg17
VC0677042
p12948
sg10
I9
sg11
Vpathology
p12949
sg13
I1
sa(dp12950
g7
I10
sg17
VC0008925
p12951
sg10
I12
sg11
Vcleft palate
p12952
sg13
I2
sa(dp12953
g7
I0
sg17
VC0432103
p12954
sg10
I22
sg11
VSubmucous cleft palate
p12955
sg13
I3
sasa(dp12956
g2
S'In this study, 366 patients with VPD were retrospectively stratified into cleft lip and palate (CLP), cleft palate (CP), submucous cleft palate (SMCP), occult submucous cleft palate (OSMCP), and non-CP groups.\n'
p12957
sg4
(lp12958
sg14
(lp12959
(dp12960
g7
I145
sg17
VC0432103
p12961
sg10
I4
sg11
VSMCP
p12962
sg13
I1
sa(dp12963
g7
I121
sg17
VC0432103
p12964
sg10
I22
sg11
Vsubmucous cleft palate
p12965
sg13
I3
sa(dp12966
g7
I152
sg17
VC0432104
p12967
sg10
I29
sg11
Voccult submucous cleft palate
p12968
sg13
I4
sa(dp12969
g7
I74
sg17
VC0158646
p12970
sg10
I20
sg11
Vcleft lip and palate
p12971
sg13
I4
sa(dp12972
g7
I116
sg17
VC0008925
p12973
sg10
I2
sg11
VCP
p12974
sg13
I1
sa(dp12975
g7
I102
sg17
VC0008925
p12976
sg10
I12
sg11
Vcleft palate
p12977
sg13
I2
sa(dp12978
g7
I116
sg17
VC0008925
p12979
sg10
I2
sg11
VCP
p12980
sg13
I1
sa(dp12981
g7
I96
sg17
VC0158646
p12982
sg10
I3
sg11
VCLP
p12983
sg13
I1
sa(dp12984
g7
I183
sg17
VC0432104
p12985
sg10
I5
sg11
VOSMCP
p12986
sg13
I1
sasa(dp12987
g2
S'The postoperative speech outcomes of submucous cleft palate (SMCP) surgery are known to be poorer than those of other types of cleft palate.\n'
p12988
sg4
(lp12989
sg14
(lp12990
(dp12991
g7
I37
sg17
VC0432103
p12992
sg10
I22
sg11
Vsubmucous cleft palate
p12993
sg13
I3
sa(dp12994
g7
I61
sg17
VC0432103
p12995
sg10
I4
sg11
VSMCP
p12996
sg13
I1
sa(dp12997
g7
I47
sg17
VC0008925
p12998
sg10
I12
sg11
Vcleft palate
p12999
sg13
I2
sasa(dp13000
g2
S'We attempted to objectively characterize the postoperative complications and speech outcomes of the surgical treatment of SMCP through a comparison with the outcomes of incomplete cleft palate (ICP).\n'
p13001
sg4
(lp13002
sg14
(lp13003
(dp13004
g7
I169
sg17
VC0268318
p13005
sg10
I23
sg11
Vincomplete cleft palate
p13006
sg13
I3
sa(dp13007
g7
I194
sg17
VC0268318
p13008
sg10
I3
sg11
VICP
p13009
sg13
I1
sa(dp13010
g7
I45
sg17
VC0032787
p13011
sg10
I27
sg11
Vpostoperative complications
p13012
sg13
I2
sasa(dp13013
g2
S'The aim of this study was to visualize bony defects of the palate and vomer in submucous cleft palate patients (SMCP) by three-dimensional (3D) computed tomography (CT) reconstruction and to classify the range of bony defects.\n'
p13014
sg4
(lp13015
sg14
(lp13016
(dp13017
g7
I79
sg17
VC0432103
p13018
sg10
I22
sg11
Vsubmucous cleft palate
p13019
sg13
I3
sasa(dp13020
g2
S'Objective : Submucous cleft palate (SMCP) is a congenital condition associated with abnormal development of the soft palate musculature.\n'
p13021
sg4
(lp13022
sg14
(lp13023
(dp13024
g7
I12
sg17
VC0432103
p13025
sg10
I22
sg11
VSubmucous cleft palate
p13026
sg13
I3
sa(dp13027
g7
I84
sg17
VC0000768
p13028
sg10
I20
sg11
Vabnormal development
p13029
sg13
I2
sa(dp13030
g7
I58
sg17
VC0012634
p13031
sg10
I9
sg11
Vcondition
p13032
sg13
I1
sa(dp13033
g7
I36
sg17
VC0432103
p13034
sg10
I4
sg11
VSMCP
p13035
sg13
I1
sasa(dp13036
g2
S'To investigate the relationship between miR-501-5p expression and the clinicopathological factors in patients with lung adenocarcinoma in Xuanwei area.\n'
p13037
sg4
(lp13038
(dp13039
g7
I40
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13040
sg13
I1
sasg14
(lp13041
(dp13042
g7
I115
sg17
VC0152013
p13043
sg10
I19
sg11
Vlung adenocarcinoma
p13044
sg13
I2
sasa(dp13045
g2
S'Surgical specimens of lung adenocarcinoma and paired adjacent tissues from 24 patients with lung adenocarcinoma from Xuanwei area were examined for miR-501-5p expression using microRNA microarray technique and qPCR.\n'
p13046
sg4
(lp13047
(dp13048
g7
I148
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13049
sg13
I1
sasg14
(lp13050
(dp13051
g7
I22
sg17
VC0152013
p13052
sg10
I19
sg11
Vlung adenocarcinoma
p13053
sg13
I2
sa(dp13054
g7
I22
sg17
VC0152013
p13055
sg10
I19
sg11
Vlung adenocarcinoma
p13056
sg13
I2
sasa(dp13057
g2
S'MicroRNA microarray analysis and qPCR validation results revealed significantly upregulated expressions of miR-501-5p in patients with lung adenocarcinoma from Xuanwei area (Plt;0.01).\n'
p13058
sg4
(lp13059
(dp13060
g7
I107
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13061
sg13
I1
sasg14
(lp13062
(dp13063
g7
I135
sg17
VC0152013
p13064
sg10
I19
sg11
Vlung adenocarcinoma
p13065
sg13
I2
sasa(dp13066
g2
S'The microarray data showed an up-regulation of miR-501-5p by 3.17 folds in lung adenocarcinoma tissue compared with the adjacent tissue (P=0.22376, FDR=0.071395).\n'
p13067
sg4
(lp13068
(dp13069
g7
I47
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13070
sg13
I1
sasg14
(lp13071
(dp13072
g7
I75
sg17
VC0152013
p13073
sg10
I19
sg11
Vlung adenocarcinoma
p13074
sg13
I2
sasa(dp13075
g2
S"miR-501-5p expression is up-regulated in lung adenocarcinoma with significant associations with the patients' age, TNM stages and serum CEA level in patients from Xuanwei area, suggesting its potential role in the tumorigenesis and progression of lung adenocarcinoma in Xuanwei area.\n"
p13076
sg4
(lp13077
(dp13078
g7
I0
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13079
sg13
I1
sa(dp13080
g7
I130
sg8
VP40198
p13081
sg10
I9
sg11
Vserum CEA
p13082
sg13
I2
sasg14
(lp13083
(dp13084
g7
I214
sg17
VC0007621
p13085
sg10
I13
sg11
Vtumorigenesis
p13086
sg13
I1
sa(dp13087
g7
I41
sg17
VC0152013
p13088
sg10
I19
sg11
Vlung adenocarcinoma
p13089
sg13
I2
sa(dp13090
g7
I41
sg17
VC0152013
p13091
sg10
I19
sg11
Vlung adenocarcinoma
p13092
sg13
I2
sasa(dp13093
g2
S'This study is aimed to study the role of miR-501-5p in the progression of gastric cancer.\n'
p13094
sg4
(lp13095
(dp13096
g7
I41
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13097
sg13
I1
sasg14
(lp13098
(dp13099
g7
I74
sg17
VC0024623
p13100
sg10
I14
sg11
Vgastric cancer
p13101
sg13
I2
sasa(dp13102
g2
S'Real-time PCR analysis was used to determine miR-501-5p expression in gastric cancer cell lines, clinical tissues and 112 clinicopathologically characterized gastric cancer specimens.\n'
p13103
sg4
(lp13104
(dp13105
g7
I45
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13106
sg13
I1
sasg14
(lp13107
(dp13108
g7
I70
sg17
VC0024623
p13109
sg10
I14
sg11
Vgastric cancer
p13110
sg13
I2
sa(dp13111
g7
I70
sg17
VC0024623
p13112
sg10
I14
sg11
Vgastric cancer
p13113
sg13
I2
sasa(dp13114
g2
S'The role of miR-501-5p in maintaining gastric cancer stem cell like phenotype was examined by tumor-sphere formation assay and expression of stem cell markers.\n'
p13115
sg4
(lp13116
(dp13117
g7
I12
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13118
sg13
I1
sasg14
(lp13119
(dp13120
g7
I38
sg17
VC0024623
p13121
sg10
I14
sg11
Vgastric cancer
p13122
sg13
I2
sa(dp13123
g7
I94
sg17
VC0027651
p13124
sg10
I5
sg11
Vtumor
p13125
sg13
I1
sasa(dp13126
g2
S'Herein, our results revealed that miR-501-5p was markedly upregulated in gastric cancer cell lines and clinical tissues.\n'
p13127
sg4
(lp13128
(dp13129
g7
I34
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13130
sg13
I1
sasg14
(lp13131
(dp13132
g7
I73
sg17
VC0024623
p13133
sg10
I14
sg11
Vgastric cancer
p13134
sg13
I2
sasa(dp13135
g2
S'High miR-501-5p levels predicted poor overall survival in gastric cancer patients.\n'
p13136
sg4
(lp13137
(dp13138
g7
I5
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13139
sg13
I1
sasg14
(lp13140
(dp13141
g7
I58
sg17
VC0024623
p13142
sg10
I14
sg11
Vgastric cancer
p13143
sg13
I2
sasa(dp13144
g2
S'Gain-of-function and loss-of-function studies showed that ectopic expression of miR-501-5p enhanced the cancer stem cell-like phenotype in gastric cancer cells.\n'
p13145
sg4
(lp13146
(dp13147
g7
I80
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13148
sg13
I1
sasg14
(lp13149
(dp13150
g7
I104
sg17
VC0006826
p13151
sg10
I6
sg11
Vcancer
p13152
sg13
I1
sa(dp13153
g7
I139
sg17
VC0024623
p13154
sg10
I14
sg11
Vgastric cancer
p13155
sg13
I2
sasa(dp13156
g2
S'Notably,wnt/Beta-catenin signaling was hyperactivated in gastric cancer cells that overexpress miR-501-5p, and mediated miR-501-5p-induced cancer stem cell-like phenotype.\n'
p13157
sg4
(lp13158
(dp13159
g7
I120
sg8
g49
sg10
I40
sg11
VmiR-501-5p-induced cancer stem cell-like
p13160
sg13
I4
sa(dp13161
g7
I95
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13162
sg13
I1
sasg14
(lp13163
(dp13164
g7
I57
sg17
VC0024623
p13165
sg10
I14
sg11
Vgastric cancer
p13166
sg13
I2
sa(dp13167
g7
I65
sg17
VC0006826
p13168
sg10
I6
sg11
Vcancer
p13169
sg13
I1
sasa(dp13170
g2
S'These results demonstrate that miR-501-5p maintains constitutively activated wnt/Beta-catenin signaling by directly targeting DKK1, NKD1 and GSK3Beta, which promotes gastric cancer stem cell like phenotype.\n'
p13171
sg4
(lp13172
(dp13173
g7
I132
sg8
g49
sg10
I4
sg11
VNKD1
p13174
sg13
I1
sa(dp13175
g7
I126
sg8
g49
sg10
I4
sg11
VDKK1
p13176
sg13
I1
sasg14
(lp13177
(dp13178
g7
I166
sg17
VC0024623
p13179
sg10
I14
sg11
Vgastric cancer
p13180
sg13
I2
sasa(dp13181
g2
S'Taken together, our findings reveal a new regulatory mechanism of miR-501-5p and suggest that miR-501-5p might be a potential target in gastric cancer therapy.\n'
p13182
sg4
(lp13183
(dp13184
g7
I66
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13185
sg13
I1
sa(dp13186
g7
I66
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13187
sg13
I1
sasg14
(lp13188
(dp13189
g7
I136
sg17
VC0024623
p13190
sg10
I14
sg11
Vgastric cancer
p13191
sg13
I2
sasa(dp13192
g2
S'Backgroud/Aims: Previous studies have shown that miR-501 is involved in the development of hepatocellular carcinoma (HCC) by promoting cell proliferation through CYLD.\n'
p13193
sg4
(lp13194
(dp13195
g7
I162
sg8
g49
sg10
I4
sg11
VCYLD
p13196
sg13
I1
sa(dp13197
g7
I49
sg8
g49
sg10
I7
sg11
VmiR-501
p13198
sg13
I1
sasg14
(lp13199
(dp13200
g7
I91
sg17
VC2239176
p13201
sg10
I24
sg11
Vhepatocellular carcinoma
p13202
sg13
I2
sa(dp13203
g7
I117
sg17
VC2239176
p13204
sg10
I3
sg11
VHCC
p13205
sg13
I1
sa(dp13206
g7
I140
sg17
VC0334094
p13207
sg10
I13
sg11
Vproliferation
p13208
sg13
I1
sasa(dp13209
g2
S'Previous studies have shown that the micro-ribonucleic acid miR-501-5p is upregulated in hepatocellular carcinoma cells and tissues with high hepatitis B virus replication, and that miR-501 overexpression significantly promotes hepatitis B virus replication.\n'
p13210
sg4
(lp13211
(dp13212
g7
I60
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13213
sg13
I1
sasg14
(lp13214
(dp13215
g7
I142
sg17
VC0019163
p13216
sg10
I11
sg11
Vhepatitis B
p13217
sg13
I2
sa(dp13218
g7
I89
sg17
VC1512411
p13219
sg10
I24
sg11
Vhepatocellular carcinoma
p13220
sg13
I2
sa(dp13221
g7
I142
sg17
VC0019163
p13222
sg10
I11
sg11
Vhepatitis B
p13223
sg13
I2
sasa(dp13224
g2
S'We further analysed a published microarray-based high-throughput dataset (NCBI/GEO/GSE36915) and found that miR-501-5p was upregulated in hepatocellular carcinoma tumour tissues.\n'
p13225
sg4
(lp13226
(dp13227
g7
I108
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13228
sg13
I1
sasg14
(lp13229
(dp13230
g7
I138
sg17
VC1512411
p13231
sg10
I24
sg11
Vhepatocellular carcinoma
p13232
sg13
I2
sa(dp13233
g7
I163
sg17
VC0027651
p13234
sg10
I6
sg11
Vtumour
p13235
sg13
I1
sasa(dp13236
g2
S'We therefore investigated the possible function of miR-501-5p during the development of hepatocellular carcinoma.\n'
p13237
sg4
(lp13238
(dp13239
g7
I51
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13240
sg13
I1
sasg14
(lp13241
(dp13242
g7
I88
sg17
VC1512411
p13243
sg10
I24
sg11
Vhepatocellular carcinoma
p13244
sg13
I2
sasa(dp13245
g2
S'Expression of miR-501-5p in human hepatocellular carcinoma specimens and cell lines was assessed, using real-time polymerase chain reaction.\n'
p13246
sg4
(lp13247
(dp13248
g7
I14
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13249
sg13
I1
sasg14
(lp13250
(dp13251
g7
I34
sg17
VC1512411
p13252
sg10
I24
sg11
Vhepatocellular carcinoma
p13253
sg13
I2
sasa(dp13254
g2
S"MiR-501-5p was upregulated in hepatocellular carcinoma specimens and cell lines, and directly targeted the 3' untranslated region of CYLD.\n"
p13255
sg4
(lp13256
(dp13257
g7
I0
sg8
g49
sg10
I10
sg11
VMiR-501-5p
p13258
sg13
I1
sa(dp13259
g7
I133
sg8
g49
sg10
I4
sg11
VCYLD
p13260
sg13
I1
sasg14
(lp13261
(dp13262
g7
I30
sg17
VC1512411
p13263
sg10
I24
sg11
Vhepatocellular carcinoma
p13264
sg13
I2
sasa(dp13265
g2
S'MiR-501-5p upregulation corresponded with a downregulation of CYLD in the same tissues and cell lines, and overexpression of MiR-501-5p decreased CYLD expression, increased expression of cyclin D1 and c-myc and promoted the proliferation of hepatocellular carcinoma cells in vitro.\n'
p13266
sg4
(lp13267
(dp13268
g7
I0
sg8
g49
sg10
I10
sg11
VMiR-501-5p
p13269
sg13
I1
sa(dp13270
g7
I187
sg8
VP24385
p13271
sg10
I9
sg11
Vcyclin D1
p13272
sg13
I2
sa(dp13273
g7
I0
sg8
g49
sg10
I10
sg11
VMiR-501-5p
p13274
sg13
I1
sa(dp13275
g7
I201
sg8
VP12524
p13276
sg10
I5
sg11
Vc-myc
p13277
sg13
I1
sa(dp13278
g7
I62
sg8
g49
sg10
I4
sg11
VCYLD
p13279
sg13
I1
sa(dp13280
g7
I62
sg8
g49
sg10
I4
sg11
VCYLD
p13281
sg13
I1
sasg14
(lp13282
(dp13283
g7
I241
sg17
VC1512411
p13284
sg10
I24
sg11
Vhepatocellular carcinoma
p13285
sg13
I2
sa(dp13286
g7
I224
sg17
VC0334094
p13287
sg10
I13
sg11
Vproliferation
p13288
sg13
I1
sasa(dp13289
g2
S'This study suggests that miR-501-5p may play an important role in the development of hepatocellular carcinoma by promoting cell proliferation, and indicates that miR-501-5p may represent a novel therapeutic target for hepatocellular carcinoma.\n'
p13290
sg4
(lp13291
(dp13292
g7
I25
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13293
sg13
I1
sa(dp13294
g7
I25
sg8
g49
sg10
I10
sg11
VmiR-501-5p
p13295
sg13
I1
sasg14
(lp13296
(dp13297
g7
I128
sg17
VC0334094
p13298
sg10
I13
sg11
Vproliferation
p13299
sg13
I1
sa(dp13300
g7
I85
sg17
VC1512411
p13301
sg10
I24
sg11
Vhepatocellular carcinoma
p13302
sg13
I2
sa(dp13303
g7
I85
sg17
VC1512411
p13304
sg10
I24
sg11
Vhepatocellular carcinoma
p13305
sg13
I2
sasa(dp13306
g2
S'Here we show that patients with clear cell kidney carcinoma that express low levels of miR501-5p exhibited a good prognosis compared with patients with unchanged or high levels of this microRNA.\n'
p13307
sg4
(lp13308
sg14
(lp13309
(dp13310
g7
I43
sg17
VC0007134
p13311
sg10
I16
sg11
Vkidney carcinoma
p13312
sg13
I2
sasa(dp13313
g2
S'Consistently, in kidney carcinoma cells the downregulation of miR501-5p induced an increased caspase-3 activity, p53 expression as well as decreased mTOR activation, leading to stimulation of the apoptotic pathway.\n'
p13314
sg4
(lp13315
(dp13316
g7
I149
sg8
VP42345
p13317
sg10
I4
sg11
VmTOR
p13318
sg13
I1
sa(dp13319
g7
I93
sg8
VP42574
p13320
sg10
I9
sg11
Vcaspase-3
p13321
sg13
I1
sa(dp13322
g7
I113
sg8
VP42771
p13323
sg10
I3
sg11
Vp53
p13324
sg13
I1
sasg14
(lp13325
(dp13326
g7
I17
sg17
VC0007134
p13327
sg10
I16
sg11
Vkidney carcinoma
p13328
sg13
I2
sasa(dp13329
g2
S'Our results support a role for miR501-5p in balancing apoptosis and cell survival in clear cell renal carcinoma.\n'
p13330
sg4
(lp13331
sg14
(lp13332
(dp13333
g7
I85
sg17
VC0279702
p13334
sg10
I26
sg11
Vclear cell renal carcinoma
p13335
sg13
I4
sasa(dp13336
g2
S'Thus, the expression of miR501-5p is a possible biomarker for the prognosis of clear cell renal carcinoma.\n'
p13337
sg4
(lp13338
sg14
(lp13339
(dp13340
g7
I79
sg17
VC0279702
p13341
sg10
I26
sg11
Vclear cell renal carcinoma
p13342
sg13
I4
sasa(dp13343
g2
S'miR-501 expression was significantly up-regulated in hepatocellular carcinoma tissues, where HBV replication kept high.\n'
p13344
sg4
(lp13345
sg14
(lp13346
(dp13347
g7
I93
sg17
VC0019163
p13348
sg10
I3
sg11
VHBV
p13349
sg13
I1
sa(dp13350
g7
I53
sg17
VC1512411
p13351
sg10
I24
sg11
Vhepatocellular carcinoma
p13352
sg13
I2
sasa(dp13353
g2
S'To assess development of reaching and head stability in infants at very high risk (VHR-infants) of cerebral palsy (CP) who did and did not develop CP.\n'
p13354
sg4
(lp13355
sg14
(lp13356
(dp13357
g7
I115
sg17
VC0007789
p13358
sg10
I2
sg11
VCP
p13359
sg13
I1
sa(dp13360
g7
I99
sg17
VC0007789
p13361
sg10
I14
sg11
Vcerebral palsy
p13362
sg13
I2
sa(dp13363
g7
I115
sg17
VC0007789
p13364
sg10
I2
sg11
VCP
p13365
sg13
I1
sasa(dp13366
g2
S'Infants with cerebral palsy (CP) show a worse reaching quality than VHR-infants without CP.\n'
p13367
sg4
(lp13368
sg14
(lp13369
(dp13370
g7
I13
sg17
VC0007789
p13371
sg10
I14
sg11
Vcerebral palsy
p13372
sg13
I2
sa(dp13373
g7
I29
sg17
VC0007789
p13374
sg10
I2
sg11
VCP
p13375
sg13
I1
sa(dp13376
g7
I29
sg17
VC0007789
p13377
sg10
I2
sg11
VCP
p13378
sg13
I1
sasa(dp13379
g2
S'Following our clinical observation of tonic responses in response to the knee jerk in infants at very high risk for cerebral palsy (VHR infants), we systematically studied tonic responses, clonus, and reflex irradiation.\n'
p13380
sg4
(lp13381
sg14
(lp13382
(dp13383
g7
I189
sg17
VC0009024
p13384
sg10
I6
sg11
Vclonus
p13385
sg13
I1
sa(dp13386
g7
I78
sg17
VC0231530
p13387
sg10
I4
sg11
Vjerk
p13388
sg13
I1
sa(dp13389
g7
I116
sg17
VC0007789
p13390
sg10
I14
sg11
Vcerebral palsy
p13391
sg13
I2
sasa(dp13392
g2
S'The described disorders include (1) hypomagnesemia with secondary hypocalcemia, an earlyonset, autosomal-recessive disease segregating with chromosome 9q12-22.2; (2) autosomal-dominant hypomagnesemia caused by isolated renal magnesium wasting, mapped to chromosome 11q23; (3) hypomagnesemia with hypercalciuria and nephrocalcinosis, a recessive condition caused by a mutation of the claudin 16 gene (3q27) coding for a tight junctional protein that regulates paracellular Mg(2+) transport in the loop of Henle; (4) autosomal-dominant hypoparathyroidism, a variably hypomagnesemic disorder caused by inactivating mutations of the extracellular Ca(2+)/Mg(2+)-sensing receptor, CASR: gene, at 3q13.3-21 (a significant association between common polymorphisms of the CASR: and extracellular Mg(2+) concentration has been demonstrated in a healthy adult population); and (5) Gitelman syndrome, a recessive form of hypomagnesemia caused by mutations in the distal tubular NaCl cotransporter gene, SLC12A3, at 16q13.\n'
p13393
sg4
(lp13394
(dp13395
g7
I675
sg8
VP41180
p13396
sg10
I4
sg11
VCASR
p13397
sg13
I1
sa(dp13398
g7
I991
sg8
VP55017
p13399
sg10
I7
sg11
VSLC12A3
p13400
sg13
I1
sa(dp13401
g7
I383
sg8
g49
sg10
I15
sg11
Vclaudin 16 gene
p13402
sg13
I3
sasg14
(lp13403
(dp13404
g7
I315
sg17
VC0027709
p13405
sg10
I16
sg11
Vnephrocalcinosis
p13406
sg13
I1
sa(dp13407
g7
I345
sg17
VC0012634
p13408
sg10
I9
sg11
Vcondition
p13409
sg13
I1
sa(dp13410
g7
I534
sg17
VC0020626
p13411
sg10
I18
sg11
Vhypoparathyroidism
p13412
sg13
I1
sa(dp13413
g7
I296
sg17
VC0020438
p13414
sg10
I14
sg11
Vhypercalciuria
p13415
sg13
I1
sa(dp13416
g7
I36
sg17
VC1865974
p13417
sg10
I42
sg11
Vhypomagnesemia with secondary hypocalcemia
p13418
sg13
I4
sa(dp13419
g7
I219
sg17
VC1835171
p13420
sg10
I23
sg11
Vrenal magnesium wasting
p13421
sg13
I3
sa(dp13422
g7
I870
sg17
VC0268450
p13423
sg10
I17
sg11
VGitelman syndrome
p13424
sg13
I2
sasa(dp13425
g2
S'Here, we focus on functional differences and individual contribution of acyl coA synthetases (ACSL) isoforms to the previously described ACSL/stearoyl-CoA desaturase (ACSL1/ACSL4/SCD) metabolic network causing invasion and poor prognosis in colorectal cancer (CRC).\n'
p13426
sg4
(lp13427
(dp13428
g7
I179
sg8
g49
sg10
I3
sg11
VSCD
p13429
sg13
I1
sa(dp13430
g7
I167
sg8
VP33121
p13431
sg10
I5
sg11
VACSL1
p13432
sg13
I1
sa(dp13433
g7
I72
sg8
g49
sg10
I20
sg11
Vacyl coA synthetases
p13434
sg13
I3
sa(dp13435
g7
I142
sg8
g49
sg10
I23
sg11
Vstearoyl-CoA desaturase
p13436
sg13
I2
sa(dp13437
g7
I173
sg8
g49
sg10
I5
sg11
VACSL4
p13438
sg13
I1
sasg14
(lp13439
(dp13440
g7
I260
sg17
VC1527249
p13441
sg10
I3
sg11
VCRC
p13442
sg13
I1
sa(dp13443
g7
I241
sg17
VC1527249
p13444
sg10
I17
sg11
Vcolorectal cancer
p13445
sg13
I2
sa(dp13446
g7
I179
sg17
VC0002895
p13447
sg10
I3
sg11
VSCD
p13448
sg13
I1
sa(dp13449
g7
I210
sg17
VC2699153
p13450
sg10
I8
sg11
Vinvasion
p13451
sg13
I1
sa(dp13452
g7
I77
sg17
VC2678439
p13453
sg10
I3
sg11
VcoA
p13454
sg13
I1
sa(dp13455
g7
I151
sg17
VC2678439
p13456
sg10
I3
sg11
VCoA
p13457
sg13
I1
sasa(dp13458
g2
S'The purpose of the present study was to explore the relationship between ACSL4 expression level and clinical prognosis of hepatocellular carcinoma (HCC) patients.\n'
p13459
sg4
(lp13460
(dp13461
g7
I73
sg8
g49
sg10
I5
sg11
VACSL4
p13462
sg13
I1
sasg14
(lp13463
(dp13464
g7
I148
sg17
VC2239176
p13465
sg10
I3
sg11
VHCC
p13466
sg13
I1
sa(dp13467
g7
I122
sg17
VC2239176
p13468
sg10
I24
sg11
Vhepatocellular carcinoma
p13469
sg13
I2
sasa(dp13470
g2
S'High ACSL4 expression has been observed in aggressive breast cancer phenotype.\n'
p13471
sg4
(lp13472
(dp13473
g7
I5
sg8
g49
sg10
I5
sg11
VACSL4
p13474
sg13
I1
sasg14
(lp13475
(dp13476
g7
I54
sg17
VC0678222
p13477
sg10
I13
sg11
Vbreast cancer
p13478
sg13
I2
sa(dp13479
g7
I43
sg17
VC0001807
p13480
sg10
I10
sg11
Vaggressive
p13481
sg13
I1
sasa(dp13482
g2
S'These results suggest that ACSL1, ACSL4 and ACSL5 expression is regulated by ER signaling pathways and ACSL5 is a potential novel biomarker for predicting prognosis of breast cancer patients.\n'
p13483
sg4
(lp13484
(dp13485
g7
I34
sg8
g49
sg10
I5
sg11
VACSL4
p13486
sg13
I1
sa(dp13487
g7
I44
sg8
g49
sg10
I5
sg11
VACSL5
p13488
sg13
I1
sa(dp13489
g7
I44
sg8
g49
sg10
I5
sg11
VACSL5
p13490
sg13
I1
sa(dp13491
g7
I27
sg8
VP33121
p13492
sg10
I5
sg11
VACSL1
p13493
sg13
I1
sasg14
(lp13494
(dp13495
g7
I168
sg17
VC0678222
p13496
sg10
I13
sg11
Vbreast cancer
p13497
sg13
I2
sasa(dp13498
g2
S'Long chain acyl-CoA synthase-4 (ACSL4) expression has been associated with an aggressive phenotype in breast carcinoma cells, whereas its role in ERAlfa-positive breast cancer has not been studied.\n'
p13499
sg4
(lp13500
(dp13501
g7
I32
sg8
g49
sg10
I5
sg11
VACSL4
p13502
sg13
I1
sa(dp13503
g7
I11
sg8
g49
sg10
I19
sg11
Vacyl-CoA synthase-4
p13504
sg13
I2
sasg14
(lp13505
(dp13506
g7
I16
sg17
VC2678439
p13507
sg10
I3
sg11
VCoA
p13508
sg13
I1
sa(dp13509
g7
I78
sg17
VC0001807
p13510
sg10
I10
sg11
Vaggressive
p13511
sg13
I1
sa(dp13512
g7
I102
sg17
VC0678222
p13513
sg10
I16
sg11
Vbreast carcinoma
p13514
sg13
I2
sa(dp13515
g7
I162
sg17
VC0678222
p13516
sg10
I13
sg11
Vbreast cancer
p13517
sg13
I2
sasa(dp13518
g2
S'Taken together, these results demonstrate that ACSL4 is a target of 17Beta-estradiol-stimulated ERAlfa and is required for the cellular uptake of exogenous PUFA and the manifestation of a more malignant phenotype in ERAlfa+ve breast carcinoma cells.\n'
p13519
sg4
(lp13520
(dp13521
g7
I47
sg8
g49
sg10
I5
sg11
VACSL4
p13522
sg13
I1
sasg14
(lp13523
(dp13524
g7
I226
sg17
VC0678222
p13525
sg10
I16
sg11
Vbreast carcinoma
p13526
sg13
I2
sasa(dp13527
g2
S'Here, we show that acyl-CoA synthetase long-chain family member 4 (ACSL4) is required for ferroptotic cancer cell death.\n'
p13528
sg4
(lp13529
(dp13530
g7
I67
sg8
g49
sg10
I5
sg11
VACSL4
p13531
sg13
I1
sa(dp13532
g7
I19
sg8
g49
sg10
I46
sg11
Vacyl-CoA synthetase long-chain family member 4
p13533
sg13
I6
sasg14
(lp13534
(dp13535
g7
I24
sg17
VC2678439
p13536
sg10
I3
sg11
VCoA
p13537
sg13
I1
sa(dp13538
g7
I102
sg17
VC0006826
p13539
sg10
I6
sg11
Vcancer
p13540
sg13
I1
sasa(dp13541
g2
S'High expression of ACSL4 predicted a worse prognosis in colorectal cancer, but predicted better prognosis in breast, brain and lung cancer.\n'
p13542
sg4
(lp13543
(dp13544
g7
I19
sg8
g49
sg10
I5
sg11
VACSL4
p13545
sg13
I1
sasg14
(lp13546
(dp13547
g7
I56
sg17
VC1527249
p13548
sg10
I17
sg11
Vcolorectal cancer
p13549
sg13
I2
sa(dp13550
g7
I127
sg17
VC0684249
p13551
sg10
I11
sg11
Vlung cancer
p13552
sg13
I2
sasa(dp13553
g2
S'Mutations in SPG4/SPAST are the most frequent molecular aetiology in the autosomal dominant form of hereditary spastic paraplegia (HSP).\n'
p13554
sg4
(lp13555
(dp13556
g7
I18
sg8
g49
sg10
I5
sg11
VSPAST
p13557
sg13
I1
sa(dp13558
g7
I13
sg8
g49
sg10
I4
sg11
VSPG4
p13559
sg13
I1
sasg14
(lp13560
(dp13561
g7
I131
sg17
VC0034152
p13562
sg10
I3
sg11
VHSP
p13563
sg13
I1
sa(dp13564
g7
I13
sg17
VC1866855
p13565
sg10
I4
sg11
VSPG4
p13566
sg13
I1
sa(dp13567
g7
I100
sg17
VC0037773
p13568
sg10
I29
sg11
Vhereditary spastic paraplegia
p13569
sg13
I3
sasa(dp13570
g2
S'Our study demonstrated further evidence of allelic heterogeneity in SPG4, dosage effects through NMD, and broad clinical features of the SPAST mutation.\n'
p13571
sg4
(lp13572
(dp13573
g7
I68
sg8
g49
sg10
I4
sg11
VSPG4
p13574
sg13
I1
sa(dp13575
g7
I137
sg8
g49
sg10
I5
sg11
VSPAST
p13576
sg13
I1
sasg14
(lp13577
(dp13578
g7
I68
sg17
VC1866855
p13579
sg10
I4
sg11
VSPG4
p13580
sg13
I1
sasa(dp13581
g2
S'Mutations of the SPAST (SPG4) gene coding for the spastin protein account for 40% of all autosomal dominant uncomplicated HSP.\n'
p13582
sg4
(lp13583
(dp13584
g7
I50
sg8
g49
sg10
I15
sg11
Vspastin protein
p13585
sg13
I2
sa(dp13586
g7
I24
sg8
g49
sg10
I4
sg11
VSPG4
p13587
sg13
I1
sa(dp13588
g7
I17
sg8
g49
sg10
I5
sg11
VSPAST
p13589
sg13
I1
sasg14
(lp13590
(dp13591
g7
I24
sg17
VC1866855
p13592
sg10
I4
sg11
VSPG4
p13593
sg13
I1
sa(dp13594
g7
I122
sg17
VC0034152
p13595
sg10
I3
sg11
VHSP
p13596
sg13
I1
sasa(dp13597
g2
S'Human skin fibroblasts were isolated from a 40-year-old hereditary spastic paraplegia patient carrying an intronic splice site mutation (c.1687+2T&gt;A) in SPAST, leading to hereditary spastic paraplegia type 4 (SPG4).\n'
p13598
sg4
(lp13599
sg14
(lp13600
(dp13601
g7
I212
sg17
VC1866855
p13602
sg10
I4
sg11
VSPG4
p13603
sg13
I1
sa(dp13604
g7
I185
sg17
VC1866855
p13605
sg10
I25
sg11
Vspastic paraplegia type 4
p13606
sg13
I4
sa(dp13607
g7
I56
sg17
VC0037773
p13608
sg10
I29
sg11
Vhereditary spastic paraplegia
p13609
sg13
I3
sa(dp13610
g7
I56
sg17
VC0037773
p13611
sg10
I29
sg11
Vhereditary spastic paraplegia
p13612
sg13
I3
sasa(dp13613
g2
S'Hereditary spastic paraplegias (HSPs; SPG1-76 plus others) are length-dependent disorders affecting long corticospinal axons, and the most common autosomal dominant forms are caused by mutations in genes that encode the spastin (SPG4), atlastin-1 (SPG3A) and REEP1 (SPG31) proteins.\n'
p13614
sg4
(lp13615
(dp13616
g7
I236
sg8
g49
sg10
I10
sg11
Vatlastin-1
p13617
sg13
I1
sa(dp13618
g7
I38
sg8
VP32004
p13619
sg10
I7
sg11
VSPG1-76
p13620
sg13
I1
sa(dp13621
g7
I266
sg8
g49
sg10
I5
sg11
VSPG31
p13622
sg13
I1
sa(dp13623
g7
I229
sg8
g49
sg10
I4
sg11
VSPG4
p13624
sg13
I1
sa(dp13625
g7
I259
sg8
g49
sg10
I5
sg11
VREEP1
p13626
sg13
I1
sa(dp13627
g7
I248
sg8
g49
sg10
I5
sg11
VSPG3A
p13628
sg13
I1
sa(dp13629
g7
I220
sg8
g49
sg10
I7
sg11
Vspastin
p13630
sg13
I1
sasg14
(lp13631
(dp13632
g7
I32
sg17
VC0037773
p13633
sg10
I4
sg11
VHSPs
p13634
sg13
I1
sa(dp13635
g7
I38
sg17
VC0795953
p13636
sg10
I4
sg11
VSPG1
p13637
sg13
I1
sa(dp13638
g7
I0
sg17
VC0037773
p13639
sg10
I30
sg11
VHereditary spastic paraplegias
p13640
sg13
I3
sa(dp13641
g7
I266
sg17
VC1853247
p13642
sg10
I5
sg11
VSPG31
p13643
sg13
I1
sa(dp13644
g7
I229
sg17
VC1866855
p13645
sg10
I4
sg11
VSPG4
p13646
sg13
I1
sa(dp13647
g7
I248
sg17
VC2931355
p13648
sg10
I5
sg11
VSPG3A
p13649
sg13
I1
sasa(dp13650
g2
S'Our data confirm the genetic heterogeneity of childhood-onset pure HSP, with SPG4/SPAST and SPG3A/ATL1 being the most frequent forms.\n'
p13651
sg4
(lp13652
(dp13653
g7
I77
sg8
g49
sg10
I4
sg11
VSPG4
p13654
sg13
I1
sa(dp13655
g7
I98
sg8
g49
sg10
I4
sg11
VATL1
p13656
sg13
I1
sa(dp13657
g7
I92
sg8
g49
sg10
I5
sg11
VSPG3A
p13658
sg13
I1
sa(dp13659
g7
I82
sg8
g49
sg10
I5
sg11
VSPAST
p13660
sg13
I1
sasg14
(lp13661
(dp13662
g7
I67
sg17
VC0034152
p13663
sg10
I3
sg11
VHSP
p13664
sg13
I1
sa(dp13665
g7
I77
sg17
VC1866855
p13666
sg10
I4
sg11
VSPG4
p13667
sg13
I1
sa(dp13668
g7
I92
sg17
VC2931355
p13669
sg10
I5
sg11
VSPG3A
p13670
sg13
I1
sasa(dp13671
g2
S'Loss-of-function mutation of the SPAST gene, also known as SPG4, is the most common cause of HSP in patients.\n'
p13672
sg4
(lp13673
(dp13674
g7
I33
sg8
g49
sg10
I10
sg11
VSPAST gene
p13675
sg13
I2
sa(dp13676
g7
I59
sg8
g49
sg10
I4
sg11
VSPG4
p13677
sg13
I1
sasg14
(lp13678
(dp13679
g7
I93
sg17
VC0034152
p13680
sg10
I3
sg11
VHSP
p13681
sg13
I1
sa(dp13682
g7
I59
sg17
VC1866855
p13683
sg10
I4
sg11
VSPG4
p13684
sg13
I1
sasa(dp13685
g2
S'Thus, Tau mediated mislocalization of TTLL6 and spastin activation reveals a pathological gain of function for Tau and spastin in this cellular model system of AD.In contrast, in hereditary spastic paraplegia (HSP) caused by mutations of the gene encoding spastin (spg4 alias SPAST), spastin function in terms of microtubule severing is decreased at least for the gene product of the mutated allele, resulting in overstable microtubules in disease model systems.\n'
p13686
sg4
(lp13687
(dp13688
g7
I242
sg8
g49
sg10
I21
sg11
Vgene encoding spastin
p13689
sg13
I3
sa(dp13690
g7
I48
sg8
g49
sg10
I7
sg11
Vspastin
p13691
sg13
I1
sa(dp13692
g7
I48
sg8
g49
sg10
I7
sg11
Vspastin
p13693
sg13
I1
sa(dp13694
g7
I265
sg8
g49
sg10
I16
sg11
Vspg4 alias SPAST
p13695
sg13
I3
sa(dp13696
g7
I48
sg8
g49
sg10
I7
sg11
Vspastin
p13697
sg13
I1
sa(dp13698
g7
I6
sg8
VP49768
p13699
sg10
I3
sg11
VTau
p13700
sg13
I1
sa(dp13701
g7
I6
sg8
VP49768
p13702
sg10
I3
sg11
VTau
p13703
sg13
I1
sasg14
(lp13704
(dp13705
g7
I265
sg17
VC1866855
p13706
sg10
I4
sg11
Vspg4
p13707
sg13
I1
sa(dp13708
g7
I210
sg17
VC0034152
p13709
sg10
I3
sg11
VHSP
p13710
sg13
I1
sa(dp13711
g7
I179
sg17
VC0037773
p13712
sg10
I29
sg11
Vhereditary spastic paraplegia
p13713
sg13
I3
sasa(dp13714
g2
S'Three genetic types, SPG3 (ATL1), SPG4 (SPAST) and SPG31 (REEP1), appear predominantly and may account for up to 50% of autosomal dominant hereditary spastic paraplegias (AD-HSPs).\n'
p13715
sg4
(lp13716
(dp13717
g7
I120
sg8
VP08107
p13718
sg10
I49
sg11
Vautosomal dominant hereditary spastic paraplegias
p13719
sg13
I5
sa(dp13720
g7
I34
sg8
g49
sg10
I4
sg11
VSPG4
p13721
sg13
I1
sa(dp13722
g7
I27
sg8
g49
sg10
I4
sg11
VATL1
p13723
sg13
I1
sa(dp13724
g7
I58
sg8
g49
sg10
I5
sg11
VREEP1
p13725
sg13
I1
sa(dp13726
g7
I21
sg8
g49
sg10
I4
sg11
VSPG3
p13727
sg13
I1
sa(dp13728
g7
I51
sg8
g49
sg10
I5
sg11
VSPG31
p13729
sg13
I1
sa(dp13730
g7
I40
sg8
g49
sg10
I5
sg11
VSPAST
p13731
sg13
I1
sa(dp13732
g7
I171
sg8
VP08107
p13733
sg10
I7
sg11
VAD-HSPs
p13734
sg13
I1
sasg14
(lp13735
(dp13736
g7
I139
sg17
VC0037773
p13737
sg10
I30
sg11
Vhereditary spastic paraplegias
p13738
sg13
I3
sa(dp13739
g7
I21
sg17
VC2931355
p13740
sg10
I4
sg11
VSPG3
p13741
sg13
I1
sa(dp13742
g7
I34
sg17
VC1866855
p13743
sg10
I4
sg11
VSPG4
p13744
sg13
I1
sa(dp13745
g7
I51
sg17
VC1853247
p13746
sg10
I5
sg11
VSPG31
p13747
sg13
I1
sasa(dp13748
g2
S'This phase was aimed at pre-qualifying the candidate BRP (cBRP) and at documenting the impact of differences in the antibody detection methodology enzyme linked immunosorbent assay (ELISA) procedures on results of pertussis antisera calibration versus the currently used standard US standard pertussis antiserum (mouse) Lot 1 (SPAM-1) (United States Food and Drug Administration (USFDA) reference serum) and the cBRP.\n'
p13749
sg4
(lp13750
(dp13751
g7
I320
sg8
g49
sg10
I5
sg11
VLot 1
p13752
sg13
I2
sa(dp13753
g7
I53
sg8
g49
sg10
I3
sg11
VBRP
p13754
sg13
I1
sa(dp13755
g7
I214
sg8
VP00966
p13756
sg10
I18
sg11
Vpertussis antisera
p13757
sg13
I2
sasg14
(lp13758
(dp13759
g7
I214
sg17
VC0043167
p13760
sg10
I9
sg11
Vpertussis
p13761
sg13
I1
sa(dp13762
g7
I214
sg17
VC0043167
p13763
sg10
I9
sg11
Vpertussis
p13764
sg13
I1
sasa(dp13765
g2
S'Calibration of the proposed International Reference Reagent of Pertussis Antiserum (pIRR) in terms of US Lot 1 gives results which are broadly consistent between laboratories for antibodies to each antigen, although the between-laboratory differences are larger than those seen for comparison of identical sera.\n'
p13766
sg4
(lp13767
(dp13768
g7
I102
sg8
g49
sg10
I8
sg11
VUS Lot 1
p13769
sg13
I3
sasg14
(lp13770
(dp13771
g7
I63
sg17
VC0043167
p13772
sg10
I9
sg11
VPertussis
p13773
sg13
I1
sasa(dp13774
g2
S'It was therefore recommended, with the agreement of all participants, that the preparation in vials coded 97/642 be established as the First International Reference Reagent for Pertussis Antiserum, mouse, with assigned unitages 16 units of anti-PT per vial, 143 units of anti-FHA per vial and 30 units of anti-PRN per vial based on its calibration in terms of US Lot 1.\n'
p13775
sg4
(lp13776
(dp13777
g7
I305
sg8
g49
sg10
I8
sg11
Vanti-PRN
p13778
sg13
I1
sasg14
(lp13779
(dp13780
g7
I177
sg17
VC0043167
p13781
sg10
I9
sg11
VPertussis
p13782
sg13
I1
sa(dp13783
g7
I276
sg17
VC1704429
p13784
sg10
I3
sg11
VFHA
p13785
sg13
I1
sasa(dp13786
g2
S'The right exotropia increased to 30 PD 2 months after surgery.\n'
p13787
sg4
(lp13788
sg14
(lp13789
(dp13790
g7
I10
sg17
VC0015310
p13791
sg10
I9
sg11
Vexotropia
p13792
sg13
I1
sasa(dp13793
g2
S'Finally, the levels of sCD40Lwere significantly increased in serum of children both with steroid-sensitive and steroid-resistant nephrotic syndrome (NS), and in adult patients with biopsy-proven FSGS, compared to healthy subjects, but neither in children with congenital NS nor in patients with membranous nephropathy.\n'
p13794
sg4
(lp13795
sg14
(lp13796
(dp13797
g7
I149
sg17
VC0403397
p13798
sg10
I2
sg11
VNS
p13799
sg13
I1
sa(dp13800
g7
I295
sg17
VC0017665
p13801
sg10
I22
sg11
Vmembranous nephropathy
p13802
sg13
I2
sa(dp13803
g7
I111
sg17
VC0403397
p13804
sg10
I36
sg11
Vsteroid-resistant nephrotic syndrome
p13805
sg13
I3
sa(dp13806
g7
I149
sg17
VC0403397
p13807
sg10
I2
sg11
VNS
p13808
sg13
I1
sasa(dp13809
g2
S'Of the 64 patients, 17 were mesangial proliferative glomerulonephritis (MsPGN), 15 were IgA nephropathy (IgAN), 12 were membranous glomerulonephritis (MGN), 11 were focal segmental glomerulosclerosis (FSGS), three were membranous proliferative glomerulonephritis (MPGN), three were immune complex glomerulonephritis (ICGN), two were minimal change disease (MCD), and one was IgM nephropathy (IgMN).\n'
p13810
sg4
(lp13811
(dp13812
g7
I105
sg8
VP11912
p13813
sg10
I4
sg11
VIgAN
p13814
sg13
I1
sa(dp13815
g7
I392
sg8
VP29965
p13816
sg10
I4
sg11
VIgMN
p13817
sg13
I1
sa(dp13818
g7
I88
sg8
VP11912
p13819
sg10
I15
sg11
VIgA nephropathy
p13820
sg13
I2
sa(dp13821
g7
I375
sg8
VP29965
p13822
sg10
I15
sg11
VIgM nephropathy
p13823
sg13
I2
sasg14
(lp13824
(dp13825
g7
I317
sg17
VC0744421
p13826
sg10
I4
sg11
VICGN
p13827
sg13
I1
sa(dp13828
g7
I120
sg17
VC0017665
p13829
sg10
I29
sg11
Vmembranous glomerulonephritis
p13830
sg13
I2
sa(dp13831
g7
I357
sg17
VC1636149
p13832
sg10
I3
sg11
VMCD
p13833
sg13
I1
sa(dp13834
g7
I333
sg17
VC1704320
p13835
sg10
I22
sg11
Vminimal change disease
p13836
sg13
I3
sa(dp13837
g7
I165
sg17
VC0017668
p13838
sg10
I34
sg11
Vfocal segmental glomerulosclerosis
p13839
sg13
I3
sa(dp13840
g7
I392
sg17
VC0403433
p13841
sg10
I4
sg11
VIgMN
p13842
sg13
I1
sa(dp13843
g7
I201
sg17
VC0017668
p13844
sg10
I4
sg11
VFSGS
p13845
sg13
I1
sa(dp13846
g7
I105
sg17
VC0017661
p13847
sg10
I4
sg11
VIgAN
p13848
sg13
I1
sa(dp13849
g7
I151
sg17
VC0017665
p13850
sg10
I3
sg11
VMGN
p13851
sg13
I1
sa(dp13852
g7
I219
sg17
VC0017662
p13853
sg10
I43
sg11
Vmembranous proliferative glomerulonephritis
p13854
sg13
I3
sa(dp13855
g7
I88
sg17
VC0017661
p13856
sg10
I15
sg11
VIgA nephropathy
p13857
sg13
I2
sa(dp13858
g7
I282
sg17
VC0744421
p13859
sg10
I33
sg11
Vimmune complex glomerulonephritis
p13860
sg13
I3
sa(dp13861
g7
I28
sg17
VC0221238
p13862
sg10
I42
sg11
Vmesangial proliferative glomerulonephritis
p13863
sg13
I3
sa(dp13864
g7
I264
sg17
VC0017662
p13865
sg10
I4
sg11
VMPGN
p13866
sg13
I1
sa(dp13867
g7
I375
sg17
VC0403433
p13868
sg10
I15
sg11
VIgM nephropathy
p13869
sg13
I2
sa(dp13870
g7
I72
sg17
VC0221238
p13871
sg10
I5
sg11
VMsPGN
p13872
sg13
I1
sasa(dp13873
g2
S'There was a wide variation in kidney pathology, some directly related to the WM: amyloidosis (n = 11, 25%), monoclonal-IgM deposition disease/cryoglobulinaemia (n = 10, 23%), lymphoplasmacytic lymphoma infiltration (n = 8, 18%), light-chain deposition disease (n = 4, 9%) and light-chain cast nephropathy (n = 4, 9%), and some probably related to the WM: thrombotic microangiopathy (TMA) (n = 3, 7%), minimal change disease (n = 2, 5%), membranous nephropathy (n = 1, 2%) and crystal-storing tubulopathy (n = 1, 2%).\n'
p13874
sg4
(lp13875
(dp13876
g7
I119
sg8
VP29965
p13877
sg10
I3
sg11
VIgM
p13878
sg13
I1
sasg14
(lp13879
(dp13880
g7
I81
sg17
VC0002726
p13881
sg10
I11
sg11
Vamyloidosis
p13882
sg13
I1
sa(dp13883
g7
I293
sg17
VC0022658
p13884
sg10
I11
sg11
Vnephropathy
p13885
sg13
I1
sa(dp13886
g7
I383
sg17
VC2717961
p13887
sg10
I3
sg11
VTMA
p13888
sg13
I1
sa(dp13889
g7
I37
sg17
VC0677042
p13890
sg10
I9
sg11
Vpathology
p13891
sg13
I1
sa(dp13892
g7
I437
sg17
VC0017665
p13893
sg10
I22
sg11
Vmembranous nephropathy
p13894
sg13
I2
sa(dp13895
g7
I175
sg17
VC0024419
p13896
sg10
I26
sg11
Vlymphoplasmacytic lymphoma
p13897
sg13
I2
sa(dp13898
g7
I355
sg17
VC2717961
p13899
sg10
I26
sg11
Vthrombotic microangiopathy
p13900
sg13
I2
sa(dp13901
g7
I142
sg17
VC0010403
p13902
sg10
I17
sg11
Vcryoglobulinaemia
p13903
sg13
I1
sa(dp13904
g7
I202
sg17
VC0332448
p13905
sg10
I12
sg11
Vinfiltration
p13906
sg13
I1
sa(dp13907
g7
I401
sg17
VC1704320
p13908
sg10
I22
sg11
Vminimal change disease
p13909
sg13
I3
sasa(dp13910
g2
S'Primary GN included mesangial proliferative GN (MePGN), IgM nephropathy, focal segmental glomerulosclerosis, minimal change disease, IgA nephropathy, membranoproliferative GN, membranous nephropathy, crescentic GN, and post-infectious GN.\n'
p13911
sg4
(lp13912
(dp13913
g7
I56
sg8
VP29965
p13914
sg10
I3
sg11
VIgM
p13915
sg13
I1
sa(dp13916
g7
I133
sg8
VP11912
p13917
sg10
I3
sg11
VIgA
p13918
sg13
I1
sasg14
(lp13919
(dp13920
g7
I56
sg17
VC0403433
p13921
sg10
I15
sg11
VIgM nephropathy
p13922
sg13
I2
sa(dp13923
g7
I224
sg17
VC0009450
p13924
sg10
I10
sg11
Vinfectious
p13925
sg13
I1
sa(dp13926
g7
I109
sg17
VC1704320
p13927
sg10
I22
sg11
Vminimal change disease
p13928
sg13
I3
sa(dp13929
g7
I176
sg17
VC0017665
p13930
sg10
I22
sg11
Vmembranous nephropathy
p13931
sg13
I2
sa(dp13932
g7
I30
sg17
VC0334094
p13933
sg10
I13
sg11
Vproliferative
p13934
sg13
I1
sa(dp13935
g7
I133
sg17
VC0017661
p13936
sg10
I15
sg11
VIgA nephropathy
p13937
sg13
I2
sa(dp13938
g7
I73
sg17
VC0017668
p13939
sg10
I34
sg11
Vfocal segmental glomerulosclerosis
p13940
sg13
I3
sasa(dp13941
g2
S'Recombination with DXS84 and DXS164 places CLS distal to DMD in Xp21-pter.\n'
p13942
sg4
(lp13943
(dp13944
g7
I29
sg8
VP11532
p13945
sg10
I6
sg11
VDXS164
p13946
sg13
I1
sasg14
(lp13947
(dp13948
g7
I43
sg17
VC0265252
p13949
sg10
I3
sg11
VCLS
p13950
sg13
I1
sa(dp13951
g7
I57
sg17
VC0013264
p13952
sg10
I3
sg11
VDMD
p13953
sg13
I1
sasa(dp13954
g2
S'Knocking down the expression of Beclin 1 efficiently suppressed autophagosome and autolysosome accumulation, and abolished the protective effects of spermidine against STS-induced neurotoxicity.\n'
p13955
sg4
(lp13956
(dp13957
g7
I32
sg8
g49
sg10
I8
sg11
VBeclin 1
p13958
sg13
I2
sasg14
(lp13959
(dp13960
g7
I168
sg17
VC0079588
p13961
sg10
I3
sg11
VSTS
p13962
sg13
I1
sasa(dp13963
g2
S'We further found the association between PYK2, S6K1, and AR in their protein expression and phosphorylation levels among normal prostate PZ-HPV-7 cells and prostate cancer LNCaP and 22Rv1 cells.\n'
p13964
sg4
(lp13965
(dp13966
g7
I41
sg8
g49
sg10
I4
sg11
VPYK2
p13967
sg13
I1
sasg14
(lp13968
(dp13969
g7
I156
sg17
VC0600139
p13970
sg10
I15
sg11
Vprostate cancer
p13971
sg13
I2
sasa(dp13972
g2
S'Since NDRG1 impacts oncogenic signaling pathways interfering with tumor progression, we suggest that the Pyk2-NDRG1 axis is possibly involved in conveying the anti-proliferative effect of Beta-ionone in prostate cancer cells.\n'
p13973
sg4
(lp13974
(dp13975
g7
I6
sg8
g49
sg10
I5
sg11
VNDRG1
p13976
sg13
I1
sa(dp13977
g7
I105
sg8
g49
sg10
I4
sg11
VPyk2
p13978
sg13
I1
sa(dp13979
g7
I6
sg8
g49
sg10
I5
sg11
VNDRG1
p13980
sg13
I1
sasg14
(lp13981
(dp13982
g7
I164
sg17
VC0334094
p13983
sg10
I13
sg11
Vproliferative
p13984
sg13
I1
sa(dp13985
g7
I203
sg17
VC0600139
p13986
sg10
I15
sg11
Vprostate cancer
p13987
sg13
I2
sa(dp13988
g7
I66
sg17
VC0178874
p13989
sg10
I17
sg11
Vtumor progression
p13990
sg13
I2
sasa(dp13991
g2
S'With gemcitabine, folate-G5-PAMAM-D delivered PSMAe/p-TK-Cx43 (folate-G5-PAMAM-D/PSMAe/p-TK-Cx43) significantly decreased prostate cancer LNCaP cell proliferation and promoted apoptosis in vitro.\n'
p13992
sg4
(lp13993
(dp13994
g7
I46
sg8
VP29401
p13995
sg10
I10
sg11
VPSMAe/p-TK
p13996
sg13
I1
sa(dp13997
g7
I52
sg8
VP29401
p13998
sg10
I9
sg11
Vp-TK-Cx43
p13999
sg13
I1
sa(dp14000
g7
I57
sg8
VP17302
p14001
sg10
I4
sg11
VCx43
p14002
sg13
I1
sasg14
(lp14003
(dp14004
g7
I122
sg17
VC0600139
p14005
sg10
I15
sg11
Vprostate cancer
p14006
sg13
I2
sa(dp14007
g7
I149
sg17
VC0334094
p14008
sg10
I13
sg11
Vproliferation
p14009
sg13
I1
sasa(dp14010
g2
S'(1) Our objective was to demonstrate tumor growth inhibition by PF-562,271, a selective inhibitor of FAK and FAK2, or Pyk2,(2) in mouse xenograft models, both subcutaneous and metastatic, employing the human prostate cancer cell line PC3M-luc-C6, a modified PC3M cell line that expresses luciferase.\n'
p14011
sg4
(lp14012
(dp14013
g7
I109
sg8
g49
sg10
I4
sg11
VFAK2
p14014
sg13
I1
sa(dp14015
g7
I101
sg8
g49
sg10
I3
sg11
VFAK
p14016
sg13
I1
sa(dp14017
g7
I118
sg8
g49
sg10
I4
sg11
VPyk2
p14018
sg13
I1
sasg14
(lp14019
(dp14020
g7
I208
sg17
VC0600139
p14021
sg10
I15
sg11
Vprostate cancer
p14022
sg13
I2
sa(dp14023
g7
I37
sg17
VC0598934
p14024
sg10
I12
sg11
Vtumor growth
p14025
sg13
I2
sasa(dp14026
g2
S'Pyk2 expression inversely correlates with malignancy of prostate cancer.\n'
p14027
sg4
(lp14028
(dp14029
g7
I0
sg8
g49
sg10
I4
sg11
VPyk2
p14030
sg13
I1
sasg14
(lp14031
(dp14032
g7
I56
sg17
VC0600139
p14033
sg10
I15
sg11
Vprostate cancer
p14034
sg13
I2
sa(dp14035
g7
I42
sg17
VC0006826
p14036
sg10
I10
sg11
Vmalignancy
p14037
sg13
I1
sasa(dp14038
g2
S'Therefore, our results indicate that RhoC promotes tumor metastasis in prostate cancer by sequential activation of Pyk2, FAK, MAPK, and Akt followed by the up-regulation of MMP2 and MMP9, which results in the stimulation of invasiveness of tumor cells.\n'
p14039
sg4
(lp14040
(dp14041
g7
I121
sg8
g49
sg10
I3
sg11
VFAK
p14042
sg13
I1
sa(dp14043
g7
I126
sg8
VP53779
p14044
sg10
I4
sg11
VMAPK
p14045
sg13
I1
sa(dp14046
g7
I173
sg8
VP08253
p14047
sg10
I4
sg11
VMMP2
p14048
sg13
I1
sa(dp14049
g7
I37
sg8
VP08134
p14050
sg10
I4
sg11
VRhoC
p14051
sg13
I1
sa(dp14052
g7
I115
sg8
g49
sg10
I4
sg11
VPyk2
p14053
sg13
I1
sa(dp14054
g7
I136
sg8
g49
sg10
I3
sg11
VAkt
p14055
sg13
I1
sa(dp14056
g7
I182
sg8
VP14780
p14057
sg10
I4
sg11
VMMP9
p14058
sg13
I1
sasg14
(lp14059
(dp14060
g7
I51
sg17
VC0027651
p14061
sg10
I5
sg11
Vtumor
p14062
sg13
I1
sa(dp14063
g7
I71
sg17
VC0600139
p14064
sg10
I15
sg11
Vprostate cancer
p14065
sg13
I2
sa(dp14066
g7
I51
sg17
VC0027627
p14067
sg10
I16
sg11
Vtumor metastasis
p14068
sg13
I2
sasa(dp14069
g2
S'Additionally, anti-CD132 mAb treatment of established chronic GVHD reversed liver and lung fibrosis, and pulmonary dysfunction characteristic of bronchiolitis obliterans.\n'
p14070
sg4
(lp14071
(dp14072
g7
I14
sg8
VP31785
p14073
sg10
I14
sg11
Vanti-CD132 mAb
p14074
sg13
I2
sasg14
(lp14075
(dp14076
g7
I145
sg17
VC0006272
p14077
sg10
I24
sg11
Vbronchiolitis obliterans
p14078
sg13
I2
sa(dp14079
g7
I54
sg17
VC0867389
p14080
sg10
I12
sg11
Vchronic GVHD
p14081
sg13
I2
sa(dp14082
g7
I86
sg17
VC0034069
p14083
sg10
I13
sg11
Vlung fibrosis
p14084
sg13
I2
sasa(dp14085
g2
S'In contrast, K. pneumoniae-infected Rag2(-/-)Il2rg(-/-) mice failed to produce IL-22.\n'
p14086
sg4
(lp14087
(dp14088
g7
I79
sg8
g49
sg10
I5
sg11
VIL-22
p14089
sg13
I1
sa(dp14090
g7
I36
sg8
VP55895
p14091
sg10
I14
sg11
VRag2(-/-)Il2rg
p14092
sg13
I1
sasg14
(lp14093
sa(dp14094
g2
S'Pleural effusion smears from 112 patients with either benign or malignant lung disease were investigated for the expression of EGFr and the oncogene proteins myc p64 and ras p21.\n'
p14095
sg4
(lp14096
(dp14097
g7
I170
sg8
VP01116
p14098
sg10
I7
sg11
Vras p21
p14099
sg13
I2
sa(dp14100
g7
I158
sg8
VP12524
p14101
sg10
I7
sg11
Vmyc p64
p14102
sg13
I2
sasg14
(lp14103
(dp14104
g7
I74
sg17
VC0024115
p14105
sg10
I12
sg11
Vlung disease
p14106
sg13
I2
sa(dp14107
g7
I0
sg17
VC0032227
p14108
sg10
I16
sg11
VPleural effusion
p14109
sg13
I2
sasa(dp14110
g2
S'The aim of this study was to investigate the protective effects of FYGL on INS-1 rat insulinoma beta cells against IAPP-induced cell apoptosis, as well as the underlying mechanisms.\n'
p14111
sg4
(lp14112
(dp14113
g7
I115
sg8
VP10997
p14114
sg10
I4
sg11
VIAPP
p14115
sg13
I1
sasg14
(lp14116
(dp14117
g7
I85
sg17
VC0021670
p14118
sg10
I10
sg11
Vinsulinoma
p14119
sg13
I1
sa(dp14120
g7
I75
sg17
VC1533172
p14121
sg10
I3
sg11
VINS
p14122
sg13
I1
sasa(dp14123
g2
S'Further testing revealed islet-type amyloid polypeptide (or amylin), a protein found in various diseases such as diabetes, insulinoma and pancreatic adenocarcinoma-none of which was seen in our patient.\n'
p14124
sg4
(lp14125
(dp14126
g7
I60
sg8
VP10997
p14127
sg10
I6
sg11
Vamylin
p14128
sg13
I1
sasg14
(lp14129
(dp14130
g7
I113
sg17
VC0011849
p14131
sg10
I8
sg11
Vdiabetes
p14132
sg13
I1
sa(dp14133
g7
I36
sg17
VC0011560
p14134
sg10
I7
sg11
Vamyloid
p14135
sg13
I1
sa(dp14136
g7
I123
sg17
VC0021670
p14137
sg10
I10
sg11
Vinsulinoma
p14138
sg13
I1
sa(dp14139
g7
I138
sg17
VC0281361
p14140
sg10
I25
sg11
Vpancreatic adenocarcinoma
p14141
sg13
I2
sasa(dp14142
g2
S'Using pancreatic rat insulinoma Beta-cells and human islets as model systems, we show that hA, following its internalization, first accumulates in the cytosol followed by its translocation into nucleus, and to a lesser extent lysosomes, keeping the net cytosolic amylin content low.\n'
p14143
sg4
(lp14144
sg14
(lp14145
(dp14146
g7
I175
sg17
VC0040715
p14147
sg10
I13
sg11
Vtranslocation
p14148
sg13
I1
sa(dp14149
g7
I21
sg17
VC0021670
p14150
sg10
I10
sg11
Vinsulinoma
p14151
sg13
I1
sasa(dp14152
g2
S'In addition to the in vitro assays, we have tested the effect of these compounds in an amyloid toxicity cell culture model and we have found that one of them, quercetin, has the ability to partly protect cultured pancreatic insulinoma cells from the cytotoxic effect of amylin.\n'
p14153
sg4
(lp14154
(dp14155
g7
I270
sg8
VP10997
p14156
sg10
I6
sg11
Vamylin
p14157
sg13
I1
sasg14
(lp14158
(dp14159
g7
I213
sg17
VC0021670
p14160
sg10
I21
sg11
Vpancreatic insulinoma
p14161
sg13
I2
sa(dp14162
g7
I87
sg17
VC0011560
p14163
sg10
I7
sg11
Vamyloid
p14164
sg13
I1
sasa(dp14165
g2
S'Our data suggests that quercetin can contribute to reduce oxidative damage in pancreatic insulinoma Beta cells by modulating the aggregation propensity of amylin.\n'
p14166
sg4
(lp14167
(dp14168
g7
I155
sg8
VP10997
p14169
sg10
I6
sg11
Vamylin
p14170
sg13
I1
sasg14
(lp14171
(dp14172
g7
I78
sg17
VC0021670
p14173
sg10
I21
sg11
Vpancreatic insulinoma
p14174
sg13
I2
sasa(dp14175
g2
S'The other patient without thymoma initiated treatment with steroid, tacrolimus and IAPP and showed complete recovery one month later.\n'
p14176
sg4
(lp14177
(dp14178
g7
I83
sg8
VP10997
p14179
sg10
I4
sg11
VIAPP
p14180
sg13
I1
sasg14
(lp14181
(dp14182
g7
I26
sg17
VC0040100
p14183
sg10
I7
sg11
Vthymoma
p14184
sg13
I1
sasa(dp14185
g2
S'C-reactive protein (CRP), which is a marker of inflammation, has not been widely studied in inflammatory thyroid disorders particularly in sub-acute thyroiditis (SAT).\n'
p14186
sg4
(lp14187
(dp14188
g7
I0
sg8
VP02741
p14189
sg10
I18
sg11
VC-reactive protein
p14190
sg13
I2
sa(dp14191
g7
I20
sg8
VP02741
p14192
sg10
I3
sg11
VCRP
p14193
sg13
I1
sasg14
(lp14194
(dp14195
g7
I47
sg17
VC0021368
p14196
sg10
I12
sg11
Vinflammation
p14197
sg13
I1
sa(dp14198
g7
I105
sg17
VC0040128
p14199
sg10
I17
sg11
Vthyroid disorders
p14200
sg13
I2
sa(dp14201
g7
I143
sg17
VC0001360
p14202
sg10
I17
sg11
Vacute thyroiditis
p14203
sg13
I2
sasa(dp14204
g2
S"The objective of the study was to estimate and compare salivary CRP levels in Hashimoto's thyroiditis (HT) and Subacute thyroiditis (SAT).\n"
p14205
sg4
(lp14206
(dp14207
g7
I55
sg8
VP02741
p14208
sg10
I12
sg11
Vsalivary CRP
p14209
sg13
I2
sasg14
(lp14210
(dp14211
g7
I111
sg17
VC0040149
p14212
sg10
I20
sg11
VSubacute thyroiditis
p14213
sg13
I2
sa(dp14214
g7
I103
sg17
VC0920350
p14215
sg10
I2
sg11
VHT
p14216
sg13
I1
sa(dp14217
g7
I133
sg17
VC0040149
p14218
sg10
I3
sg11
VSAT
p14219
sg13
I1
sa(dp14220
g7
I78
sg17
VC0920350
p14221
sg10
I23
sg11
VHashimoto's thyroiditis
p14222
sg13
I2
sasa(dp14223
g2
S"Due to fever, a high sedimentation rate and a high C-reactive protein (CRP), as well as high levels of anti-thyroid peroxidase antibodies (anti-TPOab), differential diagnostic considerations included acute and subacute thyroiditis as well as Hashimoto's thyroiditis and thyroid malignancy.\n"
p14224
sg4
(lp14225
(dp14226
g7
I71
sg8
VP02741
p14227
sg10
I3
sg11
VCRP
p14228
sg13
I1
sa(dp14229
g7
I103
sg8
VP40225
p14230
sg10
I34
sg11
Vanti-thyroid peroxidase antibodies
p14231
sg13
I3
sa(dp14232
g7
I139
sg8
VP40225
p14233
sg10
I10
sg11
Vanti-TPOab
p14234
sg13
I1
sa(dp14235
g7
I51
sg8
VP02741
p14236
sg10
I18
sg11
VC-reactive protein
p14237
sg13
I2
sasg14
(lp14238
(dp14239
g7
I278
sg17
VC0006826
p14240
sg10
I10
sg11
Vmalignancy
p14241
sg13
I1
sa(dp14242
g7
I210
sg17
VC0040149
p14243
sg10
I20
sg11
Vsubacute thyroiditis
p14244
sg13
I2
sa(dp14245
g7
I242
sg17
VC0920350
p14246
sg10
I23
sg11
VHashimoto's thyroiditis
p14247
sg13
I2
sasa(dp14248
g2
S'Immunohistochemical staining of CD4, FOXP3, CD68, TGF-Beta1, IL-10, IL-4, IFN-Gamma, and MCP-1 showed that the occurrence of Tregs and TAMs increased in parallel with disease progression in OLK and OSCC.\n'
p14249
sg4
(lp14250
(dp14251
g7
I32
sg8
VP01730
p14252
sg10
I3
sg11
VCD4
p14253
sg13
I1
sa(dp14254
g7
I68
sg8
VP05112
p14255
sg10
I4
sg11
VIL-4
p14256
sg13
I1
sa(dp14257
g7
I74
sg8
VP01579
p14258
sg10
I9
sg11
VIFN-Gamma
p14259
sg13
I1
sa(dp14260
g7
I37
sg8
g49
sg10
I5
sg11
VFOXP3
p14261
sg13
I1
sa(dp14262
g7
I44
sg8
VP34810
p14263
sg10
I4
sg11
VCD68
p14264
sg13
I1
sa(dp14265
g7
I89
sg8
VP41597
p14266
sg10
I5
sg11
VMCP-1
p14267
sg13
I1
sa(dp14268
g7
I50
sg8
VP01137
p14269
sg10
I9
sg11
VTGF-Beta1
p14270
sg13
I1
sasg14
(lp14271
(dp14272
g7
I167
sg17
VC0242656
p14273
sg10
I19
sg11
Vdisease progression
p14274
sg13
I2
sasa(dp14275
g2
S'The expression of CD68, CD14, CD163, CD200R, CD206, HLA-G, CD80, and CD86 was higher in CD14-positive cells co-cultured with the culture supernatants of CAFs established from OSCC specimens (CAF-educated cells) than in control cells.\n'
p14276
sg4
(lp14277
(dp14278
g7
I45
sg8
VP22897
p14279
sg10
I5
sg11
VCD206
p14280
sg13
I1
sa(dp14281
g7
I24
sg8
VP08571
p14282
sg10
I4
sg11
VCD14
p14283
sg13
I1
sa(dp14284
g7
I18
sg8
VP34810
p14285
sg10
I4
sg11
VCD68
p14286
sg13
I1
sa(dp14287
g7
I59
sg8
VP33681
p14288
sg10
I4
sg11
VCD80
p14289
sg13
I1
sa(dp14290
g7
I30
sg8
g49
sg10
I5
sg11
VCD163
p14291
sg13
I1
sa(dp14292
g7
I24
sg8
VP08571
p14293
sg10
I4
sg11
VCD14
p14294
sg13
I1
sa(dp14295
g7
I52
sg8
VP17693
p14296
sg10
I5
sg11
VHLA-G
p14297
sg13
I1
sa(dp14298
g7
I69
sg8
VP42081
p14299
sg10
I4
sg11
VCD86
p14300
sg13
I1
sasg14
(lp14301
(dp14302
g7
I153
sg17
VC0795907
p14303
sg10
I4
sg11
VCAFs
p14304
sg13
I1
sasa(dp14305
g2
S'Among cell surface and extracellular matrix biomarkers tissue biomarkers, matrix metalloproteinase (MMP)-2, -9, CD31 and CD68 seem to be useful for differentiation of OVC and OSCC and glucose transporter-1 (GLUT-1) can help in differentiation of OVC from oral epithelial dysplasia.\n'
p14306
sg4
(lp14307
(dp14308
g7
I184
sg8
VP11166
p14309
sg10
I21
sg11
Vglucose transporter-1
p14310
sg13
I2
sa(dp14311
g7
I112
sg8
VP69905
p14312
sg10
I4
sg11
VCD31
p14313
sg13
I1
sa(dp14314
g7
I207
sg8
VP11166
p14315
sg10
I6
sg11
VGLUT-1
p14316
sg13
I1
sa(dp14317
g7
I121
sg8
VP34810
p14318
sg10
I4
sg11
VCD68
p14319
sg13
I1
sa(dp14320
g7
I74
sg8
g49
sg10
I36
sg11
Vmatrix metalloproteinase (MMP)-2, -9
p14321
sg13
I4
sasg14
(lp14322
(dp14323
g7
I260
sg17
VC0878500
p14324
sg10
I20
sg11
Vepithelial dysplasia
p14325
sg13
I2
sasa(dp14326
g2
S'Samples from 62 patients with T1/2N0M0 OSCC were immunohistochemically stained and scored for the cellular expression of mast/stem cell growth factor receptor (c-KIT) (MCs), CD68 (macrophages), Alfa-smooth muscle actin (Alfa-SMA) (CAFs) and CD31 (endothelial cells) and this was analyzed according to disease recurrence.\n'
p14327
sg4
(lp14328
(dp14329
g7
I194
sg8
VP68032
p14330
sg10
I24
sg11
VAlfa-smooth muscle actin
p14331
sg13
I3
sa(dp14332
g7
I241
sg8
VP69905
p14333
sg10
I4
sg11
VCD31
p14334
sg13
I1
sa(dp14335
g7
I160
sg8
VP10721
p14336
sg10
I5
sg11
Vc-KIT
p14337
sg13
I1
sa(dp14338
g7
I174
sg8
VP34810
p14339
sg10
I4
sg11
VCD68
p14340
sg13
I1
sa(dp14341
g7
I121
sg8
VP10721
p14342
sg10
I37
sg11
Vmast/stem cell growth factor receptor
p14343
sg13
I5
sa(dp14344
g7
I220
sg8
g49
sg10
I8
sg11
VAlfa-SMA
p14345
sg13
I1
sasg14
(lp14346
(dp14347
g7
I309
sg17
VC1458156
p14348
sg10
I10
sg11
Vrecurrence
p14349
sg13
I1
sa(dp14350
g7
I225
sg17
VC0026847
p14351
sg10
I3
sg11
VSMA
p14352
sg13
I1
sa(dp14353
g7
I231
sg17
VC0795907
p14354
sg10
I4
sg11
VCAFs
p14355
sg13
I1
sa(dp14356
g7
I168
sg17
VC0036221
p14357
sg10
I3
sg11
VMCs
p14358
sg13
I1
sasa(dp14359
g2
S'The expression of SIRPAlfa in OLK was higher than in OSCC, correlating with the expression of CD68 and CD163 on macrophages.\n'
p14360
sg4
(lp14361
(dp14362
g7
I103
sg8
g49
sg10
I5
sg11
VCD163
p14363
sg13
I1
sa(dp14364
g7
I94
sg8
VP34810
p14365
sg10
I4
sg11
VCD68
p14366
sg13
I1
sasg14
(lp14367
sa(dp14368
g2
S'CD68 and lysozyme expression in cannibalistic tumor cells of oral squamous cell carcinoma (OSCC) is well established.\n'
p14369
sg4
(lp14370
(dp14371
g7
I0
sg8
VP34810
p14372
sg10
I4
sg11
VCD68
p14373
sg13
I1
sa(dp14374
g7
I9
sg8
VP61626
p14375
sg10
I8
sg11
Vlysozyme
p14376
sg13
I1
sasg14
(lp14377
(dp14378
g7
I46
sg17
VC0027651
p14379
sg10
I5
sg11
Vtumor
p14380
sg13
I1
sa(dp14381
g7
I66
sg17
VC0007137
p14382
sg10
I23
sg11
Vsquamous cell carcinoma
p14383
sg13
I3
sasa(dp14384
g2
S'Formalin-fixed tissues of 30 OSCC cases with cellular cannibalism (CC) (positive control), 30 OSCC cases without CC, and 17 normal oral epithelium specimens (negative control) were subjected to immunohistochemical analysis for CD68 and lysozyme expression.\n'
p14385
sg4
(lp14386
(dp14387
g7
I227
sg8
VP34810
p14388
sg10
I4
sg11
VCD68
p14389
sg13
I1
sa(dp14390
g7
I236
sg8
VP61626
p14391
sg10
I8
sg11
Vlysozyme
p14392
sg13
I1
sasg14
(lp14393
sa(dp14394
g2
S'OSCC with CC showed CD68 and lysozyme expression in 30 (100%) cases each {CD68: [weak: 21 (70%), strong: 9 (30%)]; lysozyme: [weak: 24 (80%), strong: 6 (20%)]}.\n'
p14395
sg4
(lp14396
(dp14397
g7
I20
sg8
VP34810
p14398
sg10
I4
sg11
VCD68
p14399
sg13
I1
sa(dp14400
g7
I20
sg8
VP34810
p14401
sg10
I4
sg11
VCD68
p14402
sg13
I1
sa(dp14403
g7
I29
sg8
VP61626
p14404
sg10
I8
sg11
Vlysozyme
p14405
sg13
I1
sa(dp14406
g7
I29
sg8
VP61626
p14407
sg10
I8
sg11
Vlysozyme
p14408
sg13
I1
sasg14
(lp14409
sa(dp14410
g2
S'In OSCCs without CC, CD68-positive tumor cells were present in 13 (43.33%) cases [weak: 10 (33.33%); strong: 3 (10%)] and lysozyme expression was present in 13 (43.33%) cases [weak: 12 (40%); strong: 1 (3.33%)].\n'
p14411
sg4
(lp14412
(dp14413
g7
I21
sg8
VP34810
p14414
sg10
I4
sg11
VCD68
p14415
sg13
I1
sa(dp14416
g7
I122
sg8
VP61626
p14417
sg10
I8
sg11
Vlysozyme
p14418
sg13
I1
sasg14
(lp14419
(dp14420
g7
I35
sg17
VC0027651
p14421
sg10
I5
sg11
Vtumor
p14422
sg13
I1
sasa(dp14423
g2
S'The CD68 and lysozyme expression in OSCCs without CC, OSCCs with CC, and control group showed statistically significant differences (P &lt; 0.001).\n'
p14424
sg4
(lp14425
(dp14426
g7
I4
sg8
VP34810
p14427
sg10
I4
sg11
VCD68
p14428
sg13
I1
sa(dp14429
g7
I13
sg8
VP61626
p14430
sg10
I8
sg11
Vlysozyme
p14431
sg13
I1
sasg14
(lp14432
sa(dp14433
g2
S'Significant correlation was also observed between CD68 and lysozyme expression and different grades of OSCC.\n'
p14434
sg4
(lp14435
(dp14436
g7
I50
sg8
VP34810
p14437
sg10
I4
sg11
VCD68
p14438
sg13
I1
sa(dp14439
g7
I59
sg8
VP61626
p14440
sg10
I8
sg11
Vlysozyme
p14441
sg13
I1
sasg14
(lp14442
sa(dp14443
g2
S'CD68 and lysozyme expression in non-cannibalistic tumor cells of OSCC can be related to CC.\n'
p14444
sg4
(lp14445
(dp14446
g7
I0
sg8
VP34810
p14447
sg10
I4
sg11
VCD68
p14448
sg13
I1
sa(dp14449
g7
I9
sg8
VP61626
p14450
sg10
I8
sg11
Vlysozyme
p14451
sg13
I1
sasg14
(lp14452
(dp14453
g7
I50
sg17
VC0027651
p14454
sg10
I5
sg11
Vtumor
p14455
sg13
I1
sasa(dp14456
g2
S'Prenatal diagnosis of glycogenosis type II was performed by direct assay of acid alpha-glucosidase (EC 3.2.1.20) in chorionic villous biopsy obtained by transcervical cannula aspiration from a pregnancy at risk in the 10th week of gestation.\n'
p14457
sg4
(lp14458
(dp14459
g7
I76
sg8
VP10253
p14460
sg10
I22
sg11
Vacid alpha-glucosidase
p14461
sg13
I2
sasg14
(lp14462
(dp14463
g7
I175
sg17
VC0700198
p14464
sg10
I10
sg11
Vaspiration
p14465
sg13
I1
sa(dp14466
g7
I22
sg17
VC0017921
p14467
sg10
I20
sg11
Vglycogenosis type II
p14468
sg13
I3
sasa(dp14469
g2
S'In this review, we describe the fusion genes recently reported in bone and soft-tissue tumors such as solitary fibrous tumor, aneurysmal bone cyst, nodular fasciitis, CIC-DUX4 fusion gene-positive small round cell tumors, or BCOR-CCNB3-positive sarcoma as well as other genetic aberrations in dedifferentiated liposarcoma, malignant rhabdoid tumor, cartilaginous tumor, Langerhans cell histiocytosis chondroblastoma, or giant cell tumor of the bone.\n'
p14470
sg4
(lp14471
(dp14472
g7
I171
sg8
g49
sg10
I4
sg11
VDUX4
p14473
sg13
I1
sa(dp14474
g7
I225
sg8
g49
sg10
I10
sg11
VBCOR-CCNB3
p14475
sg13
I1
sa(dp14476
g7
I167
sg8
g49
sg10
I3
sg11
VCIC
p14477
sg13
I1
sasg14
(lp14478
(dp14479
g7
I245
sg17
VC1261473
p14480
sg10
I7
sg11
Vsarcoma
p14481
sg13
I1
sa(dp14482
g7
I87
sg17
VC0027651
p14483
sg10
I6
sg11
Vtumors
p14484
sg13
I1
sa(dp14485
g7
I420
sg17
VC0017547
p14486
sg10
I5
sg11
Vgiant
p14487
sg13
I1
sa(dp14488
g7
I349
sg17
VC0476147
p14489
sg10
I19
sg11
Vcartilaginous tumor
p14490
sg13
I2
sa(dp14491
g7
I148
sg17
VC0410005
p14492
sg10
I17
sg11
Vnodular fasciitis
p14493
sg13
I2
sa(dp14494
g7
I370
sg17
VC0019621
p14495
sg10
I29
sg11
VLangerhans cell histiocytosis
p14496
sg13
I3
sa(dp14497
g7
I87
sg17
VC0027651
p14498
sg10
I6
sg11
Vtumors
p14499
sg13
I1
sa(dp14500
g7
I293
sg17
VC0205824
p14501
sg10
I28
sg11
Vdedifferentiated liposarcoma
p14502
sg13
I2
sa(dp14503
g7
I400
sg17
VC0008441
p14504
sg10
I15
sg11
Vchondroblastoma
p14505
sg13
I1
sa(dp14506
g7
I323
sg17
VC0206743
p14507
sg10
I24
sg11
Vmalignant rhabdoid tumor
p14508
sg13
I3
sa(dp14509
g7
I102
sg17
VC1266119
p14510
sg10
I22
sg11
Vsolitary fibrous tumor
p14511
sg13
I3
sa(dp14512
g7
I431
sg17
VC0005967
p14513
sg10
I17
sg11
Vtumor of the bone
p14514
sg13
I4
sa(dp14515
g7
I126
sg17
VC0152244
p14516
sg10
I20
sg11
Vaneurysmal bone cyst
p14517
sg13
I3
sasa(dp14518
g2
S'Besides, we screened for all the known genes related to axonal autosomal recessive Charcot-Marie-Tooth disease (CMT2A2/HMSN2A2/MFN2, CMT2B1/LMNA, CMT2B2/MED25, CMT2B5/NEFL, ARCMT2F/dHMN2B/HSPB1, CMT2K/GDAP1, CMT2P/LRSAM1, CMT2R/TRIM2, CMT2S/IGHMBP2, CMT2T/HSJ1, CMTRID/COX6A1, ARAN-NM/HINT and GAN/GAN), for the genes related to autosomal recessive hereditary spastic paraplegia with thin corpus callosum and axonal peripheral neuropathy (SPG7/PGN, SPG15/ZFYVE26, SPG21/ACP33, SPG35/FA2H, SPG46/GBA2, SPG55/C12orf65 and SPG56/CYP2U1), as well as for the causative gene of peripheral neuropathy with or without agenesis of the corpus callosum (SLC12A6).\n'
p14519
sg4
(lp14520
(dp14521
g7
I133
sg8
VP02545
p14522
sg10
I6
sg11
VCMT2B1
p14523
sg13
I1
sa(dp14524
g7
I112
sg8
g49
sg10
I6
sg11
VCMT2A2
p14525
sg13
I1
sa(dp14526
g7
I140
sg8
VP02545
p14527
sg10
I4
sg11
VLMNA
p14528
sg13
I1
sa(dp14529
g7
I127
sg8
g49
sg10
I4
sg11
VMFN2
p14530
sg13
I1
sa(dp14531
g7
I214
sg8
g49
sg10
I6
sg11
VLRSAM1
p14532
sg13
I1
sa(dp14533
g7
I195
sg8
g49
sg10
I5
sg11
VCMT2K
p14534
sg13
I1
sa(dp14535
g7
I235
sg8
g49
sg10
I5
sg11
VCMT2S
p14536
sg13
I1
sa(dp14537
g7
I294
sg8
g49
sg10
I3
sg11
VGAN
p14538
sg13
I1
sa(dp14539
g7
I449
sg8
g49
sg10
I5
sg11
VSPG15
p14540
sg13
I1
sa(dp14541
g7
I439
sg8
g49
sg10
I4
sg11
VSPG7
p14542
sg13
I1
sa(dp14543
g7
I294
sg8
g49
sg10
I3
sg11
VGAN
p14544
sg13
I1
sa(dp14545
g7
I483
sg8
g49
sg10
I4
sg11
VFA2H
p14546
sg13
I1
sa(dp14547
g7
I455
sg8
g49
sg10
I7
sg11
VZFYVE26
p14548
sg13
I1
sa(dp14549
g7
I241
sg8
VP38935
p14550
sg10
I7
sg11
VIGHMBP2
p14551
sg13
I1
sa(dp14552
g7
I256
sg8
VP25686
p14553
sg10
I4
sg11
VHSJ1
p14554
sg13
I1
sa(dp14555
g7
I444
sg8
VP00747
p14556
sg10
I3
sg11
VPGN
p14557
sg13
I1
sa(dp14558
g7
I228
sg8
g49
sg10
I5
sg11
VTRIM2
p14559
sg13
I1
sa(dp14560
g7
I153
sg8
g49
sg10
I5
sg11
VMED25
p14561
sg13
I1
sa(dp14562
g7
I495
sg8
g49
sg10
I4
sg11
VGBA2
p14563
sg13
I1
sa(dp14564
g7
I167
sg8
VP07196
p14565
sg10
I4
sg11
VNEFL
p14566
sg13
I1
sa(dp14567
g7
I285
sg8
VP49773
p14568
sg10
I4
sg11
VHINT
p14569
sg13
I1
sa(dp14570
g7
I507
sg8
g49
sg10
I8
sg11
VC12orf65
p14571
sg13
I1
sa(dp14572
g7
I470
sg8
g49
sg10
I5
sg11
VACP33
p14573
sg13
I1
sa(dp14574
g7
I520
sg8
g49
sg10
I12
sg11
VSPG56/CYP2U1
p14575
sg13
I1
sa(dp14576
g7
I201
sg8
g49
sg10
I5
sg11
VGDAP1
p14577
sg13
I1
sa(dp14578
g7
I119
sg8
g49
sg10
I7
sg11
VHMSN2A2
p14579
sg13
I1
sa(dp14580
g7
I464
sg8
g49
sg10
I5
sg11
VSPG21
p14581
sg13
I1
sa(dp14582
g7
I269
sg8
VP12074
p14583
sg10
I6
sg11
VCOX6A1
p14584
sg13
I1
sasg14
(lp14585
(dp14586
g7
I208
sg17
VC3280797
p14587
sg10
I5
sg11
VCMT2P
p14588
sg13
I1
sa(dp14589
g7
I146
sg17
VC1854150
p14590
sg10
I6
sg11
VCMT2B2
p14591
sg13
I1
sa(dp14592
g7
I294
sg17
VC1850386
p14593
sg10
I3
sg11
VGAN
p14594
sg13
I1
sa(dp14595
g7
I449
sg17
VC1849128
p14596
sg10
I5
sg11
VSPG15
p14597
sg13
I1
sa(dp14598
g7
I439
sg17
VC1846564
p14599
sg10
I4
sg11
VSPG7
p14600
sg13
I1
sa(dp14601
g7
I133
sg17
VC1854154
p14602
sg10
I6
sg11
VCMT2B1
p14603
sg13
I1
sa(dp14604
g7
I294
sg17
VC1850386
p14605
sg10
I3
sg11
VGAN
p14606
sg13
I1
sa(dp14607
g7
I83
sg17
VC0007959
p14608
sg10
I27
sg11
VCharcot-Marie-Tooth disease
p14609
sg13
I2
sa(dp14610
g7
I112
sg17
VC1836485
p14611
sg10
I6
sg11
VCMT2A2
p14612
sg13
I1
sa(dp14613
g7
I119
sg17
VC1836485
p14614
sg10
I7
sg11
VHMSN2A2
p14615
sg13
I1
sa(dp14616
g7
I409
sg17
VC1263857
p14617
sg10
I28
sg11
Vaxonal peripheral neuropathy
p14618
sg13
I3
sa(dp14619
g7
I181
sg17
VC2608087
p14620
sg10
I6
sg11
VdHMN2B
p14621
sg13
I1
sa(dp14622
g7
I610
sg17
VC0175754
p14623
sg10
I31
sg11
Vagenesis of the corpus callosum
p14624
sg13
I5
sa(dp14625
g7
I464
sg17
VC1855346
p14626
sg10
I5
sg11
VSPG21
p14627
sg13
I1
sa(dp14628
g7
I329
sg17
VC0751603
p14629
sg10
I49
sg11
Vautosomal recessive hereditary spastic paraplegia
p14630
sg13
I5
sa(dp14631
g7
I416
sg17
VC0031117
p14632
sg10
I21
sg11
Vperipheral neuropathy
p14633
sg13
I2
sa(dp14634
g7
I195
sg17
VC1842983
p14635
sg10
I5
sg11
VCMT2K
p14636
sg13
I1
sasa(dp14637
g2
S'To revisit the concepts of vacuole formation associated with mitochondrial dysfunction, we performed a comparative neuropathological analysis in Kearns-Sayre syndrome (KSS) and full-length peroxisome proliferator-activated receptor-g coactivator-1a (FL-PGC-1a)-deficient mice, a recently proposed morphological model of mitochondrial encephalopathies.\n'
p14638
sg4
(lp14639
(dp14640
g7
I177
sg8
VP20142
p14641
sg10
I71
sg11
Vfull-length peroxisome proliferator-activated receptor-g coactivator-1a
p14642
sg13
I5
sa(dp14643
g7
I250
sg8
VP20142
p14644
sg10
I9
sg11
VFL-PGC-1a
p14645
sg13
I1
sasg14
(lp14646
(dp14647
g7
I334
sg17
VC0085584
p14648
sg10
I16
sg11
Vencephalopathies
p14649
sg13
I1
sa(dp14650
g7
I145
sg17
VC0022541
p14651
sg10
I21
sg11
VKearns-Sayre syndrome
p14652
sg13
I2
sa(dp14653
g7
I168
sg17
VC0022541
p14654
sg10
I3
sg11
VKSS
p14655
sg13
I1
sasa(dp14656
g2
S'Brain tissues from an individual with genetically proven KSS (22-year-old man) and aged FL-PGC-1a-deficient and wild-type (male, 70-75-week-old) mice were analysed using ultrastructural and immunohistochemical methods, with a specific focus on myelin-related, oligodendroglial, axonal and astrocytic pathologies.\n'
p14657
sg4
(lp14658
sg14
(lp14659
(dp14660
g7
I57
sg17
VC0022541
p14661
sg10
I3
sg11
VKSS
p14662
sg13
I1
sasa(dp14663
g2
S'Besides demonstrating remarkable similarities in the lesion profile of KSS and FL-PGC-1a-deficient mice, this study first provides morphological evidence for the identical origin of WM and GM vacuolation as well as for the presence of intracytoplasmic oligodendroglial vacuoles in mitochondriopathies.\n'
p14664
sg4
(lp14665
sg14
(lp14666
(dp14667
g7
I71
sg17
VC0022541
p14668
sg10
I3
sg11
VKSS
p14669
sg13
I1
sasa(dp14670
g2
S'In wild type, CLN1 and CLN2 mRNAs were rapidly downregulated, while in alg7 mutants, these transcripts were only transiently repressed before becoming greatly augmented.\n'
p14671
sg4
(lp14672
(dp14673
g7
I23
sg8
g49
sg10
I10
sg11
VCLN2 mRNAs
p14674
sg13
I2
sa(dp14675
g7
I71
sg8
g49
sg10
I12
sg11
Valg7 mutants
p14676
sg13
I2
sa(dp14677
g7
I14
sg8
VP50897
p14678
sg10
I4
sg11
VCLN1
p14679
sg13
I1
sasg14
(lp14680
(dp14681
g7
I23
sg17
VC1876161
p14682
sg10
I4
sg11
VCLN2
p14683
sg13
I1
sa(dp14684
g7
I14
sg17
VC1850451
p14685
sg10
I4
sg11
VCLN1
p14686
sg13
I1
sasa(dp14687
g2
S'Thus, deregulation of ALG7 interferes with cell cycle arrest by preventing a sustained downregulation of CLN1 and CLN2 mRNAs.\n'
p14688
sg4
(lp14689
(dp14690
g7
I22
sg8
g49
sg10
I4
sg11
VALG7
p14691
sg13
I1
sa(dp14692
g7
I105
sg8
VP50897
p14693
sg10
I4
sg11
VCLN1
p14694
sg13
I1
sa(dp14695
g7
I114
sg8
g49
sg10
I10
sg11
VCLN2 mRNAs
p14696
sg13
I2
sasg14
(lp14697
(dp14698
g7
I105
sg17
VC1850451
p14699
sg10
I4
sg11
VCLN1
p14700
sg13
I1
sa(dp14701
g7
I114
sg17
VC1876161
p14702
sg10
I4
sg11
VCLN2
p14703
sg13
I1
sasa(dp14704
g2
S'Although, compared to age-matched control samples, nonphosphorylated dolichols are significantly increased in the cerebral cortex of children with the late infantile and juvenile types of neuronal ceroid-lipofuscinosis (NCL), dolichyl phosphates are increased to a much greater extent in infantile, late infantile, and juvenile forms of this disease group.\n'
p14705
sg4
(lp14706
sg14
(lp14707
(dp14708
g7
I188
sg17
VC0027877
p14709
sg10
I30
sg11
Vneuronal ceroid-lipofuscinosis
p14710
sg13
I2
sa(dp14711
g7
I220
sg17
VC0027877
p14712
sg10
I3
sg11
VNCL
p14713
sg13
I1
sasa(dp14714
g2
S'In tumors of smooth muscle differentiation, only uterine leiomyoma and lipoleiomyoma are known to be associated with the altered HMGIC.\n'
p14715
sg4
(lp14716
(dp14717
g7
I129
sg8
VP52926
p14718
sg10
I5
sg11
VHMGIC
p14719
sg13
I1
sasg14
(lp14720
(dp14721
g7
I49
sg17
VC0042133
p14722
sg10
I17
sg11
Vuterine leiomyoma
p14723
sg13
I2
sa(dp14724
g7
I71
sg17
VC1266121
p14725
sg10
I13
sg11
Vlipoleiomyoma
p14726
sg13
I1
sa(dp14727
g7
I3
sg17
VC0027651
p14728
sg10
I6
sg11
Vtumors
p14729
sg13
I1
sasa(dp14730
g2
S'We investigated molecular and genetic alterations of the HMGIC in 36 benign and malignant smooth muscle tumors arising at various anatomical sites, including 13 uterine leiomyomas, two leiomyomas of the kidney with a t(12;14), one pelvic lipoleiomyoma, one vascular leiomyoma of the foot, two uterine leiomyosarcomas, six retroperitoneal leiomyosarcomas, one leiomyosarcoma of the urinary bladder, and 10 leiomyosarcomas of external soft tissues.\n'
p14731
sg4
(lp14732
sg14
(lp14733
(dp14734
g7
I169
sg17
VC0023267
p14735
sg10
I10
sg11
Vleiomyomas
p14736
sg13
I1
sa(dp14737
g7
I257
sg17
VC0206653
p14738
sg10
I18
sg11
Vvascular leiomyoma
p14739
sg13
I2
sa(dp14740
g7
I238
sg17
VC1266121
p14741
sg10
I13
sg11
Vlipoleiomyoma
p14742
sg13
I1
sa(dp14743
g7
I301
sg17
VC0023269
p14744
sg10
I15
sg11
Vleiomyosarcomas
p14745
sg13
I1
sa(dp14746
g7
I169
sg17
VC0023267
p14747
sg10
I10
sg11
Vleiomyomas
p14748
sg13
I1
sa(dp14749
g7
I301
sg17
VC0023269
p14750
sg10
I15
sg11
Vleiomyosarcomas
p14751
sg13
I1
sa(dp14752
g7
I90
sg17
VC0206658
p14753
sg10
I20
sg11
Vsmooth muscle tumors
p14754
sg13
I3
sa(dp14755
g7
I301
sg17
VC0023269
p14756
sg10
I14
sg11
Vleiomyosarcoma
p14757
sg13
I1
sa(dp14758
g7
I301
sg17
VC0023269
p14759
sg10
I15
sg11
Vleiomyosarcomas
p14760
sg13
I1
sasa(dp14761
g2
S'Thus, the HMGIC alterations in smooth muscle tumors are not confined only to uterine leiomyoma or lipoleiomyoma.\n'
p14762
sg4
(lp14763
sg14
(lp14764
(dp14765
g7
I31
sg17
VC0206658
p14766
sg10
I20
sg11
Vsmooth muscle tumors
p14767
sg13
I3
sa(dp14768
g7
I98
sg17
VC1266121
p14769
sg10
I13
sg11
Vlipoleiomyoma
p14770
sg13
I1
sa(dp14771
g7
I77
sg17
VC0042133
p14772
sg10
I17
sg11
Vuterine leiomyoma
p14773
sg13
I2
sasa(dp14774
g2
S'We evaluated the effect of diabetic retinopathy on 25 year survival rate among a population-based cohort of type 1 diabetic patients from Fyn County, Denmark.\n'
p14775
sg4
(lp14776
sg14
(lp14777
(dp14778
g7
I27
sg17
VC0011884
p14779
sg10
I20
sg11
Vdiabetic retinopathy
p14780
sg13
I2
sasa(dp14781
g2
S'CDDP + MMC, CDDP + TXL, MMC + TXL and CDDP were effective for endocervical adenocarcinoma.\n'
p14782
sg4
(lp14783
sg14
(lp14784
(dp14785
g7
I62
sg17
VC1263762
p14786
sg10
I27
sg11
Vendocervical adenocarcinoma
p14787
sg13
I2
sasa(dp14788
g2
S'We describe the identification of apo A-I amyloidosis by mass spectrometry in a 52-year old male, with no family history of amyloidosis, presenting with nephrotic syndrome and associated with heterozygosity for a novel APOA1 mutation (c.220 T &gt; A) which encodes the known amyloidogenic Trp50Arg variant.\n'
p14789
sg4
(lp14790
(dp14791
g7
I219
sg8
VP02647
p14792
sg10
I5
sg11
VAPOA1
p14793
sg13
I1
sa(dp14794
g7
I34
sg8
VP02647
p14795
sg10
I7
sg11
Vapo A-I
p14796
sg13
I2
sasg14
(lp14797
(dp14798
g7
I42
sg17
VC0002726
p14799
sg10
I11
sg11
Vamyloidosis
p14800
sg13
I1
sa(dp14801
g7
I153
sg17
VC0027726
p14802
sg10
I18
sg11
Vnephrotic syndrome
p14803
sg13
I2
sa(dp14804
g7
I42
sg17
VC0002726
p14805
sg10
I11
sg11
Vamyloidosis
p14806
sg13
I1
sasa(dp14807
g2
S'In summary, our data demonstrate that the increase of apoA-IV caused by renal impairment is significantly modulated by low levels of serum albumin as a measure for the severity of the nephrotic syndrome.\n'
p14808
sg4
(lp14809
(dp14810
g7
I133
sg8
g49
sg10
I13
sg11
Vserum albumin
p14811
sg13
I2
sa(dp14812
g7
I54
sg8
VP06727
p14813
sg10
I7
sg11
VapoA-IV
p14814
sg13
I1
sasg14
(lp14815
(dp14816
g7
I184
sg17
VC0027726
p14817
sg10
I18
sg11
Vnephrotic syndrome
p14818
sg13
I2
sa(dp14819
g7
I72
sg17
VC0341697
p14820
sg10
I16
sg11
Vrenal impairment
p14821
sg13
I2
sasa(dp14822
g2
S'We investigated in 207 patients with nondiabetic nephrotic syndrome and 274 controls whether the apolipoprotein(a) [apo(a)] kringle-IV repeat polymorphism explains the elevated Lp(a) levels in these patients.\n'
p14823
sg4
(lp14824
(dp14825
g7
I97
sg8
g49
sg10
I3
sg11
Vapo
p14826
sg13
I1
sa(dp14827
g7
I97
sg8
VP02656
p14828
sg10
I17
sg11
Vapolipoprotein(a)
p14829
sg13
I1
sasg14
(lp14830
(dp14831
g7
I49
sg17
VC0027726
p14832
sg10
I18
sg11
Vnephrotic syndrome
p14833
sg13
I2
sasa(dp14834
g2
S'Obestatin has a role in regulating food intake and energy expenditure, but the roles of obestatin and the GPR39 receptor in obesity and type 1 and type 2 diabetes mellitus (T1DM and T2DM, respectively) are not well understood.\n'
p14835
sg4
(lp14836
(dp14837
g7
I0
sg8
g49
sg10
I9
sg11
VObestatin
p14838
sg13
I1
sa(dp14839
g7
I88
sg8
g49
sg10
I9
sg11
Vobestatin
p14840
sg13
I1
sa(dp14841
g7
I106
sg8
g49
sg10
I14
sg11
VGPR39 receptor
p14842
sg13
I2
sasg14
(lp14843
(dp14844
g7
I124
sg17
VC0028754
p14845
sg10
I7
sg11
Vobesity
p14846
sg13
I1
sa(dp14847
g7
I147
sg17
VC0011860
p14848
sg10
I24
sg11
Vtype 2 diabetes mellitus
p14849
sg13
I4
sasa(dp14850
g2
S'These data suggest that development of agonists capable of specifically activating GPR39 may be a useful new therapeutic approach for diabetes management.\n'
p14851
sg4
(lp14852
(dp14853
g7
I83
sg8
g49
sg10
I5
sg11
VGPR39
p14854
sg13
I1
sasg14
(lp14855
(dp14856
g7
I134
sg17
VC0011849
p14857
sg10
I8
sg11
Vdiabetes
p14858
sg13
I1
sasa(dp14859
g2
S'This compound was further optimized to improve ligand efficiency and pharmacokinetic properties to yield GPR39 agonists for the potential oral treatment of type 2 diabetes.\n'
p14860
sg4
(lp14861
(dp14862
g7
I105
sg8
g49
sg10
I5
sg11
VGPR39
p14863
sg13
I1
sasg14
(lp14864
(dp14865
g7
I156
sg17
VC0011860
p14866
sg10
I15
sg11
Vtype 2 diabetes
p14867
sg13
I3
sasa(dp14868
g2
S'A well-established stimulatory role for GPR39 has been defined in insulin secretion which makes the receptor an attractive target for the treatment of type 1 or 2 diabetes.\n'
p14869
sg4
(lp14870
(dp14871
g7
I66
sg8
VP01308
p14872
sg10
I7
sg11
Vinsulin
p14873
sg13
I1
sa(dp14874
g7
I40
sg8
g49
sg10
I5
sg11
VGPR39
p14875
sg13
I1
sasg14
(lp14876
(dp14877
g7
I163
sg17
VC0011849
p14878
sg10
I8
sg11
Vdiabetes
p14879
sg13
I1
sasa(dp14880
g2
S'Mice deficient in the zinc-sensor GPR39, which has been demonstrated to protect cells against endoplasmatic stress and cell death in vitro, display moderate glucose intolerance and impaired glucose-induced insulin secretion.\n'
p14881
sg4
(lp14882
(dp14883
g7
I206
sg8
VP01308
p14884
sg10
I7
sg11
Vinsulin
p14885
sg13
I1
sa(dp14886
g7
I34
sg8
g49
sg10
I5
sg11
VGPR39
p14887
sg13
I1
sasg14
(lp14888
(dp14889
g7
I157
sg17
VC0271650
p14890
sg10
I19
sg11
Vglucose intolerance
p14891
sg13
I2
sa(dp14892
g7
I181
sg17
VC0684336
p14893
sg10
I8
sg11
Vimpaired
p14894
sg13
I1
sasa(dp14895
g2
S'Here, we use the Tet-On system under the control of the proinsulin promoter to selectively overexpress GPR39 in the Beta cells in a double transgenic mouse strain and challenge them with multiple low doses of streptozotocin, which in the wild-type littermates leads to a gradual increase in nonfasting glucose levels and glucose intolerance observed during both food intake and OGTT.\n'
p14896
sg4
(lp14897
(dp14898
g7
I56
sg8
VP01308
p14899
sg10
I19
sg11
Vproinsulin promoter
p14900
sg13
I2
sa(dp14901
g7
I103
sg8
g49
sg10
I5
sg11
VGPR39
p14902
sg13
I1
sasg14
(lp14903
(dp14904
g7
I321
sg17
VC0271650
p14905
sg10
I19
sg11
Vglucose intolerance
p14906
sg13
I2
sasa(dp14907
g2
S'Although the overexpression of the constitutively active GPR39 receptor in animals not treated with streptozotocin appeared by itself to impair the glucose tolerance slightly and to decrease the Beta-cell mass, it nevertheless totally protected against the gradual hyperglycemia in the steptozotocin-treated animals.\n'
p14908
sg4
(lp14909
(dp14910
g7
I57
sg8
g49
sg10
I14
sg11
VGPR39 receptor
p14911
sg13
I2
sasg14
(lp14912
(dp14913
g7
I265
sg17
VC0020456
p14914
sg10
I13
sg11
Vhyperglycemia
p14915
sg13
I1
sa(dp14916
g7
I156
sg17
VC0020963
p14917
sg10
I9
sg11
Vtolerance
p14918
sg13
I1
sasa(dp14919
g2
S'GPR39, a constitutively active 7TM receptor important for glucose-induced insulin secretion and maturation of pancreatic Beta-cell function, is up-regulated in adipose tissue on abstinence from food and chemically induced diabetes.\n'
p14920
sg4
(lp14921
(dp14922
g7
I31
sg8
VP08172
p14923
sg10
I12
sg11
V7TM receptor
p14924
sg13
I2
sa(dp14925
g7
I0
sg8
g49
sg10
I5
sg11
VGPR39
p14926
sg13
I1
sa(dp14927
g7
I74
sg8
VP01308
p14928
sg10
I7
sg11
Vinsulin
p14929
sg13
I1
sasg14
(lp14930
(dp14931
g7
I222
sg17
VC0011849
p14932
sg10
I8
sg11
Vdiabetes
p14933
sg13
I1
sa(dp14934
g7
I203
sg17
VC0007994
p14935
sg10
I18
sg11
Vchemically induced
p14936
sg13
I2
sasa(dp14937
g2
S'The current study investigates the trimodal combination of ABT-888, a potent inhibitor of PARP1-2, ionizing radiation and temozolomide(TMZ)-based chemotherapy in glioblastoma (GBM) cells.\n'
p14938
sg4
(lp14939
(dp14940
g7
I90
sg8
VP09874
p14941
sg10
I7
sg11
VPARP1-2
p14942
sg13
I1
sasg14
(lp14943
(dp14944
g7
I176
sg17
VC0017636
p14945
sg10
I3
sg11
VGBM
p14946
sg13
I1
sa(dp14947
g7
I162
sg17
VC0017636
p14948
sg10
I12
sg11
Vglioblastoma
p14949
sg13
I1
sasa(dp14950
g2
S'This study investigated whether social defeat (SD) or exposure to an olfactory cue associated with the SD experience activated Fos and FosB/DeltaFosB (DeltaFosB) expression in brain regions implicated in the development of post-traumatic stress disorder.\n'
p14951
sg4
(lp14952
(dp14953
g7
I127
sg8
VP01100
p14954
sg10
I3
sg11
VFos
p14955
sg13
I1
sa(dp14956
g7
I135
sg8
VP53539
p14957
sg10
I4
sg11
VFosB
p14958
sg13
I1
sasg14
(lp14959
(dp14960
g7
I223
sg17
VC0038436
p14961
sg10
I30
sg11
Vpost-traumatic stress disorder
p14962
sg13
I3
sasa(dp14963
g2
S'On day 25, pulmonary eosinophilia, airway hyperresponsiveness, mucus hypersecretion, inflammatory cytokines such as IL-4, -5 and -13 in BAL fluid, gene expression of inflammatory mediators such as 5-LOX, E-selectin, VCAM-1, CCL5, TNF-Alfa, AMCase, Ym2, YKL-40, Muc5ac, CCL2 and iNOS in animal lung tissues, and serum IgE were determined.\n'
p14964
sg4
(lp14965
(dp14966
g7
I278
sg8
g49
sg10
I4
sg11
ViNOS
p14967
sg13
I1
sa(dp14968
g7
I269
sg8
VP13500
p14969
sg10
I4
sg11
VCCL2
p14970
sg13
I1
sa(dp14971
g7
I224
sg8
VP13501
p14972
sg10
I4
sg11
VCCL5
p14973
sg13
I1
sa(dp14974
g7
I311
sg8
VP01854
p14975
sg10
I9
sg11
Vserum IgE
p14976
sg13
I2
sa(dp14977
g7
I204
sg8
VP16581
p14978
sg10
I10
sg11
VE-selectin
p14979
sg13
I1
sa(dp14980
g7
I230
sg8
VP01375
p14981
sg10
I8
sg11
VTNF-Alfa
p14982
sg13
I1
sa(dp14983
g7
I197
sg8
VP09917
p14984
sg10
I5
sg11
V5-LOX
p14985
sg13
I1
sa(dp14986
g7
I116
sg8
VP05112
p14987
sg10
I4
sg11
VIL-4
p14988
sg13
I1
sa(dp14989
g7
I216
sg8
VP19320
p14990
sg10
I6
sg11
VVCAM-1
p14991
sg13
I1
sa(dp14992
g7
I253
sg8
VP36222
p14993
sg10
I6
sg11
VYKL-40
p14994
sg13
I1
sasg14
(lp14995
(dp14996
g7
I317
sg17
VC0270850
p14997
sg10
I3
sg11
VIgE
p14998
sg13
I1
sa(dp14999
g7
I11
sg17
VC0034068
p15000
sg10
I22
sg11
Vpulmonary eosinophilia
p15001
sg13
I2
sasa(dp15002
g2
S'We explored the relationship between 5-LO, central and peripheral eosinophilia, and effectiveness of DEC, using PAS or BALB/c mice and 5-LO-deficient mutants.\n'
p15003
sg4
(lp15004
sg14
(lp15005
(dp15006
g7
I66
sg17
VC0014457
p15007
sg10
I12
sg11
Veosinophilia
p15008
sg13
I1
sasa(dp15009
g2
S'5-Lipoxygenase (5-LO)-deficient mice exposed to short-term intranasal Aspergillus protease allergen showed attenuated airway inflammation, decreased airway hyper-responsiveness and reduced bronchoalveolar eosinophilia when compared to wild-type mice.\n'
p15010
sg4
(lp15011
(dp15012
g7
I0
sg8
VP09917
p15013
sg10
I14
sg11
V5-Lipoxygenase
p15014
sg13
I1
sa(dp15015
g7
I70
sg8
VP63123
p15016
sg10
I29
sg11
VAspergillus protease allergen
p15017
sg13
I3
sasg14
(lp15018
(dp15019
g7
I205
sg17
VC0014457
p15020
sg10
I12
sg11
Veosinophilia
p15021
sg13
I1
sa(dp15022
g7
I125
sg17
VC0021368
p15023
sg10
I12
sg11
Vinflammation
p15024
sg13
I1
sasa(dp15025
g2
S'We found that 5-LO knockout mice that were treated with a COX inhibitor during allergic sensitization and challenge had significantly increased airway hyperresponsiveness (AHR) (p &lt; 0.01) and airway eosinophilia (p &lt; 0.01) compared with 5-LO knockout mice that were treated with vehicle.\n'
p15026
sg4
(lp15027
(dp15028
g7
I172
sg8
VP35869
p15029
sg10
I3
sg11
VAHR
p15030
sg13
I1
sa(dp15031
g7
I144
sg8
VP35869
p15032
sg10
I26
sg11
Vairway hyperresponsiveness
p15033
sg13
I2
sasg14
(lp15034
(dp15035
g7
I202
sg17
VC0014457
p15036
sg10
I12
sg11
Veosinophilia
p15037
sg13
I1
sasa(dp15038
g2
S'The effect of LTD(4) inhalation on antigen-induced AHR and airway eosinophilia was investigated in 5-LO gene-deficient mice.\n'
p15039
sg4
(lp15040
(dp15041
g7
I51
sg8
VP35869
p15042
sg10
I3
sg11
VAHR
p15043
sg13
I1
sasg14
(lp15044
(dp15045
g7
I66
sg17
VC0014457
p15046
sg10
I12
sg11
Veosinophilia
p15047
sg13
I1
sasa(dp15048
g2
S'We have reviewed current evidence in order to compare the utility of these functional diagnostic techniques with the fecal elastase-1 (FE-1) test in the following three scenarios: screening for PEI in patients presenting with symptoms suggestive of pancreatic disease, such as abdominal pain or diarrhea; determining the presence of PEI in patients with an established diagnosis of pancreatic disease, such as chronic pancreatitis or cystic fibrosis; determining exocrine status in disorders not commonly tested for PEI, but which have a known association with this disorder.\n'
p15049
sg4
(lp15050
(dp15051
g7
I135
sg8
VP08861
p15052
sg10
I4
sg11
VFE-1
p15053
sg13
I1
sa(dp15054
g7
I117
sg8
g49
sg10
I16
sg11
Vfecal elastase-1
p15055
sg13
I2
sasg14
(lp15056
(dp15057
g7
I277
sg17
VC0000737
p15058
sg10
I14
sg11
Vabdominal pain
p15059
sg13
I2
sa(dp15060
g7
I295
sg17
VC0011991
p15061
sg10
I8
sg11
Vdiarrhea
p15062
sg13
I1
sa(dp15063
g7
I249
sg17
VC0030286
p15064
sg10
I18
sg11
Vpancreatic disease
p15065
sg13
I2
sa(dp15066
g7
I249
sg17
VC0030286
p15067
sg10
I18
sg11
Vpancreatic disease
p15068
sg13
I2
sa(dp15069
g7
I434
sg17
VC0010674
p15070
sg10
I15
sg11
Vcystic fibrosis
p15071
sg13
I2
sa(dp15072
g7
I410
sg17
VC0149521
p15073
sg10
I20
sg11
Vchronic pancreatitis
p15074
sg13
I2
sasa(dp15075
g2
S"Although the importance of USP15 in pathologic processes remains ambiguous so far, in this review, we endeavor to summarize the literature regarding the relationship of the deubiquitinating action of USP15 with the proteins involved in the regulation of Parkinson's disease, virus infection, and cancer-related signaling networks.\n"
p15076
sg4
(lp15077
(dp15078
g7
I27
sg8
g49
sg10
I5
sg11
VUSP15
p15079
sg13
I1
sa(dp15080
g7
I27
sg8
g49
sg10
I5
sg11
VUSP15
p15081
sg13
I1
sasg14
(lp15082
(dp15083
g7
I254
sg17
VC0030567
p15084
sg10
I19
sg11
VParkinson's disease
p15085
sg13
I2
sa(dp15086
g7
I275
sg17
VC0042769
p15087
sg10
I15
sg11
Vvirus infection
p15088
sg13
I2
sa(dp15089
g7
I296
sg17
VC0006826
p15090
sg10
I6
sg11
Vcancer
p15091
sg13
I1
sa(dp15092
g7
I36
sg17
VC0030660
p15093
sg10
I20
sg11
Vpathologic processes
p15094
sg13
I2
sasa(dp15095
g2
S'We identified a mutation in the gene encoding the deubiquitination enzyme USP15 (Usp15L749R) that protected mice against both experimental cerebral malaria (ECM) induced by Plasmodium berghei and experimental autoimmune encephalomyelitis (EAE).\n'
p15096
sg4
(lp15097
(dp15098
g7
I74
sg8
g49
sg10
I5
sg11
VUSP15
p15099
sg13
I1
sasg14
(lp15100
(dp15101
g7
I139
sg17
VC0024534
p15102
sg10
I16
sg11
Vcerebral malaria
p15103
sg13
I2
sa(dp15104
g7
I220
sg17
VC0014070
p15105
sg10
I17
sg11
Vencephalomyelitis
p15106
sg13
I1
sa(dp15107
g7
I239
sg17
VC0014070
p15108
sg10
I3
sg11
VEAE
p15109
sg13
I1
sa(dp15110
g7
I209
sg17
VC0443146
p15111
sg10
I10
sg11
Vautoimmune
p15112
sg13
I1
sasa(dp15113
g2
S'We conducted an optimal-dose determination of combination chemotherapy consisting of paclitaxel (TXL), doxorubicin, and carboplatin (CBDCA) (TAC) in patients with endometrial cancer.\n'
p15114
sg4
(lp15115
sg14
(lp15116
(dp15117
g7
I163
sg17
VC0476089
p15118
sg10
I18
sg11
Vendometrial cancer
p15119
sg13
I2
sasa(dp15120
g2
S'The recommended dose of TAC therapy for endometrial cancer was doxorubicin 45 mg/m(2) for day 1, TXL 150 mg/m(2) and CBDCA AUC 5 for day 2.\n'
p15121
sg4
(lp15122
sg14
(lp15123
(dp15124
g7
I40
sg17
VC0476089
p15125
sg10
I18
sg11
Vendometrial cancer
p15126
sg13
I2
sasa(dp15127
g2
S'The effective regimens were CPT-11 + TXL, CDDP + CPT-11, CDDP + CPM, CDDP + TXL for the endometrial cancer.\n'
p15128
sg4
(lp15129
(dp15130
g7
I28
sg8
VP23786
p15131
sg10
I12
sg11
VCPT-11 + TXL
p15132
sg13
I3
sa(dp15133
g7
I69
sg8
g49
sg10
I10
sg11
VCDDP + TXL
p15134
sg13
I3
sa(dp15135
g7
I57
sg8
VP14384
p15136
sg10
I10
sg11
VCDDP + CPM
p15137
sg13
I3
sa(dp15138
g7
I42
sg8
VP23786
p15139
sg10
I13
sg11
VCDDP + CPT-11
p15140
sg13
I3
sasg14
(lp15141
(dp15142
g7
I88
sg17
VC0476089
p15143
sg10
I18
sg11
Vendometrial cancer
p15144
sg13
I2
sasa(dp15145
g2
S'SFRP2 promoter methylation was investigated in stool DNA isolated from 18 colorectal cancer (CRC) patients and 22 healthy controls using the MSRH assay based on methylation-specific DNA amplification followed by reverse hybridization of biotinylated amplicons to sequence-specific methylation detection probes, with MethyLight serving as a reference method.\n'
p15146
sg4
(lp15147
(dp15148
g7
I0
sg8
g49
sg10
I5
sg11
VSFRP2
p15149
sg13
I1
sasg14
(lp15150
(dp15151
g7
I93
sg17
VC1527249
p15152
sg10
I3
sg11
VCRC
p15153
sg13
I1
sa(dp15154
g7
I186
sg17
VC1705759
p15155
sg10
I13
sg11
Vamplification
p15156
sg13
I1
sa(dp15157
g7
I74
sg17
VC1527249
p15158
sg10
I17
sg11
Vcolorectal cancer
p15159
sg13
I2
sasa(dp15160
g2
S'We performed an epigenetic analysis of the first exon of the hVIM gene and the SFRP2 in circulating tumor cells (CTCs) and correlation with the corresponding primary colorectal cancer (CRC) tissue.\n'
p15161
sg4
(lp15162
(dp15163
g7
I166
sg8
VP31749
p15164
sg10
I23
sg11
Vcolorectal cancer (CRC)
p15165
sg13
I3
sa(dp15166
g7
I79
sg8
g49
sg10
I5
sg11
VSFRP2
p15167
sg13
I1
sasg14
(lp15168
(dp15169
g7
I100
sg17
VC0027651
p15170
sg10
I5
sg11
Vtumor
p15171
sg13
I1
sa(dp15172
g7
I166
sg17
VC1527249
p15173
sg10
I17
sg11
Vcolorectal cancer
p15174
sg13
I2
sa(dp15175
g7
I185
sg17
VC1527249
p15176
sg10
I3
sg11
VCRC
p15177
sg13
I1
sasa(dp15178
g2
S'To evaluate the diagnostic value of secreted frizzled-related protein 2 (SFRP2) gene promoter hypermethylation in stool for colorectal cancer (CRC).\n'
p15179
sg4
(lp15180
(dp15181
g7
I36
sg8
g49
sg10
I35
sg11
Vsecreted frizzled-related protein 2
p15182
sg13
I4
sa(dp15183
g7
I73
sg8
g49
sg10
I5
sg11
VSFRP2
p15184
sg13
I1
sasg14
(lp15185
(dp15186
g7
I124
sg17
VC1527249
p15187
sg10
I17
sg11
Vcolorectal cancer
p15188
sg13
I2
sa(dp15189
g7
I143
sg17
VC1527249
p15190
sg10
I3
sg11
VCRC
p15191
sg13
I1
sasa(dp15192
g2
S'Finally, targeting DNMT3B by these miRs, decreased methylation of tumor suppressor genes such as SFRP1, SFRP2, WIF1 and DKK2 in the mentioned cell lines, and returned the expression of these tumor suppressor genes which can contribute to lethal effect on colon cancer cells and reducing tumorigenicity of these cells.\n'
p15193
sg4
(lp15194
(dp15195
g7
I111
sg8
g49
sg10
I4
sg11
VWIF1
p15196
sg13
I1
sa(dp15197
g7
I104
sg8
g49
sg10
I5
sg11
VSFRP2
p15198
sg13
I1
sa(dp15199
g7
I97
sg8
g49
sg10
I5
sg11
VSFRP1
p15200
sg13
I1
sa(dp15201
g7
I120
sg8
g49
sg10
I4
sg11
VDKK2
p15202
sg13
I1
sasg14
(lp15203
(dp15204
g7
I255
sg17
VC0699790
p15205
sg10
I12
sg11
Vcolon cancer
p15206
sg13
I2
sa(dp15207
g7
I66
sg17
VC0027651
p15208
sg10
I5
sg11
Vtumor
p15209
sg13
I1
sa(dp15210
g7
I66
sg17
VC0027651
p15211
sg10
I5
sg11
Vtumor
p15212
sg13
I1
sa(dp15213
g7
I287
sg17
VC1519697
p15214
sg10
I14
sg11
Vtumorigenicity
p15215
sg13
I1
sasa(dp15216
g2
S'New research implicates Myo10 in a number of disease states including cancer metastasis and pathogen infection.\n'
p15217
sg4
(lp15218
(dp15219
g7
I24
sg8
g49
sg10
I5
sg11
VMyo10
p15220
sg13
I1
sasg14
(lp15221
(dp15222
g7
I70
sg17
VC0006826
p15223
sg10
I6
sg11
Vcancer
p15224
sg13
I1
sa(dp15225
g7
I77
sg17
VC0027627
p15226
sg10
I10
sg11
Vmetastasis
p15227
sg13
I1
sa(dp15228
g7
I101
sg17
VC0009450
p15229
sg10
I9
sg11
Vinfection
p15230
sg13
I1
sasa(dp15231
g2
S'This review focuses on these developments with emphasis on the emerging roles of Myo10 in formation of cancer cell protrusions and metastasis.\n'
p15232
sg4
(lp15233
(dp15234
g7
I81
sg8
g49
sg10
I5
sg11
VMyo10
p15235
sg13
I1
sasg14
(lp15236
(dp15237
g7
I131
sg17
VC0027627
p15238
sg10
I10
sg11
Vmetastasis
p15239
sg13
I1
sa(dp15240
g7
I103
sg17
VC0006826
p15241
sg10
I6
sg11
Vcancer
p15242
sg13
I1
sa(dp15243
g7
I115
sg17
VC0333056
p15244
sg10
I11
sg11
Vprotrusions
p15245
sg13
I1
sasa(dp15246
g2
S'A number of aggressive cancers show high levels of Myo10 expression and knockdown of Myo10 has been shown to dramatically limit cancer cell motility in 2D and 3D systems.\n'
p15247
sg4
(lp15248
(dp15249
g7
I51
sg8
g49
sg10
I5
sg11
VMyo10
p15250
sg13
I1
sa(dp15251
g7
I51
sg8
g49
sg10
I5
sg11
VMyo10
p15252
sg13
I1
sasg14
(lp15253
(dp15254
g7
I12
sg17
VC0001807
p15255
sg10
I10
sg11
Vaggressive
p15256
sg13
I1
sa(dp15257
g7
I23
sg17
VC0006826
p15258
sg10
I6
sg11
Vcancer
p15259
sg13
I1
sa(dp15260
g7
I23
sg17
VC0006826
p15261
sg10
I7
sg11
Vcancers
p15262
sg13
I1
sasa(dp15263
g2
S'MYO10 was subsequently identified as a novel functional downstream target of miR-124, and was up-regulated in node-positive NSCLC tissues.\n'
p15264
sg4
(lp15265
(dp15266
g7
I77
sg8
g49
sg10
I7
sg11
VmiR-124
p15267
sg13
I1
sa(dp15268
g7
I0
sg8
g49
sg10
I5
sg11
VMYO10
p15269
sg13
I1
sasg14
(lp15270
(dp15271
g7
I124
sg17
VC0007131
p15272
sg10
I5
sg11
VNSCLC
p15273
sg13
I1
sasa(dp15274
g2
S'These results suggest that NF-KB-regulated miR-124 targets MYO10, inhibits cell invasion and metastasis, and is down-regulated in node-positive NSCLC.\n'
p15275
sg4
(lp15276
(dp15277
g7
I27
sg8
g49
sg10
I37
sg11
VNF-KB-regulated miR-124 targets MYO10
p15278
sg13
I4
sasg14
(lp15279
(dp15280
g7
I144
sg17
VC0007131
p15281
sg10
I5
sg11
VNSCLC
p15282
sg13
I1
sa(dp15283
g7
I93
sg17
VC0027627
p15284
sg10
I10
sg11
Vmetastasis
p15285
sg13
I1
sa(dp15286
g7
I75
sg17
VC2699153
p15287
sg10
I13
sg11
Vcell invasion
p15288
sg13
I2
sasa(dp15289
g2
S'Myosin X (MYO10) was recently reported to promote tumour invasion by transporting integrins to filopodial tips in breast cancer.\n'
p15290
sg4
(lp15291
(dp15292
g7
I10
sg8
g49
sg10
I5
sg11
VMYO10
p15293
sg13
I1
sa(dp15294
g7
I0
sg8
g49
sg10
I8
sg11
VMyosin X
p15295
sg13
I2
sasg14
(lp15296
(dp15297
g7
I114
sg17
VC0678222
p15298
sg10
I13
sg11
Vbreast cancer
p15299
sg13
I2
sa(dp15300
g7
I57
sg17
VC2699153
p15301
sg10
I8
sg11
Vinvasion
p15302
sg13
I1
sa(dp15303
g7
I50
sg17
VC0027651
p15304
sg10
I6
sg11
Vtumour
p15305
sg13
I1
sasa(dp15306
g2
S'The expression of MYO10 and its associations with clinicopathological and biological factors were examined in breast cancer cells and breast cancer specimens (n=120).\n'
p15307
sg4
(lp15308
(dp15309
g7
I18
sg8
g49
sg10
I5
sg11
VMYO10
p15310
sg13
I1
sasg14
(lp15311
(dp15312
g7
I110
sg17
VC0678222
p15313
sg10
I13
sg11
Vbreast cancer
p15314
sg13
I2
sa(dp15315
g7
I110
sg17
VC0678222
p15316
sg10
I13
sg11
Vbreast cancer
p15317
sg13
I2
sasa(dp15318
g2
S'Our findings suggest that elevated MYO10 expression increases the aggressiveness of breast cancer; this effect is dependent on the involvement of MYO10 in invadopodial formation.\n'
p15319
sg4
(lp15320
(dp15321
g7
I35
sg8
g49
sg10
I5
sg11
VMYO10
p15322
sg13
I1
sa(dp15323
g7
I35
sg8
g49
sg10
I5
sg11
VMYO10
p15324
sg13
I1
sasg14
(lp15325
(dp15326
g7
I84
sg17
VC0678222
p15327
sg10
I13
sg11
Vbreast cancer
p15328
sg13
I2
sa(dp15329
g7
I66
sg17
VC0001807
p15330
sg10
I14
sg11
Vaggressiveness
p15331
sg13
I1
sasa(dp15332
g2
S'Here, we demonstrate a role for the filopodia-inducing motor protein Myosin-X (Myo10) in mutant p53-driven cancer invasion.\n'
p15333
sg4
(lp15334
(dp15335
g7
I69
sg8
g49
sg10
I8
sg11
VMyosin-X
p15336
sg13
I1
sa(dp15337
g7
I79
sg8
g49
sg10
I5
sg11
VMyo10
p15338
sg13
I1
sa(dp15339
g7
I89
sg8
VP42771
p15340
sg10
I10
sg11
Vmutant p53
p15341
sg13
I2
sasg14
(lp15342
(dp15343
g7
I107
sg17
VC0006826
p15344
sg10
I6
sg11
Vcancer
p15345
sg13
I1
sa(dp15346
g7
I89
sg17
VC0596988
p15347
sg10
I6
sg11
Vmutant
p15348
sg13
I1
sa(dp15349
g7
I114
sg17
VC2699153
p15350
sg10
I8
sg11
Vinvasion
p15351
sg13
I1
sasa(dp15352
g2
S'Analysis of gene expression profiles from 2 breast cancer data sets revealed that MYO10 was highly expressed in aggressive cancer subtypes.\n'
p15353
sg4
(lp15354
(dp15355
g7
I82
sg8
g49
sg10
I5
sg11
VMYO10
p15356
sg13
I1
sasg14
(lp15357
(dp15358
g7
I112
sg17
VC2945759
p15359
sg10
I17
sg11
Vaggressive cancer
p15360
sg13
I2
sa(dp15361
g7
I44
sg17
VC0678222
p15362
sg10
I13
sg11
Vbreast cancer
p15363
sg13
I2
sasa(dp15364
g2
S'Myo10 was required for breast cancer cell invasion and dissemination in multiple cancer cell lines and murine models of cancer metastasis.\n'
p15365
sg4
(lp15366
(dp15367
g7
I0
sg8
g49
sg10
I5
sg11
VMyo10
p15368
sg13
I1
sasg14
(lp15369
(dp15370
g7
I127
sg17
VC0027627
p15371
sg10
I10
sg11
Vmetastasis
p15372
sg13
I1
sa(dp15373
g7
I37
sg17
VC2699153
p15374
sg10
I13
sg11
Vcell invasion
p15375
sg13
I2
sa(dp15376
g7
I72
sg17
VC0346429
p15377
sg10
I15
sg11
Vmultiple cancer
p15378
sg13
I2
sa(dp15379
g7
I23
sg17
VC0678222
p15380
sg10
I13
sg11
Vbreast cancer
p15381
sg13
I2
sa(dp15382
g7
I30
sg17
VC0006826
p15383
sg10
I6
sg11
Vcancer
p15384
sg13
I1
sasa(dp15385
g2
S'Introduction of mutant p53 promoted Myo10 expression in cancer cells and pancreatic ductal adenocarcinoma in mice, whereas suppression of endogenous mutant p53 attenuated Myo10 levels and cell invasion.\n'
p15386
sg4
(lp15387
(dp15388
g7
I36
sg8
g49
sg10
I5
sg11
VMyo10
p15389
sg13
I1
sa(dp15390
g7
I23
sg8
VP42771
p15391
sg10
I3
sg11
Vp53
p15392
sg13
I1
sa(dp15393
g7
I36
sg8
g49
sg10
I5
sg11
VMyo10
p15394
sg13
I1
sa(dp15395
g7
I138
sg8
VP42771
p15396
sg10
I21
sg11
Vendogenous mutant p53
p15397
sg13
I3
sasg14
(lp15398
(dp15399
g7
I188
sg17
VC2699153
p15400
sg10
I13
sg11
Vcell invasion
p15401
sg13
I2
sa(dp15402
g7
I16
sg17
VC0596988
p15403
sg10
I6
sg11
Vmutant
p15404
sg13
I1
sa(dp15405
g7
I73
sg17
VC1335302
p15406
sg10
I32
sg11
Vpancreatic ductal adenocarcinoma
p15407
sg13
I3
sa(dp15408
g7
I16
sg17
VC0596988
p15409
sg10
I6
sg11
Vmutant
p15410
sg13
I1
sa(dp15411
g7
I123
sg17
VC0221103
p15412
sg10
I11
sg11
Vsuppression
p15413
sg13
I1
sa(dp15414
g7
I56
sg17
VC0006826
p15415
sg10
I6
sg11
Vcancer
p15416
sg13
I1
sasa(dp15417
g2
S'These data indicate that Myo10 upregulation in mutant p53-driven cancers is necessary for invasion and that plasma-membrane protrusions, such as filopodia, may serve as specialized metastatic engines.\n'
p15418
sg4
(lp15419
(dp15420
g7
I25
sg8
g49
sg10
I5
sg11
VMyo10
p15421
sg13
I1
sa(dp15422
g7
I47
sg8
VP42771
p15423
sg10
I10
sg11
Vmutant p53
p15424
sg13
I2
sasg14
(lp15425
(dp15426
g7
I47
sg17
VC0596988
p15427
sg10
I6
sg11
Vmutant
p15428
sg13
I1
sa(dp15429
g7
I65
sg17
VC0006826
p15430
sg10
I7
sg11
Vcancers
p15431
sg13
I1
sa(dp15432
g7
I124
sg17
VC0333056
p15433
sg10
I11
sg11
Vprotrusions
p15434
sg13
I1
sa(dp15435
g7
I90
sg17
VC2699153
p15436
sg10
I8
sg11
Vinvasion
p15437
sg13
I1
sasa(dp15438
g2
S'We also demonstrate that fMyo10-dependent orientation of radial migration is mediated at least in part by the netrin-1 receptor deleted in colorectal cancer.\n'
p15439
sg4
(lp15440
(dp15441
g7
I110
sg8
g49
sg10
I17
sg11
Vnetrin-1 receptor
p15442
sg13
I2
sasg14
(lp15443
(dp15444
g7
I139
sg17
VC1527249
p15445
sg10
I17
sg11
Vcolorectal cancer
p15446
sg13
I2
sasa(dp15447
g2
S'Peripheral hyperinsulinemia modestly increases ISF and plasma ABeta in young and old mice, independent of neuronal insulin signaling.\n'
p15448
sg4
(lp15449
(dp15450
g7
I106
sg8
VP01308
p15451
sg10
I16
sg11
Vneuronal insulin
p15452
sg13
I2
sasg14
(lp15453
(dp15454
g7
I11
sg17
VC0020459
p15455
sg10
I16
sg11
Vhyperinsulinemia
p15456
sg13
I1
sasa(dp15457
g2
S'We found that physiological hyperinsulinemia in awake, behaving mice does not increase CNS insulin to an appreciable level yet modestly increases extracellular ABeta.\n'
p15458
sg4
(lp15459
(dp15460
g7
I87
sg8
VP01308
p15461
sg10
I11
sg11
VCNS insulin
p15462
sg13
I2
sasg14
(lp15463
(dp15464
g7
I28
sg17
VC0020459
p15465
sg10
I16
sg11
Vhyperinsulinemia
p15466
sg13
I1
sasa(dp15467
g2
S'In order to understand this relationship, we have studied an AD-prediabetes mouse model (APP/PS1) with severe hyperinsulinemia induced by long-term high fat diet (HFD), and an AD-T2D model, generated by crossing APP/PS1 and db/db mice (APP/PS1xdb/db).\n'
p15468
sg4
(lp15469
(dp15470
g7
I89
sg8
g49
sg10
I3
sg11
VAPP
p15471
sg13
I1
sa(dp15472
g7
I89
sg8
g49
sg10
I3
sg11
VAPP
p15473
sg13
I1
sa(dp15474
g7
I93
sg8
VP49768
p15475
sg10
I3
sg11
VPS1
p15476
sg13
I1
sa(dp15477
g7
I89
sg8
g49
sg10
I3
sg11
VAPP
p15478
sg13
I1
sa(dp15479
g7
I93
sg8
VP49768
p15480
sg10
I3
sg11
VPS1
p15481
sg13
I1
sasg14
(lp15482
(dp15483
g7
I64
sg17
VC0362046
p15484
sg10
I11
sg11
Vprediabetes
p15485
sg13
I1
sa(dp15486
g7
I110
sg17
VC0020459
p15487
sg10
I16
sg11
Vhyperinsulinemia
p15488
sg13
I1
sa(dp15489
g7
I179
sg17
VC0011860
p15490
sg10
I3
sg11
VT2D
p15491
sg13
I1
sasa(dp15492
g2
S'We present a mouse model of AD (APPswe/PS1dE9 mouse) with severe hyperinsulinemia induced by long-term high fat diet (HFD) treatment.\n'
p15493
sg4
(lp15494
sg14
(lp15495
(dp15496
g7
I65
sg17
VC0020459
p15497
sg10
I16
sg11
Vhyperinsulinemia
p15498
sg13
I1
sasa(dp15499
g2
S'Altogether our data suggest that early hyperinsulinemia is enough to exacerbate AD pathology observed in APP/PS1 mice, and supports the role of insulin-resistance therapies to stop or delay central complications associated.\n'
p15500
sg4
(lp15501
(dp15502
g7
I109
sg8
VP49768
p15503
sg10
I3
sg11
VPS1
p15504
sg13
I1
sa(dp15505
g7
I44
sg8
VP01308
p15506
sg10
I7
sg11
Vinsulin
p15507
sg13
I1
sa(dp15508
g7
I105
sg8
g49
sg10
I3
sg11
VAPP
p15509
sg13
I1
sasg14
(lp15510
(dp15511
g7
I83
sg17
VC0677042
p15512
sg10
I9
sg11
Vpathology
p15513
sg13
I1
sa(dp15514
g7
I39
sg17
VC0020459
p15515
sg10
I16
sg11
Vhyperinsulinemia
p15516
sg13
I1
sasa(dp15517
g2
S'To identify the risk factors of acute pancreatitis (AP) associated with different etiologies, in pregnancy (APP).\n'
p15518
sg4
(lp15519
sg14
(lp15520
(dp15521
g7
I52
sg17
VC0001339
p15522
sg10
I2
sg11
VAP
p15523
sg13
I1
sa(dp15524
g7
I32
sg17
VC0001339
p15525
sg10
I18
sg11
Vacute pancreatitis
p15526
sg13
I2
sasa(dp15527
g2
S'Forty-seven eligible patients were divided into two groups: biliary acute pancreatitis in pregnancy (BAPP, n = 31) and hypertriglyceridemic-induced pancreatitis in pregnancy (HAPP, n = 16).\n'
p15528
sg4
(lp15529
sg14
(lp15530
(dp15531
g7
I60
sg17
VC0747194
p15532
sg10
I26
sg11
Vbiliary acute pancreatitis
p15533
sg13
I3
sa(dp15534
g7
I74
sg17
VC0030305
p15535
sg10
I12
sg11
Vpancreatitis
p15536
sg13
I1
sasa(dp15537
g2
S'Instead, they have been associated with several distinct clinical phenotypes, such as epidermolysis bullosa simplex with mottled pigmentation (mutation P25L in the V1 domain of keratin 5), epidermolysis bullosa simplex with migratory circinate erythema (frameshift mutation c1649delG in the V2 domain of keratin 5), striate palmoplantar keratoderma (PPK), and ichthyosis hystrix Curth-Macklin (different frameshift mutations in the V2 domain of keratin 1 (K1)).\n'
p15538
sg4
(lp15539
(dp15540
g7
I445
sg8
VP04264
p15541
sg10
I9
sg11
Vkeratin 1
p15542
sg13
I2
sa(dp15543
g7
I177
sg8
VP02533
p15544
sg10
I9
sg11
Vkeratin 5
p15545
sg13
I2
sa(dp15546
g7
I177
sg8
VP02533
p15547
sg10
I9
sg11
Vkeratin 5
p15548
sg13
I2
sasg14
(lp15549
(dp15550
g7
I350
sg17
VC0022596
p15551
sg10
I3
sg11
VPPK
p15552
sg13
I1
sa(dp15553
g7
I360
sg17
VC0263580
p15554
sg10
I18
sg11
Vichthyosis hystrix
p15555
sg13
I2
sa(dp15556
g7
I324
sg17
VC0022596
p15557
sg10
I24
sg11
Vpalmoplantar keratoderma
p15558
sg13
I2
sa(dp15559
g7
I189
sg17
VC1836284
p15560
sg10
I63
sg11
Vepidermolysis bullosa simplex with migratory circinate erythema
p15561
sg13
I7
sa(dp15562
g7
I404
sg17
VC0079380
p15563
sg10
I20
sg11
Vframeshift mutations
p15564
sg13
I2
sa(dp15565
g7
I254
sg17
VC0079380
p15566
sg10
I19
sg11
Vframeshift mutation
p15567
sg13
I2
sa(dp15568
g7
I86
sg17
VC0432316
p15569
sg10
I55
sg11
Vepidermolysis bullosa simplex with mottled pigmentation
p15570
sg13
I6
sasa(dp15571
g2
S'Idiopathic CD4 lymphocytopenia (ICL) is a rare disorder of unknown etiology.\n'
p15572
sg4
(lp15573
(dp15574
g7
I11
sg8
VP01730
p15575
sg10
I3
sg11
VCD4
p15576
sg13
I1
sasg14
(lp15577
(dp15578
g7
I15
sg17
VC0024312
p15579
sg10
I15
sg11
Vlymphocytopenia
p15580
sg13
I1
sa(dp15581
g7
I42
sg17
VC0678236
p15582
sg10
I13
sg11
Vrare disorder
p15583
sg13
I2
sasa(dp15584
g2
S'Systemic Mycobacterium avium intracellulaire (MAI) have been reported in non-HIV patients with Idiopathic CD4 lymphocytopenia.\n'
p15585
sg4
(lp15586
(dp15587
g7
I106
sg8
VP01730
p15588
sg10
I3
sg11
VCD4
p15589
sg13
I1
sasg14
(lp15590
(dp15591
g7
I77
sg17
VC0019693
p15592
sg10
I3
sg11
VHIV
p15593
sg13
I1
sa(dp15594
g7
I110
sg17
VC0024312
p15595
sg10
I15
sg11
Vlymphocytopenia
p15596
sg13
I1
sasa(dp15597
g2
S'We report two cases of immunocompetent patients with necrotizing viral retinitis found to have idiopathic CD4 lymphocytopenia.\n'
p15598
sg4
(lp15599
(dp15600
g7
I106
sg8
VP01730
p15601
sg10
I3
sg11
VCD4
p15602
sg13
I1
sasg14
(lp15603
(dp15604
g7
I65
sg17
VC0339406
p15605
sg10
I15
sg11
Vviral retinitis
p15606
sg13
I2
sa(dp15607
g7
I110
sg17
VC0024312
p15608
sg10
I15
sg11
Vlymphocytopenia
p15609
sg13
I1
sasa(dp15610
g2
S'Idiopathic CD4 lymphocytopenia should be considered healthy patients who develop ocular infections seen in the immunocompromised.\n'
p15611
sg4
(lp15612
(dp15613
g7
I11
sg8
VP01730
p15614
sg10
I3
sg11
VCD4
p15615
sg13
I1
sasg14
(lp15616
(dp15617
g7
I15
sg17
VC0024312
p15618
sg10
I15
sg11
Vlymphocytopenia
p15619
sg13
I1
sa(dp15620
g7
I81
sg17
VC0015403
p15621
sg10
I17
sg11
Vocular infections
p15622
sg13
I2
sasa(dp15623
g2
S'Here we demonstrate that IL-21-producing CD8 T cells are not associated with CD4 depletion and are absent in patients with idiopathic CD4 lymphocytopenia.\n'
p15624
sg4
(lp15625
(dp15626
g7
I41
sg8
VP01732
p15627
sg10
I5
sg11
VCD8 T
p15628
sg13
I2
sa(dp15629
g7
I77
sg8
VP01730
p15630
sg10
I3
sg11
VCD4
p15631
sg13
I1
sa(dp15632
g7
I77
sg8
VP01730
p15633
sg10
I3
sg11
VCD4
p15634
sg13
I1
sasg14
(lp15635
(dp15636
g7
I138
sg17
VC0024312
p15637
sg10
I15
sg11
Vlymphocytopenia
p15638
sg13
I1
sasa(dp15639
g2
S'Clinicians should be aware of LOCID, which could be confused with HIV infection/AIDS or idiopathic CD4 lymphocytopenia.\n'
p15640
sg4
(lp15641
(dp15642
g7
I99
sg8
VP01730
p15643
sg10
I3
sg11
VCD4
p15644
sg13
I1
sasg14
(lp15645
(dp15646
g7
I103
sg17
VC0024312
p15647
sg10
I15
sg11
Vlymphocytopenia
p15648
sg13
I1
sa(dp15649
g7
I52
sg17
VC0009676
p15650
sg10
I8
sg11
Vconfused
p15651
sg13
I1
sa(dp15652
g7
I66
sg17
VC0019693
p15653
sg10
I13
sg11
VHIV infection
p15654
sg13
I2
sasa(dp15655
g2
S'Idiopathic CD4 lymphocytopenia is a very rare condition resulting in an immunodeficiency disorder that may or may not result in opportunistic infections.\n'
p15656
sg4
(lp15657
(dp15658
g7
I11
sg8
VP01730
p15659
sg10
I3
sg11
VCD4
p15660
sg13
I1
sasg14
(lp15661
(dp15662
g7
I128
sg17
VC0029118
p15663
sg10
I24
sg11
Vopportunistic infections
p15664
sg13
I2
sa(dp15665
g7
I72
sg17
VC0021051
p15666
sg10
I25
sg11
Vimmunodeficiency disorder
p15667
sg13
I2
sa(dp15668
g7
I15
sg17
VC0024312
p15669
sg10
I15
sg11
Vlymphocytopenia
p15670
sg13
I1
sa(dp15671
g7
I46
sg17
VC0012634
p15672
sg10
I9
sg11
Vcondition
p15673
sg13
I1
sasa(dp15674
g2
S'To our knowledge, this is the first case of neuroinvasive West Nile virus occurring in the context of a diagnosis of idiopathic CD4 lymphocytopenia.\n'
p15675
sg4
(lp15676
(dp15677
g7
I128
sg8
VP01730
p15678
sg10
I3
sg11
VCD4
p15679
sg13
I1
sasg14
(lp15680
(dp15681
g7
I132
sg17
VC0024312
p15682
sg10
I15
sg11
Vlymphocytopenia
p15683
sg13
I1
sa(dp15684
g7
I58
sg17
VC1096184
p15685
sg10
I15
sg11
VWest Nile virus
p15686
sg13
I3
sasa(dp15687
g2
S'Idiopathic CD4 lymphocytopenia is an immunodeficiency disorder with low absolute CD4 T-lymphocyte count with no evidence of human immunodeficiency virus or other known cause.\n'
p15688
sg4
(lp15689
(dp15690
g7
I11
sg8
VP01730
p15691
sg10
I3
sg11
VCD4
p15692
sg13
I1
sa(dp15693
g7
I11
sg8
VP01730
p15694
sg10
I3
sg11
VCD4
p15695
sg13
I1
sasg14
(lp15696
(dp15697
g7
I37
sg17
VC0021051
p15698
sg10
I25
sg11
Vimmunodeficiency disorder
p15699
sg13
I2
sa(dp15700
g7
I15
sg17
VC0024312
p15701
sg10
I15
sg11
Vlymphocytopenia
p15702
sg13
I1
sa(dp15703
g7
I124
sg17
VC0019693
p15704
sg10
I28
sg11
Vhuman immunodeficiency virus
p15705
sg13
I3
sasa(dp15706
g2
S'After further evaluation, idiopathic CD4 lymphocytopenia was diagnosed.\n'
p15707
sg4
(lp15708
(dp15709
g7
I37
sg8
VP01730
p15710
sg10
I3
sg11
VCD4
p15711
sg13
I1
sasg14
(lp15712
(dp15713
g7
I41
sg17
VC0024312
p15714
sg10
I15
sg11
Vlymphocytopenia
p15715
sg13
I1
sasa(dp15716
g2
S'Idiopathic CD4 lymphocytopenia is a rare acquired immunodeficiency.\n'
p15717
sg4
(lp15718
(dp15719
g7
I11
sg8
VP01730
p15720
sg10
I3
sg11
VCD4
p15721
sg13
I1
sasg14
(lp15722
(dp15723
g7
I15
sg17
VC0024312
p15724
sg10
I15
sg11
Vlymphocytopenia
p15725
sg13
I1
sa(dp15726
g7
I50
sg17
VC0021051
p15727
sg10
I16
sg11
Vimmunodeficiency
p15728
sg13
I1
sasa(dp15729
g2
S'Idiopathic CD4 lymphocytopenia (ICL) is a presumed heterogenous syndrome with key element low CD4 T-cell counts (below 300/mm^3) without evidence of HIV infection or other known immunodeficiency.\n'
p15730
sg4
(lp15731
(dp15732
g7
I11
sg8
VP01730
p15733
sg10
I3
sg11
VCD4
p15734
sg13
I1
sa(dp15735
g7
I11
sg8
VP01730
p15736
sg10
I3
sg11
VCD4
p15737
sg13
I1
sasg14
(lp15738
(dp15739
g7
I64
sg17
VC0039082
p15740
sg10
I8
sg11
Vsyndrome
p15741
sg13
I1
sa(dp15742
g7
I15
sg17
VC0024312
p15743
sg10
I15
sg11
Vlymphocytopenia
p15744
sg13
I1
sa(dp15745
g7
I149
sg17
VC0019693
p15746
sg10
I13
sg11
VHIV infection
p15747
sg13
I2
sa(dp15748
g7
I178
sg17
VC0021051
p15749
sg10
I16
sg11
Vimmunodeficiency
p15750
sg13
I1
sasa(dp15751
g2
S'Three paediatric neurologists independently scored ICARS, SARA and BARS performances recorded on video, and also phenotyped the primary and secondary movement disorder features.\n'
p15752
sg4
(lp15753
sg14
(lp15754
(dp15755
g7
I150
sg17
VC0026650
p15756
sg10
I17
sg11
Vmovement disorder
p15757
sg13
I2
sasa(dp15758
g2
S'Prevalence and incidence rates of recurrent major adverse cardiovascular events (MACE) were calculated, according to the ACC/AHA VHR criteria (cardiovascular disease combined with diabetes, smoking, dyslipidaemia, and/or recent recurrent coronary events).\n'
p15759
sg4
(lp15760
(dp15761
g7
I125
sg8
VP51452
p15762
sg10
I7
sg11
VAHA VHR
p15763
sg13
I2
sa(dp15764
g7
I121
sg8
g49
sg10
I3
sg11
VACC
p15765
sg13
I1
sasg14
(lp15766
(dp15767
g7
I143
sg17
VC0007222
p15768
sg10
I22
sg11
Vcardiovascular disease
p15769
sg13
I2
sa(dp15770
g7
I180
sg17
VC0011849
p15771
sg10
I8
sg11
Vdiabetes
p15772
sg13
I1
sa(dp15773
g7
I121
sg17
VC0175754
p15774
sg10
I3
sg11
VACC
p15775
sg13
I1
sa(dp15776
g7
I199
sg17
VC0242339
p15777
sg10
I13
sg11
Vdyslipidaemia
p15778
sg13
I1
sasa(dp15779
g2
S'Independent risk factors included inpatient status at time of open-VHR, operation time, enterolysis, underweight, diabetes, preoperative anemia, length of stay, chronic obstructive pulmonary disease, history of bleeding disorders, hernia with gangrene, and panniculectomy (all P &lt; 0.05).\n'
p15780
sg4
(lp15781
(dp15782
g7
I67
sg8
VP51452
p15783
sg10
I3
sg11
VVHR
p15784
sg13
I1
sasg14
(lp15785
(dp15786
g7
I243
sg17
VC0017086
p15787
sg10
I8
sg11
Vgangrene
p15788
sg13
I1
sa(dp15789
g7
I114
sg17
VC0011849
p15790
sg10
I8
sg11
Vdiabetes
p15791
sg13
I1
sa(dp15792
g7
I161
sg17
VC0024117
p15793
sg10
I37
sg11
Vchronic obstructive pulmonary disease
p15794
sg13
I4
sa(dp15795
g7
I137
sg17
VC0002871
p15796
sg10
I6
sg11
Vanemia
p15797
sg13
I1
sa(dp15798
g7
I211
sg17
VC0005779
p15799
sg10
I18
sg11
Vbleeding disorders
p15800
sg13
I2
sa(dp15801
g7
I231
sg17
VC0019270
p15802
sg10
I6
sg11
Vhernia
p15803
sg13
I1
sasa(dp15804
g2
S'These novel findings reveal that mutant p53-R248 maintains gain-of-function activity to stimulate cell invasion and induces the related gene expressions through an interaction with Rad21 in human ovarian cancer cells.\n'
p15805
sg4
(lp15806
(dp15807
g7
I33
sg8
VP42771
p15808
sg10
I10
sg11
Vmutant p53
p15809
sg13
I2
sa(dp15810
g7
I181
sg8
g49
sg10
I5
sg11
VRad21
p15811
sg13
I1
sasg14
(lp15812
(dp15813
g7
I98
sg17
VC2699153
p15814
sg10
I13
sg11
Vcell invasion
p15815
sg13
I2
sa(dp15816
g7
I196
sg17
VC1140680
p15817
sg10
I14
sg11
Vovarian cancer
p15818
sg13
I2
sa(dp15819
g7
I33
sg17
VC0596988
p15820
sg10
I6
sg11
Vmutant
p15821
sg13
I1
sasa(dp15822
g2
S'Here, our integrated The Cancer Genome Atlas (TCGA) data set, tissue microarray-based analyses and multiple biologic evaluations together demonstrate a new small-molecule activator of ULK1 for better understanding of how ULK1, the mammalian homolog of yeast Atg1, as a potential drug target can regulate ACD by the ULK complex (ULK1-ATG13-RB1CC1/FIP200-ATG101), as well as other possible ULK1 interactors, including ATF3, RAD21 and CASP3/caspase3 in TNBC.\n'
p15823
sg4
(lp15824
(dp15825
g7
I432
sg8
VP42574
p15826
sg10
I5
sg11
VCASP3
p15827
sg13
I1
sa(dp15828
g7
I438
sg8
VP42574
p15829
sg10
I8
sg11
Vcaspase3
p15830
sg13
I1
sa(dp15831
g7
I333
sg8
g49
sg10
I5
sg11
VATG13
p15832
sg13
I1
sa(dp15833
g7
I416
sg8
VP18847
p15834
sg10
I4
sg11
VATF3
p15835
sg13
I1
sa(dp15836
g7
I339
sg8
g49
sg10
I6
sg11
VRB1CC1
p15837
sg13
I1
sa(dp15838
g7
I388
sg8
g49
sg10
I16
sg11
VULK1 interactors
p15839
sg13
I2
sa(dp15840
g7
I353
sg8
g49
sg10
I6
sg11
VATG101
p15841
sg13
I1
sa(dp15842
g7
I315
sg8
g49
sg10
I11
sg11
VULK complex
p15843
sg13
I2
sa(dp15844
g7
I184
sg8
g49
sg10
I4
sg11
VULK1
p15845
sg13
I1
sa(dp15846
g7
I184
sg8
g49
sg10
I4
sg11
VULK1
p15847
sg13
I1
sa(dp15848
g7
I422
sg8
g49
sg10
I5
sg11
VRAD21
p15849
sg13
I1
sa(dp15850
g7
I184
sg8
g49
sg10
I4
sg11
VULK1
p15851
sg13
I1
sa(dp15852
g7
I231
sg8
g49
sg10
I31
sg11
Vmammalian homolog of yeast Atg1
p15853
sg13
I5
sa(dp15854
g7
I346
sg8
g49
sg10
I6
sg11
VFIP200
p15855
sg13
I1
sasg14
(lp15856
(dp15857
g7
I304
sg17
VC0002873
p15858
sg10
I3
sg11
VACD
p15859
sg13
I1
sa(dp15860
g7
I25
sg17
VC0006826
p15861
sg10
I6
sg11
VCancer
p15862
sg13
I1
sasa(dp15863
g2
S'Here, we report that GABA(B1), via the coiled-coil domain, can also bind to soluble proteins of unknown function, that are affected in 22q11 deletion/DiGeorge syndrome and are therefore referred to as DiGeorge critical region 6 (DGCR6).\n'
p15864
sg4
(lp15865
sg14
(lp15866
(dp15867
g7
I150
sg17
VC0012236
p15868
sg10
I17
sg11
VDiGeorge syndrome
p15869
sg13
I2
sasa(dp15870
g2
S'This region includes the genes DGCR6 (DiGeorge syndrome critical region protein 6) and PRODH (proline dehydrogenase 1), along with three open reading frames that may encode proteins of unknown function.\n'
p15871
sg4
(lp15872
(dp15873
g7
I38
sg8
g49
sg10
I43
sg11
VDiGeorge syndrome critical region protein 6
p15874
sg13
I6
sa(dp15875
g7
I31
sg8
g49
sg10
I5
sg11
VDGCR6
p15876
sg13
I1
sasg14
(lp15877
(dp15878
g7
I38
sg17
VC0012236
p15879
sg10
I17
sg11
VDiGeorge syndrome
p15880
sg13
I2
sasa(dp15881
g2
S'Embryos in which DGCR6 expression was attenuated revealed cardiovascular anomalies reminiscent of those found in DiGeorge syndrome.\n'
p15882
sg4
(lp15883
(dp15884
g7
I17
sg8
g49
sg10
I5
sg11
VDGCR6
p15885
sg13
I1
sasg14
(lp15886
(dp15887
g7
I113
sg17
VC0012236
p15888
sg10
I17
sg11
VDiGeorge syndrome
p15889
sg13
I2
sasa(dp15890
g2
S'Dgcr6 is the mouse homolog of human DGCR6, previously shown to be deleted in DiGeorge syndrome, a developmental field defect affecting the derivatives of the pharyngeal arches which is associated with 22q11.2 deletions.\n'
p15891
sg4
(lp15892
(dp15893
g7
I0
sg8
g49
sg10
I5
sg11
VDgcr6
p15894
sg13
I1
sa(dp15895
g7
I30
sg8
g49
sg10
I11
sg11
Vhuman DGCR6
p15896
sg13
I2
sasg14
(lp15897
(dp15898
g7
I77
sg17
VC0012236
p15899
sg10
I17
sg11
VDiGeorge syndrome
p15900
sg13
I2
sasa(dp15901
g2
S'We previously mapped Dgcr6 to mouse chromosome 16B1-B3, a region known to contain other mouse homologs of genes deleted in DiGeorge syndrome.\n'
p15902
sg4
(lp15903
(dp15904
g7
I21
sg8
g49
sg10
I5
sg11
VDgcr6
p15905
sg13
I1
sasg14
(lp15906
(dp15907
g7
I123
sg17
VC0012236
p15908
sg10
I17
sg11
VDiGeorge syndrome
p15909
sg13
I2
sasa(dp15910
g2
S'DGCR6 could be a candidate for involvement in the DiGeorge syndrome pathology by playing a role in neural crest cell migration into the third and fourth pharyngeal pouches, the structures from which derive the organs affected in DiGeorge syndrome.\n'
p15911
sg4
(lp15912
(dp15913
g7
I0
sg8
g49
sg10
I5
sg11
VDGCR6
p15914
sg13
I1
sasg14
(lp15915
(dp15916
g7
I50
sg17
VC0012236
p15917
sg10
I17
sg11
VDiGeorge syndrome
p15918
sg13
I2
sa(dp15919
g7
I106
sg17
VC0206138
p15920
sg10
I5
sg11
Vcrest
p15921
sg13
I1
sa(dp15922
g7
I50
sg17
VC0012236
p15923
sg10
I17
sg11
VDiGeorge syndrome
p15924
sg13
I2
sa(dp15925
g7
I68
sg17
VC0677042
p15926
sg10
I9
sg11
Vpathology
p15927
sg13
I1
sasa(dp15928
g2
S'A2 phosphofructokinase (PFKL), isocitrate dehydrogenase, pyruvate dehydrogenase, and ATP synthase subunit profiles were elevated in E/V vs. O/V; hypoglycemia augmented PFKL and Alfa-ketoglutarate dehydrogenase expression in E only.\n'
p15929
sg4
(lp15930
(dp15931
g7
I0
sg8
VP08237
p15932
sg10
I22
sg11
VA2 phosphofructokinase
p15933
sg13
I2
sa(dp15934
g7
I177
sg8
VP49366
p15935
sg10
I32
sg11
VAlfa-ketoglutarate dehydrogenase
p15936
sg13
I2
sa(dp15937
g7
I24
sg8
VP17858
p15938
sg10
I4
sg11
VPFKL
p15939
sg13
I1
sa(dp15940
g7
I57
sg8
VP49366
p15941
sg10
I22
sg11
Vpyruvate dehydrogenase
p15942
sg13
I2
sa(dp15943
g7
I31
sg8
VP48735
p15944
sg10
I24
sg11
Visocitrate dehydrogenase
p15945
sg13
I2
sa(dp15946
g7
I24
sg8
VP17858
p15947
sg10
I4
sg11
VPFKL
p15948
sg13
I1
sa(dp15949
g7
I85
sg8
g49
sg10
I20
sg11
VATP synthase subunit
p15950
sg13
I3
sasg14
(lp15951
(dp15952
g7
I145
sg17
VC0020615
p15953
sg10
I12
sg11
Vhypoglycemia
p15954
sg13
I1
sasa(dp15955
g2
S'The present study was undertaken to assess the effect of OS on three important enzymes of carbohydrate metabolism [glucokinase (GK) (EC 2.7.1.2), hexokinase (HK) (EC 2.7.1.1) and phosphofructokinase (PFK) (EC 2.7.1.11)] along with glycogen content of insulin-dependent (skeletal muscle and liver) and insulin-independent tissues (kidneys and brain) in STZ (65 mg/kg) induced model of diabetes for 30 days.\n'
p15956
sg4
(lp15957
(dp15958
g7
I200
sg8
VP08237
p15959
sg10
I3
sg11
VPFK
p15960
sg13
I1
sa(dp15961
g7
I251
sg8
VP01308
p15962
sg10
I7
sg11
Vinsulin
p15963
sg13
I1
sa(dp15964
g7
I251
sg8
VP01308
p15965
sg10
I7
sg11
Vinsulin
p15966
sg13
I1
sa(dp15967
g7
I163
sg8
VP08237
p15968
sg10
I35
sg11
VEC 2.7.1.1) and phosphofructokinase
p15969
sg13
I4
sa(dp15970
g7
I115
sg8
VP35557
p15971
sg10
I11
sg11
Vglucokinase
p15972
sg13
I1
sasg14
(lp15973
(dp15974
g7
I384
sg17
VC0011849
p15975
sg10
I8
sg11
Vdiabetes
p15976
sg13
I1
sasa(dp15977
g2
S'Three independently derived Tg-PFKL lines showed random and postprandial hyperglycemia with diminished acute insulin response following intravenous glucose tolerance load.\n'
p15978
sg4
(lp15979
(dp15980
g7
I103
sg8
VP01308
p15981
sg10
I13
sg11
Vacute insulin
p15982
sg13
I2
sa(dp15983
g7
I28
sg8
VP17858
p15984
sg10
I7
sg11
VTg-PFKL
p15985
sg13
I1
sasg14
(lp15986
(dp15987
g7
I156
sg17
VC0020963
p15988
sg10
I9
sg11
Vtolerance
p15989
sg13
I1
sa(dp15990
g7
I73
sg17
VC0020456
p15991
sg10
I13
sg11
Vhyperglycemia
p15992
sg13
I1
sasa(dp15993
g2
S'The effect of oral vanadate on intestinal sodium-dependent glucose transport and 6-phosphofructo-1-kinase (EC 2.7.1.11) activity was examined in male Sprague-Dawley rats following a 30-day period of non-treated streptozotocin-induced diabetes.\n'
p15994
sg4
(lp15995
(dp15996
g7
I42
sg8
VP19525
p15997
sg10
I63
sg11
Vsodium-dependent glucose transport and 6-phosphofructo-1-kinase
p15998
sg13
I5
sasg14
(lp15999
(dp16000
g7
I234
sg17
VC0011849
p16001
sg10
I8
sg11
Vdiabetes
p16002
sg13
I1
sasa(dp16003
g2
S'C-C chemokine receptor 7 (CCR7) has been proved to be closely associated with the metastasis of lung adenocarcinoma, and the mechanism is poorly understood.\n'
p16004
sg4
(lp16005
(dp16006
g7
I26
sg8
VP32248
p16007
sg10
I4
sg11
VCCR7
p16008
sg13
I1
sa(dp16009
g7
I0
sg8
VP61073
p16010
sg10
I24
sg11
VC-C chemokine receptor 7
p16011
sg13
I4
sasg14
(lp16012
(dp16013
g7
I82
sg17
VC0027627
p16014
sg10
I10
sg11
Vmetastasis
p16015
sg13
I1
sa(dp16016
g7
I96
sg17
VC0152013
p16017
sg10
I19
sg11
Vlung adenocarcinoma
p16018
sg13
I2
sasa(dp16019
g2
S'In order to investigate the relationship between CCR7 and lymph node metastasis in lung adenocarcinoma, and to explore the role of CCR7 in treating lung adenocarcinoma, 40 clinical specimens were collected to define the relationship between CCR7 and lymph node metastasis in lung adenocarcinoma by immunohistochemistry.\n'
p16020
sg4
(lp16021
(dp16022
g7
I49
sg8
VP32248
p16023
sg10
I4
sg11
VCCR7
p16024
sg13
I1
sa(dp16025
g7
I49
sg8
VP32248
p16026
sg10
I4
sg11
VCCR7
p16027
sg13
I1
sa(dp16028
g7
I49
sg8
VP32248
p16029
sg10
I4
sg11
VCCR7
p16030
sg13
I1
sasg14
(lp16031
(dp16032
g7
I58
sg17
VC0686619
p16033
sg10
I21
sg11
Vlymph node metastasis
p16034
sg13
I3
sa(dp16035
g7
I58
sg17
VC0686619
p16036
sg10
I21
sg11
Vlymph node metastasis
p16037
sg13
I3
sa(dp16038
g7
I83
sg17
VC0152013
p16039
sg10
I19
sg11
Vlung adenocarcinoma
p16040
sg13
I2
sa(dp16041
g7
I83
sg17
VC0152013
p16042
sg10
I19
sg11
Vlung adenocarcinoma
p16043
sg13
I2
sa(dp16044
g7
I83
sg17
VC0152013
p16045
sg10
I19
sg11
Vlung adenocarcinoma
p16046
sg13
I2
sasa(dp16047
g2
S'Clinical case studies show that higher expression of CCR7 in lung adenocarcinoma tissues was associated with a higher lymph node metastasis.\n'
p16048
sg4
(lp16049
(dp16050
g7
I53
sg8
VP32248
p16051
sg10
I4
sg11
VCCR7
p16052
sg13
I1
sasg14
(lp16053
(dp16054
g7
I118
sg17
VC0686619
p16055
sg10
I21
sg11
Vlymph node metastasis
p16056
sg13
I3
sa(dp16057
g7
I61
sg17
VC0152013
p16058
sg10
I19
sg11
Vlung adenocarcinoma
p16059
sg13
I2
sasa.